aspirin has been researched along with Bleeding in 2119 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Warfarin and aspirin are used to prevent stroke in patients with atrial fibrillation (AF)." | 10.27 | Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. ( Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M, 2013) |
| "We compared the risk of recurrent ischemic stroke, vascular events, and major bleeding between DAPT with cilostazol plus aspirin or clopidogrel and aspirin or clopidogrel alone in patients with ischemic stroke between 8 and 180 days before starting trial treatment and ECAS or without arterial stenosis." | 9.69 | Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial. ( Hoshino, H; Kimura, K; Kitagawa, K; Minematsu, K; Okamura, S; Omae, K; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2023) |
| "In patients with lacunar stroke, DAPT using cilostazol had significant benefits in reducing recurrent ischemic stroke incidence compared with SAPT without increasing the risk of severe or life-threatening bleeding." | 9.69 | Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial. ( Hoshino, H; Houkin, K; Kimura, K; Matsumoto, M; Minematsu, K; Naritomi, H; Nishiyama, Y; Okada, Y; Origasa, H; Otsuka, T; Sakai, N; Terayama, Y; Tomimoto, H; Tominaga, T; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T; Yasuda, S, 2023) |
| "We sought to explore the sex differences in clinical outcomes among patients with acute coronary syndrome treated with ticagrelor monotherapy after ticagrelor-based 3-month versus 12-month dual-antiplatelet therapy." | 9.69 | Sex Differences in Outcomes of Ticagrelor Therapy With or Without Aspirin After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Secondary Analysis of the TICO Randomized Clinical Trial. ( Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, B; Lee, SJ; Lee, YJ, 2023) |
| "The Clopidogrel With Aspirin in High-Risk Patients With Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial showed that ticagrelor-aspirin combination therapy reduced the risk of stroke compared with a clopidogrel-aspirin combination among carriers of CYP2C19 loss-of-function (LOF) alleles after a transient ischemic attack (TIA) or minor ischemic stroke." | 9.69 | Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial. ( Bath, PM; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, Y; Xie, X; Xu, A; Xu, Q; Zhao, X, 2023) |
| "Daily low-dose aspirin increases major bleeding; however, few studies have investigated its effect on iron deficiency and anemia." | 9.69 | Effect of Low-Dose Aspirin Versus Placebo on Incidence of Anemia in the Elderly : A Secondary Analysis of the Aspirin in Reducing Events in the Elderly Trial. ( Artz, AS; Bailey, M; Chan, AT; Cohen, HJ; Lockery, JE; McNeil, JJ; McQuilten, ZK; Murray, AM; Nelson, MR; Pasricha, SR; Schneider, HG; Thao, LTP; Wolfe, R; Wood, EM; Woods, RL, 2023) |
| "In this secondary analysis of a randomized controlled trial involving patients with minor ischemic stroke or TIA, compared with clopidogrel-ASA, patients with obesity received more clinical benefit from ticagrelor-ASA therapy than those without obesity." | 9.69 | Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack. ( Jiang, Y; Jing, J; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, Y; Xie, X; Zhang, J; Zhao, X, 2023) |
| "In TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention), among high-risk patients undergoing percutaneous coronary intervention (PCI), ticagrelor monotherapy vs continuation of dual antiplatelet therapy (DAPT) with aspirin and ticagrelor after completing a 3-month course of DAPT was associated with reduced bleeding, without an increase in ischemic events." | 9.69 | Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions. ( Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, D; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, CM; Gil, R; Han, YL; Huber, K; Kastrati, A; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Mendieta, G; Moliterno, DJ; Ohman, EM; Pocock, S; Sardella, G; Sartori, S; Sharma, S; Shlofmitz, R; Spirito, A; Steg, PG; Vogel, B, 2023) |
| "Nearly 20% of patients on ticagrelor experience dyspnea, which may lead to treatment discontinuation in up to one-third of cases." | 9.69 | Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention. ( Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, M; Gil, R; Huber, K; Ielasi, A; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Moliterno, DJ; Ohman, EM; Pivato, CA; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Stefanini, GG; Steg, PG; Vogel, B; Weisz, G; Witzenbichler, B; Zhang, Z, 2023) |
| " prasugrel in patients with acute coronary syndromes (ACSs) are influenced by pre-admission treatment with aspirin and/or clopidogrel." | 9.51 | Pre-admission antiplatelet therapy and treatment effect of ticagrelor vs. prasugrel in patients with acute coronary syndromes-a subgroup analysis of the ISAR-REACT 5 trial. ( Akin, I; Bernlochner, I; Cassese, S; Gewalt, S; Hemetsberger, R; Ibrahim, T; Joner, M; Kastrati, A; Kufner, S; Lahu, S; Laugwitz, KL; Mayer, K; Menichelli, M; Ndrepepa, G; Neumann, FJ; Richardt, G; Sager, HB; Schunkert, H; Schüpke, S; Valina, C; Witzenbichler, B; Wöhrle, J; Xhepa, E, 2022) |
| "Irrespective of the presence of DM, CKD, and their combination, ticagrelor monotherapy reduced the risk of bleeding without a significant increase in ischaemic events compared with ticagrelor plus aspirin." | 9.51 | Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. ( Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, DJ; Collier, T; Dangas, G; Dehghani, P; Dudek, D; Escaned, J; Gibson, M; Gil, R; Huber, K; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Moliterno, DJ; Nicolas, J; Ohman, EM; Pivato, CA; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Weisz, G; Witzenbichler, B; Zhang, Z, 2022) |
| "To test whether indobufen is non-inferior to aspirin in reducing the risk of new stroke at 3 months in patients with moderate to severe ischaemic stroke." | 9.51 | Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial. ( Bath, PM; Chen, W; Dong, Q; Jiang, Y; Jing, J; Johnston, SC; Li, H; Lin, J; Meng, X; Pan, Y; Wang, Y; Xu, AD, 2022) |
| " Aspirin increased major or CRNM bleeding, particularly in patients without prior stroke/TIA/TE." | 9.51 | Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial. ( Alexander, JH; Aronson, R; Bahit, MC; Berwanger, O; Dombrowski, KE; Goodman, SG; Granger, CB; Halvorsen, S; Jordan, JD; Kolls, BJ; Li, Z; Lopes, RD; Mehran, R; Thomas, L; Vinereanu, D; Vora, AN; Windecker, S; Wojdyla, DM, 2022) |
| "Dual antiplatelet therapy (DAPT) with ticagrelor and aspirin has been found to be effective for secondary prevention after minor ischemic stroke or transient ischemic attack (TIA) in individuals who carry CYP2C19 loss-of-function (LOF) alleles; however, uncertainties remain about the time course of benefit and risk with ticagrelor and aspirin in these patients." | 9.51 | Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial. ( Bath, PM; Cheng, J; Jiang, Y; Jin, A; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Pan, Y; Wang, Y; Wang, Z; Xie, X; Yang, H; Zhao, X, 2022) |
| "In patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in The Cardiovascular Outcomes for People Using Anticoagulation Strategies trial, the effects of rivaroxaban 2." | 9.51 | Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. ( Bhatt, DL; Bosch, J; Connolly, SJ; Eikelboom, JW; Fox, KAA; Hori, M; Liang, Y; Maggioni, A; Yusuf, S; Zhu, J, 2022) |
| "In this open-label, assessor-masked, multicentre, non-inferiority, randomised trial (TALOS-AMI), patients at 32 institutes in South Korea with acute myocardial infarction receiving aspirin and ticagrelor without major ischaemic or bleeding events during the first month after index percutaneous coronary intervention (PCI) were randomly assigned in a 1:1 ratio to a de-escalation (clopidogrel plus aspirin) or active control (ticagrelor plus aspirin) group." | 9.41 | Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. ( Ahn, Y; Chang, K; Choi, YS; Choo, EH; Hwang, BH; Jeon, DS; Jeong, MH; Jeong, YH; Kim, CJ; Kim, HY; Kim, MC; Lee, KY; Park, MW; Seung, KB; Shin, ES; Yim, HW; Yoo, KD, 2021) |
| "Background We aimed to evaluate the age-dependent effect of ticagrelor monotherapy after 3-month dual-antiplatelet therapy (DAPT) versus ticagrelor-based 12-month DAPT on major bleeding and cardiovascular events in patients with acute coronary syndrome." | 9.41 | Age-Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events: A Post Hoc Analysis of the TICO Randomized Trial. ( Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BG; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Shin, DH, 2021) |
| "Ticagrelor is slightly better than clopidogrel and aspirin in preventing stroke, especially ischemic stroke, with significant safety risks." | 9.41 | Efficacy and Safety of Ticagrelor versus Aspirin and Clopidogrel for Stroke Prevention in Patients with Vascular Disease: A Systematic Review and Meta-Analysis. ( Chen, Y; Li, D; Liu, S; Ma, X; Zhong, P, 2023) |
| " The incidence of all bleeding events with ticagrelor was higher than that with clopidogrel (RR, 1." | 9.41 | Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials. ( He, X; Li, J; Ma, S; Qiu, M; Qu, X; Wang, Q; Wang, X; Wu, C; Zhang, L, 2023) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel was recommended as the secondary prevention of minor ischemic stroke or transient ischaemic attack (TIA)." | 9.41 | Ticagrelor plus aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis. ( Ge, F; Li, M; Lin, H; Shi, J; Yang, Q; Zhang, X, 2023) |
| "The efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valves and atrial fibrillation or flutter remain uncertain." | 9.41 | A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. ( Almeida, AP; Ardito, RV; Atik, FA; Barreto, DO; Berwanger, O; Campos, VB; Cavalcante, MA; Cavalcanti, AB; D'Oliveira Vieira, R; Damiani, L; de Barros E Silva, PGM; de Lima, CEB; de Souza Neto, JD; Dos Santos, JRY; Farias, FR; Ferreira, JFM; Figueira, FAMS; Fonseca, FH; Guimarães, HP; Hoffmann-Filho, CR; Junior, RA; Kalil, PSA; Kojima, F; Lamprea, D; Laranjeira, L; Leiria, TLL; Liporace, IL; Lopes, RD; Magalhães, CC; Maldonado, JGA; Mesas, CE; Moisés, VA; Nakagawa, RH; Paiva, MSMO; Paixão, M; Patriota, R; Pavanello, R; Pinto, IM; Precoma, DB; Sampaio, BS; Sampaio, RO; Saraiva, JFK; Silveira, FS; Tarasoutchi, F; Zilli, AC, 2021) |
| "In the AFIRE trial, rivaroxaban monotherapy was noninferior to combination therapy with rivaroxaban and an antiplatelet agent for thromboembolic events or death, and superior for major bleeding in patients with atrial fibrillation (AF) and stable coronary artery disease." | 9.41 | Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis. ( Akao, M; Ako, J; Hagiwara, N; Hirayama, A; Kaikita, K; Kimura, K; Matoba, T; Matsui, K; Miyauchi, K; Nakamura, M; Ogawa, H; Yasuda, S, 2021) |
| " Approach and Results: The CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) randomized patients with acute minor ischemic stroke or high-risk transient ischemic attack to clopidogrel plus aspirin or aspirin alone from October 1, 2009, to July 30, 2012, in China." | 9.34 | Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial. ( Li, H; Li, J; Lin, J; Liu, L; Wang, A; Wang, Y; Zhao, X; Zuo, Z, 2020) |
| "Compared with ticagrelor plus aspirin, the effect of ticagrelor monotherapy in reducing the risk of clinically relevant bleeding without any increase in ischemic events was consistent among patients with or without DM undergoing PCI." | 9.34 | Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. ( Angiolillo, DJ; Baber, U; Briguori, C; Chandiramani, R; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, CM; Huber, K; Kaul, U; Kornowski, R; Kunadian, V; Mehran, R; Mehta, SR; Oldroyd, KG; Pocock, S; Sardella, G; Sartori, S; Sharma, S; Shlofmitz, RA; Weisz, G; Witzenbichler, B; Ya-Ling, H, 2020) |
| "The REDUAL PCI trial (Evaluation of Dual Therapy With Dabigatran vs Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting) demonstrated that, in patients with atrial fibrillation following percutaneous coronary intervention, bleeding risk was lower with dabigatran plus clopidogrel or ticagrelor (dual therapy) than warfarin plus clopidogrel or ticagrelor and aspirin (triple therapy)." | 9.34 | Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial. ( Berry, NC; Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Mauri, L; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2020) |
| "Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy." | 9.34 | Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. ( Ahn, CM; Cho, DK; Cho, JY; Cho, S; Cho, YH; Choi, D; Her, AY; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Jeon, DW; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Kwon, H; Nam, CM; Shin, DH; Suh, Y; Yoo, SY; Yun, KH, 2020) |
| "Trials have evaluated the use of clopidogrel and aspirin to prevent stroke after an ischemic stroke or transient ischemic attack (TIA)." | 9.34 | Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. ( Amarenco, P; Denison, H; Evans, SR; Himmelmann, A; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Molina, CA; Wang, Y, 2020) |
| "The OPT-BIRISK trial is a multicenter, double-blinded, placebo-controlled randomized study designed to test the superiority of extended antiplatelet therapy with clopidogrel monotherapy compared with aspirin and clopidogrel for reduction of bleeding events in ACS patients with both high bleeding and high ischemic risks ("bi-risk")." | 9.34 | Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the O ( Angiolillo, DJ; Chen, S; Han, Y; Jing, Q; Li, J; Li, Y; Qiao, S; Wang, B; Wang, X, 2020) |
| "Emerging evidence suggests aspirin may be an effective venous thromboembolism (VTE) prophylaxis for orthopaedic trauma patients, with fewer bleeding complications." | 9.34 | Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial. ( Castillo, RC; Haac, BE; Manson, TT; O'Hara, NN; O'Toole, RV; Slobogean, GP; Stein, DM, 2020) |
| "Dual antiplatelet therapy (DAPT) with aspirin and ticagrelor is recommended for at least 12 months in patients after an acute coronary syndrome (ACS)." | 9.34 | Improving Adherence to Ticagrelor in Patients After Acute Coronary Syndrome: Results from the PROGRESS Trial. ( Calabrò, P; Cesaro, A; Cirillo, PL; Concilio, C; Crisci, M; Di Maio, D; Di Maio, M; Diana, V; Fimiani, F; Gragnano, F; Moscarella, E; Pariggiano, I; Taglialatela, V, 2020) |
| "Adding rivaroxaban to aspirin in patients with stable atherosclerotic disease reduces the recurrence of cardiovascular disease (CVD) but increases the risk of major bleeding." | 9.30 | Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. ( Alings, M; Berkowitz, SD; Bosch, J; de Vries, TI; Dorresteijn, JAN; Dyal, L; Eikelboom, JW; Fox, KAA; van der Graaf, Y; Visseren, FLJ; Westerink, J, 2019) |
| "5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events and mortality and increased bleeding." | 9.30 | Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. ( Berkowitz, SD; Bhatt, DL; Bosch, JJ; Cairns, JA; Connolly, SJ; Cook Bruns, N; Dagenais, GR; Diaz, R; Eikelboom, JW; Fox, KAA; Hart, RG; Leong, DP; Maggioni, AP; Muehlhofer, E; O'Donnell, M; Shestakovska, O; Tasto, C; Yusuf, S, 2019) |
| "Between 1 month and 12 months after PCI in ACS, aspirin was associated with increased bleeding risk and appeared not to add to the benefit of ticagrelor on ischemic events." | 9.30 | Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial. ( Angiolillo, DJ; Bhatt, DL; Chang, CC; Chichareon, P; Dangas, GD; Deliargyris, EN; Hamm, C; Kogame, N; Modolo, R; Onuma, Y; Rademaker-Havinga, T; Serruys, PW; Steg, PG; Storey, RF; Takahashi, K; Tomaniak, M; Valgimigli, M; Vranckx, P; Windecker, S, 2019) |
| "In RE-DUAL PCI, 2,725 patients with atrial fibrillation (993 with diabetes) who had undergone PCI were assigned to warfarin triple therapy (warfarin, clopidogrel or ticagrelor, and aspirin) or dabigatran dual therapy (dabigatran 110 mg or 150 mg twice daily and clopidogrel or ticagrelor)." | 9.30 | Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes. ( Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Maeng, M; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2019) |
| "The benefits of both dabigatran 110 mg and 150 mg dual therapy compared with warfarin triple therapy in reducing bleeding risks were consistent across subgroups of patients with or without ACS, and patients treated with ticagrelor or clopidogrel." | 9.30 | Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. ( Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2019) |
| "Using the standard maintenance dose of prasugrel (10 mg/day) as part of triple therapy with aspirin and an oral anticoagulant (OAC) is not recommended in the current guidelines because it increases the risk of bleeding compared with clopidogrel." | 9.30 | Safety and Efficacy of Low-Dose Prasugrel as Part of Triple Therapy With Aspirin and Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention - From the TWMU-AF PCI Registry. ( Arashi, H; Ebihara, S; Fujii, S; Hagiwara, N; Honda, A; Jujo, K; Kawamoto, T; Mori, F; Nakao, M; Ota, Y; Otsuki, H; Saito, K; Takagi, A; Tanaka, H; Tanaka, K; Yamaguchi, J; Yoshikawa, M, 2019) |
| "Results show the short-term risk of hemorrhage in treating patients with acute transient ischemic attack (TIA) or minor acute ischemic stroke (AIS) with clopidogrel plus aspirin or aspirin alone." | 9.30 | Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. ( Barsan, W; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY; Tillman, H, 2019) |
| "We conducted a multicenter, randomized, double-blind trial of dabigatran at a dose of 150 mg or 110 mg twice daily as compared with aspirin at a dose of 100 mg once daily in patients who had had an embolic stroke of undetermined source." | 9.30 | Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. ( Bernstein, RA; Brueckmann, M; Chernyatina, M; Cotton, D; Cronin, L; Diener, HC; Donnan, G; Easton, JD; Ferro, JM; Granger, CB; Grauer, C; Grond, M; Kallmünzer, B; Kreuzer, J; Krupinski, J; Lee, BC; Lemmens, R; Masjuan, J; Odinak, M; Sacco, RL; Saver, JL; Schellinger, PD; Toni, D; Toyoda, K; Uchiyama, S, 2019) |
| "To investigate the association of mandatory reporting of CYP2C19 pharmacogenomic testing, provided to investigators with no direct recommendations on how to use these results, with changes in P2Y12 inhibitor use, particularly clopidogrel, in the Randomized Trial to Compare the Safety of Rivaroxaban vs Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome (GEMINI-ACS-1) clinical trial." | 9.30 | P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. ( Bode, C; Cornel, JH; Gibson, CM; James, S; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Plotnikov, AN; Povsic, TJ; Rockhold, FW; Roe, MT; Steg, PG; Welsh, RC; White, J, 2019) |
| "Among patients undergoing PCI, 1 month of DAPT followed by clopidogrel monotherapy, compared with 12 months of DAPT with aspirin and clopidogrel, resulted in a significantly lower rate of a composite of cardiovascular and bleeding events, meeting criteria for both noninferiority and superiority." | 9.30 | Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. ( Abe, M; Ando, K; Doi, M; Domei, T; Furukawa, Y; Hanaoka, KI; Hata, Y; Hibi, K; Ikari, Y; Kadota, K; Kawai, K; Kimura, T; Kozuma, K; Morimoto, T; Morino, Y; Nakagawa, Y; Nakao, K; Nanasato, M; Natsuaki, M; Noda, T; Ohya, M; Okayama, H; Sakamoto, H; Seino, Y; Shiomi, H; Suematsu, N; Suwa, S; Tada, T; Takagi, K; Takamisawa, I; Tanabe, K; Toyota, T; Watanabe, H; Yagi, M; Yokomatsu, T, 2019) |
| "In patients with acute minor ischemic stroke or high-risk transient ischemic attack enrolled in the POINT trial (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke [POINT] Trial), the combination of clopidogrel and aspirin for 90 days reduced major ischemic events but increased major hemorrhage in comparison to aspirin alone." | 9.30 | Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke. ( Albers, GW; Barsan, WG; Cucchiara, BL; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Kleindorfer, DO; Lindblad, AS; Lutsep, HL; Palesch, YY; Pearson, C; Sethi, P; Vora, N; Zurita, KG, 2019) |
| "In patients with stable coronary artery disease, addition of rivaroxaban to aspirin lowered major vascular events, but increased major bleeding." | 9.27 | Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. ( Anand, SS; Avezum, AA; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, SJ; Cook Bruns, N; Dagenais, G; Dans, AL; Dyal, L; Eikelboom, JW; Felix, C; Fox, KAA; Guzik, TJ; Ha, JW; Hori, M; Keltai, K; Lanas, F; Lisheng, L; Lonn, E; Maggioni, AP; Metsarinne, K; O'Donnell, M; Parkhomenko, AN; Torp-Pedersen, C; Varigos, JD; Widimsky, P; Yusoff, K; Yusuf, S, 2018) |
| "Concomitant aspirin (ASA) is often prescribed in anticoagulated patients with atrial fibrillation (AF)." | 9.27 | Impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation taking aspirin: An analysis from the SPORTIF trials. ( Lip, GYH; Proietti, M, 2018) |
| "The associations between osteoprotegerin and the composite end point of cardiovascular death, nonprocedural spontaneous myocardial infarction or stroke, and non-coronary artery bypass grafting major bleeding during 1 year of follow-up were assessed by Cox proportional hazards models." | 9.27 | Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. ( Åkerblom, A; Aukrust, P; Becker, RC; Bertilsson, M; Ghukasyan, T; Himmelmann, A; James, SK; Kontny, F; Michelsen, AE; Siegbahn, A; Storey, RF; Ueland, T; Wallentin, L, 2018) |
| "Ticagrelor plus low-dose aspirin for up to 1 year was associated with a low rate of major bleeding events and a low incidence of major CV events (CV death, myocardial infarction, stroke) in Chinese patients with ACS." | 9.27 | Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study. ( Gao, R; Han, Y; Leonsson-Zachrisson, M; Liu, H; Liu, L; Shen, L; Su, G; Wang, Y; Wang, Z; Wu, Y; Yuan, Z; Zhang, A; Zhang, H; Zheng, Y, 2018) |
| " The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days." | 9.27 | Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018) |
| "Rivaroxaban was not superior to aspirin with regard to the prevention of recurrent stroke after an initial embolic stroke of undetermined source and was associated with a higher risk of bleeding." | 9.27 | Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. ( Amarenco, P; Ameriso, SF; Arauz, A; Bangdiwala, SI; Benavente, OR; Bereczki, D; Berkowitz, SD; Bornstein, N; Brouns, R; Connolly, SJ; Cunha, L; Czlonkowska, A; Davalos, A; De Vries Basson, MM; Eckstein, J; Endres, M; Gagliardi, RJ; Hankey, GJ; Hart, RG; Joyner, C; Kasner, SE; Kirsch, B; Lang, W; Lavados, P; Lindgren, A; Mikulik, R; Muir, KW; Mundl, H; Ntaios, G; O'Donnell, MJ; Ozturk, S; Pare, G; Pater, C; Peacock, WF; Peters, G; Shamalov, N; Sharma, M; Sheridan, P; Shoamanesh, A; Swaminathan, B; Tatlisumak, T; Themeles, E; Toni, D; Uchiyama, S; Veltkamp, R; Wang, Y; Weitz, JI; Yoon, BW, 2018) |
| " Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear." | 9.27 | Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. ( Adler, A; Armitage, J; Aung, T; Baigent, C; Barton, J; Bodansky, J; Bowman, L; Buck, G; Chen, F; Collins, R; Cox, J; Farmer, A; Haynes, R; Lay, M; Mafham, M; McPherson, R; Murawska, A; Murphy, K; Neil, A; Parish, S; Peto, R; Sammons, E; Simpson, D; Stevens, W; Wallendszus, K; Waters, E; Young, A, 2018) |
| "The use of low-dose aspirin as a primary prevention strategy in older adults resulted in a significantly higher risk of major hemorrhage and did not result in a significantly lower risk of cardiovascular disease than placebo." | 9.27 | Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. ( Abhayaratna, WP; Beilin, LJ; Brauer, D; Cloud, G; Donnan, GA; Eaton, CB; Ernst, ME; Fitzgerald, SM; Grimm, R; Jelinek, M; Johnston, CI; Kirpach, B; Lockery, JE; Mahady, SE; Malik, M; Margolis, KL; McNeil, JJ; Murray, AM; Nelson, MR; Orchard, SG; Radziszewska, B; Reid, CM; Ryan, J; Satterfield, S; Shah, RC; Stocks, N; Storey, E; Tonkin, AM; Trevaks, RE; Williamson, JD; Wolfe, R; Wood, EM; Woods, RL, 2018) |
| "Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates." | 9.24 | Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. ( Bauersachs, R; Berkowitz, SD; Beyer-Westendorf, J; Bounameaux, H; Brighton, TA; Cohen, AT; Davidson, BL; Decousus, H; Freitas, MCS; Haskell, L; Holberg, G; Kakkar, AK; Lensing, AWA; Pap, AF; Prandoni, P; Prins, MH; van Bellen, B; Verhamme, P; Weitz, JI; Wells, PS, 2017) |
| "A dual pathway antithrombotic therapy approach combining low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of patients with acute coronary syndromes had similar risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor." | 9.24 | Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. ( Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J, 2017) |
| "In the SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes), ticagrelor was not superior to aspirin." | 9.24 | Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KS, 2017) |
| "To investigate the feasibility of periodontal mechanical therapy for chronic periodontitis and coronary heart disease patients with low dose of aspirin." | 9.24 | [Bleeding control of periodontal mechanical therapy for patients taking aspirin]. ( Ding, F; Duan, XQ; Han, X; Liu, DY; Lyu, YL; Xuan, W, 2017) |
| "To evaluate the difference between low-molecular-weight heparin (LMWH) and aspirin in preventing early neurological deterioration (END) and recurrent ischemic stroke (RIS), post-recovery independence, and safety outcomes in acute ischemic stroke." | 9.22 | Low-Molecular-Weight Heparin Versus Aspirin in Early Management of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. ( Liu, Z; Tian, M; Wang, Z; Xia, H; Zhou, Z, 2022) |
| "Low-dose aspirin was associated with small absolute risk reductions in major cardiovascular disease events and small absolute increases in major bleeding." | 9.22 | Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Bean, SI; Evans, CV; Guirguis-Blake, JM; Perdue, LA; Senger, CA, 2022) |
| " We aimed to perform the first systematic review and meta-analysis comparing dual antiplatelet therapy (DAPT) versus aspirin alone in terms of postendoscopic retrograde cholangiopancreatography (ERCP) bleeding." | 9.22 | No Significant Difference in Post-ERCP Bleeding Rates Between Dual Antiplatelet Agents and Aspirin Alone: A Systematic Review and Meta-analysis. ( Bansal, V; Bhurwal, A; Brahmbhatt, B; Goel, A; Mutneja, H; Patel, A; Sarkar, A, 2022) |
| "P2Y12 receptor inhibitor plus aspirin vs aspirin given within 24 h after acute noncardioembolic ischemic stroke or TIA reduces the risk of subsequent stroke." | 9.22 | P2Y12 receptor inhibitor plus aspirin versus aspirin treated within 24 hours of acute noncardioembolic ischemic stroke or TIA: Meta-analysis. ( Huang, WY; Lee, M; Ovbiagele, B, 2022) |
| "The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours." | 9.22 | Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016) |
| "Medically managed patients with ACS in the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial were randomised to clopidogrel versus prasugrel (plus aspirin), stratified by prior clopidogrel use." | 9.22 | Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. ( Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ, 2016) |
| "PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) randomized 21,162 patients with prior MI (1 to 3 years) to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo, all on a background of low-dose aspirin." | 9.22 | Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. ( Abola, MTB; Aylward, P; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Corbalán, R; Dalby, A; Dellborg, M; Goodrich, E; Held, P; Jensen, EC; Kuder, J; López-Sendón, J; Nicolau, JC; Parkhomenko, A; Sabatine, MS; Špinar, J; Steg, PG; Storey, RF, 2016) |
| "Ticagrelor may be a more effective antiplatelet therapy than aspirin for the prevention of recurrent stroke and cardiovascular events in patients with acute cerebral ischemia." | 9.22 | Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KS, 2016) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 9.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "Patients with acute minor ischemic stroke or transient ischemic attack in the trial were randomized to treatment with clopidogrel combined with aspirin or to aspirin alone." | 9.22 | Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. ( Johnston, SC; Li, H; Lin, J; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Xu, J; Zhao, X, 2016) |
| "ᅟ: We investigated the occurrence of bleeding complications in patients who underwent skin tumor surgery and compared it between Aspirin users and a placebo control group." | 9.22 | Aspirin use and bleeding volume in skin cancer patients undergoing surgery: a randomized controlled trial. ( Atri, A; Engheta, A; Hadadi Abianeh, S; Sanatkarfar, M, 2016) |
| "In the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), ticagrelor reduced the risk of major adverse cardiovascular events when added to low-dose aspirin in stable patients with prior myocardial infarction, resulting in the approval of ticagrelor 60 mg twice daily for long-term secondary prevention." | 9.22 | Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm ( Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Dalby, AJ; Goodrich, E; Goto, S; Held, P; Hu, D; Jensen, E; Mauri, L; Morrow, DA; Ophuis, TO; Ruda, M; Sabatine, MS; Seung, KB; Špinar, J; Steg, PG; Storey, RF, 2016) |
| "The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization." | 9.22 | A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016) |
| "In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding." | 9.20 | Long-term use of ticagrelor in patients with prior myocardial infarction. ( Bansilal, S; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Fish, MP; Goto, S; Hamm, C; Held, P; Im, K; Jensen, EC; Kiss, RG; Magnani, G; Murphy, SA; Nicolau, JC; Oude Ophuis, T; Ruda, M; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Theroux, P; Wiviott, SD, 2015) |
| "There is insufficient data on the efficacy of prasugrel and ticagrelor in Korean patients with ST-segment elevation myocardial infarction (STEMI)." | 9.20 | Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. ( Cho, YR; Guo, LZ; Jin, CD; Kim, MH; Kim, YD; Lee, YS; Park, JS; Park, K; Park, TH, 2015) |
| "We sought to assess the performance of existing bleeding risk scores, such as the Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly (HAS-BLED) score or the Outpatient Bleeding Risk Index (OBRI), in patients with heart failure with reduced ejection fraction (HFrEF) in sinus rhythm (SR) treated with warfarin or aspirin." | 9.20 | Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. ( Anker, SD; Buchsbaum, R; Cheng, B; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Teerlink, JR; Thompson, JL; Ye, S, 2015) |
| "Apixaban was associated with fewer strokes and systemic embolism versus aspirin across all subgroups; however, it caused more major bleeding events." | 9.20 | Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients. ( Dorian, P; Kongnakorn, T; Lanitis, T; Lip, GY; Mardekian, J; Phatak, H, 2015) |
| " Using inverse probability-weighted propensity modeling, we compared 6-month adjusted risks of Bleeding Academic Research Consortium (BARC) bleeding, stratifying by whether or not bleeding was associated with rehospitalization among patients discharged on aspirin + anticoagulant + clopidogrel (triple-C), aspirin + anticoagulant + prasugrel (triple-P), aspirin + clopidogrel (dual-C), or aspirin + prasugrel (dual-P)." | 9.20 | Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. ( Baker, BA; Cohen, DJ; Effron, M; Jackson, LR; Ju, C; Messenger, JC; Peterson, ED; Stone, GW; Wang, TY; Zettler, M, 2015) |
| "The goal of this study was to analyze the impact of dabigatran plasma concentrations, patient demographics, and aspirin (ASA) use on frequencies of ischemic strokes/systemic emboli and major bleeds in atrial fibrillation patients." | 9.19 | The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). ( Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Haertter, S; Lehr, T; Nehmiz, G; Reilly, PA; Wallentin, L; Wang, S; Yusuf, S, 2014) |
| "Apixaban had similar beneficial effects on stroke or systemic embolism and major bleeding compared with warfarin, irrespective of concomitant aspirin use." | 9.19 | Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. ( Alexander, JH; Alings, M; Atar, D; Aylward, P; Goto, S; Granger, CB; Hanna, M; Huber, K; Husted, S; Lewis, BS; Lopes, RD; McMurray, JJ; Pais, P; Pouleur, H; Steg, PG; Thomas, L; Verheugt, FW; Wallentin, L; Wojdyla, DM, 2014) |
| "To compare the therapeutic warfarin and aspirin efficacies for treatments of atrial fibrillation (AF) complicated with stable coronary heart disease particularly in older Chinese patients." | 9.19 | Warfarin compared with aspirin for older Chinese patients with stable coronary heart diseases and atrial fibrillation complications. ( Cao, G; Feng, L; Huang, H; Li, Y; Liu, X; Xu, Q; Yu, J; Zhang, S; Zhou, M, 2014) |
| "An individual patient data analysis of these trials was planned, before their results were known, to assess the effect of aspirin versus placebo on recurrent VTE, major vascular events (recurrent VTE, myocardial infarction, stroke, and cardiovascular disease death) and bleeding, overall and within predefined subgroups." | 9.19 | Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. ( Agnelli, G; Becattini, C; Brighton, TA; Eikelboom, JW; Kirby, AC; Mister, R; Prandoni, P; Simes, J, 2014) |
| "To determine whether aspirin compared with placebo, and clonidine compared with placebo, alters the risk of perioperative acute kidney injury." | 9.19 | Perioperative aspirin and clonidine and risk of acute kidney injury: a randomized clinical trial. ( Acedillo, R; Amir, M; Bergese, S; Biccard, B; Bidgoli, SJ; Cata, JP; Cegarra, V; Chan, MT; Chan, V; Clanchet, Mde N; Cuerden, M; Devereaux, PJ; Dresser, G; Fleischmann, E; Font, A; Forget, P; Garg, AX; Gomez, MF; Jones, PM; Kumar, P; Kurz, A; Leslie, K; Malaga, G; Martinsen, K; Mehra, B; Meyhoff, CS; Mizera, R; Mrkobrada, M; Myles, P; Painter, T; Parikh, CR; Parlow, J; Pasin, L; Robinson, A; Roshanov, PS; Sessler, DI; Srinathan, S; Tiboni, M; Torres, D; VanHelder, T; Villar, JC; Walsh, M; Whitlock, R; Wijeysundera, DN; Yusuf, S, 2014) |
| "To compare extended prophylaxis with aspirin and dalteparin for prevention of symptomatic venous thromboembolism (VTE) after THA." | 9.17 | Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. ( Anderson, DR; Andreou, P; Belzile, E; Bohm, ER; Carrier, M; Crowther, M; Davis, N; Dunbar, MJ; Fisher, W; Gofton, W; Gross, P; Kahn, SR; Kim, P; Kovacs, M; MacDonald, S; Pelet, S; Pleasance, S; Ramsay, T; Rodger, MA; Vendittoli, PA; Wells, P; Zukor, D, 2013) |
| "Among patients with TIA or minor stroke who can be treated within 24 hours after the onset of symptoms, the combination of clopidogrel and aspirin is superior to aspirin alone for reducing the risk of stroke in the first 90 days and does not increase the risk of hemorrhage." | 9.17 | Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. ( Cui, L; Dong, Q; Jia, J; Johnston, SC; Li, H; Li, Y; Liu, L; Meng, X; Wang, C; Wang, D; Wang, Y; Wang, Z; Xia, H; Xu, A; Zeng, J; Zhao, X, 2013) |
| "A total of 9326 medically managed patients with acute coronary syndromes from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial (<75 years of age, n=7243; ≥75 years of age, n=2083) were randomized to prasugrel (10 mg/d; 5 mg/d for those ≥75 or <75 years of age and <60 kg in weight) or clopidogrel (75 mg/d) plus aspirin for ≤30 months." | 9.17 | Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bassand, JP; Boden, WE; Dalby, AJ; Fox, KA; Goodman, SG; Gottlieb, S; Hochman, JS; Martinez, F; McGuire, DK; Ohman, EM; Prabhakaran, D; Roe, MT; Stevens, SR; White, HD; Winters, KJ, 2013) |
| "The impact of apixaban versus aspirin on ischemic stroke and major bleeding in relation to the CHADS(2) and CHA(2)DS(2)-VASc stroke risk scores in atrial fibrillation has not been investigated." | 9.17 | Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. ( Connolly, S; Eikelboom, J; Flaker, G; Hart, R; Lanas, F; Lip, GY; Shestakovska, O; Xavier, D; Yusuf, S, 2013) |
| "The aim of this subanalysis was to assess the net clinical effect of prehospital administration of tirofiban in ST-elevation myocardial infarction (STEMI) patients with high risk of bleeding." | 9.16 | Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score. ( Dambrink, JH; Gosselink, AT; Hamm, C; Hermanides, RS; Ottervanger, JP; Stella, PR; ten Berg, JM; van 't Hof, AW; van Houwelingen, G, 2012) |
| "It is unknown whether warfarin or aspirin therapy is superior for patients with heart failure who are in sinus rhythm." | 9.16 | Warfarin and aspirin in patients with heart failure and sinus rhythm. ( Ammon, SE; Anker, SD; Buchsbaum, R; del Valle, ML; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Gabriel, AP; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Massie, BM; Mejia, V; Mohr, JP; Ponikowski, P; Pullicino, PM; Sacco, RL; Sanford, AR; Teerlink, JR; Thompson, JL, 2012) |
| "Aspirin reduced the risk of recurrence when given to patients with unprovoked venous thromboembolism who had discontinued anticoagulant treatment, with no apparent increase in the risk of major bleeding." | 9.16 | Aspirin for preventing the recurrence of venous thromboembolism. ( Ageno, W; Agnelli, G; Becattini, C; Bianchi, M; Bucherini, E; Eichinger, S; Grandone, E; Moia, M; Prandoni, P; Schenone, A; Silingardi, M; Vandelli, MR, 2012) |
| "Apixaban is superior to aspirin for the prevention of stroke in patients with atrial fibrillation." | 9.16 | Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. ( Connolly, SJ; De Caterina, R; Eikelboom, JW; Gao, P; Hart, RG; Husted, S; O'Donnell, M; Paolasso, E; Yusuf, S, 2012) |
| "Among patients with recent lacunar strokes, the addition of clopidogrel to aspirin did not significantly reduce the risk of recurrent stroke and did significantly increase the risk of bleeding and death." | 9.16 | Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. ( Benavente, OR; Coffey, CS; Hart, RG; McClure, LA; Pearce, LA; Szychowski, JM, 2012) |
| "We randomly assigned 822 patients who had completed initial anticoagulant therapy after a first episode of unprovoked venous thromboembolism to receive aspirin, at a dose of 100 mg daily, or placebo for up to 4 years." | 9.16 | Low-dose aspirin for preventing recurrent venous thromboembolism. ( Brighton, TA; Diaz, R; Eikelboom, JW; Gallus, A; Gibbs, H; Hague, W; Kirby, A; Mann, K; Mister, R; Ockelford, P; Simes, J; Xavier, D, 2012) |
| " We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation." | 9.15 | Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011) |
| " In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens." | 9.15 | Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R, 2011) |
| "In a double-blind study, we randomly assigned 5599 patients with atrial fibrillation who were at increased risk for stroke and for whom vitamin K antagonist therapy was unsuitable to receive apixaban (at a dose of 5 mg twice daily) or aspirin (81 to 324 mg per day), to determine whether apixaban was superior." | 9.15 | Apixaban in patients with atrial fibrillation. ( Afzal, R; Avezum, A; Budaj, A; Commerford, P; Connolly, SJ; Dans, AL; Diaz, R; Diener, HC; Eikelboom, J; Flaker, G; Golitsyn, S; Gonzalez-Hermosillo, A; Hart, R; Hohnloser, SH; Jansky, P; Joyner, C; Kim, JH; Lanas-Zanetti, F; Lawrence, J; Lewis, BS; Lewis, G; Lip, GY; Munawar, M; O'Donnell, M; Pais, P; Parkhomenko, A; Sim, KH; Talajic, M; Tan, RS; Van Mieghem, W; Yusuf, S; Zhu, J, 2011) |
| "After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel." | 9.15 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011) |
| "Aspirin is a proven antiplatelet agent in acute ischemic stroke, and there are no current guidelines for other antiplatelet treatments." | 9.15 | Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. ( Bae, HJ; Cho, YJ; Han, MG; Hong, KS; Jung, SW; Kang, DW; Kim, DE; Kim, JS; Koo, J; Kwon, SU; Lee, BC; Lee, JH; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Rha, JH; Yu, K, 2011) |
| "The trial was terminated prematurely after recruitment of 7392 patients because of an increase in major bleeding events with apixaban in the absence of a counterbalancing reduction in recurrent ischemic events." | 9.15 | Apixaban with antiplatelet therapy after acute coronary syndrome. ( Alexander, JH; Atar, D; Bhatt, DL; Cools, F; Cornel, JH; Darius, H; De Caterina, R; Diaz, R; Flather, M; Geraldes, M; Goodman, S; Harrington, RA; He, Y; Huber, K; Husted, SE; James, S; Jansky, P; Keltai, M; Kilaru, R; Lawrence, J; Leiva-Pons, JL; Liaw, D; Lopes, RD; Lopez-Sendon, J; Mohan, P; Ogawa, H; Pais, P; Parkhomenko, A; Ruda, M; Ruzyllo, W; Verheugt, FW; Vinereanu, D; Wallentin, L; White, H, 2011) |
| "001) by adjusted-dose warfarin compared with aspirin/low-dose warfarin; there was no difference in major hemorrhage (5 patients versus 6 patients, respectively)." | 9.15 | Warfarin in atrial fibrillation patients with moderate chronic kidney disease. ( Asinger, RW; Hart, RG; Herzog, CA; Pearce, LA, 2011) |
| "Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage." | 9.15 | Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011) |
| "In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance." | 9.14 | Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. ( Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S, 2009) |
| "Adding clopidogrel to aspirin beyond 4 weeks post PCI is not associated with a significant increase in the overall rate of major or minor bleeding, although it is associated with an increase in major gastrointestinal bleeding in the year after a PCI." | 9.14 | Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. ( Aronow, HD; Berger, PB; Brennan, DM; Steinhubl, SR; Topol, EJ, 2009) |
| "Mechanical reperfusion with stenting for ST-elevation myocardial infarction (STEMI) is supported by dual antiplatelet treatment with aspirin and clopidogrel." | 9.14 | Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. ( Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Murphy, SA; Wiviott, SD, 2009) |
| "Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead." | 9.14 | Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009) |
| " Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding." | 9.14 | Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. ( Alexander, JH; Becker, RC; Bhatt, DL; Cools, F; Crea, F; Dellborg, M; Fox, KA; Goodman, SG; Harrington, RA; Huber, K; Husted, S; Lewis, BS; Lopez-Sendon, J; Mohan, P; Montalescot, G; Ruda, M; Ruzyllo, W; Verheugt, F; Wallentin, L, 2009) |
| "In this double-blind, dose-escalation, phase II study, undertaken at 297 sites in 27 countries, 3491 patients stabilised after an acute coronary syndrome were stratified on the basis of investigator decision to use aspirin only (stratum 1, n=761) or aspirin plus a thienopyridine (stratum 2, n=2730)." | 9.14 | Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. ( Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A, 2009) |
| "The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI." | 9.14 | Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009) |
| "We randomly assigned a total of 400 patients with ST-segment elevation myocardial infarction referred for primary percutaneous coronary intervention to treatment initiated before cardiac catheterization, with either heparin plus eptifibatide (201 patients) or heparin alone (199 patients), in addition to oral aspirin (160 mg) and high-dose clopidogrel (600 mg)." | 9.14 | Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi ( Froeschl, M; Glover, CA; Jadhav, S; Kass, M; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, ER; So, DY; Thomas, A; Turek, M; Wells, GA, 2009) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 9.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "In CHARISMA, there was an increased risk of bleeding with long-term clopidogrel." | 9.14 | Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR ( Berger, PB; Bhatt, DL; Brennan, DM; Fox, KA; Fuster, V; Hacke, W; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2010) |
| " Major hemorrhages were observed more frequently in the combination (warfarin plus low-dose aspirin) therapy group than in the warfarin monotherapy group." | 9.14 | [Recurrent thromboses and hemorrhagic complications in patients with antiphospholipid syndrome during therapy with warfarin plus aspirin]. ( Aleksandrova, EN; Kondrat'eva, LV; Kovalenko, TF; Ostriakova, EV; Patrushev, LI; Patrusheva, NL; Reshetniak, TM, 2010) |
| "In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke." | 9.14 | Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010) |
| "Atrial fibrillation (AF) associated to rheumatic mitral valve disease (RMVD) increases the incidence of thromboembolism (TE), with warfarin being the standard therapy, in spite of difficulties in treatment adherence and therapeutic control." | 9.14 | Warfarin or aspirin in embolism prevention in patients with mitral valvulopathy and atrial fibrillation. ( Bôer, BN; Grinberg, M; Lavitola, Pde L; Oliveira, WA; Sampaio, RO; Spina, GS; Tarasoutchi, F, 2010) |
| " The Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) study was undertaken to evaluate whether the addition of clopidogrel to aspirin inhibits SVG disease after coronary artery bypass grafting, as assessed at 1 year by intravascular ultrasound." | 9.14 | Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. ( Delarochelliere, R; Kulik, A; Le May, MR; Mesana, TG; Naidoo, S; Ruel, M; Tardif, JC; Voisine, P; Wells, GA, 2010) |
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 9.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "To investigate the efficacy of intracoronary tirofiban during primary percutaneous coronary intervention (PCI) for patients with acute coronary syndrome (ACS)." | 9.13 | Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome. ( Chen, SW; Huang, LP; Huang, WG; Wang, LX; Wei, JR; Wu, TG; Zhao, J; Zhao, Q, 2008) |
| "Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)." | 9.13 | Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008) |
| "The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade." | 9.13 | The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008) |
| "Using combined data from the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO I) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) trials (n=48 422 ST-elevation myocardial infarction patients), we compared the association between initial aspirin dose of 162 versus 325 mg and 24-hour and 7-day mortality, as well as rates of in-hospital moderate/severe bleeding." | 9.13 | Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. ( Armstrong, PW; Berger, JS; Califf, RM; Granger, CB; Harrington, RA; Ohman, EM; Peterson, ED; Simes, RJ; Stebbins, A; Van de Werf, F; White, HD, 2008) |
| "Patients experiencing acute ischemic stroke or transient ischemic attack are commonly treated with clopidogrel and/or aspirin (mono- and dual-antiplatelet therapy) to minimize the risk for recurrent stroke." | 9.12 | Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attack: An overview of systematic reviews and meta-analysis. ( Huang, Z; Yang, Y; Zhang, X, 2021) |
| "Dual antiplatelet therapy (DAPT) with aspirin and ticagrelor or prasugrel is the mainstay of treatment for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI)." | 9.12 | Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials. ( Jhaj, R; Khandelwal, G; Najmi, A; Ray, A; Sadasivam, B, 2021) |
| "Although clopidogrel is a frequently used antiplatelet medication to treat and prevent atherothrombotic disease, clinicians must balance its clinical effectiveness with the potential side effect of bleeding." | 9.12 | Risk Factors for Bleeding and Clinical Ineffectiveness Associated With Clopidogrel Therapy: A Comprehensive Meta-Analysis. ( Duong, K; Eadon, MT; Fekete, K; Kenneally, A; Milway, E; Nguyen, KA; Oh, H; Schleyer, TK; Whipple, EC; Yoo, R, 2021) |
| "To comprehensively evaluate the clinical effects of low molecular weight heparin (LMWH) and aspirin for deep vein thrombosis (DVT) patients after orthopaedic surgery." | 9.12 | Low molecular weight heparin and aspirin for prevention of deep vein thrombosisafter orthopaedic surgery: a systematic review and meta-analysis. ( Chen, B; Hu, N, 2021) |
| "Dual anti-platelet therapy (DAPT) with aspirin and clopidogrel has been the mainstay of treatment for patients with acute coronary syndrome (ACS)." | 9.12 | Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis. ( Chen, L; Devi Shamloll, Y; Jiang, Z; Jin, J; Xiao, M; Zhuo, X, 2021) |
| "As compared to aspirin alone, short-term DAPT within 24 hours of high-risk transient ischemic attack or mild-moderate ischemic stroke reduces the risk of recurrent stroke at the expense of higher risk of major bleeding." | 9.12 | Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack: Meta-Analysis of Randomized Controlled Trials. ( Aggarwal, D; Arora, S; Bhatia, K; Hussain, Z; Jain, V; Qamar, A; Ricciardi, M; Tafur, A; Uberoi, G; Vaduganathan, M; Zhang, C, 2021) |
| "In patients with noncardioembolic mild stroke or high-risk transient ischemic attack, DAPT with aspirin and clopidogrel/ticagrelor is more effective than aspirin alone for recurrent stroke prevention with a small absolute increase in the risk of severe or moderate bleeding." | 9.12 | P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack. ( Fisher, M; Gu, HQ; Johnston, SC; Li, ZX; Wang, YJ; Xian, Y; Xiong, Y, 2021) |
| "Short-term aspirin therapy can lower the risk for venous thromboembolism (VTE) in high-risk patients, but whether the long-term use of low-dose aspirin reduces risk in healthy adults is uncertain." | 9.12 | Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. ( Buring, JE; Glynn, RJ; Goldhaber, SZ; Ridker, PM, 2007) |
| "Our goal was to compare the safety and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, with clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)." | 9.12 | Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri ( Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Peters, G; Scirica, BM; Storey, RF, 2007) |
| "Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention." | 9.12 | Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007) |
| "The use of aspirin for the prevention of thrombotic complications in polycythemia vera is controversial." | 9.11 | Efficacy and safety of low-dose aspirin in polycythemia vera. ( Barbui, T; Gisslinger, H; Kutti, J; Landolfi, R; Marchioli, R; Patrono, C; Tognoni, G, 2004) |
| "To evaluate whether long-term treatment with a fixed low dose of warfarin in combination with aspirin improves the prognosis compared with aspirin treatment alone after an acute myocardial infarction (AMI)." | 9.11 | Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study. ( Erhardt, L; Haglid Evander, M; Herlitz, J; Holm, J; Karlson, BW; Peterson, M, 2004) |
| "In patients 75 years of age or younger who have myocardial infarction with ST-segment elevation and who receive aspirin and a standard fibrinolytic regimen, the addition of clopidogrel improves the patency rate of the infarct-related artery and reduces ischemic complications." | 9.11 | Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. ( Braunwald, E; Cannon, CP; Claeys, MJ; Cools, F; Gibson, CM; Hill, KA; López-Sendón, JL; McCabe, CH; Montalescot, G; Sabatine, MS; Skene, AM; Theroux, P, 2005) |
| "At coronary angiography <48 hours after fibrinolytic therapy, 308 patients receiving aspirin and intravenous heparin had a patent infarct-related artery (Thrombolysis In Myocardial Infarction [TIMI] grade 3 flow)." | 9.10 | Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. ( Aengevaeren, WR; Brouwer, MA; Hertzberger, DP; Luijten, HE; Uijen, GJ; van Boven, AJ; van den Bergh, PJ; Veen, G; Verheugt, FW; Vromans, RP, 2002) |
| "Warfarin, in combination with aspirin or given alone, was superior to aspirin alone in reducing the incidence of composite events after an acute myocardial infarction but was associated with a higher risk of bleeding." | 9.10 | Warfarin, aspirin, or both after myocardial infarction. ( Abdelnoor, M; Arnesen, H; Erikssen, J; Hurlen, M; Smith, P, 2002) |
| "We performed a randomized, double-blind, multicenter study to test the efficacy of triflusal (600 mg/d) versus aspirin (325 mg/d) for prevention of vascular events in patients with stroke or transient ischemic attack (Triflusal versus Aspirin in Cerebral Infarction Prevention [TACIP])." | 9.10 | Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. ( Alvarez-Sabín, J; Ferro, JM; Jiménez, MD; Lago, A; Matías-Guiu, J; Melo, T; Torres, F, 2003) |
| "The anticoagulant, warfarin, and the antiplatelet agent, aspirin, have been shown to have similar benefits after myocardial infarction." | 9.10 | Warfarin and aspirin give more benefit than aspirin alone but also more bleeding after myocardial infarction. ( Doggrell, SA, 2003) |
| "To reduce the incidence of pre-eclampsia in nulliparous women, in accordance with the suggestion of a recent meta-analysis that low dose aspirin might decrease this incidence by more than half if used early enough in and at a sufficient dose during pregnancy (more than 75 mg)." | 9.10 | Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (Part 1). ( Biausque, S; Breart, G; Churlet, A; Goeusse, P; Lequien, P; Marquis, P; Parmentier, D; Puech, F; Subtil, D; Uzan, S, 2003) |
| "We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS)." | 9.10 | Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. ( Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F, 2003) |
| "We investigated intolerance and bleeding while on aspirin and aspirin discontinuation using 5337 post-acute coronary syndrome patients considered appropriate for chronic antiplatelet therapy who were randomly assigned to aspirin in SYMPHONY and 2nd SYMPHONY and followed for 94 (64,157) days." | 9.10 | Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation. ( Armstrong, PW; Bhapkar, MV; Califf, RM; Kandzari, DE; Kramer, JM; LaPointe, NM; Moliterno, DJ; Newby, LK; Verheugt, FW; White, HD, 2003) |
| "Both aspirin and warfarin when used alone are effective in the secondary prevention of vascular events and death after acute myocardial infarction." | 9.10 | Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. ( Brophy, MT; Ezekowitz, MD; Fiore, LD; Lu, D; Peduzzi, P; Sacco, J, 2002) |
| "In the Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation (AFASAK 2) Study, we studied the rate of bleeding events associated with the incidence of thromboembolic events in patients receiving warfarin sodium, 1." | 9.09 | Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. ( Gulløv, AL; Koefoed, BG; Petersen, P, 1999) |
| " From 1974 to 1986 we treated 20 symptomatic ET patients with microvascular circulation disturbances including erythromelalgia (N = 18), atypical or typical transient ischemic attacks (N = 6), or acute coronary ischemic syndrome (N = 3) with aspirin and one course of busulfan." | 9.09 | Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. ( Michiels, JJ, 1999) |
| " We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding." | 9.09 | Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000) |
| "The combination of aspirin with anticoagulant is associated with increased bleeding in elderly atrial fibrillation patients." | 9.09 | Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS). ( Chaumet-Riffaud, P; Derumeaux, G; Lacomblez, L; Lardoux, H; Lechat, P; Lecompte, T; Maillard, L; Mallet, A; Mas, JL; Mentre, F; Pisica, G; Pousset, F; Raynaud, P; Sanchez, P; Solbes-Latourette, S, 2001) |
| "Over two years, we found no difference between aspirin and warfarin in the prevention of recurrent ischemic stroke or death or in the rate of major hemorrhage." | 9.09 | A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. ( Adams, HP; Albers, GW; Furie, KL; Jackson, CM; Kistler, JP; Lazar, RM; Levin, B; Mohr, JP; Pettigrew, LC; Pullicino, P; Sacco, RL; Thompson, JL, 2001) |
| "A total of 114 patients with essential thrombocythemia (77 women and 37 men; median age, 68 years; range, 40 to 85) and a median platelet count of 788,000 per cubic millimeter (range, 533,000 to 1,240,000 per cubic millimeter) were randomly assigned to receive hydroxyurea (56 patients) or no myelosuppressive therapy (58 patients)." | 9.08 | Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. ( Barbui, T; Cortelazzo, S; Finazzi, G; Galli, M; Rodeghiero, F; Ruggeri, M; Vestri, O, 1995) |
| "Our purpose was to determine the frequency and safety of the use of epidural anesthesia and the correlation between bleeding time and maternal-neonatal bleeding complications in a group of pregnant women who participated in a multicenter trial of low-dose aspirin in pregnancy." | 9.08 | Low-dose aspirin in nulliparous women: safety of continuous epidural block and correlation between bleeding time and maternal-neonatal bleeding complications. National Institute of Child Health and Human Developmental Maternal-Fetal Medicine Network. ( Caritis, SN; McNellis, D; Shaw, K; Sibai, BM; Thom, E, 1995) |
| "To determine any benefits or risks, expressed in early childhood, of low dose aspirin treatment in pregnancies at high risk of complications due to pre-eclampsia or intrauterine growth retardation." | 9.08 | Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. CLASP collaborative group. ( , 1995) |
| "Aspirin is only modestly effective in the secondary prevention after cerebral ischemia." | 9.08 | A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. ( , 1997) |
| " We evaluated tirofiban, a specific inhibitor of the platelet glycoprotein IIb/IIIa receptor, in the treatment of unstable angina and non-Q-wave myocardial infarction." | 9.08 | Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. ( , 1998) |
| "The Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study was a randomized, controlled trial examining the following therapies: warfarin sodium, 1." | 9.08 | Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. ( Andersen, ED; Boysen, G; Godtfredsen, J; Gulløv, AL; Koefoed, BG; Pedersen, TS; Petersen, P, 1998) |
| "The Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial compared the efficacy and safety of intravenous hirudin with heparin as adjunctive therapy to thrombolysis and aspirin in patients with acute myocardial infarction." | 9.07 | Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. ( Antman, EM, 1994) |
| "Clinical trials have demonstrated a prophylactic role for aspirin in myocardial infarction and in unstable angina pectoris." | 9.07 | Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. ( Edvardsson, N; Jahnmatz, B; Juul-Möller, S; Omblus, R; Rosén, A; Sørensen, S, 1992) |
| "It has been suggested that desmopressin acetate has been effective in reducing hemorrhage after coronary artery bypass grafting in patients receiving aspirin before operation." | 9.07 | The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations. ( Ablaza, SG; Afshar, M; DeCastro, N; Gratz, I; Koehler, J; Larijani, GE; Olsen, D; Spagna, PM, 1992) |
| "Data from the early stages of the thrombosis prevention trial (TPT) have been used to establish and quantify the risk of extracranial bleeding due to low dose aspirin (75 mg) and low intensity oral anticoagulation with warfarin (international normalised ratio, INR, 1." | 9.07 | Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. ( Brennan, PJ; Kelleher, CC; Meade, TW; Roderick, PJ; Wilkes, HC, 1992) |
| "We report the results of the Heparin-Aspirin Reperfusion Trial, a collaborative study comparing early intravenous heparin with oral aspirin as adjunctive treatment when recombinant tissue plasminogen activator (rt-PA) is used for coronary thrombolysis during acute myocardial infarction." | 9.06 | A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. ( Chaitman, BR; Hamilton, WP; Hsia, J; Kleiman, N; Roberts, R; Ross, AM, 1990) |
| "Long-term low-dose warfarin therapy is highly effective in preventing stroke in patients with non-rheumatic atrial fibrillation, and can be quite safe with careful monitoring." | 9.06 | The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. ( Blewett, DR; Gress, DR; Hughes, RA; Kistler, JP; Maraventano, SW; Oertel, LB; Rosner, B; Sheehan, MA; Singer, DE, 1990) |
| "A randomized, controlled study was conducted in 51 patients to investigate the effect of aspirin administration on traumatic hyphema." | 9.06 | Aspirin and secondary bleeding after traumatic hyphema. ( Biedner, B; Lifshitz, T; Marcus, M; Yassur, Y, 1988) |
| "To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia." | 9.05 | Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020) |
| "To review the clinical evidence of the effect of aspirin as primary prevention for patients with diabetes mellitus and in healthy elderly." | 9.05 | Role of Aspirin for Primary Prevention in Persons with Diabetes Mellitus and in the Elderly. ( Baliga, RR; Patel, NJ, 2020) |
| "Benefits of aspirin administration on pre-eclampsia and IUGR depend on the gestational age and dose of aspirin administration." | 9.05 | Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses. ( Banach, M; Ghazanfarpour, M; Jamialahmadi, T; Sahebkar, A; Sathyapalan, T, 2020) |
| "The results of the THEMIS trial, conducted in DM patients with stable coronary artery disease and no prior stroke or myocardial infarction, showed that although ticagrelor in addition to aspirin reduced the risk of ischemic events, this was associated with a parallel increase in bleeding complications." | 9.05 | An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. ( Angiolillo, DJ; Calderone, D; Capodanno, D, 2020) |
| " The use of aspirin has been implicated in reducing VTE events and is potentially advantageous compared to other agents in respect to cost, access, route of administration and reduced adverse effects such as bleeding." | 9.01 | Aspirin for prevention of venous thromboembolism in recipients of major lower-limb orthopedic surgery: a systematic review of Level I evidence. ( Fletcher, JP; Hitos, K; Seagrave, KG, 2019) |
| "The analysis showed lower risks of major adverse cardiovascular or cerebrovascular events, recurrent stroke, and bleeding events for clopidogrel monotherapy compared to aspirin." | 9.01 | Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis. ( Del Aguila, M; Girotra, S; Hu, B; Ince, B; Jeng, JS; Kutluk, K; Liu, L; Lou, M; Min Han, J; Paciaroni, M; Paek, D; Parfenov, V; Wong, KSL; Zamani, B, 2019) |
| "The role for aspirin in cardiovascular primary prevention remains controversial, with potential benefits limited by an increased bleeding risk." | 9.01 | Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. ( Roddick, AJ; Zheng, SL, 2019) |
| "In the context of contemporary primary prevention guidelines, the effect of aspirin on myocardial infarction risk was significantly attenuated, whereas its major bleeding and hemorrhagic stroke complications were retained." | 9.01 | A Meta-Analysis of Aspirin for the Primary Prevention of Cardiovascular Diseases in the Context of Contemporary Preventive Strategies. ( Khan, B; Khan, SA; Latham, SB; Rao, SV; Shah, R, 2019) |
| "Although aspirin (ASA) is the mainstay of treatment for the prevention of recurrent ischemic stroke, the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial showed ASA monotherapy to be inferior to clopidogrel in preventing recurrent adverse cardiovascular outcomes in patients with high cardiac risks." | 9.01 | Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis. ( Ding, J; Xu, GM; Yuan, J, 2019) |
| " This article evaluates the preventive effects of rivaroxaban versus aspirin on venous thromboembolism (VTE) through meta-analysis of recent randomized controlled trials (RCTs)." | 9.01 | Rivaroxaban versus Aspirin in Prevention of Venous Thromboembolism: A Meta-Analysis of 9 Randomized Controlled Trials comprising 7,656 Patients. ( Deng, H; Jiang, M; Li, L; Lin, Y; Xie, J; Xie, X, 2019) |
| "A systematic electronic literature search was done in MEDLINE, EMBASE, and Cochrane CENTRAL Register of Controlled Trials for studies including published data of patients ≥18 years of age with nonvalvular atrial fibrillation, randomized to either VKAs or NOACs, or receiving aspirin therapy at any time during the study that report all-cause stroke or systemic embolism, vascular death, myocardial infarction, major bleeding, or intracranial hemorrhage as an outcome." | 8.98 | Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials. ( Bennaghmouch, N; Bode, K; Brueckmann, M; de Veer, AJWM; Dewilde, WJM; Kleine, E; Lip, GYH; Mahmoodi, BK; Ten Berg, JM, 2018) |
| "We aimed to estimate the effect of aspirin on the risk of placental abruption or antepartum hemorrhage in relation to gestational age at onset of therapy and the dosage of the drug." | 8.98 | Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage. ( Bujold, E; Nicolaides, KH; Roberge, S, 2018) |
| "To assess the effectiveness and safety of dual agent antiplatelet therapy combining clopidogrel and aspirin to prevent recurrent thrombotic and bleeding events compared with aspirin alone in patients with acute minor ischaemic stroke or transient ischaemic attack (TIA)." | 8.98 | Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis. ( Foroutan, F; Guyatt, G; Hao, Q; O'Donnell, M; Siemieniuk, RA; Tampi, M, 2018) |
| "While the use of aspirin in the secondary prevention of cardiovascular (CVD) is well established, aspirin in primary prevention is not systematically recommended because the absolute CV event reduction is similar to the absolute excess in major bleedings." | 8.95 | Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk. ( Battistoni, A; Coluccia, R; De Caterina, R; Gallo, G; Volpe, M, 2017) |
| " Whether aspirin ameliorates this risk in patients with established coronary artery disease undergoing cardiac or noncardiac surgery is unknown." | 8.95 | Clinical outcomes associated with per-operative discontinuation of aspirin in patients with coronary artery disease: A systematic review and meta-analysis. ( Cooper, CJ; Husnain, M; Kanjwal, Y; Khan, AR; Khan, MS; Khuder, SA; Luni, FK; Riaz, H; Riaz, IB; Riaz, T; Taleb, M, 2017) |
| "The relative bleeding risk of aspirin versus vitamin K antagonists (VKA) is unclear." | 8.95 | Meta-analysis of major bleeding events on aspirin versus vitamin K antagonists in randomized trials. ( Ambrosi, P; Daumas, A; Giorgi, R; Villani, P, 2017) |
| "Prior meta-analysis and observational studies have suggested that the bleeding risks associated with anticoagulation using vitamin K antagonists (VKA) or aspirin (ASA) are similar." | 8.93 | Risk of major bleeding in patients receiving vitamin K antagonists or low doses of aspirin. A systematic review and meta-analysis. ( Carrier, M; Gándara, E; Gonzalez, JP; LeGal, G; Vazquez, FJ, 2016) |
| "To evaluate the risk for serious bleeding with regular aspirin use in cardiovascular disease (CVD) primary prevention." | 8.93 | Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force. ( Burda, BU; Evans, CV; Guirguis-Blake, JM; Whitlock, EP; Williams, SB, 2016) |
| "Dual antiplatelet therapy (DAPT) with aspirin combined with either a thienopyridine (clopidogrel or prasugrel) or acyclopentyl-triazolo-pyrimidine (ticagrelor) plays a vital role in the management of acute coronary syndrome (ACS) especially in those undergoing percutaneous coronary intervention (PCI) but even those being managed medically." | 8.93 | Prasugrel hydrochloride for the treatment of acute coronary syndrome patients. ( Gershlick, AH; Gunarathne, A; Hussain, S, 2016) |
| "Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events." | 8.91 | Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. ( Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M, 2015) |
| "Clopidogrel, prasugrel, and ticagrelor are the currently available oral P2Y12 inhibitors for the treatment of ST-segment elevation myocardial infarction (STEMI), in association with aspirin." | 8.91 | Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? ( Guimarães, PO; Tricoci, P, 2015) |
| " A pooled analysis showed that dual therapy with clopidogrel and aspirin had a lower stroke incidence than monotherapy in both the short term and long term (RR = 0." | 8.91 | Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis. ( Chen, J; Ding, L; Hong, H; Huang, X; Ma, H; Tan, S; Xiao, X; Xu, R; Yang, S; Yu, S; Zhang, Z, 2015) |
| "Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel." | 8.91 | Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015) |
| "To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack." | 8.91 | [Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. ( Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015) |
| "We performed a meta-analysis to determine whether aspirin has a significant protective effect on risk of first thrombosis among patients with antiphospholipid antibodies (aPL+)." | 8.90 | Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. ( Amoura, Z; Arnaud, L; Balasch, J; Cervera, R; Erkan, D; Forastiero, R; Lambert, M; Martinez-Zamora, MA; Mathian, A; Pengo, V; Ruffatti, A; Tektonidou, M; Wahl, D; Zuily, S, 2014) |
| "The discovery of the antiplatelet effect of low-dose aspirin led to the hugely successful strategy of dual antiplatelet therapy in patients with acute coronary syndromes (ACS)." | 8.90 | Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes. ( Storey, RF; Thomas, MR, 2014) |
| "To compare venous thromboembolism (VTE) and bleeding rates in adult patients receiving aspirin versus anticoagulants after major lower extremity orthopedic surgery." | 8.90 | Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: a systematic review and meta-analysis. ( Chiang, WH; Drescher, FS; Larson, RJ; Lee, A; Morrison, DH; Sirovich, BE, 2014) |
| "Whether clopidogrel should be added to aspirin for stroke prevention remained controversial for the risk of hemorrhagic complications." | 8.90 | Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials. ( Chen, S; He, L; Li, H; Li, M; Li, Y; Peng, Y; Shen, Q; Tang, Y, 2014) |
| "While there is conclusive evidence that aspirin plays a role in reducing the risk of clinically relevant venous thromboembolism (VTE) arising in a number of surgical and non-surgical situations at risk, little is known of the potential of aspirin for the long/term prevention of recurrent VTE." | 8.89 | Aspirin and recurrent venous thromboembolism. ( Milan, M; Noventa, F; Prandoni, P, 2013) |
| "Given the high risk of stroke after TIA (transient ischemia attack) or stroke and the adverse reaction of bleeding of antiplatelets, we undertook a meta-analysis, reviewed randomized controlled trials (RCTs) comparing aspirin plus clopidogrel with aspirin alone to determine the efficacy and adverse reaction of bleeding of the two protocols in the prevention of stroke." | 8.89 | The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review. ( Hu, B; Huang, Y; Li, JY; Li, M; Mao, L; Xia, YP, 2013) |
| "To provide a pooled estimate of the bleeding risk from randomized controlled trials (RCTs) comparing warfarin and ASA at the dose ranges recommended in evidence-based guidelines." | 8.88 | Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis. ( Crowther, M; Donadini, MP; Lim, W; Spencer, FA; Warkentin, AE, 2012) |
| "Overt bleeding associated with low dose aspirin (LDA) is well-recognized, little attention is given to the possibility of association between LDA and occult bleeding, although this is known to occur in healthy volunteers." | 8.86 | Is there an association between low dose aspirin and anemia (without overt bleeding)? Narrative review. ( Derry, S; Gaskell, H; Moore, RA, 2010) |
| "Despite hundreds of clinical trials, the appropriate dose of aspirin to prevent myocardial infarction (MI) and stroke is uncertain." | 8.83 | Aspirin to prevent heart attack and stroke: what's the right dose? ( Dalen, JE, 2006) |
| "We sought to compare the risk of hemorrhage due to the low (<100 mg), moderate (100 to 200 mg), and high (>200 mg) doses of aspirin (acetylsalicylic acid [ASA]) in 192,036 patients enrolled in 31 clinical trials." | 8.82 | Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. ( Baggish, JS; Berger, PB; Bhatt, DL; Malinin, AI; Serebruany, VL; Steinhubl, SR; Topol, EJ, 2005) |
| "In the secondary prevention of cardiovascular, cerebrovascular, and ischemic events, the evidence supports that the benefits of aspirin treatment significantly outweigh the risk of a major hemorrhage." | 8.82 | Risk of hemorrhagic stroke with aspirin use: an update. ( Gorelick, PB; Weisman, SM, 2005) |
| "After the acute coronary syndrome, adding warfarin to standard aspirin therapy decreases myocardial infarction and stroke but increases major bleeding." | 8.82 | Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. ( Celestin, C; Cook, JR; Fiore, LD; Lawler, E; Rothberg, MB, 2005) |
| "To compare the risk of vascular and bleeding events in patients with nonvalvular AF treated with vitamin K -inhibiting oral anticoagulants or acetylsalicylic acid (aspirin)." | 8.81 | Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. ( Chang, Y; Connolly, S; Hart, RG; Hellemons, B; Koudstaal, PJ; Laupacis, A; Petersen, P; Singer, DE; van Walraven, C, 2002) |
| "To determine the cardiovascular and coronary risk thresholds at which aspirin for primary prevention of coronary heart disease is safe and worthwhile." | 8.81 | Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. ( Ghahramani, P; Jackson, PR; Ramsay, LE; Sanmuganathan, PS; Wallis, EJ, 2001) |
| "To estimate the risk of myocardial infarction (MI) and death in patients with unstable angina who are treated with aspirin plus heparin compared with patients treated with aspirin alone." | 8.79 | Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. ( Grady, D; Oler, A; Oler, J; Whooley, MA, 1996) |
| " Indeed, few non-randomized studies previously showed an equivalent risk of bleeding in patients receiving aspirin therapy." | 8.31 | Risk of bleeding after percutaneous native kidney biopsy in patients receiving low-dose aspirin: a single-center retrospective study. ( Alfano, G; Bertolini, F; Cappelli, G; Cazzato, S; Donati, G; Fontana, F; Giaroni, F; Giovanella, S; Ligabue, G; Magistroni, R; Mori, G, 2023) |
| "In patients with ACS who were free from ischemic or major bleeding events during the first 3 months after PCI, the subsequent clopidogrel treatment might reduce minor bleeding events without increasing the risk of MACCE compared with ticagrelor." | 8.31 | Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China. ( Li, X; Lin, Y; Peng, W; Zhang, Y, 2023) |
| " We explored the outcomes of restarting aspirin use on secondary stroke and mortality in patients with chronic stroke 4 weeks after suffering from a TBI episode in Taiwan." | 8.31 | Risk of secondary stroke subsequent to restarting aspirin in chronic stroke patients suffering from traumatic brain injury in Taiwan. ( Chien, WC; Chou, CL; Chung, CH; Fann, LY; Hsu, YH; Sun, CA; Tang, SE; Wu, CC, 2023) |
| "This study evaluated the association among the plasma concentration of ticagrelor, ARC124910XX, aspirin, and salicylic acid with the risk of recent bleeding in patients with the acute coronary syndrome." | 8.31 | The Plasma Concentration of Ticagrelor and Aspirin as a Predictor of Bleeding Complications in Chinese Acute Coronary Syndrome Patients With Dual Antiplatelet Therapy: A Prospective Observational Study. ( Guo, BY; Hao, J; Liu, JM; Ren, JL; Sun, YQ; Wang, CC; Yang, XL; Zhang, XR; Zhao, JJ; Zhao, Q, 2023) |
| " Net adverse clinical events (a composite of cardiovascular death, myocardial infarction, stroke, or Bleeding Academic Research Consortium [BARC] bleeding type 2, 3, or 5) at 1 year post-PCI were compared between the de-escalation (clopidogrel plus aspirin) and the active control (ticagrelor plus aspirin) groups by HBR status, as defined by the modification of the Academic Research Consortium (ARC) criteria." | 8.31 | De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy. ( Ahn, SG; Ahn, Y; Chang, K; Cho, KH; Hong, YJ; Jeon, DS; Jeong, MH; Jeong, YH; Kim, HY; Kim, JH; Kim, MC; Lee, JW; Shin, ES; Sim, DS; Yoo, KD; Youn, YJ, 2023) |
| "Administration of aspirin for VTE prophylaxis, compared to other chemoprophylaxis agents may have an association with lower risk of major bleeding following TJA." | 8.12 | Aspirin Thromboprophylaxis Is Associated With Less Major Bleeding Events Following Total Joint Arthroplasty. ( Chisari, E; Goh, GS; Ludwick, L; Parvizi, J; Shohat, N; Streicher, S, 2022) |
| "The incidence of delayed posttraumatic intracranial hemorrhage (DH) in patients on anticoagulant (AC) and antiplatelet (AP) medications, especially with concurrent aspirin therapy, is not well established, with studies reporting disparate results with between 1-10% risk of DH and 0-3% mortality." | 8.12 | Increased relative risk of delayed hemorrhage in patients taking anticoagulant/antiplatelet medications with concurrent aspirin therapy: implications for clinical practice based on 3-year retrospective analysis in a large health system. ( Chang, W; Eisenmenger, L; Goldberg, M; Kulzer, M; Li, C; Sohn, A; Spearman, M; Tragon, T; Wanamaker, C; Weston, B; Yin, D, 2022) |
| "Aspirin has become the main agent for venous thromboembolism (VTE) prophylaxis following total knee arthroplasty (TKA)." | 8.12 | Aspirin Administered for Venous Thromboembolism Prophylaxis May Protect Against Stiffness Following Total Knee Arthroplasty. ( Chisari, E; Ludwick, L; Parvizi, J; Shohat, N; Sutton, R, 2022) |
| "The goal of this work was to investigate the short-term time-course benefit and risk of ticagrelor with aspirin in acute mild-moderate ischemic stroke or high-risk TIA in The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and ASA for Prevention of Stroke and Death (THALES) trial." | 8.12 | Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. ( Amarenco, P; Denison, H; Evans, SR; Himmelmann, A; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Li, H; Molina, CA; Pan, Y; Wang, Y, 2022) |
| "Patients diagnosed with acute coronary syndrome and receiving dual antiplatelet therapy (aspirin and ticagrelor) were enrolled and followed up for 12 months." | 8.12 | Association between ticagrelor plasma concentration and bleeding events in Chinese patients with acute coronary syndrome. ( Hu, F; Qi, G; Wang, P; Xing, Y; Yang, J; Zhang, X, 2022) |
| " This study set out to evaluate the prevalence of low platelet reactivity in patients with acute myocardial infarction treated with ticagrelor and aspirin." | 8.12 | Low platelet reactivity in patients with myocardial infarction treated with aspirin plus ticagrelor. ( Costa, TGR; Franken, M; Guerra, JCC; Katz, M; Lemos Neto, PA; Pesaro, AEP, 2022) |
| "Bleeding is the most common adverse reaction to aspirin and can lead to drug discontinuation or even be life-threatening in the secondary prevention of stroke or transient ischemic attack." | 8.12 | Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients. ( Cheng, J; Deng, X; Li, H; Ma, Y; Shi, T; Wang, X; Wu, Y; Zhang, Z; Zhu, Q, 2022) |
| "The patient developed acute profound thrombocytopenia following eptifibatide administration." | 8.12 | Eptifibatide-induced acute profound thrombocytopenia: A case report. ( Al Kindi, DI; Al-Mashdali, A; Alamin, MA; Elshaikh, EA; Othman, F, 2022) |
| "The coprescription of an angiotensin-converting enzyme inhibitor (ACEi) with clopidogrel reportedly increases bleeding risk." | 8.02 | Bleeding associated with co-administration of clopidogrel and ACEi in patients undergoing PCI and DAPT. ( Chang, SH; Chen, SW; Huang, YT; Kuo, CC; Kuo, CF; Tu, HT; Wang, CL; Wen, MS; Wu, VC, 2021) |
| "This study assessed the efficacy and safety of tirofiban in combination with dual-antiplatelet therapy (DAPT) in progressive ischemic stroke." | 8.02 | Assessing the Efficacy and Safety of Tirofiban in Combination With Dual-antiplatelet Therapy in Progressive Ischemic Stroke Patients. ( Chang, W; Li, L; Lin, F; Liu, H; Yin, J; Zhang, H; Zhao, Y, 2021) |
| "A total of 351 patients with ACS were treated with clopidogrel and aspirin for at least 12 months; we recorded major adverse cardiovascular events (MACE) or bleeding within 1 year." | 8.02 | Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study. ( Bai, H; Li, H; Li, Y; Liu, W; Sun, L; Wang, T; Wu, J; Yu, A; Yu, L; Zhu, W, 2021) |
| "Patients treated with ticagrelor and aspirin usually suffer from bleeding events, especially mild bleeding which is one of the main factors reducing patients' adherence to ticagrelor." | 7.96 | Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75-100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study. ( Chen, R; Chen, Y; Li, J; Liu, C; Sheng, Z; Song, L; Tan, Y; Yan, H; Zhao, H; Zhou, J; Zhou, P, 2020) |
| "Aspirin reduced the risks of MACCE and cancer without increasing the bleeding risk in elderly Koreans with hypertension, T2DM, or dyslipidemia." | 7.96 | Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea. ( Jung, M; Lee, S, 2020) |
| "The RE-DUAL PCI trial reported that dabigatran dual therapy (110/150 mg twice daily, plus clopidogrel or ticagrelor) reduced bleeding events versus warfarin triple therapy (warfarin plus aspirin and clopidogrel or ticagrelor) in patients with atrial fibrillation who underwent percutaneous coronary intervention, with noninferiority in composite thromboembolic events." | 7.96 | Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percut ( Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Kimura, T; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2020) |
| " Despite the modified dose, bleeding events were higher among patients receiving low-dose prasugrel than among patients receiving clopidogrel, with no difference in ischemic events between the 2 groups." | 7.96 | Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. ( Fukuda, K; Heidenreich, PA; Ikemura, N; Kohsaka, S; Numasawa, Y; Sandhu, AT; Sawano, M; Shiraishi, Y; Shoji, S; Suzuki, M; Ueno, K, 2020) |
| "Although potent P2Y12 inhibitor-based dual antiplatelet therapy (DAPT) has replaced clopidogrel-based therapy as the standard treatment in patients with acute myocardial infarction (AMI), there is a concern about the risk of bleeding in East Asian patients." | 7.96 | Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention. ( Byun, JK; Cha, J; Choi, BG; Choi, CU; Choi, JY; Choi, SY; Jang, WY; Jeong, MH; Kang, DO; Kim, EJ; Kim, JS; Kim, W; Na, JO; Oh, DJ; Park, CG; Park, Y; Rha, SW; Roh, SY; Seo, HS, 2020) |
| "Concomitant aspirin and anticoagulation in critically ill surgical patients was associated with an increased rate of major bleeding." | 7.96 | Concomitant Aspirin and Anticoagulation Is Associated With Increased Risk for Major Bleeding in Surgical Patients Requiring Postoperative Intensive Care. ( Gajic, O; Hanson, A; Johnson, MQ; Rayes, HA; Schulte, PJ; Subat, YW; Trivedi, V; Warner, MA; Weister, T, 2020) |
| "We aimed to evaluate the risk of major bleeding in non-surgical critically ill patients who received aspirin in conjunction with therapeutic anticoagulation (concomitant therapy) compared to those who received therapeutic anticoagulation alone." | 7.96 | Risk of major bleeding associated with aspirin use in non-surgical critically ill patients receiving therapeutic anticoagulation. ( Evans, K; Gajic, O; Hanson, AC; Johnson, MQ; Rayes, H; Schulte, PJ; Subat, YW; Trivedi, V; Warner, MA; Weister, T, 2020) |
| "Among older patients with cancer, aspirin was associated with lower VTE incidence and overall inhospital mortality without significantly increased bleeding." | 7.96 | Aspirin Is Associated With Reduced Rates of Venous Thromboembolism in Older Patients With Cancer. ( Cai, P; Dixon, RAF; Hadley, M; Li, M; Li, P; Liu, EY; Liu, Q; Ning, Y; Pan, S; Siddiqui, AD; Wu, F, 2020) |
| "In this observational analysis of patients with atrial fibrillation and flutter, the concomitant use of direct oral anticoagulants and aspirin was associated with an increased risk of both major adverse cardiac and bleeding events when compared to the use of direct oral anticoagulants alone." | 7.96 | Concomitant use of direct oral anticoagulants and aspirin versus direct oral anticoagulants alone in atrial fibrillation and flutter: a retrospective cohort. ( George, J; Hafeez, A; Halalau, A; Keeney, S; Matka, M; Said, A, 2020) |
| "Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial." | 7.96 | Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC, 2020) |
| "The purpose of this meta-analysis is to compare the efficacy and safety of aspirin and rivaroxaban in the prevention of venous thromboembolism (VTE) following either total knee arthroplasty or total hip arthroplasty." | 7.96 | Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty: A protocol for meta-analysis. ( Le, G; Luo, H; Tang, J; Xi, L; Yang, C; Zhang, M; Zhao, J, 2020) |
| "All acute coronary syndrome patients from the REgistry of New Antiplatelets in patients with Myocardial Infarction (RENAMI) undergoing percutaneous coronary intervention and treated with aspirin, prasugrel or ticagrelor were stratified according to DAPT duration, that is, shorter than 12 months (D1 group), 12 months (D2 group) and longer than 12 months (D3 group)." | 7.96 | Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. ( Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Bertaina, M; Blanco, PF; Boccuzzi, G; Bongiovanni, F; Cequier, A; Cerrato, E; D'Ascenzo, F; Dominguez-Rodriguez, A; Durante, A; Fernández, MC; Fioravanti, F; Gaita, F; Gallo, D; Garay, A; Gili, S; Grosso, A; Iñiguez-Romo, A; Kinnaird, T; Lüscher, TF; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Omedè, P; Paz, RC; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rinaldi, M; Rognoni, A; Taha, S; Templin, C; Valdés, M; Varbella, F; Velicki, L; Xanthopoulou, I, 2020) |
| "Whether the benefits of aspirin for the primary prevention of cardiovascular disease (CVD) outweigh its bleeding harms in some patients is unclear." | 7.91 | Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention: A Benefit-Harm Analysis. ( Choi, YH; Grey, C; Harwood, M; Jackson, R; Kerr, A; Mehta, S; Poppe, K; Pylypchuk, R; Selak, V; Wells, S; Wu, B, 2019) |
| "Many prognostic models for cardiovascular risk can be used to estimate aspirin's absolute benefits, but few bleeding risk models are available to estimate its likely harms." | 7.91 | Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Cohort Study. ( Grey, C; Harwood, M; Jackson, R; Kerr, A; Mehta, S; Poppe, K; Pylypchuk, R; Selak, V; Wells, S; Wu, B, 2019) |
| "Compared with warfarin monotherapy, receipt of combination warfarin and aspirin therapy was associated with increased bleeding and similar observed rates of thrombosis." | 7.91 | Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events. ( Almany, SL; Barnes, GD; Froehlich, JB; Gu, X; Haymart, B; Kaatz, S; Kline-Rogers, E; Kozlowski, JH; Krol, GD; Li, Y; Schaefer, JK; Sood, SL; Souphis, NM, 2019) |
| "The risks of venous thromboembolism (VTE) and bleeding with direct oral anticoagulants (DOACs) and aspirin for thromboprophylaxis after orthopedic surgery were studied." | 7.91 | Direct oral anticoagulants versus aspirin for venous thromboembolism prophylaxis after orthopedic surgery. ( Muntz, J; Murillo, M; Putney, D; Vadhariya, A; Wilson, A; Yang, T, 2019) |
| "In PEGASUS-TIMI 54, ticagrelor significantly reduced the risk of the composite of major adverse cardiovascular (CV) events by 15-16% in stable patients with a prior myocardial infarction (MI) 1-3 years earlier." | 7.91 | Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. ( Ardissino, D; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Dellborg, M; Hamm, C; Himmelmann, A; Im, KA; Johanson, P; Kamensky, G; Kiss, RG; Kontny, F; Lopez-Sendon, J; Montalescot, G; Oude Ophuis, T; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Van de Werf, F, 2019) |
| "Background Dual antithrombotic therapy comprising a vitamin K antagonist (VKA) plus clopidogrel reduces the incidence of major bleeding compared with triple therapy (VKA + clopidogrel + aspirin) in acute coronary syndrome (ACS) patients with atrial fibrillation (AF), with a similar thrombotic risk." | 7.88 | Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation. ( Bonello, L; Camoin-Jau, L; Gaubert, M; Laine, M; Paganelli, F; Resseguier, N, 2018) |
| "Aspirin is an effective prophylaxis for venous thromboembolism (VTE) after total knee arthroplasty (TKA)." | 7.88 | Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty. ( Barsoum, WK; Brigati, DP; Faour, M; Higuera, CA; Klika, AK; Mont, MA; Piuzzi, NS, 2018) |
| " The aim of this pilot prospective study was to evaluate 12-month cardiovascular outcomes in elderly patients with acute coronary syndrome (ACS) receiving dual antiplatelet therapy (aspirin and clopidogrel) according to the clustering of CYP2C19 and ABCB1 genetic variants." | 7.88 | Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel. ( Antonicelli, R; Cecchini, S; Di Pillo, R; Galeazzi, R; Giovagnetti, S; Malatesta, G; Montesanto, A; Olivieri, F; Rose, G; Spazzafumo, L, 2018) |
| "This study aimed to estimate the risk of bleeding following minor oral surgical procedures and uninterrupted aspirin therapy in high-risk patients or patients with existing chronic diseases compared to patients who did not use aspirin during minor oral surgery at a public hospital." | 7.85 | Risk of Hemorrhage Attributed to Underlying Chronic Diseases and Uninterrupted Aspirin Therapy of Patients Undergoing Minor Oral Surgical Procedures: A Retrospective Cohort Study. ( Limsawan, S; Rojanaworarit, C, 2017) |
| "Antiplatelet therapy with ticagrelor in patients with acute ischemic stroke or transient ischemic attack showed a bleeding profile similar to that of aspirin for major bleeds." | 7.85 | Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcome ( Albers, GW; Amarenco, P; Aunes, M; Bokelund-Singh, S; Denison, H; Easton, JD; Evans, SR; Held, P; Jahreskog, M; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| "Adjusted survival curves showed that the usage of aspirin was not associated with ischemic stroke, hospitalization for bleeding events, cardiovascular mortality or all-cause mortality, however, it was significantly associated with renal failure." | 7.85 | Different impact of aspirin on renal progression in patients with predialysis advanced chronic kidney disease with or without previous stroke. ( Chang, HR; Hsiao, KC; Huang, JY; Hung, TW; Lee, CT; Liaw, YP, 2017) |
| "To determine if patient aspirin exposure and timing affect bleeding risk after renal allograft biopsy." | 7.85 | Effects of Aspirin Therapy on Ultrasound-Guided Renal Allograft Biopsy Bleeding Complications. ( Atwell, TD; Baffour, FI; Dean, PG; Gunderson, TM; Hickson, LJ; Kurup, AN; Park, WD; Schmit, GD; Schmitz, JJ; Stegall, MD, 2017) |
| "To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)." | 7.85 | State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017) |
| "We conducted a post hoc ancillary analysis of clinically relevant bleeding and major bleeding events among 2293 patients receiving warfarin therapy in the AMADEUS trial." | 7.83 | Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. ( Lane, DA; Lip, GY; Proietti, M; Senoo, K, 2016) |
| " Our results suggest that this strategy is not beneficial as compared to aspirin alone in terms of ischaemic or bleeding events." | 7.83 | Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). ( Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O, 2016) |
| "The USPSTF recommends initiating low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years." | 7.83 | Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. ( Bibbins-Domingo, K, 2016) |
| "This was a retrospective study to determine if there was a higher risk of bleeding in patients on aspirin undergoing therapeutic bronchoscopy compared with those not on aspirin." | 7.83 | Aspirin use and the risk of bleeding complications after therapeutic bronchoscopy. ( Alraiyes, AH; Attwood, K; Dhillon, SS; Harris, K; Kebbe, J; Kumar, A; Modi, K, 2016) |
| "The TRA 2°P-TIMI 50 trial showed the addition of vorapaxar to standard care (SC) antiplatelet therapy reduced the combined risk of death, myocardial infarction (MI), and stroke, while exhibiting an increase in moderate, but not other bleeding events." | 7.83 | A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. ( Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD, 2016) |
| "A higher loading dose of aspirin (160-325 mg) can be beneficial in treating acute ischemic stroke, although there is an increased risk of minor bleeding." | 7.83 | To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes. ( Chan, YL; Lee, JD; Lee, M; Lee, TH; Lin, LC; Su, TH; Wen, YW, 2016) |
| "To evaluate the efficacy and safety of well-managed warfarin therapy in patients with nonvalvular AF, the risk of complications, especially intracranial bleeding, in patients with concomitant use of aspirin, and the impact of international normalized ratio (INR) control." | 7.83 | Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. ( Björck, F; Lip, GY; Renlund, H; Själander, A; Svensson, PJ; Wester, P, 2016) |
| "Aspirin use at baseline was associated with an increased risk for bleeding and all-cause death in ROCKET AF, a risk most pronounced in patients without known CAD." | 7.83 | Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. ( Becker, RC; Berkowitz, SD; Breithardt, G; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, A; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Shah, R; Singer, DE, 2016) |
| "Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin)." | 7.81 | Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. ( Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015) |
| "Aspirin use increased among Chinese patients newly diagnosed with AF, with no relationship to the patient's stroke or bleeding risk." | 7.81 | Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation. ( Guo, Y; Lip, GYH; Tian, Y; Wang, H; Wang, Y, 2015) |
| "Current guidelines recommend ticagrelor, in addition to aspirin, for patients with non-ST-segment elevation acute coronary syndromes at moderate to high-risk regardless of initial therapeutic strategy." | 7.81 | Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes. ( Aspromonte, N; Caldarola, P; Chiatto, M; Iacoviello, M; Monitillo, F; Valle, R, 2015) |
| "Despite evidence that preoperative aspirin improves outcomes in cardiac surgery, recommendations for aspirin use are inconsistent due to aspirin's anti-platelet effect and concern for bleeding." | 7.81 | The Effect of Aspirin on Bleeding and Transfusion in Contemporary Cardiac Surgery. ( Berguson, MW; Bowen, JE; Daskalakis, C; Diehl, JT; Goldhammer, JE; Marhefka, GD; Sun, J, 2015) |
| " During the beginning of warfarin treatment, INR must be assessed regularly in order to optimize treatment and minimize the risk for hemorrhage." | 7.81 | [INTERNATIONAL NORMALIZED RATIO VALUES AND HEMORRHAGE IN HOSPITALIZED PATIENTS STARTING WARFARIN THERPY: AN OBSERVATIONAL STUDY]. ( Abadi, U; Ellis, MH, 2015) |
| "In patients with both stable coronary disease and atrial fibrillation, a baseline treatment of aspirin and an oral anticoagulant is often prescribed due to the proven benefits of each therapy on cardiovascular and thromboembolic events and mortality." | 7.81 | [Long term aspirin in stable coronary disease with an indication for anticoagulation: is it reasonable?]. ( Lister, K; Louis Simonet, M, 2015) |
| " We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population." | 7.80 | Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. ( Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C, 2014) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 7.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| " Apixaban is an oral anticoagulant that has demonstrated better efficacy than warfarin and aspirin in the ARISTOTLE and AVERROES studies, respectively, and causes less bleeding than warfarin." | 7.80 | Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. ( Dorian, P; Hernandez, L; Iloeje, U; Kongnakorn, T; Kuznik, A; Lanitis, T; Lip, GY; Liu, LZ; Phatak, H; Rublee, DA, 2014) |
| "Combined anticoagulant and aspirin therapy is associated with increased bleeding risk in patients with atrial fibrillation, but the bleeding risk of combined use of anticoagulant and nonsteroidal anti-inflammatory drugs (NSAIDs) is poorly documented." | 7.80 | Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. ( Brighton, TA; Davidson, BL; Gebel, M; Lensing, AW; Lyons, RM; Prins, MH; Rehm, J; Verheijen, S, 2014) |
| "Aspirin for the primary prevention of coronary heart disease (CHD) is only recommended for individuals at high risk for CHD although the majority of CHD events occur in individuals who are at low to intermediate risk." | 7.80 | Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. ( Blaha, MJ; Blankstein, R; Budoff, MJ; Duprez, DA; Folsom, AR; Greenland, P; Miedema, MD; Misialek, JR; Nasir, K; Silverman, MG, 2014) |
| "The present study compared the effects of frequently used anti-platelet drugs, such as clopidogrel, ticlopidine, and cilostazol, on the gastric bleeding and ulcerogenic responses induced by intraluminal perfusion with 25 mM aspirin acidified with 25 mM HCl (acidified ASA) in rats." | 7.80 | Comparative effects of the anti-platelet drugs, clopidogrel, ticlopidine, and cilostazol on aspirin-induced gastric bleeding and damage in rats. ( Izuhara, C; Takayama, S; Takeuchi, K, 2014) |
| "Evidence indicates that vitamin K antagonists (VKAs) and oral anticoagulant therapy are under-utilised for stroke prevention in patients with non-valvular atrial fibrillation (AF), and patients who decline or cannot tolerate such treatment are often prescribed aspirin instead." | 7.80 | Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium. ( Annemans, L; Kongnakorn, T; Lanitis, T; Lieven, A; Marbaix, S; Thijs, V, 2014) |
| " The risks of suffering ischemic stroke, bleeding, or death with warfarin, aspirin, or no antithrombotic treatment during 2010 were related to CHA2DS2VASc scores, age, and complicating co-morbidities." | 7.80 | Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. ( Forslund, T; Hasselström, J; Hjemdahl, P; von Euler, M; Wändell, P; Wettermark, B, 2014) |
| "Aim of this multicenter retrospective study was assessment of effect of intracoronary administration of tirofiban loading dose in troponin positive patients with acute coronary syndrome (ACS)." | 7.79 | [Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome]. ( Arystanova, AZh; Balli, M; Batyraliev, TA; Fettser, DV; Kagliian, KÉ; Samko, AN; Serchelik, A; Sidorenko, BA; Tekin, K; Turkmen, S, 2013) |
| "The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear." | 7.79 | Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013) |
| "We examined the effect of local administration of tranexamic acid( TA) on reducing aspirin-induced bleeding in off-pump coronary artery bypass grafting(CABG)." | 7.79 | [Can local administration of tranexamic acid reduce aspirin-induced bleeding in off-pump coronary artery bypass grafting( CABG) ?]. ( Aoki, M; Baba, H; Goto, Y; Ogawa, S; Okawa, Y, 2013) |
| "the primary prevention of ischaemic stroke in chronic non-valvular atrial fibrillation (AF) typically involves consideration of aspirin or warfarin." | 7.78 | Aspirin versus warfarin in atrial fibrillation: decision analysis may help patients' choice. ( O'Shea, D; Romero-Ortuno, R, 2012) |
| "Compared with aspirin, apixaban reduces stroke risk in atrial fibrillation (AF) patients unsuitable for warfarin by 63% but does not increase major bleeding." | 7.78 | Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. ( Anglade, MW; Coleman, CI; Hagstrom, K; Kluger, J; Lee, S; Meng, J, 2012) |
| ", drug-adverse event pairs, found in 1,644,220 AERs from 2004 to 2009, 736 adverse events were listed as warfarin-associated adverse events, and 147 of the 736 were bleeding complications, including haemorrhage and haematoma." | 7.78 | Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS. ( Kadoyama, K; Okuno, Y; Sakaeda, T; Tamura, T, 2012) |
| "Aspirin is an antiplatelet drug widely used for the prevention of cardiovascular disease; however, it is known to increase bleeding events." | 7.78 | Impact of platelet reactivity on long-term clinical outcomes and bleeding events in Japanese patients receiving antiplatelet therapy with aspirin. ( Higashi, T; Horiuchi, H; Ikeda, T; Kawato, M; Kimura, T; Kita, T; Kondo, H; Shirakawa, R; Tabuchi, A; Takahashi, K; Tamura, T; Taniguchi, R; Toma, M; Watanabe, H; Watanabe, S; Yamane, K; Yoshikawa, Y, 2012) |
| "To determine whether patients undergoing transrectal ultrasound (TRUS)-guided prostate biopsy with increased sampling numbers are more likely to experience bleeding complications and whether warfarin or low-dose aspirin are independent risk factors." | 7.78 | Should warfarin or aspirin be stopped prior to prostate biopsy? An analysis of bleeding complications related to increasing sample number regimes. ( Abbas, A; Chowdhury, R; Hoy, A; Idriz, S; Rutherford, EE; Smart, JM, 2012) |
| "Comparing a patient's bleeding symptoms with those of healthy individuals is an important component of the diagnosis of bleeding disorders, but little is known about whether bleeding symptoms in healthy individuals vary by sex, race, ethnicity, age, or aspirin use." | 7.77 | Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults. ( Barbour, EM; Coller, BS; Khalida, C; Khazanov, NA; Levenkova, N; Mauer, AC; Tian, S; Tobin, JN, 2011) |
| " Triple therapy (OAC, clopidogrel plus aspirin) was associated with four times higher risk of any bleeding than OAC plus aspirin, adj." | 7.77 | Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome. ( Hofman-Bang, C; Lagerqvist, B; Lindbäck, J; Persson, J; Samnegard, A; Stenestrand, U, 2011) |
| "AIMS Immediate treatment with a loading dose of clopidogrel at diagnosis of ST-segment elevation myocardial infarction (STEMI) is recommended by ESC/AHA/ACC guidelines in patients eligible for primary percutaneous coronary intervention (PCI)." | 7.77 | Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Scherstén, F; Smith, JG, 2011) |
| " We sought to determine if carbon monoxide-releasing molecule-2 [tricarbonyldichlororuthenium (II) dimer, CORM-2] would improve coagulation in rabbit plasma in vitro via thrombelastography and in an in vivo preclinical rabbit model of ear bleeding time following administration of clopidogrel (20 mg/kg) with aspirin (10 mg/kg) via gavage." | 7.77 | Carbon monoxide-releasing molecule-2 enhances coagulation in rabbit plasma and decreases bleeding time in clopidogrel/aspirin-treated rabbits. ( Arkebauer, MR; Chawla, N; Gomes, SB; Mangla, D; Nielsen, VG; Sadacharam, K; Vosseller, K; Wasko, KA, 2011) |
| " The incidence of bleeding in patients taking aspirin within 10 days before biopsy was 0." | 7.76 | Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin. ( Atwell, TD; Callstrom, MR; Charboneau, JW; Harmsen, WS; Hesley, GK; Schleck, CD; Smith, RL; Welch, TJ, 2010) |
| "Aspirin plus clopidogrel (A+C) may be more effective than aspirin only (AO) acutely after TIA and minor stroke, but the risk of bleeding in the acute phase is uncertain." | 7.76 | Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke. ( Buchan, AM; Chandratheva, A; Geraghty, OC; Kennedy, J; Marquardt, L; Rothwell, PM, 2010) |
| "Combined antiplatelet agents (cAPA), aspirin plus clopidogrel, increase the risk of bleeding." | 7.76 | Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel. ( Bachelot-Loza, C; Dizier, B; Emmerich, J; Gaussem, P; Godier, A; Grelac, F; Hindy-François, C; Le Bonniec, B; Samama, CM, 2010) |
| "In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding." | 7.76 | Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010) |
| "Dual antiplatelet therapy (DAT) with clopidogrel plus aspirin is a well-established antithrombotic strategy, with hemorrhage being the chief adverse event (AE) of concern." | 7.76 | National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. ( Budnitz, DS; Kegler, SR; Shehab, N; Sperling, LS, 2010) |
| "Data regarding the influence of dose and duration of aspirin use on risk of gastrointestinal bleeding are conflicting." | 7.76 | A prospective study of aspirin use and the risk of gastrointestinal bleeding in men. ( Chan, AT; Ho, WW; Huang, ES; Lee, SS; Strate, LL, 2010) |
| "Combinations of aspirin, clopidogrel, and vitamin K antagonists are widely used in patients after myocardial infarction." | 7.75 | Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. ( Abildstrom, SZ; Andersson, C; Gislason, GH; Hansen, ML; Hansen, PR; Hvelplund, A; Jørgensen, C; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2009) |
| "The aim of this article is to examine whether clopidogrel and ticlopidine treatments produce similar clinical outcomes for patients receiving primary stenting for acute myocardial infarction (AMI)." | 7.74 | Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. ( Brener, M; Carroll, JD; Cox, DA; Cristea, E; Garcia, E; Grines, CL; Guagliumi, G; Lansky, AJ; Leon, MB; Mehran, R; Moses, J; Pietras, C; Rutherford, BD; Stone, GW; Stuckey, T; Tcheng, JE; Tsuchiya, Y; Turco, M, 2008) |
| "Patients with cancer who have thrombocytopenia may experience acute coronary syndromes (ACS), and the use of aspirin (ASA) poses an increased risk of bleeding." | 7.74 | Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. ( Botz, G; Champion, JC; Durand, JB; Hirch-Ginsburg, C; Lakkis, N; Lenihan, DJ; Sarkiss, MG; Shaw, AD; Swafford, J; Warneke, CL; Yusuf, SW, 2007) |
| "To characterize the safety of concomitant aspirin, clopidogrel, and warfarin therapy after percutaneous coronary intervention (PCI), and to identify patient characteristics that increase the risk of hemorrhage." | 7.74 | Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. ( Andrel, J; Chervoneva, I; DeCaro, M; DeEugenio, D; Duong, P; Greenspon, A; Kolman, L; Lam, L; Lee, G; McGowan, C; Ruggiero, N; Singhal, S, 2007) |
| "Clopidogrel, with or without aspirin, does not increase bleeding complications after TBLB in healthy pigs." | 7.73 | Effect of clopidogrel with and without aspirin on bleeding following transbronchial lung biopsy. ( Becker, HD; Ernst, A; Feller-Kopman, D; Garland, R; Herth, F; Wahidi, MM, 2005) |
| "We report a rare case in which life-threatening subcutaneous hemorrhage following minor blunt trauma developed in an elderly patient taking ticlopidine and aspirin." | 7.73 | Life-threatening subcutaneous hemorrhage following minor blunt trauma in an elderly patient taking ticlopidine and aspirin: a case report. ( Hagiwara, A; Matsuda, T; Shimazaki, S, 2005) |
| "We observed poor short-term outcomes and increased mortality, probably attributable to rapid enlargement of hematomas, in the subjects with ICH who had been taking regularly moderate doses of aspirin (median 250 mg) immediately before the onset of the stroke." | 7.73 | Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. ( Ahonen, M; Hillbom, M; Juvela, S; Pyhtinen, J; Saloheimo, P; Savolainen, ER, 2006) |
| " Patients who are on chronic warfarin therapy and receive a coronary stent need to be treated with the triple therapy of aspirin, clopidogrel and warfarin; however, the bleeding risk in these patients is unknown." | 7.73 | Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. ( Bergman, G; Chou, E; Hong, MK; Khurram, Z; Minutello, R; Naidu, S; Parikh, M; Wong, SC, 2006) |
| "Our study demonstrates an increased risk of major bleeding in unselected patients receiving combination therapy with ASA and clopidogrel after UAP or NSTEMI." | 7.73 | [Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome]. ( Kjaer, J; Larsen, CH; Mickley, H; Møller, JE; Poulsen, TS, 2006) |
| "Aspirin is used in combination with anticoagulant therapy in patients with atrial fibrillation (AF), but evidence of additional efficacy is not available." | 7.73 | Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. ( Chaparro, S; Connolly, SJ; Flaker, GC; Goldman, S; Gruber, M; Halinen, MO; Halperin, JL; Horrow, J; Vahanian, A, 2006) |
| " As heparin is known to increase the risk of hemorrhage when co-administered with a plasminogen activator, we asked whether adjunct antithrombotic agents such as aspirin and heparin would affect the safety of plasmin." | 7.72 | Safety of plasmin in the setting of concomitant aspirin and heparin administration in an animal model of bleeding. ( Baumbach, GA; Humphries, J; Jesmok, G; Kong, M; Marder, VJ; Sadeghi, S; Stewart, D, 2003) |
| "This study in non-human primates was designed to evaluate the bleeding propensity of a selective, small molecule inhibitor of tissue factor (TF)/VIIa in combination with acetylsalicylic acid (ASA) in comparison to the combination of ASA and warfarin." | 7.72 | Assessment of bleeding propensity in non-human primates by combination of selective tissue factor/VIIa inhibition and aspirin compared to warfarin and aspirin treatment. ( Nicholson, NS; Parlow, JJ; Salyers, AK; South, MS; Suleymanov, OD; Szalony, JA; Wood, RS, 2004) |
| "The present study was performed to determine whether the risk of bleeding after transbronchial lung biopsy is increased in patients taking aspirin." | 7.71 | Aspirin does not increase bleeding complications after transbronchial biopsy. ( Becker, HD; Ernst, A; Herth, FJ, 2002) |
| " In this experimental study we investigated whether Haemate, a von Willebrand Factor (vWF) and factor VIII containing product, could correct rH/aspirin induced bleeding in an experimental pig study." | 7.70 | Development of an anti-bleeding agent for recombinant hirudin induced skin bleeding in the pig. ( Dickneite, G; Friesen, HJ; Nicolay, U; Reers, M, 1998) |
| "Isoproterenol hydrochloride (ISO), a beta adrenergic agonist, is known to cause ischemic necrosis in rats." | 7.70 | Effect of a novel tetrapeptide derivative in a model of isoproterenol induced myocardial necrosis. ( Jayakumar, R; Jayasundar, S; Malarvannan, P; Puvanakrishnan, R; Ramesh, CV, 1998) |
| "To examine the cost-effectiveness of prescribing warfarin sodium in patients who have nonvalvular atrial fibrillation (NVAF) with or without additional stroke risk factors (a prior stroke or transient ischemic attack, diabetes, hypertension, or heart disease)." | 7.69 | Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. ( Albers, GW; Cardinalli, AB; Gage, BF; Owens, DK, 1995) |
| "Aspirin and nonsteroidal antiinflammatory drugs (NSAIDs) inhibit platelet cyclooxygenase activity, resulting in altered platelet function and thus potentially enhanced bleeding." | 7.69 | Effect of aspirin and nonsteroidal antiinflammatory drug therapy on bleeding complications in dermatologic surgical patients. ( Lawrence, C; Sakuntabhai, A; Tiling-Grosse, S, 1994) |
| "The aim of the study was to compare the incidence of bleeding complications in patients receiving warfarin alone and those receiving warfarin in combination with acetylsalicylic acid." | 7.69 | Comparison of bleeding complications of warfarin and warfarin plus acetylsalicylic acid: a study in 3166 outpatients. ( Arnesen, H; Erikssen, J; Hurlen, M; Rollag, A; Smith, P, 1994) |
| "Rats with a 10 cm full-thickness incisional wound and a 15 mL/kg hemorrhage were either not resuscitated or resuscitated with blood or diaspirin cross-linked hemoglobin (DCLHb)." | 7.69 | Cellular responses to surgical trauma, hemorrhage, and resuscitation with diaspirin cross-linked hemoglobin in rats. ( Burris, D; Leppäniemi, A; Li, Y; Malcolm, D; Nielsen, TB; Pacheco, ND; Pikoulis, E; Rollwagen, FM; Soltero, R; Sun, L; Xu, L, 1997) |
| "The effect of diaspirin cross-linked hemoglobin (DCLHb) on mean arterial pressure (MAP) and heart rate (HR) was compared to Ringer's lactate (RL) and shed blood in a 70% lethal model of hemorrhage (35 cc/kg blood loss) in conscious rats." | 7.68 | Diaspirin cross-linked hemoglobin solution as a resuscitative fluid following severe hemorrhage in the rat. ( Garrioch, M; Kissinger, D; Malcolm, D, 1992) |
| "The 'Simplate' technique for measuring skin bleeding time was adapted to quantify thromboxane A2 in the emerging blood as the stable degradation product thromboxane B2 in twelve Swedish and ten English volunteers." | 7.66 | Thromboxane A2 in skin-bleeding-time blood and in clotted venous blood before and after administration of acetylsalicylic acid. ( Born, GV; Shafi, S; Thorngren, M, 1983) |
| "Often used as an oral analgesic in the management of pain associated with traumatic hyphema, aspirin has an inhibitory effect on the blood clotting mechamism by its action on platelets." | 7.65 | The effect of aspirin on rebleeding in traumatic hyphema. ( Chan, W; Crawford, JS; Lewandowski, RL, 1975) |
| " A recent history of excessive ingestion of an aspirin-containing medication was obtained and the clinical and laboratory picture of an aspirin-induced bleeding disorder was documented." | 7.65 | Acute spinal epidural hematoma secondary to aspirin-induced prolonged bleeding. ( Biggers, SL; Giorgio, AJ; Johnson, AP; Locke, GE; Salem, F, 1976) |
| "The primary safety end point was bleeding events, as defined by the International Society on Thrombosis and Haemostasis, and the primary efficacy end point was major adverse cardiovascular events (MACEs), including cardiac death, myocardial infarction, rerevascularization, or stroke during the 6-month follow-up." | 7.30 | Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial. ( Chen, F; Fu, G; Ge, L; Huang, L; Jiang, W; Liu, C; Liu, Q; Ouyang, Z; Pan, G; Pan, H; Shen, Q; Xiao, Y; Zeng, G; Zhang, Y; Zheng, Z; Zhou, C; Zhou, S; Zhu, C, 2023) |
| "The incidence of preterm preeclampsia was 1." | 7.30 | Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial. ( Alsius, M; Bonacina, E; Caamiña, S; Carreras, E; de Mingo, L; Diaz, S; Ferrer-Costa, R; Garcia, E; Garcia-Manau, P; López, M; Lopez-Quesada, E; Maiz, N; Maroto, A; Martin, L; Mendoza, M; Millán, P; Ocaña, V; Orizales-Lago, C; Pallarols, M; Pérez-Gomez, A; Pintado, E; Puerto, L; Ricart, M; Rodríguez-Zurita, A; Suy, A; Teixidor, M; Vidal-Sagnier, L; Vives, À, 2023) |
| "Postprocedural bleeding is the main complication of percutaneous kidney biopsy (PKB)." | 7.01 | Effects of Aspirin on Kidney Biopsy Bleeding Complications: A Systematic Review and Meta-Analysis (PROSPERO 2021 CRD42021261005). ( Castro, I; Coentrão, L; Diniz, H; Gonçalves, J; Mendonça, L; Relvas, M, 2023) |
| "The risk of bleeding is a major concern when oral anticoagulation is required to prevent stroke, and concomitant therapy with antiplatelet agents is required to minimize recurrent ischemic events." | 6.87 | An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rat ( Alexander, JH; Darius, H; Goodman, SG; Granger, CB; Liaw, D; Lopes, RD; Mehran, R; Vora, AN; Windecker, S, 2018) |
| " The primary efficacy endpoint was the incidence of major adverse cardiovascular events (MACE) at 24 weeks, defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke." | 6.79 | Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. ( Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014) |
| "Bleeding was reported according to Bleeding Academic Research Consortium (BARC) definition." | 6.78 | Increased risk of minor bleeding and antiplatelet therapy cessation in patients with acute coronary syndromes and low on-aspirin platelet reactivity. A prospective cohort study. ( Filipiak, KJ; Grabowski, M; Huczek, Z; Kochman, J; Michalak, M; Opolski, G, 2013) |
| "Fatal bleeding was low and did not differ between groups." | 6.76 | Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM, 2011) |
| "Patients with lower extremity peripheral artery disease (PAD) are at increased risk of major adverse limb events (MALE)." | 6.72 | The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials. ( Costa, G; Gonçalves, L; Teixeira, R, 2021) |
| "Patients with minor ischemic stroke or transient ischemic attack represent a high-risk population for recurrent stroke." | 6.72 | Ticagrelor vs Clopidogrel in addition to Aspirin in minor ischemic stroke/ transient ischemic attack-Protocol for a systematic review and network meta-analysis. ( Dhaliwal, S; Dowlatshahi, D; Hutton, B; Lun, R; Roy, DC; Shorr, R; Zitikyte, G, 2021) |
| "Bleedings were documented in 19 versus four patients (W/A 5." | 6.71 | Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. ( Edvardsson, N; Juul-Möller, S; Omblus, R; Pehrsson, K, 2003) |
| "Aspirin has long been an inexpensive cornerstone of arterial vascular disease therapy, but its role in the primary or secondary prophylaxis of VTE has been debated." | 6.66 | Does aspirin prevent venous thromboembolism? ( Diep, R; Garcia, D, 2020) |
| "Recurrent stroke is common immediately following a transient ischemic attack (TIA) or ischemic stroke." | 6.61 | Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. ( Abdalla, A; Ahmed, S; Al Qasmi, M; Bachuwa, G; Bhatt, DL; Chahine, A; Hassan, M; Haykal, T; Kheiri, B; Osman, M; Swaid, B, 2019) |
| "Aspirin has a complex matrix of benefits and risks, and its use in primary prevention requires individualized decision-making." | 6.58 | Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach. ( Ames, JM; Dugani, S; Manson, JE; Mora, S, 2018) |
| "0) combined with ASA (mean dose ≥100 mg/day) and ASA." | 6.55 | Efficacy and safety of aspirin combined with warfarin after acute coronary syndrome : A meta-analysis. ( Huang, X; Li, J; Li, L; Shen, C; Wu, C; Zhang, P; Zhang, W, 2017) |
| "5, and aspirin was administered at a dosage of 75 to 325 mg/d." | 6.52 | Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis. ( Chen, KP; Zhang, JT; Zhang, S, 2015) |
| "Is it better to continue treatment of deep venous thrombosis or pulmonary embolism with LMWH or switch to an oral anticoagulant? What is the optimal duration of treatment? To answer these questions, we conducted a review of the literature using the standard Prescrire methodology." | 6.49 | Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months. ( , 2013) |
| "Current acetylsalicylic acid (ASA) dosing algorithms for the prevention of secondary thrombotic events in acute coronary syndrome (ACS) patients are inconsistent and lack sufficient data support." | 6.48 | Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. ( Berger, JS; Katona, B; Maya, J; Mwamburi, M; Ranganathan, G; Sallum, RH; Xu, Y, 2012) |
| " The data reported in the literature do not however enable any evidenced-based decision on dosing for the diabetic population with numerous cardiovascular risks." | 6.41 | [Prevention of cardiovascular diseases in type 2 diabetes with aspirin]. ( Duly-Bouhanick, B; Guilloteau, G; Hadjadj, S; Menard, S; Plun-Favreau, J; Soares-Barbosa, S, 2001) |
| "Aspirin is an approximately 150- to 200-fold more potent inhibitor of the (constitutive) isoform of the platelet enzyme (COX-1) than the (inducible) isoform (COX-2) which is expressed by cytokines, inflammatory stimuli, and some growth factors." | 6.40 | Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. ( Schrör, K, 1997) |
| "Warfarin and aspirin are used to prevent stroke in patients with atrial fibrillation (AF)." | 6.27 | Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. ( Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M, 2013) |
| "Combining aspirin or nonsteroidal anti-inflammatory drugs with SSRIs for the treatment of interferon-associated neuropsychiatric side effects increases the risks of hemorrhage in patients with HCV who have developed cirrhosis and either portal hypertension or hepatic failure or both." | 6.20 | A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients. ( Auriacombe, M; Chang, KM; Lewis, JD; Lynch, KG; Weinrieb, RM, 2003) |
| "To assess the balance of benefits and risks of aspirin in particular categories of patient with acute stroke (eg, the elderly, those without a CT scan, or those with atrial fibrillation), a prospectively planned meta-analysis is presented of the data from 40 000 individual patients from both trials on events that occurred in the hospital during the scheduled treatment period (4 weeks in CAST, 2 weeks in IST), with 10 characteristics used to define 28 subgroups." | 6.19 | Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. ( Chen, ZM; Collins, R; Counsell, C; Liu, LS; Pan, HC; Peto, R; Sandercock, P; Warlow, C; Xie, JX, 2000) |
| " The risk of bleeding during anticoagulant therapy has been evaluated in 10 recent studies of warfarin treatment for the prevention of arterial thromboembolism." | 6.17 | [Bleeding complications in oral anticoagulant treatment]. ( Gulløv, AL; Koefoed, BG; Petersen, P, 1995) |
| "Rates of hemorrhage were similar for aspirin in combination with warfarin or direct-acting oral anticoagulants." | 5.72 | Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study. ( Colucci, PM; Grunwald, MR; Lessen, DS; Paranagama, D; Zwicker, JI, 2022) |
| "We compared the risk of recurrent ischemic stroke, vascular events, and major bleeding between DAPT with cilostazol plus aspirin or clopidogrel and aspirin or clopidogrel alone in patients with ischemic stroke between 8 and 180 days before starting trial treatment and ECAS or without arterial stenosis." | 5.69 | Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial. ( Hoshino, H; Kimura, K; Kitagawa, K; Minematsu, K; Okamura, S; Omae, K; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2023) |
| "Among women and men undergoing CABG, ticagrelor monotherapy was associated with a similar risk of the primary efficacy endpoint and bleeding compared with aspirin." | 5.69 | Sex differences among patients receiving ticagrelor monotherapy or aspirin after coronary bypass surgery: A prespecified subgroup analysis of the TiCAB trial. ( Böning, A; Conradi, L; Danner, B; Färber, G; Kastrati, A; Manville, E; Niessner, A; Sandner, S; Schunkert, H; von Scheidt, M; Zeymer, U; Zimpfer, D, 2023) |
| "In Chinese patients with negative cardiac troponin undergoing drug-eluting stent implantation, indobufen plus clopidogrel DAPT compared with aspirin plus clopidogrel DAPT significantly reduced the risk of 1-year net clinical outcomes, which was driven mainly by a reduction in bleeding events without an increase in ischemic events." | 5.69 | Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial. ( Chen, M; Cheng, K; Ge, J; Huang, J; Lan, J; Li, G; Qian, J; Wang, X; Wang, Y; Wei, G; Wu, H; Xu, L; Zhang, C; Zhang, H; Zhao, X, 2023) |
| "5 mg twice daily to aspirin or dual antiplatelet therapy significantly reduced this risk, with an increase in the bleeding risk, but had a favorable benefit risk for patients treated with bypass surgery, regardless of conduit type." | 5.69 | Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits. ( Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Capell, WH; Chung, J; Conte, MS; Debus, S; Dorigo, W; Govsyeyev, N; Gudz, I; Haskell, LP; Hess, CN; Jaeger, N; Krievins, D; Mills, J; Moll, F; Muehlhofer, E; Nehler, M; Norgren, L; Patel, MR; Piffaretti, G; Powell, R; Sillesen, H; Szalay, D; Szarek, M; Wohlauer, M, 2023) |
| "In this pilot study, there were no significant differences in any outcome assessed; however, recurrent thromboembolic events and minor bleeding events occurred numerically less frequently in the rivaroxaban plus aspirin group." | 5.69 | Rivaroxaban plus aspirin versus acenocoumarol to manage recurrent venous thromboembolic events despite systemic anticoagulation with rivaroxaban. ( Erika, MH; Jaime, GC; Maximiliano, CL, 2023) |
| "This study was performed to investigate whether ticagrelor/aspirin versus clopidogrel/aspirin can further reduce the residual risk of stroke recurrence in patients with positive diffusion-weighted imaging (DWI) in the High-Risk Patients with Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial." | 5.69 | Genotype-Guided Dual Antiplatelet Use for Transient Ischemic Attack and Minor Stroke by Imaging Status: Subgroup Analysis of the CHANCE-2 Trial. ( Bath, PM; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Wang, A; Wang, Y; Xie, X; Xu, Q; Zhao, X, 2023) |
| "In high-risk patients undergoing PCI, ticagrelor monotherapy after 3 months of ticagrelor-based dual antiplatelet therapy was associated with a reduced risk of clinically relevant bleeding without any increase in ischaemic events irrespective of anaemia status (TWILIGHT: NCT02270242)." | 5.69 | Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial. ( Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, CM; Han, YL; Huber, K; Kastrati, A; Kaul, U; Kornowski, R; Kunadian, V; Mehran, R; Mehta, SR; Pocock, S; Sardella, G; Sartori, S; Sharma, S; Shlofmitz, RA; Spirito, A; Vogel, B; Zhang, Z, 2023) |
| "In patients with extremity fractures that had been treated operatively or with any pelvic or acetabular fracture, thromboprophylaxis with aspirin was noninferior to low-molecular-weight heparin in preventing death and was associated with low incidences of deep-vein thrombosis and pulmonary embolism and low 90-day mortality." | 5.69 | Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture. ( Bosse, MJ; Carlini, AR; Castillo, RC; Degani, Y; Firoozabadi, R; Frey, KP; Goldhaber, SZ; Haut, ER; Marvel, D; O'Hara, NN; O'Toole, RV; Obremskey, W; Scharfstein, DO; Slobogean, GP; Stein, DM; Sudini, K; Taylor, TJ, 2023) |
| "In patients with lacunar stroke, DAPT using cilostazol had significant benefits in reducing recurrent ischemic stroke incidence compared with SAPT without increasing the risk of severe or life-threatening bleeding." | 5.69 | Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial. ( Hoshino, H; Houkin, K; Kimura, K; Matsumoto, M; Minematsu, K; Naritomi, H; Nishiyama, Y; Okada, Y; Origasa, H; Otsuka, T; Sakai, N; Terayama, Y; Tomimoto, H; Tominaga, T; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T; Yasuda, S, 2023) |
| "The optimal duration of dual antiplatelet therapy (DAPT) with clopidogrel-aspirin for the large artery atherosclerotic (LAA) stroke subtype has been debated." | 5.69 | Dual antiplatelet Use for extended period taRgeted to AcuTe ischemic stroke with presumed atherosclerotic OrigiN (DURATION) trial: Rationale and design. ( Bae, HJ; Cha, JK; Cho, KH; Cho, YJ; Choi, JC; Choi, JK; Choi, KH; Gorelick, PB; Gwak, DS; Han, MK; Hong, JH; Hong, KS; Jeong, HB; Kang, CH; Kang, J; Kang, K; Kim, BJ; Kim, C; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, JY; Kim, WJ; Kim, YS; Kwon, DH; Kwon, JH; Lee, BC; Lee, J; Lee, K; Lee, M; Lee, SH; Lee, SJ; Norrving, B; Oh, MS; Park, H; Park, HK; Park, JM; Park, KY; Park, MS; Park, SS; Park, TH; Shin, DI; Sohn, SI; Yu, KH; Yum, KS, 2023) |
| "The aim of this study was to determine the effect of smoking status on subsequent stroke risk in patients with minor ischemic stroke or TIA and to determine whether smoking modifies the effect of clopidogrel-based DAPT on subsequent stroke risk." | 5.69 | Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial. ( de Havenon, A; Easton, JD; Furie, KL; Henninger, N; Johnston, SC; Kim, A; Lang, AE; Mac Grory, B; Shu, L; Yaghi, S, 2023) |
| "We sought to explore the sex differences in clinical outcomes among patients with acute coronary syndrome treated with ticagrelor monotherapy after ticagrelor-based 3-month versus 12-month dual-antiplatelet therapy." | 5.69 | Sex Differences in Outcomes of Ticagrelor Therapy With or Without Aspirin After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Secondary Analysis of the TICO Randomized Clinical Trial. ( Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, B; Lee, SJ; Lee, YJ, 2023) |
| "A multicenter randomized controlled trial (OPtimal management of anTIthroMbotic Agents [OPTIMA]-4) is designed to test the hypothesis that, for ACS patients with concomitant nonvalvular atrial fibrillation (NVAF) and having low-to-moderate risk of bleeding, clopidogrel is comparable in efficacy but superior in safety compared to ticagrelor while being used in combination with dabigatran after new-generation drug-eluting stent (DES) implantation." | 5.69 | Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new-generation drug-eluting stent: OPtimal management of anTIthroMbotic Agents (OPTIMA)-4 trial. ( Bai, J; Chen, Y; Dong, P; Gong, X; Hua, R; Ke, Y; Li, C; Liu, K; Wang, Q; Wang, X; Wu, T; Xiao, J; Ying, L; Zhang, B; Zhang, J; Zhang, W; Zhang, X; Zhu, L, 2023) |
| "The Clopidogrel With Aspirin in High-Risk Patients With Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial showed that ticagrelor-aspirin combination therapy reduced the risk of stroke compared with a clopidogrel-aspirin combination among carriers of CYP2C19 loss-of-function (LOF) alleles after a transient ischemic attack (TIA) or minor ischemic stroke." | 5.69 | Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial. ( Bath, PM; Jiang, Y; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, Y; Xie, X; Xu, A; Xu, Q; Zhao, X, 2023) |
| "Daily low-dose aspirin increases major bleeding; however, few studies have investigated its effect on iron deficiency and anemia." | 5.69 | Effect of Low-Dose Aspirin Versus Placebo on Incidence of Anemia in the Elderly : A Secondary Analysis of the Aspirin in Reducing Events in the Elderly Trial. ( Artz, AS; Bailey, M; Chan, AT; Cohen, HJ; Lockery, JE; McNeil, JJ; McQuilten, ZK; Murray, AM; Nelson, MR; Pasricha, SR; Schneider, HG; Thao, LTP; Wolfe, R; Wood, EM; Woods, RL, 2023) |
| "In this secondary analysis of a randomized controlled trial involving patients with minor ischemic stroke or TIA, compared with clopidogrel-ASA, patients with obesity received more clinical benefit from ticagrelor-ASA therapy than those without obesity." | 5.69 | Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack. ( Jiang, Y; Jing, J; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Tian, X; Wang, A; Wang, Y; Xie, X; Zhang, J; Zhao, X, 2023) |
| "In TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention), among high-risk patients undergoing percutaneous coronary intervention (PCI), ticagrelor monotherapy vs continuation of dual antiplatelet therapy (DAPT) with aspirin and ticagrelor after completing a 3-month course of DAPT was associated with reduced bleeding, without an increase in ischemic events." | 5.69 | Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions. ( Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, D; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, CM; Gil, R; Han, YL; Huber, K; Kastrati, A; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Mendieta, G; Moliterno, DJ; Ohman, EM; Pocock, S; Sardella, G; Sartori, S; Sharma, S; Shlofmitz, R; Spirito, A; Steg, PG; Vogel, B, 2023) |
| "The beneficial effect of clopidogrel over aspirin monotherapy was consistent regardless of clinical risk or relative ischemic and bleeding risks compared with aspirin monotherapy." | 5.69 | Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks. ( Ahn, HS; Cha, KS; Choi, HH; Han, JK; Hur, SH; Hwang, D; Jo, SH; Kang, J; Kim, HS; Koo, BK; Lee, NH; Park, KW; Ryu, JK; Shin, ES; Suh, IW; Woo, SI; Yang, HM; Yang, S, 2023) |
| "Nearly 20% of patients on ticagrelor experience dyspnea, which may lead to treatment discontinuation in up to one-third of cases." | 5.69 | Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention. ( Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, M; Gil, R; Huber, K; Ielasi, A; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Moliterno, DJ; Ohman, EM; Pivato, CA; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Stefanini, GG; Steg, PG; Vogel, B; Weisz, G; Witzenbichler, B; Zhang, Z, 2023) |
| "To assess the association of aspirin, clopidogrel, and their combination with gastrointestinal injury progression among patients without high bleeding risk after PCI." | 5.69 | Progression of Gastrointestinal Injury During Antiplatelet Therapy After Percutaneous Coronary Intervention: A Secondary Analysis of the OPT-PEACE Randomized Clinical Trial. ( Bao, D; Cui, M; Deng, J; Feng, J; Gao, W; Han, Y; Han, YL; He, C; Huang, YH; Jia, SB; Jiang, CM; Jiang, MN; Jiang, X; Li, JX; Li, Y; Li, ZS; Liao, Z; Ma, SC; Ma, SR; Ma, YT; Qiu, MH; Qu, P; Ru, LS; Sheng, JQ; Stone, GW; Tao, L; Wang, BM; Wang, JH; Wang, XY; Wang, XZ; Yang, K; Yang, SQ; Yang, YL; Zhang, WJ; Zhao, XX, 2023) |
| " The Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study clarified the rates of major CV and bleeding events with long-term use of aspirin in patients with prior CV diseases in real-world clinical practice." | 5.56 | Major cardiovascular and bleeding events with long-term use of aspirin in patients with prior cardiovascular diseases: 1-year follow-up results from the Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study. ( Goto, S; Hiraishi, H; Ikeda, Y; Okada, Y; Origasa, H; Shimada, K; Sugano, K; Uchiyama, S; Uemura, N, 2020) |
| "Aspirin was administered to all patients once a day." | 5.56 | Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action. ( Frigieri, FC; Gianesello, L; Meconi, T; Pavoni, V; Pazzi, M; Stera, C, 2020) |
| " prasugrel in patients with acute coronary syndromes (ACSs) are influenced by pre-admission treatment with aspirin and/or clopidogrel." | 5.51 | Pre-admission antiplatelet therapy and treatment effect of ticagrelor vs. prasugrel in patients with acute coronary syndromes-a subgroup analysis of the ISAR-REACT 5 trial. ( Akin, I; Bernlochner, I; Cassese, S; Gewalt, S; Hemetsberger, R; Ibrahim, T; Joner, M; Kastrati, A; Kufner, S; Lahu, S; Laugwitz, KL; Mayer, K; Menichelli, M; Ndrepepa, G; Neumann, FJ; Richardt, G; Sager, HB; Schunkert, H; Schüpke, S; Valina, C; Witzenbichler, B; Wöhrle, J; Xhepa, E, 2022) |
| "This post hoc subanalysis of the open-label, all-comers, randomised GLOBAL LEADERS trial, which compared 23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT) with 12-month aspirin monotherapy following 12-month DAPT, only included patients who, at 12 months, were free from ischaemic and bleeding events and were adherent to their assigned antiplatelet therapy." | 5.51 | Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial. ( Gao, C; Garg, S; Hamm, C; Hara, H; Kawashima, H; Ono, M; Onuma, Y; Piek, JJ; Serruys, PW; Steg, PG; Valgimigli, M; Vranckx, P; Wang, R; Windecker, S; Wykrzykowska, JJ, 2022) |
| "Ticagrelor monotherapy significantly reduced clinically relevant bleeding without increasing ischemic events as compared with ticagrelor plus aspirin in Chinese patients undergoing high-risk percutaneous coronary intervention." | 5.51 | Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. ( Angiolillo, DJ; Baber, U; Bian, L; Chen, J; Chen, SL; Cheng, X; Chunguang, Q; Claessen, BE; Cohen, DJ; Dangas, G; Gibson, CM; Goel, R; Hailong, L; Han, Y; Kastrati, A; Krucoff, M; Li, Y; Liu, Y; Luo, S; Mehran, R; Mehta, SR; Ohman, EM; Qiang, W; Sartori, S; Sharma, S; Steg, PG; Su, X; Sun, Y; Tao, J; Wang, G; Wang, J; Xu, Y; Zhang, R; Zhang, Z; Zhao, X; Zhou, Y; Zhu, J, 2022) |
| "Irrespective of the presence of DM, CKD, and their combination, ticagrelor monotherapy reduced the risk of bleeding without a significant increase in ischaemic events compared with ticagrelor plus aspirin." | 5.51 | Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. ( Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, DJ; Collier, T; Dangas, G; Dehghani, P; Dudek, D; Escaned, J; Gibson, M; Gil, R; Huber, K; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Moliterno, DJ; Nicolas, J; Ohman, EM; Pivato, CA; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Weisz, G; Witzenbichler, B; Zhang, Z, 2022) |
| "To test whether indobufen is non-inferior to aspirin in reducing the risk of new stroke at 3 months in patients with moderate to severe ischaemic stroke." | 5.51 | Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial. ( Bath, PM; Chen, W; Dong, Q; Jiang, Y; Jing, J; Johnston, SC; Li, H; Lin, J; Meng, X; Pan, Y; Wang, Y; Xu, AD, 2022) |
| " Low-dose aspirin is of proven benefit in the secondary prevention of myocardial infarction (MI) and stroke in people with pre-existing CVD." | 5.51 | Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiov ( Dumbleton, J; Fitzmaurice, D; Fraser, SD; Fuat, A; Gallagher, H; Griffith, KE; Hawkey, CJ; Henderson, RA; Lord, J; Lown, M; Maishman, T; Moore, MV; Roderick, PJ; Stevens, P; Stevenson, D; Taal, MW; Whitehead, A, 2022) |
| "In patients undergoing drug-eluting stent implantation for non-complex lesions, the benefits of 1-month DAPT followed by aspirin monotherapy for a composite of ischaemic and bleeding outcomes were found in patients with stable CAD, but not in those with ACS." | 5.51 | Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial. ( Ahn, CM; Cho, JY; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Lee, YJ; Yun, KH, 2022) |
| "5 mg twice daily plus aspirin, and to report their clinical outcomes and bleeding rates in clinical practice compared to the COMPASS randomized trial, which provided the basis for using DPI in this patient population." | 5.51 | Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry. ( Aboyans, V; Anand, SS; Bosch, J; Cowie, MR; Debus, ES; Fox, KAA; Gay, A; Patel, M; Vogtländer, K; Welsh, RC; Zeymer, U, 2022) |
| " Aspirin increased major or CRNM bleeding, particularly in patients without prior stroke/TIA/TE." | 5.51 | Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial. ( Alexander, JH; Aronson, R; Bahit, MC; Berwanger, O; Dombrowski, KE; Goodman, SG; Granger, CB; Halvorsen, S; Jordan, JD; Kolls, BJ; Li, Z; Lopes, RD; Mehran, R; Thomas, L; Vinereanu, D; Vora, AN; Windecker, S; Wojdyla, DM, 2022) |
| "Dual antiplatelet therapy (DAPT) with ticagrelor and aspirin has been found to be effective for secondary prevention after minor ischemic stroke or transient ischemic attack (TIA) in individuals who carry CYP2C19 loss-of-function (LOF) alleles; however, uncertainties remain about the time course of benefit and risk with ticagrelor and aspirin in these patients." | 5.51 | Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial. ( Bath, PM; Cheng, J; Jiang, Y; Jin, A; Jing, J; Johnston, SC; Li, H; Li, Z; Lin, J; Liu, L; Meng, X; Pan, Y; Wang, Y; Wang, Z; Xie, X; Yang, H; Zhao, X, 2022) |
| "In patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in The Cardiovascular Outcomes for People Using Anticoagulation Strategies trial, the effects of rivaroxaban 2." | 5.51 | Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. ( Bhatt, DL; Bosch, J; Connolly, SJ; Eikelboom, JW; Fox, KAA; Hori, M; Liang, Y; Maggioni, A; Yusuf, S; Zhu, J, 2022) |
| "In a real-world population with ACS, DAPT with ticagrelor or prasugrel are associated with increased bleeding compared with DAPT with clopidogrel." | 5.51 | Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'targe ( Harris, J; Johnson, TW; Lasserson, D; Loke, YK; Mahadevan, K; Mumford, A; Pouwels, K; Pufulete, M; Reeves, BC, 2022) |
| "In high-risk patients with prior CABG, ticagrelor monotherapy reduced bleeding without compromising ischaemic outcomes compared with ticagrelor plus aspirin." | 5.51 | Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. ( Angiolillo, DJ; Baber, U; Beerkens, FJ; Briguori, C; Cao, D; Claessen, B; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, CM; Gil, R; Huber, K; Kastrati, A; Kornowski, R; Krucoff, MW; Kunadian, V; Marx, S; Mehran, R; Mehta, S; Moliterno, DJ; Nicolas, J; Ohman, EM; Pocock, S; Sardella, G; Sartori, S; Sharma, S; Shlofmitz, R; Steg, PG; Weisz, G; Zhang, Z, 2022) |
| "In patients with recent acute MI, 3 doses of asundexian, when added to aspirin plus a P2Y12 inhibitor, resulted in dose-dependent, near-complete inhibition of FXIa activity without a significant increase in bleeding and a low rate of ischemic events." | 5.51 | A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. ( Alexander, JH; Bhatt, DL; Budaj, A; Campo, G; Coppolecchia, R; Eikelboom, J; Ferreiro, JL; Hermanides, RS; James, SK; Jones, WS; Keller, L; Kirsch, B; Merkely, B; Mundl, H; Rao, SV; Shibasaki, T, 2022) |
| "The Clopidogrel and Acetylsalicylic Acid in Bypass Surgery for Peripheral Arterial Disease (CASPAR) trial is the only large, double-blind, placebo-controlled trial of dual antiplatelet therapy (DAPT) versus aspirin in patients with peripheral artery disease (PAD) after lower extremity revascularization (LER)." | 5.51 | Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD. ( Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Debus, ES; Haskell, LP; Muehlhofer, E; Nehler, MR; Patel, MR; Szarek, M, 2022) |
| "The rate of surgical site infection was similar between the aspirin group and the warfarin group (1." | 5.43 | Aspirin Can Be Used as Prophylaxis for Prevention of Venous Thromboembolism After Revision Hip and Knee Arthroplasty. ( Chen, AF; Deirmengian, GK; Heller, S; Maltenfort, M; Parvizi, J; Smith, EB, 2016) |
| "The major result events, included: (1) recurrence of ischemic stroke; (2) hemorrhagic transformation of ischemic stroke; (3) myocardial infarction; (4) the digestive hemorrhage." | 5.43 | [Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy]. ( Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ, 2016) |
| "7, p NS], and in adverse cardiac or cerebrovascular events (MACCE) (5 vs." | 5.42 | Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. ( Almendro-Delia, M; Blanco Ponce, E; Caballero-Garcia, A; Cruz-Fernandez, MJ; Garcia-Rubira, JC; Gomez-Domínguez, R; Gonzalez-Matos, C; Hidalgo-Urbano, R; Lobo-Gonzalez, M, 2015) |
| "Vorapaxar is a novel protease-activated receptor-1 (PAR-1) antagonist recently approved for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease." | 5.42 | Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist. ( Cai, TQ; Chintala, M; Forrest, M; Handt, L; Michener, MS; Raubertas, R; Seiffert, D; Sitko, G; Wickham, LA, 2015) |
| "When aspirin was compared to no treatment, NCB was neutral or negative for both risk strata." | 5.42 | Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. ( Larsen, TB; Lip, GY; Nielsen, PB; Skjøth, F, 2015) |
| "In this open-label, assessor-masked, multicentre, non-inferiority, randomised trial (TALOS-AMI), patients at 32 institutes in South Korea with acute myocardial infarction receiving aspirin and ticagrelor without major ischaemic or bleeding events during the first month after index percutaneous coronary intervention (PCI) were randomly assigned in a 1:1 ratio to a de-escalation (clopidogrel plus aspirin) or active control (ticagrelor plus aspirin) group." | 5.41 | Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. ( Ahn, Y; Chang, K; Choi, YS; Choo, EH; Hwang, BH; Jeon, DS; Jeong, MH; Jeong, YH; Kim, CJ; Kim, HY; Kim, MC; Lee, KY; Park, MW; Seung, KB; Shin, ES; Yim, HW; Yoo, KD, 2021) |
| "Background We aimed to evaluate the age-dependent effect of ticagrelor monotherapy after 3-month dual-antiplatelet therapy (DAPT) versus ticagrelor-based 12-month DAPT on major bleeding and cardiovascular events in patients with acute coronary syndrome." | 5.41 | Age-Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events: A Post Hoc Analysis of the TICO Randomized Trial. ( Ahn, CM; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BG; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Shin, DH, 2021) |
| "Anticoagulation with apixaban after minimally invasive robotic MVRep is safe and has similar rates of bleeding and thromboembolism compared to patients treated with warfarin." | 5.41 | Apixaban for Anticoagulation After Robotic Mitral Valve Repair. ( Arghami, A; Crestanello, JA; Daly, RC; Dearani, JA; King, KS; Macielak, SA; Mazur, PK; Nei, SD; Schaff, HV; Viehman, JK, 2023) |
| "Evidence regarding using acetylsalicylic acid (aspirin) for the prevention of cardiovascular (CV) events in patients with diabetes mellitus (DM) is inconsistent." | 5.41 | Acetylsalicylic Acid (Aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( Cheema, AN; Eckstein, J; Lam, A; Liu, S, 2023) |
| "Considering MACEs, myocardial infarction, all kinds of stroke, ischemic stroke, and major bleeding, low-dose aspirin plus rivaroxaban 2." | 5.41 | Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis. ( Chen, X; Jiang, L; Liu, C; Su, J; Zheng, N; Zhong, J, 2023) |
| "Single antiplatelet therapy (SAPT) with aspirin or clopidogrel reduces the risk of recurrent ischemic stroke in patients with non-cardioembolic ischemic stroke or TIA." | 5.41 | Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines. ( Alsbrook, DL; Bhatia, K; Carr, KH; Di Napoli, M; Divani, AA; Hinduja, A; Hosseini Farahabadi, M; Jafarli, A; Ladd, LM; McCullough, LD; Ortiz Garcia, JG; Sabbagh, SY; Saver, JL, 2023) |
| "Ticagrelor is slightly better than clopidogrel and aspirin in preventing stroke, especially ischemic stroke, with significant safety risks." | 5.41 | Efficacy and Safety of Ticagrelor versus Aspirin and Clopidogrel for Stroke Prevention in Patients with Vascular Disease: A Systematic Review and Meta-Analysis. ( Chen, Y; Li, D; Liu, S; Ma, X; Zhong, P, 2023) |
| " Guideline-recommended dual antiplatelet therapy (DAPT; aspirin plus prasugrel/ticagrelor) for 12 months in acute coronary syndrome (ACS) patients increases bleeding, with East Asians (EAs) exhibiting higher bleeding and lower ischemic risk, compared with non-East Asians (nEAs)." | 5.41 | Comparison of De-escalation of DAPT Intensity or Duration in East Asian and Western Patients with ACS Undergoing PCI: A Systematic Review and Meta-analysis. ( Farag, M; Gorog, DA; Jeong, YH; Jeyalan, V; Markides, RIL; Navarese, EP, 2023) |
| " The incidence of all bleeding events with ticagrelor was higher than that with clopidogrel (RR, 1." | 5.41 | Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials. ( He, X; Li, J; Ma, S; Qiu, M; Qu, X; Wang, Q; Wang, X; Wu, C; Zhang, L, 2023) |
| " Antiplatelet drugs such as aspirin and P2Y12 inhibitors are commonly used to reduce the risk of thrombotic events, including myocardial infarction, stroke, and stent thrombosis." | 5.41 | Personalised antiplatelet therapies for coronary artery disease: what the future holds. ( Angiolillo, DJ; Capodanno, D, 2023) |
| "Aspirin is the only antiplatelet agent with a Class I recommendation for long-term prevention of cardiovascular events in patients with coronary artery disease (CAD)." | 5.41 | P2Y ( Arnesen, H; Bhatt, DL; Calabrò, P; Cao, D; Chiarito, M; Franzone, A; Gragnano, F; Kang, J; Kastrati, A; Kim, HS; McFadden, EP; Mehran, R; Park, KW; Pettersen, AR; Pirondini, L; Pocock, S; Schunkert, H; Seljeflot, I; Steg, PG; Valgimigli, M; von Scheidt, M; Windecker, S; Woodward, M; Zhao, Q; Zhu, Y, 2023) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel was recommended as the secondary prevention of minor ischemic stroke or transient ischaemic attack (TIA)." | 5.41 | Ticagrelor plus aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis. ( Ge, F; Li, M; Lin, H; Shi, J; Yang, Q; Zhang, X, 2023) |
| "Myocardial infarction was significantly lower when adding clopidogrel or ticagrelor 90 mg to aspirin than those in the aspirin alone group." | 5.41 | Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis. ( Liu, C; Ma, L, 2023) |
| "5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events (MACE) in patients with chronic coronary artery disease or peripheral artery disease by 24% during a mean follow-up of 23 months." | 5.41 | Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. ( Anand, SS; Berkowitz, SD; Bosch, J; Connolly, SJ; Dagenais, GR; Eikelboom, JW; Fox, KA; Guzik, TJ; Keller, L; Liang, Y; Liu, L; Muehlhofer, E; O'Donnell, M; Shestakovska, O; Yusuf, S; Zhu, J, 2021) |
| "The efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valves and atrial fibrillation or flutter remain uncertain." | 5.41 | A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. ( Almeida, AP; Ardito, RV; Atik, FA; Barreto, DO; Berwanger, O; Campos, VB; Cavalcante, MA; Cavalcanti, AB; D'Oliveira Vieira, R; Damiani, L; de Barros E Silva, PGM; de Lima, CEB; de Souza Neto, JD; Dos Santos, JRY; Farias, FR; Ferreira, JFM; Figueira, FAMS; Fonseca, FH; Guimarães, HP; Hoffmann-Filho, CR; Junior, RA; Kalil, PSA; Kojima, F; Lamprea, D; Laranjeira, L; Leiria, TLL; Liporace, IL; Lopes, RD; Magalhães, CC; Maldonado, JGA; Mesas, CE; Moisés, VA; Nakagawa, RH; Paiva, MSMO; Paixão, M; Patriota, R; Pavanello, R; Pinto, IM; Precoma, DB; Sampaio, BS; Sampaio, RO; Saraiva, JFK; Silveira, FS; Tarasoutchi, F; Zilli, AC, 2021) |
| " However, it is unclear whether antiplatelet monotherapy with ticagrelor alone versus ticagrelor plus aspirin reduces the incidence of clinically relevant bleeding without increasing the risk of major adverse cardiovascular and cerebrovascular events (MACCEs) in ACS patients undergoing percutaneous coronary intervention (PCI) with DES implantation guided by either intravascular ultrasound (IVUS) or angiography who have completed a 1-month course of DAPT with aspirin plus ticagrelor." | 5.41 | Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multice ( Chen, F; Chen, SL; Gao, DS; Gao, XF; Ge, Z; Han, YL; He, YQ; Kan, J; Kong, XQ; Li, F; Lin, S; Liu, ZZ; Qian, XS; Qu, H; Shao, YB; Tao, L; Tian, NL; Wang, Y; Wang, ZZ; Wen, SY; Xia, Y; Xiao, PX; Yang, Q; Yang, S; Ye, F; Zeng, HS; Zhang, JJ; Zuo, GF, 2021) |
| "In the AFIRE trial, rivaroxaban monotherapy was noninferior to combination therapy with rivaroxaban and an antiplatelet agent for thromboembolic events or death, and superior for major bleeding in patients with atrial fibrillation (AF) and stable coronary artery disease." | 5.41 | Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis. ( Akao, M; Ako, J; Hagiwara, N; Hirayama, A; Kaikita, K; Kimura, K; Matoba, T; Matsui, K; Miyauchi, K; Nakamura, M; Ogawa, H; Yasuda, S, 2021) |
| "The appropriate dose of aspirin to lower the risk of death, myocardial infarction, and stroke and to minimize major bleeding in patients with established atherosclerotic cardiovascular disease is a subject of controversy." | 5.41 | Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. ( Ahmad, FS; Alikhaani, JD; Anderson, RD; Antman, EM; Bell, DS; Benziger, CP; Berdan, LG; Bradley, SM; Brown, LS; Campbell, JR; Carton, TW; Crenshaw, DL; Curtis, LH; Davidson, DR; DeWalt, DA; Edgley, K; Effron, MB; Farrehi, P; Fintel, DJ; Fonarow, GC; Ford, DE; Girotra, S; Goldberg, YH; Gregoire, KC; Gupta, K; Hammill, BG; Handberg, EM; Harrington, RA; Harris, DF; Haynes, K; Hernandez, AF; Hess, R; Jain, SK; Jones, WS; Kaushal, R; Kho, AN; Knowlton, KU; Kraschnewski, JL; Kripalani, S; Manning, BR; Marcus, GM; Marquis-Gravel, G; Masoudi, FA; McClay, JC; McCormick, TE; McTigue, KM; Merritt, JG; Modrow, MF; Mulder, H; Muñoz, D; Nauman, E; Paranjape, A; Pencina, MJ; Pepine, CJ; Polonsky, TS; Qualls, LG; Re, RN; Riley, D; Robertson, HR; Roe, MT; Roger, VL; Rothman, RL; Sharlow, AG; Shenkman, EA; VanWormer, JJ; Waitman, LR; Whittle, J; Wruck, LM; Zemon, DN; Zhou, L, 2021) |
| "Switching warfarin to aspirin 3 months after successful RFCA of AF could be as safe and efficacious as long-term anticoagulation even in patients with CHA₂DS₂-VASc score≥2." | 5.40 | Safety and efficacy of switching anticoagulation to aspirin three months after successful radiofrequency catheter ablation of atrial fibrillation. ( Choi, KJ; Joung, B; Kim, YH; Lee, MH; Nam, GB; Pak, HN; Uhm, JS; Won, H, 2014) |
| "Dabigatran is a new anticoagulant and may be useful after AF ablation to prevent thromboembolic events." | 5.38 | The use of dabigatran immediately after atrial fibrillation ablation. ( Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA, 2012) |
| "Despite aspirin's established role in the treatment of atherosclerotic vascular disease, considerable controversy exists regarding its most effective dosing strategy." | 5.35 | Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). ( Amarenco, P; Aronow, HD; Califf, RM; Davis, S; Diener, HC; Easton, JD; Ferguson, J; Fitzgerald, DJ; Graffagnino, C; Harrington, RA; Koudstaal, PJ; Shuaib, A; Theroux, P; Topol, EJ; Vallee, M; Van de Werf, F, 2008) |
| "In patients without an established indication for oral anticoagulation after successful TAVR, a treatment strategy including rivaroxaban at a dose of 10 mg daily was associated with a higher risk of death or thromboembolic complications and a higher risk of bleeding than an antiplatelet-based strategy." | 5.34 | A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. ( Baldus, S; Dangas, GD; De Backer, O; Gilard, M; Giustino, G; Guimarães, AHC; Gullestad, L; Herrmann, HC; Kini, A; Mack, M; Makkar, RR; Mehran, R; Möllmann, H; Moreno, R; Schäfer, U; Seeger, J; Søndergaard, L; Tchétché, D; Thomitzek, K; Tijssen, JGP; Valgimigli, M; van Amsterdam, RGM; Volkl, AA; von Lewinski, D; Vranckx, P; Welsh, RC; Wildgoose, P; Windecker, S; Wöhrle, J; Zazula, A, 2020) |
| " Approach and Results: The CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) randomized patients with acute minor ischemic stroke or high-risk transient ischemic attack to clopidogrel plus aspirin or aspirin alone from October 1, 2009, to July 30, 2012, in China." | 5.34 | Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial. ( Li, H; Li, J; Lin, J; Liu, L; Wang, A; Wang, Y; Zhao, X; Zuo, Z, 2020) |
| "In STEMI patients with HPR, identified by vasodilator stimulated phosphoprotein (VASP)-determined PFT, switching clopidogrel to ticagrelor could significantly improve 1-year clinical outcomes without increasing the risk of bleeding." | 5.34 | Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study. ( Gao, L; Geng, L; Guo, W; Li, H; Li, J; Wan, Q; Wang, X; Wang, Y; You, J; Zhang, Q, 2020) |
| "5 mg twice daily plus aspirin was associated with a significantly lower incidence of the composite outcome of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes than aspirin alone." | 5.34 | Rivaroxaban in Peripheral Artery Disease after Revascularization. ( Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Brodmann, M; Capell, WH; Debus, ES; Diao, L; Diaz, R; Fanelli, F; Gudz, I; Haskell, LP; Hess, CN; Hiatt, WR; Jaeger, N; Kittelson, JM; Krievins, DK; Mátyás, L; Muehlhofer, E; Nehler, MR; Pap, AF; Patel, MR, 2020) |
| "Compared with ticagrelor plus aspirin, the effect of ticagrelor monotherapy in reducing the risk of clinically relevant bleeding without any increase in ischemic events was consistent among patients with or without DM undergoing PCI." | 5.34 | Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. ( Angiolillo, DJ; Baber, U; Briguori, C; Chandiramani, R; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, CM; Huber, K; Kaul, U; Kornowski, R; Kunadian, V; Mehran, R; Mehta, SR; Oldroyd, KG; Pocock, S; Sardella, G; Sartori, S; Sharma, S; Shlofmitz, RA; Weisz, G; Witzenbichler, B; Ya-Ling, H, 2020) |
| " Compared to ticagrelor plus aspirin, ticagrelor plus placebo resulted in significantly lower rates of Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding (4." | 5.34 | Ticagrelor With or Without Aspirin After Complex PCI. ( Angiolillo, DJ; Baber, U; Briguori, C; Chandiramani, R; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, CM; Giustino, G; Huber, K; Kaul, U; Kornowski, R; Kunadian, V; Mehran, R; Mehta, S; Oldroyd, K; Pocock, S; Sardella, G; Sartori, S; Sharma, S; Shlofmitz, R; Witzenbichler, B; Ya-Ling, H, 2020) |
| "The REDUAL PCI trial (Evaluation of Dual Therapy With Dabigatran vs Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting) demonstrated that, in patients with atrial fibrillation following percutaneous coronary intervention, bleeding risk was lower with dabigatran plus clopidogrel or ticagrelor (dual therapy) than warfarin plus clopidogrel or ticagrelor and aspirin (triple therapy)." | 5.34 | Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial. ( Berry, NC; Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Mauri, L; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2020) |
| "Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy." | 5.34 | Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. ( Ahn, CM; Cho, DK; Cho, JY; Cho, S; Cho, YH; Choi, D; Her, AY; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Jeon, DW; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Kwon, H; Nam, CM; Shin, DH; Suh, Y; Yoo, SY; Yun, KH, 2020) |
| "Trials have evaluated the use of clopidogrel and aspirin to prevent stroke after an ischemic stroke or transient ischemic attack (TIA)." | 5.34 | Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. ( Amarenco, P; Denison, H; Evans, SR; Himmelmann, A; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Molina, CA; Wang, Y, 2020) |
| "The present results are similar to those observed in clinical trials where administration of low-dose aspirin plus prasugrel was associated with a low rate of major bleeding and CV events." | 5.34 | Incidence of Cardiovascular Events and Safety Profile of Prasugrel in Korean Patients With Acute Coronary Syndrome. ( Choi, JH; Chon, MK; Chun, KJ; Hwang, KW; Jung, SM; Kim, JH; Kim, JS; Lee, SH; Lee, SY; Park, YH, 2020) |
| "The OPT-BIRISK trial is a multicenter, double-blinded, placebo-controlled randomized study designed to test the superiority of extended antiplatelet therapy with clopidogrel monotherapy compared with aspirin and clopidogrel for reduction of bleeding events in ACS patients with both high bleeding and high ischemic risks ("bi-risk")." | 5.34 | Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the O ( Angiolillo, DJ; Chen, S; Han, Y; Jing, Q; Li, J; Li, Y; Qiao, S; Wang, B; Wang, X, 2020) |
| "Emerging evidence suggests aspirin may be an effective venous thromboembolism (VTE) prophylaxis for orthopaedic trauma patients, with fewer bleeding complications." | 5.34 | Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial. ( Castillo, RC; Haac, BE; Manson, TT; O'Hara, NN; O'Toole, RV; Slobogean, GP; Stein, DM, 2020) |
| "Among patients undergoing TAVI who did not have an indication for oral anticoagulation, the incidence of bleeding and the composite of bleeding or thromboembolic events at 1 year were significantly less frequent with aspirin than with aspirin plus clopidogrel administered for 3 months." | 5.34 | Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. ( Baan, J; Brouwer, J; Buysschaert, I; Chan Pin Yin, DRPP; De Bruyne, B; Delewi, R; Dubois, CLF; Ferdinande, B; Frambach, P; Hermanides, RS; Holvoet, W; Kelder, JC; Nijenhuis, VJ; Peper, J; Rensing, BJWM; Roosen, J; Schotborgh, CE; Stella, PR; Swaans, MJ; Ten Berg, JM; Thielen, FWF; Timmers, L; Toušek, P; van 't Hof, AWJ; van der Harst, P; Van Der Heyden, JAS; van der Kley, F; van Houwelingen, GK; Veenstra, L, 2020) |
| "The stroke rate was numerically lower in the group on clopidogrel vs off clopidogrel among both the AMM alone arm (6." | 5.34 | Dual Antiplatelet Therapy Beyond 90 days in Symptomatic Intracranial Stenosis in the SAMMPRIS Trial. ( Abdul Rahman, L; Almallouhi, E; Chimowitz, MI; Cotsonis, G; Holmstedt, CA; Turan, TN, 2020) |
| "Dual antiplatelet therapy (DAPT) with aspirin and ticagrelor is recommended for at least 12 months in patients after an acute coronary syndrome (ACS)." | 5.34 | Improving Adherence to Ticagrelor in Patients After Acute Coronary Syndrome: Results from the PROGRESS Trial. ( Calabrò, P; Cesaro, A; Cirillo, PL; Concilio, C; Crisci, M; Di Maio, D; Di Maio, M; Diana, V; Fimiani, F; Gragnano, F; Moscarella, E; Pariggiano, I; Taglialatela, V, 2020) |
| " Low-dose razaxaban was useful in combination with sub-optimal doses of aspirin and/or clopidogrel for the prevention of occlusive arterial thrombosis without excessive bleeding." | 5.34 | Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. ( Crain, EJ; Knabb, RM; Lam, PY; Quan, ML; Watson, CA; Wexler, RR; Wong, PC, 2007) |
| "In patients with stable coronary artery disease and diabetes without a history of myocardial infarction or stroke, those who received ticagrelor plus aspirin had a lower incidence of ischemic cardiovascular events but a higher incidence of major bleeding than those who received placebo plus aspirin." | 5.30 | Ticagrelor in Patients with Stable Coronary Disease and Diabetes. ( Andersson, M; Bhatt, DL; Corbalán, R; Cornel, JH; Fox, K; Ge, J; Harrington, RA; Held, C; Himmelmann, A; Leiter, LA; Leonsson-Zachrisson, M; Liu, Y; Mehta, SR; Nicolau, JC; Opolski, G; Ridderstråle, W; Simon, T; Steg, PG; Widimský, P; Zateyshchikov, D, 2019) |
| "Adding rivaroxaban to aspirin in patients with stable atherosclerotic disease reduces the recurrence of cardiovascular disease (CVD) but increases the risk of major bleeding." | 5.30 | Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. ( Alings, M; Berkowitz, SD; Bosch, J; de Vries, TI; Dorresteijn, JAN; Dyal, L; Eikelboom, JW; Fox, KAA; van der Graaf, Y; Visseren, FLJ; Westerink, J, 2019) |
| "5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events and mortality and increased bleeding." | 5.30 | Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. ( Berkowitz, SD; Bhatt, DL; Bosch, JJ; Cairns, JA; Connolly, SJ; Cook Bruns, N; Dagenais, GR; Diaz, R; Eikelboom, JW; Fox, KAA; Hart, RG; Leong, DP; Maggioni, AP; Muehlhofer, E; O'Donnell, M; Shestakovska, O; Tasto, C; Yusuf, S, 2019) |
| "In a double-blind trial, we examined the effect of ticagrelor alone as compared with ticagrelor plus aspirin with regard to clinically relevant bleeding among patients who were at high risk for bleeding or an ischemic event and had undergone PCI." | 5.30 | Ticagrelor with or without Aspirin in High-Risk Patients after PCI. ( Angiolillo, DJ; Baber, U; Briguori, C; Cha, JY; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Džavík, V; Escaned, J; Gibson, CM; Gil, R; Gurbel, P; Hamm, CW; Han, YL; Henry, T; Huber, K; Kastrati, A; Kaul, U; Kornowski, R; Krucoff, M; Kunadian, V; Marx, SO; Mehran, R; Mehta, SR; Moliterno, D; Ohman, EM; Oldroyd, K; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Steg, PG; Weisz, G; Witzenbichler, B, 2019) |
| "Between 1 month and 12 months after PCI in ACS, aspirin was associated with increased bleeding risk and appeared not to add to the benefit of ticagrelor on ischemic events." | 5.30 | Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial. ( Angiolillo, DJ; Bhatt, DL; Chang, CC; Chichareon, P; Dangas, GD; Deliargyris, EN; Hamm, C; Kogame, N; Modolo, R; Onuma, Y; Rademaker-Havinga, T; Serruys, PW; Steg, PG; Storey, RF; Takahashi, K; Tomaniak, M; Valgimigli, M; Vranckx, P; Windecker, S, 2019) |
| "Long-term ticagrelor monotherapy following 1-month DAPT can favorably balance ischemic and bleeding risks in patients with multivessel PCI." | 5.30 | Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. ( Carrie, D; Chang, CC; Chichareon, P; Chowdhary, S; de Winter, RJ; Eitel, I; Garg, S; Hamm, C; Kogame, N; Magro, M; Modolo, R; Ong, P; Onuma, Y; Ottesen, MM; Serruys, PW; Steg, PG; Stoll, HP; Takahashi, K; Tijssen, JGP; Tomaniak, M; Valgimigli, M; Vranckx, P; Windecker, S; Wykrzykowska, JJ; Zweiker, R, 2019) |
| "In RE-DUAL PCI, 2,725 patients with atrial fibrillation (993 with diabetes) who had undergone PCI were assigned to warfarin triple therapy (warfarin, clopidogrel or ticagrelor, and aspirin) or dabigatran dual therapy (dabigatran 110 mg or 150 mg twice daily and clopidogrel or ticagrelor)." | 5.30 | Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes. ( Bhatt, DL; Cannon, CP; Hohnloser, SH; Kimura, T; Lip, GYH; Maeng, M; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2019) |
| "Triflusal has demonstrated an efficacy similar to aspirin in the prevention of vascular events in patients with acute myocardial infarction (ΜΙ) and ischaemic stroke but with less bleeding events." | 5.30 | Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial. ( Adamopoulos, D; Asimakopoulos, C; Bourdakis, A; Chantzichristos, VG; Darmanis, P; Dimitriadou, A; Gkiokas, S; Goudevenos, JA; Ipeirotis, K; Kalantzi, KI; Kitikidou, K; Klonaris, I; Kostaki, A; Logothetis, D; Mainas, K; Mais, T; Maragiannis, A; Martiadou, K; Mavronasos, K; Michelongonas, I; Mitropoulos, D; Ntalas, IV; Panagiotakos, DB; Papadimitriou, G; Papadopoulos, A; Papaioakeim, M; Sofillas, K; Stabola, S; Stefanakis, E; Stergiou, D; Thoma, M; Tselepis, AD; Tsoumani, ME; Zenetos, A; Zisekas, S, 2019) |
| " The addition of cilostazol to clopidogrel may provide a more rapid decrease in PRU to therapeutic levels without increasing the risk of hemorrhage." | 5.30 | DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan. ( Chang, CC; Chen, SM; Chen, YC; Cheng, SM; Chuang, CL; Lin, FY; Lin, RH; Lin, YW; Sheu, JS; Tsai, CS, 2019) |
| " In patients with prior coronary artery disease or peripheral arterial disease the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial revealed that compared with acetylsalicylic acid alone, dual pathway inhibition with low-dose rivaroxaban (2." | 5.30 | Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. ( Coppens, M; Eikelboom, JWA; Weitz, JI, 2019) |
| "The benefits of both dabigatran 110 mg and 150 mg dual therapy compared with warfarin triple therapy in reducing bleeding risks were consistent across subgroups of patients with or without ACS, and patients treated with ticagrelor or clopidogrel." | 5.30 | Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. ( Bhatt, DL; Brueckmann, M; Cannon, CP; Hohnloser, SH; Kimura, T; Kleine, E; Lip, GYH; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2019) |
| "Using the standard maintenance dose of prasugrel (10 mg/day) as part of triple therapy with aspirin and an oral anticoagulant (OAC) is not recommended in the current guidelines because it increases the risk of bleeding compared with clopidogrel." | 5.30 | Safety and Efficacy of Low-Dose Prasugrel as Part of Triple Therapy With Aspirin and Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention - From the TWMU-AF PCI Registry. ( Arashi, H; Ebihara, S; Fujii, S; Hagiwara, N; Honda, A; Jujo, K; Kawamoto, T; Mori, F; Nakao, M; Ota, Y; Otsuki, H; Saito, K; Takagi, A; Tanaka, H; Tanaka, K; Yamaguchi, J; Yoshikawa, M, 2019) |
| "Results show the short-term risk of hemorrhage in treating patients with acute transient ischemic attack (TIA) or minor acute ischemic stroke (AIS) with clopidogrel plus aspirin or aspirin alone." | 5.30 | Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. ( Barsan, W; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY; Tillman, H, 2019) |
| "5 mg bd plus aspirin), versus aspirin alone, are preserved in patients with moderate renal dysfunction without evidence of an excess hazard of bleeding." | 5.30 | Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. ( Connolly, SJ; Eikelboom, JW; Fox, KAA; Metsarinne, KP; Shestakovska, O; Yusuf, S, 2019) |
| "We conducted a multicenter, randomized, double-blind trial of dabigatran at a dose of 150 mg or 110 mg twice daily as compared with aspirin at a dose of 100 mg once daily in patients who had had an embolic stroke of undetermined source." | 5.30 | Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. ( Bernstein, RA; Brueckmann, M; Chernyatina, M; Cotton, D; Cronin, L; Diener, HC; Donnan, G; Easton, JD; Ferro, JM; Granger, CB; Grauer, C; Grond, M; Kallmünzer, B; Kreuzer, J; Krupinski, J; Lee, BC; Lemmens, R; Masjuan, J; Odinak, M; Sacco, RL; Saver, JL; Schellinger, PD; Toni, D; Toyoda, K; Uchiyama, S, 2019) |
| "SOCRATES compared ticagrelor and aspirin in 13,199 patients with acute minor stroke or high-risk transient ischemic attack." | 5.30 | Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Johnston, SC; Knutsson, M; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KL, 2019) |
| "Antiplatelet therapy combining aspirin and clopidogrel is considered to be a key intervention for acute ischaemic minor stroke (AIMS) and transient ischaemic attack (TIA)." | 5.30 | Personalised antiplatelet therapy based on pharmacogenomics in acute ischaemic minor stroke and transient ischaemic attack: study protocol for a randomised controlled trial. ( Hu, L; Jiang, HY; Li, ZZ; Xue, J; Yue, YH; Zhang, XG; Zhu, XQ, 2019) |
| "To investigate the association of mandatory reporting of CYP2C19 pharmacogenomic testing, provided to investigators with no direct recommendations on how to use these results, with changes in P2Y12 inhibitor use, particularly clopidogrel, in the Randomized Trial to Compare the Safety of Rivaroxaban vs Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome (GEMINI-ACS-1) clinical trial." | 5.30 | P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. ( Bode, C; Cornel, JH; Gibson, CM; James, S; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Plotnikov, AN; Povsic, TJ; Rockhold, FW; Roe, MT; Steg, PG; Welsh, RC; White, J, 2019) |
| "Among patients undergoing PCI, 1 month of DAPT followed by clopidogrel monotherapy, compared with 12 months of DAPT with aspirin and clopidogrel, resulted in a significantly lower rate of a composite of cardiovascular and bleeding events, meeting criteria for both noninferiority and superiority." | 5.30 | Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. ( Abe, M; Ando, K; Doi, M; Domei, T; Furukawa, Y; Hanaoka, KI; Hata, Y; Hibi, K; Ikari, Y; Kadota, K; Kawai, K; Kimura, T; Kozuma, K; Morimoto, T; Morino, Y; Nakagawa, Y; Nakao, K; Nanasato, M; Natsuaki, M; Noda, T; Ohya, M; Okayama, H; Sakamoto, H; Seino, Y; Shiomi, H; Suematsu, N; Suwa, S; Tada, T; Takagi, K; Takamisawa, I; Tanabe, K; Toyota, T; Watanabe, H; Yagi, M; Yokomatsu, T, 2019) |
| "In patients with acute minor ischemic stroke or high-risk transient ischemic attack enrolled in the POINT trial (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke [POINT] Trial), the combination of clopidogrel and aspirin for 90 days reduced major ischemic events but increased major hemorrhage in comparison to aspirin alone." | 5.30 | Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke. ( Albers, GW; Barsan, WG; Cucchiara, BL; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Kleindorfer, DO; Lindblad, AS; Lutsep, HL; Palesch, YY; Pearson, C; Sethi, P; Vora, N; Zurita, KG, 2019) |
| "In patients with stable coronary artery disease, addition of rivaroxaban to aspirin lowered major vascular events, but increased major bleeding." | 5.27 | Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. ( Anand, SS; Avezum, AA; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, SJ; Cook Bruns, N; Dagenais, G; Dans, AL; Dyal, L; Eikelboom, JW; Felix, C; Fox, KAA; Guzik, TJ; Ha, JW; Hori, M; Keltai, K; Lanas, F; Lisheng, L; Lonn, E; Maggioni, AP; Metsarinne, K; O'Donnell, M; Parkhomenko, AN; Torp-Pedersen, C; Varigos, JD; Widimsky, P; Yusoff, K; Yusuf, S, 2018) |
| " The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0·72, 95% CI 0·57-0·90, p=0·0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0·54 95% CI 0·35-0·82, p=0·0037)." | 5.27 | Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. ( Aboyans, V; Alings, M; Anand, SS; Avezum, AA; Bangdiwala, SI; Bhatt, DL; Bosch, J; Branch, K; Chen, E; Commerford, PJ; Connolly, SJ; Diaz, R; Eikelboom, JW; Fox, KAA; Hart, RG; Kakkar, AK; Keltai, K; Leong, DP; Lewis, BS; Lopez-Jaramillo, P; Maggioni, AP; Misselwitz, F; O'Donnell, M; Pogosova, N; Ryden, L; Störk, S; Vanassche, T; Varigos, JD; Vinereanu, D; Widimsky, P; Yusuf, S; Zhu, J, 2018) |
| "Concomitant aspirin (ASA) is often prescribed in anticoagulated patients with atrial fibrillation (AF)." | 5.27 | Impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation taking aspirin: An analysis from the SPORTIF trials. ( Lip, GYH; Proietti, M, 2018) |
| "The associations between osteoprotegerin and the composite end point of cardiovascular death, nonprocedural spontaneous myocardial infarction or stroke, and non-coronary artery bypass grafting major bleeding during 1 year of follow-up were assessed by Cox proportional hazards models." | 5.27 | Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. ( Åkerblom, A; Aukrust, P; Becker, RC; Bertilsson, M; Ghukasyan, T; Himmelmann, A; James, SK; Kontny, F; Michelsen, AE; Siegbahn, A; Storey, RF; Ueland, T; Wallentin, L, 2018) |
| "This trial aims to determine whether the addition of GXNT will further improve prognosis without increasing bleeding risk for patients with coronary artery disease who have switched from DAPT to aspirin alone after PCI." | 5.27 | Guanxinning tablet for patients who switch from dual antiplatelet therapy to aspirin alone after percutaneous coronary intervention: study protocol for a cluster randomized controlled trial. ( Chen, Z; Gao, R; Ju, J; Li, J; Liu, J; Lu, F; Xu, H, 2018) |
| "Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces thrombotic events in patients undergoing percutaneous coronary intervention (PCI), but these benefits come at the expense of increased risk of bleeding when compared with aspirin monotherapy." | 5.27 | Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial. ( Cho, BR; Cho, DK; Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Im, ES; Lee, JM; Lee, JY; Lee, SH; Oh, JH; Oh, SK; Park, TK; Song, YB; Yang, JH, 2018) |
| "Clinical trials and meta-analyses have suggested that aspirin may be effective for the prevention of venous thromboembolism (proximal deep-vein thrombosis or pulmonary embolism) after total hip or total knee arthroplasty, but comparisons with direct oral anticoagulants are lacking for prophylaxis beyond hospital discharge." | 5.27 | Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. ( Abianui, A; Anderson, DR; Andreou, P; Belzile, E; Bohm, E; Carrier, M; Coyle, D; Crowther, M; Dolan, S; Doucette, S; Dunbar, M; Fisher, W; Forsythe, M; Gofton, W; Gross, P; Kahn, SR; Kim, P; Kovacs, MJ; MacDonald, SJ; Murnaghan, J; Pelet, S; Pleasance, S; Rodger, MA; Theriault, C; Vendittoli, PA; Wells, PS; Zukor, D, 2018) |
| "Ticagrelor plus low-dose aspirin for up to 1 year was associated with a low rate of major bleeding events and a low incidence of major CV events (CV death, myocardial infarction, stroke) in Chinese patients with ACS." | 5.27 | Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study. ( Gao, R; Han, Y; Leonsson-Zachrisson, M; Liu, H; Liu, L; Shen, L; Su, G; Wang, Y; Wang, Z; Wu, Y; Yuan, Z; Zhang, A; Zhang, H; Zheng, Y, 2018) |
| "These results suggest that patients who have undergone EVT have similar risks for major and life-threatening bleeding events with edoxaban and aspirin compared with clopidogrel and aspirin." | 5.27 | Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial. ( Adams, G; Ansel, G; Baumgartner, I; Grosso, M; Jaff, M; Lin, M; Mercur, MF; Minar, E; Moll, F; Nwachuku, C; Rundback, J; Tangelder, M; Zeller, T, 2018) |
| " The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days." | 5.27 | Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018) |
| "Rivaroxaban was not superior to aspirin with regard to the prevention of recurrent stroke after an initial embolic stroke of undetermined source and was associated with a higher risk of bleeding." | 5.27 | Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. ( Amarenco, P; Ameriso, SF; Arauz, A; Bangdiwala, SI; Benavente, OR; Bereczki, D; Berkowitz, SD; Bornstein, N; Brouns, R; Connolly, SJ; Cunha, L; Czlonkowska, A; Davalos, A; De Vries Basson, MM; Eckstein, J; Endres, M; Gagliardi, RJ; Hankey, GJ; Hart, RG; Joyner, C; Kasner, SE; Kirsch, B; Lang, W; Lavados, P; Lindgren, A; Mikulik, R; Muir, KW; Mundl, H; Ntaios, G; O'Donnell, MJ; Ozturk, S; Pare, G; Pater, C; Peacock, WF; Peters, G; Shamalov, N; Sharma, M; Sheridan, P; Shoamanesh, A; Swaminathan, B; Tatlisumak, T; Themeles, E; Toni, D; Uchiyama, S; Veltkamp, R; Wang, Y; Weitz, JI; Yoon, BW, 2018) |
| "Form II clopidogrel bisulfate (Plavix) has been extensively used in patients with acute coronary syndrome." | 5.27 | Clinical pharmacodynamics and long-term efficacy of Talcom vs. Plavix in patients undergoing coronary stent implantation: a randomized study with 5-year follow-up. ( Chen, J; Fan, Y; Ji, Y; Kong, D; Li, C; Li, J; Meng, H; Xu, K; Ye, S; Zhang, J; Zhu, T, 2018) |
| " Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear." | 5.27 | Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. ( Adler, A; Armitage, J; Aung, T; Baigent, C; Barton, J; Bodansky, J; Bowman, L; Buck, G; Chen, F; Collins, R; Cox, J; Farmer, A; Haynes, R; Lay, M; Mafham, M; McPherson, R; Murawska, A; Murphy, K; Neil, A; Parish, S; Peto, R; Sammons, E; Simpson, D; Stevens, W; Wallendszus, K; Waters, E; Young, A, 2018) |
| "The use of low-dose aspirin as a primary prevention strategy in older adults resulted in a significantly higher risk of major hemorrhage and did not result in a significantly lower risk of cardiovascular disease than placebo." | 5.27 | Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. ( Abhayaratna, WP; Beilin, LJ; Brauer, D; Cloud, G; Donnan, GA; Eaton, CB; Ernst, ME; Fitzgerald, SM; Grimm, R; Jelinek, M; Johnston, CI; Kirpach, B; Lockery, JE; Mahady, SE; Malik, M; Margolis, KL; McNeil, JJ; Murray, AM; Nelson, MR; Orchard, SG; Radziszewska, B; Reid, CM; Ryan, J; Satterfield, S; Shah, RC; Stocks, N; Storey, E; Tonkin, AM; Trevaks, RE; Williamson, JD; Wolfe, R; Wood, EM; Woods, RL, 2018) |
| "Aspirin use in healthy elderly persons did not prolong disability-free survival over a period of 5 years but led to a higher rate of major hemorrhage than placebo." | 5.27 | Effect of Aspirin on Disability-free Survival in the Healthy Elderly. ( Abhayaratna, WP; Beilin, LJ; Donnan, GA; Ernst, ME; Fitzgerald, SM; Gibbs, P; Grimm, R; Johnston, CI; Kirpach, B; Lockery, JE; Margolis, KL; McNeil, JJ; Murray, AM; Nelson, MR; Newman, AB; Orchard, SG; Radziszewska, B; Reid, CM; Ryan, J; Shah, RC; Stocks, N; Storey, E; Tonkin, AM; Trevaks, RE; Williamson, JD; Wolfe, R; Woods, RL, 2018) |
| "Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates." | 5.24 | Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. ( Bauersachs, R; Berkowitz, SD; Beyer-Westendorf, J; Bounameaux, H; Brighton, TA; Cohen, AT; Davidson, BL; Decousus, H; Freitas, MCS; Haskell, L; Holberg, G; Kakkar, AK; Lensing, AWA; Pap, AF; Prandoni, P; Prins, MH; van Bellen, B; Verhamme, P; Weitz, JI; Wells, PS, 2017) |
| "A dual pathway antithrombotic therapy approach combining low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of patients with acute coronary syndromes had similar risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor." | 5.24 | Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. ( Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J, 2017) |
| "The DAPT (Dual Antiplatelet Therapy) study randomized 11,648 patients free from ischemic and bleeding events 12 months after coronary stenting to continued thienopyridine plus aspirin therapy for an additional 18 months versus aspirin therapy alone." | 5.24 | Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. ( Apruzzese, PK; Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017) |
| "Newer P2Y12 blockers (prasugrel and ticagrelor) demonstrated significant ischaemic benefit over clopidogrel after acute coronary syndrome (ACS)." | 5.24 | Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. ( Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deffarges, S; Deharo, P; Fourcade, L; Johnson, TW; Lambert, M; Morange, PE; Mouret, JP; Quilici, J; Verdier, V, 2017) |
| "The aim of this study was to compare aspirin plus clopidogrel with aspirin alone as antithrombotic treatment following transcatheter aortic valve replacement (TAVR) for the prevention of ischemic events, bleeding events, and death." | 5.24 | Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi ( Al-Qoofi, F; Chamandi, C; Côté, M; Dumont, E; Garcia Del Blanco, B; Généreux, P; Maluenda, G; Masson, JB; Paradis, JM; Pelletier, M; Rodés-Cabau, J; Serra, V; Thoenes, M; Webb, JG; Welsh, RC, 2017) |
| " Ticagrelor was more effective than clopidogrel in TAPT; however, when using the combination of aspirin, ticagrelor, and tirofiban, close monitoring is required for possible bleeding complications." | 5.24 | Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study. ( Chen, Q; Geng, G; Han, W; Hao, Y; Hao, Z; Jia, K; Liu, H; Liu, L; Liu, Y; Wang, D; Zhou, Y, 2017) |
| "The ITALIC (Is There a Life for DES After Discontinuation of Clopidogrel) trial showed that rates of bleeding and thrombotic events at 1 year were much the same with 6 versus 12 months of DAPT after percutaneous coronary intervention with second-generation drug-eluting stents." | 5.24 | 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel). ( Armengaud, J; Barragan, P; Ben Amer, H; Berlan, J; Blanchard, D; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Didier, R; Druelles, P; Dupouy, P; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J, 2017) |
| "5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone." | 5.24 | Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. ( Alings, M; Anand, SS; Avezum, A; Bhatt, DL; Bosch, J; Branch, KRH; Chen, E; Commerford, PJ; Connolly, SJ; Cook Bruns, N; Dagenais, GR; Dans, AL; Diaz, R; Eikelboom, JW; Ertl, G; Felix, C; Fox, KAA; Guzik, TJ; Hart, RG; Hori, M; Kakkar, AK; Keltai, M; Kim, JH; Lanas, F; Leong, D; Lewis, BS; Liang, Y; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; Metsarinne, KP; Misselwitz, F; O'Donnell, M; Parkhomenko, AN; Piegas, LS; Pogosova, N; Probstfield, J; Ryden, L; Shestakovska, O; Steg, PG; Störk, S; Tonkin, AM; Torp-Pedersen, C; Verhamme, PB; Vinereanu, D; Widimsky, P; Yusoff, K; Yusuf, S; Zhu, J, 2017) |
| "Acute coronary syndrome patients, 1 month after coronary stenting and event free, were randomly assigned to aspirin and clopidogrel (switched DAPT) or continuation of drug regimen (unchanged DAPT)." | 5.24 | Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study. ( Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Camoin-Jau, L; Cuisset, T; Deharo, P; Fernandez, M; Fourcade, L; Ibrahim, M; Johnson, TW; Morange, PE; Quilici, J; Suchon, P; Verdier, V, 2017) |
| "Tranexamic acid reduces the risk of bleeding among patients undergoing cardiac surgery, but it is unclear whether this leads to improved outcomes." | 5.24 | Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. ( Bussières, JS; Byrne, K; Chan, MT; Cooper, DJ; Forbes, A; Jayarajah, M; Landoni, G; Marasco, S; McGuinness, S; McNeil, J; Myles, PS; Painter, T; Silbert, B; Smith, JA; Wallace, S, 2017) |
| "In the SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes), ticagrelor was not superior to aspirin." | 5.24 | Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KS, 2017) |
| "Our results suggest that aspirin might be equally effective as warfarin in preventing thromboembolic events after BAVR, but with less major bleedings." | 5.24 | Antithrombotic therapy after bioprosthetic aortic valve implantation: Warfarin versus aspirin, a randomized controlled trial. ( Køber, L; Lilleør, NB; Lund, JT; Møller, CH; Olsen, PS; Rafiq, S; Steinbrüchel, DA; Thiis, JJ, 2017) |
| "In the PRODIGY trial, prolonging clopidogrel-based DAPT beyond six months in elderly patients increased the risk of bleeding, without affording a significant prevention of ischaemic events." | 5.24 | Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial. ( Ariotti, S; Franzone, A; Gargiulo, G; Heg, D; Magnani, G; Marino, M; Piccolo, R; Santucci, A; Tebaldi, M; Valgimigli, M; Windecker, S, 2017) |
| "Accordingly, 50 mg clopidogrel plus aspirin, and 75 mg clopidogrel plus aspirin were all superior to aspirin alone as stroke prevention in patients with cerebral infarction or transient ischemic attack combined with intracranial and extracranial arteriostenosis." | 5.24 | The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients: A randomized and controlled trail. ( Dong, AQ; Liu, H; Liu, JQ; Su, N; Wu, HJ; Zuo, FT, 2017) |
| "To investigate the feasibility of periodontal mechanical therapy for chronic periodontitis and coronary heart disease patients with low dose of aspirin." | 5.24 | [Bleeding control of periodontal mechanical therapy for patients taking aspirin]. ( Ding, F; Duan, XQ; Han, X; Liu, DY; Lyu, YL; Xuan, W, 2017) |
| "The use of aspirin in subjects with no overt CVD was associated with a neutral effect on all-cause death and a modest lower risk of major cardiovascular events at the price of an increased risk in major bleeding." | 5.22 | Efficacy and Safety of Aspirin for Primary Cardiovascular Risk Prevention in Younger and Older Age: An Updated Systematic Review and Meta-analysis of 173,810 Subjects from 21 Randomized Studies. ( Agnello, F; Buccheri, S; Calderone, D; Capodanno, D; Franchina, G; Greco, A; Ingala, S; Scalia, L, 2022) |
| "A systematic electronic search of the literature was performed using PubMed/MEDLINE, Scopus, and CENTRAL, to assess the risk of bleeding in patients who do not interrupt single antiplatelet therapy (P2Y12 inhibitors or aspirin) and undergone colonoscopy with polypectomy." | 5.22 | Risk of colonoscopic post-polypectomy bleeding in patients on single antiplatelet therapy: systematic review with meta-analysis. ( Fabiani, S; Latella, G; Longo, S; Magistroni, M; Mancusi, A; Romano, S; Stefanelli, G; Valvano, M; Vernia, F; Viscido, A, 2022) |
| " Clinical equipoise also persists around questions such as the utility of dual antiplatelet therapy in conjunction with rivaroxaban after high-risk endovascular interventions and the optimal therapy for patients experiencing acute limb ischemia." | 5.22 | Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making. ( Anand, SS; Chan, N; Kaplovitch, E; McClure, GR, 2022) |
| "To evaluate the difference between low-molecular-weight heparin (LMWH) and aspirin in preventing early neurological deterioration (END) and recurrent ischemic stroke (RIS), post-recovery independence, and safety outcomes in acute ischemic stroke." | 5.22 | Low-Molecular-Weight Heparin Versus Aspirin in Early Management of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. ( Liu, Z; Tian, M; Wang, Z; Xia, H; Zhou, Z, 2022) |
| "To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on the effectiveness of aspirin to reduce the risk of CVD events (myocardial infarction and stroke), cardiovascular mortality, and all-cause mortality in persons without a history of CVD." | 5.22 | Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. ( Barry, MJ; Cabana, M; Chelmow, D; Coker, TR; Davidson, KW; Davis, EM; Donahue, KE; Jaén, CR; Krist, AH; Kubik, M; Li, L; Mangione, CM; Ogedegbe, G; Pbert, L; Ruiz, JM; Stevermer, J; Tseng, CW; Wong, JB, 2022) |
| "Low-dose aspirin was associated with small absolute risk reductions in major cardiovascular disease events and small absolute increases in major bleeding." | 5.22 | Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Bean, SI; Evans, CV; Guirguis-Blake, JM; Perdue, LA; Senger, CA, 2022) |
| " In patients with established cardiovascular disease, clopidogrel was associated with a 17% relative-risk reduction for nonfatal MI, borderline decreased risk for MACE, and similar risk for all-cause mortality, stroke, and major bleeding compared with aspirin." | 5.22 | Clopidogrel Monotherapy versus Aspirin Monotherapy in Patients with Established Cardiovascular Disease: Systematic Review and Meta-Analysis. ( Diener, HC; Kyriakoulis, IG; Ntaios, G; Sagris, D; Tasoudis, PT, 2022) |
| "This meta-analysis found that aspirin use was associated with a reduction in mortality in patients with COVID-19 and not with an increased risk of bleeding." | 5.22 | Does aspirin have an effect on risk of death in patients with COVID-19? A meta-analysis. ( Feng, L; Gao, J; Liu, H; Lowe, S; Ma, S; Qu, G; Su, W; Sun, C; Sun, Y; Wu, B; Xia, W; Xie, P; Zhou, Z, 2022) |
| " One study (CAPRIE; ASA versus clopidogrel) included patients diagnosed with hypertension (mean age 62." | 5.22 | Antiplatelet agents and anticoagulants for hypertension. ( Kozieł-Siołkowska, M; Lip, GY; Shantsila, E, 2022) |
| "To compare the risks of vein graft failure and bleeding associated with ticagrelor dual antiplatelet therapy (DAPT) or ticagrelor monotherapy vs aspirin among patients undergoing coronary artery bypass graft surgery." | 5.22 | Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure After Coronary Artery Bypass Graft Surgery: A Systematic Review and Meta-analysis. ( Angiolillo, DJ; Audisio, K; Fremes, SE; Gaudino, M; Janssen, PWA; Kulik, A; Mehran, R; Peper, J; Redfors, B; Ruel, M; Sandner, S; Saw, J; Soletti, GJ; Starovoytov, A; Ten Berg, JM; Willemsen, LM; Zhao, Q; Zhu, Y, 2022) |
| " Cilostazol proved to be the most efficacious in reducing stroke recurrence and the risk of bleeding (RR = 0." | 5.22 | Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials. ( Bálint, A; El Abdallaoui, OEA; Komócsi, A; Kupó, P; Szapáry, L; Szapáry, LB; Tornyos, D, 2022) |
| "High-quality evidence from trials directly comparing single antiplatelet therapies in symptomatic peripheral arterial disease (PAD) to dual antiplatelet therapies or acetylsalicylic acid (ASA) plus low-dose rivaroxaban is lacking." | 5.22 | Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis. ( de Borst, GJ; Hannink, G; Kramers, K; Maas, DPMSM; Mees, BME; Reijnen, MMPJ; Riksen, NP; Ten Cate, H; van der Vijver-Coppen, RJ; Warlé, MC; Willems, LH; Zeebregts, CJ, 2022) |
| "Long-term therapy with aspirin, clopidogrel, or aspirin plus extended-release dipyridamole is recommended for secondary stroke prevention in patients with noncardioembolic ischemic stroke." | 5.22 | Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies. ( Moustafa, B; Testai, FD, 2022) |
| "Our systematic review and meta-analysis suggested that aspirin alone could decrease the risk of bleeding and was not associated with higher risk of mortality, stroke or myocardial infarction compared with DAPT." | 5.22 | Aspirin Alone Versus Dual Antiplatelet Therapy after Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis. ( Guan, Y; Huang, J; Lin, X; Wang, L; Wang, S, 2022) |
| " There was a 51% reduction in major or life-threatening bleeding with aspirin compared with DAPT [RR 0." | 5.22 | Aspirin Versus Dual Antiplatelet Therapy in Patients Undergoing Trans-Catheter Aortic Valve Implantation, Updated Meta-Analysis. ( Alkhalil, M; Das, R; Edwards, R; Kalra, A; Puri, R; Zaman, A, 2022) |
| " We aimed to perform the first systematic review and meta-analysis comparing dual antiplatelet therapy (DAPT) versus aspirin alone in terms of postendoscopic retrograde cholangiopancreatography (ERCP) bleeding." | 5.22 | No Significant Difference in Post-ERCP Bleeding Rates Between Dual Antiplatelet Agents and Aspirin Alone: A Systematic Review and Meta-analysis. ( Bansal, V; Bhurwal, A; Brahmbhatt, B; Goel, A; Mutneja, H; Patel, A; Sarkar, A, 2022) |
| "P2Y12 receptor inhibitor plus aspirin vs aspirin given within 24 h after acute noncardioembolic ischemic stroke or TIA reduces the risk of subsequent stroke." | 5.22 | P2Y12 receptor inhibitor plus aspirin versus aspirin treated within 24 hours of acute noncardioembolic ischemic stroke or TIA: Meta-analysis. ( Huang, WY; Lee, M; Ovbiagele, B, 2022) |
| "Aspirin cannot be routinely recommended for the primary prevention of CVD in individuals with CKD as there is no evidence for its benefit but there is an increased risk of bleeding." | 5.22 | Aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. ( Ashton, L; Brunskill, NJ; Burton, JO; Gray, LJ; Major, RW; Pallikadavath, S, 2022) |
| "We examined the effects of cytochrome P450 2C19 (CYP2C19) polymorphisms on the efficacy and safety of prasugrel and clopidogrel in a post hoc analysis of the PRASugrel compared with clopidogrel For Japanese patIenTs with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) (PRASFIT-ACS) study." | 5.22 | Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. ( Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Tanaka, Y; Yokoi, H, 2016) |
| "Bleeding accounted for a minority of deaths among patients treated with continued thienopyridine." | 5.22 | Causes of late mortality with dual antiplatelet therapy after coronary stents. ( Braunwald, E; Cohen, DJ; Cutlip, DE; D'Agostino, RB; Elmariah, S; Kereiakes, DJ; Massaro, JM; Mauri, L; Steg, PG; Windecker, S; Wiviott, SD; Yeh, RW, 2016) |
| "compared with aspirin, apixaban was more efficacious for preventing strokes and systemic embolism in patients ≥85 years (absolute rate [AR] 1%/year on apixaban versus 7." | 5.22 | Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. ( Avezum, A; Connolly, SJ; Diaz, R; Eikelboom, JW; Hart, RG; Lanas, F; Ng, KH; Shestakovska, O; Yusuf, S, 2016) |
| "Patients (n >16,000) are randomised (1:1 ratio) to ticagrelor 90 mg twice daily for 24 months plus ASA ≤100 mg for one month versus DAPT with either ticagrelor (acute coronary syndrome) or clopidogrel (stable coronary artery disease) for 12 months plus ASA ≤100 mg for 24 months." | 5.22 | Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. ( Garcia-Garcia, HM; Hamm, C; Jüni, P; Serruys, PW; Steg, PG; Valgimigli, M; van Es, GA; Vranckx, P; Windecker, S, 2016) |
| "In EES-treated subjects, significant reductions in stent thrombosis and MI and an increase in bleeding were observed with continued thienopyridine beyond 1 year compared with aspirin alone." | 5.22 | Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. ( Cohen, DJ; Cutlip, DE; Hermiller, JB; Hsieh, WH; Kereiakes, DJ; Krucoff, MW; Massaro, JM; Mauri, L; Steg, PG; Windecker, S; Yeh, RW, 2016) |
| "The objective of the present substudy was to examine whether aspirin poor/high responsiveness (APR/AHR) is associated with increased rates of major adverse cardiovascular events (MACE) and serious bleeding after primary percutaneous coronary intervention (PPCI)." | 5.22 | Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention. ( Asanin, M; Čolić, M; Krljanac, G; Kruzliak, P; Lasica, R; Marinkovic, J; Mrdovic, I; Savic, L; Stanković, S, 2016) |
| "The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours." | 5.22 | Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016) |
| " The prediction rule assigned 1 point each for myocardial infarction at presentation, prior myocardial infarction or PCI, diabetes, stent diameter less than 3 mm, smoking, and paclitaxel-eluting stent; 2 points each for history of congestive heart failure/low ejection fraction and vein graft intervention; -1 point for age 65 to younger than 75 years; and -2 points for age 75 years or older." | 5.22 | Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. ( Apruzzese, PK; Camenzind, E; Cohen, DJ; Cutlip, DE; Gershlick, AH; Kereiakes, DJ; Massaro, JM; Mauri, L; Normand, SL; Rinaldi, MJ; Secemsky, EA; Song, Y; Spertus, JA; Steg, PG; Wijns, W; Yeh, RW, 2016) |
| "Medically managed patients with ACS in the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial were randomised to clopidogrel versus prasugrel (plus aspirin), stratified by prior clopidogrel use." | 5.22 | Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. ( Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ, 2016) |
| " Patients randomized to continued thienopyridine and aspirin after 12 months had lower ischemic risk but higher bleeding risk than those treated with placebo and aspirin." | 5.22 | DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. ( Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Steg, PG; Wiviott, SD; Yeh, RW, 2016) |
| "PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) randomized 21,162 patients with prior MI (1 to 3 years) to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo, all on a background of low-dose aspirin." | 5.22 | Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. ( Abola, MTB; Aylward, P; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Corbalán, R; Dalby, A; Dellborg, M; Goodrich, E; Held, P; Jensen, EC; Kuder, J; López-Sendón, J; Nicolau, JC; Parkhomenko, A; Sabatine, MS; Špinar, J; Steg, PG; Storey, RF, 2016) |
| " In contrast to overall PLATO results, but similar to PLATO-US cohort, PHILO revealed numerical inferiority of ticagrelor with regard to death, myocardial infarction, stroke, and bleeding over clopidogrel." | 5.22 | Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA? ( Bekbossynova, M; Kim, MH; Pya, Y; Serebruany, VL; Tomek, A, 2016) |
| "Ticagrelor may be a more effective antiplatelet therapy than aspirin for the prevention of recurrent stroke and cardiovascular events in patients with acute cerebral ischemia." | 5.22 | Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KS, 2016) |
| "Compared with 12-month DAPT, 6-month DAPT did not increase the composite events of cardiac death, myocardial infarction, stroke, or TIMI major bleeding at 1 year in patients who underwent everolimus-eluting stent implantation." | 5.22 | 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial. ( Choi, D; Her, AY; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Shin, DH, 2016) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 5.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "Policosanol reduced platelet reactivity to a similar extent as high maintenance dose of clopidogrel without increasing bleeding rate." | 5.22 | Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results. ( Guo, L; Han, Y; Li, Y; Liu, X; Wang, X; Wang, Y; Xu, K; Zang, H; Zhao, W, 2016) |
| "Patients with acute minor ischemic stroke or transient ischemic attack in the trial were randomized to treatment with clopidogrel combined with aspirin or to aspirin alone." | 5.22 | Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. ( Johnston, SC; Li, H; Lin, J; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, Y; Xu, J; Zhao, X, 2016) |
| "ᅟ: We investigated the occurrence of bleeding complications in patients who underwent skin tumor surgery and compared it between Aspirin users and a placebo control group." | 5.22 | Aspirin use and bleeding volume in skin cancer patients undergoing surgery: a randomized controlled trial. ( Atri, A; Engheta, A; Hadadi Abianeh, S; Sanatkarfar, M, 2016) |
| "In the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), ticagrelor reduced the risk of major adverse cardiovascular events when added to low-dose aspirin in stable patients with prior myocardial infarction, resulting in the approval of ticagrelor 60 mg twice daily for long-term secondary prevention." | 5.22 | Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm ( Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Dalby, AJ; Goodrich, E; Goto, S; Held, P; Hu, D; Jensen, E; Mauri, L; Morrow, DA; Ophuis, TO; Ruda, M; Sabatine, MS; Seung, KB; Špinar, J; Steg, PG; Storey, RF, 2016) |
| "The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization." | 5.22 | A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016) |
| "TWILIGHT is the largest study to date that is specifically designed and powered to demonstrate reductions in bleeding with ticagrelor monotherapy versus ticagrelor plus ASA beyond 3 months post-procedure in a high-risk PCI population treated with DES." | 5.22 | Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. ( Angiolillo, DJ; Aquino, M; Baber, U; Badimon, J; Chandrasekhar, J; Cohen, DJ; Dangas, G; Gibson, CM; Kastrati, A; Krucoff, MW; Mehran, R; Mehta, SR; Ohman, EM; Pocock, SJ; Sartori, S; Steg, PG; Zafar, MU, 2016) |
| "Rates of bleeding and thrombotic events were not significantly different according to 6- versus 24-month DAPT after PCI with new-generation DES in good aspirin responders." | 5.20 | 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. ( Armengaud, J; Barragan, P; Benamer, H; Berland, J; Blanchard, D; Boschat, J; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Druelles, P; Dupouy, P; Endresen, K; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J, 2015) |
| "This prospective, randomized, multicenter study is going to assess the hypothesis that in persistent or permanent AF patients (score of CHA₂DS₂VASc≥2) after PCI-eS, the combination therapy of oral anticoagulation (warfarin) and ticagrelor (90 mg/bid) could reduce the risk of bleeding events." | 5.20 | Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS. ( Chen, L; Fu, C; Lu, W; Ma, G; Wang, Y; Yao, Y; Zuo, P, 2015) |
| "In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding." | 5.20 | Long-term use of ticagrelor in patients with prior myocardial infarction. ( Bansilal, S; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Fish, MP; Goto, S; Hamm, C; Held, P; Im, K; Jensen, EC; Kiss, RG; Magnani, G; Murphy, SA; Nicolau, JC; Oude Ophuis, T; Ruda, M; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Theroux, P; Wiviott, SD, 2015) |
| "International, multicenter, randomized, double-blinded, placebo-controlled trial comparing extended (30-months) thienopyridine vs placebo in patients taking aspirin who completed 12 months of DAPT without bleeding or ischemic events after receiving stents." | 5.20 | Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. ( Cutlip, DE; Darius, H; Driscoll-Shempp, P; Garratt, KN; Gershlick, AH; Iancu, AC; Kandzari, DE; Kereiakes, DJ; Lee, DP; Massaro, JM; Mauri, L; Meredith, IT; Ormiston, J; Simon, DI; Steg, PG; Tanguay, JF; Trebacz, J; Windecker, S; Yeh, RW, 2015) |
| "There is insufficient data on the efficacy of prasugrel and ticagrelor in Korean patients with ST-segment elevation myocardial infarction (STEMI)." | 5.20 | Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. ( Cho, YR; Guo, LZ; Jin, CD; Kim, MH; Kim, YD; Lee, YS; Park, JS; Park, K; Park, TH, 2015) |
| "We sought to assess the performance of existing bleeding risk scores, such as the Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly (HAS-BLED) score or the Outpatient Bleeding Risk Index (OBRI), in patients with heart failure with reduced ejection fraction (HFrEF) in sinus rhythm (SR) treated with warfarin or aspirin." | 5.20 | Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. ( Anker, SD; Buchsbaum, R; Cheng, B; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Teerlink, JR; Thompson, JL; Ye, S, 2015) |
| "Apixaban was associated with fewer strokes and systemic embolism versus aspirin across all subgroups; however, it caused more major bleeding events." | 5.20 | Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients. ( Dorian, P; Kongnakorn, T; Lanitis, T; Lip, GY; Mardekian, J; Phatak, H, 2015) |
| " Using inverse probability-weighted propensity modeling, we compared 6-month adjusted risks of Bleeding Academic Research Consortium (BARC) bleeding, stratifying by whether or not bleeding was associated with rehospitalization among patients discharged on aspirin + anticoagulant + clopidogrel (triple-C), aspirin + anticoagulant + prasugrel (triple-P), aspirin + clopidogrel (dual-C), or aspirin + prasugrel (dual-P)." | 5.20 | Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. ( Baker, BA; Cohen, DJ; Effron, M; Jackson, LR; Ju, C; Messenger, JC; Peterson, ED; Stone, GW; Wang, TY; Zettler, M, 2015) |
| "The current results suggest that continued use of anti-aggregant monotherapy does not increase the risk of overall bleeding or reintervention for patients undergoing transurethral resection of bladder neoplasms and that suspending aspirin before such a procedure is therefore unnecessary." | 5.19 | Risks and complications of transurethral resection of bladder tumor among patients taking antiplatelet agents for cardiovascular disease. ( Bozzini, G; Carmignani, L; Casellato, S; Marenghi, C; Picozzi, S; Ricci, C, 2014) |
| "The goal of this study was to analyze the impact of dabigatran plasma concentrations, patient demographics, and aspirin (ASA) use on frequencies of ischemic strokes/systemic emboli and major bleeds in atrial fibrillation patients." | 5.19 | The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). ( Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Haertter, S; Lehr, T; Nehmiz, G; Reilly, PA; Wallentin, L; Wang, S; Yusuf, S, 2014) |
| "Apixaban had similar beneficial effects on stroke or systemic embolism and major bleeding compared with warfarin, irrespective of concomitant aspirin use." | 5.19 | Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. ( Alexander, JH; Alings, M; Atar, D; Aylward, P; Goto, S; Granger, CB; Hanna, M; Huber, K; Husted, S; Lewis, BS; Lopes, RD; McMurray, JJ; Pais, P; Pouleur, H; Steg, PG; Thomas, L; Verheugt, FW; Wallentin, L; Wojdyla, DM, 2014) |
| "The AVERROES double-blinded, randomized trial demonstrated that apixaban reduces the risk of stroke or systemic embolism (SSE) by 55% compared with aspirin without an increase in major bleeding in patients with atrial fibrillation either who previously tried but failed vitamin K antagonists (VKA) therapy or who were expected to be unsuitable for VKA therapy." | 5.19 | Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. ( Connolly, SJ; Coppens, M; Eikelboom, JW; Shestakovska, O; Synhorst, D; Yusuf, S, 2014) |
| "To compare the therapeutic warfarin and aspirin efficacies for treatments of atrial fibrillation (AF) complicated with stable coronary heart disease particularly in older Chinese patients." | 5.19 | Warfarin compared with aspirin for older Chinese patients with stable coronary heart diseases and atrial fibrillation complications. ( Cao, G; Feng, L; Huang, H; Li, Y; Liu, X; Xu, Q; Yu, J; Zhang, S; Zhou, M, 2014) |
| "In TRITON-TIMI 38, patients with acute coronary syndromes were treated with prasugrel or clopidogrel, with aspirin, for a median of 14." | 5.19 | An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. ( Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R, 2014) |
| "An individual patient data analysis of these trials was planned, before their results were known, to assess the effect of aspirin versus placebo on recurrent VTE, major vascular events (recurrent VTE, myocardial infarction, stroke, and cardiovascular disease death) and bleeding, overall and within predefined subgroups." | 5.19 | Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. ( Agnelli, G; Becattini, C; Brighton, TA; Eikelboom, JW; Kirby, AC; Mister, R; Prandoni, P; Simes, J, 2014) |
| "To determine whether aspirin compared with placebo, and clonidine compared with placebo, alters the risk of perioperative acute kidney injury." | 5.19 | Perioperative aspirin and clonidine and risk of acute kidney injury: a randomized clinical trial. ( Acedillo, R; Amir, M; Bergese, S; Biccard, B; Bidgoli, SJ; Cata, JP; Cegarra, V; Chan, MT; Chan, V; Clanchet, Mde N; Cuerden, M; Devereaux, PJ; Dresser, G; Fleischmann, E; Font, A; Forget, P; Garg, AX; Gomez, MF; Jones, PM; Kumar, P; Kurz, A; Leslie, K; Malaga, G; Martinsen, K; Mehra, B; Meyhoff, CS; Mizera, R; Mrkobrada, M; Myles, P; Painter, T; Parikh, CR; Parlow, J; Pasin, L; Robinson, A; Roshanov, PS; Sessler, DI; Srinathan, S; Tiboni, M; Torres, D; VanHelder, T; Villar, JC; Walsh, M; Whitlock, R; Wijeysundera, DN; Yusuf, S, 2014) |
| "Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding." | 5.19 | Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. ( Braunwald, E; Cohen, DJ; Cutlip, DE; Dauerman, HL; Driscoll-Shempp, P; Garratt, KN; Hermiller, J; Holmes, DR; Kandzari, DE; Kereiakes, DJ; Krucoff, MW; Lee, DP; Massaro, JM; Mauri, L; Normand, SL; Pow, TK; Rinaldi, MJ; Simon, DI; Steg, PG; Ver Lee, P; Wiviott, SD; Yeh, RW, 2014) |
| "Once-daily, low-dose aspirin did not significantly reduce the risk of the composite outcome of cardiovascular death, nonfatal stroke, and nonfatal myocardial infarction among Japanese patients 60 years or older with atherosclerotic risk factors." | 5.19 | Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. ( Ando, K; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamazaki, T; Yokoyama, K, 2014) |
| "Definite/probable ST and MB (TIMI major and Bleeding Academic Research Consortium (BARC) ≥ 3) were compared in 2 subsequent trials with similar inclusion criteria but different DAPT duration, that is, BASKET (6 months; n = 557) and BASKET-PROVE (12 months; n = 2,314), between months 0 to 6 (DAPT in both trials), 7 to 12 (DAPT in BASKET-PROVE only), and 13 to 24 (aspirin in both trials) using propensity score-adjusted, time-stratified Cox proportional hazard models." | 5.19 | Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations. ( Alber, H; Bonetti, PO; Eberli, F; Erne, P; Galatius, S; Jeger, RV; Kaiser, CA; Pedrazzini, G; Pfisterer, ME; Rickli, H; Sørensen, R; von Felten, S, 2014) |
| "If percutaneous coronary intervention (PCI) is required in patients taking oral anticoagulants, antiplatelet therapy with aspirin and clopidogrel is indicated, but such triple therapy increases the risk of serious bleeding." | 5.17 | Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. ( Adriaenssens, T; De Smet, BJ; Dewilde, WJ; Heestermans, AA; Herrman, JP; Kelder, JC; Oirbans, T; ten Berg, JM; Tijsen, JG; van 't Hof, AW; Verheugt, FW; Vis, MM; Vrolix, M, 2013) |
| " Then, patients with no MACCE or major bleeding will be randomized to receive either 36 additional months of clopidogrel plus aspirin or aspirin only." | 5.17 | Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. ( Carrie, D; Cattan, S; Cayla, G; Eltchaninoff, H; Furber, A; Georges, JL; Helft, G; Le Feuvre, C; Leclercq, F; Metzger, JP; Prunier, F; Sebagh, L; Vicaut, E, 2013) |
| "To compare extended prophylaxis with aspirin and dalteparin for prevention of symptomatic venous thromboembolism (VTE) after THA." | 5.17 | Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. ( Anderson, DR; Andreou, P; Belzile, E; Bohm, ER; Carrier, M; Crowther, M; Davis, N; Dunbar, MJ; Fisher, W; Gofton, W; Gross, P; Kahn, SR; Kim, P; Kovacs, M; MacDonald, S; Pelet, S; Pleasance, S; Ramsay, T; Rodger, MA; Vendittoli, PA; Wells, P; Zukor, D, 2013) |
| "Among patients with TIA or minor stroke who can be treated within 24 hours after the onset of symptoms, the combination of clopidogrel and aspirin is superior to aspirin alone for reducing the risk of stroke in the first 90 days and does not increase the risk of hemorrhage." | 5.17 | Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. ( Cui, L; Dong, Q; Jia, J; Johnston, SC; Li, H; Li, Y; Liu, L; Meng, X; Wang, C; Wang, D; Wang, Y; Wang, Z; Xia, H; Xu, A; Zeng, J; Zhao, X, 2013) |
| "A total of 9326 medically managed patients with acute coronary syndromes from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial (<75 years of age, n=7243; ≥75 years of age, n=2083) were randomized to prasugrel (10 mg/d; 5 mg/d for those ≥75 or <75 years of age and <60 kg in weight) or clopidogrel (75 mg/d) plus aspirin for ≤30 months." | 5.17 | Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bassand, JP; Boden, WE; Dalby, AJ; Fox, KA; Goodman, SG; Gottlieb, S; Hochman, JS; Martinez, F; McGuire, DK; Ohman, EM; Prabhakaran, D; Roe, MT; Stevens, SR; White, HD; Winters, KJ, 2013) |
| " Eligible patients were those with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing PCI with zotarolimus-eluting stents." | 5.17 | Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. ( Abizaid, A; Abizaid, AS; Bhatt, DL; Botelho, RV; Castello, HJ; Costa, JR; Costa, RA; de Castro, JP; de Paula, JE; Devito, FS; Feres, F; Gusmão, M; King, SB; Labrunie, A; Leon, MB; Liu, M; Mangione, JA; Marin-Neto, JA; Meireles, GX; Negoita, M; Nicolela, EL; Perin, MA; Salvadori, D; Staico, R, 2013) |
| "The impact of apixaban versus aspirin on ischemic stroke and major bleeding in relation to the CHADS(2) and CHA(2)DS(2)-VASc stroke risk scores in atrial fibrillation has not been investigated." | 5.17 | Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. ( Connolly, S; Eikelboom, J; Flaker, G; Hart, R; Lanas, F; Lip, GY; Shestakovska, O; Xavier, D; Yusuf, S, 2013) |
| "Co-medication use with rivaroxaban or enoxaparin resulted in non-significant increases in bleeding events." | 5.16 | Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. ( Dahl, OE; Eriksson, BI; Friedman, RJ; Homering, M; Rosencher, N, 2012) |
| "The aim of this subanalysis was to assess the net clinical effect of prehospital administration of tirofiban in ST-elevation myocardial infarction (STEMI) patients with high risk of bleeding." | 5.16 | Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score. ( Dambrink, JH; Gosselink, AT; Hamm, C; Hermanides, RS; Ottervanger, JP; Stella, PR; ten Berg, JM; van 't Hof, AW; van Houwelingen, G, 2012) |
| "It is unknown whether warfarin or aspirin therapy is superior for patients with heart failure who are in sinus rhythm." | 5.16 | Warfarin and aspirin in patients with heart failure and sinus rhythm. ( Ammon, SE; Anker, SD; Buchsbaum, R; del Valle, ML; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Gabriel, AP; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Massie, BM; Mejia, V; Mohr, JP; Ponikowski, P; Pullicino, PM; Sacco, RL; Sanford, AR; Teerlink, JR; Thompson, JL, 2012) |
| "Aspirin reduced the risk of recurrence when given to patients with unprovoked venous thromboembolism who had discontinued anticoagulant treatment, with no apparent increase in the risk of major bleeding." | 5.16 | Aspirin for preventing the recurrence of venous thromboembolism. ( Ageno, W; Agnelli, G; Becattini, C; Bianchi, M; Bucherini, E; Eichinger, S; Grandone, E; Moia, M; Prandoni, P; Schenone, A; Silingardi, M; Vandelli, MR, 2012) |
| "A subset of the TRITON-TIMI 38 study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38), in which patients with acute coronary syndrome were randomized to treatment with aspirin and either clopidogrel or prasugrel, underwent isolated CABG (N = 346)." | 5.16 | Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. ( Goodnough, LT; Lenarz, LA; Levy, JH; Poston, RS; Short, MA; Smith, PK; Weerakkody, GJ, 2012) |
| "Apixaban is superior to aspirin for the prevention of stroke in patients with atrial fibrillation." | 5.16 | Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. ( Connolly, SJ; De Caterina, R; Eikelboom, JW; Gao, P; Hart, RG; Husted, S; O'Donnell, M; Paolasso, E; Yusuf, S, 2012) |
| "Among patients with recent lacunar strokes, the addition of clopidogrel to aspirin did not significantly reduce the risk of recurrent stroke and did significantly increase the risk of bleeding and death." | 5.16 | Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. ( Benavente, OR; Coffey, CS; Hart, RG; McClure, LA; Pearce, LA; Szychowski, JM, 2012) |
| "We randomly assigned 822 patients who had completed initial anticoagulant therapy after a first episode of unprovoked venous thromboembolism to receive aspirin, at a dose of 100 mg daily, or placebo for up to 4 years." | 5.16 | Low-dose aspirin for preventing recurrent venous thromboembolism. ( Brighton, TA; Diaz, R; Eikelboom, JW; Gallus, A; Gibbs, H; Hague, W; Kirby, A; Mann, K; Mister, R; Ockelford, P; Simes, J; Xavier, D, 2012) |
| "Presentation with an acute coronary syndrome (ACS) on chronic aspirin therapy is an independent predictor of adverse short-term outcomes." | 5.15 | Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. ( Ambrosio, G; Bertrand, ME; Gresele, P; Lincoff, AM; Mehran, R; Moses, JW; Ohman, EM; Steinhubl, S; Stone, GW; Tritto, I; White, HD; Zuchi, C, 2011) |
| " We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation." | 5.15 | Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011) |
| "To determine whether low molecular weight heparin (LMWH) plus low-dose aspirin (LDA) is comparable in efficacy and safety to unfractionated heparin (UFH) plus LDA in the management of pregnant women with a history of recurrent spontaneous abortion secondary to antiphospholipid syndrome (APS)." | 5.15 | Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. ( Abdou, AM; Fouda, IM; Fouda, UM; Ramadan, DI; Sayed, AM; Zaki, MM, 2011) |
| "Any bleeding and TIMI major bleeding complications increase in patients aged ≥75 years treated with clopidogrel in addition to aspirin." | 5.15 | Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study. ( Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Demir, AD; Erbay, AR; Maden, O; Sen, N, 2011) |
| " In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens." | 5.15 | Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R, 2011) |
| "In a double-blind study, we randomly assigned 5599 patients with atrial fibrillation who were at increased risk for stroke and for whom vitamin K antagonist therapy was unsuitable to receive apixaban (at a dose of 5 mg twice daily) or aspirin (81 to 324 mg per day), to determine whether apixaban was superior." | 5.15 | Apixaban in patients with atrial fibrillation. ( Afzal, R; Avezum, A; Budaj, A; Commerford, P; Connolly, SJ; Dans, AL; Diaz, R; Diener, HC; Eikelboom, J; Flaker, G; Golitsyn, S; Gonzalez-Hermosillo, A; Hart, R; Hohnloser, SH; Jansky, P; Joyner, C; Kim, JH; Lanas-Zanetti, F; Lawrence, J; Lewis, BS; Lewis, G; Lip, GY; Munawar, M; O'Donnell, M; Pais, P; Parkhomenko, A; Sim, KH; Talajic, M; Tan, RS; Van Mieghem, W; Yusuf, S; Zhu, J, 2011) |
| "After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel." | 5.15 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011) |
| "Aspirin is a proven antiplatelet agent in acute ischemic stroke, and there are no current guidelines for other antiplatelet treatments." | 5.15 | Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. ( Bae, HJ; Cho, YJ; Han, MG; Hong, KS; Jung, SW; Kang, DW; Kim, DE; Kim, JS; Koo, J; Kwon, SU; Lee, BC; Lee, JH; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Rha, JH; Yu, K, 2011) |
| "The trial was terminated prematurely after recruitment of 7392 patients because of an increase in major bleeding events with apixaban in the absence of a counterbalancing reduction in recurrent ischemic events." | 5.15 | Apixaban with antiplatelet therapy after acute coronary syndrome. ( Alexander, JH; Atar, D; Bhatt, DL; Cools, F; Cornel, JH; Darius, H; De Caterina, R; Diaz, R; Flather, M; Geraldes, M; Goodman, S; Harrington, RA; He, Y; Huber, K; Husted, SE; James, S; Jansky, P; Keltai, M; Kilaru, R; Lawrence, J; Leiva-Pons, JL; Liaw, D; Lopes, RD; Lopez-Sendon, J; Mohan, P; Ogawa, H; Pais, P; Parkhomenko, A; Ruda, M; Ruzyllo, W; Verheugt, FW; Vinereanu, D; Wallentin, L; White, H, 2011) |
| "Following mechanical valve replacement, combined low dose aspirin and warfarin therapy was associated with a greater reduction in thromboembolism events than warfarin therapy alone." | 5.15 | Anticoagulation therapy with combined low dose aspirin and warfarin following mechanical heart valve replacement. ( Chai, SD; Dong, MF; Ma, SJ; Ma, ZS; Tang, PZ; Wang, LX; Yao, DK, 2011) |
| " As the indications for clopidogrel expand, an increasing number of patients undergoing off-pump coronary artery bypass surgery (OPCAB) are also undergoing dual antiplatelet therapy (DAPT), with its higher risk of bleeding complications." | 5.15 | Effect of hydroxyethyl starch 130/0.4 on blood loss and coagulation in patients with recent exposure to dual antiplatelet therapy undergoing off-pump coronary artery bypass graft surgery. ( Ahn, SW; Kwak, YL; Lee, JS; Shim, JK; Song, JW; Yoo, KJ, 2011) |
| "001) by adjusted-dose warfarin compared with aspirin/low-dose warfarin; there was no difference in major hemorrhage (5 patients versus 6 patients, respectively)." | 5.15 | Warfarin in atrial fibrillation patients with moderate chronic kidney disease. ( Asinger, RW; Hart, RG; Herzog, CA; Pearce, LA, 2011) |
| "Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage." | 5.15 | Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. ( Connolly, SJ; de Caterina, R; Eikelboom, JW; Hart, RG; Hirsh, J; Hohnloser, S; Ng, J; Pogue, J; Yusuf, S, 2011) |
| "In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance." | 5.14 | Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. ( Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S, 2009) |
| "Adding clopidogrel to aspirin beyond 4 weeks post PCI is not associated with a significant increase in the overall rate of major or minor bleeding, although it is associated with an increase in major gastrointestinal bleeding in the year after a PCI." | 5.14 | Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. ( Aronow, HD; Berger, PB; Brennan, DM; Steinhubl, SR; Topol, EJ, 2009) |
| "This was a prospective observational study of 15 532 patients enrolled in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial who were randomly assigned to clopidogrel or placebo, and followed-up for a median of 28 months for the occurrence of the primary endpoint (cardiovascular death, myocardial infarction, or stroke), all-cause mortality, and bleeding complications." | 5.14 | The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. ( Bhatt, DL; Fox, KA; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2009) |
| "Patients with thrombolysis in myocardial infarction (TIMI) 3 flow <48 hours after fibrinolysis for ST-elevation myocardial infarction were randomized to aspirin plus coumarin, with prolonged heparinization until the target international normalized ratio (2-3) was reached, or aspirin with standard heparinization." | 5.14 | Prolonged anticoagulation therapy adjunctive to aspirin after successful fibrinolysis: from early reduction in reocclusion to improved long-term clinical outcome. ( Aengevaeren, WR; Brouwer, MA; Kievit, PC; van den Bergh, PJ; Veen, G; Verheugt, FW, 2009) |
| "Mechanical reperfusion with stenting for ST-elevation myocardial infarction (STEMI) is supported by dual antiplatelet treatment with aspirin and clopidogrel." | 5.14 | Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. ( Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Murphy, SA; Wiviott, SD, 2009) |
| "Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead." | 5.14 | Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ( Chrolavicius, S; Connolly, SJ; Hart, RG; Hohnloser, SH; Pfeffer, M; Pogue, J; Yusuf, S, 2009) |
| " Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding." | 5.14 | Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. ( Alexander, JH; Becker, RC; Bhatt, DL; Cools, F; Crea, F; Dellborg, M; Fox, KA; Goodman, SG; Harrington, RA; Huber, K; Husted, S; Lewis, BS; Lopez-Sendon, J; Mohan, P; Montalescot, G; Ruda, M; Ruzyllo, W; Verheugt, F; Wallentin, L, 2009) |
| "In this double-blind, dose-escalation, phase II study, undertaken at 297 sites in 27 countries, 3491 patients stabilised after an acute coronary syndrome were stratified on the basis of investigator decision to use aspirin only (stratum 1, n=761) or aspirin plus a thienopyridine (stratum 2, n=2730)." | 5.14 | Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. ( Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A, 2009) |
| "The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI." | 5.14 | Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009) |
| "We randomly assigned a total of 400 patients with ST-segment elevation myocardial infarction referred for primary percutaneous coronary intervention to treatment initiated before cardiac catheterization, with either heparin plus eptifibatide (201 patients) or heparin alone (199 patients), in addition to oral aspirin (160 mg) and high-dose clopidogrel (600 mg)." | 5.14 | Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi ( Froeschl, M; Glover, CA; Jadhav, S; Kass, M; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, ER; So, DY; Thomas, A; Turek, M; Wells, GA, 2009) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 5.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "The Japanese Primary Prevention Project (JPPP) is a multicenter, open-label, randomized, parallel-group trial that is evaluating primary prevention with low-dose aspirin in Japanese patients aged 60 to 85 years with hypertension, dyslipidemia, or diabetes mellitus." | 5.14 | Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. ( Ando, K; Goto, Y; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamada, N; Yamazaki, T; Yokoyama, K, 2010) |
| "In CHARISMA, there was an increased risk of bleeding with long-term clopidogrel." | 5.14 | Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR ( Berger, PB; Bhatt, DL; Brennan, DM; Fox, KA; Fuster, V; Hacke, W; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2010) |
| "In a double-blind randomized controlled trial, 108 patients undergoing infrainguinal revascularization or amputation for critical limb ischemia were maintained on aspirin (75 mg daily) and randomized to clopidogrel (600 mg prior to surgery, and 75 mg daily for 3 days; n = 50) or matched placebo (n = 58)." | 5.14 | Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. ( Burdess, A; Dawson, AR; Fox, KA; Garden, OJ; Murie, JA; Newby, DE; Nimmo, AF, 2010) |
| " Major hemorrhages were observed more frequently in the combination (warfarin plus low-dose aspirin) therapy group than in the warfarin monotherapy group." | 5.14 | [Recurrent thromboses and hemorrhagic complications in patients with antiphospholipid syndrome during therapy with warfarin plus aspirin]. ( Aleksandrova, EN; Kondrat'eva, LV; Kovalenko, TF; Ostriakova, EV; Patrushev, LI; Patrusheva, NL; Reshetniak, TM, 2010) |
| " In the 3371 patients randomized to vitamin K antagonists and the 3335 patients randomized to clopidogrel plus aspirin in ACTIVE-W, the hazard ratio (HR) and 95% confidence intervals (95% CIs) for subsequent death associated with the occurrence of non-fatal stroke was 5." | 5.14 | Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. ( Budaj, A; Chrolavicius, S; Connolly, SJ; De Caterina, R; Morais, J; Pogue, J; Renda, G; Yusuf, S, 2010) |
| "In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke." | 5.14 | Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010) |
| "The HOT (Hypertension Optimal Treatment) study randomly assigned participants with diastolic hypertension to aspirin (75 mg) or placebo." | 5.14 | Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. ( Cass, A; Chalmers, J; Gallagher, MP; Jardine, MJ; Lambers Heerspink, HJ; Ninomiya, T; Perkovic, V; Turnbull, F; Zanchetti, A; Zoungas, S, 2010) |
| "Atrial fibrillation (AF) associated to rheumatic mitral valve disease (RMVD) increases the incidence of thromboembolism (TE), with warfarin being the standard therapy, in spite of difficulties in treatment adherence and therapeutic control." | 5.14 | Warfarin or aspirin in embolism prevention in patients with mitral valvulopathy and atrial fibrillation. ( Bôer, BN; Grinberg, M; Lavitola, Pde L; Oliveira, WA; Sampaio, RO; Spina, GS; Tarasoutchi, F, 2010) |
| " The Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) study was undertaken to evaluate whether the addition of clopidogrel to aspirin inhibits SVG disease after coronary artery bypass grafting, as assessed at 1 year by intravascular ultrasound." | 5.14 | Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. ( Delarochelliere, R; Kulik, A; Le May, MR; Mesana, TG; Naidoo, S; Ruel, M; Tardif, JC; Voisine, P; Wells, GA, 2010) |
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 5.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "To investigate the efficacy of intracoronary tirofiban during primary percutaneous coronary intervention (PCI) for patients with acute coronary syndrome (ACS)." | 5.13 | Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome. ( Chen, SW; Huang, LP; Huang, WG; Wang, LX; Wei, JR; Wu, TG; Zhao, J; Zhao, Q, 2008) |
| "Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)." | 5.13 | Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008) |
| "The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade." | 5.13 | The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008) |
| "The present study suggested benefit of tailored antiplatelet therapy during elective PCI with GP IIb/IIIa antagonist for clopidogrel nonresponders without increased bleeding risk." | 5.13 | Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. ( Alessi, MC; Bali, L; Bonnet, JL; Cuisset, T; Frere, C; Lambert, M; Morange, PE; Moro, PJ; Mouret, JP; Quilici, J, 2008) |
| "Using combined data from the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO I) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) trials (n=48 422 ST-elevation myocardial infarction patients), we compared the association between initial aspirin dose of 162 versus 325 mg and 24-hour and 7-day mortality, as well as rates of in-hospital moderate/severe bleeding." | 5.13 | Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. ( Armstrong, PW; Berger, JS; Califf, RM; Granger, CB; Harrington, RA; Ohman, EM; Peterson, ED; Simes, RJ; Stebbins, A; Van de Werf, F; White, HD, 2008) |
| "There was a trend toward excess bleeding in long-term aspirin recipients, compared with placebo recipients (P = ." | 5.13 | Effect of long-term aspirin use on embolic events in infective endocarditis. ( Chan, KL; Cujec, B; Dumesnil, JG; Jue, J; Robinson, T; Sanfilippo, AJ; Tam, J; Turek, M; Williams, K, 2008) |
| "Prasugrel is superior to clopidogrel in preventing ischemic events in patients with an acute coronary syndrome who are undergoing percutaneous coronary intervention, but it is associated with an increased risk of major bleeding." | 5.13 | Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys ( Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD, 2008) |
| "Although aspirin has no significant risk on primary endpoints of cardiovascular events and bleeding outcomes in patients with diabetes compared to control, major adverse cardiovascular events (MACE) were significantly lower in the aspirin group." | 5.12 | Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis. ( Gu, Q; Li, X; Ma, H; Niu, H; Wang, R, 2021) |
| "The study reports higher risks of venous thromboembolism, pulmonary embolism, and overall mortality for the patients receiving aspirin before undergoing." | 5.12 | Comparison between use of direct oral anticoagulants and aspirin for risk of thromboembolism complications in patients undergoing total knee and hip arthroplasty: a systematic review and meta-analysis. ( Cai, JY; Cao, YQ; Cui, CM; Min, JK; Zhang, LY, 2021) |
| "Patients experiencing acute ischemic stroke or transient ischemic attack are commonly treated with clopidogrel and/or aspirin (mono- and dual-antiplatelet therapy) to minimize the risk for recurrent stroke." | 5.12 | Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attack: An overview of systematic reviews and meta-analysis. ( Huang, Z; Yang, Y; Zhang, X, 2021) |
| "Patients with coronary artery disease (CAD) presenting with acute coronary syndrome or undergoing coronary stenting are indicated to treatment with dual antiplatelet therapy (DAPT) combining aspirin with a P2Y12 receptor inhibitor." | 5.12 | Complexity of Antiplatelet Therapy in Coronary Artery Disease Patients. ( Costa, F; Fischman, D; Sabouret, P; Savage, MP, 2021) |
| "Dual antiplatelet therapy (DAPT) with aspirin and ticagrelor or prasugrel is the mainstay of treatment for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI)." | 5.12 | Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials. ( Jhaj, R; Khandelwal, G; Najmi, A; Ray, A; Sadasivam, B, 2021) |
| "Although clopidogrel is a frequently used antiplatelet medication to treat and prevent atherothrombotic disease, clinicians must balance its clinical effectiveness with the potential side effect of bleeding." | 5.12 | Risk Factors for Bleeding and Clinical Ineffectiveness Associated With Clopidogrel Therapy: A Comprehensive Meta-Analysis. ( Duong, K; Eadon, MT; Fekete, K; Kenneally, A; Milway, E; Nguyen, KA; Oh, H; Schleyer, TK; Whipple, EC; Yoo, R, 2021) |
| "To comprehensively evaluate the clinical effects of low molecular weight heparin (LMWH) and aspirin for deep vein thrombosis (DVT) patients after orthopaedic surgery." | 5.12 | Low molecular weight heparin and aspirin for prevention of deep vein thrombosisafter orthopaedic surgery: a systematic review and meta-analysis. ( Chen, B; Hu, N, 2021) |
| "Dual anti-platelet therapy (DAPT) with aspirin and clopidogrel has been the mainstay of treatment for patients with acute coronary syndrome (ACS)." | 5.12 | Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis. ( Chen, L; Devi Shamloll, Y; Jiang, Z; Jin, J; Xiao, M; Zhuo, X, 2021) |
| "As compared to aspirin alone, short-term DAPT within 24 hours of high-risk transient ischemic attack or mild-moderate ischemic stroke reduces the risk of recurrent stroke at the expense of higher risk of major bleeding." | 5.12 | Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack: Meta-Analysis of Randomized Controlled Trials. ( Aggarwal, D; Arora, S; Bhatia, K; Hussain, Z; Jain, V; Qamar, A; Ricciardi, M; Tafur, A; Uberoi, G; Vaduganathan, M; Zhang, C, 2021) |
| " The evidence is uncertain if warfarin has any effect on all-cause death compared to placebo or no treatment, but it may increase the risk of major bleeding events." | 5.12 | Anticoagulation versus placebo for heart failure in sinus rhythm. ( Kozieł, M; Lip, GY; Shantsila, E, 2021) |
| "In patients with noncardioembolic mild stroke or high-risk transient ischemic attack, DAPT with aspirin and clopidogrel/ticagrelor is more effective than aspirin alone for recurrent stroke prevention with a small absolute increase in the risk of severe or moderate bleeding." | 5.12 | P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack. ( Fisher, M; Gu, HQ; Johnston, SC; Li, ZX; Wang, YJ; Xian, Y; Xiong, Y, 2021) |
| "Warfarin, aspirin, and the combination of these, have all proven to be efficacious in preventing future events after myocardial infarction." | 5.12 | Occult bleeding in three different antithrombotic regimes after myocardial infarction. A WARIS-II subgroup analysis. ( Arnesen, H; Eikvar, L; Hurlen, M; Seljeflot, I, 2006) |
| " Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes." | 5.12 | Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. ( Berger, PB; Bhatt, DL; Black, HR; Boden, WE; Booth, J; Brennan, DM; Cacoub, P; Cohen, EA; Creager, MA; Easton, JD; Fabry-Ribaudo, L; Flather, MD; Fox, KA; Hacke, W; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Mas, JL; Montalescot, G; Pearson, TA; Steg, PG; Steinhubl, SR; Topol, EJ; Weber, MA, 2006) |
| "Addition of clopidogrel to medical reperfusion of STEMI with fibrinolysis, heparin, and aspirin before reaching the hospital is feasible in medically equipped ambulances without an apparent increase in bleeding." | 5.12 | Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial. ( Adgey, J; Cannon, CP; Lambert, Y; Lapostolle, F; Montalescot, G; Sabatine, MS; Soulat, L; Verheugt, FW, 2007) |
| " The recently published European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), an open-label randomised controlled study, compared long-term treatment of patients randomised to aspirin 30-325 mg daily with (n = 1363) or without (n = 1376) dipyridamole 200 mg twice daily." | 5.12 | ESPRIT study design and outcomes--a critical appraisal. ( Einhäupl, K, 2007) |
| "Short-term aspirin therapy can lower the risk for venous thromboembolism (VTE) in high-risk patients, but whether the long-term use of low-dose aspirin reduces risk in healthy adults is uncertain." | 5.12 | Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. ( Buring, JE; Glynn, RJ; Goldhaber, SZ; Ridker, PM, 2007) |
| "Our goal was to compare the safety and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, with clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)." | 5.12 | Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri ( Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Peters, G; Scirica, BM; Storey, RF, 2007) |
| "Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention." | 5.12 | Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007) |
| "The use of aspirin for the prevention of thrombotic complications in polycythemia vera is controversial." | 5.11 | Efficacy and safety of low-dose aspirin in polycythemia vera. ( Barbui, T; Gisslinger, H; Kutti, J; Landolfi, R; Marchioli, R; Patrono, C; Tognoni, G, 2004) |
| "To evaluate whether long-term treatment with a fixed low dose of warfarin in combination with aspirin improves the prognosis compared with aspirin treatment alone after an acute myocardial infarction (AMI)." | 5.11 | Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study. ( Erhardt, L; Haglid Evander, M; Herlitz, J; Holm, J; Karlson, BW; Peterson, M, 2004) |
| "In the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial, 12 562 patients were randomized to clopidogrel or placebo in addition to aspirin, and the primary outcome was cardiovascular (CV) death, myocardial infarction (MI), or stroke." | 5.11 | Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. ( Fox, KA; Gersh, BJ; Lakkis, N; Mehta, SR; Peters, R; Yusuf, S; Zhao, F, 2004) |
| "During a 1-year treatment period, simvastatin, 20 mg/d, produced a sustained reduction of approximately one quarter in low-density lipoprotein cholesterol levels, with no evidence of toxicity, and aspirin, 100 mg/d, did not substantially increase the risk for a major bleeding episode." | 5.11 | First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. ( Altmann, P; Armitage, J; Baigent, C; Baxter, A; Cairns, HS; Collins, R; Foley, RN; Frighi, V; Kourellias, K; Landray, M; Leaper, C; Ratcliffe, PJ; Rogerson, M; Scoble, JE; Tomson, CR; Warwick, G; Wheeler, DC, 2005) |
| "In patients 75 years of age or younger who have myocardial infarction with ST-segment elevation and who receive aspirin and a standard fibrinolytic regimen, the addition of clopidogrel improves the patency rate of the infarct-related artery and reduces ischemic complications." | 5.11 | Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. ( Braunwald, E; Cannon, CP; Claeys, MJ; Cools, F; Gibson, CM; Hill, KA; López-Sendón, JL; McCabe, CH; Montalescot, G; Sabatine, MS; Skene, AM; Theroux, P, 2005) |
| "We randomly assigned patients with transient ischemic attack or stroke caused by angiographically verified 50 to 99 percent stenosis of a major intracranial artery to receive warfarin (target international normalized ratio, 2." | 5.11 | Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. ( Benesch, CG; Chaturvedi, S; Chimowitz, MI; Frankel, MR; Hertzberg, VS; Howlett-Smith, H; Jovin, TG; Kasner, SE; Levine, SR; Lynn, MJ; Romano, JG; Sila, CA; Stern, BJ, 2005) |
| " As compared with hydroxyurea plus aspirin, anagrelide plus aspirin was associated with increased rates of arterial thrombosis (P=0." | 5.11 | Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. ( Bareford, D; Buck, G; Campbell, PJ; East, CL; Green, AR; Grigg, AP; Harrison, CN; Reilly, JT; Revell, P; van der Walt, JD; Wheatley, K; Wilkins, BS; Woodcock, BE, 2005) |
| "Antiplatelet treatment with aspirin and oral anticoagulants reduces recurrence of ischaemic events after myocardial infarction." | 5.10 | Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. ( Deckers, JW; Grobbee, DE; Jonker, JJ; van Es, RF; Verheugt, FW, 2002) |
| "At coronary angiography <48 hours after fibrinolytic therapy, 308 patients receiving aspirin and intravenous heparin had a patent infarct-related artery (Thrombolysis In Myocardial Infarction [TIMI] grade 3 flow)." | 5.10 | Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. ( Aengevaeren, WR; Brouwer, MA; Hertzberger, DP; Luijten, HE; Uijen, GJ; van Boven, AJ; van den Bergh, PJ; Veen, G; Verheugt, FW; Vromans, RP, 2002) |
| "Our objective was to provide estimates of the frequency of bleeding complications, as defined by means of the Thrombolysis In Myocardial Infarction(TIMI) group, and collect data on clinical efficacy of the combination of tirofiban with enoxaparin plus ASA." | 5.10 | Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and ( Bigonzi, F; Borzak, S; Cohen, M; Frey, MJ; Harris, K; Lis, J; Mukherjee, R; Senatore, F; Théroux, P; Van Mieghem, W; White, HD, 2002) |
| "Warfarin, in combination with aspirin or given alone, was superior to aspirin alone in reducing the incidence of composite events after an acute myocardial infarction but was associated with a higher risk of bleeding." | 5.10 | Warfarin, aspirin, or both after myocardial infarction. ( Abdelnoor, M; Arnesen, H; Erikssen, J; Hurlen, M; Smith, P, 2002) |
| "We performed a randomized, double-blind, multicenter study to test the efficacy of triflusal (600 mg/d) versus aspirin (325 mg/d) for prevention of vascular events in patients with stroke or transient ischemic attack (Triflusal versus Aspirin in Cerebral Infarction Prevention [TACIP])." | 5.10 | Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. ( Alvarez-Sabín, J; Ferro, JM; Jiménez, MD; Lago, A; Matías-Guiu, J; Melo, T; Torres, F, 2003) |
| "The anticoagulant, warfarin, and the antiplatelet agent, aspirin, have been shown to have similar benefits after myocardial infarction." | 5.10 | Warfarin and aspirin give more benefit than aspirin alone but also more bleeding after myocardial infarction. ( Doggrell, SA, 2003) |
| "To reduce the incidence of pre-eclampsia in nulliparous women, in accordance with the suggestion of a recent meta-analysis that low dose aspirin might decrease this incidence by more than half if used early enough in and at a sufficient dose during pregnancy (more than 75 mg)." | 5.10 | Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (Part 1). ( Biausque, S; Breart, G; Churlet, A; Goeusse, P; Lequien, P; Marquis, P; Parmentier, D; Puech, F; Subtil, D; Uzan, S, 2003) |
| " Although the dose of aspirin was not randomly assigned, the finding of increased bleeding with doses >162 mg/d is noteworthy." | 5.10 | Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. ( Amarenco, P; Califf, RM; Davis, S; Diener, HC; Easton, D; Ferguson, J; Fitzgerald, D; Graffagnino, C; Granett, J; Harrington, RA; Koudstaal, PJ; Pieper, K; Shuaib, A; Sigmon, K; Theroux, P; Topol, EJ; Vallee, M; Van de Werf, F; Willerson, JT, 2003) |
| "In endocarditis patients already receiving antibiotic treatment, the addition of aspirin does not appear to reduce the risk of embolic events and is likely associated with an increased risk of bleeding." | 5.10 | A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. ( Chan, KL; Cujec, B; Dumesnil, JG; Jue, J; Moher, D; Robinson, TI; Sanfilippo, AJ; Turek, MA, 2003) |
| "We studied the benefits and risks of adding clopidogrel to different doses of aspirin in the treatment of patients with acute coronary syndrome (ACS)." | 5.10 | Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. ( Commerford, PJ; Diaz, R; Fox, KA; Kopecky, SL; Lewis, BS; Mehta, SR; Peters, RJ; Valentin, V; Yusuf, S; Zhao, F, 2003) |
| "We investigated intolerance and bleeding while on aspirin and aspirin discontinuation using 5337 post-acute coronary syndrome patients considered appropriate for chronic antiplatelet therapy who were randomly assigned to aspirin in SYMPHONY and 2nd SYMPHONY and followed for 94 (64,157) days." | 5.10 | Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation. ( Armstrong, PW; Bhapkar, MV; Califf, RM; Kandzari, DE; Kramer, JM; LaPointe, NM; Moliterno, DJ; Newby, LK; Verheugt, FW; White, HD, 2003) |
| "Both aspirin and warfarin when used alone are effective in the secondary prevention of vascular events and death after acute myocardial infarction." | 5.10 | Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. ( Brophy, MT; Ezekowitz, MD; Fiore, LD; Lu, D; Peduzzi, P; Sacco, J, 2002) |
| " Furthermore, the simpler dosing regimen, the absence of neutropenia, and the lower frequency of other side effects make it a safe alternative to ticlopidine." | 5.09 | Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. ( Collins, M; Colombo, A; Iyer, S; Kreps, E; Maida, R; Moses, JW; Moussa, I; Oetgen, M; Roubin, G; Wang, X, 1999) |
| "In the Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation (AFASAK 2) Study, we studied the rate of bleeding events associated with the incidence of thromboembolic events in patients receiving warfarin sodium, 1." | 5.09 | Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. ( Gulløv, AL; Koefoed, BG; Petersen, P, 1999) |
| "Compared with aspirin, clopidogrel reduced the combined risk of ischaemic stroke, myocardial infarction or vascular death by 8." | 5.09 | Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. ( Boissel, JP; Gent, M; Harker, LA; Pilgrim, AJ, 1999) |
| " From 1974 to 1986 we treated 20 symptomatic ET patients with microvascular circulation disturbances including erythromelalgia (N = 18), atypical or typical transient ischemic attacks (N = 6), or acute coronary ischemic syndrome (N = 3) with aspirin and one course of busulfan." | 5.09 | Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. ( Michiels, JJ, 1999) |
| " We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding." | 5.09 | Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000) |
| "Combining aspirin with LDS did not improve outcomes after acute coronary syndromes and caused more bleeding compared with aspirin alone." | 5.09 | Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. ( , 2001) |
| "The combination of aspirin with anticoagulant is associated with increased bleeding in elderly atrial fibrillation patients." | 5.09 | Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS). ( Chaumet-Riffaud, P; Derumeaux, G; Lacomblez, L; Lardoux, H; Lechat, P; Lecompte, T; Maillard, L; Mallet, A; Mas, JL; Mentre, F; Pisica, G; Pousset, F; Raynaud, P; Sanchez, P; Solbes-Latourette, S, 2001) |
| "In this cohort of stroke patients with atrial fibrillation, anticoagulation was superior to aspirin in preventing cardioembolic but not lacunar recurrence." | 5.09 | Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation? ( Evans, A; Kalra, L; Perez, I; Yu, G, 2001) |
| "Over two years, we found no difference between aspirin and warfarin in the prevention of recurrent ischemic stroke or death or in the rate of major hemorrhage." | 5.09 | A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. ( Adams, HP; Albers, GW; Furie, KL; Jackson, CM; Kistler, JP; Lazar, RM; Levin, B; Mohr, JP; Pettigrew, LC; Pullicino, P; Sacco, RL; Thompson, JL, 2001) |
| "A total of 114 patients with essential thrombocythemia (77 women and 37 men; median age, 68 years; range, 40 to 85) and a median platelet count of 788,000 per cubic millimeter (range, 533,000 to 1,240,000 per cubic millimeter) were randomly assigned to receive hydroxyurea (56 patients) or no myelosuppressive therapy (58 patients)." | 5.08 | Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. ( Barbui, T; Cortelazzo, S; Finazzi, G; Galli, M; Rodeghiero, F; Ruggeri, M; Vestri, O, 1995) |
| "Our purpose was to determine the frequency and safety of the use of epidural anesthesia and the correlation between bleeding time and maternal-neonatal bleeding complications in a group of pregnant women who participated in a multicenter trial of low-dose aspirin in pregnancy." | 5.08 | Low-dose aspirin in nulliparous women: safety of continuous epidural block and correlation between bleeding time and maternal-neonatal bleeding complications. National Institute of Child Health and Human Developmental Maternal-Fetal Medicine Network. ( Caritis, SN; McNellis, D; Shaw, K; Sibai, BM; Thom, E, 1995) |
| "The combination of aspirin and warfarin is likely to be more effective than either agent alone in the prevention of ischemic heart disease (IHD), but its practical value also crucially depends on a low incidence of serious bleeding." | 5.08 | Combined use of aspirin and warfarin in primary prevention of ischemic heart disease in men at high risk. ( Meade, TW; Miller, GJ, 1995) |
| "The authors examined the bleeding complications in 75 patients who received acenocoumarol and acetylsalicylic acid combined therapy." | 5.08 | [Adverse effects of combined use of acenocoumarol and acetylsalicylic acid after myocardial infarct and unstable angina]. ( Farkas, A; Sámóczi, M; Sipos, E; Tarján, J, 1995) |
| "To determine any benefits or risks, expressed in early childhood, of low dose aspirin treatment in pregnancies at high risk of complications due to pre-eclampsia or intrauterine growth retardation." | 5.08 | Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. CLASP collaborative group. ( , 1995) |
| "The Stroke Prevention in Atrial Fibrillation II study compared warfarin vs aspirin for stroke prevention in atrial fibrillation." | 5.08 | Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. ( , 1996) |
| "These results suggest that poststenting treatment by ticlopidine/aspirin is an effective alternative to coumadin anticoagulation, achieving low rates of subacute closure and bleeding complications." | 5.08 | Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry. ( Aubry, P; Benveniste, E; Bunouf, P; Cattan, S; Chevalier, B; Commeau, P; Cribier, A; Eiferman, C; Grollier, G; Guerin, Y; Henry, M; Karrillon, GJ; Lefevre, T; Livarek, B; Louvard, Y; Makowski, S; Marco, J; Monassier, JP; Morice, MC; Pernes, JM; Rioux, P; Spaulding, C; Zemour, G, 1996) |
| "Antithrombotic therapy with enoxaparin plus aspirin was more effective than unfractionated heparin plus aspirin in reducing the incidence of ischemic events in patients with unstable angina or non-Q-wave myocardial infarction in the early phase." | 5.08 | A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. ( Bigonzi, F; Califf, RM; Cohen, M; Demers, C; Fox, KA; Fromell, GJ; Goodman, S; Gurfinkel, EP; Langer, A; Premmereur, J; Turpie, AG, 1997) |
| "Aspirin is only modestly effective in the secondary prevention after cerebral ischemia." | 5.08 | A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. ( , 1997) |
| " We evaluated tirofiban, a specific inhibitor of the platelet glycoprotein IIb/IIIa receptor, in the treatment of unstable angina and non-Q-wave myocardial infarction." | 5.08 | Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. ( , 1998) |
| "The Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study was a randomized, controlled trial examining the following therapies: warfarin sodium, 1." | 5.08 | Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. ( Andersen, ED; Boysen, G; Godtfredsen, J; Gulløv, AL; Koefoed, BG; Pedersen, TS; Petersen, P, 1998) |
| "As compared with aspirin alone and a combination of aspirin and warfarin, treatment with aspirin and ticlopidine resulted in a lower rate of stent thrombosis, although there were more hemorrhagic complications than with aspirin alone." | 5.08 | A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. ( Baim, DS; Cutlip, DE; Diver, DJ; Giambartolomei, A; Gordon, PC; Ho, KK; Kuntz, RE; Lasorda, DM; Leon, MB; Pocock, SJ; Popma, JJ; Williams, DO, 1998) |
| "The Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial compared the efficacy and safety of intravenous hirudin with heparin as adjunctive therapy to thrombolysis and aspirin in patients with acute myocardial infarction." | 5.07 | Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. ( Antman, EM, 1994) |
| "In patients with mechanical heart valves and high-risk patients with prosthetic tissue valves, the addition of aspirin to warfarin therapy reduced mortality, particularly mortality from vascular causes, together with major systemic embolism." | 5.07 | A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. ( Basile, F; Gent, M; Gunstensen, J; Hirsh, J; Klimek, M; Latour, Y; Laupacis, A; Turpie, AG, 1993) |
| "Clinical trials have demonstrated a prophylactic role for aspirin in myocardial infarction and in unstable angina pectoris." | 5.07 | Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. ( Edvardsson, N; Jahnmatz, B; Juul-Möller, S; Omblus, R; Rosén, A; Sørensen, S, 1992) |
| "It has been suggested that desmopressin acetate has been effective in reducing hemorrhage after coronary artery bypass grafting in patients receiving aspirin before operation." | 5.07 | The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations. ( Ablaza, SG; Afshar, M; DeCastro, N; Gratz, I; Koehler, J; Larijani, GE; Olsen, D; Spagna, PM, 1992) |
| "Data from the early stages of the thrombosis prevention trial (TPT) have been used to establish and quantify the risk of extracranial bleeding due to low dose aspirin (75 mg) and low intensity oral anticoagulation with warfarin (international normalised ratio, INR, 1." | 5.07 | Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. ( Brennan, PJ; Kelleher, CC; Meade, TW; Roderick, PJ; Wilkes, HC, 1992) |
| "The Stroke Prevention in Atrial Fibrillation Study, a multicenter, randomized trial, compared 325 mg/day aspirin (double-blind) or warfarin with placebo for prevention of ischemic stroke and systemic embolism (primary events), and included 1,330 inpatients and outpatients with constant or intermittent atrial fibrillation." | 5.07 | Stroke Prevention in Atrial Fibrillation Study. Final results. ( , 1991) |
| "We report the results of the Heparin-Aspirin Reperfusion Trial, a collaborative study comparing early intravenous heparin with oral aspirin as adjunctive treatment when recombinant tissue plasminogen activator (rt-PA) is used for coronary thrombolysis during acute myocardial infarction." | 5.06 | A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. ( Chaitman, BR; Hamilton, WP; Hsia, J; Kleiman, N; Roberts, R; Ross, AM, 1990) |
| "Long-term low-dose warfarin therapy is highly effective in preventing stroke in patients with non-rheumatic atrial fibrillation, and can be quite safe with careful monitoring." | 5.06 | The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. ( Blewett, DR; Gress, DR; Hughes, RA; Kistler, JP; Maraventano, SW; Oertel, LB; Rosner, B; Sheehan, MA; Singer, DE, 1990) |
| "A randomized, controlled study was conducted in 51 patients to investigate the effect of aspirin administration on traumatic hyphema." | 5.06 | Aspirin and secondary bleeding after traumatic hyphema. ( Biedner, B; Lifshitz, T; Marcus, M; Yassur, Y, 1988) |
| "Literature on the efficacy and safety of enoxaparin for thromboembolism and thromboprophylaxis remains scanty, and therefore efficacy was not assessed; in terms of safety, when including other indications for enoxaparin in pregnancy, we found that enoxaparin was associated with significantly lower complications than aspirin." | 5.05 | Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis. ( Jacobson, B; Leisegang, R; Naidoo, P; Paek, D; Rambiritch, V; Sayre, T; Shan, J, 2020) |
| "Our review indicated that aspirin use in CKD patients had no prevention effect on cardiovascular events and no statistically significant reduction in risk of cardiovascular or all-cause mortality, with a significant increased risk of minor bleeding and renal events." | 5.05 | Is there a cardiovascular protective effect of aspirin in chronic kidney disease patients? A systematic review and meta-analysis. ( He, Y; Li, M; Lu, H; Qu, B; Wu, H; Wu, L, 2020) |
| " Older studies on aspirin for primary prevention were positive or neutral as to the primary ischemic endpoint (often represented by MACE), but the reduction in nonfatal ischemic events seemed largely counterbalanced by an increase in bleeding events." | 5.05 | Aspirin for primary cardiovascular prevention: why the wonder drug should not be precipitously dismissed. ( Aimo, A; De Caterina, R, 2020) |
| " In addition, among HBR patients, (i) new recommendations prefer direct oral anticoagulants (DOAC) over vitamin K antagonists in DOAC-eligible patients with atrial fibrillation and coronary artery disease; (ii) measures to minimize bleedings while on DAPT should be pursued, including de-escalation of P2Y12 receptor inhibitor therapy; and (iii) new studies are testing reversal strategies for short DAPT regimens, with early discontinuation of aspirin." | 5.05 | [Short dual antiplatelet therapy: how, when and why]. ( Carrozzi, C; Ditali, V; Leonardi, S, 2020) |
| "To evaluate the effectiveness and adverse effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or secondary prevention of dementia." | 5.05 | Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. ( Devane, D; Jordan, F; Kelly, JP; McGuinness, B; Murphy, K; Passmore, P; Quinn, TJ; Tudur Smith, C, 2020) |
| "To review the clinical evidence of the effect of aspirin as primary prevention for patients with diabetes mellitus and in healthy elderly." | 5.05 | Role of Aspirin for Primary Prevention in Persons with Diabetes Mellitus and in the Elderly. ( Baliga, RR; Patel, NJ, 2020) |
| "Benefits of aspirin administration on pre-eclampsia and IUGR depend on the gestational age and dose of aspirin administration." | 5.05 | Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses. ( Banach, M; Ghazanfarpour, M; Jamialahmadi, T; Sahebkar, A; Sathyapalan, T, 2020) |
| " An updated meta analysis was done to determine the effect of the various dual antiplatelets vs aspirin alone on recurrence rate of ischemic stroke, cardiovascular morbidity and mortality, and its safety profile as reported through major bleeding." | 5.05 | Dual versus mono antiplatelet therapy for acute non- cardio embolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis - updated meta-analysis. ( Albay, CEQ; Cheng, FC; Leyson, FGD, 2020) |
| " Dual-antiplatelet therapy is the standard of care for secondary prevention in patients with acute coronary syndrome (ACS), whereas single antiplatelet therapy, generally with aspirin, is the standard of care for secondary prevention in stable patients with coronary artery disease (CAD), peripheral artery disease (PAD), or cerebrovascular disease." | 5.05 | Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence. ( Angiolillo, DJ; Geisler, T; Heitmeier, S; Weitz, JI, 2020) |
| "The results of the THEMIS trial, conducted in DM patients with stable coronary artery disease and no prior stroke or myocardial infarction, showed that although ticagrelor in addition to aspirin reduced the risk of ischemic events, this was associated with a parallel increase in bleeding complications." | 5.05 | An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. ( Angiolillo, DJ; Calderone, D; Capodanno, D, 2020) |
| "The COMPASS trial demonstrated that in patients with stable atherosclerotic disease, very low-dose rivaroxaban, a direct factor Xa inhibitor, when combined with aspirin, reduced the rate of recurrent ischemic events, at the cost of increased bleeding." | 5.05 | Aspirin and low-dose rivaroxaban - the dual pathway concept in patients with stable atherosclerotic disease: a comprehensive review. ( Eisen, A; Parascandolo, E, 2020) |
| " In patients with previous myocardial infarction completing at least 1 year of DAPT, continuing DAPT with a reduced dose of ticagrelor 60 mg BID is a regimen to be considered for these patients; in general ACS patients, a reduced dose of 60 mg BID of ticagrelor after the first year of DAPT should be considered; and in the post-percutaneous coronary intervention patients, DAPT beyond 1 year should be considered after careful evaluation of the patient's thrombotic and bleeding risks." | 5.05 | Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events. ( Dobesh, PP; Finks, SW; Trujillo, TC, 2020) |
| "Aspirin was associated with a slight decrease in AMI and ischemic stroke in absolute terms, with no differences in cardiovascular mortality." | 5.05 | Aspirin in primary prevention. Meta-analysis stratified by baseline cardiovascular risk. ( Lobo, M; Masson, G; Masson, W; Molinero, G, 2020) |
| " The use of aspirin has been implicated in reducing VTE events and is potentially advantageous compared to other agents in respect to cost, access, route of administration and reduced adverse effects such as bleeding." | 5.01 | Aspirin for prevention of venous thromboembolism in recipients of major lower-limb orthopedic surgery: a systematic review of Level I evidence. ( Fletcher, JP; Hitos, K; Seagrave, KG, 2019) |
| "The analysis showed lower risks of major adverse cardiovascular or cerebrovascular events, recurrent stroke, and bleeding events for clopidogrel monotherapy compared to aspirin." | 5.01 | Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis. ( Del Aguila, M; Girotra, S; Hu, B; Ince, B; Jeng, JS; Kutluk, K; Liu, L; Lou, M; Min Han, J; Paciaroni, M; Paek, D; Parfenov, V; Wong, KSL; Zamani, B, 2019) |
| " The objective of this study was to evaluate how treatment with DOACs affects stroke and bleeding outcomes compared with warfarin or aspirin." | 5.01 | A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. ( Battistella, M; Cameron, K; Farrell, A; Feldberg, J; Ma, J; Patel, P; Sivarajahkumar, S, 2019) |
| "The role for aspirin in cardiovascular primary prevention remains controversial, with potential benefits limited by an increased bleeding risk." | 5.01 | Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. ( Roddick, AJ; Zheng, SL, 2019) |
| " The 2017 European Society of Cardiology (ESC)/European Society for Vascular Surgery (ESVS) guidelines recommend for patients with asymptomatic CAAD ≥60% the use of aspirin 75 to 100 mg once daily or clopidogrel 75 mg once daily at the exception of patient at very high bleeding risk." | 5.01 | Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. ( Aboyans, V; Anand, SS; Bauersachs, R; Bosch, J; Debus, ES; Eikelboom, JW; Mazzolai, L; Nehler, M; Nikol, S; Pastori, D; Patel, MR; Ricco, JB; Tanguay, JF; Verhamme, P; Violi, F, 2019) |
| "The result of Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events and the secondary analysis of Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) have shown that treatment with clopidogrel and aspirin for 21 days reduced the risk of recurrent stroke with no significant increase in bleeding risk." | 5.01 | Early Secondary Prevention in Transient Ischemic Attack (TIA) and Minor Stroke. ( Coutts, SB; Hill, MD; Tse, D, 2019) |
| "In the context of contemporary primary prevention guidelines, the effect of aspirin on myocardial infarction risk was significantly attenuated, whereas its major bleeding and hemorrhagic stroke complications were retained." | 5.01 | A Meta-Analysis of Aspirin for the Primary Prevention of Cardiovascular Diseases in the Context of Contemporary Preventive Strategies. ( Khan, B; Khan, SA; Latham, SB; Rao, SV; Shah, R, 2019) |
| "Although aspirin (ASA) is the mainstay of treatment for the prevention of recurrent ischemic stroke, the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial showed ASA monotherapy to be inferior to clopidogrel in preventing recurrent adverse cardiovascular outcomes in patients with high cardiac risks." | 5.01 | Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis. ( Ding, J; Xu, GM; Yuan, J, 2019) |
| "The recent trials confirm that, in modern primary prevention populations, the cardiovascular benefit of aspirin is small and comes with a clear increase in risk for bleeding." | 5.01 | Aspirin for primary prevention of cardiovascular disease: is it time to move on? ( Knickelbine, T; Miedema, MD, 2019) |
| " This article evaluates the preventive effects of rivaroxaban versus aspirin on venous thromboembolism (VTE) through meta-analysis of recent randomized controlled trials (RCTs)." | 5.01 | Rivaroxaban versus Aspirin in Prevention of Venous Thromboembolism: A Meta-Analysis of 9 Randomized Controlled Trials comprising 7,656 Patients. ( Deng, H; Jiang, M; Li, L; Lin, Y; Xie, J; Xie, X, 2019) |
| "A systematic electronic literature search was done in MEDLINE, EMBASE, and Cochrane CENTRAL Register of Controlled Trials for studies including published data of patients ≥18 years of age with nonvalvular atrial fibrillation, randomized to either VKAs or NOACs, or receiving aspirin therapy at any time during the study that report all-cause stroke or systemic embolism, vascular death, myocardial infarction, major bleeding, or intracranial hemorrhage as an outcome." | 4.98 | Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials. ( Bennaghmouch, N; Bode, K; Brueckmann, M; de Veer, AJWM; Dewilde, WJM; Kleine, E; Lip, GYH; Mahmoodi, BK; Ten Berg, JM, 2018) |
| "We aimed to estimate the effect of aspirin on the risk of placental abruption or antepartum hemorrhage in relation to gestational age at onset of therapy and the dosage of the drug." | 4.98 | Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage. ( Bujold, E; Nicolaides, KH; Roberge, S, 2018) |
| "Across trials of cardiovascular and cerebrovascular disease, extended-duration clopidogrel on a background of aspirin has no overall effect on mortality or cancer but does reduce rates of myocardial infarction and stroke and increase rates of bleeding." | 4.98 | Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis. ( Benavente, OR; Bhatt, DL; Connolly, SJ; Doros, G; Elmariah, S; Hsieh, WH; Liu, Y; Mauri, L; Steinhubl, SR; Yeh, RW; Yusuf, S, 2018) |
| "For stroke prevention in elderly patients with IS or TIA, DAPT is superior to aspirin monotherapy but appears to be equivalent to clopidogrel monotherapy, and is accompanied by an increased risk of bleeding." | 4.98 | Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis. ( Ding, L; Peng, B, 2018) |
| "Dual antiplatelet therapy (DAPT) including aspirin and a P2Y12 inhibitor is the cornerstone for the treatment of patients with acute coronary syndrome (ACS)." | 4.98 | [Bleeding risk in patients with acute coronary syndromes treated with antiplatelet agents: incidence, prognosis and clinical evaluation. From research to clinical practice]. ( Demarchi, A; Ferlini, M; Mauri, S; Portolan, M; Visconti, LO, 2018) |
| "To assess the effectiveness and safety of dual agent antiplatelet therapy combining clopidogrel and aspirin to prevent recurrent thrombotic and bleeding events compared with aspirin alone in patients with acute minor ischaemic stroke or transient ischaemic attack (TIA)." | 4.98 | Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis. ( Foroutan, F; Guyatt, G; Hao, Q; O'Donnell, M; Siemieniuk, RA; Tampi, M, 2018) |
| "Aspirin use in PVD might not be associated with improved cardiovascular outcomes or worse bleeding outcomes." | 4.95 | Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials. ( Bavry, AA; Elgendy, AY; Elgendy, IY; Mahmoud, AN; Mahtta, D; Rambarat, C, 2017) |
| "LMWH increased the risk of surgical site bleeding compared with control, warfarin." | 4.95 | Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty. ( Churilov, L; Hardidge, AJ; Suen, K; Westh, RN, 2017) |
| "While the use of aspirin in the secondary prevention of cardiovascular (CVD) is well established, aspirin in primary prevention is not systematically recommended because the absolute CV event reduction is similar to the absolute excess in major bleedings." | 4.95 | Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk. ( Battistoni, A; Coluccia, R; De Caterina, R; Gallo, G; Volpe, M, 2017) |
| " With respect to intracranial hemorrhage, aspirin + clopidogrel yielded worse outcomes than 7 treatments, including placebo, apixaban, aspirin, aspirin + dipyridamole, cilostazol, clopidogrel, and dabigatran (OR, 2." | 4.95 | The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis. ( Chang, S; Chang, Y; Lu, S; Sun, Q; Zhang, Y, 2017) |
| " The cluster ranking of major outcomes indicated that FXI-ASO, ardeparin, aspirin, and apixaban were ideal for preventing all-cause VTE and avoiding all bleeding events." | 4.95 | Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis. ( Chen, X; Jin, Y; Wang, Z; Xiang, Y; Zhao, Y; Zheng, J, 2017) |
| "The Dual Antiplatelet Therapy (DAPT) study demonstrated that DAPT beyond 1-year after drug-eluting stent (DES) implantation, as compared with aspirin therapy alone, significantly reduced the risk of major cardiovascular and cerebrovascular events, which was mainly driven by the large risk reduction for myocardial infarction (MI)." | 4.95 | Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: A comparison between the DAPT study and 9 other trials evaluating DAPT duration. ( Kimura, T; Morimoto, T; Natsuaki, M; Shiomi, H; Toyota, T, 2017) |
| " The combination of aspirin and a P2Y12 inhibitor in patients who receive a coronary stent reduces the rate of stent thrombosis and the rates of major adverse cardiovascular events." | 4.95 | The role of prasugrel in the management of acute coronary syndromes: a systematic review. ( Athanasiou, A; Damaskos, C; Moris, D; Politou, M; Spartalis, E; Spartalis, M; Tzatzaki, E, 2017) |
| "The available evidence demonstrates that the use of clopidogrel plus aspirin in people at high risk of cardiovascular disease and people with established cardiovascular disease without a coronary stent is associated with a reduction in the risk of myocardial infarction and ischaemic stroke, and an increased risk of major and minor bleeding compared with aspirin alone." | 4.95 | Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. ( Bellesini, M; Donadini, MP; Middeldorp, S; Squizzato, A; Takeda, A, 2017) |
| " Whether aspirin ameliorates this risk in patients with established coronary artery disease undergoing cardiac or noncardiac surgery is unknown." | 4.95 | Clinical outcomes associated with per-operative discontinuation of aspirin in patients with coronary artery disease: A systematic review and meta-analysis. ( Cooper, CJ; Husnain, M; Kanjwal, Y; Khan, AR; Khan, MS; Khuder, SA; Luni, FK; Riaz, H; Riaz, IB; Riaz, T; Taleb, M, 2017) |
| "The relative bleeding risk of aspirin versus vitamin K antagonists (VKA) is unclear." | 4.95 | Meta-analysis of major bleeding events on aspirin versus vitamin K antagonists in randomized trials. ( Ambrosi, P; Daumas, A; Giorgi, R; Villani, P, 2017) |
| "Prior meta-analysis and observational studies have suggested that the bleeding risks associated with anticoagulation using vitamin K antagonists (VKA) or aspirin (ASA) are similar." | 4.93 | Risk of major bleeding in patients receiving vitamin K antagonists or low doses of aspirin. A systematic review and meta-analysis. ( Carrier, M; Gándara, E; Gonzalez, JP; LeGal, G; Vazquez, FJ, 2016) |
| "Cilostazol was significantly more effective than aspirin and clopidogrel alone in the long-term prevention of serious vascular events in patients with prior non-cardioembolic ischaemic stroke or transient ischaemic attack." | 4.93 | Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. ( Guo, ZN; Jin, H; Niu, PP; Xing, YQ; Yang, Y, 2016) |
| "To evaluate the risk for serious bleeding with regular aspirin use in cardiovascular disease (CVD) primary prevention." | 4.93 | Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force. ( Burda, BU; Evans, CV; Guirguis-Blake, JM; Whitlock, EP; Williams, SB, 2016) |
| "Aspirin, both alone and in multimodal approaches to thromboprophylaxis, confers a low rate of VTE, with a low risk of major bleeding complications." | 4.93 | Aspirin as Thromboprophylaxis in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis. ( An, VV; Bruce, WJ; Levy, YD; Phan, K, 2016) |
| "The net clinical benefit of aspirin in primary prevention is uncertain as the reduction in occlusive events needs to be balanced against the increase in gastro-intestinal and cerebral bleedings." | 4.93 | Aspirin use for primary prevention in elderly patients. ( Terrosu, P, 2016) |
| " While aspirin remains the cornerstone for secondary prevention of CAD, DAPT significantly reduces recurrent ischemic adverse events at the expense of an increased risk of major bleeding complications." | 4.93 | [Dual antiplatelet therapy for treatment and secondary prevention of coronary artery disease: indications, modalities and duration]. ( Degrauwe, S; Iglesias, JF, 2016) |
| "Dual antiplatelet therapy (DAPT) with aspirin combined with either a thienopyridine (clopidogrel or prasugrel) or acyclopentyl-triazolo-pyrimidine (ticagrelor) plays a vital role in the management of acute coronary syndrome (ACS) especially in those undergoing percutaneous coronary intervention (PCI) but even those being managed medically." | 4.93 | Prasugrel hydrochloride for the treatment of acute coronary syndrome patients. ( Gershlick, AH; Gunarathne, A; Hussain, S, 2016) |
| " Two weeks after the regular dose was restarted (month 3), the patient had repeated bleeding (patient was receiving aspirin for previous MI) and had to stop ibrutinib again." | 4.93 | Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly. ( Ruella, M; Soubeyran, P, 2016) |
| "Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events." | 4.91 | Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. ( Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M, 2015) |
| "DAPT continued beyond 6 months after second generation DES implantation decreases stent thrombosis and myocardial infarction, but increases major bleeding and all-causes mortality compared to shorter DAPT (aspirin alone)." | 4.91 | Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents: Meta-Analysis of Randomized Trials. ( Abo-Salem, E; Alsidawi, S; Effat, M; Helmy, T; Jamali, H, 2015) |
| "This study compared proton pump inhibitors (PPIs) and histamine H2 receptor antagonists (H2RAs) for prevention of low-dose aspirin (LDA)-related gastrointestinal (GI) erosion, ulcer and bleeding." | 4.91 | PPI versus Histamine H2 Receptor Antagonists for Prevention of Upper Gastrointestinal Injury Associated with Low-Dose Aspirin: Systematic Review and Meta-analysis. ( Lu, ML; Mo, C; Sun, G; Wang, YZ; Yang, YS, 2015) |
| "Among adults undergoing non-cardiac surgery who are at risk of a myocardial infarction, a long-standing question has been whether these patients should receive aspirin throughout the perioperative period." | 4.91 | Role of aspirin for prevention and treatment of perioperative cardiovascular events. ( Devereaux, PJ; Duceppe, E; Mrkobrada, M; Thomas, S, 2015) |
| "Clopidogrel, prasugrel, and ticagrelor are the currently available oral P2Y12 inhibitors for the treatment of ST-segment elevation myocardial infarction (STEMI), in association with aspirin." | 4.91 | Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? ( Guimarães, PO; Tricoci, P, 2015) |
| " A pooled analysis showed that dual therapy with clopidogrel and aspirin had a lower stroke incidence than monotherapy in both the short term and long term (RR = 0." | 4.91 | Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis. ( Chen, J; Ding, L; Hong, H; Huang, X; Ma, H; Tan, S; Xiao, X; Xu, R; Yang, S; Yu, S; Zhang, Z, 2015) |
| " However, prasugrel and ticagrelor have a more consistent, faster-acting and more potent antiplatelet effect than clopidogrel, which translates into improved clinical outcomes, although at the expense of an increased bleeding risk." | 4.91 | Antiplatelet therapy in acute coronary syndromes. ( Grove, EL; Kristensen, SD; Thomas, MR; Würtz, M, 2015) |
| "Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel." | 4.91 | Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015) |
| "A systematic review and meta-analysis to determine the risks (major bleeding) and benefits (recurrent VTE and mortality) of extended anticoagulation with vitamin k antagonists (VKA), DOACs and aspirin in patients with an unprovoked VTE and in those patients with clinical equipoise regarding continuation or cessation of anticoagulant therapy." | 4.91 | Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis. ( Cavallazzi, R; Marik, PE, 2015) |
| "To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack." | 4.91 | [Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. ( Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015) |
| "We performed a meta-analysis to determine whether aspirin has a significant protective effect on risk of first thrombosis among patients with antiphospholipid antibodies (aPL+)." | 4.90 | Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. ( Amoura, Z; Arnaud, L; Balasch, J; Cervera, R; Erkan, D; Forastiero, R; Lambert, M; Martinez-Zamora, MA; Mathian, A; Pengo, V; Ruffatti, A; Tektonidou, M; Wahl, D; Zuily, S, 2014) |
| "The discovery of the antiplatelet effect of low-dose aspirin led to the hugely successful strategy of dual antiplatelet therapy in patients with acute coronary syndromes (ACS)." | 4.90 | Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes. ( Storey, RF; Thomas, MR, 2014) |
| "Current guidelines for the management of patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) recommend the administration of dual antiplatelet therapy with aspirin and an ADP receptor blocker "as early as possible" before angiography (upstream), though this suggestion is not based on the results of randomized clinical trials designed to investigate pre-hospital rather than in-hospital drug administration." | 4.90 | [Upstream administration of oral antiplatelet agents in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention]. ( Bramucci, E; Ferlini, M; Mafrici, A; Marzegalli, M; Piccaluga, E; Sponzilli, C; Visconti, LO, 2014) |
| "To compare venous thromboembolism (VTE) and bleeding rates in adult patients receiving aspirin versus anticoagulants after major lower extremity orthopedic surgery." | 4.90 | Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: a systematic review and meta-analysis. ( Chiang, WH; Drescher, FS; Larson, RJ; Lee, A; Morrison, DH; Sirovich, BE, 2014) |
| "Whether clopidogrel should be added to aspirin for stroke prevention remained controversial for the risk of hemorrhagic complications." | 4.90 | Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials. ( Chen, S; He, L; Li, H; Li, M; Li, Y; Peng, Y; Shen, Q; Tang, Y, 2014) |
| " In patients on triple antithrombotic therapy with vitamin K antagonists, aspirin, and clopidogrel, a single clinical trial indicates that withdrawal of aspirin may reduce bleeding risk without increasing the risk of coronary thrombosis." | 4.90 | Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease. ( Thompson, PL; Verheugt, FW, 2014) |
| "Despite well-documented efficacy, recurrent thrombotic event occurrences, particularly stent thrombosis, have been repeatedly demonstrated in stented patients treated with aspirin and clopidogrel." | 4.90 | Resistance to antiplatelet drugs: what progress has been made? ( Bliden, KP; Gesheff, M; Gurbel, PA; Liu, F; Tantry, US, 2014) |
| " In the second part of the review is discussed higher incidence of myocardial infarction in controlled group in the trial comparing treatment of dabigatran with warfarin." | 4.90 | [Anticoagulant therapy in secondary prevention of coronary events]. ( Bultas, J, 2014) |
| "While there is conclusive evidence that aspirin plays a role in reducing the risk of clinically relevant venous thromboembolism (VTE) arising in a number of surgical and non-surgical situations at risk, little is known of the potential of aspirin for the long/term prevention of recurrent VTE." | 4.89 | Aspirin and recurrent venous thromboembolism. ( Milan, M; Noventa, F; Prandoni, P, 2013) |
| "Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor (eg, ticlopidine, clopidogrel, prasugrel, ticagrelor) reduces the risk of stent thrombosis and subsequent cardiovascular events post-PCI (number needed to treat, 33-53) and is the current standard of care." | 4.89 | Medical management after coronary stent implantation: a review. ( Banerjee, S; Brilakis, ES; Patel, VG, 2013) |
| "Given the high risk of stroke after TIA (transient ischemia attack) or stroke and the adverse reaction of bleeding of antiplatelets, we undertook a meta-analysis, reviewed randomized controlled trials (RCTs) comparing aspirin plus clopidogrel with aspirin alone to determine the efficacy and adverse reaction of bleeding of the two protocols in the prevention of stroke." | 4.89 | The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review. ( Hu, B; Huang, Y; Li, JY; Li, M; Mao, L; Xia, YP, 2013) |
| " Bleeding is the most common complication observed after prostate biopsy, but the use of aspirin or nonsteroidal anti-inflammatory drugs is not an absolute contraindication to prostate biopsy." | 4.89 | Complications of prostate biopsy. ( Anastasiadis, A; Antoniewicz, A; Cordeiro, E; De Reijke, T; Dimitriadis, G; Zapała, L, 2013) |
| " As part of a planned re-evaluation within 2 years, we conducted an extensive literature search encompassing all topics included in the 2010 CCS Guidelines, and concluded that there were sufficient new data to merit revisiting the guidance on antiplatelet therapy for secondary prevention in the first year after acute coronary syndrome (ACS), percutaneous coronary intervention, or coronary artery bypass grafting, and the interaction between clopidogrel and proton pump inhibitors." | 4.89 | Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. ( Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G, 2013) |
| "To summarise and compare the efficacy and safety of various oral anticoagulants (dabigatran, rivaroxaban, apixaban, and vitamin K antagonists) and antiplatelet agents (acetylsalicylic acid) for the secondary prevention of venous thromboembolism." | 4.89 | Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. ( Cameron, C; Carrier, M; Castellucci, LA; Clifford, T; Coyle, D; Gandara, E; Le Gal, G; Rodger, MA; Wells, G; Wells, PS, 2013) |
| " Of 2 treatment trials meeting inclusion criteria, 1 large trial (n = 3350) showed that low-dose aspirin did not prevent CVD events in persons with a screen-detected low ABI but may have increased the risk for major bleeding events." | 4.89 | The ankle-brachial index for peripheral artery disease screening and cardiovascular disease prediction among asymptomatic adults: a systematic evidence review for the U.S. Preventive Services Task Force. ( Johnson, ES; Lin, JS; Olson, CM; Whitlock, EP, 2013) |
| " The combination of acetylsalicylic acid (ASA) plus dipyridamole (DP) was more protective against recurrent stroke than ASA alone (RR = 0." | 4.89 | Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis. ( Donovan, JL; Kanaan, AO; Malloy, RJ; Silva, MA, 2013) |
| "To provide a pooled estimate of the bleeding risk from randomized controlled trials (RCTs) comparing warfarin and ASA at the dose ranges recommended in evidence-based guidelines." | 4.88 | Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis. ( Crowther, M; Donadini, MP; Lim, W; Spencer, FA; Warkentin, AE, 2012) |
| "Although the addition of aspirin to clopidogrel resulted in small relative reductions in major cardiovascular events, myocardial infarction, and stroke, it also resulted in a relative increase in major bleeding events." | 4.88 | Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis. ( He, J; Lu, J; Qin, YY; Wei, X; Wu, MJ; Xu, JF; Ye, XF; Zhou, YH, 2012) |
| "P2Y12 adenosine di-phosphate (ADP) receptor antagonists are critical to reduce thrombotic recurrences in acute coronary syndromes patients and for those undergoing percutaneous coronary revascularization." | 4.88 | Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome? ( Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A, 2012) |
| " Addition of clopidogrel was associated with an increase in fatal hemorrhage (OR, 1." | 4.88 | Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials. ( Benavente, OR; Hart, RG; Palacio, S; Pearce, LA, 2012) |
| "The meta-analysis results consistently indicate that, in individuals at low risk for cardiovascular disease, aspirin reduces the risk of MI at the cost of an increase in major bleeding and produces a modest nominally significant reduction in total mortality." | 4.88 | The aspirin controversy in primary prevention. ( Eikelboom, JW; Raju, NC, 2012) |
| " The withdrawal of clopidogrel earlier than 4-6 weeks after bare metal stent implantation or less than 12 months after drug-eluting stent implantation is very risky and poses a high risk of stent thrombosis and high perioperative mortality." | 4.87 | Antiplatelet therapy in the perioperative period. ( Táborský, M; Václavík, J, 2011) |
| " In absolute terms, these relative risks indicate that for every 10,000 diabetic patients treated with aspirin, 109 MACE may be prevented at the expense of 19 major bleeding events (with the caveat that the relative risk for the latter is not statistically significant)." | 4.87 | Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. ( Butalia, S; Ghali, WA; Leung, AA; Rabi, DM, 2011) |
| "The benefit of aspirin to prevent cardiovascular events in subjects without clinical cardiovascular disease relative to the increased risk of bleeding is uncertain." | 4.87 | Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. ( Baker, GS; Berger, JS; Hiatt, WR; Krantz, MJ; Lala, A, 2011) |
| "The aim of this systematic review and meta-analysis was to understand whether continued aspirin therapy is a risk factor for bleeding complications after ultrasound-guided biopsy of the prostate." | 4.87 | Transrectal ultrasound-guided prostate biopsies in patients taking aspirin for cardiovascular disease: A meta-analysis. ( Bozzini, G; Carmignani, L; Gaeta, M; Negri, E; Pavesi, M; Picozzi, S; Ricci, C, 2011) |
| "Current guidelines recommend dual antiplatelet therapy, a combination of aspirin and a P2Y(12) inhibitor, for 6?12 months after percutaneous coronary intervention with drug-eluting stent implantation in all patients and for 1 year in all patients after an acute coronary syndrome (ACS), irrespective of revascularization strategy." | 4.87 | Antiplatelet options for secondary prevention in acute coronary syndromes. ( Cayla, G; Collet, JP; Montalescot, G; O'Connor, SA; Silvain, J, 2011) |
| " Aspirin and, more recently, clopidogrel are among the most important treatments of cardiovascular diseases." | 4.86 | [Long-term use of oral antiplatelet therapy: from studies to practice]. ( Helft, G, 2010) |
| "Both clopidogrel and aspirin have been shown to decrease the rate of cardiovascular events and especially stent thrombosis in patients undergoing percutaneous coronary intervention (PCI)." | 4.86 | Dosing strategies for antiplatelet therapy in percutaneous coronary intervention. ( Bauters, C; Bonello, L; Delhaye, C; Lablanche, JM; Lemesle, G; Maluenda, G; Sudre, A, 2010) |
| " Newer agents, such as bivalirudin or fondaparinux, reduce bleeding complications, with no improvement in anti-ischemic efficacy." | 4.86 | Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy. ( Aïssaoui, N; Danchin, N, 2010) |
| "Overt bleeding associated with low dose aspirin (LDA) is well-recognized, little attention is given to the possibility of association between LDA and occult bleeding, although this is known to occur in healthy volunteers." | 4.86 | Is there an association between low dose aspirin and anemia (without overt bleeding)? Narrative review. ( Derry, S; Gaskell, H; Moore, RA, 2010) |
| "Patients with acute coronary syndromes and patients who undergo coronary stent implantation frequently receive dual antiplatelet therapy with aspirin and a thienopyridine." | 4.85 | Monitoring platelet function to reduce the risk of ischemic and bleeding complications. ( Price, MJ, 2009) |
| " Administration of antiplatelet therapy--a glycoprotein IIb-IIIa inhibitor with or without clopidogrel--before catheterization in patients with high-risk features confers substantially reduced risk of ischemic events while potentially increasing bleeding risk." | 4.85 | Does timing matter? Upstream or downstream administration of antiplatelet therapy. ( Pollack, CV; Slattery, D, 2009) |
| " Clinical trials have demonstrated that patients with antiphospholipid antibodies and venous thromboembolism should be treated with vitamin K antagonists (warfarin); that ischemic stroke may be treated with aspirin or warfarin; and that women with recurrent pregnancy loss should receive prophylactic-dose heparin and aspirin." | 4.85 | Antiphospholipid antibody syndrome. ( Lim, W, 2009) |
| "Our findings question the current practice of using combined aspirin-OAC therapy except in patients with a mechanical heart valve, given the questionable benefits in reducing thromboembolic events and the increased risk of major bleeding." | 4.84 | Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. ( Crowther, M; Dentali, F; Douketis, JD; Lim, W, 2007) |
| " The relationship between low-dose aspirin and bleeding was explored by incidence rates and rates per 100 person-years." | 4.84 | Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. ( Bergsland, E; Gerber, HP; Holden, SN; Holmgren, E; Hurwitz, H; Kabbinavar, F; Miller, K; Ngai, J; Scappaticci, FA; Skillings, JR; Wang, J, 2007) |
| "To quantify the impact of clopidogrel plus aspirin on the individual outcomes of death, myocardial infarction, or stroke in patients with established cardiovascular disease, or in patients with multiple risk factors for vascular disease." | 4.84 | Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. ( Bavry, AA; Bhatt, DL; Duggal, S; Helton, TJ; Kumbhani, DJ; Roukoz, H, 2007) |
| "Clopidogrel has demonstrated improved outcomes for patients with acute coronary syndromes in several large randomized controlled trials." | 4.84 | Clopidogrel: who, when, and how? ( Cannon, CP, 2007) |
| " We explore the role of glycoprotein IIb-IIIa inhibitors and the direct thrombin inhibitor bivalirudin in ACS patients, and consider the difficulties involved in reducing ischemic events while limiting bleeding risks." | 4.84 | Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy. ( Kwa, AT; Rogers, JH, 2008) |
| "Dual antiplatelet therapy with aspirin and clopidogrel is currently the standard therapy after coronary stent implantation to prevent a life-threatening stent thrombosis." | 4.84 | Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding. ( Gawaz, M; Geisler, T; May, AE, 2008) |
| "To review the rationale, clinical practice guideline recommendations, and clinical trial data describing bleeding and clinical outcomes associated with the use of the combination of aspirin, a thienopyridine, and warfarin." | 4.84 | Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? ( Hermosillo, AJ; Spinler, SA, 2008) |
| " Eligible studies were prospective, randomized controlled trials of aspirin therapy in participants without cardiovascular disease that reported data on myocardial infarction (MI), stroke, and cardiovascular mortality." | 4.83 | Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. ( Avanzini, F; Berger, JS; Brown, DL; Pangrazzi, I; Roncaglioni, MC; Tognoni, G, 2006) |
| "Despite hundreds of clinical trials, the appropriate dose of aspirin to prevent myocardial infarction (MI) and stroke is uncertain." | 4.83 | Aspirin to prevent heart attack and stroke: what's the right dose? ( Dalen, JE, 2006) |
| "The long-awaited results of the Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack (MATCH) study, a large-scale trial undertaken to evaluate the safety and efficacy of clopidogrel + aspirin for secondary prevention of stroke, have been published." | 4.83 | MATCH results: implications for the internist. ( Lutsep, HL, 2006) |
| " Results of the first phase III trial (PT1) that compared anagrelide/aspirin with hydroxyurea/aspirin have sparked an intense discussion, given that the combination of anagrelide and aspirin causes more bleeding complications in the gastrointestinal tract." | 4.83 | Anagrelide: what was new in 2004 and 2005? ( Petrides, PE, 2006) |
| "We sought to compare the risk of hemorrhage due to the low (<100 mg), moderate (100 to 200 mg), and high (>200 mg) doses of aspirin (acetylsalicylic acid [ASA]) in 192,036 patients enrolled in 31 clinical trials." | 4.82 | Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. ( Baggish, JS; Berger, PB; Bhatt, DL; Malinin, AI; Serebruany, VL; Steinhubl, SR; Topol, EJ, 2005) |
| "In the secondary prevention of cardiovascular, cerebrovascular, and ischemic events, the evidence supports that the benefits of aspirin treatment significantly outweigh the risk of a major hemorrhage." | 4.82 | Risk of hemorrhagic stroke with aspirin use: an update. ( Gorelick, PB; Weisman, SM, 2005) |
| "After the acute coronary syndrome, adding warfarin to standard aspirin therapy decreases myocardial infarction and stroke but increases major bleeding." | 4.82 | Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. ( Celestin, C; Cook, JR; Fiore, LD; Lawler, E; Rothberg, MB, 2005) |
| " Addition of aspirin and clopidogrel to patients already on warfarin increases the risk of bleeding, while withholding antiplatelet therapy increases the risk of stent thrombosis." | 4.82 | Antiplatelet therapy in anticoagulated patients requiring coronary intervention. ( Arab, D; Cho, L; Joyal, D; Lewis, B; Leya, F; Steen, L, 2005) |
| "To compare the risk of vascular and bleeding events in patients with nonvalvular AF treated with vitamin K -inhibiting oral anticoagulants or acetylsalicylic acid (aspirin)." | 4.81 | Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. ( Chang, Y; Connolly, S; Hart, RG; Hellemons, B; Koudstaal, PJ; Laupacis, A; Petersen, P; Singer, DE; van Walraven, C, 2002) |
| "To examine the benefits and risks of long term anticoagulation (warfarin) compared with antiplatelet treatment (aspirin/indobufen) [corrected] in patients with non-rheumatic atrial fibrillation." | 4.81 | Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. ( Cohen, H; Ebrahim, S; Taylor, FC, 2001) |
| "To determine the cardiovascular and coronary risk thresholds at which aspirin for primary prevention of coronary heart disease is safe and worthwhile." | 4.81 | Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. ( Ghahramani, P; Jackson, PR; Ramsay, LE; Sanmuganathan, PS; Wallis, EJ, 2001) |
| " Thus, physiological and pathophysiological roles of COX-2 were considered from the standpoint of clinical effects of the two latest COX-2 selective inhibitors, celecoxib and rofecoxib, on inflammation, pain, fever and colorectal cancer together with their adverse effects on gastrointestinal, renal and platelet functions; and the usefulness and limits of COX-2-selective inhibitors were discussed with the trends of new NSAIDs development." | 4.81 | [Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]. ( Nakamura, H, 2001) |
| " Aspirin prophylaxis begun for suspected rheumatic fever led to compartment syndromes of all four extremities, which resolved with high-dose FVIII and surgical decompression." | 4.81 | Acquired anti-FVIII inhibitors in children. ( Moraca, RJ; Ragni, MV, 2002) |
| " The gastrointestinal bleeding risk was significantly lower with ticlopidine and clopidogrel, which were both somewhat more effective than aspirin in the prevention of vascular events." | 4.80 | Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis. ( Boysen, G, 1999) |
| "Adjusted-dose warfarin and aspirin reduce stroke in patients with atrial fibrillation, and warfarin is substantially more efficacious than aspirin." | 4.80 | Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. ( Benavente, O; Hart, RG; McBride, R; Pearce, LA, 1999) |
| " Randomized studies have shown that the risk of thrombosis was significantly reduced in ET with the use of hydroxyurea (HU) and in PV with the use of chlorambucil or 32P." | 4.80 | Treatment of polycythaemia vera and essential thrombocythaemia. ( Silverstein, MN; Tefferi, A, 1998) |
| "Randomized trials of aspirin have been conducted in three main populations: patients with evolving acute myocardial infarction (MI), patients with a history of cardiovascular disease and apparently healthy subjects." | 4.80 | Aspirin in the treatment and prevention of cardiovascular disease. ( Buring, JE; Gaziano, JM; Skerrett, PJ, 2000) |
| " The recent clinical reports suggest that there is a narrower window of safety with recombinant hirudin than initially thought particularly when it is used in conjunction with thrombolytic agents and aspirin in acute myocardial infarction." | 4.79 | Advances in antithrombotic therapy: novel agents. ( Hirsh, J; Turpie, AG; Weitz, JI, 1995) |
| "To estimate the risk of myocardial infarction (MI) and death in patients with unstable angina who are treated with aspirin plus heparin compared with patients treated with aspirin alone." | 4.79 | Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. ( Grady, D; Oler, A; Oler, J; Whooley, MA, 1996) |
| "Aspirin has a well established role in the prevention of arterial thrombosis." | 4.79 | Aspirin in essential thrombocythemia: status quo and quo vadis. ( Bangerter, M; Griesshammer, M; Michiels, JJ; van Vliet, HH, 1997) |
| " Patients with rheumatic heart disease complicated by atrial fibrillation should receive long-term warfarin therapy to reduce the risk of stroke unless an absolute contraindication exists." | 4.78 | Anticoagulant therapy for atrial fibrillation. Recommendations from major studies. ( Kahn, JK, 1992) |
| " In selected patients at high risk of event and low risk of bleeding, especially those undergoing recent and complex coronary revascularization using drug-eluting stents (DES) ("revascularization-driven effect"), DAPT is superior to single antiplatelet therapy with aspirin." | 4.31 | Dual pathway inhibition in atherothrombosis prevention: yes, now we can! ( Bhatt, DL; Biondi-Zoccai, G; Franchi, F; Gaspardone, A; Lavalle, C; Mamas, MA; Romagnoli, E; Severino, P; Summaria, F; Versaci, F, 2023) |
| " To better understand this apparent paradox, we measured ARS gene expression and score in volunteers to determine aspirin dose-response and ticagrelor relationships with ARS score and separately in patients to assess whether ARS is associated with incident bleeding." | 4.31 | An antiplatelet response gene expression signature is associated with bleeding. ( Friede, KA; Gales, J; Ginsburg, GS; Kraus, WE; Myers, RA; Ortel, TL; Shah, SH; Voora, D; Zhbannikov, I, 2023) |
| " A tool for evaluating the risk of bleeding in patients with MN was proposed in the KDIGO 2021 guideline, and individuals with low risk of bleeding as well as high risk of VTE were suggested to use warfarin or low-molecular-weight heparin (LMWH) combined with aspirin, as an alternative regimen for warfarin." | 4.31 | Some Points for the KDIGO 2021 Guideline for Prophylactic Anticoagulation in Membranous Nephropathy: Is It Clear Enough for Us to Follow? ( Li, X; Shao, H; Wang, G; Xie, X; Zhang, X; Zhao, Y, 2023) |
| " Indeed, few non-randomized studies previously showed an equivalent risk of bleeding in patients receiving aspirin therapy." | 4.31 | Risk of bleeding after percutaneous native kidney biopsy in patients receiving low-dose aspirin: a single-center retrospective study. ( Alfano, G; Bertolini, F; Cappelli, G; Cazzato, S; Donati, G; Fontana, F; Giaroni, F; Giovanella, S; Ligabue, G; Magistroni, R; Mori, G, 2023) |
| "Considering the 11 trials that reported > 10 ischemic strokes during follow-up (97,578 participants, 1195 ischemic strokes), 1 tested apixaban (57 strokes), 1 betrixaban (52 strokes), and 9 rivaroxaban (1086 strokes)." | 4.31 | Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials. ( Eikelboom, JW; Hart, RG; Katsanos, AH; Perera, KS, 2023) |
| "In patients with ACS who were free from ischemic or major bleeding events during the first 3 months after PCI, the subsequent clopidogrel treatment might reduce minor bleeding events without increasing the risk of MACCE compared with ticagrelor." | 4.31 | Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China. ( Li, X; Lin, Y; Peng, W; Zhang, Y, 2023) |
| " Key consensus points include efforts to improve medical adherence through deprescribing and polypill use; adoption of universal risk definitions for bleeding, myocardial infarction, stroke and cause-specific death; multiple bleeding-avoidance strategies, ranging from gastroprotection with aspirin use to selection of antithrombotic-drug composition, dosing and duration tailored to multiple variables (setting, history, overall risk, age, weight, renal function, comedications, procedures) that need special consideration when managing older adults." | 4.31 | Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis ( Andreotti, F; Collet, JP; Geisler, T; Gigante, B; Gorog, DA; Halvorsen, S; Lip, GYH; Morais, J; Navarese, EP; Patrono, C; Rocca, B; Rubboli, A; Sibbing, D; Storey, RF; Verheugt, FWA; Vilahur, G, 2023) |
| "Several trials demonstrated that aspirin monotherapy compared with aspirin plus clopidogrel is associated with a lower incidence of bleeding without an increased risk of ischemic events in patients after transcatheter aortic valve replacement (TAVR); however, there remains a paucity of data to prove the necessity of even aspirin monotherapy." | 4.31 | No Antithrombotic Therapy After Transcatheter Aortic Valve Replacement: Insight From the OCEAN-TAVI Registry. ( Fukuda, K; Hayashida, K; Inohara, T; Kobari, Y; Mizutani, K; Naganuma, T; Shimizu, H; Shirai, S; Tabata, M; Tada, N; Takagi, K; Tsuruta, H; Ueno, H; Watanabe, Y; Yamamoto, M; Yamanaka, F; Yamawaki, M; Yashima, F, 2023) |
| "Rivaroxaban chemoprophylaxis following TKA and THA was associated with an increased risk of bleeding and prothrombotic complications compared to aspirin and enoxaparin." | 4.31 | Safety and Efficacy of Rivaroxaban in Primary Total Hip and Knee Arthroplasty. ( Christ, AB; Heckmann, ND; Kang, HP; Lieberman, JR; Mayfield, CK; Mills, ES; Piple, AS; Wang, JC, 2023) |
| "Within 12 months, ticagrelor 90 mg monotherapy was the only treatment associated with lower mortality, without bleeding risk trade-off compared with aspirin and clopidogrel." | 4.31 | Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneou ( Aboyans, V; Angiolillo, D; Atar, D; Capodanno, D; Fox, KAA; Halvorsen, S; James, S; Jüni, P; Kunadian, V; Landi, A; Leonardi, S; Mehran, R; Montalescot, G; Navarese, EP; Niebauer, J; Oliva, A; Piccolo, R; Price, S; Storey, RF; Valgimigli, M; Völler, H; Vranckx, P; Windecker, S, 2023) |
| " We explored the outcomes of restarting aspirin use on secondary stroke and mortality in patients with chronic stroke 4 weeks after suffering from a TBI episode in Taiwan." | 4.31 | Risk of secondary stroke subsequent to restarting aspirin in chronic stroke patients suffering from traumatic brain injury in Taiwan. ( Chien, WC; Chou, CL; Chung, CH; Fann, LY; Hsu, YH; Sun, CA; Tang, SE; Wu, CC, 2023) |
| " The purpose of this study was to compare bleeding and thrombotic events in patients treated with cangrelor plus aspirin versus oral dual antiplatelet therapy (DAPT) while supported with VA-ECMO." | 4.31 | Comparison of clinical outcomes with cangrelor plus aspirin versus oral dual antiplatelet therapy in patients supported with venoarterial extracorporeal membrane oxygenation. ( Cohan, D; Konopka, CI; Montepara, CA; Uricchio, MN; Verlinden, NJ, 2023) |
| " DOAC, vitamin K antagonist and aspirin treatment were assessed in the 6 months prior to the start of each year while strokes and bleeds were assessed during the year." | 4.31 | Heterogeneity after harmonisation: A retrospective cohort study of bleeding and stroke risk after the introduction of direct oral anticoagulants in four Western European countries. ( Bennie, M; Carragher, R; Forslund, T; Hjemdahl, P; Hunt, NB; Karlstad, Ø; Kjerpeseth, LJ; Klungel, OH; Komen, JJ; Mueller, T; Olesen, M; Pottegård, A; Wettermark, B, 2023) |
| "Among patients with established cardiovascular disease, the ADAPTABLE trial found no significant differences in cardiovascular events and bleeding rates between 81 mg and 325 mg of aspirin (ASA) daily." | 4.31 | Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE. ( Anderson, RD; Benziger, CP; Bradley, SM; DeWalt, DA; Effron, MB; Farrehi, P; Girotra, S; Gupta, K; Harrington, RA; Hernandez, AF; Jain, SK; Jones, WS; Kim, H; Knowlton, KU; Mehta, H; Muñoz, D; Pepine, CJ; Polonsky, TS; Rothman, RL; Stebbins, A; Whittle, J; Wruck, LM; Zhou, L, 2023) |
| "This study evaluated the association among the plasma concentration of ticagrelor, ARC124910XX, aspirin, and salicylic acid with the risk of recent bleeding in patients with the acute coronary syndrome." | 4.31 | The Plasma Concentration of Ticagrelor and Aspirin as a Predictor of Bleeding Complications in Chinese Acute Coronary Syndrome Patients With Dual Antiplatelet Therapy: A Prospective Observational Study. ( Guo, BY; Hao, J; Liu, JM; Ren, JL; Sun, YQ; Wang, CC; Yang, XL; Zhang, XR; Zhao, JJ; Zhao, Q, 2023) |
| " In patients administered ticagrelor-aspirin and clopidogrel-aspirin, respectively, stroke recurred in 85 (9." | 4.31 | Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial. ( Bath, PM; Claiborne Johnston, S; Jiang, Y; Jing, J; Li, H; Li, Z; Liu, L; Meng, X; Wang, A; Wang, Y; Xie, X; Xu, Q; Zhao, X, 2023) |
| " Net adverse clinical events (a composite of cardiovascular death, myocardial infarction, stroke, or Bleeding Academic Research Consortium [BARC] bleeding type 2, 3, or 5) at 1 year post-PCI were compared between the de-escalation (clopidogrel plus aspirin) and the active control (ticagrelor plus aspirin) groups by HBR status, as defined by the modification of the Academic Research Consortium (ARC) criteria." | 4.31 | De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy. ( Ahn, SG; Ahn, Y; Chang, K; Cho, KH; Hong, YJ; Jeon, DS; Jeong, MH; Jeong, YH; Kim, HY; Kim, JH; Kim, MC; Lee, JW; Shin, ES; Sim, DS; Yoo, KD; Youn, YJ, 2023) |
| "Administration of aspirin for VTE prophylaxis, compared to other chemoprophylaxis agents may have an association with lower risk of major bleeding following TJA." | 4.12 | Aspirin Thromboprophylaxis Is Associated With Less Major Bleeding Events Following Total Joint Arthroplasty. ( Chisari, E; Goh, GS; Ludwick, L; Parvizi, J; Shohat, N; Streicher, S, 2022) |
| "Aspirin contributes significantly to haemorrhagic events in the background of acquired vW disease; its discontinuation significantly reduces bleeding recurrence." | 4.12 | Bleeding in patients with continuous-flow left ventricular assist devices: acquired von Willebrand disease or antithrombotics? ( Bonora, M; Consolo, F; D'Angelo, A; Della Valle, P; Marasi, A; Pappalardo, F; Pieri, M; Redaelli, A; Scandroglio, AM; Zangrillo, A, 2022) |
| "The incidence of delayed posttraumatic intracranial hemorrhage (DH) in patients on anticoagulant (AC) and antiplatelet (AP) medications, especially with concurrent aspirin therapy, is not well established, with studies reporting disparate results with between 1-10% risk of DH and 0-3% mortality." | 4.12 | Increased relative risk of delayed hemorrhage in patients taking anticoagulant/antiplatelet medications with concurrent aspirin therapy: implications for clinical practice based on 3-year retrospective analysis in a large health system. ( Chang, W; Eisenmenger, L; Goldberg, M; Kulzer, M; Li, C; Sohn, A; Spearman, M; Tragon, T; Wanamaker, C; Weston, B; Yin, D, 2022) |
| "Aspirin has become the main agent for venous thromboembolism (VTE) prophylaxis following total knee arthroplasty (TKA)." | 4.12 | Aspirin Administered for Venous Thromboembolism Prophylaxis May Protect Against Stiffness Following Total Knee Arthroplasty. ( Chisari, E; Ludwick, L; Parvizi, J; Shohat, N; Sutton, R, 2022) |
| " This study aimed to evaluate whether our approach of administering only oral antiplatelets without warfarin due to serious bleeding complication risks in children is reasonable." | 4.12 | Anticoagulation Therapy After the Fontan Procedure. ( Iwai, S; Miwa, K; Nagashima, T, 2022) |
| "In this study based on high-intensity statin therapy, clopidogrel-aspirin reduced the risk of compound vascular events and did not increase the risk of hemorrhage during patients' hospitalization after mild-to-moderate ischemic stroke within 72 h." | 4.12 | Dual versus mono antiplatelet therapy in mild-to-moderate stroke during hospitalization. ( Fan, H; Li, J; Li, X; Li, Y; Liu, T; Niu, X; Ren, J; Wang, Y; Wu, X; Zhang, K, 2022) |
| "The goal of this work was to investigate the short-term time-course benefit and risk of ticagrelor with aspirin in acute mild-moderate ischemic stroke or high-risk TIA in The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and ASA for Prevention of Stroke and Death (THALES) trial." | 4.12 | Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. ( Amarenco, P; Denison, H; Evans, SR; Himmelmann, A; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Li, H; Molina, CA; Pan, Y; Wang, Y, 2022) |
| "Continuation of aspirin therapy during ICU stay in critically ill patients with COVID-19 who were receiving it prior to ICU admission may have a mortality benefit; nevertheless, it may be associated with an increased risk of significant bleeding." | 4.12 | Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study. ( Al Enazi, H; Al Harbi, S; Al Harthi, AF; Al Sulaiman, K; Alawad, A; Alenezi, RS; Alhuthaili, O; Aljuhani, O; Almazrou, S; Alotaibi, R; Alqahtani, RA; Alshehri, A; Alsulaiman, T; Altebainawi, AF; Bin Saleh, K; Gramish, J; Hafidh, A; Hussain, S; Kensara, R; Korayem, GB; Vishwakarma, R, 2022) |
| "Clopidogrel in combination with aspirin after acute coronary syndromes (ACS) reduces recurrent ischaemic events compared to aspirin alone." | 4.12 | Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population. ( Amos, D; Brieger, D; Chew, DP; Hou, M; Hyun, K; Kritharides, L, 2022) |
| "Patients diagnosed with acute coronary syndrome and receiving dual antiplatelet therapy (aspirin and ticagrelor) were enrolled and followed up for 12 months." | 4.12 | Association between ticagrelor plasma concentration and bleeding events in Chinese patients with acute coronary syndrome. ( Hu, F; Qi, G; Wang, P; Xing, Y; Yang, J; Zhang, X, 2022) |
| " This study set out to evaluate the prevalence of low platelet reactivity in patients with acute myocardial infarction treated with ticagrelor and aspirin." | 4.12 | Low platelet reactivity in patients with myocardial infarction treated with aspirin plus ticagrelor. ( Costa, TGR; Franken, M; Guerra, JCC; Katz, M; Lemos Neto, PA; Pesaro, AEP, 2022) |
| "Bleeding is the most common adverse reaction to aspirin and can lead to drug discontinuation or even be life-threatening in the secondary prevention of stroke or transient ischemic attack." | 4.12 | Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients. ( Cheng, J; Deng, X; Li, H; Ma, Y; Shi, T; Wang, X; Wu, Y; Zhang, Z; Zhu, Q, 2022) |
| "Fatal AEs related to rivaroxaban combined with aspirin, including bleeding and ischemic events, have been reported mostly in the elderly, and sometimes involved medication errors." | 4.12 | Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase. ( Ding, Q; Yan, S; Yue, QY; Zhang, Q, 2022) |
| "To investigate the associations of perioperative P2Y12 reaction units (PRU) measured using VerifyNow with ischemic and bleeding events, and to determine the PRU threshold in the setting of elective neuro-endovascular treatment (EVT) for intracranial/extracranial vascular disease in patients taking aspirin and clopidogrel." | 4.12 | P2Y12 reaction units and ischemic and bleeding events after neuro-endovascular treatment. ( Fujii, S; Fujita, K; Hirai, S; Ishikawa, M; Karakama, J; Miki, K; Nemoto, S; Sumita, K; Yamaoka, H; Yoshimura, M, 2022) |
| "Clopidogrel monotherapy after 1-month DAPT compared with 12-month DAPT with aspirin and clopidogrel had a benefit in reducing major bleeding events without being associated with increase in cardiovascular events." | 4.12 | Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort. ( Abe, M; Akao, M; Ando, K; Domei, T; Furukawa, Y; Hata, Y; Ikari, Y; Inada, T; Isawa, T; Kadota, K; Kawai, K; Kimura, T; Morimoto, T; Morino, Y; Morishima, I; Nakagawa, Y; Nakao, K; Natsuaki, M; Obayashi, Y; Okayama, H; Sakamoto, H; Suematsu, N; Suwa, S; Suzuki, H; Tamura, T; Tanabe, K; Tokuyama, H; Wakabayashi, K; Watanabe, H; Yagi, M; Yamaji, K; Yamamoto, K; Yoshida, R, 2022) |
| "We aimed to investigate the effectiveness and safety of ticagrelor in comparison with clopidogrel on a background of aspirin for elderly Chinese patients with coronary artery disease 12 months after percutaneous coronary intervention." | 4.12 | Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study. ( Chen, Y; Gao, H; Han, P; Li, C; Lian, K; Liang, Y; Liu, Y; Tan, Z; Tao, F; Wang, Q; Wang, Z; Xu, S; Yang, L; Zhang, A; Zhang, Y; Zhao, S; Zhu, B, 2022) |
| "For some patients receiving warfarin, adding aspirin (acetylsalicylic acid) increases bleeding risk with unclear treatment benefit." | 4.12 | Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation. ( Alexandris-Souphis, T; Ali, MA; Barnes, GD; Errickson, J; Froehlich, JB; Gu, X; Haymart, B; Kaatz, S; Kline-Rogers, E; Kozlowski, JH; Krol, GD; Schaefer, JK; Shah, V; Sood, SL, 2022) |
| "The patient developed acute profound thrombocytopenia following eptifibatide administration." | 4.12 | Eptifibatide-induced acute profound thrombocytopenia: A case report. ( Al Kindi, DI; Al-Mashdali, A; Alamin, MA; Elshaikh, EA; Othman, F, 2022) |
| "Background The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial decreased major adverse cardiovascular events with very low-dose rivaroxaban and aspirin in patients with coronary artery disease and peripheral artery disease." | 4.12 | Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study. ( Abdel-Qadir, H; Chu, A; Farkouh, ME; Ferreira-Legere, LE; Goodman, SG; Ko, DT; Porter, J; Sheth, MS; Tam, DY; Udell, JA; Yu, B, 2022) |
| "Recent trials and metanalyses in the context of primary prevention highlighted a modest reduction in ischemic events with aspirin use, counterbalanced by a significant increase in bleeding events." | 4.02 | Appraising the contemporary role of aspirin for primary and secondary prevention of atherosclerotic cardiovascular events. ( Angiolillo, DJ; Calderone, D; Capodanno, D; Ingala, S; Mauro, MS, 2021) |
| "Warfarin is the most effective intervention for preventing thromboembolism within 6 months post-bioprosthetic MVR surgery in Chinese patients in sinus rhythm." | 4.02 | Comparison of Antithrombotic Strategies in Chinese Patients in Sinus Rhythm after Bioprosthetic Mitral Valve Replacement: Early Outcomes from a Multicenter Registry in China. ( Ao, X; Dong, L; Dong, Y; Fu, B; Zhang, H, 2021) |
| "To examine the association between CAC, bleeding, and ASCVD and explore the net estimated effect of aspirin at different CAC thresholds." | 4.02 | Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease. ( Ajufo, E; Ayers, CR; de Lemos, JA; Joshi, PH; Khera, A; Rohatgi, A; Vigen, R, 2021) |
| "The aim of this study was to compare thromboembolic events, bleeding, and all-cause mortality between DAPT and warfarin following TAVR." | 4.02 | Comparison of Warfarin to Dual Antiplatelet Therapy Following Transcatheter Aortic Valve Replacement. ( Greason, KL; Nei, SD; Scott, R; Wieruszewski, PM, 2021) |
| " To investigate the safety of aspirin continuation, patients who continued taking aspirin perioperatively (Group C) were matched to other patients (Group O), using a propensity score, and bleeding outcomes were compared." | 4.02 | Continuation of aspirin perioperatively for lung resection: a propensity matched analysis. ( Aokage, K; Katsumata, S; Miyoshi, T; Sakai, T; Tane, K; Tsuboi, M, 2021) |
| " Bleeding (n = 100) and quality of life (n = 90) were assessed using validated questionnaires: Warfarin and Aspirin Bleeding assessment tool and Pediatric Quality of Life Inventory, respectively." | 4.02 | Long-term outcomes of warfarin versus aspirin after Fontan surgery. ( Attard, C; Briody, J; Cordina, R; d'Udekem, Y; Hassan, EB; Ignjatovic, V; Mackay, MT; Monagle, PT; Rice, K; Simm, P, 2021) |
| " Anticipated bleeding event rates (including both minor and major bleeds) with aspirin, dabigatran 150 mg, and rivaroxaban 20 mg were sourced from published meta-analyses, whilst a 30% ischaemic stroke reduction for both DOACs was assumed." | 4.02 | Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation. ( de Brouwer, B; Egea, M; Eggington, S; Franco, N; Huynh, M; Ismyrloglou, E; Joglekar, R; Liu, S; Lyon, J; Reynolds, MR; Rosemas, SC; Thijs, V; Tsintzos, SI; Tsivgoulis, G; Witte, KK; Ziegler, PD, 2021) |
| "The coprescription of an angiotensin-converting enzyme inhibitor (ACEi) with clopidogrel reportedly increases bleeding risk." | 4.02 | Bleeding associated with co-administration of clopidogrel and ACEi in patients undergoing PCI and DAPT. ( Chang, SH; Chen, SW; Huang, YT; Kuo, CC; Kuo, CF; Tu, HT; Wang, CL; Wen, MS; Wu, VC, 2021) |
| "This study assessed the efficacy and safety of tirofiban in combination with dual-antiplatelet therapy (DAPT) in progressive ischemic stroke." | 4.02 | Assessing the Efficacy and Safety of Tirofiban in Combination With Dual-antiplatelet Therapy in Progressive Ischemic Stroke Patients. ( Chang, W; Li, L; Lin, F; Liu, H; Yin, J; Zhang, H; Zhao, Y, 2021) |
| "A total of 351 patients with ACS were treated with clopidogrel and aspirin for at least 12 months; we recorded major adverse cardiovascular events (MACE) or bleeding within 1 year." | 4.02 | Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study. ( Bai, H; Li, H; Li, Y; Liu, W; Sun, L; Wang, T; Wu, J; Yu, A; Yu, L; Zhu, W, 2021) |
| "Patients treated with ticagrelor and aspirin usually suffer from bleeding events, especially mild bleeding which is one of the main factors reducing patients' adherence to ticagrelor." | 3.96 | Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75-100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study. ( Chen, R; Chen, Y; Li, J; Liu, C; Sheng, Z; Song, L; Tan, Y; Yan, H; Zhao, H; Zhou, J; Zhou, P, 2020) |
| "Aspirin reduced the risks of MACCE and cancer without increasing the bleeding risk in elderly Koreans with hypertension, T2DM, or dyslipidemia." | 3.96 | Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea. ( Jung, M; Lee, S, 2020) |
| "The RE-DUAL PCI trial reported that dabigatran dual therapy (110/150 mg twice daily, plus clopidogrel or ticagrelor) reduced bleeding events versus warfarin triple therapy (warfarin plus aspirin and clopidogrel or ticagrelor) in patients with atrial fibrillation who underwent percutaneous coronary intervention, with noninferiority in composite thromboembolic events." | 3.96 | Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percut ( Bhatt, DL; Cannon, CP; de Veer, A; Hohnloser, SH; Kimura, T; Lip, GYH; Miede, C; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM, 2020) |
| "Bleeding is a frequently encountered complication in patients undergoing percutaneous coronary intervention (PCI) treated with a dual antiplatelet therapy regimen with aspirin plus an oral inhibitor of the P2Y12 platelet receptor (clopidogrel, prasugrel, ticagrelor) or with the combination of antiplatelet drugs and an anticoagulant in patients who have a specific indication for chronic anticoagulation therapy such as atrial fibrillation." | 3.96 | [Management of antithrombotic therapy in patients with bleeding after percutaneous coronary intervention]. ( Capodanno, D; Capranzano, P; Francaviglia, B; Tamburino, C, 2020) |
| "In AUGUSTUS (Open-Label, 2×2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention), patients with atrial fibrillation and a recent acute coronary syndrome and those undergoing percutaneous coronary intervention had less bleeding with apixaban than vitamin K antagonist (VKA) and with placebo than aspirin." | 3.96 | Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. ( Alexander, JH; Aronson, R; Goodman, SG; Granger, CB; Lopes, RD; Mehran, R; Thomas, L; Vora, AN; Windecker, S; Wojdyla, D, 2020) |
| "Recent American College of Cardiology/American Heart Association Primary Prevention Guidelines recommended considering low-dose aspirin therapy only among adults 40 to 70 years of age who are at higher atherosclerotic cardiovascular disease (ASCVD) risk but not at high risk of bleeding." | 3.96 | Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis). ( Al Rifai, M; Blaha, MJ; Blumenthal, RS; Budoff, M; Cainzos-Achirica, M; Dardari, Z; Duprez, DA; Dzaye, O; Greenland, P; Hong, J; McEvoy, JW; Miedema, MD; Mortensen, MB; Nasir, K; Yeboah, J, 2020) |
| " Despite the modified dose, bleeding events were higher among patients receiving low-dose prasugrel than among patients receiving clopidogrel, with no difference in ischemic events between the 2 groups." | 3.96 | Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. ( Fukuda, K; Heidenreich, PA; Ikemura, N; Kohsaka, S; Numasawa, Y; Sandhu, AT; Sawano, M; Shiraishi, Y; Shoji, S; Suzuki, M; Ueno, K, 2020) |
| "Although potent P2Y12 inhibitor-based dual antiplatelet therapy (DAPT) has replaced clopidogrel-based therapy as the standard treatment in patients with acute myocardial infarction (AMI), there is a concern about the risk of bleeding in East Asian patients." | 3.96 | Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention. ( Byun, JK; Cha, J; Choi, BG; Choi, CU; Choi, JY; Choi, SY; Jang, WY; Jeong, MH; Kang, DO; Kim, EJ; Kim, JS; Kim, W; Na, JO; Oh, DJ; Park, CG; Park, Y; Rha, SW; Roh, SY; Seo, HS, 2020) |
| "Concomitant aspirin and anticoagulation in critically ill surgical patients was associated with an increased rate of major bleeding." | 3.96 | Concomitant Aspirin and Anticoagulation Is Associated With Increased Risk for Major Bleeding in Surgical Patients Requiring Postoperative Intensive Care. ( Gajic, O; Hanson, A; Johnson, MQ; Rayes, HA; Schulte, PJ; Subat, YW; Trivedi, V; Warner, MA; Weister, T, 2020) |
| "We aimed to evaluate the risk of major bleeding in non-surgical critically ill patients who received aspirin in conjunction with therapeutic anticoagulation (concomitant therapy) compared to those who received therapeutic anticoagulation alone." | 3.96 | Risk of major bleeding associated with aspirin use in non-surgical critically ill patients receiving therapeutic anticoagulation. ( Evans, K; Gajic, O; Hanson, AC; Johnson, MQ; Rayes, H; Schulte, PJ; Subat, YW; Trivedi, V; Warner, MA; Weister, T, 2020) |
| "Among older patients with cancer, aspirin was associated with lower VTE incidence and overall inhospital mortality without significantly increased bleeding." | 3.96 | Aspirin Is Associated With Reduced Rates of Venous Thromboembolism in Older Patients With Cancer. ( Cai, P; Dixon, RAF; Hadley, M; Li, M; Li, P; Liu, EY; Liu, Q; Ning, Y; Pan, S; Siddiqui, AD; Wu, F, 2020) |
| "In this observational analysis of patients with atrial fibrillation and flutter, the concomitant use of direct oral anticoagulants and aspirin was associated with an increased risk of both major adverse cardiac and bleeding events when compared to the use of direct oral anticoagulants alone." | 3.96 | Concomitant use of direct oral anticoagulants and aspirin versus direct oral anticoagulants alone in atrial fibrillation and flutter: a retrospective cohort. ( George, J; Hafeez, A; Halalau, A; Keeney, S; Matka, M; Said, A, 2020) |
| "BACKGROUND The purpose of this study was to investigate factors influencing bleeding in patients with acute coronary syndrome (ACS) who are on aspirin and ticagrelor as dual antiplatelet therapy." | 3.96 | Lower Platelet Aggregation Is a Risk Factor for Dual Antiplatelet Therapy-Associated Bleeding: A Preliminary Retrospective Study with Genotype Analysis. ( Guo, L; Huang, Q; Shi, X; Wang, G; Yang, Y; Yuan, D; Yuan, Y; Zhang, H; Zhao, Y, 2020) |
| " In the GLOBAL LEADERS study, time-to-first-event analysis did not show superiority of ticagrelor monotherapy following one-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention to conventional 12-month DAPT followed by aspirin monotherapy in the reduction of the primary composite end point of all-cause mortality or new Q-wave myocardial infarction." | 3.96 | Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. ( Angioi, M; Barbato, E; Chichareon, P; Fontos, G; Gao, C; Hamm, C; Hara, H; Jüni, P; Kawashima, H; Kogame, N; Leandro, S; Modolo, R; Niethammer, M; Ono, M; Onuma, Y; Ribeiro, VG; Serruys, PW; Sharif, F; Steg, PG; Takahashi, K; Tijssen, JGP; Tomaniak, M; Valgimigli, M; van Klaveren, D; Verbeeck, J; Wang, R; Windecker, S, 2020) |
| "Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial." | 3.96 | Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC, 2020) |
| "The purpose of this meta-analysis is to compare the efficacy and safety of aspirin and rivaroxaban in the prevention of venous thromboembolism (VTE) following either total knee arthroplasty or total hip arthroplasty." | 3.96 | Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty: A protocol for meta-analysis. ( Le, G; Luo, H; Tang, J; Xi, L; Yang, C; Zhang, M; Zhao, J, 2020) |
| "All acute coronary syndrome patients from the REgistry of New Antiplatelets in patients with Myocardial Infarction (RENAMI) undergoing percutaneous coronary intervention and treated with aspirin, prasugrel or ticagrelor were stratified according to DAPT duration, that is, shorter than 12 months (D1 group), 12 months (D2 group) and longer than 12 months (D3 group)." | 3.96 | Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. ( Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Bertaina, M; Blanco, PF; Boccuzzi, G; Bongiovanni, F; Cequier, A; Cerrato, E; D'Ascenzo, F; Dominguez-Rodriguez, A; Durante, A; Fernández, MC; Fioravanti, F; Gaita, F; Gallo, D; Garay, A; Gili, S; Grosso, A; Iñiguez-Romo, A; Kinnaird, T; Lüscher, TF; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Omedè, P; Paz, RC; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rinaldi, M; Rognoni, A; Taha, S; Templin, C; Valdés, M; Varbella, F; Velicki, L; Xanthopoulou, I, 2020) |
| " For patients with MINS who are not at high risk of bleeding, physicians should consider initiating dabigatran 110 mg twice daily and low-dose aspirin." | 3.96 | Myocardial injury after non-cardiac surgery: diagnosis and management. ( Devereaux, PJ; Szczeklik, W, 2020) |
| "Discrepancies in preclinical studies of aspirin (ASA) antiplatelet activity in mouse models of bleeding and arterial thrombosis led us to evaluate commonly reported methods in order to propose a procedure for reliably measuring the effects of single dose ASA on mouse hemostasis." | 3.91 | Evaluation of commonly used tests to measure the effect of single-dose aspirin on mouse hemostasis. ( Bachelot-Loza, C; Belleville-Rolland, T; Decouture, B; Dizier, B; Gaussem, P; Leuci, A; Mansour, A; Martin, F; Pidard, D, 2019) |
| "Whether the benefits of aspirin for the primary prevention of cardiovascular disease (CVD) outweigh its bleeding harms in some patients is unclear." | 3.91 | Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention: A Benefit-Harm Analysis. ( Choi, YH; Grey, C; Harwood, M; Jackson, R; Kerr, A; Mehta, S; Poppe, K; Pylypchuk, R; Selak, V; Wells, S; Wu, B, 2019) |
| "In contrast to that in a nonoperative setting, it has been shown that perioperative administration of aspirin did not decrease the rate of death or myocardial infarction but increased major bleeding risk." | 3.91 | Preoperative continuation of aspirin administration in patients undergoing major abdominal malignancy surgery. ( Hidaka, H; Nakatsuka, H; Ono, K; Sato, M, 2019) |
| "Many prognostic models for cardiovascular risk can be used to estimate aspirin's absolute benefits, but few bleeding risk models are available to estimate its likely harms." | 3.91 | Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Cohort Study. ( Grey, C; Harwood, M; Jackson, R; Kerr, A; Mehta, S; Poppe, K; Pylypchuk, R; Selak, V; Wells, S; Wu, B, 2019) |
| "Compared with warfarin monotherapy, receipt of combination warfarin and aspirin therapy was associated with increased bleeding and similar observed rates of thrombosis." | 3.91 | Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events. ( Almany, SL; Barnes, GD; Froehlich, JB; Gu, X; Haymart, B; Kaatz, S; Kline-Rogers, E; Kozlowski, JH; Krol, GD; Li, Y; Schaefer, JK; Sood, SL; Souphis, NM, 2019) |
| "The results of this study clearly show that aspirin, as part of a multimodal thromboprophylactic regime, is an effective and safe regime in preventing venous thromboembolism with respect to risk of deep vein thrombosis or pulmonary embolism when compared to LMWH." | 3.91 | Clinical Effectiveness of Aspirin as Multimodal Thromboprophylaxis in Primary Total Hip and Knee Arthroplasty: A Review of 6078 Cases. ( Best, AJ; Chatterji, U; Ghosh, A; Rudge, SJ, 2019) |
| "The risks of venous thromboembolism (VTE) and bleeding with direct oral anticoagulants (DOACs) and aspirin for thromboprophylaxis after orthopedic surgery were studied." | 3.91 | Direct oral anticoagulants versus aspirin for venous thromboembolism prophylaxis after orthopedic surgery. ( Muntz, J; Murillo, M; Putney, D; Vadhariya, A; Wilson, A; Yang, T, 2019) |
| "For patients with bifurcation lesions after PCI, ticagrelor treatment shows lower MACE and MI rates than the clopidogrel one, along with comparable major bleeding." | 3.91 | Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention. ( Azzalini, L; Li, L; Li, Y; Mao, Q; Tian, J; Tong, W; Xie, L; Zhao, X; Zheng, W; Zhou, D, 2019) |
| "We examined whether the efficacy of low-dose acetylsalicylic acid (aspirin) for primary prevention of cardiovascular events is influenced by blood pressure (BP) using data from patients aged 60-85 years with hypertension, dyslipidemia, and/or diabetes, but without cardiovascular disease of the Japanese Primary Prevention Project." | 3.91 | Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks. ( Ando, K; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Uemura, Y; Yamazaki, T; Yokoyama, K, 2019) |
| "In PEGASUS-TIMI 54, ticagrelor significantly reduced the risk of the composite of major adverse cardiovascular (CV) events by 15-16% in stable patients with a prior myocardial infarction (MI) 1-3 years earlier." | 3.91 | Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. ( Ardissino, D; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Dellborg, M; Hamm, C; Himmelmann, A; Im, KA; Johanson, P; Kamensky, G; Kiss, RG; Kontny, F; Lopez-Sendon, J; Montalescot, G; Oude Ophuis, T; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Van de Werf, F, 2019) |
| "The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial found clinical benefit of low-dose rivaroxaban plus aspirin, but at the expense of increased bleeding risk in patients with stable vascular disease." | 3.91 | Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. ( Abtan, J; Bhatt, DL; Darmon, A; Ducrocq, G; Elbez, Y; Montalescot, G; Ohman, EM; Popovic, B; Röther, J; Sorbets, E; Steg, PG; Wilson, PF; Zeymer, U, 2019) |
| "Background Dual antithrombotic therapy comprising a vitamin K antagonist (VKA) plus clopidogrel reduces the incidence of major bleeding compared with triple therapy (VKA + clopidogrel + aspirin) in acute coronary syndrome (ACS) patients with atrial fibrillation (AF), with a similar thrombotic risk." | 3.88 | Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation. ( Bonello, L; Camoin-Jau, L; Gaubert, M; Laine, M; Paganelli, F; Resseguier, N, 2018) |
| "8 years) with non-valvular atrial fibrillation (NVAF) underwent LAAC procedure using a Watchman device followed by DAPT (75 mg/d aspirin and 75 mg/d clopidogrel)." | 3.88 | Dual antiplatelet therapy is safe and efficient after left atrial appendage closure. ( Czub, P; Fojt, A; Grygier, M; Hendzel, P; Kapłon-Cieślicka, A; Karolczak, N; Kochman, J; Lodziński, P; Maksym, J; Marchel, M; Mazurek, T; Opolski, G; Piątkowski, R; Wilimski, R, 2018) |
| "Eighty-two consecutive patients with stable angina pectoris who received Resolute zotarolimus-eluting stents (R-ZESs; Medtronic Cardiovascular, Santa Rosa, CA, USA) were enrolled." | 3.88 | Comparison of the 9-month intra-stent conditions and 2-year clinical outcomes after Resolute zotarolimus-eluting stent implantation between 3-month and standard dual antiplatelet therapy. ( Fujimoto, W; Kawai, H; Miyata, T; Oishi, S; Onishi, T; Osue, T; Sawada, T; Shimane, A; Takahashi, Y; Takaya, T; Taniguchi, Y; Toba, T; Yasaka, Y, 2018) |
| "Aspirin is an effective prophylaxis for venous thromboembolism (VTE) after total knee arthroplasty (TKA)." | 3.88 | Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty. ( Barsoum, WK; Brigati, DP; Faour, M; Higuera, CA; Klika, AK; Mont, MA; Piuzzi, NS, 2018) |
| "Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the cornerstone of the pharmacologic management of patients with acute coronary syndrome (ACS) and/or receiving coronary stents." | 3.88 | [ANMCO/ANCE/ARCA/GICR-IACPR intersociety consensus document: long-term antiplatelet therapy in patients with coronary artery disease]. ( Abrignani, MG; Ambrosetti, M; Aspromonte, N; Barile, G; Caporale, R; Casolo, G; Chiuini, E; Colivicchi, F; De Luca, L; Di Lenarda, A; Faggiano, P; Gabrielli, D; Geraci, G; Gulizia, MM; La Manna, AG; Maggioni, AP; Marchese, A; Massari, FM; Mureddu, GF; Musumeci, G; Nardi, F; Panno, AV; Pedretti, RFE; Piredda, M; Pusineri, E; Riccio, C; Rossini, R; Scotto Di Uccio, F; Urbinati, S; Varbella, F; Zito, GB, 2018) |
| " The aim of this pilot prospective study was to evaluate 12-month cardiovascular outcomes in elderly patients with acute coronary syndrome (ACS) receiving dual antiplatelet therapy (aspirin and clopidogrel) according to the clustering of CYP2C19 and ABCB1 genetic variants." | 3.88 | Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel. ( Antonicelli, R; Cecchini, S; Di Pillo, R; Galeazzi, R; Giovagnetti, S; Malatesta, G; Montesanto, A; Olivieri, F; Rose, G; Spazzafumo, L, 2018) |
| "Clopidogrel plus aspirin is associated with a reduced risk for myocardial infarction and ischemic stroke and an increased risk for major bleeding compared with aspirin alone among patients at high risk for or with an established cardiovascular disease but without a coronary stent." | 3.88 | Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events. ( Bellesini, M; Donadini, MP; Squizzato, A, 2018) |
| " Therefore, we evaluated the rate of thromboembolic and bleeding complications of two antithrombotic prevention strategies: vitamin K antagonists (VKA) versus aspirin." | 3.88 | Antithrombotic therapy after mitral valve repair: VKA or aspirin? ( Heuts, S; Huisman, MV; Jansen, EK; Klautz, RJM; Klok, FA; Olsthoorn, JR; Sardari Nia, P; Tomsic, A; van der Wall, SJ; Vonk, ABA, 2018) |
| "Using data from the Reduced-Dose Rivaroxaban in the Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism (EINSTEIN-CHOICE) trial, this study assessed cost impact of continued anticoagulation therapy with rivaroxaban vs aspirin." | 3.88 | Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population. ( Ashton, V; Beyer-Westendorf, J; Crivera, C; Haskell, L; Laliberté, F; Lefebvre, P; Lejeune, D; Lensing, AWA; Levitan, B; Prandoni, P; Prins, MH; Schein, J; Wells, PS; Xiao, Y; Yuan, Z; Zhao, Q, 2018) |
| "The authors investigated the risk of bleeding, ischemic stroke, MI, and all-cause mortality associated with direct oral anticoagulants (DOACs) compared with vitamin K antagonists (VKAs) in combination with aspirin, clopidogrel, or both in patients with AF following MI and/or PCI." | 3.88 | Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease. ( Berger, JS; Gislason, GH; Lamberts, M; Lock Hansen, M; Nissen Bonde, A; Olesen, JB; Pallisgaard, JL; Sindet-Pedersen, C; Staerk, L; Torp-Pedersen, C, 2018) |
| "Major bleeding rates were obtained from the PREDICT primary care study, a large New Zealand cohort of people eligible for CVD risk assessment, after excluding those with no other indications for (eg, established CVD) or contraindications/cautions (eg, prior major bleed) to aspirin use." | 3.88 | Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease? ( Jackson, R; Kerr, A; Poppe, K; Selak, V; Wells, S, 2018) |
| " Main causes of oral anticoagulant treatment cessation were switch from vitamin K antagonists to aspirin in 15 patients, prolonged disappearance of antiphospholipid antibodies in ten, bleeding complications in nine and a poor therapeutic adherence in six." | 3.85 | Cessation of oral anticoagulants in antiphospholipid syndrome. ( Cacoub, P; Castel, B; Comarmond, C; de Menthon, M; Decaux, O; Elmaleh-Sachs, A; Ferreira-Maldent, N; Fraisse, T; Goujard, C; Hyvernat, H; Jego, P; Khau, D; Leroux, G; Marie, I; Mekinian, A; Michon, A; Monnier, S; Nguen, Y; Oziol, E; Piette, JC; Saadoun, D; Sarrot-Reynauld, F; Thiercein-Legrand, MF; Veyssier-Belot, C, 2017) |
| "This study aimed to estimate the risk of bleeding following minor oral surgical procedures and uninterrupted aspirin therapy in high-risk patients or patients with existing chronic diseases compared to patients who did not use aspirin during minor oral surgery at a public hospital." | 3.85 | Risk of Hemorrhage Attributed to Underlying Chronic Diseases and Uninterrupted Aspirin Therapy of Patients Undergoing Minor Oral Surgical Procedures: A Retrospective Cohort Study. ( Limsawan, S; Rojanaworarit, C, 2017) |
| " Upper gastrointestinal bleeding is a serious complication, but had low case fatality in trials of aspirin and is not generally thought to cause long-term disability." | 3.85 | Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. ( Geraghty, OC; Li, L; Mehta, Z; Rothwell, PM, 2017) |
| " Parameters associated with a presumably higher risk of bleeding and side-effects against the more effective P2Y12 inhibitors were the most prominent factors for the prescription of clopidogrel." | 3.85 | Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry. ( Adlbrecht, C; Eber, B; Egger, F; Hajos, J; Helmreich, W; Huber, K; Machata, M; Michael, N; Neumayr, M; Rohla, M; Suppan, M; Tscharre, M; Weiss, TW; Zweiker, R, 2017) |
| "There was no evidence that fondaparinux, enoxaparin, or warfarin were superior to aspirin in the prevention of pulmonary embolism, deep vein thrombosis, or venous thromboembolism or that aspirin was safer than these alternatives." | 3.85 | Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty. ( Bini, SA; Cafri, G; Cheetham, CT; Chen, Y; Gould, MK; Khatod, M; Paxton, EW; Sluggett, J, 2017) |
| "Antiplatelet therapy with ticagrelor in patients with acute ischemic stroke or transient ischemic attack showed a bleeding profile similar to that of aspirin for major bleeds." | 3.85 | Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcome ( Albers, GW; Amarenco, P; Aunes, M; Bokelund-Singh, S; Denison, H; Easton, JD; Evans, SR; Held, P; Jahreskog, M; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| "The present study confirms the strong relationship of high platelet reactivity on clopidogrel to 2-year ischemic and bleeding outcomes after DES." | 3.85 | Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. ( Ben-Yehuda, O; Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Gurbel, PA; Henry, TD; Kirtane, AJ; Litherland, C; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Rinaldi, MJ; Simonton, CA; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B, 2017) |
| " Bleeding represents one of the most reported events (ticlopidine 40%, clopidogrel 26%, prasugrel 42%, ticagrelor 30%) and aspirin was the most frequently associated suspected drug." | 3.85 | Safety of Antiplatelet Agents: Analysis of 'Real-World' Data from the Italian National Pharmacovigilance Network. ( Benfatto, G; Drago, F; Gozzo, L; Longo, L; Mansueto, S; Navarria, A; Pani, L; Salomone, S; Sottosanti, L, 2017) |
| "The present study indicated that long-term oral low-dose aspirin was safe for patients with both TBAD and coronary heart disease who underwent EVAR." | 3.85 | Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease. ( Fu, WX; He, RX; Jing, QM; Liu, HW; Liu, YJ; Wang, XZ; Yuan, WJ; Zhang, L; Zhou, TN, 2017) |
| "The risk of excessive bleeding often prompts physicians to interrupt the antiplatelet agents as acetylsalicilyc acid and clopidogrel before dental extractions which puts patients at risk of adverse thrombotic events." | 3.85 | Discontinuation of Oral Antiplatelet Agents before Dental Extraction - Necessity or Myth? ( Atanasov, DT; Dinkova, AS; Vladimirova-Kitova, LG, 2017) |
| " Low molecular weight heparin (LMWH) together with ticagrelor 90 mg twice a day and acetylsalicylic acid (Aspirin) were started after PCI due to high risk of stent thrombosis." | 3.85 | Diffuse alveolar hemorrhage associated with low molecular weight heparin and dual anti-platelet therapy after percutaneous coronary intervention. ( Abacı, A; Aygencel, G; Kara, İ; Okuyan, H; Türkoğlu, M; Yıldırım, F, 2017) |
| " Commonly used medications such as warfarin, heparin, aspirin, clopidogrel, and Opalmon (limaprost alfadex) were included as medications associated with bleeding tendency." | 3.85 | Effect of Drugs Associated With Bleeding Tendency on the Complications and Outcomes of Transforaminal Epidural Steroid Injection. ( Lee, JH; Park, TK; Shin, SJ, 2017) |
| "In clopidogrel treated PCI patients, the 2-year adjusted risk of MACE and NACE was significantly higher in PPI users driven by higher TLR compared to non-PPI users, without a difference in bleeding." | 3.85 | Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. ( Aquino, M; Ariti, C; Baber, U; Bansilal, S; Chandrasekhar, J; Chieffo, A; Cohen, D; Colombo, A; Dangas, G; Faggioni, M; Farhan, S; Gabriel Steg, P; Giustino, G; Henry, T; Kini, A; Mehran, R; Michael Gibson, C; Moliterno, D; Pocock, S; Saporito, R; Sartori, S; Stuckey, T; Vogel, B; Witzenbichler, B, 2017) |
| "Scarce and conflicting evidence exists on whether clopidogrel is effective and whether dual antiplatelet treatment (DAPT) is safe in patients with acute coronary syndrome and chronic kidney disease (CKD)." | 3.85 | Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. ( Carrero, JJ; Evans, M; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Spaak, J; Szummer, K; Varenhorst, C, 2017) |
| "Adjusted survival curves showed that the usage of aspirin was not associated with ischemic stroke, hospitalization for bleeding events, cardiovascular mortality or all-cause mortality, however, it was significantly associated with renal failure." | 3.85 | Different impact of aspirin on renal progression in patients with predialysis advanced chronic kidney disease with or without previous stroke. ( Chang, HR; Hsiao, KC; Huang, JY; Hung, TW; Lee, CT; Liaw, YP, 2017) |
| "To determine if patient aspirin exposure and timing affect bleeding risk after renal allograft biopsy." | 3.85 | Effects of Aspirin Therapy on Ultrasound-Guided Renal Allograft Biopsy Bleeding Complications. ( Atwell, TD; Baffour, FI; Dean, PG; Gunderson, TM; Hickson, LJ; Kurup, AN; Park, WD; Schmit, GD; Schmitz, JJ; Stegall, MD, 2017) |
| "There are few data to guide aspirin therapy to prevent shunt thrombosis in infants." | 3.85 | Platelet Inhibition in Shunted Infants on Aspirin at Short and Midterm Follow-Up. ( Bailly, DK; Burch, PT; Clawson, JR; Johnson, JT; LuAnn Minich, L; Sheng, X; Truong, DT; Witte, MK, 2017) |
| "Aspirin and clopidogrel are both acceptable antiplatelet options for the secondary prevention of noncardioembolic ischemic stroke." | 3.85 | Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up. ( Dai, H; He, P; Li, W; Lin, H; Ping, Y; Xu, H, 2017) |
| " DPP-4 inhibitor-related bleeding was assessed with metformin as negative control, and aspirin, clopidogrel, and prasugrel illustrated positive comparators." | 3.85 | Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events. ( Hansen, RA; Rahman, MM; Scalese, MJ, 2017) |
| "To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)." | 3.85 | State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017) |
| " There was a significant excess of bleeding in patients who received prasugrel or ticagrelor compared to clopidogrel as part of triple therapy (28." | 3.85 | Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention: An Evaluation of Prasugrel or Ticagrelor Versus Clopidogrel. ( Coons, JC; Iasella, CJ; Kane-Gill, SL; Verlinden, NJ, 2017) |
| " Individuals who underwent coronary stenting and completed 12 months of thienopyridine plus aspirin therapy without ischemic or bleeding events remained on an aspirin regimen and were randomized to continued thienopyridine therapy vs placebo for 18 additional months." | 3.85 | Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. ( Apruzzese, PK; Cannon, CP; Cohen, DJ; Cutlip, DE; D'Agostino, RB; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017) |
| "Cilostazol was associated with a significant reduction in late loss in BMS (mean difference 0." | 3.84 | Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. ( Chen, KY; Chetcuti, S; Grossman, MP; Gurm, H; Meier, P; Rha, SW; Tamhane, U, 2009) |
| " The individual duration of either VKAs (acenocoumarol) or aspirin was determined and related to thrombotic and bleeding events." | 3.83 | Antithrombotic strategy after bioprosthetic aortic valve replacement in patients in sinus rhythm: evaluation of guideline implementation. ( Huisman, MV; Jansen, EK; Keijzers, M; Schotten, J; Umans, VA; van der Wall, SJ; Vonk, AB; Wolterbeek, R, 2016) |
| "We conducted a post hoc ancillary analysis of clinically relevant bleeding and major bleeding events among 2293 patients receiving warfarin therapy in the AMADEUS trial." | 3.83 | Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. ( Lane, DA; Lip, GY; Proietti, M; Senoo, K, 2016) |
| " Compared to patients treated with aspirin+clopidogrel, patients treated with aspirin+prasugrel had fewer BARC 3 or 5 bleedings (two [0." | 3.83 | Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study). ( Auffret, V; Avez, B; Bacquelin, R; Bedossa, M; Boulanger, B; Boulmier, D; Castellant, P; Coudert, I; Druelles, P; Filippi, E; Gilard, M; Hacot, JP; Le Breton, H; Le Guellec, M; Leurent, G; Moquet, B; Oger, E; Rialan, A; Rouault, G; Treuil, J, 2016) |
| "High-dose ASA in Heart Mate II patients treated concomitantly with warfarin is associated with an increased hazard of bleeding but does not reduce thrombotic events." | 3.83 | Antiplatelet Therapy and Adverse Hematologic Events During Heart Mate II Support. ( D'Alessandro, D; Goldstein, DJ; Guerrero, C; Jermyn, R; Jorde, UP; Kargoli, F; Levin, AP; Madan, S; Nguyen, J; Patel, SR; Saeed, O; Shah, A; Shin, J; Sims, DB, 2016) |
| "This study's purpose was to present our institution's experience with the use of a risk stratification protocol for venous thromboembolism (VTE) prophylaxis in joint arthroplasty in which "routine" risk patients receive a mobile compression device in conjunction with aspirin and "high"-risk patients receive warfarin for thromboprophylaxis." | 3.83 | The Effectiveness of a Risk Stratification Protocol for Thromboembolism Prophylaxis After Hip and Knee Arthroplasty. ( Barrack, RL; Clohisy, JC; Johnson, SR; Keeney, JA; Nam, D; Nunley, RM, 2016) |
| " Our results suggest that this strategy is not beneficial as compared to aspirin alone in terms of ischaemic or bleeding events." | 3.83 | Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study). ( Bauters, C; Caudmont, S; Ketelers, R; Lamblin, N; Lemaire, N; Lemesle, G; Meurice, T; Philias, A; Schurtz, G; Tricot, O, 2016) |
| "Sarpogrelate-containing triple antiplatelet therapy demonstrated comparable rates of MACCE prevention to the conventional dual antiplatelet therapy after PCI without significantly increasing bleeding risk during the two-year follow-up period." | 3.83 | Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database. ( Bae, SK; Kim, GJ; Kim, JH; Lee, J; Lee, S; Lim, HS; Noh, Y; Oh, E; Shin, S, 2016) |
| "The USPSTF recommends initiating low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years." | 3.83 | Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. ( Bibbins-Domingo, K, 2016) |
| "Dual-antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention reduces the risk for coronary thrombotic events (CTEs) at the expense of increasing risk for major bleeding (MB)." | 3.83 | Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. ( Ariti, C; Baber, U; Chieffo, A; Cohen, DJ; Colombo, A; Dangas, G; Gibson, CM; Giustino, G; Henry, TD; Kini, AS; Kirtane, AJ; Krucoff, MW; Litherland, C; Mehran, R; Moliterno, DJ; Pocock, S; Sartori, S; Steg, PG; Stone, GW; Weisz, G; Witzenbichler, B, 2016) |
| "This was a retrospective study to determine if there was a higher risk of bleeding in patients on aspirin undergoing therapeutic bronchoscopy compared with those not on aspirin." | 3.83 | Aspirin use and the risk of bleeding complications after therapeutic bronchoscopy. ( Alraiyes, AH; Attwood, K; Dhillon, SS; Harris, K; Kebbe, J; Kumar, A; Modi, K, 2016) |
| "The TRA 2°P-TIMI 50 trial showed the addition of vorapaxar to standard care (SC) antiplatelet therapy reduced the combined risk of death, myocardial infarction (MI), and stroke, while exhibiting an increase in moderate, but not other bleeding events." | 3.83 | A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction. ( Bash, LD; Davies, G; Du, M; Oguz, M; Ozer-Stillman, I; Whalen, JD, 2016) |
| "2% of dabigatran-treated patients had renal insufficiency requiring a dose reduction." | 3.83 | Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. ( Barra, ME; Connors, JM; Fanikos, J; Goldhaber, SZ; Piazza, G; Sylvester, KW, 2016) |
| "A higher loading dose of aspirin (160-325 mg) can be beneficial in treating acute ischemic stroke, although there is an increased risk of minor bleeding." | 3.83 | To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes. ( Chan, YL; Lee, JD; Lee, M; Lee, TH; Lin, LC; Su, TH; Wen, YW, 2016) |
| "To evaluate the efficacy and safety of well-managed warfarin therapy in patients with nonvalvular AF, the risk of complications, especially intracranial bleeding, in patients with concomitant use of aspirin, and the impact of international normalized ratio (INR) control." | 3.83 | Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. ( Björck, F; Lip, GY; Renlund, H; Själander, A; Svensson, PJ; Wester, P, 2016) |
| "Aspirin use at baseline was associated with an increased risk for bleeding and all-cause death in ROCKET AF, a risk most pronounced in patients without known CAD." | 3.83 | Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. ( Becker, RC; Berkowitz, SD; Breithardt, G; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, A; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Shah, R; Singer, DE, 2016) |
| "Plasma anticoagulation with warfarin during the early postoperative phase was shown statistically to be inferior to platelet aggregation inhibition by aspirin with regards to postoperative bleeding risk, cerebral ischemic events, and survival." | 3.83 | Anticoagulation After Biological Aortic Valve Replacement: Is There An Optimal Regimen? ( Breuer, M; Fuchs, J; Hüter, L; Kuntze, T; Lauer, B; Owais, T; Rouman, M, 2016) |
| "This study explores bleeding risk of warfarin patients undergoing radial catheterization." | 3.81 | Warfarin: Impact on hemostasis after radial catheterization. ( Gilchrist, IC; Kunselman, AR; Lippe, CM; Reineck, EA, 2015) |
| " aspirin to achieve a reduction in three strokes in 100 patients over a 2-year period." | 3.81 | Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives. ( Alonso-Coello, P; Coll-Vinent, B; Devereaux, PJ; Díaz, MG; Diez, AI; Gich, I; Guyatt, G; Mas, G; Montori, VM; Oliver, S; Roura, M; Ruiz, R; Schünemann, HJ; Solà, I; Souto, JC, 2015) |
| "Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin)." | 3.81 | Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. ( Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015) |
| "Aspirin use increased among Chinese patients newly diagnosed with AF, with no relationship to the patient's stroke or bleeding risk." | 3.81 | Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation. ( Guo, Y; Lip, GYH; Tian, Y; Wang, H; Wang, Y, 2015) |
| "Several trials have compared aspirin or warfarin with either placebo or no antithrombotic drug therapy in a total of a few hundred patients with heart failure in sinus rhythm and no particular thrombotic risk." | 3.81 | Heart failure in sinus rhythm: no routine antithrombotic therapy. ( , 2015) |
| "Current guidelines recommend ticagrelor, in addition to aspirin, for patients with non-ST-segment elevation acute coronary syndromes at moderate to high-risk regardless of initial therapeutic strategy." | 3.81 | Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes. ( Aspromonte, N; Caldarola, P; Chiatto, M; Iacoviello, M; Monitillo, F; Valle, R, 2015) |
| " For subgroup analysis, all patients were stratified by the following factors: age (above 75), disease (presence of hypertension, diabetes, congestive heart failure, and a history of stroke or thromboembolism), rhythm control procedure, and concurrent aspirin therapy." | 3.81 | INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation. ( Choi, YR; Chung, JE; Gwak, HS; La, HO; Seong, JM, 2015) |
| " As stents are prone to thrombosis, which can potentially be devastating, patients are treated with dual antiplatelet therapy with aspirin plus a thienopyridine for at least 6-12 months after stent placement." | 3.81 | Assessing the optimal strategy for dual antiplatelet therapy. ( Chang, L; Yeh, RW, 2015) |
| "Despite evidence that preoperative aspirin improves outcomes in cardiac surgery, recommendations for aspirin use are inconsistent due to aspirin's anti-platelet effect and concern for bleeding." | 3.81 | The Effect of Aspirin on Bleeding and Transfusion in Contemporary Cardiac Surgery. ( Berguson, MW; Bowen, JE; Daskalakis, C; Diehl, JT; Goldhammer, JE; Marhefka, GD; Sun, J, 2015) |
| "Patients with cardiovascular disease are frequently on aspirin, which may place them at risk for bleeding during surgical procedures." | 3.81 | Utility of VerifyNow for Point-of-Care Identification of an Aspirin Effect Prior to Emergency Cardiac Surgery. ( Dasgupta, A; Nguyen, AN; Wahed, A; Welsh, KJ, 2015) |
| " During the beginning of warfarin treatment, INR must be assessed regularly in order to optimize treatment and minimize the risk for hemorrhage." | 3.81 | [INTERNATIONAL NORMALIZED RATIO VALUES AND HEMORRHAGE IN HOSPITALIZED PATIENTS STARTING WARFARIN THERPY: AN OBSERVATIONAL STUDY]. ( Abadi, U; Ellis, MH, 2015) |
| "In patients with both stable coronary disease and atrial fibrillation, a baseline treatment of aspirin and an oral anticoagulant is often prescribed due to the proven benefits of each therapy on cardiovascular and thromboembolic events and mortality." | 3.81 | [Long term aspirin in stable coronary disease with an indication for anticoagulation: is it reasonable?]. ( Lister, K; Louis Simonet, M, 2015) |
| "Patients with high PR on clopidogrel have a greater incidence of adverse ischemic events after stent implantation, whereas low PR may increase bleeding." | 3.81 | Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). ( Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Henry, TD; Kirtane, AJ; Maehara, A; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Parikh, PB; Parvataneni, R; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Xu, K, 2015) |
| "This ecological comparison of bleeding reports and dispensed prescriptions showed a signal towards a higher prevalence of bleeding reports in women on clopidogrel treatment while the opposite was found for low-dose aspirin." | 3.80 | Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment. ( Holm, L; Loikas, D; Malmström, RE; Mejyr, S; Rydberg, DM; Schenck-Gustafsson, K; von Euler, M; Wettermark, B, 2014) |
| " We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population." | 3.80 | Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. ( Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C, 2014) |
| " However, in patients with atrial fibrillation (AF), there is a concern that combining warfarin with dual antiplatelet therapy may increase the risk of bleeding." | 3.80 | Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents. ( Araki, T; Enomoto, Y; Hara, H; Hori, M; Iijima, R; Itaya, H; Ito, N; Nagashima, Y; Nakamura, M; Shiba, M; Sugi, K; Tokue, M; Utsunomiya, M; Yamazaki, K, 2014) |
| "Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction." | 3.80 | Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014) |
| "In cardiac surgical patients who are treated with ticagrelor + ASA until surgery, ticagrelor therapy is associated with a significantly higher blood loss, a significantly higher use of blood products and coagulation factors and higher incidence of rethoracotomies for bleeding compared with patients treated with clopidogrel + ASA." | 3.80 | Perioperative outcomes of cardiac surgery patients with ongoing ticagrelor therapy: boon and bane of a new drug. ( Bauer, M; Bräuer, A; Danner, BC; Hinz, J; Meyer, K; Mohite, PN; Popov, AF; Schöndube, FA; Schotola, H; Sossalla, S, 2014) |
| " Apixaban is an oral anticoagulant that has demonstrated better efficacy than warfarin and aspirin in the ARISTOTLE and AVERROES studies, respectively, and causes less bleeding than warfarin." | 3.80 | Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. ( Dorian, P; Hernandez, L; Iloeje, U; Kongnakorn, T; Kuznik, A; Lanitis, T; Lip, GY; Liu, LZ; Phatak, H; Rublee, DA, 2014) |
| "Combined anticoagulant and aspirin therapy is associated with increased bleeding risk in patients with atrial fibrillation, but the bleeding risk of combined use of anticoagulant and nonsteroidal anti-inflammatory drugs (NSAIDs) is poorly documented." | 3.80 | Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. ( Brighton, TA; Davidson, BL; Gebel, M; Lensing, AW; Lyons, RM; Prins, MH; Rehm, J; Verheijen, S, 2014) |
| "Aspirin for the primary prevention of coronary heart disease (CHD) is only recommended for individuals at high risk for CHD although the majority of CHD events occur in individuals who are at low to intermediate risk." | 3.80 | Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. ( Blaha, MJ; Blankstein, R; Budoff, MJ; Duprez, DA; Folsom, AR; Greenland, P; Miedema, MD; Misialek, JR; Nasir, K; Silverman, MG, 2014) |
| " Aspirin should be continued perioperatively in the majority of surgical operations, whereas dual antiplatelet therapy should not be withdrawn for surgery in the case of low bleeding risk." | 3.80 | Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies. ( Angiolillo, DJ; Antonelli, M; Biglioli, F; Boni, L; Bovenzi, F; Bozzani, A; Bramucci, E; Buffoli, F; Capodanno, D; Castiglioni, B; Comel, A; Cremonesi, A; Crescini, C; D'Angelo, F; De Servi, S; Dionigi, G; Droghetti, A; Francetti, L; Gadda, F; Guagliumi, G; Lettieri, C; Lettino, M; Lorini, L; Musumeci, G; Parolari, A; Piccaluga, E; Ravelli, P; Rossini, R; Salvi, L; Savonitto, S; Scarone, P; Setacci, C; Staurenghi, G; Trabattoni, D; Valdatta, L; Visconti, LO, 2014) |
| "Very few studies have examined the risk of short-term adverse hemorrhage of low-dose aspirin use in primary prevention." | 3.80 | A short-term effect of low-dose aspirin on major hemorrhagic risks in primary prevention: a case-crossover design. ( Chiu, KF; Hsieh, HM; Lin, MY; Wu, IC; Wu, MT; Yu, FJ, 2014) |
| "The present study compared the effects of frequently used anti-platelet drugs, such as clopidogrel, ticlopidine, and cilostazol, on the gastric bleeding and ulcerogenic responses induced by intraluminal perfusion with 25 mM aspirin acidified with 25 mM HCl (acidified ASA) in rats." | 3.80 | Comparative effects of the anti-platelet drugs, clopidogrel, ticlopidine, and cilostazol on aspirin-induced gastric bleeding and damage in rats. ( Izuhara, C; Takayama, S; Takeuchi, K, 2014) |
| " camphorata), a fungus commonly used in Chinese folk medicine for treatment of viral hepatitis and cancer, alone or in combination with aspirin was investigated in a rat embolic stroke model." | 3.80 | Extract of Antrodia camphorata exerts neuroprotection against embolic stroke in rats without causing the risk of hemorrhagic incidence. ( Chang, CY; Geraldine, P; Lan, CC; Lee, JJ; Lee, YM; Sheu, JR; Yen, TL, 2014) |
| "Evidence indicates that vitamin K antagonists (VKAs) and oral anticoagulant therapy are under-utilised for stroke prevention in patients with non-valvular atrial fibrillation (AF), and patients who decline or cannot tolerate such treatment are often prescribed aspirin instead." | 3.80 | Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium. ( Annemans, L; Kongnakorn, T; Lanitis, T; Lieven, A; Marbaix, S; Thijs, V, 2014) |
| " The risks of suffering ischemic stroke, bleeding, or death with warfarin, aspirin, or no antithrombotic treatment during 2010 were related to CHA2DS2VASc scores, age, and complicating co-morbidities." | 3.80 | Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. ( Forslund, T; Hasselström, J; Hjemdahl, P; von Euler, M; Wändell, P; Wettermark, B, 2014) |
| " The net clinical benefit of warfarin was assessed using 4 endpoints: a composite endpoint of death/hospitalization from stroke/bleeding; a composite endpoint of fatal stroke/fatal bleeding; cardiovascular death; and all-cause death." | 3.80 | Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. ( Bonde, AN; Gislason, GH; Hansen, ML; Hansen, PR; Hommel, K; Kamper, AL; Lamberts, M; Lip, GY; Olesen, JB; Torp-Pedersen, C, 2014) |
| "Aim of this multicenter retrospective study was assessment of effect of intracoronary administration of tirofiban loading dose in troponin positive patients with acute coronary syndrome (ACS)." | 3.79 | [Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome]. ( Arystanova, AZh; Balli, M; Batyraliev, TA; Fettser, DV; Kagliian, KÉ; Samko, AN; Serchelik, A; Sidorenko, BA; Tekin, K; Turkmen, S, 2013) |
| "The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear." | 3.79 | Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013) |
| "We examined the effect of local administration of tranexamic acid( TA) on reducing aspirin-induced bleeding in off-pump coronary artery bypass grafting(CABG)." | 3.79 | [Can local administration of tranexamic acid reduce aspirin-induced bleeding in off-pump coronary artery bypass grafting( CABG) ?]. ( Aoki, M; Baba, H; Goto, Y; Ogawa, S; Okawa, Y, 2013) |
| "the primary prevention of ischaemic stroke in chronic non-valvular atrial fibrillation (AF) typically involves consideration of aspirin or warfarin." | 3.78 | Aspirin versus warfarin in atrial fibrillation: decision analysis may help patients' choice. ( O'Shea, D; Romero-Ortuno, R, 2012) |
| "For patients with nonrheumatic AF, including those with paroxysmal AF, who are (1) at low risk of stroke (eg, CHADS(2) [congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack] score of 0), we suggest no therapy rather than antithrombotic therapy, and for patients choosing antithrombotic therapy, we suggest aspirin rather than oral anticoagulation or combination therapy with aspirin and clopidogrel; (2) at intermediate risk of stroke (eg, CHADS(2) score of 1), we recommend oral anticoagulation rather than no therapy, and we suggest oral anticoagulation rather than aspirin or combination therapy with aspirin and clopidogrel; and (3) at high risk of stroke (eg, CHADS(2) score of ≥ 2), we recommend oral anticoagulation rather than no therapy, aspirin, or combination therapy with aspirin and clopidogrel." | 3.78 | Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. ( Eckman, MH; Fang, MC; Go, AS; Halperin, JL; Howard, PA; Hughes, M; Hylek, EM; Lane, DA; Lip, GYH; Manning, WJ; Schulman, S; Singer, DE; Spencer, FA; You, JJ, 2012) |
| " In patients with patent foramen ovale (PFO) and stroke or transient ischemic attack, we recommend initial aspirin therapy (Grade 1B) and suggest substitution of VKA if recurrence (Grade 2C)." | 3.78 | Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. ( Fremes, SE; Rubens, FD; Sun, JC; Teoh, KH; Whitlock, RP, 2012) |
| " Aspirin has been increasingly recognised as an inferior choice for stroke prevention, and may not be any safer than warfarin in terms of major bleeding, especially in the elderly." | 3.78 | What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation? ( Lip, GY, 2012) |
| " The majority of patients had stable coronary artery disease (73%) and received sirolimus-eluting stents (93%), and approximately 90% of thienopyridine was ticlopidine." | 3.78 | Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2. ( Abe, M; Araki, M; Byrne, RA; Ehara, N; Eizawa, H; Fujiwara, H; Furukawa, Y; Inada, T; Iwabuchi, M; Kaburagi, S; Kadota, K; Kastrati, A; Kimura, T; Kita, T; Mitsudo, K; Mitsuoka, H; Mizoguchi, T; Morimoto, T; Nakagawa, Y; Nakano, A; Natsuaki, M; Nobuyoshi, M; Nohara, R; Shiomi, H; Shizuta, S; Suwa, S; Tada, T; Takizawa, A; Taniguchi, R; Tazaki, J, 2012) |
| "Patients receiving clopidogrel beyond 12 months had a lower risk of death or myocardial infarction compared patients receiving clopidogrel ≤12 months." | 3.78 | Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study. ( Faxon, DP; Gaziano, M; Kinlay, S; Lawler, E; Young, M, 2012) |
| "Compared with aspirin, apixaban reduces stroke risk in atrial fibrillation (AF) patients unsuitable for warfarin by 63% but does not increase major bleeding." | 3.78 | Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. ( Anglade, MW; Coleman, CI; Hagstrom, K; Kluger, J; Lee, S; Meng, J, 2012) |
| "Use of warfarin at discharge in patients with atrial fibrillation is greater among those with higher stroke and bleeding risks, but despite higher-risk profiles, less than half received warfarin at discharge." | 3.78 | Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. ( Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY, 2012) |
| "We compared efficacy and safety of warfarin, direct thrombin inhibitor dabigatran and clopidogrel in prevention of stroke in 210 patients with nonvalvular atrial fibrillation (AF) aged 65-80 years." | 3.78 | [Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation]. ( Kanorskiĭ, SG; Shevelev, VI, 2012) |
| ", drug-adverse event pairs, found in 1,644,220 AERs from 2004 to 2009, 736 adverse events were listed as warfarin-associated adverse events, and 147 of the 736 were bleeding complications, including haemorrhage and haematoma." | 3.78 | Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS. ( Kadoyama, K; Okuno, Y; Sakaeda, T; Tamura, T, 2012) |
| " Fatal or nonfatal (requiring hospitalization) bleeding was determined according to antithrombotic treatment regimen: triple therapy (TT) with vitamin K antagonist (VKA)+aspirin+clopidogrel, VKA+antiplatelet, and dual antiplatelet therapy with aspirin+clopidogrel." | 3.78 | Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. ( Gislason, GH; Hansen, CM; Hansen, ML; Karasoy, D; Kristensen, SL; Køber, L; Lamberts, M; Olesen, JB; Ruwald, MH; Torp-Pedersen, C, 2012) |
| "Aspirin is an antiplatelet drug widely used for the prevention of cardiovascular disease; however, it is known to increase bleeding events." | 3.78 | Impact of platelet reactivity on long-term clinical outcomes and bleeding events in Japanese patients receiving antiplatelet therapy with aspirin. ( Higashi, T; Horiuchi, H; Ikeda, T; Kawato, M; Kimura, T; Kita, T; Kondo, H; Shirakawa, R; Tabuchi, A; Takahashi, K; Tamura, T; Taniguchi, R; Toma, M; Watanabe, H; Watanabe, S; Yamane, K; Yoshikawa, Y, 2012) |
| " Compared with aspirin-only, aspirin plus warfarin was associated with a reduced risk of death and embolic events, but at the cost of an increased bleeding risk." | 3.78 | Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. ( Booth, ME; Brennan, JM; Dokholyan, RS; Douglas, PS; Edwards, FH; O'Brien, S; Peterson, ED; Zhao, Y, 2012) |
| "To determine whether patients undergoing transrectal ultrasound (TRUS)-guided prostate biopsy with increased sampling numbers are more likely to experience bleeding complications and whether warfarin or low-dose aspirin are independent risk factors." | 3.78 | Should warfarin or aspirin be stopped prior to prostate biopsy? An analysis of bleeding complications related to increasing sample number regimes. ( Abbas, A; Chowdhury, R; Hoy, A; Idriz, S; Rutherford, EE; Smart, JM, 2012) |
| "The aim of this study was to evaluate the prevalence of triple antithrombotic therapy (TT) (warfarin, aspirin and clopidogrel) in patients following an acute coronary syndrome (ACS), the bleeding risk compared to double antiplatelet therapy (DAPT) (aspirin and clopidogrel) and evaluate the accuracy of the HAS-BLED risk score in predicting serious bleeding events in TT patients." | 3.78 | Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. ( Braun, OÖ; Koul, S; Lumsden, J; Ohman, J; Rydell, E; Scherstén, F; Smith, JG; Svensson, PJ; van der Pals, J; Wieloch, M, 2012) |
| "The injection of aspirin on lymph nodes caused necrosis and an increase of apoptosis after 24 hours and after seven days of treatment there was regeneration of the lymph nodes, with intense decrease of necrosis and a great elevation of apoptosis." | 3.78 | Effects of aspirin on mesenteric lymph nodes of rabbits as basis for its use on lymph nodes metastases. ( Batista, RP; Denadai, R; Saad-Hossne, R, 2012) |
| "In this relatively small, nonrandomized study comparing endovenous thermal ablation in patients with and without warfarin, no differences were found in periprocedural risk of major bleeding or closure rate of the treated venous segments." | 3.77 | Effect of anticoagulation on endothermal ablation of the great saphenous vein. ( Bay, C; Emrani, F; Mehdipour, M; Sharifi, J; Sharifi, M, 2011) |
| "Comparing a patient's bleeding symptoms with those of healthy individuals is an important component of the diagnosis of bleeding disorders, but little is known about whether bleeding symptoms in healthy individuals vary by sex, race, ethnicity, age, or aspirin use." | 3.77 | Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults. ( Barbour, EM; Coller, BS; Khalida, C; Khazanov, NA; Levenkova, N; Mauer, AC; Tian, S; Tobin, JN, 2011) |
| " Triple therapy (OAC, clopidogrel plus aspirin) was associated with four times higher risk of any bleeding than OAC plus aspirin, adj." | 3.77 | Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome. ( Hofman-Bang, C; Lagerqvist, B; Lindbäck, J; Persson, J; Samnegard, A; Stenestrand, U, 2011) |
| "AIMS Immediate treatment with a loading dose of clopidogrel at diagnosis of ST-segment elevation myocardial infarction (STEMI) is recommended by ESC/AHA/ACC guidelines in patients eligible for primary percutaneous coronary intervention (PCI)." | 3.77 | Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Scherstén, F; Smith, JG, 2011) |
| "The tool provides education incorporating patients ' illness perceptions to explain the relationship between NVAF and stroke, and then presents individualized risk estimates, derived using separate risk calculators for stroke and bleeding over a clinically meaningful time period (5 years) associated with no treatment, aspirin, and warfarin." | 3.77 | Development of a tool to improve the quality of decision making in atrial fibrillation. ( Fraenkel, L; Fried, TR; Street, RL, 2011) |
| " We sought to determine if carbon monoxide-releasing molecule-2 [tricarbonyldichlororuthenium (II) dimer, CORM-2] would improve coagulation in rabbit plasma in vitro via thrombelastography and in an in vivo preclinical rabbit model of ear bleeding time following administration of clopidogrel (20 mg/kg) with aspirin (10 mg/kg) via gavage." | 3.77 | Carbon monoxide-releasing molecule-2 enhances coagulation in rabbit plasma and decreases bleeding time in clopidogrel/aspirin-treated rabbits. ( Arkebauer, MR; Chawla, N; Gomes, SB; Mangla, D; Nielsen, VG; Sadacharam, K; Vosseller, K; Wasko, KA, 2011) |
| "In AF patients with CHADS(2) score 1, warfarin was better to prevent ischemic stroke than aspirin without increasing the incidence of major bleeding complications." | 3.76 | The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1. ( Choi, DH; Hwang, ES; Kim, SK; Kim, YH; Kwak, JJ; Lee, BH; Pak, HN; Park, JH; Park, JS, 2010) |
| " The incidence of bleeding in patients taking aspirin within 10 days before biopsy was 0." | 3.76 | Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin. ( Atwell, TD; Callstrom, MR; Charboneau, JW; Harmsen, WS; Hesley, GK; Schleck, CD; Smith, RL; Welch, TJ, 2010) |
| "Aspirin plus clopidogrel (A+C) may be more effective than aspirin only (AO) acutely after TIA and minor stroke, but the risk of bleeding in the acute phase is uncertain." | 3.76 | Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke. ( Buchan, AM; Chandratheva, A; Geraghty, OC; Kennedy, J; Marquardt, L; Rothwell, PM, 2010) |
| "In patients receiving the HeartMate II LVAD who were directly transitioned to warfarin and aspirin therapy without intravenous heparin there was no short-term increase in risk of thrombotic or thromboembolic events, and bleeding requiring transfusion was significantly reduced." | 3.76 | Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. ( Aaronson, KD; Boyle, A; Conte, JV; Farrar, DJ; John, R; Naka, Y; Pagani, FD; Russell, SD; Slaughter, MS; Sundareswaran, KS, 2010) |
| "Previous DAPT studies consistently demonstrated greater efficacy but an increased risk of bleeding compared with aspirin alone in patients with acute coronary syndromes or undergoing percutaneous coronary intervention." | 3.76 | Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective. ( Bhatt, DL; Boden, WE; Flather, MD, 2010) |
| "Combined antiplatelet agents (cAPA), aspirin plus clopidogrel, increase the risk of bleeding." | 3.76 | Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel. ( Bachelot-Loza, C; Dizier, B; Emmerich, J; Gaussem, P; Godier, A; Grelac, F; Hindy-François, C; Le Bonniec, B; Samama, CM, 2010) |
| " All patients had the replanted nail plate removed and received intravenous dextran-40, heparin, and aspirin to promote fingertip bleeding and vascular outflow." | 3.76 | Standardized protocol for artery-only fingertip replantation. ( Brooks, D; Buntic, RF, 2010) |
| "In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding." | 3.76 | Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010) |
| "Dual antiplatelet therapy (DAT) with clopidogrel plus aspirin is a well-established antithrombotic strategy, with hemorrhage being the chief adverse event (AE) of concern." | 3.76 | National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. ( Budnitz, DS; Kegler, SR; Shehab, N; Sperling, LS, 2010) |
| "Data regarding the influence of dose and duration of aspirin use on risk of gastrointestinal bleeding are conflicting." | 3.76 | A prospective study of aspirin use and the risk of gastrointestinal bleeding in men. ( Chan, AT; Ho, WW; Huang, ES; Lee, SS; Strate, LL, 2010) |
| "Non-steroidal anti-inflammatory drugs (NSAIDs) may be prothrombotic, may worsen hypertension or congestive heart failure and obstruct access to the binding site of aspirin to cyclooxygenase-1 and thereby interfere with aspirin's mechanism of action in reducing death and recurrent myocardial infarction (MI)." | 3.75 | Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. ( Antman, EM; Aylward, PE; Bergovec, M; Buros, JL; Col, JJ; Gibson, CM; Goodman, SG; Gulba, D; Kunadian, V; Murphy, SA; Pride, YB; Zorkun, C, 2009) |
| "The aim of this study was to determine the prescribing patterns, risks, and benefits of anticoagulation with warfarin or acetylsalicylic acid (ASA) in elderly patients with AF at risk for stroke and hemorrhage, including those with falls and/or dementia." | 3.75 | Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study. ( Billett, HH; Dinglas, C; Freeman, K; Jacobs, LG; Jumaquio, L, 2009) |
| "(1) For patients with acute coronary syndromes who have undergone percutaneous angioplasty and stenting, the best-assessed treatment for preventing relapses is a combination of aspirin and clopidogrel; (2) Prasugrel, an antiplatelet drug belonging the same chemical class as clopidogrel, is authorized in the EU for use in this indication; (3) Clinical evaluation is based on a randomized double-blind trial comparing prasugrel + aspirin versus clopidogrel + aspirin in 13 608 patients with acute coronary syndromes, half of whom were treated for at least 15 months." | 3.75 | Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. ( , 2009) |
| "The P2Y12 receptor has proven to be a key target in the prevention of complications associated with atherosclerotic vascular disease especially in the context of acute coronary syndrome and percutaneous coronary intervention in addition to aspirin." | 3.75 | P2Y12 inhibitors: thienopyridines and direct oral inhibitors. ( Collet, JP; Montalescot, G, 2009) |
| "Acute coronary syndrome (ACS) guidelines recommend that most patients receive dual antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) at the time of presentation to prevent recurrent ischemic events." | 3.75 | Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society. ( Bittira, B; Brister, S; Eikelboom, J; Fitchett, D; Fremes, S; Graham, J; Gupta, M; Karkouti, K; Lee, A; Love, M; Mazer, D; McArthur, R; Peterson, M; Singh, S; Verma, S; Yau, T, 2009) |
| "Combinations of aspirin, clopidogrel, and vitamin K antagonists are widely used in patients after myocardial infarction." | 3.75 | Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. ( Abildstrom, SZ; Andersson, C; Gislason, GH; Hansen, ML; Hansen, PR; Hvelplund, A; Jørgensen, C; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2009) |
| " The patient had been treated for chronic heart failure and prescribed 100 mg/day of acetylsalicylic acid (aspirin) for its antiplatelet effect." | 3.75 | Detection of presumed hemorrhage in the ampullar endolymph of the semicircular canal: a case report. ( Ishihara, S; Iwano, S; Naganawa, S; Nakashima, T; Sone, M, 2009) |
| " 2 patients who were treated with concomitant warfarin had bleeding complications (severe epistaxis and gastrointestinal bleeding)." | 3.74 | Safety and efficacy of clopidogrel in children with heart disease. ( Boshoff, D; Eyskens, B; Gewillig, M; Mertens, L, 2008) |
| "The rate of clopidogrel use within 30 days after hospital discharge following myocardial infarction increased from 35% in the prior-authorization period to 88% in the limited-use period." | 3.74 | Cardiovascular outcomes after a change in prescription policy for clopidogrel. ( Behlouli, H; Cox, J; Demers, V; Jackevicius, CA; Johansen, H; Kalavrouziotis, D; Melo, M; Newman, A; Pilote, L; Rinfret, S; Tu, JV, 2008) |
| "The aim of this article is to examine whether clopidogrel and ticlopidine treatments produce similar clinical outcomes for patients receiving primary stenting for acute myocardial infarction (AMI)." | 3.74 | Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. ( Brener, M; Carroll, JD; Cox, DA; Cristea, E; Garcia, E; Grines, CL; Guagliumi, G; Lansky, AJ; Leon, MB; Mehran, R; Moses, J; Pietras, C; Rutherford, BD; Stone, GW; Stuckey, T; Tcheng, JE; Tsuchiya, Y; Turco, M, 2008) |
| " Because of recurrent gastrointestinal bleeding episodes, 7 patients discontinued warfarin for a total duration of 39." | 3.74 | Low thromboembolic risk for patients with the Heartmate II left ventricular assist device. ( Boyle, A; Colvin-Adams, M; John, R; Joyce, L; Kamdar, F; Liao, K; Miller, L, 2008) |
| "In patients undergoing coronary stenting, long-term dual antiplatelet therapy with aspirin and clopidogrel reduces atherothrombotic events but also increases the risk of bleeding." | 3.74 | Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. ( Angiolillo, DJ; Bass, TA; Della Rovere, F; Gavazzi, A; Lettieri, C; Mantovani, P; Mihalcsik, L; Molfese, M; Musumeci, G; Rossini, R; Sirbu, V, 2008) |
| "Based on the risk-benefit analysis, warfarin prophylaxis for cardioembolic stroke in Chagas' disease is recommended for patients with a score of 4-5 points, in whom the risk of CE overweighs the risk of a major bleeding." | 3.74 | Prevention strategies of cardioembolic ischemic stroke in Chagas' disease. ( Freitas, GR; Hasslocher-Moreno, A; Sousa, AS; Xavier, SS, 2008) |
| "Patients with cancer who have thrombocytopenia may experience acute coronary syndromes (ACS), and the use of aspirin (ASA) poses an increased risk of bleeding." | 3.74 | Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. ( Botz, G; Champion, JC; Durand, JB; Hirch-Ginsburg, C; Lakkis, N; Lenihan, DJ; Sarkiss, MG; Shaw, AD; Swafford, J; Warneke, CL; Yusuf, SW, 2007) |
| " hypertension, aspirin use) with emergency department admission due to epistaxis." | 3.74 | Research for bleeding tendency in patients presenting with significant epistaxis. ( Buyukasik, Y; Coşkun, F; Dizdar, O; Kalyoncu, U; Karadag, O; Karakiliç, E; Onal, IK; Ozakin, E, 2007) |
| "To characterize the safety of concomitant aspirin, clopidogrel, and warfarin therapy after percutaneous coronary intervention (PCI), and to identify patient characteristics that increase the risk of hemorrhage." | 3.74 | Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. ( Andrel, J; Chervoneva, I; DeCaro, M; DeEugenio, D; Duong, P; Greenspon, A; Kolman, L; Lam, L; Lee, G; McGowan, C; Ruggiero, N; Singhal, S, 2007) |
| "We analysed data from 800 patients with an acute coronary syndrome who underwent coronary stenting (130 patients received a drug-eluting stent) and were discharged on warfarin and either dual (n = 580) or single (n = 220) antiplatelet therapy." | 3.74 | Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent? ( Agnelli, G; Allegrone, J; Brieger, D; Budaj, A; Goodman, SG; Gulba, DC; Lefkovits, J; Lim, YL; Nguyen, MC; Walton, A, 2007) |
| " Bleeding caused by some combination of nonsteroidal antiinflammatory drugs (NSAIDs), cyclooxygenase-2-selective NSAIDS, aspirin, and clopidogrel was the most common reason for ADR-related MICU admissions." | 3.74 | Admissions to a medical intensive care unit related to adverse drug reactions. ( Rivkin, A, 2007) |
| " Fibrin(ogen) deposition, light transmittance aggregometry (LTA; collagen, U46619, and ADP), and bleeding time (BT) were also evaluated." | 3.74 | A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. ( Badimon, L; Casaní, L; Vilahur, G, 2007) |
| "To determine the risk of major and minor bleeding associated with the CTT compared with two other regimens using the combination of either ASA and clopidogrel or ASA and warfarin in patients with cardiovascular disease." | 3.74 | Safety of the cardiac triple therapy: the experience of the Quebec Heart Institute. ( Bergeron, S; Brulotte, S; Lemieux, A; Magne, J; Nguyen, CM; Poirier, P; Sénéchal, M, 2007) |
| "The risk for major bleeding episodes in hemodialysis patients increases significantly while on aspirin and/or warfarin, although warfarin alone did not reach statistical significance." | 3.74 | Major bleeding in hemodialysis patients. ( Day, AG; Harman, GJ; Holden, RM; Holland, D; Wang, M, 2008) |
| "We sought to assess the effect of clopidogrel on in-hospital events in unselected patients with acute ST elevation myocardial infarction (STEMI)." | 3.74 | Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial. ( Bauer, T; Gitt, A; Gottwik, M; Heer, T; Jünger, C; Koeth, O; Mark, B; Senges, J; Zahn, R; Zeymer, U, 2008) |
| "The current standard of care for anti-thrombotic therapy with primary PCI for acute ST elevation myocardial infarction (STEMI) is aspirin, clopidogrel, unfractionated heparin and platelet glycoprotein IIb/IIIa inhibitors." | 3.74 | What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice? ( Brodie, BR, 2008) |
| "In patients with RI undergoing PCI, adding abciximab to clopidogrel plus aspirin increases the risk of bleeding without benefit in reducing the risk of ischemic complications within the first 30 days." | 3.74 | Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function. ( Kastrati, A; Mann, JF; Mehilli, J; Ndrepepa, G; Pinkau, T; Schömig, A; Schulz, S, 2008) |
| " The cost-effectiveness of longer combination therapy depends critically on the balance of thrombotic event rates, durable efficacy, and the increased bleeding rate in patients taking clopidogrel." | 3.73 | A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. ( Heidenreich, PA; Schleinitz, MD, 2005) |
| "Clopidogrel, with or without aspirin, does not increase bleeding complications after TBLB in healthy pigs." | 3.73 | Effect of clopidogrel with and without aspirin on bleeding following transbronchial lung biopsy. ( Becker, HD; Ernst, A; Feller-Kopman, D; Garland, R; Herth, F; Wahidi, MM, 2005) |
| "We report a rare case in which life-threatening subcutaneous hemorrhage following minor blunt trauma developed in an elderly patient taking ticlopidine and aspirin." | 3.73 | Life-threatening subcutaneous hemorrhage following minor blunt trauma in an elderly patient taking ticlopidine and aspirin: a case report. ( Hagiwara, A; Matsuda, T; Shimazaki, S, 2005) |
| "We observed poor short-term outcomes and increased mortality, probably attributable to rapid enlargement of hematomas, in the subjects with ICH who had been taking regularly moderate doses of aspirin (median 250 mg) immediately before the onset of the stroke." | 3.73 | Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. ( Ahonen, M; Hillbom, M; Juvela, S; Pyhtinen, J; Saloheimo, P; Savolainen, ER, 2006) |
| " Patients who are on chronic warfarin therapy and receive a coronary stent need to be treated with the triple therapy of aspirin, clopidogrel and warfarin; however, the bleeding risk in these patients is unknown." | 3.73 | Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. ( Bergman, G; Chou, E; Hong, MK; Khurram, Z; Minutello, R; Naidu, S; Parikh, M; Wong, SC, 2006) |
| "To assess bleeding complications among patients undergoing percutaneous coronary intervention (PCI) and receiving triple therapy of warfarin, aspirin, and a thienopyridine." | 3.73 | Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention. ( Battler, A; Hasdai, D; Iakobishvili, Z; Konstantino, Y; Porter, A; Shachar, L, 2006) |
| " Bleeding complications occurred in 2 patients receiving aspirin, 1 patient receiving warfarin, and 5 patients who did not receive anticoagulant or antiplatelet therapy." | 3.73 | Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. ( Galor, A; Hoffman, GS; Lee, MS; Smith, SD, 2006) |
| "Our study demonstrates an increased risk of major bleeding in unselected patients receiving combination therapy with ASA and clopidogrel after UAP or NSTEMI." | 3.73 | [Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome]. ( Kjaer, J; Larsen, CH; Mickley, H; Møller, JE; Poulsen, TS, 2006) |
| "Aspirin is used in combination with anticoagulant therapy in patients with atrial fibrillation (AF), but evidence of additional efficacy is not available." | 3.73 | Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. ( Chaparro, S; Connolly, SJ; Flaker, GC; Goldman, S; Gruber, M; Halinen, MO; Halperin, JL; Horrow, J; Vahanian, A, 2006) |
| "Medical records of all patients with atrial fibrillation admitted to acute internal medicine wards in April 2000 and between July and October 2001 were reviewed for details of antithrombotics given, results of international normalised ratio monitoring for patients receiving warfarin, side-effects, and additional risk factors for complications of atrial fibrillation." | 3.72 | Antithrombotic treatment of atrial fibrillation in a regional hospital in Hong Kong. ( Leung, CS; Tam, KM, 2003) |
| " As heparin is known to increase the risk of hemorrhage when co-administered with a plasminogen activator, we asked whether adjunct antithrombotic agents such as aspirin and heparin would affect the safety of plasmin." | 3.72 | Safety of plasmin in the setting of concomitant aspirin and heparin administration in an animal model of bleeding. ( Baumbach, GA; Humphries, J; Jesmok, G; Kong, M; Marder, VJ; Sadeghi, S; Stewart, D, 2003) |
| "This study in non-human primates was designed to evaluate the bleeding propensity of a selective, small molecule inhibitor of tissue factor (TF)/VIIa in combination with acetylsalicylic acid (ASA) in comparison to the combination of ASA and warfarin." | 3.72 | Assessment of bleeding propensity in non-human primates by combination of selective tissue factor/VIIa inhibition and aspirin compared to warfarin and aspirin treatment. ( Nicholson, NS; Parlow, JJ; Salyers, AK; South, MS; Suleymanov, OD; Szalony, JA; Wood, RS, 2004) |
| "We performed a retrospective analysis of the Mayo Clinic PCI database and identified 66 consecutive patients who were discharged from hospital after PCI between January 2000 and August 2002 (inclusive) receiving a combination of dual antiplatelet therapy (aspirin and clopidogrel) and systemic anticoagulation (warfarin) to determine the incidence of bleeding and other clinical events during the treatment period." | 3.72 | Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. ( Berger, PB; Burger, K; Fasseas, P; Holmes, DR; Melby, S; Orford, JL; Steinhubl, SR, 2004) |
| "Although recent randomized trials with antithrombotic therapy in nonrheumatic atrial fibrillation (AF) patients emphasized the benefits of warfarin in preventing stroke, warfarin treatment is still far from optimal." | 3.72 | Thromboembolic prophylaxis in nonrheumatic atrial fibrillation: utilization patterns, efficacy, and complications in a long-term follow-up of community patients. ( Blich, M; Gross, B, 2004) |
| "The present study was performed to determine whether the risk of bleeding after transbronchial lung biopsy is increased in patients taking aspirin." | 3.71 | Aspirin does not increase bleeding complications after transbronchial biopsy. ( Becker, HD; Ernst, A; Herth, FJ, 2002) |
| " Thresholds were determined for the minimum reduction in risk of stroke necessary and the maximum increase in risk of excess bleeding acceptable for treatment with aspirin and warfarin in people with atrial fibrillation." | 3.71 | Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. ( Anderson, DR; Brownell, BF; Cox, JL; Devereaux, PJ; Flowerdew, GJ; Gardner, MJ; Nagpal, S; Putnam, W, 2001) |
| "Isoflurane-anesthetized sheep were transfused with packed red blood cells (pRBCs) or diaspirin cross-linked hemoglobin (DCLHb) for treatment of intraoperative hemorrhage." | 3.71 | Comparison of transfusion with DCLHb or pRBCs for treatment of intraoperative anemia in sheep. ( Deyo, DJ; Funston, JS; Harper, D; Kirschner, R; Kramer, GC; Traber, DL; Traber, LL; Vane, LA, 2002) |
| " We aimed to compare the morbidity related to the treatment of atrial fibrillation with warfarin seen in one year at our hospital, with the morbidity in those patients in whom embolism was potentially preventable." | 3.71 | The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable. ( Campbell, Do; Davis, S; Evans, A; Gerraty, R; Greenberg, P; Kilpatrick, C, 2002) |
| "In the Heparin in Early Patency (HEAP) pilot study, 108 patients with signs and symptoms of acute myocardial infarction < 6 h eligible for primary angioplasty received a single intravenous bolus of 300 U/kg of heparin together with aspirin (160 mg chewed) in the emergency room." | 3.70 | High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study. ( Bronzwaer, JG; Liem, A; Marsh, RC; Veen, G; Verheugt, FW; Zijlstra, F, 1998) |
| " In this experimental study we investigated whether Haemate, a von Willebrand Factor (vWF) and factor VIII containing product, could correct rH/aspirin induced bleeding in an experimental pig study." | 3.70 | Development of an anti-bleeding agent for recombinant hirudin induced skin bleeding in the pig. ( Dickneite, G; Friesen, HJ; Nicolay, U; Reers, M, 1998) |
| "Isoproterenol hydrochloride (ISO), a beta adrenergic agonist, is known to cause ischemic necrosis in rats." | 3.70 | Effect of a novel tetrapeptide derivative in a model of isoproterenol induced myocardial necrosis. ( Jayakumar, R; Jayasundar, S; Malarvannan, P; Puvanakrishnan, R; Ramesh, CV, 1998) |
| "We have measured plasma volume expansion (Evans blue and hematocrit changes) and hemodynamic responses in conscious hemorrhaged and normovolemic splenectomized sheep after a 30-min infusion of either 20 ml/kg of diaspirin cross-linked hemoglobin (DCLHb), 20 ml/kg of human albumin (Alb), or 60 ml/kg of a solution of Ringer lactate (RL)." | 3.70 | Plasma volume expansion with solutions of hemoglobin, albumin, and Ringer lactate in sheep. ( Burnet, M; Fischer, SR; Kramer, GC; Prough, DS; Traber, DL, 1999) |
| "To examine the cost-effectiveness of prescribing warfarin sodium in patients who have nonvalvular atrial fibrillation (NVAF) with or without additional stroke risk factors (a prior stroke or transient ischemic attack, diabetes, hypertension, or heart disease)." | 3.69 | Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. ( Albers, GW; Cardinalli, AB; Gage, BF; Owens, DK, 1995) |
| "Aspirin and nonsteroidal antiinflammatory drugs (NSAIDs) inhibit platelet cyclooxygenase activity, resulting in altered platelet function and thus potentially enhanced bleeding." | 3.69 | Effect of aspirin and nonsteroidal antiinflammatory drug therapy on bleeding complications in dermatologic surgical patients. ( Lawrence, C; Sakuntabhai, A; Tiling-Grosse, S, 1994) |
| "To assess the risk of bleeding complications in patients treated with combination aspirin and heparin for cerebral ischemia." | 3.69 | Safety of combination aspirin and anticoagulation in acute ischemic stroke. ( Fagan, SC; Kertland, HR; Tietjen, GE, 1994) |
| "The aim of the study was to compare the incidence of bleeding complications in patients receiving warfarin alone and those receiving warfarin in combination with acetylsalicylic acid." | 3.69 | Comparison of bleeding complications of warfarin and warfarin plus acetylsalicylic acid: a study in 3166 outpatients. ( Arnesen, H; Erikssen, J; Hurlen, M; Rollag, A; Smith, P, 1994) |
| "Rats with a 10 cm full-thickness incisional wound and a 15 mL/kg hemorrhage were either not resuscitated or resuscitated with blood or diaspirin cross-linked hemoglobin (DCLHb)." | 3.69 | Cellular responses to surgical trauma, hemorrhage, and resuscitation with diaspirin cross-linked hemoglobin in rats. ( Burris, D; Leppäniemi, A; Li, Y; Malcolm, D; Nielsen, TB; Pacheco, ND; Pikoulis, E; Rollwagen, FM; Soltero, R; Sun, L; Xu, L, 1997) |
| "The efficacy and safety of aspirin in the prevention and treatment of thrombosis in essential thrombocythaemia (ET) was retrospectively analysed in a cohort of 68 ET patients." | 3.69 | Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. ( Michiels, JJ; Mulder, PG; van de Moesdijk, D; van Genderen, PJ; Waleboer, M, 1997) |
| "Recurrent chest pain with new ST-segment elevation was observed in 26 of 652 patients (4%) with myocardial infarction in a clinical trial of alteplase (recombinant tissue-type plasminogen activator; 100 mg) and aspirin with or without heparin." | 3.68 | Retreatment with alteplase for early signs of reocclusion after thrombolysis. The European Cooperative Study Group. ( Arnout, J; Nÿssen, K; Simoons, ML; van den Brand, M; Verstraete, M, 1993) |
| "To study the effectiveness of the protein polymer sheath (PPS), a device intended to limit hemorrhage caused by percutaneous biopsy, in the setting of platelet dysfunction (which may be an important cause of such hemorrhage), percutaneous biopsies were performed in eight anesthetized pigs: four control pigs and four pigs treated with the experimental aspirinlike drug venopirin." | 3.68 | Hemostatic protein polymer sheath: improvement in hemostasis at percutaneous biopsy in the setting of platelet dysfunction. ( Gazelle, GS; Haaga, JR; Halpern, EF, 1993) |
| "The effect of diaspirin cross-linked hemoglobin (DCLHb) on mean arterial pressure (MAP) and heart rate (HR) was compared to Ringer's lactate (RL) and shed blood in a 70% lethal model of hemorrhage (35 cc/kg blood loss) in conscious rats." | 3.68 | Diaspirin cross-linked hemoglobin solution as a resuscitative fluid following severe hemorrhage in the rat. ( Garrioch, M; Kissinger, D; Malcolm, D, 1992) |
| "Antacids containing aluminum hydroxide are protective for the stomach in that they prevent grossly visible mucosal necrosis and hemorrhages produced by noxious agents such as aspirin or absolute ethanol." | 3.67 | Antacid protection of gastric mucosa. ( Domschke, W; Hagel, J; Kaduk, B; Ruppin, H, 1986) |
| "The 'Simplate' technique for measuring skin bleeding time was adapted to quantify thromboxane A2 in the emerging blood as the stable degradation product thromboxane B2 in twelve Swedish and ten English volunteers." | 3.66 | Thromboxane A2 in skin-bleeding-time blood and in clotted venous blood before and after administration of acetylsalicylic acid. ( Born, GV; Shafi, S; Thorngren, M, 1983) |
| "The prolongation of the bleeding time by aspirin is presumably due to interfering with platelet function." | 3.66 | The effect of aspirin on the size of the hemostatic plug. ( Carter, CJ; Kelton, JG, 1983) |
| " Twenty-four hours after an uncomplicated procedure she had a severe bleeding diathesis following the ingestion of a small amount of aspirin." | 3.66 | Salicylate-induced bleeding problem in ophthalmic plastic surgery. ( Paris, GL; Waltuch, GF, 1982) |
| "To evaluate the potential effect of aspirin, a platelet inhibitory agent, on postoperative bleeding complications after coronary artery bypass graft surgery, we compared each of nine patients who had taken aspirin within 7 days prior to operation to one or two control subjects (total 16 patients) matched for age, sex, extent of coronary disease, number of grafts placed total operative time, bypass time, and preoperative use of propranolol." | 3.66 | Relation of preoperative use of aspirin to increased mediastinal blood loss after coronary artery bypass graft surgery. ( Mac Vaugh, H; Michelson, EL; Morganroth, J; Torosian, M, 1978) |
| "Often used as an oral analgesic in the management of pain associated with traumatic hyphema, aspirin has an inhibitory effect on the blood clotting mechamism by its action on platelets." | 3.65 | The effect of aspirin on rebleeding in traumatic hyphema. ( Chan, W; Crawford, JS; Lewandowski, RL, 1975) |
| " A recent history of excessive ingestion of an aspirin-containing medication was obtained and the clinical and laboratory picture of an aspirin-induced bleeding disorder was documented." | 3.65 | Acute spinal epidural hematoma secondary to aspirin-induced prolonged bleeding. ( Biggers, SL; Giorgio, AJ; Johnson, AP; Locke, GE; Salem, F, 1976) |
| "The primary safety end point was bleeding events, as defined by the International Society on Thrombosis and Haemostasis, and the primary efficacy end point was major adverse cardiovascular events (MACEs), including cardiac death, myocardial infarction, rerevascularization, or stroke during the 6-month follow-up." | 3.30 | Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial. ( Chen, F; Fu, G; Ge, L; Huang, L; Jiang, W; Liu, C; Liu, Q; Ouyang, Z; Pan, G; Pan, H; Shen, Q; Xiao, Y; Zeng, G; Zhang, Y; Zheng, Z; Zhou, C; Zhou, S; Zhu, C, 2023) |
| "It is unclear whether infarct location affects stroke recurrence after index ischemic stroke." | 3.30 | Stroke Recurrence and Antiplatelets in Posterior Versus Anterior Circulation Minor Stroke or Transient Ischemic Attack. ( Jing, J; Li, H; Li, Z; Liu, H; Meng, X; Wang, A; Wang, Y; Xu, Q, 2023) |
| "The incidence of preterm preeclampsia was 1." | 3.30 | Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial. ( Alsius, M; Bonacina, E; Caamiña, S; Carreras, E; de Mingo, L; Diaz, S; Ferrer-Costa, R; Garcia, E; Garcia-Manau, P; López, M; Lopez-Quesada, E; Maiz, N; Maroto, A; Martin, L; Mendoza, M; Millán, P; Ocaña, V; Orizales-Lago, C; Pallarols, M; Pérez-Gomez, A; Pintado, E; Puerto, L; Ricart, M; Rodríguez-Zurita, A; Suy, A; Teixidor, M; Vidal-Sagnier, L; Vives, À, 2023) |
| " The secondary endpoint is a composite of major adverse cardiovascular and cerebrovascular events (MACCE), including all-cause death, cardiac death, nonfatal myocardial infarction, stent thrombosis, ischemia-driven target vessel revascularization, and stroke." | 3.30 | Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority ra ( Gong, Y; Li, J; Wang, X; Wang, Y; Zhou, T, 2023) |
| "Stroke and bleeding are complications after transcatheter aortic valve replacement (TAVR)." | 3.30 | Sex Differences in Outcomes After Transcatheter Aortic Valve Replacement: A POPular TAVI Subanalysis. ( Brouwer, J; Nijenhuis, VJ; Ten Berg, JM; van Bergeijk, KH; van den Heuvel, AFM; van der Werf, HW; van Ginkel, DJ; Voors, AA; Wykrzykowska, JJ, 2023) |
| "Bleeding was defined using the International Society on Thrombosis and Haemostasis five-level ordered categorical scale: fatal, major, moderate, minor, none." | 3.30 | Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia. ( Appleton, JP; Bath, PM; Christensen, H; Dineen, RA; England, TJ; James, M; Krishnan, K; Montgomery, AA; Ranta, A; Robinson, TG; Sprigg, N; Woodhouse, LJ, 2023) |
| " We aimed to evaluate the dose-response relationship of milvexian in participants treated with dual antiplatelets." | 3.11 | Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention. ( Amarenco, P; Bereczki, D; Czlonkowska, A; Diener, HC; Donovan, M; Endres, M; Gailani, D; Hankey, GJ; Kahl, A; Kasner, SE; Li, D; Lutsep, HL; Molina, CA; Ntaios, G; Perera, V; Sharma, M; Shuaib, A; Toyoda, K; Tsivgoulis, G, 2022) |
| " The UNIVERSE Study evaluated the efficacy and safety of a novel liquid rivaroxaban formulation, using a body weight-adjusted dosing regimen, versus acetylsalicylic acid (ASA) in children post-Fontan." | 3.01 | Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study. ( Harris, KC; Jefferies, JL; Justino, H; Li, JS; Lu, W; McCrindle, BW; Michelson, AD; Miriam Pina, L; Nessel, K; Pablo Sandoval, J; Peluso, C; Suzana Horowitz, E; Van Bergen, AH, 2021) |
| "Cardiac death (RR 0." | 3.01 | Clopidogrel Vs Aspirin Monotherapy Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. ( Azhar, AZ; Baibhav, B; Cheung, JW; Rao, M; Tan, BE; Thakkar, S; Wong, PY, 2023) |
| " A comparison of hemocompatibility-related adverse events (HRAEs), hemocompatibility score (HCS), and hemocoagulative laboratory markers, both qualitative and quantitative, between the 2 groups were performed." | 3.01 | Anticoagulation alone as an effective and safe antithrombotic therapy in LVAD: When less is more. ( Bagozzi, L; Bottigliengo, D; Bottio, T; Fabozzo, A; Fagan, D; Gerosa, G; Gregori, D; Mastro, FR; Pagnin, C; Tarzia, V; Tessari, C, 2023) |
| " We also discuss the available pharmacodynamic (PD) evidence and clinical implications with the use of DPI in patients with atherosclerotic disease." | 3.01 | Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications. ( Angiolillo, DJ; D'Amario, D; De Caterina, R; Franchi, F; Galli, M; Gibson, CM; Mehran, R; Ortega-Paz, L; Rollini, F, 2023) |
| "Postprocedural bleeding is the main complication of percutaneous kidney biopsy (PKB)." | 3.01 | Effects of Aspirin on Kidney Biopsy Bleeding Complications: A Systematic Review and Meta-Analysis (PROSPERO 2021 CRD42021261005). ( Castro, I; Coentrão, L; Diniz, H; Gonçalves, J; Mendonça, L; Relvas, M, 2023) |
| "Aspirin was not associated with significant bleeding excess." | 3.01 | Fixed dose combination therapies in primary cardiovascular disease prevention in different groups: an individual participant meta-analysis. ( Dagenais, GR; Gao, P; Joseph, P; Malekzadeh, R; Pais, P; Roshandel, G; Yusuf, S, 2023) |
| "Asymptomatic carotid stenosis is when this narrowing occurs in people without a history or symptoms of this disease." | 3.01 | Pharmacological interventions for asymptomatic carotid stenosis. ( Cassola, N; Clezar, CN; Flumignan, CD; Flumignan, RL; Nakano, LC; Trevisani, VF, 2023) |
| "Patients with a recent embolic stroke of undetermined source were randomized to dabigatran (150 or 110 mg BID) or aspirin (100 mg QD)." | 3.01 | Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis. ( Brueckmann, M; Easton, JD; Grauer, C; Lee, BC; Liou, CW; Taniguchi, A; Toyoda, K; Uchiyama, S; Urano, Y; Wong, LKS, 2021) |
| "Aspirin treatment may have reduced CVEs within a high CVE risk elderly population subgroup." | 2.90 | Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70). ( Ando, K; Goto, Y; Ikeda, Y; Ishizuka, N; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Uemura, Y; Yamazaki, T; Yokoyama, K, 2019) |
| "Major bleeding was the primary safety end point." | 2.90 | Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Knutsson, M; Ladenvall, P; Minematsu, K; Molina, CA; Röther, J; Wang, Y; Wong, KSL, 2019) |
| "The risk of bleeding is a major concern when oral anticoagulation is required to prevent stroke, and concomitant therapy with antiplatelet agents is required to minimize recurrent ischemic events." | 2.87 | An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rat ( Alexander, JH; Darius, H; Goodman, SG; Granger, CB; Liaw, D; Lopes, RD; Mehran, R; Vora, AN; Windecker, S, 2018) |
| "Aspirin treatment (100 mg/day) (n = 50) or usual therapy (n = 61)." | 2.87 | Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study). ( Abad, S; Arroyo, D; Bernis, C; de Sequera, P; de Vinuesa, SG; Delgado, R; Fernández-Juárez, G; Goicoechea, M; Luño, J; Morales, E; Ortiz, A; Quiroga, B; Torres, A; Verdalles, U; Verde, E, 2018) |
| "Cancer was the major contributor to the higher mortality in the aspirin group, accounting for 1." | 2.87 | Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. ( Abhayaratna, WP; Beilin, LJ; Donnan, GA; Ernst, ME; Fitzgerald, SM; Gibbs, P; Grimm, R; Ives, DG; Johnston, CI; Kirpach, B; Lockery, JE; Margolis, KL; McNeil, JJ; Murray, AM; Nelson, MR; Newman, AB; Orchard, SG; Radziszewska, B; Reid, CM; Ryan, J; Shah, RC; Stocks, N; Storey, E; Tonkin, AM; Trevaks, RE; Williamson, JD; Wolfe, R; Woods, RL, 2018) |
| " Secondary outcomes include target lesion revascularization, major bleeding, ipsilateral major amputation, all-cause mortality, and all adverse events that take place in those six months." | 2.84 | SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial. ( Ahn, S; Cho, MJ; Cho, S; Ha, J; Kim, SY; Lee, J; Min, SI; Min, SK, 2017) |
| "aspirin monotherapy was carried out, to determine optimal peri-operative management with these antiplatelet agents." | 2.82 | Editor's Choice - Peri-Operative Outcomes of Carotid Endarterectomy are Not Improved on Dual Antiplatelet Therapy vs. Aspirin Monotherapy: A Systematic Review and Meta-Analysis. ( Bissacco, D; Chechik, O; Chisci, E; Cusimano, MD; Ku, JC; Larrue, V; Macdonald, RL; Michelagnoli, S; Nasr, N; Pasarikovski, CR; Priola, SM; Rabinovich, Y; Settembrini, PG; Taslimi, S; Yang, VXD; Zuccato, J, 2022) |
| "Our primary outcomes were pulmonary embolism (PE), symptomatic DVT, asymptomatic DVT, and all-cause mortality." | 2.82 | Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. ( Badariotti, G; Chahla, J; Perrotta, C; Ramos, J, 2022) |
| " Because increased platelet reactivity and/or turnover are postulated mechanisms, we examined whether higher and/or more frequent aspirin dosing might reduce platelet reactivity more effectively." | 2.82 | Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes. ( Bethel, MA; Coleman, RL; Harrison, P; Hill, L; Holman, RR; Kennedy, I; Oulhaj, A; Sourij, H; Sun, Y; Tucker, L; White, S, 2016) |
| "Aspirin was started within 12 h, and study medication within 72 h after CABG." | 2.82 | Ticagrelor and aspirin for the prevention of cardiovascular events after coronary artery bypass graft surgery. ( Bernstein, V; Cairns, J; Mancini, GB; Mayo, J; Saw, J; Skarsgard, P; Starovoytov, A; Wong, GC; Ye, J, 2016) |
| "Risk factors for hemorrhage are less well defined than those for thrombosis." | 2.80 | Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. ( Gao, J; Kander, EM; McMahon, BJ; Raza, S; Stein, BL; Zakarija, A; Zhou, Z, 2015) |
| "60." | 2.79 | Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up. ( Alvarez-Sabín, J; Maisterra, O; Quintana, M; Santamarina, E, 2014) |
| " The primary efficacy endpoint was the incidence of major adverse cardiovascular events (MACE) at 24 weeks, defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke." | 2.79 | Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. ( Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014) |
| "Bleeding was reported according to Bleeding Academic Research Consortium (BARC) definition." | 2.78 | Increased risk of minor bleeding and antiplatelet therapy cessation in patients with acute coronary syndromes and low on-aspirin platelet reactivity. A prospective cohort study. ( Filipiak, KJ; Grabowski, M; Huczek, Z; Kochman, J; Michalak, M; Opolski, G, 2013) |
| "Major bleeding was strongly associated with 30-day mortality (OR 50." | 2.76 | Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study. ( Aout, M; Barthelemy, O; Bellemain-Appaix, A; Beygui, F; Cayla, G; Collet, JP; Connor, S'; Montalescot, G; Payot, L; Silvain, J; Vicaut, E, 2011) |
| "Serious bleeding was associated with a significantly increased adjusted hazard ratio of 5." | 2.76 | Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON- ( Antman, EM; Braunwald, E; Contant, CF; Dalby, AJ; Giugliano, RP; Guo, J; Hochholzer, W; Montalescot, G; Wiviott, SD, 2011) |
| "Fatal bleeding was low and did not differ between groups." | 2.76 | Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM, 2011) |
| " Monafram was introduced intravenously to 284 patients just before angioplasty at standard dosage - 0." | 2.75 | [Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation]. ( Frolova, NS; Mazurov, AV; Pevzner, DV; Ruda, MY; Samko, AN; Staroverov, II, 2010) |
| "Major bleeding was less frequent in the <2-h group (1." | 2.74 | Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. ( Aymong, E; Buller, CE; Carere, RG; Densem, C; Fox, RS; Fung, AY; Hamburger, JN; Humphries, KH; Jokhi, P; Ricci, DR; Saw, J; Starovoytov, A; Walsh, SJ; Webb, JG, 2009) |
| "Major bleeding was associated with a 3-fold increased risk of subsequent ischemic events (crude hazard ratio, 3." | 2.74 | Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. ( Algra, A; Eikelboom, BC; Lawson, JA; Moll, FL; Tangelder, MJ; van Hattum, ES, 2009) |
| "Aspirin has emerged as a promising intervention in cancer in the past decade." | 2.72 | Current Studies of Aspirin as an Anticancer Agent and Strategies to Strengthen its Therapeutic Application in Cancer. ( Lee, BJ; Tran, PHL; Tran, TTD, 2021) |
| "Aspirin has been the mainstay of both secondary and primary prevention of cardiovascular disease for half a century." | 2.72 | Aspirin in Primary Prevention: What Changed? A Critical Appraisal of Current Evidence. ( Dasa, O; Pearson, TA; Pepine, CJ, 2021) |
| "G6PD deficiency is typically asymptomatic and many CVD patients with this enzyme defect start to take long-term aspirin therapy without G6PD activity examination; however, no consensus on the safety of aspirin in this population has been reached." | 2.72 | Aspirin Therapy in Cardiovascular Disease with Glucose-6-Phosphate Dehydrogenase Deficiency, Safe or Not? ( Chen, C; Chen, J; Chen, Y; Jiang, Z; Li, J; Li, P; Liang, J; Ou, Z; Ouyang, F; Wei, J; Zeng, J, 2021) |
| "The prevention of fetal growth restriction (FGR) is challenging in clinical practice." | 2.72 | Pharmacological Interventions for the Prevention of Fetal Growth Restriction: A Systematic Review and Network Meta-Analysis. ( Avagliano, L; Bettiol, A; Crescioli, G; Emmi, G; Lombardi, N; Ravaldi, C; Urban, ML; Vannacci, A; Virgili, G, 2021) |
| "Patients with lower extremity peripheral artery disease (PAD) are at increased risk of major adverse limb events (MALE)." | 2.72 | The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials. ( Costa, G; Gonçalves, L; Teixeira, R, 2021) |
| "Graft thrombosis is a well-recognised complication of solid organ transplantation and is one of the leading causes of graft failure." | 2.72 | Interventions for preventing thrombosis in solid organ transplant recipients. ( Hanley, J; Hoather, TJ; Surianarayanan, V; Thompson, ER; Tingle, SJ; Wilson, CH, 2021) |
| "Patients with minor ischemic stroke or transient ischemic attack represent a high-risk population for recurrent stroke." | 2.72 | Ticagrelor vs Clopidogrel in addition to Aspirin in minor ischemic stroke/ transient ischemic attack-Protocol for a systematic review and network meta-analysis. ( Dhaliwal, S; Dowlatshahi, D; Hutton, B; Lun, R; Roy, DC; Shorr, R; Zitikyte, G, 2021) |
| "Minor bleeding was more frequent in the enoxaparin group (30." | 2.71 | Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. ( Armstrong, PW; Fitchett, D; Goodman, SG; Langer, A; Tan, M, 2003) |
| "Bleedings were documented in 19 versus four patients (W/A 5." | 2.71 | Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. ( Edvardsson, N; Juul-Möller, S; Omblus, R; Pehrsson, K, 2003) |
| " It is not clear if combining enoxaparin with glycoprotein IIb/IIIa inhibitors is as safe or as effective as the current standard combination of unfractionated heparin with glycoprotein IIb/IIIa inhibitors." | 2.71 | Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. ( Ardissino, D; Bilheimer, DW; Blazing, MA; Braunwald, E; Califf, RM; de Lemos, JA; DiBattiste, PM; Fox, KA; Gardner, LH; Hasselblad, V; Lewis, EF; Palmisano, J; Pfeffer, MA; Ramsey, KE; Snapinn, SM; Verheugt, FW; White, HD, 2004) |
| "Stroke and systemic thromboembolism are serious problems for patients with atrial fibrillation (AF), but their incidence can be substantially reduced by appropriate anticoagulation." | 2.71 | Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. ( Corley, SD; DiMarco, JP; Flaker, G; Greene, HL; Mitrani, G; Nemeth, M; Rosenfeld, LE; Safford, RE; Waldo, AL, 2005) |
| "The benefits of the long-term administration of oral anticoagulant therapy remain unclear in patients with lower extremity arterial bypass surgery." | 2.70 | Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. ( Johnson, WC; Williford, WO, 2002) |
| "Dipyridamole was associated with a slight increase in headache, which resolved in most patients if therapy was continued." | 2.69 | Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study. ( Forbes, CD, 1998) |
| "The six patients with Haemophilia A ranged in severity from moderately to mildly affected." | 2.69 | Cardiac surgery and catheterization in patients with haemophilia. ( MacKinlay, N; Renisson, F; Rickard, K; Taper, J, 2000) |
| " A new therapeutic regimen of ticlopidine and aspirin without further heparin after coronary stenting in patients without AMI has been shown to be safe and reduce the incidence of stent thrombosis." | 2.69 | A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction. ( Chang, HW; Chen, MC; Fang, CY; Hang, CL; Hsieh, KY; Wu, CJ; Yip, HK, 2000) |
| "Nonfatal myocardial infarction was present in seven patients in group A, four in group B and none in group C (group B vs." | 2.68 | Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. ( Cerdá, MA; Daroca, AM; Duronto, EA; García, CN; Gurfinkel, EP; Manos, EJ; Mautner, B; Mejaíl, RI, 1995) |
| "Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events." | 2.68 | A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. ( , 1996) |
| "Patients with prior stroke or transient ischemic attack (TIA) were randomized to treatment with ASA alone (50 mg daily), modified-release dipyridamole alone (400 mg daily), the two agents in a combined formulation, or placebo." | 2.68 | European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. ( Cunha, L; Diener, HC; Forbes, C; Lowenthal, A; Sivenius, J; Smets, P, 1996) |
| "The efficacy of aspirin for prevention of thrombotic graft occlusion after coronary artery bypass grafting (CABG) depends both on the dosage and time window of administration." | 2.67 | Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. ( Baron, DW; Gavaghan, TP; Gebski, V, 1991) |
| "Cardiovascular diseases are the leading cause of deaths in the world." | 2.66 | [Current antiplatelet agents, new inhibitors and therapeutic targets]. ( Benomar, A; Cadi, R; Cherrah, Y; El Alaoui, MZ; Guy, A; Khalki, L; Limami, Y; Mekhfi, H; Zaid, N; Zaid, Y, 2020) |
| "The incidence of pulmonary embolism (PE) in all trials combined was low, with seven cases in 3818 participants." | 2.66 | Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. ( Badariotti, G; Chahla, J; Perrotta, C; Ramos, J, 2020) |
| "Aspirin has long been an inexpensive cornerstone of arterial vascular disease therapy, but its role in the primary or secondary prophylaxis of VTE has been debated." | 2.66 | Does aspirin prevent venous thromboembolism? ( Diep, R; Garcia, D, 2020) |
| "Dabigatran was shown to be safer than vitamin K antagonists and similarly effective for the prevention of recurrent VTE." | 2.66 | Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study. ( Imberti, D; Mastroiacovo, D; Pomero, F, 2020) |
| "Proximal vein thrombosis or pulmonary embolism occurred in 6 patients (9." | 2.66 | A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. ( Gent, M; Hirsh, J; Jay, RM; Julian, DH; Levine, M; Powers, PJ; Turpie, AG, 1989) |
| "In a double-blind crossover study acetylsalicylic acid (ASA) in low (2 g daily) or high (4 g daily) dosage was tested against placebo in two groups of 20 patients who each underwent identical oral surgical procedures on two separate occasions." | 2.65 | The effects of acetylsalicylic acid on swelling, pain and other events after surgery. ( Skjelbred, P, 1984) |
| "Recurrent stroke is common immediately following a transient ischemic attack (TIA) or ischemic stroke." | 2.61 | Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. ( Abdalla, A; Ahmed, S; Al Qasmi, M; Bachuwa, G; Bhatt, DL; Chahine, A; Hassan, M; Haykal, T; Kheiri, B; Osman, M; Swaid, B, 2019) |
| " Regarding antithrombotic prophylaxis, data are lacking on DOAC use in general surgical patients, while DOACs appear to be more effective than and as safe as LMWHs in VTE prophylaxis for major orthopedic surgical patients." | 2.61 | Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. ( Agnelli, G; Becattini, C; Franco, L; Giustozzi, M; Vedovati, MC, 2019) |
| "Aspirin has potential benefits in cardiovascular primary prevention in diabetes." | 2.61 | Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. ( Buring, JE; Gaziano, JM; Khunti, K; Kunutsor, SK; Roncaglioni, MC; Seidu, S; Sesso, HD, 2019) |
| "Aspirin has a complex matrix of benefits and risks, and its use in primary prevention requires individualized decision-making." | 2.58 | Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach. ( Ames, JM; Dugani, S; Manson, JE; Mora, S, 2018) |
| " Efficacy outcomes included ischemic stroke, stent thrombosis, major adverse cardiovascular event (MACE), all-cause mortality and myocardial infarction (MI); safety outcome was major bleeding." | 2.58 | Efficacy and safety of triple therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing coronary stenting: A meta-analysis. ( Huang, J; Liu, L; Tang, X; Zhang, X, 2018) |
| "Major bleeding was significantly higher with DAPT (OR 1." | 2.58 | Dual versus single antiplatelet therapy after coronary artery bypass graft surgery: An updated meta-analysis. ( Blumenthal, RS; Cardoso, R; Gluckman, TJ; Knijnik, L; McEvoy, JW; Metkus, TS; Rivera, M; Whelton, SP, 2018) |
| "Peripheral artery disease is a common manifestation of systemic atherosclerosis which strongly correlates to cardiovascular morbidity and mortality." | 2.58 | Novel Oral Anticoagulants in Peripheral Artery Disease: Current Evidence. ( Argyriou, C; Georgakarakos, EI; Georgiadis, GS; Koutsoumpelis, A; Tasopoulou, KM, 2018) |
| "0) combined with ASA (mean dose ≥100 mg/day) and ASA." | 2.55 | Efficacy and safety of aspirin combined with warfarin after acute coronary syndrome : A meta-analysis. ( Huang, X; Li, J; Li, L; Shen, C; Wu, C; Zhang, P; Zhang, W, 2017) |
| "Performance in patients with cerebral ischemia was poor." | 2.53 | Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study. ( Algra, A; Greving, JP; Hilkens, NA, 2016) |
| "Aspirin has been the cornerstone of therapy for the secondary prevention treatment of patients with cardiovascular disease since landmark trials were completed in the late 1970s and early 1980s that demonstrated the efficacy of aspirin for reducing the risk of ischemic events." | 2.53 | Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease. ( Fanaroff, AC; Roe, MT, 2016) |
| "Aspirin is likely to increase the risk of major bleeding events." | 2.53 | Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis. ( Brunskill, NJ; Dawson, S; Gray, LJ; Major, RW; Oozeerally, I; Riddleston, H, 2016) |
| "Aspirin was established more than a quarter century ago as an evidence-based therapy to reduce recurrent cardiovascular events in patients with coronary artery disease based on limited data by contemporary standards." | 2.53 | A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. ( Bode, C; Gibson, CM; James, S; Ohman, EM; Povsic, TJ; Roe, MT; Steg, PG; Welsh, RC, 2016) |
| "5, and aspirin was administered at a dosage of 75 to 325 mg/d." | 2.52 | Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis. ( Chen, KP; Zhang, JT; Zhang, S, 2015) |
| "Major bleeding was the primary end point, whereas all-cause death, myocardial infarction (MI), stent thrombosis, and stroke were secondary ones." | 2.52 | Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention. ( Ballocca, F; Bangalore, S; Barbero, U; Capodanno, D; Cerrato, E; Conrotto, F; D'Ascenzo, F; Dewilde, W; DiNicolantonio, J; Fernández, S; Gaita, F; Giordana, F; Grossomarra, W; Lamberts, M; Meier, P; Meynet, I; Moretti, C; Omedè, P; Persson, J; Quadri, G; Reed, M; Rubboli, A; Taha, S; Zoccai, G, 2015) |
| " However, NSAIDs are associated with a number of adverse effects, especially in patients with cardiovascular disease (CVD)." | 2.52 | Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease. ( Cicci, JD; Danelich, IM; Lose, JM; Reed, BN; Tefft, BJ; Wright, SS, 2015) |
| " Endpoints included major adverse cardiac effects (MACEs), target lesion revascularization (TLR), target vessel revascularization (TVR), death, stent thrombosis, bleeding and adverse drug reactions during a 9-12 months period, as well as platelet activities." | 2.52 | Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. ( Bundhun, PK; Chen, MH; Qin, T, 2015) |
| "Bleeding is the most important adverse effect of antithrombotic treatment and may be a major cause of morbidity, longstanding debilitation, and even mortality." | 2.52 | Emergency Reversal Strategies for Anticoagulation and Platelet Disorders. ( Levi, M, 2015) |
| "Warfarin has been the traditional choice, but the recently introduced novel oral anticoagulants offer similar efficacy with less bleeding risk." | 2.52 | Evolving strategies to prevent stroke and thromboembolism in nonvalvular atrial fibrillation. ( Hussein, A; Saliba, W; Wazni, OM, 2015) |
| " The included end-points were major adverse cardiovascular event (MACE), target lesion revascularization (TLR), target vessel revascularization (TVR), death, myocardial infarction (MI), stent thrombosis, bleeding and other drug adverse events." | 2.50 | Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. ( Chen, Y; Huang, X; Tang, Y; Xie, Y; Zhang, Y, 2014) |
| "Uncorrected bleeding diathesis might increase the risk and is considered to be an absolute contraindication for SWL." | 2.50 | Antiplatelet and anticoagulative medication during shockwave lithotripsy. ( Bründl, J; Burger, M; Chaussy, CG; Fritsche, HM; Gierth, M; Schnabel, MJ, 2014) |
| "Essential thrombocythemia is a chronic myeloproliferative neoplasm characterized by sustained thrombocytosis, bone marrow megakaryocytic hyperplasia and an increased risk of thrombosis and hemorrhage." | 2.49 | [Treatment of essential thrombocythemia]. ( Alvarez-Larrán, A; Besses, C; Cervantes, F, 2013) |
| "Is it better to continue treatment of deep venous thrombosis or pulmonary embolism with LMWH or switch to an oral anticoagulant? What is the optimal duration of treatment? To answer these questions, we conducted a review of the literature using the standard Prescrire methodology." | 2.49 | Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months. ( , 2013) |
| "The risk of major bleeding is increased with antiplatelet therapy." | 2.49 | Antiplatelet and anticoagulation for patients with prosthetic heart valves. ( Little, SH; Massel, DR, 2013) |
| " Dans certaines situations de risque par contre, une adaption du dosage est conseillée pour minimiser les effets secondaires négatifs: Chez les patients de plus de 75 ans, et/ou d'un poids corporel de moins de 60 kg, une réduction du dosage de prasugrel est conseillée en raison d'un risque élevé d'hémorragie." | 2.49 | [Thrombocyte aggregation inhibitors: what are the risks?]. ( Curkovic, I; Egbring, M; Kullak-Ublick, GA, 2013) |
| " The emergence of new anticoagulants that offer equal or superior efficacy, greater safety and the convenience of fixed oral dosing may make warfarin the less preferred option." | 2.48 | Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. ( Halperin, JL; Varughese, CJ, 2012) |
| "Aspirin is an antiplatelet drug, inhibiting the cyclooxygenase activity of platelet prostaglandin H synthase-1 and almost complete suppressing platelet capacity to generate the prothrombotic and proatherogenic thromboxane A2." | 2.48 | Clinical use of aspirin in ischemic heart disease: past, present and future. ( De Caterina, R; Renda, G, 2012) |
| "Aspirin is a cornerstone in secondary cardiovascular prevention and has been thoroughly investigated." | 2.48 | Pharmacogenetics of the antiplatelet effect of aspirin. ( Grove, EL; Hvas, AM; Kristensen, SD; Würtz, M, 2012) |
| "Current acetylsalicylic acid (ASA) dosing algorithms for the prevention of secondary thrombotic events in acute coronary syndrome (ACS) patients are inconsistent and lack sufficient data support." | 2.48 | Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. ( Berger, JS; Katona, B; Maya, J; Mwamburi, M; Ranganathan, G; Sallum, RH; Xu, Y, 2012) |
| "Aspirin has been used for the prevention and treatment of cardiovascular disease (CVD) for several decades." | 2.48 | Aspirin for primary prevention of cardiovascular disease events. ( Morbitzer, KA; Moser, LR; Nemerovski, CW; Salinitri, FD, 2012) |
| " The secondary end point assessed by three of these studies was major adverse cardiac events (MACEs: cardiovascular death, myocardial infarction and thromboembolic complications)." | 2.47 | Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation. ( Arora, R; Bedi, U; Khosla, S; Molnar, J; Singh, M; Singh, PP, 2011) |
| "Bleeding is potentially the most significant antiplatelet-associated side effect." | 2.47 | Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events. ( Guthrie, R, 2011) |
| "Tirofiban is safe and effective in patients with ACS." | 2.46 | Safety evaluation of tirofiban. ( Tebaldi, M; Valgimigli, M, 2010) |
| "Sudden cardiac death is a leading cause of death in Europe." | 2.46 | [Thrombolysis during cardio-pulmonary resuscitation]. ( Böttiger, BW; Padosch, SA; Spöhr, F; Teschendorf, P; Wetsch, WA, 2010) |
| " We conclude that the benefits of prasugrel are overestimated, and the risks, especially during chronic use are underestimated." | 2.45 | Prasugrel development - claims and achievements. ( Kopyleva, O; Serebruany, V; Shalito, I, 2009) |
| "Aspirin plus ER-DP has a greater bleeding rate than clopidogrel but a lower rate than aspirin (< or =325 mg/day) alone." | 2.45 | Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? ( Brahin, E; Dessain, S; Ezekowitz, MD; Gracely, E; Nagarakanti, R; Notaro, LA; Usman, MH, 2009) |
| " For antiplatelet agents, the most important risk is excess bleeding, especially as emerging evidence suggests that excess bleeding is associated with adverse long-term outcomes; thus prevention and management of excess bleeding is critically important." | 2.45 | Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease. ( Spinler, SA, 2009) |
| "Aspirin has potential risks." | 2.44 | Aspirin and reproductive outcomes. ( Brancazio, LR; James, AH; Price, T, 2008) |
| "Fibrinolysis is the reference treatment for most myocardial infarctions with ST-segment elevation; alternatives are angioplasty, with or without stent." | 2.43 | New anticoagulants in ischemic heart disease. ( Verheugt, FW, 2005) |
| "Aspirin also has been studied and is effective, but with a more modest benefit (relative risk reduction of 22%)." | 2.42 | Prevention of vascular events in patients with atrial fibrillation: evidence, guidelines, and practice. ( Connolly, SJ, 2003) |
| "Aspirin, however, has become a lifelong therapy for many patients, based on clinical trials and medical experience." | 2.42 | Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice. ( Kerr, JL; Oppelt, TF; Rowen, RC, 2004) |
| " The data reported in the literature do not however enable any evidenced-based decision on dosing for the diabetic population with numerous cardiovascular risks." | 2.41 | [Prevention of cardiovascular diseases in type 2 diabetes with aspirin]. ( Duly-Bouhanick, B; Guilloteau, G; Hadjadj, S; Menard, S; Plun-Favreau, J; Soares-Barbosa, S, 2001) |
| "Aspirin has stood the test of time over decades as the gold standard for relatively effective, safe, and inexpensive antiplatelet therapy." | 2.40 | Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents. ( Schafer, AI, 1997) |
| "Aspirin is an approximately 150- to 200-fold more potent inhibitor of the (constitutive) isoform of the platelet enzyme (COX-1) than the (inducible) isoform (COX-2) which is expressed by cytokines, inflammatory stimuli, and some growth factors." | 2.40 | Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. ( Schrör, K, 1997) |
| " The safety profiles of various GP IIb-IIIa inhibitors are largely a function of their pharmacokinetic and pharmacodynamic properties, most notably the reversibility of platelet inhibition and the rate of plasma clearance." | 2.40 | Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors. ( Kleiman, NS, 1999) |
| "Placental infarction due to thrombosis seems to be the most consistent event." | 2.40 | Fertility, pregnancy and the management of myeloproliferative disorders. ( Bergmann, L; Griesshammer, M; Pearson, T, 1998) |
| "Nonaspirin NSAIDs inhibit cyclooxygenase reversibly and, therefore, the duration of their action depends on specific drug dose, serum level, and half-life." | 2.39 | Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. ( Schafer, AI, 1995) |
| " The present article reviews the literature on oral anticoagulants combined with aspirin in the prevention and treatment of arterial thromboembolism and draws a comparison to oral anticoagulation alone and aspirin alone, respectively." | 2.39 | Oral anticoagulation alone or in combination with aspirin: risks and benefits. ( Bounameaux, H; de Moerloose, P; Hafner, J, 1996) |
| "Erythromelalgia was localized in the forefoot sole and toes in 28, the fingertips in 9, the handpalm in 2." | 2.39 | Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. ( Lindemans, J; Michiels, JJ; van Genderen, PJ; van Vliet, HH, 1996) |
| "Aspirin (ASS) was the most frequently used drug in 47 of 93 recorded cases (51%)." | 2.39 | Essential thrombocythemia and pregnancy. ( Griesshammer, M; Heimpel, H; Pearson, TC, 1996) |
| "Bleeding and thrombosis are major causes of morbidity and mortality in patients with myeloproliferative disorders." | 2.37 | Bleeding and thrombosis in the myeloproliferative disorders. ( Schafer, AI, 1984) |
| "The fatalistic attitude of hemophiliacs toward hepatitis is discussed, along with admonitions to avoid the use of aspirin, alcohol, and buttock injections." | 2.35 | Orthodontics and dentistry for the hemophilic patient. ( Grossman, RC, 1975) |
| "Aspirin was administered to 180 (93." | 1.91 | Acute coronary syndrome in very elderly patients-a real-world experience. ( Baralis, G; Bianco, M; Cerrato, E; Cinconze, S; Giordana, F; Mottola, FF; Musumeci, G; Rossini, R; Verra, A, 2023) |
| "Minor bleedings were observed in 19 (17." | 1.91 | [Comparison of Various Regimens of Antithrombotic Therapy in Patients With Valvular Heart Disease and Coronary Artery Disease After Surgical and Interventional Interventions]. ( Berdibekov, BS; Bulaeva, NI; Golukhova, EZ; Kubova, MC; Ruzina, EV, 2023) |
| "Death, stroke, and device-related thrombus were also similar; major bleeding was slightly increased in DOAC/aspirin patients (DAPT = 2." | 1.91 | DAPT Is Comparable to OAC Following LAAC With WATCHMAN FLX: A National Registry Analysis. ( Allocco, DJ; Coylewright, M; Freeman, JV; Gibson, DN; Holmes, DR; Hsu, JC; Kapadia, SR; Nair, DG; Piccini, JP; Price, MJ; Yeh, RW, 2023) |
| "OACs plus single antiplatelet therapy and dual antiplatelet therapy alone are both safe and efficacious management strategies after CVSS stent placement." | 1.72 | Safety and efficacy comparison between OACs plus single antiplatelet and dual antiplatelet therapy in patients with cerebral venous sinus stenosis poststenting. ( Bai, C; Chen, Z; Ding, Y; Ilagan, R; Ji, X; Meng, R; Wu, X, 2022) |
| "Tirofiban is a safe addition to SOC and may be an effective strategy to prevent early mBTTS thrombosis." | 1.72 | Exploratory Use of Glycoprotein IIb/IIIa Inhibition in Prevention of Blalock-Taussig Shunt Thrombosis. ( Emani, SM; Piekarski, BL; Rogers, J; Thiagarajan, R; Zurakowski, D, 2022) |
| " The effectiveness outcome was major adverse cardiovascular events (MACE) defined as a composite of recurrent myocardial infarction, repeat revascularization, stroke, or cardiovascular death at 12 months." | 1.72 | Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study. ( Bhatt, DL; Butt, JH; Christensen, MK; Fosbøl, EL; Gislason, G; Godtfredsen, SJ; Jørgensen, SH; Kragholm, KH; Køber, L; Leutscher, P; Pareek, M; Sessa, M; Torp-Pedersen, C, 2022) |
| "Rates of hemorrhage were similar for aspirin in combination with warfarin or direct-acting oral anticoagulants." | 1.72 | Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study. ( Colucci, PM; Grunwald, MR; Lessen, DS; Paranagama, D; Zwicker, JI, 2022) |
| "High ADP inhibition after trauma is common, limiting its utility to accurately identify preinjury APA use." | 1.62 | Thromboelastography with platelet mapping: Limited predictive ability in detecting preinjury antiplatelet agent use. ( Barton, CA; Dewey, EN; Goodman, A; Oetken, HJ; Roberti, GJ; Schreiber, M, 2021) |
| "Treatment with ticagrelor on discharge was associated with improved survival rates during 4 years of follow-up." | 1.62 | Risk definition and outcomes with the application of the PEGASUS-TIMI 54 trial inclusion criteria to a "real world" STEMI population: results from the Italian "CARDIO-STEMI SANREMO" registry. ( Boasi, V; Cannarile, P; Cattunar, S; Gomez, L; Mascelli, G; Perri, D; Pingelli, N; Sanchez, F; Tacchi, C; Vercellino, M, 2021) |
| " The Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study clarified the rates of major CV and bleeding events with long-term use of aspirin in patients with prior CV diseases in real-world clinical practice." | 1.56 | Major cardiovascular and bleeding events with long-term use of aspirin in patients with prior cardiovascular diseases: 1-year follow-up results from the Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study. ( Goto, S; Hiraishi, H; Ikeda, Y; Okada, Y; Origasa, H; Shimada, K; Sugano, K; Uchiyama, S; Uemura, N, 2020) |
| " Concomitant administration of single-dose DS-1040 with multiple-dose aspirin, multiple-dose clopidogrel, or single-dose enoxaparin, consistent with clinically relevant dose regimens, was safe and well tolerated with no serious treatment-emergent adverse events (TEAEs), TEAEs leading to discontinuation, bleeding-related TEAEs, and no significant changes in coagulation parameters." | 1.56 | Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin. ( Dishy, V; Kobayashi, F; Kochan, J; Limsakun, T; McPhillips, P; Mendell, J; Orihashi, Y; Pav, J; Pizzagalli, F; Rambaran, C; Vandell, AG; Warren, V; Zhou, J, 2020) |
| "Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the only option for complete revascularization in some patients with diffuse coronary artery disease." | 1.56 | Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study. ( Feng, W; Song, Y; Tiemuerniyazi, X; Xu, F; Yan, H, 2020) |
| "His course was complicated by cytokine storm and COVID-19-associated coagulopathy." | 1.56 | Successful management of COVID-19 and associated coagulopathy in a patient with durable left ventricular assist device. ( Estep, J; Hodges, K; Hsich, E; Insler, J; Insler, S; Mubashir, M; Soltesz, E; Tong, M, 2020) |
| "Aspirin was administered to all patients once a day." | 1.56 | Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action. ( Frigieri, FC; Gianesello, L; Meconi, T; Pavoni, V; Pazzi, M; Stera, C, 2020) |
| "After adjustment, 3-month DAPT was not inferior to longer DAPT after BP-SES implantation in terms of net adverse clinical events." | 1.56 | 1-Year Safety of 3-Month Dual Antiplatelet Therapy Followed by Aspirin or P2Y ( Ako, J; Hibi, K; Hioki, H; Hirohata, A; Ikari, Y; Ito, Y; Kinoshita, Y; Kozuma, K; Morino, Y; Nakagawa, Y; Nanasato, M; Shiode, N; Sonoda, S; Tanabe, K; Yamaguchi, J, 2020) |
| "The aim of this study is to assess patterns of potential drug-drug interactions (DDIs) with direct oral anticoagulants (DOACs) in an inpatient hospital setting." | 1.56 | Evaluation of Potential Drug-Drug Interactions With Direct Oral Anticoagulants in a Large Urban Hospital. ( Karakas-Torgut, A; Mo, Y; Pham, AQ, 2020) |
| "TAT under TEG guidance appears to be a safe antiplatelet strategy in patients undergoing stenting for extracranial and/or intracranial artery stenosis." | 1.51 | The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. ( Jiang, WJ; Li, C; Liu, AF; Qiu, H; Wang, K; Wu, Z; Zhang, Y; Zhou, J, 2019) |
| "Risk of thrombosis is higher in JAK2-mutated ET." | 1.51 | Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2019) |
| "Peripheral artery disease affects 1." | 1.51 | Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective. ( Ademi, Z; Hird, TR; Liew, D; Owen, AJ; Reid, CM; Si, S; Tonkin, A; Zomer, E, 2019) |
| "Geographic region, patient age, gender, deep vein thrombosis prophylaxis strategy, and complications were obtained." | 1.51 | Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates. ( Gottschalk, MB; Pour, AE; Roberson, JR; Runner, RP; Staley, CA, 2019) |
| " Major adverse cardiac and cerebrovascular events (MACCE) [death, myocardial infarction (MI), stroke, and unplanned reintervention] and thrombolysis in myocardial infarction (TIMI) bleeding (major/minor) were registered during hospitalization and follow-up." | 1.48 | Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction. ( Dannenberg, L; Dimitroulis, D; Golabkesh, M; Helten, C; Jung, C; Kelm, M; Knoop, B; Naguib, D; Pöhl, M; Polzin, A; Zeus, T, 2018) |
| "Funded studies reported less pulmonary embolisms, fewer events of major bleeding, and significantly less 90-day mortality compared with nonfunded studies." | 1.48 | Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty. ( Azboy, I; Groff, H; Parvizi, J, 2018) |
| "Major bleeding was documented in 0." | 1.48 | Clinical Characteristics, Procedural Factors, and Outcomes of Percutaneous Coronary Intervention in Patients With Mechanical and Bioprosthetic Heart Valves. ( Ben-Dor, I; Buchanan, KD; Gajanana, D; Iantorno, M; Okubagzi, PG; Pichard, AD; Rogers, T; Satler, LF; Thourani, VH; Torguson, R; Waksman, R; Weintraub, WS, 2018) |
| "One-year bleedings were assessed using TIMI (Thrombolysis in Myocardial Infarction), GUSTO (Global Use of Strategies to Open Occluded Arteries), and BARC (Bleeding Academic Research Consortium)." | 1.48 | Performance of PRECISE-DAPT Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy. ( Cho, YR; Choi, SY; Kim, MH; Min Lee, K; Park, TH; Sung Park, J; Yun, SC, 2018) |
| "Bleeding was the primary outcome." | 1.46 | Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions. ( Agarwal, S; Barakat, AF; Chaudhury, P; Ellis, SG; Faza, NN; Kapadia, SR; Mentias, A; Murat Tuzcu, E; Parashar, A; Wayangankar, S, 2017) |
| "The optimal duration and cancer risks of antiplatelet therapy following percutaneous coronary intervention (PCI) are unclear." | 1.46 | Mortality and cancer after 12 versus 30 months dual antiplatelet therapy. The Korean Outcomes Registry Evaluating Antithrombotics (KOREA). ( Cabrera-Fuentes, HA; Cho, YR; Kim, MH; Kim, YD; Lee, K; Park, K; Park, TH; Serebruany, VL; Yoon, SC, 2017) |
| "Immunological TRALI was tested in mice exhibiting severe thrombocytopenia or platelet dysfunction." | 1.43 | Platelets are dispensable for antibody-mediated transfusion-related acute lung injury in the mouse. ( de la Salle, H; El Mdawar, MB; Gachet, C; Hechler, B; Heim, V; Magnenat, S; Maître, B, 2016) |
| "The rate of surgical site infection was similar between the aspirin group and the warfarin group (1." | 1.43 | Aspirin Can Be Used as Prophylaxis for Prevention of Venous Thromboembolism After Revision Hip and Knee Arthroplasty. ( Chen, AF; Deirmengian, GK; Heller, S; Maltenfort, M; Parvizi, J; Smith, EB, 2016) |
| "There was no major adverse cardiac event (MACE) and pouch infection were observed among 3 groups in perioperation." | 1.43 | [Safety of implantation permanent pacemaker at different times in patients with dual antiplatelet therapy]. ( Cong, H; Li, X; Li, Z; Wang, Z; Zhang, F; Zhang, L, 2016) |
| "The major result events, included: (1) recurrence of ischemic stroke; (2) hemorrhagic transformation of ischemic stroke; (3) myocardial infarction; (4) the digestive hemorrhage." | 1.43 | [Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy]. ( Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ, 2016) |
| "7, p NS], and in adverse cardiac or cerebrovascular events (MACCE) (5 vs." | 1.42 | Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. ( Almendro-Delia, M; Blanco Ponce, E; Caballero-Garcia, A; Cruz-Fernandez, MJ; Garcia-Rubira, JC; Gomez-Domínguez, R; Gonzalez-Matos, C; Hidalgo-Urbano, R; Lobo-Gonzalez, M, 2015) |
| "Major bleeding was a significant correlate of DAPT ANA within 6 months." | 1.42 | Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. ( Cutlip, DE; Dauerman, HL; Kereiakes, DJ; Mauri, L; Stoler, R, 2015) |
| "Vorapaxar is a novel protease-activated receptor-1 (PAR-1) antagonist recently approved for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease." | 1.42 | Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist. ( Cai, TQ; Chintala, M; Forrest, M; Handt, L; Michener, MS; Raubertas, R; Seiffert, D; Sitko, G; Wickham, LA, 2015) |
| "When aspirin was compared to no treatment, NCB was neutral or negative for both risk strata." | 1.42 | Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. ( Larsen, TB; Lip, GY; Nielsen, PB; Skjøth, F, 2015) |
| "Thulium VapoEnucleation of the prostate seems to be a safe and efficacious procedure for the treatment of symptomatic BPO in patients at high cardiopulmonary risk on OA." | 1.40 | Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy. ( Bach, T; Brüning, M; Gabuev, A; Gross, AJ; Herrmann, TR; Netsch, C; Stoehrer, M, 2014) |
| "Bleeding was assessed using the Bleeding Academic Research Consortium criteria." | 1.40 | Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes. ( Byrne, RA; Kastrati, A; Laugwitz, KL; Ndrepepa, G; Neumann, FJ; Pache, J; Pöhler, A; Richardt, G; Schulz, S, 2014) |
| "We described the cardioembolic (Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack [CHADS2]/Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack, Vascular disease, Age 65-75, Sex category i." | 1.40 | Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey. ( Crijns, HJ; Iorio, A; Lip, GY; Marcucci, M; Nieuwlaat, R; Pisters, R, 2014) |
| "Switching warfarin to aspirin 3 months after successful RFCA of AF could be as safe and efficacious as long-term anticoagulation even in patients with CHA₂DS₂-VASc score≥2." | 1.40 | Safety and efficacy of switching anticoagulation to aspirin three months after successful radiofrequency catheter ablation of atrial fibrillation. ( Choi, KJ; Joung, B; Kim, YH; Lee, MH; Nam, GB; Pak, HN; Uhm, JS; Won, H, 2014) |
| "Medical records of patients operated for abdominal hernia were analysed." | 1.40 | Anticoagulants as a risk factor in patients operated on for abdominal hernia. ( Piątek, B; Piwnik, M; Podgórski, M; Strzelczyk, J, 2014) |
| " Moreover, light transmission aggregometry may detect impaired ristocetin-induced platelet agglutination, enabling dosage of aspirin to be adjusted." | 1.40 | Assessment of platelet function with light transmission aggregometry in 24 patients supported with a continuous-flow left ventricular assist device: a single-center experience. ( Barandon, L; Calderon, J; Fiore, M; James, C; Mouton, C; Ouattara, A; Picard, F, 2014) |
| "Rebleeding was diagnosed when the previously treated lesion bled again within 30 days of the initial episode." | 1.40 | Rebleeding after initial endoscopic hemostasis in peptic ulcer disease. ( Hong, MJ; Jin, CJ; Kim, JH; Lee, SY; Park, HS; Shim, CS; Sung, IK, 2014) |
| " The aim of this retrospective study was to measure the therapeutic response to standard dosing with LMWH (using anti-Xa) in patients after ablative and reconstructive surgery for head and neck cancer, and to review the associated risk of bleeding." | 1.39 | Low molecular weight heparin in patients undergoing free tissue transfer following head and neck ablative surgery: review of efficacy and associated complications. ( Eley, KA; Parker, RJ; Watt-Smith, SR, 2013) |
| "While a stroke or transient ischemic attack or history of systemic thromboembolism was detected in 15." | 1.39 | Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study. ( Acar, G; Akıl, MA; Arıbaş, A; Aydın, M; Bilik, MZ; Bulur, S; Cağlıyan, CE; Ergene, O; Ertaş, F; Gedik, S; Gül, M; Kahya Eren, N; Kanadaşı, M; Kaya, H; Kaya, Z; Köroğlu, B; Köse, N; Oylumlu, M; Ozhan, H; Simşek, Z; Ulgen, MS; Vatan, B; Yeter, E; Yıldız, A; Yılmaz, R; Yüksel, M, 2013) |
| "Dabigatran is a new anticoagulant and may be useful after AF ablation to prevent thromboembolic events." | 1.38 | The use of dabigatran immediately after atrial fibrillation ablation. ( Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA, 2012) |
| "Bleeding has emerged as a predictor of early and late mortality after percutaneous coronary interventions." | 1.38 | Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. ( Angiolillo, DJ; Capodanno, D; Gavazzi, A; Guagliumi, G; Lettieri, C; Musumeci, G; Romano, M; Rosiello, R; Rossini, R; Valsecchi, O, 2012) |
| "Acute liver failure was associated with increased risk for major complications (odds ratio 26." | 1.38 | Evaluation of risk factors for bleeding after liver biopsy in children. ( Aagenæs, I; Almaas, R; Sanengen, T; Westheim, BH; Østensen, AB, 2012) |
| "We compared patients undergoing PCI who received aspirin and clopidogrel loading dose in addition to either conventional bivalirudin dosing (intravenous [IV] bolus of 0." | 1.38 | Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study. ( Ghosn, S; Sheikh-Taha, M, 2012) |
| "Warfarin treatment was associated with a decreased risk of stroke or systemic thromboembolism among patients with chronic kidney disease, whereas warfarin and aspirin were associated with an increased risk of bleeding." | 1.38 | Stroke and bleeding in atrial fibrillation with chronic kidney disease. ( Gislason, GH; Hommel, K; Kamper, AL; Køber, L; Lane, DA; Lindhardsen, J; Lip, GY; Olesen, JB; Torp-Pedersen, C, 2012) |
| "Hemorrhages were graded as follows: 1=spot ecchymosis; 2=lid ecchymosis involving half of the lid surface area or less; 3=lid ecchymosis all around the eye, without increase in intra-ocular pressure; 4=retrobulbar hemorrhage with increased intraocular pressure." | 1.37 | Peribulbar block in 500 patients scheduled for eye procedures and treated with acetyl salicylic acid. ( Calenda, E; Cardon-Guiton, A; Genevois, O; Gueudry, J; Muraine, M, 2011) |
| "Thrombosis is still the first cause of microsurgery failure." | 1.36 | [Multicentric study of thrombosis prevention in upper-extremity microsurgery. Survey at the Fesum centers]. ( Dumont, LA; Gangloff, D; Garrido-Stowhas, I; Rongières, M; Tchénio, P, 2010) |
| "Nuisance bleeding is common in patients on prolonged DAPT post-DES implantation and can impact compliance." | 1.36 | Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. ( Ben-Dor, I; Collins, SD; Delhaye, C; Gaglia, MA; Gonzalez, MA; Kaneshige, K; Kent, KM; Li, Y; Maluenda, G; Pichard, AD; Satler, LF; Scheinowitz, M; Suddath, WO; Syed, AI; Torguson, R; Wakabayashi, K; Waksman, R; Xue, Z, 2010) |
| "Approaches to the treatment of acute coronary syndrome in patients with thrombocytopenia might be better directed toward the evaluation of platelet function rather than toward absolute platelet count, and the risk-benefit equation of invasive procedures and antithrombotic therapies may need to incorporate this information." | 1.36 | Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia. ( Bathina, JD; Daher, IN; Durand, JB; Iliescu, C; Yusuf, SW, 2010) |
| "Hemorrhagic cholecystitis is a rare and potentially fatal complication of biliary tract disease." | 1.36 | Hemorrhagic cholecystitis after anticoagulation therapy. ( Chen, CL; Chen, YY; Hsu, YH; Huang, SC; Yi, CH, 2010) |
| "We report on a severely injured trauma patient who suffered a high velocity motorcycle accident." | 1.36 | High-dose fibrinogen concentrate for haemostatic therapy of a major trauma patient with recent clopidogrel and aspirin intake. ( Hanke, A; Posch, A; Schöchl, H; Solomon, C; Voelckel, W, 2010) |
| " Proved herein is the necessity of long-term administration of antiplatelet drugs in order to prevent vascular complications on the part of the heart, brain, and peripheral arteries, with a description of the drugs most commonly used for these purposes." | 1.36 | [Antiplatelet therapy in patients with chronic obliterating diseases of lower-limb arteries]. ( Dzhalilova, NS; Kuznetsov, MR; Sizarev, AV; Tepliakov, SA; Tugdumov, BV, 2010) |
| "Ticagrelor has shown a significant ischemic benefit and an increase in non-surgical bleeding over clopidogrel in the large phase 3 Platelet Inhibition and Patient Outcomes trial." | 1.36 | Emerging oral antiplatelet therapies for acute coronary syndromes. ( Pollack, CV, 2010) |
| " The long-term use of antiplatelet agents is a key component of secondary prevention measures following acute coronary syndromes, including ST-segment elevation myocardial infarction." | 1.36 | Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy. ( Minarelli, M; Valgimigli, M, 2010) |
| "8%) compared to the patients who were using non-ASA NSAID, at therapeutic dosage (1." | 1.35 | A new model of pharmacovigilance? A pilot study. ( Bacis, G; Locatelli, C; Manzo, L; Ramella, F; Tatoni, P; Vecchio, S; Zancan, A, 2009) |
| "Bleeding was defined as non-coronary artery bypass graft-related Thrombolysis of Myocardial Infarction major/minor bleeding or transfusion among patients with baseline hematocrit > or =28%." | 1.35 | Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. ( Alexander, KP; Kosiborod, MN; Peterson, ED; Rao, SV; Rumsfeld, JS; Spertus, JA; Wang, TY; Xiao, L, 2008) |
| "Despite aspirin's established role in the treatment of atherosclerotic vascular disease, considerable controversy exists regarding its most effective dosing strategy." | 1.35 | Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). ( Amarenco, P; Aronow, HD; Califf, RM; Davis, S; Diener, HC; Easton, JD; Ferguson, J; Fitzgerald, DJ; Graffagnino, C; Harrington, RA; Koudstaal, PJ; Shuaib, A; Theroux, P; Topol, EJ; Vallee, M; Van de Werf, F, 2008) |
| "Age and left bundle branch block were strong negative predictors for early reperfusion therapy in patients with prior antithrombotic treatment." | 1.35 | Impact of chronic antithrombotic therapy on hospital course of patients with acute myocardial infarction. ( Bauer, T; Bestehorn, K; Gitt, A; Jünger, C; Koeth, O; Senges, J; Towae, F; Zahn, R; Zeymer, U, 2009) |
| "We histologically assessed thrombus formation, cellular elements, localization of TRX and of oxidized low density lipoprotein (ox-LDL), intraplaque hemorrhage, and transition metal iron (Fe(2+), Fe(3+)) deposition in these specimens." | 1.35 | Thioredoxin in coronary culprit lesions: possible relationship to oxidative stress and intraplaque hemorrhage. ( Asada, Y; Hatakeyama, K; Imamura, T; Kitamura, K; Nakamura, H; Nishihira, K; Ogawa, H; Sato, Y; Yamashita, A; Yodoi, J, 2008) |
| " Low-dose razaxaban was useful in combination with sub-optimal doses of aspirin and/or clopidogrel for the prevention of occlusive arterial thrombosis without excessive bleeding." | 1.34 | Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. ( Crain, EJ; Knabb, RM; Lam, PY; Quan, ML; Watson, CA; Wexler, RR; Wong, PC, 2007) |
| " At the antithrombotic dosage they were free from prohemorrhagic side effect at variance with acetylsalicylic acid used as reference drug." | 1.34 | Protective effect of Foeniculum vulgare essential oil and anethole in an experimental model of thrombosis. ( Ballabeni, V; Barocelli, E; Bertoni, S; Bruni, R; Impicciatore, M; Tognolini, M, 2007) |
| "Portal hypertension was produced by calibrated stenosis of the portal vein." | 1.33 | Platelet aggregation in portal hypertension and its modification by ultra-low doses of aspirin. ( Aguejouf, O; Belon, P; Doutremepuich, C; Eizayaga, FX, 2005) |
| "EUS-FNA or TCB is safe in patients taking aspirin or NSAIDS." | 1.33 | A prospective control study of the safety and cellular yield of EUS-guided FNA or Trucut biopsy in patients taking aspirin, nonsteroidal anti-inflammatory drugs, or prophylactic low molecular weight heparin. ( Chang, F; Doig, L; Kien-Fong Vu, C; Meenan, J, 2006) |
| "Aspirin treatment for primary prevention is safe and useful at an annual coronary event risk > or = 1." | 1.32 | [Anticoagulation and antiaggregation in cardiac patients]. ( Meyer, BJ, 2003) |
| "Severe bleeding was defined by the need for admission to hospital." | 1.31 | Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment. ( Castellino, G; Cuadrado, MJ; Godfrey, T; Hughes, GR; Khamashta, MA, 2001) |
| " We present several illustrative cases in which platelet monitoring with the Rapid Platelet Function Assay (RPFA, Accumetrics) was used to guide dosing of a glycoprotein (GP) IIb/IIIa inhibitor for coronary and peripheral intervention among patients at increased bleeding risk." | 1.31 | Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. ( Chew, DP; Moliterno, DJ; Mukherjee, D; Raymond, RE; Robbins, M; Yadav, JS, 2001) |
| "Hemorrhage was present in 9 cases of group B (21." | 1.30 | [Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses]. ( Azaceta, G; Civeira, E; Cornudella, R; Iturbe, T; Moreno, JA; Olave, T; Peleato, J; Sánchez, C; Varo, MJ, 1997) |
| " In this study, we investigated the effect of a combination between a high and an ultra-low dosage (100 mg/kg+ 10(-30) mg/kg) on an arterial thrombosis induced by a laser beam." | 1.30 | Combination of two doses of acetyl salicylic acid: experimental study of arterial thrombosis. ( Aguejouf, O; Belon, P; Belougne-Malfatti, E; Doutremepuich, C; Doutremepuich, F, 1998) |
| " Administration of ASA at a dosage of 10 and 25 mg/kg BW orally and intravenously yielded a plasma concentration of salicylic acid of 30-42 micrograms/ml (10 mg/kg BW) and 50-70 micrograms/ml (25 mg/kg BW)." | 1.29 | [Effect of acetylsalicylic acid on platelet aggregation and capillary bleeding in healthy cats]. ( Deniz, A; Hart, S; Kietzmann, M; Nolte, I; Sommer, B, 1995) |
| "Aspirin was used by 91 physicians (36." | 1.28 | Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. ( Kutner, M; Nixon, G; Silverstone, F, 1991) |
| "alteplase for the treatment of acute myocardial infarction (AMI) in two community hospitals is described." | 1.28 | Use of alteplase for myocardial infarction in two community hospitals. ( Finley, RC; Grabavoy, G; Hamid, I; Krichbaum, DW, 1990) |
| "In 8 patients with liver cirrhosis who underwent hepatectomy, one patient with a prolonged T2 (260 secs) and a normal skin BT bled postoperatively, however, 3 patients with a prolonged skin BT (greater than 15 min) and a normal T2 had no hemorrhagic complications." | 1.27 | Clinical application of a new in vitro bleeding time device on surgical patients. ( Itoh, T; Kambayashi, J; Mori, T; Sakon, M; Tsujinaka, T; Uemura, Y, 1988) |
| " Possible explanations for these negative findings include inadequate dosage or form of omega-3 fatty acids and the antiplatelet drugs administered, excessive variability in graft response due to uncharacterized immunologic histocompatibility, and the possible influence of non-platelet-mediated mechanisms." | 1.27 | Effects of aspirin, dipyridamole, and cod liver oil on accelerated myointimal proliferation in canine veno-arterial allografts. ( DeCampli, WM; Handen, CE; Kosek, JC; Miller, DC; Mitchell, RS, 1988) |
| "Bleeding and thrombosis are well known major causes of morbidity and mortality in patients with myeloproliferative disorders (MPD) but the relationship between these clinical events and the commonly found platelet function abnormalities have not been established." | 1.27 | Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with time. ( Baker, RI; Manoharan, A, 1988) |
| "The incidence of late cardiac tamponade rose significantly (p less than 0." | 1.27 | Late postoperative tamponade following coronary artery bypass grafting in patients on antiplatelet therapy. ( Breyer, RH; Engelman, RM; Lemeshow, S; Rousou, JA, 1985) |
| "Acute edematous pancreatitis was induced in cats by perfusing activated pancreatic enzymes through their pancreatic ducts." | 1.27 | A model of hemorrhagic pancreatitis in cats--role of 16,16-dimethyl prostaglandin E2. ( Farmer, RC; Reber, HA; Wedgwood, KR, 1986) |
| "Seven children with juvenile rheumatoid arthritis had a syndrome characterized by hemorrhage and neurologic, hepatic, hematologic, and metabolic manifestations." | 1.27 | Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. ( Griscelli, C; Hadchouel, M; Prieur, AM, 1985) |
| "Warfarin-treated patients were at increased risk of hemorrhage (5 of 20 [25%], or 22 per 100 patient-years, vs 0 of 10 [0%], or 0 per 100 patient-years, p less than 0." | 1.27 | Anticoagulation therapy in children with mechanical prosthetic cardiac valves. ( Bradley, LM; Getson, PR; Midgley, FM; Scott, LP; Watson, DC, 1985) |
| "Maternal bleeding was confined to excessive intrapartum or post-partum blood loss." | 1.26 | Effects of acetylsalicylic-acid ingestion on maternal and neonatal hemostasis. ( Elrad, H; Graeber, JE; Gross, SJ; Stuart, MJ, 1982) |
| " Laboratory determinations were used to directly evaluate therapeutic anticoagulant effects, and dosage regimens were adjusted to achieve desired anticoagulant levels." | 1.26 | Case study: complications associated with anticoagulant therapy. ( Davis, GL; Mutnick, AH, 1981) |
| "Two severe anaphylactoid reactions were seen under dextran prophylaxis resulting in the death of one newborn." | 1.26 | [Side effects of drug for thromboembolism prophylaxis. Results from the University Women's Clinic Freiburg/Br]. ( Ardelt, W; Hillemanns, HG; Pasold, K, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 244 (11.51) | 18.7374 |
| 1990's | 166 (7.83) | 18.2507 |
| 2000's | 387 (18.26) | 29.6817 |
| 2010's | 906 (42.76) | 24.3611 |
| 2020's | 416 (19.63) | 2.80 |
| Authors | Studies |
|---|---|
| Misra, A | 1 |
| Anil Kumar, KS | 1 |
| Jain, M | 2 |
| Bajaj, K | 1 |
| Shandilya, S | 1 |
| Srivastava, S | 1 |
| Shukla, P | 1 |
| Barthwal, MK | 1 |
| Dikshit, M | 1 |
| Dikshit, DK | 1 |
| Anand, SS | 20 |
| Hiatt, W | 1 |
| Dyal, L | 4 |
| Bauersachs, R | 4 |
| Berkowitz, SD | 15 |
| Branch, KRH | 4 |
| Debus, S | 3 |
| Fox, KAA | 13 |
| Liang, Y | 5 |
| Muehlhofer, E | 10 |
| Nehler, M | 4 |
| Haskell, LP | 6 |
| Patel, M | 2 |
| Szarek, M | 5 |
| Yusuf, S | 41 |
| Eikelboom, J | 6 |
| Bonaca, MP | 11 |
| Vranckx, P | 18 |
| Valgimigli, M | 36 |
| Odutayo, A | 1 |
| Serruys, PW | 12 |
| Hamm, C | 13 |
| Steg, PG | 58 |
| Heg, D | 5 |
| Mc Fadden, EP | 1 |
| Onuma, Y | 10 |
| Benit, E | 2 |
| Janssens, L | 1 |
| Diletti, R | 1 |
| Ferrario, M | 3 |
| Huber, K | 22 |
| Räber, L | 2 |
| Windecker, S | 31 |
| Jüni, P | 7 |
| Ma, H | 2 |
| Gu, Q | 1 |
| Niu, H | 1 |
| Li, X | 9 |
| Wang, R | 4 |
| Yashima, F | 2 |
| Inohara, T | 2 |
| Nishida, H | 1 |
| Shimoji, K | 1 |
| Ueno, K | 2 |
| Noma, S | 1 |
| Yamaji, K | 2 |
| Ishii, H | 1 |
| Tanaka, N | 1 |
| Kohsaka, S | 2 |
| Amano, T | 1 |
| Ikari, Y | 6 |
| McCrindle, BW | 1 |
| Michelson, AD | 2 |
| Van Bergen, AH | 1 |
| Suzana Horowitz, E | 1 |
| Pablo Sandoval, J | 1 |
| Justino, H | 1 |
| Harris, KC | 1 |
| Jefferies, JL | 1 |
| Miriam Pina, L | 1 |
| Peluso, C | 1 |
| Nessel, K | 1 |
| Lu, W | 2 |
| Li, JS | 2 |
| Yorkgitis, BK | 1 |
| Tatum, DM | 1 |
| Taghavi, S | 1 |
| Schroeppel, TJ | 1 |
| Noorbakhsh, MR | 1 |
| Philps, FH | 1 |
| Bugaev, N | 1 |
| Mukherjee, K | 1 |
| Bellora, M | 1 |
| Ong, AW | 1 |
| Ratnasekera, A | 1 |
| Nordham, KD | 1 |
| Carrick, MM | 1 |
| Haan, JM | 1 |
| Lightwine, KL | 1 |
| Lottenberg, L | 1 |
| Borrego, R | 1 |
| Cullinane, DC | 1 |
| Berne, JD | 1 |
| Rodriguez Mederos, D | 1 |
| Hayward, TZ | 1 |
| Kerwin, AJ | 1 |
| Crandall, M | 1 |
| McCarthy, L | 1 |
| Kim, CJ | 2 |
| Park, MW | 2 |
| Kim, MC | 2 |
| Choo, EH | 1 |
| Hwang, BH | 1 |
| Lee, KY | 1 |
| Choi, YS | 3 |
| Kim, HY | 3 |
| Yoo, KD | 3 |
| Jeon, DS | 4 |
| Shin, ES | 10 |
| Jeong, YH | 6 |
| Seung, KB | 5 |
| Jeong, MH | 7 |
| Yim, HW | 1 |
| Ahn, Y | 2 |
| Chang, K | 3 |
| Connors, JM | 3 |
| Brooks, MM | 1 |
| Sciurba, FC | 1 |
| Krishnan, JA | 1 |
| Bledsoe, JR | 1 |
| Kindzelski, A | 1 |
| Baucom, AL | 1 |
| Kirwan, BA | 1 |
| Eng, H | 1 |
| Martin, D | 1 |
| Zaharris, E | 1 |
| Everett, B | 1 |
| Castro, L | 1 |
| Shapiro, NL | 1 |
| Lin, JY | 1 |
| Hou, PC | 1 |
| Pepine, CJ | 4 |
| Handberg, E | 1 |
| Haight, DO | 1 |
| Wilson, JW | 1 |
| Majercik, S | 1 |
| Fu, Z | 1 |
| Zhong, Y | 1 |
| Venugopal, V | 1 |
| Beach, S | 1 |
| Wisniewski, S | 1 |
| Ridker, PM | 4 |
| Lyu, SQ | 1 |
| Zhu, J | 7 |
| Wang, J | 5 |
| Wu, S | 1 |
| Zhang, H | 6 |
| Shao, XH | 1 |
| Yang, YM | 1 |
| Calderone, D | 5 |
| Greco, A | 4 |
| Ingala, S | 3 |
| Agnello, F | 1 |
| Franchina, G | 1 |
| Scalia, L | 2 |
| Buccheri, S | 1 |
| Capodanno, D | 22 |
| Shohat, N | 2 |
| Ludwick, L | 2 |
| Goh, GS | 1 |
| Streicher, S | 1 |
| Chisari, E | 2 |
| Parvizi, J | 4 |
| Falasconi, G | 1 |
| Gaspardone, C | 1 |
| Godino, C | 4 |
| Gaspardone, A | 2 |
| Radinovic, A | 1 |
| Pannone, L | 1 |
| Leo, G | 1 |
| Posteraro, GA | 1 |
| Slavich, M | 1 |
| Melillo, F | 3 |
| Marzi, A | 1 |
| D'Angelo, G | 1 |
| Limite, LR | 1 |
| Frontera, A | 1 |
| Brugliera, L | 1 |
| Agricola, E | 1 |
| Margonato, A | 1 |
| Della Bella, P | 1 |
| Mazzone, P | 1 |
| Lv, WH | 1 |
| Dong, JZ | 1 |
| Du, X | 1 |
| Hu, R | 1 |
| He, L | 2 |
| Long, DY | 1 |
| Sang, CH | 1 |
| Jia, CQ | 1 |
| Feng, L | 3 |
| Ning, M | 1 |
| Chen, X | 4 |
| Cui, YK | 1 |
| Tang, RB | 1 |
| Ma, CS | 1 |
| Barton, CA | 1 |
| Oetken, HJ | 1 |
| Roberti, GJ | 1 |
| Dewey, EN | 1 |
| Goodman, A | 1 |
| Schreiber, M | 1 |
| Consolo, F | 1 |
| Marasi, A | 1 |
| Della Valle, P | 1 |
| Bonora, M | 1 |
| Pieri, M | 1 |
| Scandroglio, AM | 1 |
| Redaelli, A | 1 |
| Zangrillo, A | 1 |
| D'Angelo, A | 2 |
| Pappalardo, F | 1 |
| Cai, JY | 1 |
| Cui, CM | 1 |
| Min, JK | 1 |
| Cao, YQ | 1 |
| Zhang, LY | 1 |
| Summaria, F | 1 |
| Biondi-Zoccai, G | 3 |
| Romagnoli, E | 1 |
| Mamas, MA | 1 |
| Franchi, F | 6 |
| Severino, P | 1 |
| Lavalle, C | 1 |
| Versaci, F | 1 |
| Bhatt, DL | 62 |
| Barry, HC | 1 |
| Cao, D | 10 |
| Angiolillo, DJ | 35 |
| Bangalore, S | 4 |
| Ge, J | 8 |
| Hermiller, J | 3 |
| Makkar, RR | 3 |
| Neumann, FJ | 13 |
| Saito, S | 4 |
| Picon, H | 2 |
| Toelg, R | 2 |
| Maksoud, A | 2 |
| Chehab, BM | 2 |
| Choi, JW | 3 |
| Campo, G | 3 |
| De la Torre Hernandez, JM | 1 |
| Kunadian, V | 12 |
| Sardella, G | 10 |
| Thiele, H | 3 |
| Varenne, O | 1 |
| Zhou, Y | 5 |
| Krucoff, MW | 11 |
| Ruster, K | 1 |
| Zheng, Y | 3 |
| Mehran, R | 52 |
| Zakko, A | 1 |
| Zakko, L | 1 |
| Grimshaw, AA | 1 |
| Laine, L | 2 |
| Selvadurai, MV | 1 |
| Riaz, M | 2 |
| Xie, S | 2 |
| Tonkin, AM | 8 |
| McNeil, JJ | 8 |
| Lacaze, P | 2 |
| Hamilton, JR | 1 |
| Kim, BG | 1 |
| Hong, SJ | 9 |
| Kim, BK | 9 |
| Lee, SJ | 6 |
| Ahn, CM | 6 |
| Shin, DH | 3 |
| Kim, JS | 11 |
| Ko, YG | 6 |
| Choi, D | 6 |
| Hong, MK | 9 |
| Jang, Y | 9 |
| Marquis-Gravel, G | 3 |
| Hammill, BG | 3 |
| Mulder, H | 3 |
| Roe, MT | 13 |
| Robertson, HR | 2 |
| Wruck, LM | 3 |
| Sharlow, A | 2 |
| Harris, DF | 2 |
| Pohlman, FW | 1 |
| Hernandez, AF | 5 |
| Jones, WS | 9 |
| Schultz-Lebahn, A | 1 |
| Nissen, PH | 1 |
| Pedersen, TF | 1 |
| Tang, M | 1 |
| Hvas, AM | 2 |
| Mauro, MS | 1 |
| Yang, Y | 5 |
| Huang, Z | 1 |
| Zhang, X | 7 |
| Wang, A | 8 |
| Meng, X | 13 |
| Tian, X | 2 |
| Johnston, SC | 23 |
| Li, H | 19 |
| Bath, PM | 11 |
| Zuo, Y | 1 |
| Xie, X | 8 |
| Jing, J | 11 |
| Lin, J | 7 |
| Wang, Y | 48 |
| Zhao, X | 14 |
| Li, Z | 11 |
| Jiang, Y | 7 |
| Liu, L | 17 |
| Wang, F | 2 |
| Li, Y | 21 |
| Liu, J | 4 |
| Jávor, P | 1 |
| Rárosi, F | 1 |
| Horváth, T | 1 |
| Török, L | 1 |
| Hartmann, P | 1 |
| Chang, W | 2 |
| Yin, D | 2 |
| Li, C | 8 |
| Weston, B | 1 |
| Sohn, A | 1 |
| Wanamaker, C | 1 |
| Kulzer, M | 1 |
| Tragon, T | 1 |
| Spearman, M | 1 |
| Eisenmenger, L | 1 |
| Goldberg, M | 1 |
| Passacquale, G | 1 |
| Sharma, P | 2 |
| Perera, D | 1 |
| Ferro, A | 1 |
| Sutton, R | 1 |
| Valvano, M | 1 |
| Fabiani, S | 1 |
| Magistroni, M | 1 |
| Mancusi, A | 1 |
| Longo, S | 1 |
| Stefanelli, G | 1 |
| Vernia, F | 1 |
| Viscido, A | 1 |
| Romano, S | 1 |
| Latella, G | 1 |
| Cook, HE | 1 |
| Hewitt, JH | 1 |
| Patterson, EP | 1 |
| Randolph, AE | 1 |
| Alkhalil, M | 3 |
| Kuzemczak, M | 1 |
| Bell, A | 1 |
| Stern, S | 1 |
| Welsford, M | 1 |
| Cantor, WJ | 1 |
| Goodman, SG | 15 |
| Welsh, RC | 8 |
| Dehghani, P | 2 |
| Lopes, R | 1 |
| Wojdyla, DM | 7 |
| Aronson, R | 6 |
| Granger, CB | 17 |
| Vora, AN | 6 |
| Vinereanu, D | 7 |
| Halvorsen, S | 9 |
| Parkhomenko, A | 8 |
| Alexander, JH | 13 |
| Goodman, S | 3 |
| Lahu, S | 2 |
| Ndrepepa, G | 4 |
| Menichelli, M | 1 |
| Bernlochner, I | 4 |
| Richardt, G | 2 |
| Wöhrle, J | 3 |
| Witzenbichler, B | 19 |
| Hemetsberger, R | 1 |
| Mayer, K | 3 |
| Akin, I | 1 |
| Cassese, S | 2 |
| Gewalt, S | 2 |
| Xhepa, E | 2 |
| Kufner, S | 3 |
| Valina, C | 1 |
| Sager, HB | 2 |
| Joner, M | 2 |
| Ibrahim, T | 3 |
| Laugwitz, KL | 6 |
| Schunkert, H | 7 |
| Schüpke, S | 3 |
| Kastrati, A | 17 |
| Espinola-Klein, C | 1 |
| Miwa, K | 1 |
| Iwai, S | 1 |
| Nagashima, T | 1 |
| McClure, GR | 1 |
| Kaplovitch, E | 2 |
| Chan, N | 1 |
| Kirchner, VA | 1 |
| O'Farrell, B | 1 |
| Imber, C | 1 |
| McCormack, L | 1 |
| Northup, PG | 1 |
| Song, GW | 1 |
| Spiro, M | 1 |
| Raptis, DA | 1 |
| Durand, F | 1 |
| Ku, JC | 1 |
| Taslimi, S | 1 |
| Zuccato, J | 1 |
| Pasarikovski, CR | 1 |
| Nasr, N | 1 |
| Chechik, O | 1 |
| Chisci, E | 1 |
| Bissacco, D | 1 |
| Larrue, V | 1 |
| Rabinovich, Y | 1 |
| Michelagnoli, S | 1 |
| Settembrini, PG | 1 |
| Priola, SM | 1 |
| Cusimano, MD | 1 |
| Yang, VXD | 1 |
| Macdonald, RL | 1 |
| Pop, R | 1 |
| Severac, F | 1 |
| Hasiu, A | 1 |
| Mihoc, D | 1 |
| Mangin, PH | 1 |
| Chibbaro, S | 1 |
| Simu, M | 1 |
| Tudor, R | 1 |
| Gheoca, R | 1 |
| Quenardelle, V | 1 |
| Wolff, V | 1 |
| Beaujeux, R | 1 |
| Ono, M | 3 |
| Hara, H | 4 |
| Kawashima, H | 4 |
| Gao, C | 3 |
| Wykrzykowska, JJ | 5 |
| Piek, JJ | 3 |
| Garg, S | 5 |
| Cavallari, I | 2 |
| Patti, G | 4 |
| Maddaloni, E | 1 |
| Veneziano, F | 1 |
| Mangiacapra, F | 1 |
| Ricottini, E | 1 |
| Buzzetti, R | 1 |
| Ussia, GP | 2 |
| Grigioni, F | 1 |
| Fan, H | 1 |
| Liu, T | 2 |
| Zhang, K | 2 |
| Ren, J | 1 |
| Li, J | 14 |
| Wu, X | 2 |
| Niu, X | 2 |
| Xia, H | 2 |
| Wang, Z | 9 |
| Tian, M | 1 |
| Liu, Z | 1 |
| Zhou, Z | 3 |
| Heitmeier, S | 2 |
| Visser, M | 1 |
| Tersteegen, A | 1 |
| Dietze-Torres, J | 1 |
| Glunz, J | 1 |
| Gerdes, C | 1 |
| Laux, V | 1 |
| Stampfuss, J | 1 |
| Roehrig, S | 1 |
| Džavík, V | 2 |
| Mehta, SR | 17 |
| Bradbury, CA | 1 |
| Lawler, PR | 1 |
| Stanworth, SJ | 1 |
| McVerry, BJ | 1 |
| McQuilten, Z | 1 |
| Higgins, AM | 1 |
| Mouncey, PR | 1 |
| Al-Beidh, F | 1 |
| Rowan, KM | 1 |
| Berry, LR | 1 |
| Lorenzi, E | 1 |
| Zarychanski, R | 1 |
| Arabi, YM | 1 |
| Annane, D | 1 |
| Beane, A | 1 |
| van Bentum-Puijk, W | 1 |
| Bhimani, Z | 1 |
| Bihari, S | 1 |
| Bonten, MJM | 1 |
| Brunkhorst, FM | 1 |
| Buzgau, A | 1 |
| Buxton, M | 1 |
| Carrier, M | 5 |
| Cheng, AC | 1 |
| Cove, M | 1 |
| Detry, MA | 1 |
| Estcourt, LJ | 1 |
| Fitzgerald, M | 1 |
| Girard, TD | 1 |
| Goligher, EC | 1 |
| Goossens, H | 1 |
| Haniffa, R | 1 |
| Hills, T | 1 |
| Huang, DT | 1 |
| Horvat, CM | 1 |
| Hunt, BJ | 2 |
| Ichihara, N | 1 |
| Lamontagne, F | 1 |
| Leavis, HL | 1 |
| Linstrum, KM | 1 |
| Litton, E | 1 |
| Marshall, JC | 1 |
| McAuley, DF | 1 |
| McGlothlin, A | 1 |
| McGuinness, SP | 1 |
| Middeldorp, S | 2 |
| Montgomery, SK | 1 |
| Morpeth, SC | 1 |
| Murthy, S | 1 |
| Neal, MD | 1 |
| Nichol, AD | 1 |
| Parke, RL | 1 |
| Parker, JC | 1 |
| Reyes, LF | 1 |
| Saito, H | 1 |
| Santos, MS | 1 |
| Saunders, CT | 1 |
| Serpa-Neto, A | 1 |
| Seymour, CW | 1 |
| Shankar-Hari, M | 1 |
| Singh, V | 1 |
| Tolppa, T | 1 |
| Turgeon, AF | 1 |
| Turner, AM | 1 |
| van de Veerdonk, FL | 1 |
| Green, C | 1 |
| Lewis, RJ | 1 |
| Angus, DC | 1 |
| McArthur, CJ | 1 |
| Berry, S | 1 |
| Derde, LPG | 1 |
| Webb, SA | 1 |
| Gordon, AC | 1 |
| Han, Y | 7 |
| Claessen, BE | 4 |
| Chen, SL | 2 |
| Chunguang, Q | 1 |
| Xu, Y | 2 |
| Hailong, L | 1 |
| Chen, J | 4 |
| Qiang, W | 1 |
| Zhang, R | 1 |
| Luo, S | 1 |
| Cheng, X | 1 |
| Su, X | 1 |
| Tao, J | 1 |
| Sun, Y | 4 |
| Wang, G | 5 |
| Bian, L | 1 |
| Goel, R | 1 |
| Sartori, S | 16 |
| Zhang, Z | 8 |
| Cohen, DJ | 21 |
| Gibson, CM | 24 |
| Krucoff, M | 3 |
| Ohman, EM | 17 |
| Liu, Y | 6 |
| Dangas, G | 15 |
| Sharma, S | 7 |
| Baber, U | 22 |
| Nicolas, J | 3 |
| Pivato, CA | 3 |
| Briguori, C | 11 |
| Collier, T | 8 |
| Dudek, D | 8 |
| Gibson, M | 4 |
| Gil, R | 5 |
| Kaul, U | 7 |
| Kornowski, R | 8 |
| Mehta, S | 8 |
| Moliterno, DJ | 14 |
| Escaned, J | 8 |
| Sharma, SK | 3 |
| Shlofmitz, R | 6 |
| Weisz, G | 15 |
| Pocock, S | 14 |
| Ullah, W | 2 |
| Zahid, S | 1 |
| Sandhyavenu, H | 1 |
| Faisaluddin, M | 1 |
| Khalil, F | 1 |
| Pasha, AK | 1 |
| Alraies, MC | 2 |
| Cuisset, T | 10 |
| Rao, SV | 6 |
| Sabouret, P | 3 |
| Savage, MP | 2 |
| Fischman, DL | 1 |
| D'Ascenzo, F | 6 |
| DE Filippo, O | 1 |
| Angelini, F | 2 |
| Piroli, F | 1 |
| DE Lio, G | 1 |
| Bocchino, PP | 1 |
| Baldetti, L | 2 |
| Chieffo, A | 8 |
| Saglietto, A | 1 |
| Omedè, P | 3 |
| Montefusco, A | 1 |
| Conrotto, F | 3 |
| de Ferrari, GM | 3 |
| Tan, BE | 1 |
| Wong, PY | 2 |
| Baibhav, B | 1 |
| Thakkar, S | 1 |
| Azhar, AZ | 1 |
| Rao, M | 1 |
| Cheung, JW | 1 |
| Bor, WL | 1 |
| de Veer, AJW | 1 |
| Olie, RH | 1 |
| Rikken, SAOF | 1 |
| Chan Pin Yin, DRPP | 2 |
| Herrman, JPR | 1 |
| Vrolix, M | 4 |
| Meuwissen, M | 1 |
| Vandendriessche, T | 1 |
| van Mieghem, C | 1 |
| Magro, M | 2 |
| Bennaghmouch, N | 2 |
| Hermanides, R | 1 |
| Adriaenssens, T | 4 |
| Dewilde, WJM | 2 |
| Ten Berg, JM | 23 |
| Park, SH | 2 |
| Park, SK | 1 |
| Yang, HJ | 2 |
| Jung, YS | 1 |
| Park, JH | 4 |
| Sohn, CI | 1 |
| Park, DI | 1 |
| Pan, Y | 7 |
| Chen, W | 2 |
| Dong, Q | 2 |
| Xu, AD | 1 |
| Sheng, XY | 1 |
| An, HJ | 1 |
| He, YY | 1 |
| Ye, YF | 1 |
| Zhao, JL | 1 |
| Li, S | 3 |
| Xiang, F | 1 |
| Lin, Y | 7 |
| Chen, B | 2 |
| Amarenco, P | 12 |
| Denison, H | 7 |
| Evans, SR | 7 |
| Himmelmann, A | 7 |
| James, S | 12 |
| Knutsson, M | 4 |
| Ladenvall, P | 4 |
| Molina, CA | 8 |
| Gallagher, H | 2 |
| Dumbleton, J | 1 |
| Maishman, T | 1 |
| Whitehead, A | 1 |
| Moore, MV | 1 |
| Fuat, A | 1 |
| Fitzmaurice, D | 1 |
| Henderson, RA | 1 |
| Lord, J | 1 |
| Griffith, KE | 1 |
| Stevens, P | 1 |
| Taal, MW | 1 |
| Stevenson, D | 1 |
| Fraser, SD | 1 |
| Lown, M | 1 |
| Hawkey, CJ | 1 |
| Roderick, PJ | 2 |
| Al Harthi, AF | 1 |
| Aljuhani, O | 1 |
| Korayem, GB | 1 |
| Altebainawi, AF | 1 |
| Alenezi, RS | 1 |
| Al Harbi, S | 1 |
| Gramish, J | 1 |
| Kensara, R | 1 |
| Hafidh, A | 1 |
| Al Enazi, H | 1 |
| Alawad, A | 1 |
| Alotaibi, R | 1 |
| Alshehri, A | 1 |
| Alhuthaili, O | 1 |
| Vishwakarma, R | 1 |
| Bin Saleh, K | 1 |
| Alsulaiman, T | 1 |
| Alqahtani, RA | 1 |
| Hussain, S | 2 |
| Almazrou, S | 1 |
| Al Sulaiman, K | 1 |
| Lee, YJ | 3 |
| Cho, JY | 3 |
| Yun, KH | 4 |
| Davidson, KW | 1 |
| Barry, MJ | 1 |
| Mangione, CM | 1 |
| Cabana, M | 1 |
| Chelmow, D | 1 |
| Coker, TR | 1 |
| Davis, EM | 1 |
| Donahue, KE | 1 |
| Jaén, CR | 1 |
| Krist, AH | 1 |
| Kubik, M | 1 |
| Li, L | 7 |
| Ogedegbe, G | 1 |
| Pbert, L | 1 |
| Ruiz, JM | 1 |
| Stevermer, J | 1 |
| Tseng, CW | 1 |
| Wong, JB | 1 |
| Guirguis-Blake, JM | 2 |
| Evans, CV | 2 |
| Perdue, LA | 1 |
| Bean, SI | 1 |
| Senger, CA | 1 |
| Nicol, C | 1 |
| Ajzenberg, N | 1 |
| Lacut, K | 3 |
| Couturaud, F | 1 |
| Lippert, E | 1 |
| Pan-Petesch, B | 1 |
| Ianotto, JC | 1 |
| Friede, KA | 1 |
| Myers, RA | 1 |
| Gales, J | 1 |
| Zhbannikov, I | 1 |
| Ortel, TL | 1 |
| Shah, SH | 1 |
| Kraus, WE | 1 |
| Ginsburg, GS | 1 |
| Voora, D | 1 |
| Tasoudis, PT | 1 |
| Kyriakoulis, IG | 1 |
| Sagris, D | 1 |
| Diener, HC | 12 |
| Ntaios, G | 3 |
| Smits, PC | 2 |
| Frigoli, E | 1 |
| Bongiovanni, D | 1 |
| Tijssen, J | 1 |
| Hovasse, T | 3 |
| Mafragi, A | 1 |
| Ruifrok, WT | 1 |
| Karageorgiev, D | 1 |
| Aminian, A | 1 |
| Garducci, S | 1 |
| Merkely, B | 4 |
| Routledge, H | 1 |
| Ando, K | 11 |
| Diaz Fernandez, JF | 1 |
| Nesa Malik, FT | 1 |
| Halabi, M | 1 |
| Belle, L | 2 |
| Din, J | 1 |
| Beygui, F | 5 |
| Abhyankar, A | 1 |
| Reczuch, K | 1 |
| Pedrazzini, G | 3 |
| Hou, M | 1 |
| Hyun, K | 1 |
| Chew, DP | 3 |
| Kritharides, L | 1 |
| Amos, D | 1 |
| Brieger, D | 3 |
| Aboyans, V | 6 |
| Debus, ES | 5 |
| Zeymer, U | 9 |
| Cowie, MR | 1 |
| Bosch, J | 11 |
| Gay, A | 1 |
| Vogtländer, K | 1 |
| Fanelli, SJ | 1 |
| Elzeneini, M | 1 |
| Meece, LE | 1 |
| Mahmoud, A | 1 |
| Jeng, EI | 1 |
| Harris, N | 1 |
| Ahmed, MM | 1 |
| Bahit, MC | 4 |
| Thomas, L | 6 |
| Jordan, JD | 1 |
| Kolls, BJ | 1 |
| Dombrowski, KE | 1 |
| Berwanger, O | 4 |
| Lopes, RD | 21 |
| Yang, J | 3 |
| Qi, G | 1 |
| Hu, F | 1 |
| Xing, Y | 1 |
| Wang, P | 1 |
| Reynard, ME | 1 |
| Dufour, JF | 1 |
| Bai, C | 1 |
| Chen, Z | 3 |
| Ilagan, R | 1 |
| Ding, Y | 1 |
| Ji, X | 1 |
| Meng, R | 1 |
| Costa, TGR | 1 |
| Katz, M | 1 |
| Lemos Neto, PA | 1 |
| Guerra, JCC | 1 |
| Franken, M | 2 |
| Pesaro, AEP | 1 |
| Piekarski, BL | 1 |
| Rogers, J | 1 |
| Zurakowski, D | 1 |
| Thiagarajan, R | 1 |
| Emani, SM | 1 |
| Hess, CN | 5 |
| Baumgartner, I | 4 |
| Nehler, MR | 3 |
| Patel, MR | 7 |
| Capell, W | 1 |
| Bauersachs, RM | 5 |
| Hsia, J | 4 |
| Jin, A | 1 |
| Yang, H | 2 |
| Cheng, J | 2 |
| Ma, S | 2 |
| Su, W | 1 |
| Sun, C | 1 |
| Lowe, S | 1 |
| Liu, H | 7 |
| Qu, G | 1 |
| Xia, W | 1 |
| Xie, P | 1 |
| Wu, B | 4 |
| Gao, J | 2 |
| Nugteren, MJ | 1 |
| de Borst, GJ | 3 |
| van den Broek, WWA | 1 |
| Kappelle, LJ | 2 |
| Ünlü, Ç | 1 |
| Wang, X | 15 |
| Zhu, Q | 1 |
| Wu, Y | 3 |
| Deng, X | 1 |
| Ma, Y | 2 |
| Shi, T | 1 |
| Hori, M | 4 |
| Connolly, SJ | 24 |
| Maggioni, A | 1 |
| Eikelboom, JW | 32 |
| Uchiyama, S | 12 |
| Toyoda, K | 5 |
| Okamura, S | 1 |
| Omae, K | 1 |
| Hoshino, H | 2 |
| Kimura, K | 4 |
| Kitagawa, K | 3 |
| Minematsu, K | 7 |
| Yamaguchi, T | 2 |
| Al-Abdouh, A | 2 |
| Abusnina, W | 1 |
| Mhanna, M | 1 |
| Radideh, Q | 1 |
| Alzu'bi, H | 1 |
| Rmilah, AA | 1 |
| Jabri, A | 1 |
| Barbarawi, M | 3 |
| Obeidat, K | 1 |
| Alabduh, T | 1 |
| Michos, ED | 1 |
| Alnabelsi, T | 1 |
| Paul, TK | 1 |
| Zhang, Q | 3 |
| Ding, Q | 1 |
| Yan, S | 1 |
| Yue, QY | 1 |
| Eman, A | 1 |
| Balaban, O | 1 |
| Süner, KÖ | 1 |
| Cırdı, Y | 1 |
| Şahin, F | 1 |
| Demir, G | 1 |
| Pekşen, Ö | 1 |
| Musmul, A | 1 |
| Erdem, AF | 1 |
| Fujita, K | 1 |
| Fujii, S | 2 |
| Hirai, S | 1 |
| Yamaoka, H | 1 |
| Ishikawa, M | 1 |
| Karakama, J | 1 |
| Miki, K | 1 |
| Yoshimura, M | 1 |
| Nemoto, S | 1 |
| Sumita, K | 1 |
| Kostev, K | 1 |
| Tanislav, C | 1 |
| Shantsila, E | 4 |
| Kozieł-Siołkowska, M | 1 |
| Lip, GY | 28 |
| Zhao, Y | 6 |
| Shao, H | 1 |
| Obayashi, Y | 1 |
| Watanabe, H | 8 |
| Morimoto, T | 6 |
| Yamamoto, K | 4 |
| Natsuaki, M | 6 |
| Domei, T | 4 |
| Suwa, S | 5 |
| Isawa, T | 2 |
| Yoshida, R | 1 |
| Sakamoto, H | 4 |
| Akao, M | 2 |
| Hata, Y | 3 |
| Morishima, I | 1 |
| Tokuyama, H | 1 |
| Yagi, M | 3 |
| Suzuki, H | 1 |
| Wakabayashi, K | 2 |
| Suematsu, N | 4 |
| Inada, T | 2 |
| Tamura, T | 3 |
| Okayama, H | 4 |
| Abe, M | 5 |
| Kawai, K | 3 |
| Nakao, K | 3 |
| Tanabe, K | 6 |
| Morino, Y | 5 |
| Kadota, K | 5 |
| Furukawa, Y | 4 |
| Nakagawa, Y | 5 |
| Kimura, T | 17 |
| Sandner, S | 2 |
| Redfors, B | 2 |
| Audisio, K | 1 |
| Fremes, SE | 2 |
| Janssen, PWA | 1 |
| Kulik, A | 2 |
| Peper, J | 2 |
| Ruel, M | 3 |
| Saw, J | 4 |
| Soletti, GJ | 1 |
| Starovoytov, A | 4 |
| Willemsen, LM | 1 |
| Zhao, Q | 7 |
| Zhu, Y | 4 |
| Gaudino, M | 1 |
| Godtfredsen, SJ | 1 |
| Kragholm, KH | 1 |
| Leutscher, P | 1 |
| Jørgensen, SH | 1 |
| Christensen, MK | 1 |
| Butt, JH | 1 |
| Gislason, G | 1 |
| Køber, L | 7 |
| Fosbøl, EL | 1 |
| Sessa, M | 1 |
| Torp-Pedersen, C | 11 |
| Pareek, M | 2 |
| Pufulete, M | 3 |
| Harris, J | 2 |
| Pouwels, K | 1 |
| Reeves, BC | 3 |
| Lasserson, D | 2 |
| Loke, YK | 1 |
| Mumford, A | 3 |
| Mahadevan, K | 1 |
| Johnson, TW | 4 |
| Mazur, PK | 1 |
| Arghami, A | 1 |
| Macielak, SA | 1 |
| Nei, SD | 2 |
| Viehman, JK | 1 |
| King, KS | 1 |
| Daly, RC | 1 |
| Crestanello, JA | 1 |
| Schaff, HV | 3 |
| Dearani, JA | 1 |
| Tornyos, D | 1 |
| Komócsi, A | 2 |
| Bálint, A | 1 |
| Kupó, P | 1 |
| El Abdallaoui, OEA | 1 |
| Szapáry, L | 1 |
| Szapáry, LB | 1 |
| Beerkens, FJ | 1 |
| Claessen, B | 1 |
| Marx, S | 1 |
| Perrotta, C | 2 |
| Chahla, J | 2 |
| Badariotti, G | 2 |
| Ramos, J | 2 |
| Xu, S | 1 |
| Chen, Y | 10 |
| Gao, H | 2 |
| Tan, Z | 1 |
| Wang, Q | 4 |
| Zhu, B | 1 |
| Tao, F | 1 |
| Zhao, S | 1 |
| Yang, L | 1 |
| Zhang, Y | 10 |
| Han, P | 1 |
| Zhang, A | 2 |
| Lian, K | 1 |
| Willems, LH | 1 |
| Maas, DPMSM | 1 |
| Kramers, K | 1 |
| Reijnen, MMPJ | 1 |
| Riksen, NP | 1 |
| Ten Cate, H | 2 |
| van der Vijver-Coppen, RJ | 1 |
| Mees, BME | 1 |
| Zeebregts, CJ | 1 |
| Hannink, G | 1 |
| Warlé, MC | 1 |
| Kirsch, B | 2 |
| Budaj, A | 15 |
| Coppolecchia, R | 1 |
| James, SK | 6 |
| Keller, L | 2 |
| Hermanides, RS | 3 |
| Ferreiro, JL | 2 |
| Shibasaki, T | 1 |
| Mundl, H | 4 |
| Sharma, M | 3 |
| Bereczki, D | 2 |
| Kasner, SE | 3 |
| Lutsep, HL | 3 |
| Tsivgoulis, G | 3 |
| Czlonkowska, A | 2 |
| Shuaib, A | 3 |
| Endres, M | 2 |
| Gailani, D | 1 |
| Kahl, A | 1 |
| Donovan, M | 1 |
| Perera, V | 1 |
| Li, D | 3 |
| Hankey, GJ | 7 |
| Cruz Silva, J | 1 |
| Constâncio, V | 1 |
| Lima, P | 1 |
| Anacleto, G | 1 |
| Fonseca, M | 1 |
| Schaefer, JK | 3 |
| Errickson, J | 2 |
| Gu, X | 2 |
| Alexandris-Souphis, T | 2 |
| Ali, MA | 2 |
| Haymart, B | 3 |
| Kaatz, S | 3 |
| Kline-Rogers, E | 4 |
| Kozlowski, JH | 3 |
| Krol, GD | 3 |
| Shah, V | 1 |
| Sood, SL | 3 |
| Froehlich, JB | 3 |
| Barnes, GD | 3 |
| Won, KB | 2 |
| Kang, J | 8 |
| Yang, HM | 7 |
| Park, KW | 11 |
| Han, KR | 2 |
| Moon, KW | 2 |
| Oh, SK | 5 |
| Kim, U | 1 |
| Rhee, MY | 1 |
| Kim, DI | 1 |
| Kim, SY | 2 |
| Lee, SY | 4 |
| Han, JK | 6 |
| Koo, BK | 9 |
| Kim, HS | 15 |
| Fontana, F | 1 |
| Cazzato, S | 1 |
| Giaroni, F | 1 |
| Bertolini, F | 1 |
| Alfano, G | 1 |
| Mori, G | 1 |
| Giovanella, S | 1 |
| Ligabue, G | 1 |
| Magistroni, R | 1 |
| Cappelli, G | 1 |
| Donati, G | 1 |
| Michelotti, E | 1 |
| Negro, F | 1 |
| Morganti, R | 1 |
| De Caterina, R | 19 |
| Choi, KH | 2 |
| Park, YH | 4 |
| Song, YB | 8 |
| Park, TK | 6 |
| Lee, JM | 6 |
| Yang, JH | 5 |
| Choi, JH | 7 |
| Choi, SH | 7 |
| Oh, JH | 7 |
| Chun, WJ | 2 |
| Jang, WJ | 2 |
| Im, ES | 3 |
| Jeong, JO | 3 |
| Cho, BR | 3 |
| Cho, DK | 6 |
| Lee, JY | 3 |
| Koh, YY | 2 |
| Bae, JW | 7 |
| Lee, WS | 2 |
| Yoon, HJ | 2 |
| Lee, SU | 3 |
| Cho, JH | 2 |
| Choi, WG | 2 |
| Rha, SW | 9 |
| Gwon, HC | 8 |
| Hahn, JY | 8 |
| Hart, RG | 15 |
| Katsanos, AH | 1 |
| Perera, KS | 1 |
| Erba, N | 1 |
| Tosetto, A | 1 |
| Langer, M | 1 |
| Abdallah, SA | 1 |
| Giovanella, E | 1 |
| Lentini, S | 1 |
| Masini, F | 1 |
| Mocini, A | 1 |
| Portella, G | 1 |
| Salvati, AC | 1 |
| Squizzato, A | 3 |
| Testa, S | 1 |
| Lip, GYH | 18 |
| Poli, D | 1 |
| Moustafa, B | 1 |
| Testai, FD | 1 |
| Haim-Pinhas, H | 1 |
| Yoskovitz, G | 1 |
| Lishner, M | 1 |
| Pereg, D | 1 |
| Kitay-Cohen, Y | 1 |
| Topaz, G | 1 |
| Sela, Y | 1 |
| Wand, O | 1 |
| Rozenberg, I | 1 |
| Benchetrit, S | 1 |
| Cohen-Hagai, K | 1 |
| Alamin, MA | 1 |
| Al-Mashdali, A | 1 |
| Al Kindi, DI | 1 |
| Elshaikh, EA | 1 |
| Othman, F | 1 |
| Fernandez, A | 1 |
| Loza, G | 1 |
| Parma, G | 1 |
| Florio, L | 1 |
| Estigarribia, J | 1 |
| Soca, G | 1 |
| Robaina, R | 1 |
| Duran, A | 1 |
| Brusich, D | 1 |
| Dayan, V | 1 |
| O'Brien, EC | 1 |
| Curtis, LH | 2 |
| Niessner, A | 2 |
| Böning, A | 1 |
| Conradi, L | 1 |
| Danner, B | 1 |
| Zimpfer, D | 1 |
| Färber, G | 1 |
| Manville, E | 1 |
| von Scheidt, M | 2 |
| Shao, T | 1 |
| Yang, T | 2 |
| Wang, H | 2 |
| Cheng, Y | 2 |
| Zhang, T | 1 |
| Zhang, J | 7 |
| Wu, H | 3 |
| Xu, L | 2 |
| Cheng, K | 1 |
| Chen, M | 2 |
| Li, G | 1 |
| Huang, J | 3 |
| Lan, J | 1 |
| Wei, G | 1 |
| Zhang, C | 5 |
| Qian, J | 5 |
| Lee, H | 3 |
| Hwang, D | 3 |
| Lee, NH | 6 |
| Hur, SH | 6 |
| Rychen, J | 2 |
| Saemann, A | 1 |
| Fingerlin, T | 1 |
| Guzman, R | 3 |
| Mariani, L | 2 |
| Greuter, L | 1 |
| Soleman, J | 2 |
| Tarzia, V | 3 |
| Tessari, C | 3 |
| Bagozzi, L | 3 |
| Bottigliengo, D | 3 |
| Fagan, D | 3 |
| Fabozzo, A | 3 |
| Mastro, FR | 3 |
| Pagnin, C | 3 |
| Bottio, T | 3 |
| Gregori, D | 3 |
| Gerosa, G | 3 |
| Peng, W | 3 |
| Andò, G | 5 |
| De Santis, GA | 3 |
| Pistelli, L | 3 |
| Francaviglia, B | 4 |
| Capranzano, P | 5 |
| Montalto, C | 4 |
| Costa, F | 8 |
| Leonardi, S | 8 |
| Micari, A | 3 |
| Oreglia, JA | 3 |
| Ten Berg, J | 4 |
| Galli, M | 8 |
| Rollini, F | 6 |
| Ortega-Paz, L | 3 |
| D'Amario, D | 5 |
| Govsyeyev, N | 2 |
| Conte, MS | 2 |
| Chung, J | 2 |
| Dorigo, W | 2 |
| Gudz, I | 3 |
| Krievins, D | 2 |
| Mills, J | 2 |
| Moll, F | 3 |
| Norgren, L | 3 |
| Piffaretti, G | 3 |
| Powell, R | 2 |
| Szalay, D | 2 |
| Sillesen, H | 2 |
| Wohlauer, M | 2 |
| Capell, WH | 3 |
| Jaeger, N | 3 |
| Andreotti, F | 8 |
| Geisler, T | 6 |
| Collet, JP | 15 |
| Gigante, B | 2 |
| Gorog, DA | 4 |
| Morais, J | 5 |
| Navarese, EP | 8 |
| Patrono, C | 8 |
| Rocca, B | 2 |
| Rubboli, A | 7 |
| Sibbing, D | 7 |
| Storey, RF | 24 |
| Verheugt, FWA | 5 |
| Vilahur, G | 3 |
| Sheth, MS | 2 |
| Yu, B | 2 |
| Chu, A | 2 |
| Porter, J | 2 |
| Tam, DY | 2 |
| Ferreira-Legere, LE | 2 |
| Farkouh, ME | 2 |
| Ko, DT | 2 |
| Abdel-Qadir, H | 2 |
| Udell, JA | 3 |
| Chiarito, M | 3 |
| Spirito, A | 4 |
| Giustino, G | 7 |
| Beerkens, F | 1 |
| Camaj, A | 1 |
| Vogel, B | 8 |
| Maximiliano, CL | 1 |
| Jaime, GC | 1 |
| Erika, MH | 1 |
| Xu, Q | 5 |
| Marcaccio, CL | 1 |
| Patel, PB | 1 |
| Rastogi, V | 1 |
| Stangenberg, L | 1 |
| Liang, P | 1 |
| Wyers, MC | 1 |
| Jim, J | 1 |
| Schneider, PA | 1 |
| Schermerhorn, ML | 1 |
| De Servi, S | 5 |
| Landi, A | 4 |
| Savonitto, S | 3 |
| De Luca, L | 2 |
| De Luca, G | 4 |
| Morici, N | 3 |
| Crimi, G | 2 |
| Cattaneo, M | 2 |
| Clemmensen, P | 1 |
| Kobari, Y | 1 |
| Tsuruta, H | 1 |
| Shimizu, H | 1 |
| Fukuda, K | 2 |
| Naganuma, T | 1 |
| Mizutani, K | 1 |
| Yamawaki, M | 1 |
| Tada, N | 2 |
| Yamanaka, F | 1 |
| Shirai, S | 1 |
| Tabata, M | 1 |
| Ueno, H | 1 |
| Takagi, K | 3 |
| Watanabe, Y | 1 |
| Yamamoto, M | 1 |
| Hayashida, K | 1 |
| Papaxanthos, J | 1 |
| Cagnazzo, F | 1 |
| Collemiche, FL | 1 |
| Barreau, X | 1 |
| Radu, RA | 1 |
| Gariel, F | 1 |
| Derraz, I | 1 |
| Gascou, G | 1 |
| Riquelme, C | 1 |
| Ferreira, I | 1 |
| Lefevre, PH | 1 |
| Berge, J | 1 |
| Costalat, V | 1 |
| Dargazanli, C | 1 |
| Marnat, G | 1 |
| Probstfield, JL | 1 |
| Maggioni, AP | 8 |
| Avezum, A | 7 |
| Widimsky, P | 10 |
| Yi, Q | 1 |
| Shestakovska, O | 10 |
| Han, YL | 7 |
| Shlofmitz, RA | 2 |
| O'Toole, RV | 2 |
| Stein, DM | 2 |
| O'Hara, NN | 2 |
| Frey, KP | 1 |
| Taylor, TJ | 1 |
| Scharfstein, DO | 1 |
| Carlini, AR | 1 |
| Sudini, K | 1 |
| Degani, Y | 1 |
| Slobogean, GP | 2 |
| Haut, ER | 1 |
| Obremskey, W | 1 |
| Firoozabadi, R | 1 |
| Bosse, MJ | 1 |
| Goldhaber, SZ | 3 |
| Marvel, D | 1 |
| Castillo, RC | 2 |
| Yin, J | 2 |
| Zhang, W | 3 |
| Shen, L | 2 |
| Ge, L | 2 |
| Van den Eynde, J | 1 |
| Possner, M | 1 |
| Alahdab, F | 1 |
| Veldtman, G | 1 |
| Goldstein, BH | 1 |
| Rathod, RH | 1 |
| Hoskoppal, AK | 1 |
| Saraf, A | 1 |
| Feingold, B | 1 |
| Alsaied, T | 1 |
| Gao, Y | 1 |
| Han, S | 2 |
| Wang, C | 8 |
| Wang, T | 2 |
| Liu, S | 5 |
| Eckstein, J | 3 |
| Lam, A | 1 |
| Cheema, AN | 3 |
| Gangwani, MK | 1 |
| Aziz, M | 1 |
| Aziz, A | 1 |
| Priyanka, F | 1 |
| Patel, A | 2 |
| Ghaffar, U | 1 |
| Weissman, S | 1 |
| Asif, M | 1 |
| Lee-Smith, W | 1 |
| Javaid, T | 1 |
| Nawras, A | 1 |
| Hart, B | 1 |
| Marcucci, R | 1 |
| Berteotti, M | 1 |
| Gragnano, F | 4 |
| Renda, G | 3 |
| Santilli, F | 1 |
| Cirillo, P | 1 |
| Calabrò, P | 7 |
| Nishiyama, Y | 1 |
| Otsuka, T | 1 |
| Sakai, N | 1 |
| Okada, Y | 2 |
| Origasa, H | 2 |
| Naritomi, H | 1 |
| Houkin, K | 1 |
| Yamaguchi, K | 1 |
| Matsumoto, M | 1 |
| Tominaga, T | 1 |
| Tomimoto, H | 1 |
| Terayama, Y | 1 |
| Yasuda, S | 2 |
| Branca, M | 1 |
| Franzone, A | 5 |
| Dangas, GD | 7 |
| McFadden, EP | 3 |
| Zhou, S | 1 |
| Xiao, Y | 2 |
| Zhou, C | 1 |
| Zheng, Z | 1 |
| Jiang, W | 1 |
| Shen, Q | 2 |
| Zhu, C | 1 |
| Pan, H | 1 |
| Liu, C | 4 |
| Zeng, G | 1 |
| Ouyang, Z | 1 |
| Fu, G | 1 |
| Pan, G | 1 |
| Chen, F | 3 |
| Huang, L | 1 |
| Liu, Q | 2 |
| Caglioni, S | 1 |
| Piple, AS | 1 |
| Wang, JC | 1 |
| Kang, HP | 1 |
| Mills, ES | 1 |
| Mayfield, CK | 1 |
| Lieberman, JR | 1 |
| Christ, AB | 1 |
| Heckmann, ND | 1 |
| Mendoza, M | 1 |
| Bonacina, E | 1 |
| Garcia-Manau, P | 1 |
| López, M | 1 |
| Caamiña, S | 1 |
| Vives, À | 1 |
| Lopez-Quesada, E | 1 |
| Ricart, M | 1 |
| Maroto, A | 1 |
| de Mingo, L | 1 |
| Pintado, E | 1 |
| Ferrer-Costa, R | 1 |
| Martin, L | 1 |
| Rodríguez-Zurita, A | 1 |
| Garcia, E | 3 |
| Pallarols, M | 1 |
| Vidal-Sagnier, L | 1 |
| Teixidor, M | 1 |
| Orizales-Lago, C | 1 |
| Pérez-Gomez, A | 1 |
| Ocaña, V | 1 |
| Puerto, L | 1 |
| Millán, P | 1 |
| Alsius, M | 1 |
| Diaz, S | 1 |
| Maiz, N | 1 |
| Carreras, E | 1 |
| Suy, A | 1 |
| Serebruany, VL | 9 |
| Tanguay, JF | 5 |
| Gurvich, ML | 1 |
| Marciniak, TA | 1 |
| Atar, D | 4 |
| Zheng, N | 1 |
| Zhong, J | 1 |
| Su, J | 1 |
| Jiang, L | 1 |
| Oliva, A | 1 |
| Piccolo, R | 4 |
| Angiolillo, D | 1 |
| Montalescot, G | 28 |
| Niebauer, J | 1 |
| Price, S | 1 |
| Völler, H | 1 |
| Muramatsu, T | 1 |
| Masuda, S | 1 |
| Kotoku, N | 1 |
| Kozuma, K | 6 |
| Ishibashi, Y | 1 |
| Nakazawa, G | 1 |
| Takahashi, K | 8 |
| Okamura, T | 1 |
| Miyazaki, Y | 1 |
| Tateishi, H | 1 |
| Nakamura, M | 8 |
| Kogame, N | 6 |
| Asano, T | 1 |
| Nakatani, S | 1 |
| Katagiri, Y | 1 |
| Ninomiya, K | 1 |
| Kageyama, S | 1 |
| Takahashi, H | 1 |
| Tu, S | 1 |
| Ozaki, Y | 1 |
| Morin, J | 1 |
| Delaney, J | 1 |
| Nunes, GC | 1 |
| Simoneau, J | 1 |
| Beltempo, M | 1 |
| Goudie, C | 1 |
| Malhamé, I | 1 |
| Altit, G | 1 |
| Zhou, T | 1 |
| Gong, Y | 1 |
| Ten Haaf, ME | 1 |
| van Geuns, RJ | 1 |
| van der Linden, MMJM | 1 |
| de Vries, AG | 1 |
| Doevendans, PA | 1 |
| Appelman, Y | 2 |
| Boersma, E | 1 |
| Relvas, M | 1 |
| Gonçalves, J | 1 |
| Castro, I | 1 |
| Diniz, H | 1 |
| Mendonça, L | 1 |
| Coentrão, L | 1 |
| Kim, JT | 1 |
| Kim, BJ | 1 |
| Kim, JY | 1 |
| Han, MK | 1 |
| Cho, KH | 2 |
| Park, MS | 1 |
| Park, JM | 2 |
| Kang, K | 1 |
| Kim, YS | 1 |
| Kim, JG | 2 |
| Cha, JK | 1 |
| Kim, DH | 1 |
| Park, TH | 6 |
| Park, SS | 1 |
| Choi, JK | 1 |
| Lee, K | 6 |
| Park, KY | 1 |
| Jeong, HB | 1 |
| Lee, J | 6 |
| Kwon, DH | 1 |
| Cho, YJ | 3 |
| Hong, KS | 2 |
| Park, HK | 1 |
| Lee, BC | 4 |
| Yu, KH | 1 |
| Oh, MS | 1 |
| Lee, M | 4 |
| Kim, DE | 2 |
| Gwak, DS | 1 |
| Choi, JC | 1 |
| Kang, CH | 1 |
| Kwon, JH | 1 |
| Kim, WJ | 1 |
| Shin, DI | 2 |
| Yum, KS | 1 |
| Sohn, SI | 1 |
| Hong, JH | 1 |
| Park, H | 1 |
| Kim, C | 1 |
| Lee, SH | 7 |
| Gorelick, PB | 2 |
| Norrving, B | 1 |
| Bae, HJ | 2 |
| Bianco, M | 2 |
| Mottola, FF | 1 |
| Cerrato, E | 4 |
| Giordana, F | 2 |
| Cinconze, S | 1 |
| Baralis, G | 1 |
| Verra, A | 1 |
| Musumeci, G | 8 |
| Rossini, R | 7 |
| Lang, AE | 1 |
| de Havenon, A | 1 |
| Mac Grory, B | 1 |
| Henninger, N | 1 |
| Shu, L | 1 |
| Furie, KL | 2 |
| Easton, JD | 14 |
| Kim, A | 1 |
| Yaghi, S | 1 |
| Lee, B | 1 |
| Bhatia, K | 2 |
| Ladd, LM | 1 |
| Carr, KH | 1 |
| Di Napoli, M | 1 |
| Saver, JL | 2 |
| McCullough, LD | 1 |
| Hosseini Farahabadi, M | 1 |
| Alsbrook, DL | 1 |
| Hinduja, A | 1 |
| Ortiz Garcia, JG | 1 |
| Sabbagh, SY | 1 |
| Jafarli, A | 1 |
| Divani, AA | 1 |
| Jun, EJ | 1 |
| Kim, B | 2 |
| Rhee, TM | 2 |
| Kwak, SH | 1 |
| Chae, IH | 4 |
| Shin, WY | 1 |
| Kim, DK | 1 |
| Kim, YH | 7 |
| Yoon, J | 1 |
| Ma, X | 1 |
| Zhong, P | 1 |
| Jeyalan, V | 1 |
| Markides, RIL | 1 |
| Farag, M | 1 |
| Chandiramani, R | 3 |
| Johnson, JW | 1 |
| Mehta, A | 1 |
| Faillace, RT | 1 |
| Wu, C | 3 |
| Qu, X | 1 |
| Zhang, L | 5 |
| He, X | 1 |
| Qiu, M | 1 |
| Tanaka, J | 1 |
| Koseki, T | 1 |
| Sekido, K | 1 |
| Kimata, M | 1 |
| Ito, Y | 3 |
| Yamada, S | 3 |
| van Bergeijk, KH | 1 |
| van Ginkel, DJ | 1 |
| Brouwer, J | 2 |
| Nijenhuis, VJ | 2 |
| van der Werf, HW | 1 |
| van den Heuvel, AFM | 1 |
| Voors, AA | 1 |
| Gong, X | 1 |
| Hua, R | 1 |
| Bai, J | 1 |
| Wu, T | 1 |
| Ying, L | 1 |
| Ke, Y | 1 |
| Liu, K | 1 |
| Zhang, B | 1 |
| Dong, P | 1 |
| Xiao, J | 1 |
| Zhu, L | 1 |
| Shiomi, H | 5 |
| Miyazawa, A | 1 |
| Nakamura, S | 2 |
| Ono, K | 2 |
| Shigetoshi, M | 1 |
| Taniguchi, R | 3 |
| Yokomatsu, T | 3 |
| Muto, M | 1 |
| Kawaguchi, R | 1 |
| Kishi, K | 1 |
| Hadase, M | 1 |
| Fujita, T | 1 |
| Nishida, Y | 2 |
| Nishino, M | 1 |
| Otake, H | 1 |
| Hibi, K | 5 |
| Chou, CL | 1 |
| Chung, CH | 2 |
| Hsu, YH | 2 |
| Wu, CC | 1 |
| Sun, CA | 1 |
| Chien, WC | 1 |
| Tang, SE | 1 |
| Fann, LY | 1 |
| Cohan, D | 1 |
| Uricchio, MN | 1 |
| Konopka, CI | 1 |
| Montepara, CA | 1 |
| Verlinden, NJ | 2 |
| Kanagaratnam, P | 1 |
| Francis, DP | 1 |
| Chamie, D | 1 |
| Coyle, C | 1 |
| Marynina, A | 1 |
| Katritsis, G | 1 |
| Paiva, P | 1 |
| Szigeti, M | 1 |
| Cole, G | 1 |
| de Andrade Nunes, D | 1 |
| Howard, J | 1 |
| Esper, R | 1 |
| Khan, M | 1 |
| More, R | 1 |
| Barreto, G | 1 |
| Meneguz-Moreno, R | 1 |
| Arnold, A | 1 |
| Nowbar, A | 1 |
| Kaura, A | 1 |
| Mariveles, M | 1 |
| March, K | 1 |
| Shah, J | 1 |
| Nijjer, S | 1 |
| Mills, N | 1 |
| Camm, AJ | 2 |
| Cooke, GS | 1 |
| Corbett, SJ | 1 |
| Llewelyn, MJ | 1 |
| Ghanima, W | 1 |
| Toshner, M | 1 |
| Peters, N | 1 |
| Petraco, R | 1 |
| Al-Lamee, R | 1 |
| Boshoff, ASM | 1 |
| Durkina, M | 1 |
| Malik, I | 1 |
| Ruparelia, N | 1 |
| Cornelius, V | 1 |
| Shun-Shin, M | 1 |
| Dagenais, GR | 4 |
| Pais, P | 6 |
| Gao, P | 5 |
| Roshandel, G | 1 |
| Malekzadeh, R | 1 |
| Joseph, P | 1 |
| Shpigelman, J | 1 |
| Proshkina, A | 1 |
| Daly, MJ | 1 |
| Cox, D | 1 |
| Wlodarczak, A | 1 |
| Tölg, R | 2 |
| Kelbæk, H | 1 |
| Legutko, J | 1 |
| Galli, S | 1 |
| Godin, M | 1 |
| Toth, GG | 1 |
| Lhermusier, T | 1 |
| Honton, B | 1 |
| Dietrich, PL | 1 |
| Stammen, F | 1 |
| Ferdinande, B | 2 |
| Silvain, J | 4 |
| Cayla, G | 7 |
| Xu, A | 2 |
| Kar, S | 2 |
| Doshi, SK | 1 |
| Alkhouli, M | 1 |
| Coylewright, M | 3 |
| Gibson, MC | 1 |
| Gurol, ME | 1 |
| Mansour, M | 1 |
| Nair, DG | 2 |
| Natale, A | 1 |
| Pocock, SJ | 4 |
| Reddy, VR | 1 |
| Saliba, W | 3 |
| Christen, T | 2 |
| Allocco, DJ | 3 |
| Ellenbogen, KA | 1 |
| Leon, MB | 5 |
| Komen, JJ | 1 |
| Hunt, NB | 1 |
| Pottegård, A | 2 |
| Hjemdahl, P | 2 |
| Wettermark, B | 3 |
| Olesen, M | 1 |
| Bennie, M | 1 |
| Mueller, T | 1 |
| Carragher, R | 1 |
| Karlstad, Ø | 1 |
| Kjerpeseth, LJ | 1 |
| Klungel, OH | 2 |
| Forslund, T | 2 |
| Gupta, K | 3 |
| Mehta, H | 1 |
| Kim, H | 1 |
| Stebbins, A | 3 |
| Muñoz, D | 3 |
| Effron, MB | 5 |
| Anderson, RD | 3 |
| Jain, SK | 3 |
| Girotra, S | 4 |
| DeWalt, DA | 2 |
| Whittle, J | 3 |
| Benziger, CP | 3 |
| Farrehi, P | 3 |
| Zhou, L | 2 |
| Knowlton, KU | 2 |
| Polonsky, TS | 3 |
| Bradley, SM | 3 |
| Harrington, RA | 16 |
| Rothman, RL | 3 |
| Wang, CC | 1 |
| Guo, BY | 1 |
| Hao, J | 1 |
| Zhao, JJ | 1 |
| Ren, JL | 1 |
| Sun, YQ | 1 |
| Zhang, XR | 1 |
| Yang, XL | 1 |
| Liu, JM | 1 |
| Guimarães, PO | 3 |
| Tavares, CAM | 1 |
| Silveira, FS | 2 |
| Antunes, MO | 1 |
| Bergo, RR | 1 |
| Joaquim, RM | 1 |
| Hirai, JCS | 1 |
| Andrade, PB | 1 |
| Pitta, FG | 1 |
| Mariani, J | 1 |
| Nascimento, BR | 1 |
| de Paula, JET | 1 |
| Silveira, MS | 1 |
| Costa, TAO | 1 |
| Dall'Orto, FTC | 1 |
| Serpa, RG | 1 |
| Sampaio, FBA | 1 |
| Ohe, LN | 1 |
| Mangione, FM | 1 |
| Furtado, RHM | 1 |
| Sarmento-Leite, R | 1 |
| Monfardini, F | 1 |
| Assis, SRL | 1 |
| Nicolau, JC | 6 |
| Sposito, AC | 1 |
| Bacal, F | 1 |
| Lemos, PA | 1 |
| McQuilten, ZK | 1 |
| Thao, LTP | 1 |
| Pasricha, SR | 1 |
| Artz, AS | 1 |
| Bailey, M | 1 |
| Chan, AT | 2 |
| Cohen, HJ | 1 |
| Lockery, JE | 6 |
| Murray, AM | 7 |
| Nelson, MR | 6 |
| Schneider, HG | 1 |
| Wolfe, R | 7 |
| Woods, RL | 6 |
| Wood, EM | 3 |
| Pirondini, L | 1 |
| Pettersen, AR | 1 |
| Woodward, M | 1 |
| Seljeflot, I | 3 |
| Arnesen, H | 5 |
| Lei, M | 1 |
| An, L | 1 |
| Zhou, H | 1 |
| Zhao, Z | 1 |
| Nie, S | 2 |
| Hau, WK | 1 |
| Xue, Z | 2 |
| Faridi, KF | 1 |
| Strom, JB | 1 |
| Kundi, H | 1 |
| Butala, NM | 1 |
| Curtis, JP | 1 |
| Gao, Q | 1 |
| Song, Y | 3 |
| Zheng, L | 2 |
| Tamez, H | 1 |
| Shen, C | 2 |
| Secemsky, EA | 4 |
| Yeh, RW | 16 |
| Woodhouse, LJ | 2 |
| Appleton, JP | 2 |
| Christensen, H | 2 |
| Dineen, RA | 2 |
| England, TJ | 2 |
| James, M | 2 |
| Krishnan, K | 2 |
| Montgomery, AA | 2 |
| Ranta, A | 2 |
| Robinson, TG | 2 |
| Sprigg, N | 2 |
| Ahrens, I | 1 |
| Ako, J | 5 |
| Siller-Matula, JM | 1 |
| Tan, JWC | 1 |
| Vandenbriele, C | 1 |
| van der Sangen, NMR | 1 |
| Küçük, IT | 1 |
| Sivanesan, S | 1 |
| Verburg, A | 1 |
| Azzahhafi, J | 1 |
| Arkenbout, EK | 1 |
| Kikkert, WJ | 2 |
| Pisters, R | 2 |
| Jukema, JW | 1 |
| Arslan, F | 1 |
| van 't Hof, A | 1 |
| Ilhan, M | 1 |
| Hoebers, LP | 1 |
| van der Schaaf, RJ | 1 |
| Damman, P | 1 |
| Woudstra, P | 1 |
| van de Hoef, TP | 1 |
| Bax, M | 1 |
| Anthonio, RL | 1 |
| Polad, J | 1 |
| Dewilde, W | 2 |
| Zivelonghi, C | 1 |
| Laanmets, P | 1 |
| Majas, R | 1 |
| Dijkgraaf, MGW | 1 |
| Claessen, BEPM | 1 |
| Henriques, JPS | 1 |
| Almarzooq, ZI | 1 |
| Al-Roub, NM | 1 |
| Kinlay, S | 3 |
| Ruzina, EV | 1 |
| Berdibekov, BS | 1 |
| Bulaeva, NI | 1 |
| Kubova, MC | 1 |
| Golukhova, EZ | 1 |
| Claiborne Johnston, S | 1 |
| Smith, CL | 1 |
| Kasza, J | 3 |
| Kirpach, B | 4 |
| Reid, CM | 9 |
| Storey, E | 4 |
| Shah, RC | 5 |
| Orchard, SG | 4 |
| Ernst, ME | 5 |
| Clezar, CN | 1 |
| Flumignan, CD | 1 |
| Cassola, N | 1 |
| Nakano, LC | 1 |
| Trevisani, VF | 1 |
| Flumignan, RL | 1 |
| Li, M | 6 |
| Yang, Q | 2 |
| Shi, J | 1 |
| Lin, H | 2 |
| Ge, F | 1 |
| Mendieta, G | 1 |
| Cohen, D | 2 |
| Ahn, SG | 1 |
| Sim, DS | 1 |
| Hong, YJ | 1 |
| Kim, JH | 6 |
| Lee, JW | 2 |
| Youn, YJ | 1 |
| Weiger, VF | 1 |
| Halbeisen, FS | 1 |
| Ebel, F | 1 |
| Ullmann, M | 1 |
| Yang, S | 3 |
| Ahn, HS | 1 |
| Cha, KS | 2 |
| Jo, SH | 1 |
| Ryu, JK | 1 |
| Suh, IW | 2 |
| Choi, HH | 1 |
| Woo, SI | 1 |
| Wruck, L | 1 |
| Kripalani, S | 2 |
| Ahmad, FS | 2 |
| Premji, AM | 1 |
| Blegen, MB | 1 |
| Corley, AM | 1 |
| Ulloa, J | 1 |
| Booth, MS | 1 |
| Begashaw, M | 1 |
| Larkin, J | 1 |
| Shekelle, P | 1 |
| Girgis, MD | 1 |
| Maggard-Gibbons, M | 1 |
| Rickenberg, A | 1 |
| Holinstat, M | 1 |
| Liu, HZ | 1 |
| Liang, J | 2 |
| Hu, AX | 1 |
| Ielasi, A | 1 |
| Stefanini, GG | 2 |
| Tannu, M | 1 |
| Newby, LK | 2 |
| Holmes, DR | 3 |
| Kapadia, SR | 2 |
| Hsu, JC | 1 |
| Gibson, DN | 1 |
| Freeman, JV | 1 |
| Piccini, JP | 5 |
| Price, MJ | 5 |
| He, C | 1 |
| Jiang, X | 1 |
| Jiang, MN | 1 |
| Zhao, XX | 1 |
| Ma, SR | 1 |
| Bao, D | 1 |
| Qiu, MH | 1 |
| Deng, J | 2 |
| Wang, JH | 1 |
| Qu, P | 1 |
| Jiang, CM | 1 |
| Jia, SB | 1 |
| Yang, SQ | 1 |
| Ru, LS | 1 |
| Feng, J | 1 |
| Gao, W | 1 |
| Huang, YH | 1 |
| Tao, L | 2 |
| Yang, K | 1 |
| Wang, XY | 1 |
| Zhang, WJ | 1 |
| Wang, BM | 1 |
| Yang, YL | 1 |
| Li, JX | 1 |
| Sheng, JQ | 1 |
| Ma, YT | 1 |
| Cui, M | 1 |
| Ma, SC | 1 |
| Wang, XZ | 3 |
| Li, ZS | 1 |
| Liao, Z | 1 |
| Stone, GW | 17 |
| Her, AY | 3 |
| Ma, L | 1 |
| Kovacevic, M | 1 |
| Pompei, G | 1 |
| Lattuca, B | 1 |
| Chichareon, P | 5 |
| Tomaniak, M | 6 |
| Modolo, R | 5 |
| Chang, CC | 5 |
| Komiyama, H | 2 |
| Soliman, O | 1 |
| de Winter, RJ | 3 |
| Dominici, M | 1 |
| Buszman, P | 1 |
| Bolognese, L | 2 |
| Tumscitz, C | 2 |
| Stoll, HP | 2 |
| Colombo, A | 15 |
| Resnick, MJ | 1 |
| Lewis, S | 1 |
| Glen, J | 1 |
| Dawoud, D | 1 |
| Dias, S | 1 |
| Cobb, J | 1 |
| Griffin, X | 1 |
| Reed, M | 2 |
| Sharpin, C | 1 |
| Stansby, G | 1 |
| Barry, P | 1 |
| Schrör, K | 5 |
| Kristensen, SD | 6 |
| Decouture, B | 1 |
| Leuci, A | 1 |
| Dizier, B | 2 |
| Belleville-Rolland, T | 2 |
| Mansour, A | 1 |
| Martin, F | 1 |
| Pidard, D | 1 |
| Gaussem, P | 3 |
| Bachelot-Loza, C | 3 |
| Goto, S | 5 |
| Uemura, N | 2 |
| Sugano, K | 1 |
| Hiraishi, H | 1 |
| Shimada, K | 5 |
| Ikeda, Y | 7 |
| Elvira Ruiz, G | 1 |
| Caro Martínez, C | 1 |
| Flores Blanco, PJ | 1 |
| Cerezo Manchado, JJ | 1 |
| Albendín Iglesias, H | 1 |
| Lova Navarro, A | 1 |
| Arregui Montoya, F | 1 |
| García Alberola, A | 1 |
| Pascual Figal, DA | 1 |
| Bailén Lorenzo, JL | 1 |
| Manzano-Fernández, S | 3 |
| Simon, T | 1 |
| Fox, K | 1 |
| Held, C | 4 |
| Andersson, M | 2 |
| Ridderstråle, W | 1 |
| Leonsson-Zachrisson, M | 2 |
| Opolski, G | 4 |
| Zateyshchikov, D | 1 |
| Corbalán, R | 4 |
| Cornel, JH | 6 |
| Leiter, LA | 1 |
| Lanas, A | 1 |
| Vergallo, R | 2 |
| Montone, RA | 1 |
| Porto, I | 2 |
| Crea, F | 3 |
| de Vries, TI | 1 |
| Westerink, J | 1 |
| Dorresteijn, JAN | 1 |
| Alings, M | 5 |
| van der Graaf, Y | 2 |
| Visseren, FLJ | 1 |
| Jiménez-García, N | 1 |
| de la Torre Lima, J | 1 |
| García Alegría, J | 1 |
| Catapano, JS | 1 |
| Israr, S | 1 |
| Whiting, AC | 1 |
| Hussain, OM | 1 |
| Snyder, LA | 1 |
| Albuquerque, FC | 1 |
| Ducruet, AF | 1 |
| Nakaji, P | 2 |
| Lawton, MT | 1 |
| Weinberg, JA | 1 |
| Zabramski, JM | 1 |
| Kostis, JB | 1 |
| Selak, V | 4 |
| Jackson, R | 4 |
| Poppe, K | 4 |
| Harwood, M | 3 |
| Grey, C | 3 |
| Pylypchuk, R | 2 |
| Choi, YH | 2 |
| Kerr, A | 4 |
| Wells, S | 4 |
| Bosch, JJ | 1 |
| Leong, DP | 3 |
| O'Donnell, M | 9 |
| Cairns, JA | 2 |
| Tasto, C | 1 |
| Cook Bruns, N | 3 |
| Diaz, R | 13 |
| Bode, C | 4 |
| Olivier, CB | 1 |
| Duerschmied, D | 1 |
| Darius, H | 8 |
| Averkov, O | 2 |
| Kong, DF | 1 |
| Kobalava, Z | 1 |
| Mehta, RH | 1 |
| Mirza, Z | 1 |
| Quadros, A | 1 |
| Cha, JY | 1 |
| Gurbel, P | 2 |
| Hamm, CW | 3 |
| Henry, T | 2 |
| Marx, SO | 1 |
| Moliterno, D | 3 |
| Oldroyd, K | 2 |
| Massaro, T | 2 |
| Jones-Burton, C | 1 |
| Heizer, G | 2 |
| Aschermann, M | 1 |
| Cura, F | 1 |
| Engstrøm, T | 1 |
| Fridrich, V | 1 |
| Kang, HJ | 4 |
| Leiva-Pons, JL | 4 |
| Lewis, BS | 8 |
| Malaga, G | 2 |
| Meneveau, N | 1 |
| Milicic, D | 1 |
| Potpara, TS | 2 |
| Raev, D | 1 |
| Sabaté, M | 2 |
| de Waha-Thiele, S | 1 |
| Xavier, D | 4 |
| Deliargyris, EN | 1 |
| Rademaker-Havinga, T | 1 |
| Toyota, T | 3 |
| Ohya, M | 2 |
| Nanasato, M | 3 |
| Takamisawa, I | 2 |
| Doi, M | 2 |
| Noda, T | 2 |
| Seino, Y | 2 |
| Tada, T | 3 |
| Hanaoka, KI | 2 |
| Seagrave, KG | 1 |
| Fletcher, JP | 1 |
| Hitos, K | 1 |
| Hardung, D | 1 |
| Behne, A | 1 |
| Langhoff, R | 1 |
| Lewis, J | 1 |
| Bethishou, L | 1 |
| Tsu, LV | 1 |
| Chowdhary, S | 1 |
| Eitel, I | 1 |
| Zweiker, R | 2 |
| Ong, P | 1 |
| Ottesen, MM | 1 |
| Tijssen, JGP | 3 |
| Carrie, D | 6 |
| Sheng, Z | 1 |
| Tan, Y | 1 |
| Zhou, P | 1 |
| Zhou, J | 3 |
| Chen, R | 1 |
| Song, L | 1 |
| Zhao, H | 1 |
| Yan, H | 2 |
| Katzman, BM | 1 |
| Wockenfus, AM | 1 |
| Scott, RJ | 1 |
| Bryant, SC | 1 |
| Jaffe, AS | 1 |
| Karon, BS | 2 |
| Hesterberg, K | 1 |
| Rawal, A | 1 |
| Khan, S | 1 |
| Rashid, A | 1 |
| Jones, D | 1 |
| Siddiqui, T | 1 |
| Khader, TA | 1 |
| Nayyar, M | 1 |
| Shah, R | 5 |
| Wu, Q | 2 |
| Leung, EL | 1 |
| Jacobson, B | 1 |
| Rambiritch, V | 1 |
| Paek, D | 2 |
| Sayre, T | 1 |
| Naidoo, P | 1 |
| Shan, J | 1 |
| Leisegang, R | 1 |
| Wernly, B | 2 |
| Rezar, R | 1 |
| Jung, C | 3 |
| Kerkmeijer, L | 1 |
| Moccetti, T | 1 |
| Talwar, S | 1 |
| Maillard, L | 4 |
| Barlis, P | 1 |
| Wykrzykowska, J | 2 |
| Kan, I | 1 |
| Ishibashi, T | 1 |
| Sakuta, K | 1 |
| Fujimura, S | 1 |
| Yuki, I | 2 |
| Kaku, S | 1 |
| Kodama, T | 1 |
| Kato, N | 1 |
| Nishimura, K | 1 |
| Aoki, K | 1 |
| Sasaki, Y | 1 |
| Karagiozov, K | 1 |
| Murayama, Y | 2 |
| De Backer, O | 2 |
| Jilaihawi, H | 1 |
| Leipsic, JA | 1 |
| Terkelsen, CJ | 1 |
| Makkar, R | 1 |
| Kini, AS | 4 |
| Veien, KT | 1 |
| Abdel-Wahab, M | 1 |
| Kim, WK | 1 |
| Balan, P | 1 |
| Van Mieghem, N | 1 |
| Mathiassen, ON | 1 |
| Jeger, RV | 3 |
| Arnold, M | 1 |
| Guimarães, AHC | 2 |
| Nørgaard, BL | 1 |
| Kofoed, KF | 1 |
| Blanke, P | 1 |
| Søndergaard, L | 2 |
| Gilard, M | 5 |
| Möllmann, H | 1 |
| Herrmann, HC | 1 |
| Baldus, S | 1 |
| Gullestad, L | 1 |
| Kini, A | 3 |
| von Lewinski, D | 1 |
| Mack, M | 2 |
| Moreno, R | 1 |
| Schäfer, U | 1 |
| Seeger, J | 1 |
| Tchétché, D | 1 |
| Thomitzek, K | 1 |
| Wildgoose, P | 1 |
| Volkl, AA | 1 |
| Zazula, A | 1 |
| van Amsterdam, RGM | 1 |
| Childers, C | 1 |
| Kitazono, T | 1 |
| Sekine, T | 1 |
| Shiosakai, K | 1 |
| Iizuka, T | 1 |
| Jung, M | 1 |
| Lee, S | 4 |
| de Veer, A | 2 |
| Oldgren, J | 7 |
| Zateyshchikov, DA | 1 |
| Jansky, P | 3 |
| Hohnloser, SH | 8 |
| Nordaby, M | 6 |
| Kleine, E | 4 |
| Cannon, CP | 15 |
| Maeng, M | 4 |
| Miede, C | 3 |
| Alexopoulos, D | 4 |
| Mpahara, A | 2 |
| Kassimis, G | 1 |
| Liagkos, G | 1 |
| Spyropoulos, C | 1 |
| Chouliaras, C | 1 |
| Tsourouflis, G | 1 |
| Kouraklis, G | 1 |
| Vagianos, CE | 1 |
| Qu, B | 1 |
| He, Y | 2 |
| Wu, L | 1 |
| Lu, H | 1 |
| Liao, YWB | 1 |
| Wang, TKM | 1 |
| Zhang, F | 2 |
| Zheng, M | 2 |
| Cao, R | 1 |
| Dai, Y | 1 |
| Yao, K | 1 |
| Paciaroni, M | 1 |
| Ince, B | 1 |
| Hu, B | 2 |
| Jeng, JS | 1 |
| Kutluk, K | 1 |
| Lou, M | 1 |
| Parfenov, V | 1 |
| Wong, KSL | 3 |
| Zamani, B | 1 |
| Min Han, J | 1 |
| Del Aguila, M | 1 |
| Aimo, A | 2 |
| García-Ropero, Á | 1 |
| Vargas-Delgado, AP | 1 |
| Santos-Gallego, CG | 1 |
| Badimon, JJ | 1 |
| Faggioni, M | 4 |
| Crowley, A | 1 |
| Farhan, S | 4 |
| Mastoris, I | 2 |
| Maehara, A | 4 |
| Généreux, P | 7 |
| Ben-Yehuda, O | 4 |
| Kirtane, AJ | 12 |
| Zuo, Z | 1 |
| You, J | 1 |
| Guo, W | 1 |
| Gao, L | 1 |
| Geng, L | 2 |
| Wan, Q | 1 |
| Raco, DL | 1 |
| Aung, K | 1 |
| Htay, T | 1 |
| Martí, D | 1 |
| Carballeira, D | 1 |
| Morales, MJ | 1 |
| Concepción, R | 1 |
| Del Castillo, H | 1 |
| Marschall, A | 1 |
| Delgado-Calva, FA | 1 |
| Dejuán-Bitriá, C | 1 |
| Pérez-Guzmán, J | 1 |
| López-Soberón, E | 1 |
| Palazuelos, J | 1 |
| Álvarez-Antón, S | 1 |
| Limsakun, T | 1 |
| Dishy, V | 1 |
| Mendell, J | 1 |
| Pizzagalli, F | 1 |
| Pav, J | 1 |
| Kochan, J | 1 |
| Vandell, AG | 1 |
| Rambaran, C | 1 |
| Kobayashi, F | 1 |
| Orihashi, Y | 1 |
| Warren, V | 1 |
| McPhillips, P | 1 |
| Ravach, G | 1 |
| Fournier, S | 1 |
| Mazzolai, L | 2 |
| Nanchen, D | 1 |
| Ditali, V | 1 |
| Carrozzi, C | 1 |
| Tamburino, C | 2 |
| Gowda, SN | 1 |
| Bell, M | 1 |
| Jahraus, M | 1 |
| Fanciullo, J | 1 |
| Benetou, DR | 1 |
| Varlamos, C | 1 |
| Pande, SD | 1 |
| Win, MM | 1 |
| Khine, AA | 1 |
| Zaw, EM | 1 |
| Manoharraj, N | 1 |
| Lolong, L | 1 |
| Tin, AS | 1 |
| Fanelli, F | 1 |
| Diao, L | 1 |
| Pap, AF | 3 |
| Kittelson, JM | 1 |
| Mátyás, L | 2 |
| Krievins, DK | 1 |
| Brodmann, M | 1 |
| Hiatt, WR | 3 |
| Wojdyla, D | 1 |
| Cainzos-Achirica, M | 1 |
| Miedema, MD | 4 |
| McEvoy, JW | 3 |
| Al Rifai, M | 1 |
| Greenland, P | 2 |
| Dardari, Z | 1 |
| Budoff, M | 1 |
| Blumenthal, RS | 2 |
| Yeboah, J | 1 |
| Duprez, DA | 2 |
| Mortensen, MB | 1 |
| Dzaye, O | 1 |
| Hong, J | 1 |
| Nasir, K | 2 |
| Blaha, MJ | 2 |
| Shoji, S | 1 |
| Sawano, M | 1 |
| Sandhu, AT | 1 |
| Heidenreich, PA | 2 |
| Shiraishi, Y | 1 |
| Ikemura, N | 1 |
| Suzuki, M | 1 |
| Numasawa, Y | 1 |
| Oldroyd, KG | 1 |
| Ya-Ling, H | 2 |
| Berry, NC | 1 |
| Mauri, L | 16 |
| Kubicek, P | 1 |
| Boughalem, E | 1 |
| Frere, C | 3 |
| Kim, W | 1 |
| Choi, BG | 1 |
| Jang, WY | 1 |
| Kang, DO | 2 |
| Park, Y | 4 |
| Choi, JY | 1 |
| Roh, SY | 1 |
| Na, JO | 1 |
| Choi, CU | 1 |
| Kim, EJ | 1 |
| Park, CG | 1 |
| Seo, HS | 1 |
| Choi, SY | 3 |
| Byun, JK | 1 |
| Cha, J | 1 |
| Oh, DJ | 1 |
| Gajanana, D | 2 |
| Rogers, T | 3 |
| Weintraub, WS | 4 |
| Kolm, P | 1 |
| Iantorno, M | 2 |
| Khalid, N | 1 |
| Shlofmitz, E | 1 |
| Khan, JM | 1 |
| Musallam, A | 1 |
| Ben-Dor, I | 4 |
| Satler, LF | 5 |
| Torguson, R | 4 |
| Waksman, R | 6 |
| Piggott, C | 1 |
| Lyon, C | 1 |
| Guzik, TJ | 3 |
| Fox, KA | 21 |
| Liu, X | 3 |
| Zhang, D | 1 |
| Liu, F | 3 |
| Rayes, HA | 1 |
| Subat, YW | 2 |
| Weister, T | 2 |
| Johnson, MQ | 2 |
| Hanson, A | 1 |
| Schulte, PJ | 2 |
| Trivedi, V | 2 |
| Gajic, O | 2 |
| Warner, MA | 3 |
| Moroni, F | 1 |
| Gallone, G | 1 |
| Pagnesi, M | 1 |
| Venuti, A | 1 |
| Beneduce, A | 1 |
| Calvo, F | 1 |
| Gramegna, M | 1 |
| Cappelletti, AM | 1 |
| Rayes, H | 1 |
| Hanson, AC | 1 |
| Evans, K | 1 |
| Jordan, F | 1 |
| Quinn, TJ | 1 |
| McGuinness, B | 1 |
| Passmore, P | 1 |
| Kelly, JP | 1 |
| Tudur Smith, C | 1 |
| Murphy, K | 2 |
| Devane, D | 1 |
| El Alaoui, MZ | 1 |
| Guy, A | 1 |
| Khalki, L | 1 |
| Limami, Y | 1 |
| Benomar, A | 1 |
| Zaid, N | 1 |
| Cherrah, Y | 1 |
| Mekhfi, H | 1 |
| Cadi, R | 1 |
| Zaid, Y | 1 |
| Shufelt, CL | 1 |
| Manson, JE | 3 |
| Dai, C | 1 |
| Fu, J | 1 |
| Filipescu, DC | 1 |
| Stefan, MG | 1 |
| Valeanu, L | 1 |
| Popescu, WM | 1 |
| Sanz-Sánchez, J | 1 |
| Cannata, F | 1 |
| Sturla, M | 1 |
| Panico, C | 1 |
| Regazzoli, D | 1 |
| Reimers, B | 2 |
| Condorelli, G | 2 |
| Ferrante, G | 2 |
| Fischman, D | 1 |
| Moroi, MK | 1 |
| Loloi, J | 1 |
| Songdej, N | 1 |
| Li, P | 2 |
| Ning, Y | 1 |
| Cai, P | 1 |
| Siddiqui, AD | 1 |
| Liu, EY | 1 |
| Hadley, M | 1 |
| Wu, F | 1 |
| Pan, S | 1 |
| Dixon, RAF | 1 |
| Magness, JW | 1 |
| Arnwine, C | 1 |
| Lockwood, K | 1 |
| Reinert, A | 1 |
| Synnott, PG | 1 |
| McQueen, RB | 1 |
| Ollendorf, DA | 1 |
| Campbell, JD | 1 |
| Pearson, SD | 1 |
| Patel, NJ | 1 |
| Baliga, RR | 1 |
| Ghazanfarpour, M | 1 |
| Sathyapalan, T | 1 |
| Banach, M | 2 |
| Jamialahmadi, T | 1 |
| Sahebkar, A | 1 |
| Verdoia, M | 3 |
| Khedi, E | 1 |
| Suryapranata, H | 4 |
| Said, A | 1 |
| Keeney, S | 1 |
| Matka, M | 1 |
| Hafeez, A | 1 |
| George, J | 1 |
| Halalau, A | 1 |
| Albay, CEQ | 1 |
| Leyson, FGD | 1 |
| Cheng, FC | 1 |
| Mohamed-Hussein, AAR | 1 |
| Aly, KME | 1 |
| Ibrahim, MAA | 1 |
| Yuan, D | 1 |
| Shi, X | 1 |
| Guo, L | 2 |
| Huang, Q | 1 |
| Yuan, Y | 1 |
| Cho, YH | 1 |
| Suh, Y | 1 |
| Cho, S | 2 |
| Jeon, DW | 3 |
| Yoo, SY | 1 |
| Hong, BK | 1 |
| Kwon, H | 1 |
| Nam, CM | 1 |
| O'Donoghue, ML | 2 |
| Murphy, SA | 9 |
| Sabatine, MS | 9 |
| Sulaica, EM | 1 |
| Asias-Dinh, BD | 1 |
| Wanat, MA | 1 |
| Birtcher, KK | 1 |
| Lewis, JP | 1 |
| Polekhina, G | 1 |
| Nelson, M | 1 |
| Shuldiner, AR | 1 |
| Krishnan, B | 1 |
| Prasad, GA | 1 |
| Madhan, B | 1 |
| Saravanan, R | 1 |
| Mote, NP | 1 |
| Akilesh, R | 1 |
| Weitz, JI | 9 |
| Tiemuerniyazi, X | 1 |
| Xu, F | 2 |
| Feng, W | 1 |
| Gryaznov, AA | 1 |
| Saeyeldin, A | 1 |
| Abdelbaky, M | 1 |
| Zafar, MA | 1 |
| Tanweer, M | 1 |
| Papanikolaou, D | 1 |
| Imran, M | 1 |
| Ziganshin, BA | 1 |
| Elefteriades, JA | 1 |
| Marone, EM | 1 |
| Rinaldi, LF | 1 |
| Chierico, S | 1 |
| Marazzi, G | 1 |
| Palmieri, P | 1 |
| Lovotti, M | 1 |
| Klersy, C | 1 |
| Chon, MK | 1 |
| Jung, SM | 1 |
| Hwang, KW | 1 |
| Chun, KJ | 2 |
| Fiala, C | 1 |
| Pasic, MD | 1 |
| Jing, Q | 1 |
| Wang, B | 1 |
| Qiao, S | 1 |
| Chen, S | 5 |
| Haac, BE | 1 |
| Manson, TT | 1 |
| Parascandolo, E | 1 |
| Eisen, A | 1 |
| van Klaveren, D | 2 |
| Niethammer, M | 1 |
| Fontos, G | 1 |
| Angioi, M | 1 |
| Ribeiro, VG | 1 |
| Barbato, E | 2 |
| Leandro, S | 1 |
| Verbeeck, J | 1 |
| Sharif, F | 2 |
| Bouget, J | 1 |
| Balusson, F | 1 |
| Viglino, D | 1 |
| Roy, PM | 1 |
| Pavageau, L | 1 |
| Oger, E | 2 |
| Benz, AP | 1 |
| Darmon, A | 2 |
| Elbez, Y | 2 |
| Abtan, J | 3 |
| Mas, JL | 4 |
| Cacoub, P | 3 |
| Billaut-Laden, I | 1 |
| Ducrocq, G | 2 |
| Ayoub, A | 1 |
| Ayinapudi, K | 1 |
| Al-Ogaili, A | 1 |
| Panhwar, MS | 1 |
| Dakkak, W | 1 |
| LeJemtel, T | 1 |
| Hodges, K | 1 |
| Mubashir, M | 1 |
| Insler, J | 1 |
| Estep, J | 1 |
| Hsich, E | 1 |
| Tong, M | 1 |
| Insler, S | 1 |
| Soltesz, E | 1 |
| Ray, A | 1 |
| Najmi, A | 1 |
| Khandelwal, G | 1 |
| Jhaj, R | 1 |
| Sadasivam, B | 1 |
| Santana, DC | 1 |
| Emara, AK | 1 |
| Orr, MN | 1 |
| Klika, AK | 3 |
| Higuera, CA | 3 |
| Krebs, VE | 1 |
| Molloy, RM | 1 |
| Piuzzi, NS | 3 |
| Delewi, R | 2 |
| Holvoet, W | 1 |
| Dubois, CLF | 1 |
| Frambach, P | 1 |
| De Bruyne, B | 1 |
| van Houwelingen, GK | 1 |
| Van Der Heyden, JAS | 1 |
| Toušek, P | 1 |
| van der Kley, F | 1 |
| Buysschaert, I | 1 |
| Schotborgh, CE | 1 |
| van der Harst, P | 1 |
| Roosen, J | 1 |
| Thielen, FWF | 1 |
| Veenstra, L | 1 |
| Swaans, MJ | 1 |
| Rensing, BJWM | 1 |
| van 't Hof, AWJ | 1 |
| Timmers, L | 1 |
| Kelder, JC | 4 |
| Stella, PR | 2 |
| Baan, J | 2 |
| Conway, J | 1 |
| Friedman, BW | 1 |
| Dobesh, PP | 1 |
| Finks, SW | 1 |
| Trujillo, TC | 1 |
| Kataruka, A | 1 |
| Mahtta, D | 2 |
| Akeroyd, JM | 1 |
| Hira, RS | 1 |
| Kazi, DS | 2 |
| Spertus, JA | 4 |
| Petersen, LA | 1 |
| Ballantyne, CM | 1 |
| Virani, SS | 2 |
| Rhew, JY | 2 |
| Lim, YH | 1 |
| Bong, JM | 1 |
| Lee, BK | 2 |
| Sticchi, A | 1 |
| Verolino, G | 1 |
| Pasceri, V | 1 |
| Vizzi, V | 1 |
| Brscic, E | 1 |
| Casu, G | 1 |
| Golino, P | 1 |
| Russo, V | 1 |
| Rapacciuolo, A | 1 |
| Boccuzzi, G | 2 |
| Mangieri, A | 1 |
| Pagnotta, PA | 1 |
| Wetmore, JB | 1 |
| Roderick, P | 1 |
| Walker, R | 1 |
| Abhayaratna, WP | 4 |
| Gibbs, P | 3 |
| Mahady, SE | 2 |
| Williamson, JD | 4 |
| Donnan, GA | 6 |
| Cloud, GC | 1 |
| Polkinghorne, KR | 1 |
| Asad, ZUA | 1 |
| Elgendy, IY | 2 |
| Dong, Y | 2 |
| Ao, X | 1 |
| Fu, B | 1 |
| Dong, L | 1 |
| Masson, G | 1 |
| Lobo, M | 1 |
| Masson, W | 1 |
| Molinero, G | 1 |
| Yerasi, C | 3 |
| Case, BC | 3 |
| Forrestal, BJ | 2 |
| Garcia-Garcia, HM | 2 |
| Xiong, Y | 2 |
| Pavoni, V | 1 |
| Gianesello, L | 1 |
| Pazzi, M | 1 |
| Stera, C | 1 |
| Meconi, T | 1 |
| Frigieri, FC | 1 |
| Abdul Rahman, L | 1 |
| Turan, TN | 1 |
| Cotsonis, G | 1 |
| Almallouhi, E | 1 |
| Holmstedt, CA | 1 |
| Chimowitz, MI | 2 |
| Abola, MT | 1 |
| Verhamme, P | 5 |
| Bangdiwala, SI | 3 |
| Wang, LJ | 1 |
| Guimarães, HP | 1 |
| de Barros E Silva, PGM | 1 |
| Liporace, IL | 1 |
| Sampaio, RO | 2 |
| Tarasoutchi, F | 2 |
| Paixão, M | 1 |
| Hoffmann-Filho, CR | 1 |
| Patriota, R | 1 |
| Leiria, TLL | 1 |
| Lamprea, D | 1 |
| Precoma, DB | 1 |
| Atik, FA | 1 |
| Farias, FR | 1 |
| Barreto, DO | 1 |
| Almeida, AP | 1 |
| Zilli, AC | 1 |
| de Souza Neto, JD | 1 |
| Cavalcante, MA | 1 |
| Figueira, FAMS | 1 |
| Junior, RA | 1 |
| Moisés, VA | 1 |
| Mesas, CE | 1 |
| Ardito, RV | 1 |
| Kalil, PSA | 1 |
| Paiva, MSMO | 1 |
| Maldonado, JGA | 1 |
| de Lima, CEB | 1 |
| D'Oliveira Vieira, R | 1 |
| Laranjeira, L | 1 |
| Kojima, F | 1 |
| Damiani, L | 1 |
| Nakagawa, RH | 1 |
| Dos Santos, JRY | 1 |
| Sampaio, BS | 1 |
| Campos, VB | 1 |
| Saraiva, JFK | 1 |
| Fonseca, FH | 1 |
| Pinto, IM | 1 |
| Magalhães, CC | 1 |
| Ferreira, JFM | 1 |
| Pavanello, R | 1 |
| Cavalcanti, AB | 1 |
| Thury, A | 2 |
| Walsh, S | 2 |
| Cotton, J | 1 |
| Steinwender, C | 1 |
| Leibundgut, G | 1 |
| Singletary, EM | 3 |
| Zideman, DA | 3 |
| Bendall, JC | 1 |
| Berry, DC | 1 |
| Borra, V | 1 |
| Carlson, JN | 1 |
| Cassan, P | 1 |
| Chang, WT | 2 |
| Charlton, NP | 2 |
| Djärv, T | 1 |
| Douma, MJ | 1 |
| Epstein, JL | 2 |
| Hood, NA | 2 |
| Markenson, DS | 2 |
| Meyran, D | 1 |
| Orkin, AM | 1 |
| Sakamoto, T | 1 |
| Swain, JM | 3 |
| Woodin, JA | 2 |
| You, SC | 1 |
| Rho, Y | 1 |
| Bikdeli, B | 1 |
| Kim, J | 1 |
| Siapos, A | 1 |
| Weaver, J | 1 |
| Londhe, A | 1 |
| Cho, J | 1 |
| Park, J | 1 |
| Schuemie, M | 1 |
| Suchard, MA | 1 |
| Madigan, D | 1 |
| Hripcsak, G | 1 |
| Gupta, A | 1 |
| Reich, CG | 1 |
| Ryan, PB | 1 |
| Park, RW | 1 |
| Krumholz, HM | 1 |
| Ajufo, E | 1 |
| Ayers, CR | 1 |
| Vigen, R | 1 |
| Joshi, PH | 1 |
| Rohatgi, A | 1 |
| de Lemos, JA | 3 |
| Khera, A | 1 |
| Tran, PHL | 1 |
| Lee, BJ | 1 |
| Tran, TTD | 1 |
| Xie, J | 2 |
| Yuan, B | 1 |
| Guo, Y | 2 |
| Wang, PH | 1 |
| Wu, J | 2 |
| Zhang, S | 3 |
| Yuan, J | 2 |
| Miao, X | 1 |
| Lin, X | 2 |
| Shi, Z | 1 |
| Kinoshita, Y | 1 |
| Hioki, H | 1 |
| Yamaguchi, J | 2 |
| Shiode, N | 1 |
| Hirohata, A | 1 |
| Sonoda, S | 1 |
| Kargiotis, O | 1 |
| Nguyen, KA | 1 |
| Eadon, MT | 1 |
| Yoo, R | 1 |
| Milway, E | 1 |
| Kenneally, A | 1 |
| Fekete, K | 1 |
| Oh, H | 1 |
| Duong, K | 1 |
| Whipple, EC | 1 |
| Schleyer, TK | 1 |
| Dasa, O | 1 |
| Pearson, TA | 3 |
| Diep, R | 1 |
| Garcia, D | 2 |
| Wang, HY | 1 |
| Cai, ZX | 1 |
| Yang, YJ | 1 |
| Song, WH | 1 |
| Dou, KF | 1 |
| Le, G | 1 |
| Yang, C | 4 |
| Zhang, M | 1 |
| Xi, L | 1 |
| Luo, H | 1 |
| Tang, J | 1 |
| Zhao, J | 3 |
| Belcher, A | 1 |
| Zulfiker, AHM | 1 |
| Li, OQ | 1 |
| Yue, H | 1 |
| Gupta, AS | 1 |
| Li, W | 2 |
| Ou, Z | 1 |
| Ouyang, F | 1 |
| Jiang, Z | 2 |
| Chen, C | 2 |
| Wei, J | 1 |
| Zeng, J | 2 |
| Kesarwani, M | 1 |
| Wieruszewski, PM | 1 |
| Scott, R | 1 |
| Greason, KL | 1 |
| Hu, N | 1 |
| Sakai, T | 1 |
| Aokage, K | 1 |
| Katsumata, S | 1 |
| Tane, K | 1 |
| Miyoshi, T | 1 |
| Tsuboi, M | 1 |
| Toleva, O | 1 |
| Yanagawa, B | 1 |
| Verma, S | 4 |
| Schofield, JR | 1 |
| Hughes, HN | 1 |
| Birlea, M | 1 |
| Hassell, KL | 1 |
| Wiebe, J | 1 |
| Lahmann, AL | 2 |
| Kuna, C | 1 |
| Voll, F | 1 |
| Gosetti, R | 1 |
| Bettiol, A | 1 |
| Avagliano, L | 1 |
| Lombardi, N | 1 |
| Crescioli, G | 1 |
| Emmi, G | 1 |
| Urban, ML | 1 |
| Virgili, G | 1 |
| Ravaldi, C | 1 |
| Vannacci, A | 1 |
| Zghouzi, M | 1 |
| Ahmad, B | 1 |
| Biswas, S | 1 |
| Zaher, N | 1 |
| Sattar, Y | 1 |
| Pacha, HM | 1 |
| Goldsweig, AM | 1 |
| Velagapudi, P | 1 |
| Fichman, DL | 1 |
| Prasad, A | 1 |
| Davis, KAS | 1 |
| Bishara, D | 1 |
| Molokhia, M | 1 |
| Mueller, C | 1 |
| Perera, G | 1 |
| Stewart, RJ | 1 |
| Major, RW | 3 |
| Burton, JO | 2 |
| Magnani, G | 6 |
| Ardissino, D | 8 |
| Im, K | 2 |
| Cohen, M | 10 |
| Oude Ophius, T | 1 |
| Goudev, A | 1 |
| Kamensky, G | 2 |
| López-Sendón, J | 7 |
| Johanson, P | 2 |
| Braunwald, E | 18 |
| Attard, C | 2 |
| Monagle, PT | 1 |
| d'Udekem, Y | 2 |
| Mackay, MT | 1 |
| Briody, J | 1 |
| Cordina, R | 1 |
| Hassan, EB | 1 |
| Simm, P | 1 |
| Rice, K | 1 |
| Ignjatovic, V | 1 |
| Wang, S | 2 |
| Wang, L | 1 |
| Guan, Y | 1 |
| Edwards, R | 1 |
| Puri, R | 1 |
| Kalra, A | 1 |
| Zaman, A | 3 |
| Das, R | 1 |
| Liou, CW | 1 |
| Wong, LKS | 1 |
| Grauer, C | 2 |
| Brueckmann, M | 4 |
| Taniguchi, A | 1 |
| Urano, Y | 1 |
| Tefferi, A | 5 |
| Szuber, N | 1 |
| Pardanani, A | 2 |
| Hanson, CA | 2 |
| Vannucchi, AM | 3 |
| Barbui, T | 6 |
| Gangat, N | 2 |
| Ge, Z | 2 |
| Gao, XF | 1 |
| Kan, J | 1 |
| Kong, XQ | 1 |
| Zuo, GF | 1 |
| Ye, F | 1 |
| Tian, NL | 1 |
| Lin, S | 1 |
| Liu, ZZ | 1 |
| Shao, YB | 1 |
| He, YQ | 1 |
| Wen, SY | 1 |
| Xia, Y | 1 |
| Wang, ZZ | 1 |
| Xiao, PX | 1 |
| Li, F | 1 |
| Zeng, HS | 1 |
| Gao, DS | 1 |
| Qu, H | 1 |
| Qian, XS | 1 |
| Zhang, JJ | 1 |
| Kaikita, K | 3 |
| Matoba, T | 1 |
| Miyauchi, K | 1 |
| Hagiwara, N | 3 |
| Hirayama, A | 1 |
| Matsui, K | 1 |
| Ogawa, H | 6 |
| Tong, S | 1 |
| Walker, S | 1 |
| Cluver, C | 1 |
| Hastie, R | 1 |
| Clarkson, SA | 1 |
| Heindl, B | 1 |
| Cai, A | 1 |
| Beasley, M | 1 |
| Dillon, C | 1 |
| Limdi, N | 1 |
| Brown, TM | 1 |
| Costa, G | 1 |
| Gonçalves, L | 1 |
| Teixeira, R | 1 |
| Surianarayanan, V | 1 |
| Hoather, TJ | 1 |
| Tingle, SJ | 1 |
| Thompson, ER | 1 |
| Hanley, J | 1 |
| Wilson, CH | 1 |
| Sanchez, F | 1 |
| Boasi, V | 1 |
| Vercellino, M | 1 |
| Tacchi, C | 1 |
| Cannarile, P | 1 |
| Pingelli, N | 1 |
| Perri, D | 1 |
| Gomez, L | 1 |
| Cattunar, S | 1 |
| Mascelli, G | 1 |
| Mintz, GS | 1 |
| Jin, J | 1 |
| Zhuo, X | 1 |
| Xiao, M | 1 |
| Chen, L | 2 |
| Devi Shamloll, Y | 1 |
| Witte, KK | 1 |
| Reynolds, MR | 1 |
| Tsintzos, SI | 1 |
| Eggington, S | 1 |
| Ismyrloglou, E | 1 |
| Lyon, J | 1 |
| Huynh, M | 1 |
| Egea, M | 1 |
| de Brouwer, B | 1 |
| Ziegler, PD | 1 |
| Franco, N | 1 |
| Joglekar, R | 1 |
| Rosemas, SC | 1 |
| Thijs, V | 2 |
| Tanner, R | 1 |
| Cronin, M | 1 |
| Macken, L | 1 |
| Murphy, R | 1 |
| Maree, AO | 2 |
| Ullah, I | 1 |
| Cosgrave, J | 2 |
| O'Connor, S | 1 |
| Daly, C | 1 |
| Wu, VC | 1 |
| Wang, CL | 1 |
| Huang, YT | 1 |
| Tu, HT | 1 |
| Kuo, CF | 1 |
| Chen, SW | 2 |
| Wen, MS | 1 |
| Kuo, CC | 1 |
| Chang, SH | 1 |
| Kong, X | 2 |
| Decamillo, D | 1 |
| Shankar, SR | 1 |
| Jain, V | 1 |
| Aggarwal, D | 1 |
| Vaduganathan, M | 2 |
| Arora, S | 1 |
| Hussain, Z | 1 |
| Uberoi, G | 1 |
| Tafur, A | 1 |
| Ricciardi, M | 1 |
| Qamar, A | 2 |
| Zitikyte, G | 1 |
| Roy, DC | 1 |
| Dhaliwal, S | 1 |
| Lun, R | 1 |
| Hutton, B | 1 |
| Shorr, R | 1 |
| Dowlatshahi, D | 1 |
| Pencina, MJ | 2 |
| Crenshaw, DL | 1 |
| Re, RN | 1 |
| Handberg, EM | 1 |
| Manning, BR | 1 |
| Riley, D | 1 |
| Goldberg, YH | 1 |
| Roger, VL | 1 |
| Hess, R | 1 |
| Ford, DE | 1 |
| Haynes, K | 2 |
| VanWormer, JJ | 1 |
| Kraschnewski, JL | 1 |
| Fintel, DJ | 1 |
| McClay, JC | 1 |
| Campbell, JR | 1 |
| Bell, DS | 1 |
| Fonarow, GC | 3 |
| Paranjape, A | 1 |
| Sharlow, AG | 1 |
| Berdan, LG | 1 |
| Qualls, LG | 1 |
| Modrow, MF | 1 |
| Marcus, GM | 1 |
| Carton, TW | 1 |
| Nauman, E | 1 |
| Waitman, LR | 1 |
| Kho, AN | 1 |
| Shenkman, EA | 1 |
| McTigue, KM | 1 |
| Kaushal, R | 1 |
| Masoudi, FA | 1 |
| Antman, EM | 11 |
| Davidson, DR | 1 |
| Edgley, K | 1 |
| Merritt, JG | 1 |
| Brown, LS | 1 |
| Zemon, DN | 1 |
| McCormick, TE | 1 |
| Alikhaani, JD | 1 |
| Gregoire, KC | 1 |
| Kozieł, M | 1 |
| Song, PS | 1 |
| Bhurwal, A | 1 |
| Mutneja, H | 1 |
| Goel, A | 1 |
| Bansal, V | 1 |
| Brahmbhatt, B | 1 |
| Sarkar, A | 1 |
| Li, ZX | 1 |
| Gu, HQ | 1 |
| Fisher, M | 3 |
| Xian, Y | 2 |
| Wang, YJ | 2 |
| Knijnik, L | 2 |
| Fernandes, M | 1 |
| Rivera, M | 2 |
| Cardoso, R | 2 |
| Goyal, A | 1 |
| Liberman, H | 1 |
| Sperling, LS | 2 |
| McDaniel, MC | 1 |
| Lin, F | 1 |
| Mach, M | 1 |
| Watzal, V | 1 |
| Cuhaj, C | 1 |
| Hasan, W | 1 |
| Poschner, T | 1 |
| Szalkiewicz, P | 1 |
| Strouhal, A | 1 |
| Adlbrecht, C | 2 |
| Delle-Karth, G | 1 |
| Grabenwöger, M | 1 |
| Winkler, B | 1 |
| Guglielmelli, P | 1 |
| Al-Kali, A | 1 |
| Wolanskyj-Spinner, AP | 1 |
| Camoriano, J | 1 |
| Patnaik, MM | 1 |
| Thosani, N | 1 |
| Rashtak, S | 1 |
| Kannadath, BS | 1 |
| Munjal, A | 1 |
| Meriwether, M | 1 |
| Yoon, ED | 1 |
| Hermann, A | 1 |
| Ali, S | 1 |
| Haddad, PG | 1 |
| Patil, P | 1 |
| Ramireddy, S | 1 |
| Badillo, R | 1 |
| DaVee, RT | 1 |
| Guha, S | 1 |
| Zwicker, JI | 1 |
| Paranagama, D | 1 |
| Lessen, DS | 1 |
| Colucci, PM | 1 |
| Grunwald, MR | 1 |
| Vanassche, T | 2 |
| Christensen, MB | 1 |
| Jimenez-Solem, E | 1 |
| Ernst, MT | 1 |
| Schmidt, M | 1 |
| Grove, EL | 5 |
| Bahrani, S | 1 |
| Teimouri-Jervekani, Z | 1 |
| Sadeghi, M | 1 |
| Medranda, GA | 1 |
| Doros, G | 2 |
| Bristot, P | 1 |
| Goedel, A | 1 |
| Giacoppo, D | 3 |
| Sarafoff, N | 2 |
| Naguib, D | 3 |
| Helten, C | 3 |
| Zako, S | 1 |
| Mourikis, P | 1 |
| M'Pembele, R | 1 |
| Trojovsky, K | 1 |
| Ahlbrecht, S | 1 |
| Zikeli, D | 1 |
| Zeus, T | 6 |
| Kelm, M | 7 |
| Dannenberg, L | 4 |
| Polzin, A | 6 |
| Parker, WAE | 1 |
| Yu, L | 1 |
| Bai, H | 1 |
| Zhu, W | 1 |
| Liu, W | 1 |
| Sun, L | 2 |
| Yu, A | 1 |
| Huang, WY | 1 |
| Ovbiagele, B | 1 |
| Pallikadavath, S | 1 |
| Ashton, L | 1 |
| Brunskill, NJ | 2 |
| Gray, LJ | 2 |
| Ambler, GK | 1 |
| Nordanstig, J | 1 |
| Behrendt, CA | 1 |
| Twine, CP | 1 |
| Lensing, AWA | 2 |
| Prins, MH | 3 |
| Beyer-Westendorf, J | 3 |
| Bounameaux, H | 4 |
| Brighton, TA | 5 |
| Cohen, AT | 2 |
| Davidson, BL | 3 |
| Decousus, H | 1 |
| Freitas, MCS | 1 |
| Holberg, G | 2 |
| Kakkar, AK | 3 |
| Haskell, L | 3 |
| van Bellen, B | 2 |
| Wells, PS | 5 |
| Prandoni, P | 6 |
| Pehrsson, S | 1 |
| Johansson, KJ | 1 |
| Janefeldt, A | 1 |
| Sandinge, AS | 1 |
| Maqbool, S | 1 |
| Goodman, J | 1 |
| Sanchez, J | 1 |
| Almquist, J | 1 |
| Gennemark, P | 1 |
| Nylander, S | 2 |
| Povsic, TJ | 3 |
| White, J | 4 |
| Rockhold, F | 1 |
| Plotnikov, A | 1 |
| Strony, J | 1 |
| Sun, X | 1 |
| Husted, S | 8 |
| Tendera, M | 1 |
| Bueno, H | 1 |
| Claeys, MJ | 3 |
| Kiss, RG | 6 |
| Güray, Ü | 1 |
| Park, DW | 3 |
| Henry, TD | 9 |
| Ariti, C | 4 |
| Aquino, M | 5 |
| Chandrasekhar, J | 5 |
| Comarmond, C | 1 |
| Jego, P | 1 |
| Veyssier-Belot, C | 1 |
| Marie, I | 1 |
| Mekinian, A | 1 |
| Elmaleh-Sachs, A | 1 |
| Leroux, G | 1 |
| Saadoun, D | 1 |
| Oziol, E | 1 |
| Fraisse, T | 1 |
| Hyvernat, H | 1 |
| Thiercein-Legrand, MF | 1 |
| Sarrot-Reynauld, F | 1 |
| Ferreira-Maldent, N | 1 |
| de Menthon, M | 1 |
| Goujard, C | 1 |
| Khau, D | 1 |
| Nguen, Y | 1 |
| Monnier, S | 1 |
| Michon, A | 1 |
| Castel, B | 1 |
| Decaux, O | 1 |
| Piette, JC | 1 |
| Lee, SI | 1 |
| Lee, KS | 1 |
| Kim, JB | 1 |
| Choo, SJ | 1 |
| Jung, SH | 1 |
| Boyina, KK | 1 |
| Nakkana, G | 1 |
| Murthy, VV | 1 |
| Melkonian, M | 1 |
| Jarzebowski, W | 1 |
| Pautas, E | 1 |
| Siguret, V | 1 |
| Belmin, J | 1 |
| Lafuente-Lafuente, C | 1 |
| Huynh, K | 1 |
| Mahmoud, AN | 1 |
| Elgendy, AY | 1 |
| Rambarat, C | 1 |
| Bavry, AA | 2 |
| Lindholm, D | 1 |
| Hagström, E | 2 |
| Becker, RC | 9 |
| Katus, HA | 4 |
| Maurer, G | 2 |
| López-Sendón, JL | 2 |
| Siegbahn, A | 3 |
| Wallentin, L | 13 |
| Qiao, M | 1 |
| Bi, Q | 1 |
| Fu, P | 1 |
| Song, Z | 1 |
| Guo, F | 1 |
| Oimatsu, Y | 1 |
| Ishii, M | 1 |
| Mitsuse, T | 1 |
| Ito, M | 1 |
| Arima, Y | 1 |
| Sueta, D | 1 |
| Takahashi, A | 1 |
| Iwashita, S | 1 |
| Yamamoto, E | 1 |
| Kojima, S | 1 |
| Hokimoto, S | 1 |
| Tsujita, K | 2 |
| Jang, HJ | 1 |
| Park, SD | 1 |
| Park, HW | 1 |
| Suh, J | 1 |
| Oh, PC | 2 |
| Moon, J | 1 |
| Kang, WC | 2 |
| Kwon, SW | 1 |
| Kim, TH | 2 |
| Kereiakes, DJ | 15 |
| Cutlip, DE | 11 |
| Massaro, JM | 9 |
| Apruzzese, PK | 3 |
| Pagnotta, P | 1 |
| Zwart, B | 1 |
| Deharo, P | 2 |
| Quilici, J | 5 |
| Deffarges, S | 1 |
| Bassez, C | 2 |
| Bonnet, G | 2 |
| Fourcade, L | 3 |
| Mouret, JP | 2 |
| Lambert, M | 3 |
| Verdier, V | 2 |
| Morange, PE | 5 |
| Alessi, MC | 5 |
| Bonnet, JL | 5 |
| Suen, K | 1 |
| Westh, RN | 1 |
| Churilov, L | 1 |
| Hardidge, AJ | 1 |
| Shavadia, J | 1 |
| Welsh, R | 1 |
| Gershlick, A | 1 |
| Van de Werf, F | 7 |
| Armstrong, PW | 8 |
| Rodés-Cabau, J | 4 |
| Masson, JB | 1 |
| Garcia Del Blanco, B | 1 |
| Pelletier, M | 1 |
| Webb, JG | 3 |
| Al-Qoofi, F | 1 |
| Maluenda, G | 3 |
| Thoenes, M | 1 |
| Paradis, JM | 1 |
| Chamandi, C | 1 |
| Serra, V | 1 |
| Dumont, E | 1 |
| Côté, M | 1 |
| Choi, HI | 1 |
| Ahn, JM | 2 |
| Kang, SH | 2 |
| Lee, PH | 1 |
| Kang, SJ | 2 |
| Lee, SW | 3 |
| Lee, CW | 2 |
| Park, SW | 2 |
| Park, SJ | 2 |
| Martin, AC | 2 |
| Houssany-Pissot, S | 1 |
| Zlotnik, D | 1 |
| Taylor, G | 2 |
| Godier, A | 3 |
| Hansson, EC | 1 |
| Jeppsson, A | 1 |
| Volpe, M | 1 |
| Battistoni, A | 1 |
| Gallo, G | 1 |
| Coluccia, R | 1 |
| Paravattil, B | 1 |
| Elewa, H | 1 |
| Bartlett, M | 1 |
| Mauck, KF | 1 |
| Bierle, DM | 1 |
| Saadiq, RA | 1 |
| Daniels, PR | 1 |
| Gargiulo, G | 3 |
| Santucci, A | 3 |
| Ariotti, S | 4 |
| Baldo, A | 2 |
| Moschovitis, A | 1 |
| Rojanaworarit, C | 1 |
| Limsawan, S | 1 |
| Sun, Q | 1 |
| Chang, S | 1 |
| Lu, S | 1 |
| Chang, Y | 2 |
| Hao, Y | 2 |
| Hao, Z | 2 |
| Geng, G | 1 |
| Han, W | 1 |
| Chen, Q | 1 |
| Wang, D | 5 |
| Jia, K | 1 |
| Buhatem Medeiros, F | 1 |
| Pepe Medeiros de Rezende, N | 1 |
| Bertoldi Franco, J | 1 |
| Porrio de Andrade, AC | 1 |
| Timerman, L | 1 |
| Gallottini, M | 1 |
| Itagiba Neves, IL | 1 |
| Ortega, KL | 1 |
| Geraghty, OC | 2 |
| Mehta, Z | 1 |
| Rothwell, PM | 2 |
| Sumner, JD | 1 |
| Zinser, B | 1 |
| Smith, A | 1 |
| Dunn, A | 1 |
| Tscharre, M | 1 |
| Egger, F | 2 |
| Machata, M | 1 |
| Rohla, M | 2 |
| Michael, N | 1 |
| Neumayr, M | 1 |
| Hajos, J | 1 |
| Suppan, M | 1 |
| Helmreich, W | 1 |
| Eber, B | 1 |
| Weiss, TW | 2 |
| Cafri, G | 1 |
| Paxton, EW | 1 |
| Cheetham, CT | 1 |
| Gould, MK | 1 |
| Sluggett, J | 1 |
| Bini, SA | 1 |
| Khatod, M | 1 |
| Gordon, RJ | 1 |
| Lombard, FW | 1 |
| Iijima, R | 2 |
| Shinke, T | 1 |
| Okada, H | 1 |
| Anzai, H | 1 |
| Tanaka, H | 2 |
| Ueda, Y | 1 |
| Takiuchi, S | 1 |
| Ohira, H | 1 |
| Kawaguchi, K | 1 |
| Kadotani, M | 1 |
| Niinuma, H | 1 |
| Omiya, K | 1 |
| Morita, T | 1 |
| Zen, K | 1 |
| Yasaka, Y | 2 |
| Inoue, K | 1 |
| Ishiwata, S | 1 |
| Ochiai, M | 1 |
| Hamasaki, T | 1 |
| Yokoi, H | 4 |
| Didier, R | 1 |
| Morice, MC | 4 |
| Barragan, P | 2 |
| Noryani, AAL | 2 |
| Noor, HA | 2 |
| Majwal, T | 2 |
| Castellant, P | 3 |
| Schneeberger, M | 2 |
| Bressolette, E | 2 |
| Wojcik, J | 2 |
| Delarche, N | 3 |
| Blanchard, D | 3 |
| Jouve, B | 2 |
| Ormezzano, O | 2 |
| Paganelli, F | 4 |
| Levy, G | 2 |
| Sainsous, J | 2 |
| Furber, A | 3 |
| Berlan, J | 1 |
| Darremont, O | 2 |
| Le Breton, H | 3 |
| Lyuycx-Bore, A | 2 |
| Gommeaux, A | 2 |
| Cassat, C | 2 |
| Kermarrec, A | 2 |
| Cazaux, P | 3 |
| Druelles, P | 3 |
| Dauphin, R | 2 |
| Armengaud, J | 2 |
| Dupouy, P | 3 |
| Champagnac, D | 2 |
| Ohlmann, P | 3 |
| Ben Amer, H | 1 |
| Ungi, I | 3 |
| Vlachakis, P | 1 |
| Lekakis, J | 1 |
| Helley, D | 1 |
| Yuan, C | 1 |
| Zhong, L | 1 |
| Huang, RC | 1 |
| Aunes, M | 1 |
| Albers, GW | 11 |
| Bokelund-Singh, S | 1 |
| Held, P | 7 |
| Jahreskog, M | 1 |
| Jonasson, J | 3 |
| Jiang, M | 2 |
| You, JHS | 1 |
| Amano, H | 1 |
| Saito, D | 1 |
| Yabe, T | 1 |
| Okubo, R | 1 |
| Toda, M | 1 |
| Ikeda, T | 2 |
| Jung, CW | 1 |
| Jeon, Y | 1 |
| Kim, TK | 1 |
| Koo, CH | 1 |
| Kim, KB | 1 |
| Hwang, HY | 1 |
| Kim, HR | 1 |
| Park, JY | 1 |
| Aceves-Velázquez, E | 1 |
| Vieyra-Herrera, G | 1 |
| Rodríguez-Chávez, L | 1 |
| Herrera-Alarcón, V | 1 |
| Karmali, KN | 1 |
| Huffman, MD | 1 |
| Stuckey, TD | 7 |
| Brodie, BR | 8 |
| Litherland, C | 2 |
| Rinaldi, MJ | 9 |
| Metzger, DC | 6 |
| Cox, DA | 8 |
| Duffy, PL | 6 |
| Mazzaferri, EL | 6 |
| Gurbel, PA | 8 |
| Simonton, CA | 1 |
| Harada, Y | 1 |
| Michel, J | 1 |
| Lohaus, R | 1 |
| Emmer, R | 1 |
| Colleran, R | 1 |
| Wolk, A | 1 |
| Seyfarth, M | 1 |
| Zrenner, B | 1 |
| Jacobshagen, C | 1 |
| Morath, T | 1 |
| Fischer, M | 1 |
| Mehilli, J | 2 |
| Byrne, RA | 4 |
| Schulz-Schüpke, S | 1 |
| Zheng, J | 1 |
| Xiang, Y | 1 |
| Jin, Y | 1 |
| Serebruany, V | 2 |
| Golukhova, E | 1 |
| Klok, FA | 2 |
| Huisman, MV | 3 |
| Rosenberg, K | 2 |
| Ellis, SG | 4 |
| Gropper, S | 1 |
| Harper, R | 1 |
| Manassie, J | 1 |
| Januzzi, JL | 1 |
| Lonn, EM | 1 |
| Piegas, LS | 1 |
| Probstfield, J | 1 |
| Lopez-Jaramillo, P | 2 |
| Parkhomenko, AN | 2 |
| Ertl, G | 1 |
| Störk, S | 2 |
| Keltai, M | 5 |
| Ryden, L | 2 |
| Pogosova, N | 2 |
| Dans, AL | 3 |
| Lanas, F | 4 |
| Commerford, PJ | 4 |
| Verhamme, PB | 1 |
| Felix, C | 2 |
| Yusoff, K | 2 |
| Metsarinne, KP | 2 |
| Misselwitz, F | 3 |
| Chen, E | 2 |
| Leong, D | 1 |
| Stylos, E | 1 |
| Chatziathanasiadou, MV | 1 |
| Tsiailanis, A | 1 |
| Kellici, TF | 1 |
| Tsoumani, M | 1 |
| Kostagianni, AD | 1 |
| Deligianni, M | 1 |
| Tselepis, AD | 2 |
| Tzakos, AG | 1 |
| Gozzo, L | 1 |
| Navarria, A | 1 |
| Benfatto, G | 1 |
| Longo, L | 1 |
| Mansueto, S | 1 |
| Sottosanti, L | 1 |
| Pani, L | 1 |
| Salomone, S | 1 |
| Drago, F | 1 |
| Benedetto, U | 3 |
| Moretti, C | 2 |
| D'Onofrio, A | 1 |
| Agrifoglio, M | 1 |
| Ribichini, F | 1 |
| Tarantini, G | 2 |
| D'Amico, M | 1 |
| Salizzoni, S | 1 |
| Rinaldi, M | 2 |
| Ponzetto, A | 1 |
| Figura, N | 1 |
| Feagins, LA | 1 |
| McDonald, MM | 1 |
| Almaghrabi, TS | 1 |
| Saenz, DM | 1 |
| Cai, C | 1 |
| Rahbar, MH | 1 |
| Choi, HA | 1 |
| Grotta, JC | 1 |
| Chang, TR | 1 |
| He, RX | 1 |
| Zhou, TN | 1 |
| Yuan, WJ | 1 |
| Liu, YJ | 1 |
| Fu, WX | 1 |
| Jing, QM | 2 |
| Liu, HW | 1 |
| Ahn, S | 1 |
| Min, SK | 1 |
| Ha, J | 1 |
| Min, SI | 1 |
| Cho, MJ | 1 |
| Gui, L | 1 |
| Zheng, H | 1 |
| Liu, LP | 1 |
| Wang, YL | 1 |
| Zhao, XQ | 1 |
| Yudi, MB | 2 |
| Farouque, O | 2 |
| Andrianopoulos, N | 2 |
| Ajani, AE | 2 |
| Brennan, A | 2 |
| Lefkovits, J | 2 |
| Chan, W | 2 |
| Duffy, SJ | 2 |
| Clark, DJ | 2 |
| Dinkova, AS | 1 |
| Atanasov, DT | 1 |
| Vladimirova-Kitova, LG | 1 |
| Prader, R | 1 |
| De Broca, B | 1 |
| Chevallier, D | 1 |
| Amiel, J | 1 |
| Durand, M | 1 |
| Casella, G | 1 |
| Resciniti, E | 1 |
| Gallo, P | 1 |
| Moon, JY | 1 |
| Qiu, J | 1 |
| Grine, K | 1 |
| Hawks, MK | 1 |
| Dixon, MA | 1 |
| Ahmad, T | 1 |
| Davies, R | 1 |
| Alagona, P | 1 |
| de Veer, AJWM | 1 |
| Bode, K | 1 |
| Mahmoodi, BK | 2 |
| Kuiper, GJAJM | 1 |
| Christiaans, MHL | 1 |
| Mullens, MHJM | 1 |
| Hamulýak, K | 1 |
| Henskens, YMC | 1 |
| Llau, JV | 1 |
| Kamphuisen, P | 1 |
| Albaladejo, P | 3 |
| Baos, S | 1 |
| Underwood, W | 1 |
| Culliford, L | 1 |
| Rogers, CA | 2 |
| Bowles, R | 1 |
| Johnson, T | 1 |
| Baumbach, A | 1 |
| Spartalis, M | 1 |
| Tzatzaki, E | 1 |
| Spartalis, E | 1 |
| Damaskos, C | 1 |
| Athanasiou, A | 1 |
| Moris, D | 1 |
| Politou, M | 1 |
| Graham, MM | 1 |
| Sessler, DI | 2 |
| Parlow, JL | 1 |
| Biccard, BM | 1 |
| Guyatt, G | 3 |
| Leslie, K | 2 |
| Chan, MTV | 3 |
| Meyhoff, CS | 2 |
| Sigamani, A | 1 |
| Kumar, PA | 1 |
| Mrkobrada, M | 3 |
| Cook, DJ | 1 |
| Tandon, V | 1 |
| Alvarez-Garcia, J | 1 |
| Villar, JC | 2 |
| Painter, TW | 1 |
| Landoni, G | 3 |
| Fleischmann, E | 2 |
| Lamy, A | 1 |
| Whitlock, R | 2 |
| Le Manach, Y | 1 |
| Aphang-Lam, M | 1 |
| Cata, JP | 2 |
| Terblanche, NCS | 1 |
| Ramana, PV | 1 |
| Jamieson, KA | 1 |
| Bessissow, A | 1 |
| Mendoza, GR | 1 |
| Ramirez, S | 1 |
| Diemunsch, PA | 1 |
| Devereaux, PJ | 6 |
| Dagenais, G | 1 |
| Metsarinne, K | 1 |
| Ha, JW | 1 |
| Avezum, AA | 2 |
| Lonn, E | 1 |
| Lisheng, L | 1 |
| Keltai, K | 2 |
| Varigos, JD | 2 |
| Branch, K | 1 |
| Zocca, P | 1 |
| van der Heijden, LC | 1 |
| Kok, MM | 1 |
| Löwik, MM | 1 |
| Hartmann, M | 1 |
| Stoel, MG | 1 |
| Louwerenburg, JW | 1 |
| de Man, FHAF | 1 |
| Linssen, GCM | 1 |
| Knottnerus, IL | 1 |
| Doggen, CJM | 1 |
| van Houwelingen, KG | 1 |
| von Birgelen, C | 1 |
| Borzak, S | 2 |
| Lazar, HL | 1 |
| Fluschnik, N | 1 |
| Becher, PM | 1 |
| Schnabel, R | 1 |
| Blankenberg, S | 1 |
| Westermann, D | 1 |
| Stähli, BE | 1 |
| Landmesser, U | 1 |
| Bellesini, M | 2 |
| Takeda, A | 1 |
| Donadini, MP | 3 |
| Robertson, L | 1 |
| Yeoh, SE | 1 |
| Ramli, A | 1 |
| Proietti, M | 3 |
| Camoin-Jau, L | 3 |
| Fernandez, M | 1 |
| Ibrahim, M | 1 |
| Suchon, P | 1 |
| Kounis, NG | 1 |
| Koniari, I | 1 |
| Tsigkas, G | 1 |
| Chourdakis, E | 1 |
| Roumeliotis, A | 1 |
| Patsouras, N | 1 |
| Soufras, G | 1 |
| Hahalis, G | 1 |
| Gaubert, M | 1 |
| Resseguier, N | 1 |
| Laine, M | 2 |
| Bonello, L | 4 |
| Beridze, M | 1 |
| Duley, L | 1 |
| Flaherty, K | 1 |
| Havard, D | 1 |
| Heptinstall, S | 2 |
| Markus, HS | 2 |
| Randall, M | 1 |
| Scutt, P | 1 |
| Venables, GS | 1 |
| Roberge, S | 1 |
| Bujold, E | 1 |
| Nicolaides, KH | 1 |
| Elmariah, S | 2 |
| Benavente, OR | 5 |
| Steinhubl, SR | 10 |
| Hsieh, WH | 3 |
| Ueland, T | 1 |
| Åkerblom, A | 2 |
| Ghukasyan, T | 1 |
| Michelsen, AE | 1 |
| Aukrust, P | 1 |
| Bertilsson, M | 1 |
| Kontny, F | 2 |
| Kruger, PC | 2 |
| Maksym, J | 1 |
| Mazurek, T | 2 |
| Kochman, J | 3 |
| Grygier, M | 2 |
| Kapłon-Cieślicka, A | 1 |
| Marchel, M | 1 |
| Lodziński, P | 1 |
| Piątkowski, R | 1 |
| Wilimski, R | 2 |
| Czub, P | 1 |
| Fojt, A | 1 |
| Karolczak, N | 1 |
| Hendzel, P | 1 |
| Weise, FK | 2 |
| Bordignon, S | 1 |
| Perrotta, L | 1 |
| Konstantinou, A | 1 |
| Bologna, F | 1 |
| Nagase, T | 1 |
| Chun, KRJ | 2 |
| Schmidt, B | 2 |
| Ju, J | 1 |
| Lu, F | 1 |
| Gao, R | 2 |
| Xu, H | 2 |
| Kopin, D | 1 |
| Sherwood, MW | 1 |
| Fujimoto, W | 1 |
| Sawada, T | 1 |
| Toba, T | 1 |
| Takahashi, Y | 1 |
| Miyata, T | 1 |
| Oishi, S | 1 |
| Osue, T | 1 |
| Onishi, T | 1 |
| Takaya, T | 1 |
| Shimane, A | 1 |
| Taniguchi, Y | 1 |
| Kawai, H | 1 |
| Labovitz, DL | 1 |
| Dhamoon, MS | 1 |
| Dugani, S | 1 |
| Ames, JM | 2 |
| Mora, S | 2 |
| Anderson, DR | 3 |
| Dunbar, M | 1 |
| Murnaghan, J | 1 |
| Kahn, SR | 2 |
| Gross, P | 2 |
| Forsythe, M | 1 |
| Pelet, S | 2 |
| Fisher, W | 2 |
| Belzile, E | 2 |
| Dolan, S | 1 |
| Crowther, M | 4 |
| Bohm, E | 1 |
| MacDonald, SJ | 1 |
| Gofton, W | 2 |
| Kim, P | 2 |
| Zukor, D | 2 |
| Pleasance, S | 2 |
| Andreou, P | 2 |
| Doucette, S | 1 |
| Theriault, C | 1 |
| Abianui, A | 1 |
| Kovacs, MJ | 1 |
| Rodger, MA | 3 |
| Coyle, D | 2 |
| Vendittoli, PA | 2 |
| Godschalk, TC | 1 |
| Gimbel, ME | 1 |
| Nolet, WW | 1 |
| van Kessel, DJ | 1 |
| Amoroso, G | 1 |
| Dewilde, WJ | 2 |
| Janssen, PW | 1 |
| Bergmeijer, TO | 1 |
| Heestermans, T | 1 |
| Je, NK | 1 |
| Su, G | 1 |
| Yuan, Z | 3 |
| Feldberg, J | 1 |
| Patel, P | 2 |
| Farrell, A | 1 |
| Sivarajahkumar, S | 1 |
| Cameron, K | 1 |
| Ma, J | 1 |
| Battistella, M | 1 |
| Pöhl, M | 2 |
| Ayhan, A | 1 |
| Hohlfeld, T | 2 |
| Levkau, B | 1 |
| Box, HN | 1 |
| Shahrestani, S | 1 |
| Huo, MH | 1 |
| Raheja, H | 1 |
| Garg, A | 1 |
| Goel, S | 1 |
| Banerjee, K | 1 |
| Hollander, G | 1 |
| Shani, J | 1 |
| Mick, S | 1 |
| Krishnaswamy, A | 1 |
| Kapadia, S | 1 |
| Wolff, G | 1 |
| Brockmeyer, M | 1 |
| Karathanos, A | 1 |
| Kołodziejczak, M | 2 |
| Kubica, J | 1 |
| Westenfeld, R | 1 |
| Schulze, V | 2 |
| Jaff, M | 2 |
| Nwachuku, C | 1 |
| Tangelder, M | 1 |
| Ansel, G | 2 |
| Adams, G | 2 |
| Zeller, T | 1 |
| Rundback, J | 1 |
| Grosso, M | 2 |
| Lin, M | 1 |
| Mercur, MF | 1 |
| Minar, E | 5 |
| Chi, G | 1 |
| Jamil, A | 1 |
| Radulovic, M | 1 |
| Jamil, U | 1 |
| Balouch, MA | 1 |
| Marszalek, J | 1 |
| Karimi, Z | 1 |
| Pahlavani, S | 1 |
| Jafarizade, M | 1 |
| Shaukat, H | 1 |
| Kumar, S | 1 |
| Kalayci, A | 1 |
| Zhao, G | 1 |
| Zhou, M | 2 |
| Ma, C | 1 |
| Huo, Y | 1 |
| Smith, SC | 2 |
| Taubert, KA | 1 |
| Morgan, L | 1 |
| Zhao, D | 1 |
| Mant, J | 1 |
| Faour, M | 2 |
| Brigati, DP | 2 |
| Mont, MA | 2 |
| Barsoum, WK | 2 |
| May, J | 1 |
| Xu, Z | 1 |
| Cheng, Z | 1 |
| Mei, J | 1 |
| Arioli, D | 1 |
| Donelli, D | 1 |
| Morini, L | 1 |
| Leone, MC | 1 |
| Negri, EA | 1 |
| Boyce, ML | 1 |
| Zayac, A | 1 |
| Davis, A | 1 |
| Badrick, T | 1 |
| Anoopkumar-Dukie, S | 1 |
| Bernaitis, N | 1 |
| Farrant, M | 3 |
| Barsan, W | 2 |
| Conwit, RA | 1 |
| Elm, JJ | 3 |
| Kim, AS | 3 |
| Lindblad, AS | 3 |
| Palesch, YY | 3 |
| Swaminathan, B | 1 |
| Lavados, P | 1 |
| Davalos, A | 1 |
| Shamalov, N | 1 |
| Mikulik, R | 1 |
| Cunha, L | 3 |
| Lindgren, A | 1 |
| Arauz, A | 1 |
| Lang, W | 1 |
| Gagliardi, RJ | 1 |
| Ameriso, SF | 1 |
| Tatlisumak, T | 1 |
| Veltkamp, R | 1 |
| Toni, D | 3 |
| Yoon, BW | 2 |
| Brouns, R | 1 |
| Muir, KW | 1 |
| Bornstein, N | 2 |
| Ozturk, S | 1 |
| O'Donnell, MJ | 1 |
| De Vries Basson, MM | 1 |
| Pare, G | 1 |
| Pater, C | 1 |
| Sheridan, P | 1 |
| Peters, G | 2 |
| Peacock, WF | 1 |
| Shoamanesh, A | 1 |
| Joyner, C | 3 |
| Themeles, E | 1 |
| Gibler, WB | 2 |
| Gulizia, MM | 1 |
| Colivicchi, F | 1 |
| Abrignani, MG | 1 |
| Ambrosetti, M | 1 |
| Aspromonte, N | 2 |
| Barile, G | 1 |
| Caporale, R | 1 |
| Casolo, G | 1 |
| Chiuini, E | 1 |
| Di Lenarda, A | 1 |
| Faggiano, P | 1 |
| Gabrielli, D | 1 |
| Geraci, G | 1 |
| La Manna, AG | 1 |
| Marchese, A | 1 |
| Massari, FM | 1 |
| Mureddu, GF | 1 |
| Nardi, F | 1 |
| Panno, AV | 1 |
| Pedretti, RFE | 1 |
| Piredda, M | 1 |
| Pusineri, E | 1 |
| Riccio, C | 1 |
| Scotto Di Uccio, F | 1 |
| Urbinati, S | 1 |
| Varbella, F | 2 |
| Zito, GB | 1 |
| Ding, L | 2 |
| Peng, B | 1 |
| Kalantzi, KI | 1 |
| Ntalas, IV | 1 |
| Chantzichristos, VG | 1 |
| Tsoumani, ME | 1 |
| Adamopoulos, D | 1 |
| Asimakopoulos, C | 1 |
| Bourdakis, A | 1 |
| Darmanis, P | 1 |
| Dimitriadou, A | 1 |
| Gkiokas, S | 1 |
| Ipeirotis, K | 1 |
| Kitikidou, K | 1 |
| Klonaris, I | 1 |
| Kostaki, A | 1 |
| Logothetis, D | 1 |
| Mainas, K | 1 |
| Mais, T | 1 |
| Maragiannis, A | 1 |
| Martiadou, K | 1 |
| Mavronasos, K | 1 |
| Michelongonas, I | 1 |
| Mitropoulos, D | 1 |
| Papadimitriou, G | 1 |
| Papadopoulos, A | 1 |
| Papaioakeim, M | 1 |
| Sofillas, K | 1 |
| Stabola, S | 1 |
| Stefanakis, E | 1 |
| Stergiou, D | 1 |
| Thoma, M | 1 |
| Zenetos, A | 1 |
| Zisekas, S | 1 |
| Goudevenos, JA | 1 |
| Panagiotakos, DB | 1 |
| Tang, QJ | 1 |
| Lei, HP | 1 |
| Chen, JY | 1 |
| Deng, CY | 1 |
| Sheng, WS | 1 |
| Fu, YH | 1 |
| Li, XH | 1 |
| Lin, YB | 1 |
| Zhong, SL | 1 |
| Liaw, D | 2 |
| Tang, X | 3 |
| Galeazzi, R | 1 |
| Olivieri, F | 1 |
| Spazzafumo, L | 1 |
| Rose, G | 1 |
| Montesanto, A | 1 |
| Giovagnetti, S | 1 |
| Cecchini, S | 1 |
| Malatesta, G | 1 |
| Di Pillo, R | 1 |
| Antonicelli, R | 1 |
| Goicoechea, M | 1 |
| de Vinuesa, SG | 1 |
| Quiroga, B | 1 |
| Verde, E | 1 |
| Bernis, C | 1 |
| Morales, E | 1 |
| Fernández-Juárez, G | 1 |
| de Sequera, P | 1 |
| Verdalles, U | 1 |
| Delgado, R | 1 |
| Torres, A | 1 |
| Arroyo, D | 1 |
| Abad, S | 1 |
| Ortiz, A | 1 |
| Luño, J | 1 |
| Dimitroulis, D | 1 |
| Golabkesh, M | 1 |
| Knoop, B | 1 |
| Mo, Y | 1 |
| Karakas-Torgut, A | 1 |
| Pham, AQ | 1 |
| Groff, H | 1 |
| Azboy, I | 1 |
| Lewis, SR | 1 |
| Pritchard, MW | 1 |
| Schofield-Robinson, OJ | 1 |
| Alderson, P | 1 |
| Smith, AF | 1 |
| Khan, SU | 1 |
| Talluri, S | 1 |
| Rahman, H | 1 |
| Lekkala, M | 1 |
| Khan, MS | 3 |
| Riaz, H | 3 |
| Shah, H | 1 |
| Kaluski, E | 1 |
| Sattur, S | 1 |
| Wustrow, I | 1 |
| Haller, B | 1 |
| Rössner, L | 1 |
| Anetsberger, A | 1 |
| Hoorntje, JCA | 1 |
| Whelton, SP | 1 |
| Gluckman, TJ | 1 |
| Metkus, TS | 1 |
| Daimon, S | 1 |
| Wu, Z | 1 |
| Liu, AF | 1 |
| Wang, K | 1 |
| Qiu, H | 1 |
| Jiang, WJ | 1 |
| Fortuni, F | 1 |
| Ferlini, M | 4 |
| Somaschini, A | 1 |
| Cornara, S | 1 |
| Potenza, A | 1 |
| Oltrona Visconti, L | 1 |
| Fan, Y | 1 |
| Zhu, T | 1 |
| Kong, D | 1 |
| Meng, H | 1 |
| Xu, K | 5 |
| Ye, S | 2 |
| Ji, Y | 1 |
| van der Wall, SJ | 2 |
| Olsthoorn, JR | 1 |
| Heuts, S | 1 |
| Klautz, RJM | 1 |
| Tomsic, A | 1 |
| Jansen, EK | 2 |
| Vonk, ABA | 1 |
| Sardari Nia, P | 1 |
| Leggio, M | 1 |
| Fusco, A | 1 |
| Severi, P | 1 |
| Lombardi, M | 1 |
| Caldarone, E | 1 |
| D'Emidio, S | 1 |
| Armeni, M | 1 |
| Mereu, D | 1 |
| Bendini, MG | 1 |
| Mazza, A | 1 |
| Calnan, MW | 1 |
| Crawford, AN | 1 |
| Bowman, L | 1 |
| Mafham, M | 1 |
| Wallendszus, K | 1 |
| Stevens, W | 1 |
| Buck, G | 2 |
| Barton, J | 1 |
| Aung, T | 1 |
| Haynes, R | 1 |
| Cox, J | 2 |
| Murawska, A | 1 |
| Young, A | 1 |
| Lay, M | 1 |
| Sammons, E | 1 |
| Waters, E | 1 |
| Adler, A | 1 |
| Bodansky, J | 1 |
| Farmer, A | 1 |
| McPherson, R | 1 |
| Neil, A | 1 |
| Simpson, D | 1 |
| Peto, R | 4 |
| Baigent, C | 4 |
| Collins, R | 5 |
| Parish, S | 1 |
| Armitage, J | 2 |
| Baumann Kreuziger, L | 1 |
| Karkouti, K | 2 |
| Tweddell, J | 1 |
| Massicotte, MP | 1 |
| Ueda, P | 1 |
| Jernberg, T | 3 |
| Alfredsson, J | 1 |
| Erlinge, D | 3 |
| Omerovic, E | 1 |
| Persson, J | 3 |
| Ravn-Fischer, A | 1 |
| Tornvall, P | 1 |
| Svennblad, B | 1 |
| Varenhorst, C | 3 |
| Buchanan, KD | 1 |
| Pichard, AD | 2 |
| Thourani, VH | 1 |
| Okubagzi, PG | 1 |
| Levitan, B | 2 |
| Laliberté, F | 1 |
| Ashton, V | 1 |
| Lejeune, D | 1 |
| Crivera, C | 1 |
| Lefebvre, P | 1 |
| Schein, J | 1 |
| de Vries, TAC | 1 |
| Dauerman, HL | 4 |
| Meredith, IT | 2 |
| Margolis, KL | 3 |
| Stocks, N | 3 |
| Fitzgerald, SM | 3 |
| Trevaks, RE | 3 |
| Beilin, LJ | 3 |
| Johnston, CI | 3 |
| Ryan, J | 3 |
| Radziszewska, B | 3 |
| Jelinek, M | 1 |
| Malik, M | 1 |
| Eaton, CB | 2 |
| Brauer, D | 1 |
| Cloud, G | 1 |
| Satterfield, S | 1 |
| Grimm, R | 3 |
| Ives, DG | 1 |
| Newman, AB | 2 |
| Frieden, RW | 1 |
| Bhattarai, M | 1 |
| Hudali, T | 1 |
| Robinson, R | 1 |
| Al-Akchar, M | 1 |
| Vogler, C | 1 |
| Chami, Y | 1 |
| Sindet-Pedersen, C | 1 |
| Lamberts, M | 5 |
| Staerk, L | 1 |
| Nissen Bonde, A | 1 |
| Berger, JS | 6 |
| Pallisgaard, JL | 1 |
| Lock Hansen, M | 1 |
| Gislason, GH | 8 |
| Olesen, JB | 6 |
| Savarese, G | 1 |
| Della Bona, R | 1 |
| Calò, L | 1 |
| Saito, Y | 1 |
| Kobayashi, Y | 1 |
| Lichtenauer, M | 1 |
| Hoppe, UC | 1 |
| Lauten, A | 1 |
| Peñaloza-Martínez, E | 1 |
| Demelo-Rodríguez, P | 1 |
| Soria Fernández-Llamazares, G | 1 |
| Llamazares-Mendo, C | 1 |
| Álvarez-Sala Walther, L | 1 |
| Marra, AM | 1 |
| Del Toro-Cervera, J | 1 |
| Lippi, G | 1 |
| Danese, E | 1 |
| Favaloro, EJ | 1 |
| Boden, WE | 6 |
| Brener, SJ | 3 |
| McAndrew, T | 1 |
| Hu, X | 1 |
| Yang, FY | 1 |
| Myles, PS | 3 |
| Smith, JA | 3 |
| Silbert, B | 3 |
| Jayarajah, M | 3 |
| Painter, T | 4 |
| Cooper, DJ | 3 |
| Marasco, S | 3 |
| McNeil, J | 3 |
| Bussières, JS | 3 |
| McGuinness, S | 3 |
| Wallace, S | 3 |
| Forbes, A | 3 |
| Mauri, S | 1 |
| Demarchi, A | 1 |
| Portolan, M | 1 |
| Visconti, LO | 3 |
| Hawkins, RB | 1 |
| Mehaffey, JH | 1 |
| Byrne, K | 2 |
| Chen, YC | 1 |
| Lin, FY | 1 |
| Lin, YW | 1 |
| Cheng, SM | 1 |
| Lin, RH | 1 |
| Chuang, CL | 1 |
| Sheu, JS | 1 |
| Chen, SM | 1 |
| Tsai, CS | 1 |
| Hidaka, H | 1 |
| Sato, M | 1 |
| Nakatsuka, H | 1 |
| Çelik, O | 1 |
| Çil, C | 1 |
| Özlek, B | 1 |
| Özlek, E | 1 |
| Doğan, V | 1 |
| Başaran, Ö | 1 |
| Demirci, E | 1 |
| Bekar, L | 1 |
| Kalçık, M | 1 |
| Karaarslan, O | 1 |
| Yetim, M | 1 |
| Doğan, T | 1 |
| Demir, V | 1 |
| Kalkan, S | 1 |
| Özkan, B | 1 |
| Hidayet, Ş | 1 |
| Taylan, G | 1 |
| Küçüksu, Z | 1 |
| Çelik, Y | 1 |
| Efe, SÇ | 1 |
| Aslan, O | 1 |
| Biteker, M | 1 |
| Kheiri, B | 3 |
| Osman, M | 1 |
| Abdalla, A | 1 |
| Haykal, T | 1 |
| Swaid, B | 1 |
| Ahmed, S | 1 |
| Chahine, A | 1 |
| Hassan, M | 1 |
| Bachuwa, G | 3 |
| Al Qasmi, M | 1 |
| Zomer, E | 1 |
| Si, S | 1 |
| Hird, TR | 1 |
| Liew, D | 2 |
| Owen, AJ | 1 |
| Tonkin, A | 1 |
| Ademi, Z | 2 |
| Kim, MH | 5 |
| Cho, YR | 3 |
| Sung Park, J | 1 |
| Min Lee, K | 1 |
| Yun, SC | 1 |
| Santulli, G | 1 |
| Hao, Q | 1 |
| Tampi, M | 1 |
| Foroutan, F | 1 |
| Siemieniuk, RA | 1 |
| Sugawara, M | 4 |
| Goto, Y | 3 |
| Yamazaki, T | 4 |
| Teramoto, T | 4 |
| Oikawa, S | 4 |
| Ishizuka, N | 4 |
| Murata, M | 4 |
| Yokoyama, K | 4 |
| Uemura, Y | 3 |
| Dargham, BB | 1 |
| Baskar, A | 1 |
| Tejani, I | 1 |
| Cui, Z | 1 |
| Chauhan, S | 1 |
| Sum-Ping, J | 1 |
| Weideman, RA | 1 |
| Banerjee, S | 2 |
| Koutsoumpelis, A | 1 |
| Argyriou, C | 1 |
| Tasopoulou, KM | 1 |
| Georgakarakos, EI | 1 |
| Georgiadis, GS | 1 |
| Masjuan, J | 2 |
| Salido, L | 1 |
| DeFelipe, A | 1 |
| Hernández-Antolín, R | 1 |
| Fernández-Golfín, C | 1 |
| Cruz-Culebras, A | 1 |
| Matute, C | 1 |
| Vera, R | 1 |
| Pérez-Torre, P | 1 |
| Zamorano, JL | 1 |
| Khan, SA | 2 |
| Khan, B | 2 |
| Latham, SB | 2 |
| Moalem, K | 1 |
| Iakovou, I | 2 |
| Sang, W | 1 |
| Wei, M | 1 |
| Guedeney, P | 1 |
| Hirsch, C | 2 |
| Pfisterer, M | 1 |
| Vogt, DR | 1 |
| Galatius, S | 2 |
| Abildgaard, U | 1 |
| Naber, C | 1 |
| Alber, H | 2 |
| Eberli, F | 2 |
| Kurz, DJ | 1 |
| Vuilliomenet, A | 1 |
| Weilenmann, D | 1 |
| Rickli, H | 2 |
| Hansen, KW | 1 |
| Rickenbacher, P | 1 |
| Conen, D | 1 |
| Müller, C | 1 |
| Osswald, S | 1 |
| Gilgen, N | 1 |
| Kaiser, C | 1 |
| Gaziano, JM | 3 |
| Zheng, SL | 2 |
| Roddick, AJ | 2 |
| Tousoulis, D | 1 |
| Nicholls, SJ | 1 |
| Nelson, AJ | 1 |
| Runner, RP | 1 |
| Gottschalk, MB | 1 |
| Staley, CA | 1 |
| Pour, AE | 1 |
| Roberson, JR | 1 |
| Chan, NC | 2 |
| Coppens, M | 2 |
| Eikelboom, JWA | 1 |
| Pastori, D | 1 |
| Ricco, JB | 1 |
| Nikol, S | 1 |
| Violi, F | 1 |
| Pokorney, SD | 1 |
| Gersh, BJ | 4 |
| Ahmad, A | 1 |
| Al-Khatib, SM | 1 |
| Blank, M | 1 |
| DiBattiste, P | 1 |
| Healey, JS | 2 |
| Hedrich, O | 1 |
| Hylek, EM | 2 |
| Peterson, ED | 11 |
| Mendys, P | 1 |
| Mirro, MJ | 1 |
| Naccarelli, G | 1 |
| Ruff, CT | 1 |
| Rutman, H | 1 |
| Stockbridge, N | 1 |
| Temple, R | 1 |
| Mirkazemi, C | 1 |
| Bereznicki, LR | 1 |
| Peterson, GM | 2 |
| Kessler, T | 1 |
| Wolf, B | 1 |
| Eriksson, N | 1 |
| Kofink, D | 1 |
| Rai, H | 1 |
| Tragante, V | 1 |
| Bopp, R | 1 |
| Munz, M | 1 |
| Nordio, F | 1 |
| Solakov, L | 1 |
| Wobst, J | 1 |
| Asselbergs, FW | 1 |
| Erdmann, J | 1 |
| Koenig, W | 1 |
| Röther, J | 2 |
| Al-Jazairi, AS | 1 |
| Al Alshaykh, HA | 1 |
| Di Salvo, G | 1 |
| De Vol, EB | 1 |
| Alhalees, ZY | 1 |
| Levi, C | 1 |
| King, A | 1 |
| Madigan, J | 1 |
| Norris, J | 1 |
| Whitlock, EP | 3 |
| Johnson, ES | 2 |
| Nagalla, S | 1 |
| Sarode, R | 1 |
| Souphis, NM | 1 |
| Almany, SL | 1 |
| Urs, AP | 1 |
| Rudresha, GV | 1 |
| Manjuprasanna, VN | 1 |
| Suvilesh, KN | 1 |
| Gowda, MDM | 1 |
| Yariswamy, M | 1 |
| Hiremath, V | 1 |
| Ramakrishnan, C | 1 |
| Savitha, MN | 1 |
| Jayachandra, K | 1 |
| Sharanappa, P | 1 |
| Vishwanath, BS | 1 |
| Upadhaya, S | 1 |
| Madala, S | 1 |
| Baniya, R | 1 |
| Saginala, K | 1 |
| Khan, J | 1 |
| Bertaina, M | 1 |
| Fioravanti, F | 1 |
| Bongiovanni, F | 1 |
| Raposeiras-Roubin, S | 1 |
| Abu-Assi, E | 1 |
| Kinnaird, T | 2 |
| Ariza-Solé, A | 1 |
| Templin, C | 1 |
| Velicki, L | 1 |
| Xanthopoulou, I | 1 |
| Rognoni, A | 2 |
| Montabone, A | 1 |
| Taha, S | 2 |
| Durante, A | 1 |
| Gili, S | 1 |
| Autelli, M | 1 |
| Grosso, A | 1 |
| Blanco, PF | 1 |
| Garay, A | 1 |
| Quadri, G | 2 |
| Queija, BC | 1 |
| Paz, RC | 1 |
| Fernández, MC | 1 |
| Pousa, IM | 1 |
| Gallo, D | 1 |
| Morbiducci, U | 1 |
| Dominguez-Rodriguez, A | 1 |
| Valdés, M | 2 |
| Cequier, A | 1 |
| Iñiguez-Romo, A | 1 |
| Gaita, F | 2 |
| Lüscher, TF | 2 |
| Ting, LH | 1 |
| Feghhi, S | 1 |
| Taparia, N | 1 |
| Smith, AO | 1 |
| Karchin, A | 1 |
| Lim, E | 1 |
| John, AS | 1 |
| Rue, T | 1 |
| White, NJ | 1 |
| Sniadecki, NJ | 1 |
| Murphy, S | 2 |
| McCarthy, CP | 1 |
| Hijazi, Z | 1 |
| Sinnaeve, P | 1 |
| Otsuki, H | 1 |
| Kawamoto, T | 1 |
| Yoshikawa, M | 1 |
| Ebihara, S | 1 |
| Tanaka, K | 1 |
| Nakao, M | 1 |
| Jujo, K | 1 |
| Arashi, H | 1 |
| Ota, Y | 1 |
| Saito, K | 1 |
| Takagi, A | 2 |
| Honda, A | 1 |
| Mori, F | 2 |
| Mai, V | 1 |
| Bertoletti, L | 1 |
| Cucherat, M | 1 |
| Jardel, S | 1 |
| Grange, C | 1 |
| Provencher, S | 1 |
| Lega, JC | 1 |
| George, S | 1 |
| Onwordi, ENC | 1 |
| Gamal, A | 1 |
| Ghosh, A | 1 |
| Best, AJ | 1 |
| Rudge, SJ | 1 |
| Chatterji, U | 1 |
| Murillo, M | 1 |
| Vadhariya, A | 1 |
| Wilson, A | 1 |
| Putney, D | 1 |
| Muntz, J | 1 |
| Eizayaga, FX | 2 |
| Belon, P | 4 |
| Desplat, V | 2 |
| Aguejouf, O | 4 |
| Doutremepuich, C | 4 |
| Zheng, W | 1 |
| Tian, J | 1 |
| Xie, L | 1 |
| Mao, Q | 1 |
| Tong, W | 1 |
| Zhou, D | 1 |
| Azzalini, L | 1 |
| Tillman, H | 1 |
| Ma, Q | 1 |
| Chung, H | 1 |
| Shambhu, S | 1 |
| Roe, M | 1 |
| Cziraky, M | 1 |
| Jeong, L | 1 |
| Jung, E | 1 |
| Ko, C | 1 |
| Seon, S | 1 |
| Noh, J | 1 |
| Lee, D | 1 |
| Tse, D | 1 |
| Hill, MD | 1 |
| Coutts, SB | 1 |
| Sacco, RL | 5 |
| Bernstein, RA | 1 |
| Kreuzer, J | 1 |
| Cronin, L | 1 |
| Cotton, D | 2 |
| Chernyatina, M | 1 |
| Donnan, G | 1 |
| Ferro, JM | 2 |
| Grond, M | 1 |
| Kallmünzer, B | 1 |
| Krupinski, J | 1 |
| Lemmens, R | 1 |
| Odinak, M | 1 |
| Schellinger, PD | 1 |
| Wong, KL | 1 |
| Horie, K | 1 |
| Matsumoto, T | 1 |
| Mizutani, Y | 1 |
| Osai, N | 1 |
| Taguri, M | 1 |
| Kato, S | 1 |
| Honda, T | 1 |
| Ootomo, T | 1 |
| Inoue, N | 1 |
| Szczeklik, W | 1 |
| Giustozzi, M | 1 |
| Franco, L | 1 |
| Vedovati, MC | 1 |
| Becattini, C | 3 |
| Agnelli, G | 5 |
| Gao, X | 1 |
| Zuo, G | 1 |
| Atencio, A | 1 |
| Zhang, XG | 1 |
| Zhu, XQ | 1 |
| Xue, J | 1 |
| Li, ZZ | 1 |
| Jiang, HY | 1 |
| Hu, L | 1 |
| Yue, YH | 1 |
| Tatarunas, V | 1 |
| Kupstyte-Kristapone, N | 1 |
| Norvilaite, R | 1 |
| Tamakauskas, V | 1 |
| Skipskis, V | 1 |
| Audrone, V | 1 |
| Jurgaityte, J | 1 |
| Stuoka, M | 1 |
| Lesauskaite, V | 1 |
| Crisci, M | 1 |
| Di Maio, M | 1 |
| Diana, V | 1 |
| Moscarella, E | 3 |
| Pariggiano, I | 1 |
| Di Maio, D | 1 |
| Concilio, C | 1 |
| Taglialatela, V | 1 |
| Fimiani, F | 1 |
| Cesaro, A | 1 |
| Cirillo, PL | 1 |
| Rockhold, FW | 1 |
| Plotnikov, AN | 1 |
| DeMets, D | 1 |
| Thompson, D | 1 |
| Xu, GM | 1 |
| Ding, J | 1 |
| Seidu, S | 1 |
| Kunutsor, SK | 1 |
| Sesso, HD | 1 |
| Buring, JE | 4 |
| Roncaglioni, MC | 3 |
| Khunti, K | 1 |
| Shapiro, MD | 1 |
| Sterne, JAC | 1 |
| Doble, B | 1 |
| Wordsworth, S | 1 |
| Loke, Y | 1 |
| Pithara, C | 1 |
| Redwood, S | 1 |
| Imberti, D | 2 |
| Pomero, F | 1 |
| Mastroiacovo, D | 1 |
| Syn, NL | 1 |
| Wee, IJY | 1 |
| Kedhi, E | 2 |
| Latib, A | 2 |
| Abizaid, A | 4 |
| Kandzari, D | 1 |
| Simon, D | 1 |
| Worthley, S | 1 |
| Brar, S | 1 |
| Liu, M | 3 |
| Xiang, L | 1 |
| Dellborg, M | 4 |
| Im, KA | 1 |
| Oude Ophuis, T | 2 |
| Spinar, J | 4 |
| Bengtsson, O | 2 |
| Knickelbine, T | 1 |
| Barsan, WG | 1 |
| Zurita, KG | 1 |
| Cucchiara, BL | 1 |
| Kleindorfer, DO | 1 |
| Pearson, C | 1 |
| Sethi, P | 1 |
| Vora, N | 1 |
| Sorbets, E | 1 |
| Popovic, B | 1 |
| Wilson, PF | 1 |
| Gremmel, T | 1 |
| Sulzgruber, P | 1 |
| Sanmartín, M | 1 |
| Bellmunt, S | 1 |
| Cosín-Sales, J | 1 |
| García-Moll, X | 1 |
| Riera-Mestre, A | 1 |
| Almendro-Delia, M | 2 |
| Hernández, JL | 1 |
| Lozano, F | 1 |
| Mazón, P | 1 |
| Suarez Fernández, C | 1 |
| Zayed, Y | 1 |
| Gakhal, I | 1 |
| Barbarawi, O | 1 |
| Rashdan, L | 1 |
| Rizk, F | 1 |
| Alkotob, ML | 1 |
| Plazak, ME | 1 |
| Mouradjian, MT | 1 |
| Watson, K | 1 |
| Reed, BN | 2 |
| Noel, ZR | 1 |
| Devabhakthuni, S | 1 |
| Gale, SE | 1 |
| Sharma, A | 1 |
| Neely, ML | 3 |
| Hosokawa, K | 1 |
| Dahlen, JR | 1 |
| Ajrouche, A | 1 |
| Estellat, C | 1 |
| De Rycke, Y | 1 |
| Tubach, F | 2 |
| Sorrentino, S | 1 |
| Stuckey, T | 4 |
| Deng, H | 1 |
| Oirbans, T | 1 |
| Verheugt, FW | 17 |
| De Smet, BJ | 1 |
| Herrman, JP | 1 |
| Heestermans, AA | 2 |
| Vis, MM | 1 |
| Tijsen, JG | 1 |
| van 't Hof, AW | 3 |
| Narum, S | 1 |
| Solhaug, V | 1 |
| Myhr, K | 1 |
| Brørs, O | 1 |
| Kringen, MK | 1 |
| Helft, G | 2 |
| Le Feuvre, C | 1 |
| Georges, JL | 1 |
| Leclercq, F | 1 |
| Eltchaninoff, H | 2 |
| Prunier, F | 1 |
| Sebagh, L | 1 |
| Cattan, S | 2 |
| Vicaut, E | 3 |
| Metzger, JP | 2 |
| Mischnik, M | 1 |
| Boyanova, D | 1 |
| Hubertus, K | 1 |
| Geiger, J | 1 |
| Philippi, N | 1 |
| Dittrich, M | 1 |
| Wangorsch, G | 1 |
| Timmer, J | 1 |
| Dandekar, T | 1 |
| Noventa, F | 1 |
| Milan, M | 1 |
| Schellong, S | 1 |
| Alvarez-Larrán, A | 1 |
| Cervantes, F | 1 |
| Besses, C | 1 |
| Turkmen, S | 1 |
| Fettser, DV | 3 |
| Kagliian, KÉ | 1 |
| Serchelik, A | 1 |
| Arystanova, AZh | 1 |
| Tekin, K | 1 |
| Balli, M | 1 |
| Batyraliev, TA | 3 |
| Samko, AN | 2 |
| Sidorenko, BA | 3 |
| Attia, JR | 1 |
| Pearce, R | 1 |
| Eley, KA | 1 |
| Parker, RJ | 1 |
| Watt-Smith, SR | 1 |
| Osinski, D | 1 |
| Thevenin, A | 1 |
| Devys, JM | 1 |
| Matthys, F | 1 |
| De Backer, T | 1 |
| De Backer, G | 1 |
| Stichele, RV | 1 |
| Kim, SJ | 1 |
| Bang, OY | 1 |
| Netsch, C | 1 |
| Stoehrer, M | 1 |
| Brüning, M | 1 |
| Gabuev, A | 1 |
| Bach, T | 1 |
| Herrmann, TR | 1 |
| Gross, AJ | 1 |
| Ertaş, F | 1 |
| Kaya, H | 1 |
| Kaya, Z | 1 |
| Bulur, S | 1 |
| Köse, N | 1 |
| Gül, M | 1 |
| Kahya Eren, N | 1 |
| Cağlıyan, CE | 1 |
| Köroğlu, B | 1 |
| Vatan, B | 1 |
| Acar, G | 1 |
| Yüksel, M | 1 |
| Bilik, MZ | 1 |
| Gedik, S | 1 |
| Simşek, Z | 1 |
| Akıl, MA | 1 |
| Yılmaz, R | 1 |
| Oylumlu, M | 1 |
| Arıbaş, A | 1 |
| Yıldız, A | 1 |
| Aydın, M | 1 |
| Yeter, E | 1 |
| Kanadaşı, M | 1 |
| Ergene, O | 1 |
| Ozhan, H | 1 |
| Ulgen, MS | 1 |
| Dunbar, MJ | 1 |
| Bohm, ER | 1 |
| MacDonald, S | 2 |
| Davis, N | 1 |
| Wells, P | 1 |
| Kovacs, M | 1 |
| Ramsay, T | 1 |
| Cui, L | 1 |
| Jia, J | 1 |
| Stöllberger, C | 1 |
| Finsterer, J | 1 |
| Callender, RA | 1 |
| Mukalel, J | 1 |
| Altamirano, AV | 1 |
| Pivalizza, EG | 1 |
| Cattano, D | 1 |
| Brilakis, ES | 1 |
| Patel, VG | 1 |
| Massel, DR | 1 |
| Little, SH | 1 |
| Huang, Y | 1 |
| Li, JY | 1 |
| Xia, YP | 1 |
| Mao, L | 1 |
| Stevens, SR | 1 |
| Hochman, JS | 1 |
| Gottlieb, S | 3 |
| Martinez, F | 2 |
| Dalby, AJ | 4 |
| White, HD | 9 |
| Prabhakaran, D | 4 |
| Winters, KJ | 4 |
| Aylward, PE | 2 |
| Bassand, JP | 4 |
| McGuire, DK | 2 |
| Steinberg, BA | 1 |
| Kim, S | 2 |
| Ezekowitz, MD | 5 |
| Ansell, J | 1 |
| Kowey, P | 1 |
| Singer, DE | 6 |
| Gersh, B | 1 |
| Mahaffey, KW | 4 |
| Hylek, E | 2 |
| Go, AS | 2 |
| Chang, P | 1 |
| Assiri, A | 1 |
| Al-Majzoub, O | 1 |
| Kanaan, AO | 2 |
| Donovan, JL | 2 |
| Silva, M | 1 |
| Anastasiadis, A | 1 |
| Zapała, L | 1 |
| Cordeiro, E | 1 |
| Antoniewicz, A | 1 |
| Dimitriadis, G | 1 |
| De Reijke, T | 1 |
| Lane, DA | 10 |
| Raichand, S | 1 |
| Moore, D | 1 |
| Connock, M | 1 |
| Fry-Smith, A | 1 |
| Fitzmaurice, DA | 2 |
| Her, SH | 1 |
| Park, CS | 1 |
| Koh, YS | 1 |
| Park, HJ | 1 |
| Kim, PJ | 1 |
| Seo, SM | 1 |
| Kim, DB | 1 |
| Chung, WS | 1 |
| Shin, JG | 1 |
| Darvish-Kazem, S | 1 |
| Gandhi, M | 1 |
| Marcucci, M | 2 |
| Douketis, JD | 2 |
| Wilhelm, TJ | 1 |
| Post, S | 1 |
| Suh, SY | 1 |
| Choi, H | 1 |
| Moon, CI | 1 |
| Han, SH | 1 |
| Ahn, T | 2 |
| Choi, IS | 1 |
| Shin, EK | 1 |
| Bell, AD | 1 |
| Ackman, ML | 2 |
| Bauer, RD | 1 |
| Cartier, R | 1 |
| Chan, WS | 1 |
| Douketis, J | 1 |
| Roussin, A | 1 |
| Schnell, G | 1 |
| Wong, G | 2 |
| Castellucci, LA | 1 |
| Cameron, C | 1 |
| Le Gal, G | 1 |
| Clifford, T | 1 |
| Gandara, E | 2 |
| Wells, G | 1 |
| Picozzi, S | 2 |
| Marenghi, C | 1 |
| Ricci, C | 2 |
| Bozzini, G | 2 |
| Casellato, S | 1 |
| Carmignani, L | 2 |
| Fiaccadori, E | 1 |
| Maggiore, U | 1 |
| Regolisti, G | 1 |
| Lin, JS | 1 |
| Olson, CM | 1 |
| Moyer, VA | 1 |
| Gulba, DC | 2 |
| Park, JJ | 2 |
| Park, BE | 1 |
| Jeon, HK | 2 |
| Hwang, KK | 1 |
| Yoon, JH | 3 |
| Kwon, HM | 2 |
| Aradi, D | 1 |
| Trenk, D | 2 |
| Gulba, D | 3 |
| Reilly, PA | 2 |
| Lehr, T | 1 |
| Haertter, S | 1 |
| Nehmiz, G | 2 |
| Tang, Y | 2 |
| Huang, X | 3 |
| Xie, Y | 1 |
| Curkovic, I | 1 |
| Egbring, M | 1 |
| Kullak-Ublick, GA | 1 |
| Harris, NS | 1 |
| Kristensen, SR | 1 |
| Rydberg, DM | 1 |
| Holm, L | 1 |
| Mejyr, S | 1 |
| Loikas, D | 1 |
| Schenck-Gustafsson, K | 1 |
| von Euler, M | 2 |
| Malmström, RE | 1 |
| Lee, SG | 1 |
| Seong, IW | 1 |
| Lim, DS | 4 |
| Yang, JY | 1 |
| Kim, KS | 1 |
| Chae, JK | 1 |
| Cheong, SS | 1 |
| Park, HS | 4 |
| Nah, DY | 1 |
| Jang, JS | 1 |
| Hreinsson, JP | 1 |
| Jonasson, JG | 1 |
| Bjornsson, ES | 1 |
| Jensevik, K | 2 |
| Sundström, A | 1 |
| Hasvold, P | 1 |
| Lagerqvist, B | 4 |
| Bosch, X | 3 |
| Marrugat, J | 4 |
| Sanchis, J | 3 |
| Malloy, RJ | 1 |
| Silva, MA | 1 |
| Aylward, P | 2 |
| Hanna, M | 1 |
| McMurray, JJ | 1 |
| Pouleur, H | 1 |
| Feres, F | 4 |
| Costa, RA | 1 |
| Marin-Neto, JA | 1 |
| Botelho, RV | 1 |
| King, SB | 2 |
| Negoita, M | 1 |
| de Paula, JE | 1 |
| Mangione, JA | 2 |
| Meireles, GX | 1 |
| Castello, HJ | 1 |
| Nicolela, EL | 1 |
| Perin, MA | 1 |
| Devito, FS | 1 |
| Labrunie, A | 1 |
| Salvadori, D | 1 |
| Gusmão, M | 1 |
| Staico, R | 2 |
| Costa, JR | 2 |
| de Castro, JP | 1 |
| Abizaid, AS | 1 |
| Arnaud, L | 1 |
| Mathian, A | 1 |
| Ruffatti, A | 1 |
| Erkan, D | 1 |
| Tektonidou, M | 1 |
| Cervera, R | 1 |
| Forastiero, R | 1 |
| Pengo, V | 3 |
| Martinez-Zamora, MA | 1 |
| Balasch, J | 1 |
| Zuily, S | 1 |
| Wahl, D | 1 |
| Amoura, Z | 1 |
| Kolber, MR | 1 |
| Korownyk, C | 1 |
| Nakagawa, I | 2 |
| Wada, T | 2 |
| Nishimura, F | 1 |
| Nakagawa, H | 1 |
| Kichikawa, K | 2 |
| Nakase, H | 2 |
| Thomas, MR | 2 |
| Aoki, M | 1 |
| Ogawa, S | 1 |
| Baba, H | 1 |
| Okawa, Y | 1 |
| Medjeral-Thomas, N | 1 |
| Ziaj, S | 1 |
| Condon, M | 1 |
| Galliford, J | 1 |
| Levy, J | 1 |
| Cairns, T | 1 |
| Griffith, M | 1 |
| Enomoto, Y | 1 |
| Tokue, M | 1 |
| Ito, N | 1 |
| Nagashima, Y | 1 |
| Araki, T | 1 |
| Yamazaki, K | 1 |
| Utsunomiya, M | 1 |
| Itaya, H | 1 |
| Shiba, M | 1 |
| Sugi, K | 1 |
| Takahashi, S | 1 |
| Mizuno, O | 1 |
| Sakaguchi, T | 1 |
| Yamada, T | 1 |
| Inuyama, L | 1 |
| Schotola, H | 1 |
| Bräuer, A | 1 |
| Meyer, K | 1 |
| Hinz, J | 1 |
| Schöndube, FA | 1 |
| Bauer, M | 1 |
| Mohite, PN | 1 |
| Danner, BC | 1 |
| Sossalla, S | 1 |
| Popov, AF | 1 |
| Schäfer, A | 1 |
| Arntz, HR | 1 |
| Boudriot, E | 1 |
| Garlichs, C | 1 |
| Hoffmann, S | 1 |
| Ince, H | 1 |
| Klingenheben, T | 1 |
| Weil, J | 1 |
| Zugck, C | 1 |
| Helms, TM | 1 |
| Silber, S | 1 |
| Wiedemann, S | 1 |
| Henke, C | 1 |
| Strasser, RH | 1 |
| Lassen, JF | 1 |
| Mikkelsen, AP | 1 |
| Sørensen, R | 4 |
| Hansen, ML | 6 |
| Lippe, CM | 1 |
| Reineck, EA | 1 |
| Kunselman, AR | 1 |
| Gilchrist, IC | 2 |
| Alcocer, F | 1 |
| Novak, Z | 1 |
| Combs, BR | 1 |
| Lowman, B | 1 |
| Passman, MA | 1 |
| Mujib, M | 1 |
| Jordan, WD | 1 |
| Alvarez-Sabín, J | 2 |
| Quintana, M | 1 |
| Santamarina, E | 1 |
| Maisterra, O | 1 |
| Dorian, P | 2 |
| Kongnakorn, T | 3 |
| Phatak, H | 2 |
| Rublee, DA | 1 |
| Kuznik, A | 1 |
| Lanitis, T | 3 |
| Liu, LZ | 1 |
| Iloeje, U | 1 |
| Hernandez, L | 1 |
| Synhorst, D | 2 |
| Ma, YY | 1 |
| Xu, B | 1 |
| Gao, RL | 1 |
| Mafrici, A | 1 |
| Marzegalli, M | 1 |
| Piccaluga, E | 2 |
| Sponzilli, C | 1 |
| Bramucci, E | 2 |
| Loidi Pascual, L | 1 |
| Valcayo Peñalba, A | 1 |
| Yerani Ruiz de Azúa Ciria, A | 1 |
| Yanguas Bayona, I | 1 |
| Vandegriff, KD | 1 |
| Malavalli, A | 1 |
| Lohman, J | 1 |
| Young, MA | 1 |
| Terraneo, L | 1 |
| Virgili, E | 1 |
| Bianciardi, P | 1 |
| Caretti, A | 1 |
| Samaja, M | 1 |
| Schulz, S | 2 |
| Pöhler, A | 1 |
| Pache, J | 1 |
| Verheijen, S | 1 |
| Lensing, AW | 2 |
| Gebel, M | 1 |
| Lyons, RM | 1 |
| Rehm, J | 1 |
| Pandit, A | 2 |
| Giri, S | 1 |
| Hakim, FA | 1 |
| Fortuin, FD | 2 |
| Tebaldi, M | 4 |
| Biscaglia, S | 1 |
| Parrinello, G | 1 |
| Huang, H | 1 |
| Yu, J | 2 |
| Cao, G | 1 |
| Isshiki, T | 3 |
| Nanto, S | 2 |
| Takayama, M | 2 |
| Nishikawa, M | 2 |
| Miyazaki, S | 2 |
| DiNicolantonio, JJ | 1 |
| Norgard, NB | 1 |
| Meier, P | 3 |
| Lavie, CJ | 1 |
| O'Keefe, JH | 1 |
| Niazi, AK | 1 |
| Chatterjee, S | 1 |
| Packard, KA | 1 |
| Fuchs, FD | 1 |
| Rangé, G | 2 |
| Yayehd, K | 1 |
| Thuaire, C | 1 |
| Richard, P | 1 |
| Barbou, F | 1 |
| Köning, R | 1 |
| Chassaing, S | 1 |
| Teiger, E | 1 |
| Berthier, R | 1 |
| Decomis, MP | 1 |
| Claudel, JP | 1 |
| Brunel, P | 1 |
| De Poli, F | 2 |
| Albert, F | 1 |
| Wada, H | 1 |
| Sakakura, K | 1 |
| Ikeda, N | 1 |
| Yamada, Y | 1 |
| Katayama, T | 1 |
| Sugawara, Y | 1 |
| Mitsuhashi, T | 1 |
| Momomura, S | 1 |
| Misialek, JR | 1 |
| Silverman, MG | 1 |
| Blankstein, R | 1 |
| Budoff, MJ | 1 |
| Folsom, AR | 1 |
| Alonso-Coello, P | 1 |
| Montori, VM | 1 |
| Díaz, MG | 1 |
| Mas, G | 1 |
| Diez, AI | 1 |
| Solà, I | 1 |
| Roura, M | 1 |
| Souto, JC | 1 |
| Oliver, S | 1 |
| Ruiz, R | 1 |
| Coll-Vinent, B | 1 |
| Gich, I | 1 |
| Schünemann, HJ | 1 |
| Burton, P | 2 |
| Poulos, C | 1 |
| Brett Hauber, A | 1 |
| Berlin, JA | 1 |
| Castiglioni, B | 1 |
| Lettieri, C | 5 |
| Lettino, M | 1 |
| Trabattoni, D | 1 |
| Buffoli, F | 1 |
| Parolari, A | 1 |
| Dionigi, G | 1 |
| Boni, L | 1 |
| Biglioli, F | 1 |
| Valdatta, L | 1 |
| Droghetti, A | 1 |
| Bozzani, A | 1 |
| Setacci, C | 1 |
| Ravelli, P | 1 |
| Crescini, C | 1 |
| Staurenghi, G | 1 |
| Scarone, P | 1 |
| Francetti, L | 1 |
| D'Angelo, F | 1 |
| Gadda, F | 1 |
| Comel, A | 1 |
| Salvi, L | 1 |
| Lorini, L | 1 |
| Antonelli, M | 1 |
| Bovenzi, F | 1 |
| Cremonesi, A | 1 |
| Guagliumi, G | 6 |
| Nieuwlaat, R | 1 |
| Crijns, HJ | 1 |
| Iorio, A | 1 |
| Schnabel, MJ | 1 |
| Gierth, M | 1 |
| Bründl, J | 1 |
| Chaussy, CG | 1 |
| Burger, M | 1 |
| Fritsche, HM | 1 |
| Wu, IC | 3 |
| Lin, MY | 1 |
| Yu, FJ | 2 |
| Hsieh, HM | 3 |
| Chiu, KF | 1 |
| Wu, MT | 3 |
| Legrand, V | 3 |
| Chenu, P | 1 |
| Martinez, C | 1 |
| Dens, J | 1 |
| Gach, O | 1 |
| Boland, J | 2 |
| Magne, J | 2 |
| Wijns, W | 2 |
| Takeuchi, K | 1 |
| Takayama, S | 1 |
| Izuhara, C | 1 |
| Wilcox, R | 1 |
| Iqbal, K | 1 |
| Costigan, T | 1 |
| Ramos, Y | 1 |
| Barthélémy, O | 2 |
| Van Belle, E | 2 |
| Elhadad, S | 1 |
| Schiele, F | 2 |
| Lhoest, N | 1 |
| Rousseau, H | 1 |
| Aubry, P | 2 |
| Monségu, J | 1 |
| O'Connor, SA | 2 |
| Kerneis, M | 1 |
| Saint-Etienne, C | 1 |
| Drescher, FS | 1 |
| Sirovich, BE | 1 |
| Lee, A | 2 |
| Morrison, DH | 1 |
| Chiang, WH | 1 |
| Larson, RJ | 2 |
| Uhm, JS | 1 |
| Won, H | 1 |
| Joung, B | 1 |
| Nam, GB | 1 |
| Choi, KJ | 1 |
| Lee, MH | 1 |
| Pak, HN | 2 |
| Kim, AJ | 1 |
| Lim, HJ | 1 |
| Ro, H | 1 |
| Ko, KP | 1 |
| Han, SY | 1 |
| Chang, JH | 1 |
| Lee, HH | 1 |
| Chung, W | 1 |
| Jung, JY | 1 |
| Peng, Y | 1 |
| Lee, YM | 1 |
| Chang, CY | 1 |
| Yen, TL | 1 |
| Geraldine, P | 1 |
| Lan, CC | 1 |
| Sheu, JR | 1 |
| Lee, JJ | 1 |
| Sood, A | 1 |
| Trinh, QD | 1 |
| Simes, J | 2 |
| Kirby, AC | 1 |
| Mister, R | 2 |
| Pearce, LA | 5 |
| Anderson, DC | 1 |
| Palacio, S | 2 |
| Coffey, CS | 2 |
| Lieven, A | 1 |
| Annemans, L | 1 |
| Marbaix, S | 1 |
| Gabrilovich, MI | 1 |
| Buxton, DE | 1 |
| Lykins, DM | 1 |
| McMillen, SM | 1 |
| Onadeko, OOA | 1 |
| Piątek, B | 1 |
| Piwnik, M | 1 |
| Podgórski, M | 1 |
| Strzelczyk, J | 1 |
| Fiore, M | 1 |
| James, C | 1 |
| Mouton, C | 1 |
| Calderon, J | 1 |
| Barandon, L | 1 |
| Ouattara, A | 1 |
| Picard, F | 1 |
| Wändell, P | 1 |
| Hasselström, J | 1 |
| Steurer, J | 1 |
| Thompson, PL | 1 |
| Aryal, MR | 1 |
| Karmacharya, P | 1 |
| Hakim, F | 1 |
| Pathak, R | 1 |
| Mainali, NR | 1 |
| Ukaigwe, A | 1 |
| Mahmood, M | 1 |
| Badal, M | 1 |
| Blanco Ponce, E | 1 |
| Gomez-Domínguez, R | 1 |
| Gonzalez-Matos, C | 1 |
| Lobo-Gonzalez, M | 1 |
| Caballero-Garcia, A | 1 |
| Hidalgo-Urbano, R | 1 |
| Cruz-Fernandez, MJ | 1 |
| Garcia-Rubira, JC | 1 |
| Limbruno, U | 2 |
| Russo, N | 1 |
| Calabria, P | 1 |
| Romano, M | 2 |
| Inashvili, A | 1 |
| Sirbu, V | 2 |
| Valsecchi, O | 3 |
| Senni, M | 3 |
| Gavazzi, A | 3 |
| Tantry, US | 4 |
| Gesheff, M | 1 |
| Bliden, KP | 1 |
| Saia, F | 2 |
| Sciahbasi, A | 2 |
| Bacchi-Reggiani, ML | 1 |
| Steffanon, L | 1 |
| Palmieri, C | 1 |
| Rizzi, A | 1 |
| Imperadore, F | 1 |
| Sangiorgi, GM | 2 |
| Carosio, G | 1 |
| Steffenino, G | 1 |
| Galvani, M | 1 |
| Di Pasquale, G | 1 |
| La Vecchia, L | 1 |
| Hong, MJ | 1 |
| Sung, IK | 1 |
| Shim, CS | 1 |
| Jin, CJ | 1 |
| Garg, AX | 1 |
| Kurz, A | 1 |
| Cuerden, M | 1 |
| Robinson, A | 1 |
| Parikh, CR | 1 |
| Mizera, R | 1 |
| Jones, PM | 1 |
| Tiboni, M | 1 |
| Font, A | 1 |
| Cegarra, V | 1 |
| Gomez, MF | 1 |
| VanHelder, T | 1 |
| Chan, MT | 2 |
| Torres, D | 1 |
| Parlow, J | 1 |
| Clanchet, Mde N | 1 |
| Amir, M | 1 |
| Bidgoli, SJ | 1 |
| Pasin, L | 1 |
| Martinsen, K | 1 |
| Myles, P | 1 |
| Acedillo, R | 1 |
| Roshanov, PS | 1 |
| Walsh, M | 1 |
| Dresser, G | 1 |
| Kumar, P | 1 |
| Biccard, B | 1 |
| Bergese, S | 1 |
| Srinathan, S | 1 |
| Chan, V | 1 |
| Mehra, B | 1 |
| Wijeysundera, DN | 2 |
| Forget, P | 1 |
| Driscoll-Shempp, P | 2 |
| Normand, SL | 2 |
| Wiviott, SD | 9 |
| Simon, DI | 2 |
| Kandzari, DE | 3 |
| Garratt, KN | 2 |
| Lee, DP | 2 |
| Pow, TK | 1 |
| Ver Lee, P | 1 |
| Deitelzweig, SB | 1 |
| Jing, Y | 1 |
| Swindle, JP | 1 |
| Makenbaeva, D | 1 |
| Pfisterer, ME | 1 |
| von Felten, S | 1 |
| Bonetti, PO | 1 |
| Erne, P | 1 |
| Kaiser, CA | 1 |
| Psotka, MA | 1 |
| Fleischmann, KE | 1 |
| Berland, J | 1 |
| Endresen, K | 1 |
| Benamer, H | 1 |
| Boschat, J | 1 |
| Geersing, GJ | 1 |
| Braun, OÖ | 2 |
| Bico, B | 1 |
| Chaudhry, U | 1 |
| Wagner, H | 1 |
| Koul, S | 3 |
| Tydén, P | 1 |
| Scherstén, F | 3 |
| Jovinge, S | 1 |
| Svensson, PJ | 3 |
| Gustav Smith, J | 1 |
| van der Pals, J | 2 |
| Warren, J | 1 |
| Alotaibi, GS | 1 |
| Alsaleh, K | 1 |
| Linkins, LA | 1 |
| McMurtry, MS | 1 |
| Bonde, AN | 1 |
| Kamper, AL | 2 |
| Hansen, PR | 3 |
| Hommel, K | 2 |
| Tian, Y | 1 |
| Sáez, ME | 1 |
| González-Pérez, A | 1 |
| Johansson, S | 1 |
| Nagy, P | 1 |
| Rodríguez, LA | 1 |
| Wada, N | 1 |
| Okazaki, S | 1 |
| Kobayashi, S | 1 |
| Hashizume, K | 1 |
| Hori, J | 1 |
| Azumi, M | 1 |
| Kita, M | 1 |
| Iwata, T | 1 |
| Matsumoto, S | 2 |
| Kakizaki, H | 1 |
| Yao, Y | 1 |
| Fu, C | 1 |
| Zuo, P | 1 |
| Ma, G | 1 |
| Yadav, M | 1 |
| Parvataneni, R | 3 |
| Hahn, R | 1 |
| Kodali, SK | 1 |
| Ferraris, VA | 3 |
| Bolanos, MD | 1 |
| Shang, X | 1 |
| Yan, C | 1 |
| Gallice, M | 1 |
| Rouberol, F | 1 |
| Brillat Zaratzian, E | 1 |
| Palombi, K | 1 |
| Aptel, F | 1 |
| Romanet, JP | 1 |
| Chiquet, C | 1 |
| Zhang, JT | 1 |
| Chen, KP | 1 |
| Garg, P | 1 |
| Galper, BZ | 1 |
| Bultas, J | 1 |
| Stoler, R | 1 |
| Oreto, G | 2 |
| Zijlstra, F | 3 |
| Patialiakas, A | 1 |
| McFadden, E | 1 |
| Colangelo, S | 1 |
| Tondi, S | 2 |
| Roffi, M | 1 |
| Menozzi, A | 1 |
| de Cesare, N | 1 |
| Garbo, R | 1 |
| Meliga, E | 1 |
| Testa, L | 1 |
| Gabriel, HM | 1 |
| Airoldi, F | 2 |
| Liistro, F | 1 |
| Dellavalle, A | 1 |
| Yu, CW | 1 |
| Kim, HD | 1 |
| Joo, HJ | 1 |
| Choi, RK | 1 |
| Park, JS | 5 |
| Lee, HJ | 1 |
| Jensen, EC | 2 |
| Bansilal, S | 3 |
| Fish, MP | 1 |
| Theroux, P | 5 |
| Ruda, M | 5 |
| Gershlick, AH | 3 |
| Ormiston, J | 1 |
| Iancu, AC | 1 |
| Trebacz, J | 1 |
| Sobieraj, DM | 1 |
| Coleman, CI | 2 |
| Pasupuleti, V | 1 |
| Deshpande, A | 1 |
| Kaw, R | 1 |
| Hernandez, AV | 1 |
| Grossomarra, W | 1 |
| Fernández, S | 1 |
| Meynet, I | 1 |
| Ballocca, F | 1 |
| Barbero, U | 1 |
| DiNicolantonio, J | 1 |
| Zoccai, G | 1 |
| Aguilar, C | 1 |
| Tangelder, MJ | 3 |
| Nwachuku, CE | 1 |
| Duggal, A | 1 |
| Mercuri, M | 1 |
| Shi, M | 1 |
| Moll, FL | 3 |
| Angoulvant, D | 1 |
| Villejoubert, O | 1 |
| Bejan-Angoulvant, T | 1 |
| Ivanes, F | 1 |
| Saint Etienne, C | 1 |
| Fauchier, L | 1 |
| Cai, TQ | 1 |
| Wickham, LA | 1 |
| Sitko, G | 1 |
| Michener, MS | 1 |
| Raubertas, R | 1 |
| Handt, L | 1 |
| Chintala, M | 1 |
| Seiffert, D | 2 |
| Forrest, M | 1 |
| Taylor, J | 1 |
| Monitillo, F | 1 |
| Iacoviello, M | 1 |
| Caldarola, P | 1 |
| Valle, R | 1 |
| Chiatto, M | 1 |
| Buffon, A | 1 |
| Brouwer, M | 1 |
| Kowalewski, M | 1 |
| Parati, G | 1 |
| Lee, SA | 1 |
| Suh, JW | 1 |
| Yoon, CH | 1 |
| Cho, YS | 1 |
| Youn, TJ | 1 |
| Kim, SH | 2 |
| Choi, DJ | 1 |
| Valenzuela, A | 1 |
| Aizman, A | 1 |
| Binder, A | 1 |
| Aledort, L | 1 |
| Danelich, IM | 1 |
| Wright, SS | 1 |
| Lose, JM | 1 |
| Tefft, BJ | 1 |
| Cicci, JD | 1 |
| Hassell, ME | 1 |
| Hildick-Smith, D | 1 |
| Durand, E | 1 |
| Wiegerinck, EM | 1 |
| Stabile, E | 1 |
| Rubino, P | 1 |
| Barbanti, M | 1 |
| Poliacikova, P | 1 |
| Lee, YS | 2 |
| Jin, CD | 1 |
| Guo, LZ | 2 |
| Park, K | 2 |
| Kim, YD | 2 |
| Kakkar, A | 1 |
| Prins, M | 1 |
| Gao, F | 2 |
| Shen, H | 2 |
| Wang, ZJ | 2 |
| Yang, SW | 2 |
| Liu, XL | 2 |
| Zhou, YJ | 2 |
| Huczek, Z | 2 |
| Parma, R | 1 |
| Scislo, P | 1 |
| Ochala, A | 1 |
| Lesiak, M | 1 |
| Olasinska-Wisniewska, A | 1 |
| Grabowski, M | 2 |
| Filipiak, KJ | 2 |
| Abo-Salem, E | 1 |
| Alsidawi, S | 1 |
| Jamali, H | 1 |
| Effat, M | 1 |
| Helmy, T | 1 |
| Eccleston, D | 1 |
| Reid, C | 1 |
| Bethel, MA | 1 |
| Harrison, P | 1 |
| Sourij, H | 1 |
| Tucker, L | 1 |
| Kennedy, I | 1 |
| White, S | 1 |
| Hill, L | 1 |
| Oulhaj, A | 1 |
| Coleman, RL | 1 |
| Holman, RR | 1 |
| Chung, JE | 1 |
| Choi, YR | 1 |
| Seong, JM | 1 |
| La, HO | 1 |
| Gwak, HS | 1 |
| Wågberg, F | 1 |
| Skärby, T | 1 |
| Gustafsson, D | 1 |
| Mo, C | 1 |
| Sun, G | 1 |
| Wang, YZ | 1 |
| Lu, ML | 1 |
| Yang, YS | 1 |
| Duceppe, E | 1 |
| Thomas, S | 1 |
| Ong, WL | 1 |
| Koh, TL | 1 |
| Fletcher, J | 1 |
| Gruen, R | 1 |
| Royce, P | 1 |
| Nam, D | 2 |
| Nunley, RM | 2 |
| Johnson, SR | 2 |
| Keeney, JA | 2 |
| Clohisy, JC | 2 |
| Barrack, RL | 2 |
| An, J | 1 |
| Niu, F | 1 |
| Lang, DT | 1 |
| Jazdzewski, KP | 1 |
| Le, PT | 1 |
| Rashid, N | 1 |
| Meissner, B | 1 |
| Mendes, R | 1 |
| Dills, DG | 1 |
| Aranda, G | 1 |
| Bruno, A | 1 |
| Cheng, B | 1 |
| Buchsbaum, R | 2 |
| Levin, B | 3 |
| Di Tullio, MR | 2 |
| Qian, M | 1 |
| Mann, DL | 2 |
| Pullicino, PM | 2 |
| Freudenberger, RS | 2 |
| Teerlink, JR | 2 |
| Mohr, JP | 3 |
| Graham, S | 2 |
| Labovitz, AJ | 2 |
| Estol, CJ | 2 |
| Lok, DJ | 2 |
| Ponikowski, P | 2 |
| Anker, SD | 3 |
| Thompson, JL | 3 |
| Homma, S | 4 |
| Oo, W | 1 |
| Kozikowski, A | 1 |
| Stein, J | 1 |
| Lolis, J | 1 |
| Pekmezaris, R | 1 |
| Makaryus, AN | 1 |
| Wolf-Klein, G | 1 |
| Skjøth, F | 1 |
| Nielsen, PB | 1 |
| Larsen, TB | 1 |
| Tricoci, P | 1 |
| Chang, L | 1 |
| Goldhammer, JE | 1 |
| Marhefka, GD | 1 |
| Daskalakis, C | 1 |
| Berguson, MW | 1 |
| Bowen, JE | 1 |
| Diehl, JT | 1 |
| Sun, J | 1 |
| Umans, VA | 1 |
| Schotten, J | 1 |
| Keijzers, M | 1 |
| Wolterbeek, R | 1 |
| Vonk, AB | 1 |
| Afzal, S | 1 |
| Balzer, J | 1 |
| Rassaf, T | 1 |
| Peng, SA | 1 |
| Fosbol, EL | 2 |
| Saucedo, JF | 1 |
| Wang, TY | 7 |
| Tan, S | 1 |
| Xiao, X | 1 |
| Yu, S | 1 |
| Xu, R | 1 |
| Hong, H | 1 |
| Welsh, KJ | 1 |
| Dasgupta, A | 1 |
| Nguyen, AN | 1 |
| Wahed, A | 1 |
| Tsoi, MF | 2 |
| Cheung, CL | 1 |
| Cheung, TT | 2 |
| Wong, IC | 1 |
| Kumana, CR | 1 |
| Tse, HF | 1 |
| Cheung, BM | 2 |
| Würtz, M | 2 |
| Nishi, H | 1 |
| Nakahara, I | 1 |
| Hashimoto, T | 1 |
| Ohta, T | 1 |
| Sadamasa, N | 1 |
| Ishibashi, R | 1 |
| Gomi, M | 1 |
| Saka, M | 1 |
| Miyata, H | 1 |
| Watanabe, S | 2 |
| Okata, T | 1 |
| Sonoda, K | 1 |
| Kouge, J | 1 |
| Ishii, A | 2 |
| Nagata, I | 1 |
| Kira, J | 1 |
| Mardekian, J | 1 |
| Calcagno, S | 1 |
| Lucisano, L | 1 |
| Mancone, M | 1 |
| Cavallo, E | 1 |
| Pennacchi, M | 1 |
| Stio, RE | 1 |
| Arif, SA | 1 |
| D'Souza, J | 1 |
| Gil, M | 1 |
| Gim, S | 1 |
| Bhal, V | 1 |
| Herr, MJ | 1 |
| Dixon, M | 1 |
| Akins, S | 1 |
| Hord, E | 1 |
| White, MM | 1 |
| Kotha, J | 1 |
| Jennings, LK | 2 |
| Triscott, J | 1 |
| Mercer, S | 1 |
| Tian, PG | 1 |
| Dobbs, B | 1 |
| Kander, EM | 1 |
| Raza, S | 2 |
| Zakarija, A | 1 |
| McMahon, BJ | 1 |
| Stein, BL | 1 |
| Mohar, DS | 1 |
| Seto, AH | 1 |
| Kern, MJ | 1 |
| Bundhun, PK | 1 |
| Qin, T | 1 |
| Chen, MH | 1 |
| Nagata, N | 1 |
| Niikura, R | 1 |
| Aoki, T | 1 |
| Moriyasu, S | 1 |
| Sakurai, T | 1 |
| Shimbo, T | 1 |
| Sekine, K | 1 |
| Okubo, H | 1 |
| Watanabe, K | 1 |
| Yokoi, C | 1 |
| Akiyama, J | 1 |
| Yanase, M | 1 |
| Mizokami, M | 1 |
| Fujimoto, K | 1 |
| De Buck, ED | 1 |
| Jensen, JL | 2 |
| Blanchard, IE | 1 |
| Herrington, RA | 1 |
| Pellegrino, JL | 2 |
| Lojero-Wheatley, LF | 2 |
| Ferguson, JD | 1 |
| MacPherson, AI | 1 |
| Smith, WW | 1 |
| Abadi, U | 1 |
| Ellis, MH | 1 |
| Senoo, K | 1 |
| Bacquelin, R | 1 |
| Filippi, E | 1 |
| Hacot, JP | 1 |
| Auffret, V | 1 |
| Le Guellec, M | 1 |
| Coudert, I | 1 |
| Moquet, B | 1 |
| Rialan, A | 1 |
| Rouault, G | 1 |
| Boulanger, B | 1 |
| Treuil, J | 1 |
| Leurent, G | 1 |
| Bedossa, M | 1 |
| Boulmier, D | 1 |
| Avez, B | 1 |
| Tanaka, Y | 1 |
| Karnyski, J | 1 |
| Dhillon, SS | 2 |
| Kumar, A | 2 |
| Harris, K | 3 |
| Sophia Popp, V | 1 |
| Hilkens, NA | 1 |
| Algra, A | 4 |
| Greving, JP | 1 |
| D'Agostino, RB | 2 |
| Levi, M | 2 |
| Marik, PE | 1 |
| Cavallazzi, R | 1 |
| Ng, KH | 1 |
| Samorodskaya, IV | 1 |
| Bolotova, EV | 1 |
| Boytsov, SA | 1 |
| van Es, GA | 1 |
| Wu, MC | 1 |
| Wu, TS | 1 |
| Tijssen, JG | 2 |
| Giatti, S | 1 |
| Guastaroba, P | 1 |
| De Palma, R | 1 |
| Lister, K | 1 |
| Louis Simonet, M | 1 |
| Hunter, JB | 1 |
| Carlson, ML | 1 |
| Sweeney, AD | 1 |
| Tombers, NM | 1 |
| Wanna, GB | 1 |
| Driscoll, CL | 1 |
| Haynes, DS | 1 |
| Hussein, A | 1 |
| Wazni, OM | 1 |
| Huang, F | 1 |
| Zou, Y | 1 |
| Zhu, E | 1 |
| Jackson, LR | 2 |
| Ju, C | 1 |
| Zettler, M | 1 |
| Messenger, JC | 1 |
| Baker, BA | 1 |
| Effron, M | 1 |
| Saeed, O | 1 |
| Shah, A | 1 |
| Kargoli, F | 1 |
| Madan, S | 1 |
| Levin, AP | 1 |
| Patel, SR | 1 |
| Jermyn, R | 1 |
| Guerrero, C | 1 |
| Nguyen, J | 1 |
| Sims, DB | 1 |
| Shin, J | 1 |
| D'Alessandro, D | 1 |
| Goldstein, DJ | 1 |
| Jorde, UP | 1 |
| Parikh, PB | 1 |
| Yıldırım, F | 1 |
| Kara, İ | 1 |
| Okuyan, H | 1 |
| Abacı, A | 1 |
| Türkoğlu, M | 1 |
| Aygencel, G | 1 |
| Kwon, TJ | 1 |
| Choi, YM | 1 |
| Ahn, JH | 1 |
| Kim, KH | 1 |
| Koh, JS | 1 |
| Park, JR | 1 |
| Hwang, SJ | 2 |
| Kwak, CH | 2 |
| Hwang, JY | 2 |
| Hermiller, JB | 1 |
| Lemesle, G | 2 |
| Schurtz, G | 1 |
| Meurice, T | 1 |
| Tricot, O | 1 |
| Lemaire, N | 1 |
| Caudmont, S | 1 |
| Philias, A | 1 |
| Ketelers, R | 1 |
| Lamblin, N | 1 |
| Bauters, C | 2 |
| Maehata, Y | 1 |
| Esaki, M | 1 |
| Kameda, M | 1 |
| Akiyoshi, D | 1 |
| Vazquez, FJ | 1 |
| Gonzalez, JP | 1 |
| LeGal, G | 1 |
| Mrdovic, I | 1 |
| Čolić, M | 1 |
| Savic, L | 1 |
| Krljanac, G | 1 |
| Kruzliak, P | 1 |
| Lasica, R | 1 |
| Asanin, M | 1 |
| Stanković, S | 1 |
| Marinkovic, J | 1 |
| Hu, Y | 1 |
| Parker, WA | 1 |
| Dan, GA | 1 |
| Trendafilova, E | 1 |
| Goda, A | 1 |
| Kusljugic, Z | 1 |
| Manola, S | 1 |
| Music, L | 1 |
| Musetescu, R | 1 |
| Badila, E | 1 |
| Mitic, G | 1 |
| Paparisto, V | 1 |
| Dimitrova, ES | 1 |
| Polovina, MM | 1 |
| Petranov, SL | 1 |
| Djergo, H | 1 |
| Loncar, D | 1 |
| Bijedic, A | 1 |
| Brusich, S | 1 |
| Wong, GC | 1 |
| Mayo, J | 1 |
| Bernstein, V | 1 |
| Mancini, GB | 4 |
| Ye, J | 1 |
| Skarsgard, P | 1 |
| Cairns, J | 1 |
| Green, SA | 1 |
| Cherian, T | 1 |
| Devlin, G | 1 |
| Jin, E | 1 |
| Shim, CH | 1 |
| Noh, Y | 1 |
| Shin, S | 1 |
| Lim, HS | 1 |
| Bae, SK | 1 |
| Oh, E | 1 |
| Kim, GJ | 1 |
| Jones, DW | 1 |
| Goodney, PP | 1 |
| Conrad, MF | 1 |
| Nolan, BW | 1 |
| Rzucidlo, EM | 1 |
| Powell, RJ | 1 |
| Cronenwett, JL | 1 |
| Stone, DH | 1 |
| Allende, M | 1 |
| Molina, E | 1 |
| Guruceaga, E | 1 |
| Tamayo, I | 1 |
| González-Porras, JR | 1 |
| Gonzalez-López, TJ | 1 |
| Toledo, E | 1 |
| Rabal, O | 1 |
| Ugarte, A | 1 |
| Roldán, V | 2 |
| Rivera, J | 1 |
| Oyarzabal, J | 1 |
| Montes, R | 1 |
| Hermida, J | 1 |
| Niu, PP | 1 |
| Guo, ZN | 1 |
| Jin, H | 1 |
| Xing, YQ | 1 |
| Yang, X | 1 |
| Camenzind, E | 1 |
| Bittl, JA | 1 |
| Fanaroff, AC | 1 |
| Chin, CT | 1 |
| Neely, B | 3 |
| Otoshi, T | 1 |
| Kataoka, Y | 1 |
| Nakagawa, A | 1 |
| Otsuka, K | 1 |
| Tomii, K | 1 |
| Kuder, J | 1 |
| Goodrich, E | 2 |
| Dalby, A | 1 |
| Abola, MTB | 1 |
| Elosua, R | 1 |
| Grau, M | 1 |
| Sayols-Baixeras, S | 1 |
| Dégano, IR | 1 |
| Hechler, B | 1 |
| Maître, B | 1 |
| Magnenat, S | 1 |
| Heim, V | 1 |
| El Mdawar, MB | 1 |
| Gachet, C | 2 |
| de la Salle, H | 1 |
| Burda, BU | 1 |
| Williams, SB | 1 |
| Bibbins-Domingo, K | 1 |
| Egholm, G | 1 |
| Thim, T | 1 |
| Olesen, KK | 1 |
| Madsen, M | 1 |
| Sorensen, HT | 1 |
| Jensen, SE | 1 |
| Jensen, LO | 1 |
| Botker, HE | 1 |
| Basaraba, JE | 2 |
| Barry, AR | 2 |
| Deirmengian, GK | 1 |
| Heller, S | 1 |
| Smith, EB | 1 |
| Maltenfort, M | 1 |
| Chen, AF | 1 |
| Tomek, A | 1 |
| Pya, Y | 1 |
| Bekbossynova, M | 1 |
| Metzger, C | 1 |
| Francese, DP | 1 |
| Ozan, O | 1 |
| Wong, KS | 3 |
| Kebbe, J | 1 |
| Modi, K | 1 |
| Alraiyes, AH | 1 |
| Attwood, K | 1 |
| Alansari, SA | 1 |
| Riaz, T | 2 |
| Luni, FK | 2 |
| Khan, AR | 2 |
| Riaz, IB | 2 |
| Krasuski, RA | 1 |
| An, VV | 1 |
| Phan, K | 1 |
| Levy, YD | 1 |
| Bruce, WJ | 1 |
| Cong, H | 1 |
| Shah, RR | 1 |
| Pillai, A | 1 |
| Omar, A | 1 |
| Arora, V | 1 |
| Kapoor, D | 1 |
| Poommipanit, P | 1 |
| Bagai, A | 1 |
| Cohen, EA | 3 |
| Vijayaraghavan, R | 1 |
| Niznick, J | 1 |
| Faza, NN | 1 |
| Mentias, A | 1 |
| Parashar, A | 1 |
| Chaudhury, P | 1 |
| Barakat, AF | 1 |
| Agarwal, S | 1 |
| Wayangankar, S | 2 |
| Murat Tuzcu, E | 1 |
| Iyengar, AJ | 1 |
| Winlaw, DS | 1 |
| Galati, JC | 1 |
| Wheaton, GR | 1 |
| Gentles, TL | 1 |
| Grigg, LE | 1 |
| Justo, RN | 1 |
| Radford, DJ | 1 |
| Weintraub, RG | 1 |
| Bullock, A | 1 |
| Sholler, GS | 1 |
| Celermajer, DS | 1 |
| Whalen, JD | 1 |
| Davies, G | 2 |
| Du, M | 2 |
| Oguz, M | 2 |
| Bash, LD | 1 |
| Ozer-Stillman, I | 1 |
| Moeschler, SM | 1 |
| Warner, NS | 1 |
| Lamer, TJ | 1 |
| Bendel, MA | 1 |
| Eldrige, JS | 1 |
| Mauck, WD | 1 |
| Gazelka, HM | 1 |
| Kor, DJ | 1 |
| Hoelzer, BC | 1 |
| Shimada, YJ | 1 |
| Zhang, YQ | 1 |
| Wei, CL | 1 |
| Hu, YH | 1 |
| Zang, H | 1 |
| Zhao, W | 1 |
| Timmis, A | 1 |
| Rapsomaniki, E | 1 |
| Chung, SC | 1 |
| Pujades-Rodriguez, M | 1 |
| Moayyeri, A | 1 |
| Stogiannis, D | 1 |
| Shah, AD | 1 |
| Pasea, L | 1 |
| Denaxas, S | 1 |
| Emmas, C | 1 |
| Hemingway, H | 1 |
| Oozeerally, I | 1 |
| Dawson, S | 1 |
| Riddleston, H | 1 |
| Barra, ME | 1 |
| Fanikos, J | 1 |
| Sylvester, KW | 1 |
| Piazza, G | 1 |
| Xu, J | 1 |
| Butt, M | 1 |
| Abdul, F | 1 |
| Yazji, K | 1 |
| Hailan, A | 1 |
| Gallagher, S | 1 |
| Ossei-Gerning, N | 1 |
| Chase, A | 1 |
| Choudhury, A | 2 |
| Smith, D | 1 |
| Anderson, R | 1 |
| Terrosu, P | 1 |
| Su, TH | 1 |
| Chan, YL | 1 |
| Lee, JD | 1 |
| Lin, LC | 1 |
| Wen, YW | 1 |
| Lee, TH | 1 |
| Fei, Y | 1 |
| Degrauwe, S | 1 |
| Iglesias, JF | 1 |
| Björck, F | 1 |
| Renlund, H | 1 |
| Wester, P | 1 |
| Själander, A | 1 |
| Hoshi, T | 1 |
| Sato, A | 1 |
| Nogami, A | 1 |
| Gosho, M | 1 |
| Aonuma, K | 1 |
| Westerman, ME | 1 |
| Sharma, V | 1 |
| Scales, J | 1 |
| Gearman, DJ | 1 |
| Ingimarsson, JP | 1 |
| Krambeck, AE | 1 |
| Koscielny, J | 1 |
| von Heymann, C | 1 |
| Spannagl, M | 1 |
| Labenz, J | 1 |
| Cremer, J | 1 |
| Giannitsis, E | 1 |
| Goss, F | 1 |
| Engheta, A | 1 |
| Hadadi Abianeh, S | 1 |
| Atri, A | 1 |
| Sanatkarfar, M | 1 |
| Cyr, DD | 1 |
| Magnus Ohman, E | 1 |
| Camaro, C | 1 |
| Damen, SA | 1 |
| Brouwer, MA | 3 |
| Barbieri, L | 2 |
| van T Hof, AW | 1 |
| Ligtenberg, E | 1 |
| de Boer, MJ | 2 |
| Marino, M | 2 |
| Esposito, G | 1 |
| Godley, RW | 1 |
| Hernandez-Vila, E | 1 |
| Koenig-Oberhuber, V | 1 |
| Filipovic, M | 1 |
| Resor, CD | 1 |
| Nathan, A | 1 |
| Gabriel Steg, P | 2 |
| Ophuis, TO | 1 |
| Hu, D | 1 |
| Jensen, E | 1 |
| Morrow, DA | 4 |
| Hellkamp, A | 1 |
| Lokhnygina, Y | 1 |
| Breithardt, G | 1 |
| Hacke, W | 5 |
| Halperin, JL | 5 |
| Nessel, CC | 1 |
| Shin, SJ | 1 |
| Lee, JH | 3 |
| Barillà, F | 1 |
| Pelliccia, F | 1 |
| Borzi, M | 1 |
| Camici, P | 1 |
| Cas, LD | 1 |
| Di Biase, M | 1 |
| Indolfi, C | 1 |
| Mercuro, G | 1 |
| Montemurro, V | 1 |
| Padeletti, L | 1 |
| Filardi, PP | 1 |
| Vizza, CD | 1 |
| Romeo, F | 1 |
| Saporito, R | 1 |
| Michael Gibson, C | 1 |
| Husnain, M | 1 |
| Taleb, M | 1 |
| Kanjwal, Y | 1 |
| Cooper, CJ | 1 |
| Khuder, SA | 1 |
| Gunarathne, A | 1 |
| Cosmi, B | 1 |
| Schaffer, A | 1 |
| Zhang, P | 1 |
| Jakubowski, JA | 2 |
| Ferri, LA | 1 |
| Grosseto, D | 1 |
| Tortorella, G | 1 |
| Bossi, I | 1 |
| Sganzerla, P | 1 |
| Cacucci, M | 1 |
| Sibilio, G | 1 |
| Toso, A | 1 |
| Gandolfo, N | 1 |
| Ravera, A | 1 |
| Mariani, M | 1 |
| Corrada, E | 1 |
| Di Ascenzo, L | 1 |
| Petronio, AS | 1 |
| Cavallini, C | 1 |
| Moffa, N | 1 |
| Wimmer, NJ | 1 |
| Dufour, AB | 1 |
| Cho, K | 1 |
| Gagnon, DR | 1 |
| Quach, L | 1 |
| Ly, S | 1 |
| Do, JM | 1 |
| Ostrowski, S | 1 |
| Michael Gaziano, J | 1 |
| Faxon, DP | 2 |
| Carrero, JJ | 1 |
| Szummer, K | 1 |
| Evans, M | 1 |
| Spaak, J | 1 |
| Aschenbrenner, DS | 1 |
| Hsiao, KC | 1 |
| Huang, JY | 1 |
| Lee, CT | 1 |
| Hung, TW | 1 |
| Liaw, YP | 1 |
| Chang, HR | 1 |
| Ruella, M | 1 |
| Soubeyran, P | 1 |
| Lee, JB | 1 |
| Doh, JH | 1 |
| Grodzinsky, A | 1 |
| Arnold, SV | 1 |
| Gosch, K | 1 |
| Jones, PG | 1 |
| Chhatriwalla, AK | 2 |
| Lind, M | 1 |
| Graham, G | 1 |
| Kosiborod, M | 1 |
| Badimon, J | 1 |
| Zafar, MU | 1 |
| Rafiq, S | 1 |
| Steinbrüchel, DA | 1 |
| Lilleør, NB | 1 |
| Møller, CH | 1 |
| Lund, JT | 1 |
| Thiis, JJ | 1 |
| Olsen, PS | 1 |
| Wong, CW | 1 |
| Owais, T | 1 |
| Rouman, M | 1 |
| Breuer, M | 1 |
| Hüter, L | 1 |
| Fuchs, J | 1 |
| Lauer, B | 1 |
| Kuntze, T | 1 |
| Baffour, FI | 1 |
| Hickson, LJ | 1 |
| Stegall, MD | 1 |
| Dean, PG | 1 |
| Gunderson, TM | 1 |
| Atwell, TD | 2 |
| Kurup, AN | 1 |
| Schmitz, JJ | 1 |
| Park, WD | 1 |
| Schmit, GD | 1 |
| Kukula, K | 1 |
| Klopotowski, M | 1 |
| Kunicki, P | 1 |
| Jamiolkowski, J | 1 |
| Debski, A | 1 |
| Bekta, P | 1 |
| Chmielak, Z | 1 |
| Witkowski, A | 2 |
| Stevens, SM | 1 |
| Doty, JR | 1 |
| Truong, DT | 1 |
| Johnson, JT | 1 |
| Bailly, DK | 1 |
| Clawson, JR | 1 |
| Sheng, X | 1 |
| Burch, PT | 1 |
| Witte, MK | 1 |
| LuAnn Minich, L | 1 |
| Ping, Y | 1 |
| He, P | 1 |
| Dai, H | 1 |
| Ambrosi, P | 1 |
| Daumas, A | 1 |
| Villani, P | 1 |
| Giorgi, R | 1 |
| Jalal, Z | 1 |
| Dinet, ML | 1 |
| Combes, N | 1 |
| Pillois, X | 1 |
| Renou, P | 1 |
| Sibon, I | 1 |
| Iriart, X | 1 |
| Thambo, JB | 1 |
| Zuo, FT | 1 |
| Wu, HJ | 1 |
| Su, N | 1 |
| Liu, JQ | 1 |
| Dong, AQ | 1 |
| Vom Dahl, J | 1 |
| Erbel, R | 1 |
| Münzel, T | 1 |
| Zahn, R | 5 |
| Roitenberg, A | 1 |
| Breitenstein, S | 1 |
| Desborough, MJR | 1 |
| Keeling, DM | 1 |
| Palmerini, T | 2 |
| Della Riva, D | 1 |
| Bacchi Reggiani, L | 1 |
| Sangiorgi, D | 1 |
| Angelini, GD | 1 |
| Oualim, S | 1 |
| Elharda, CA | 1 |
| Benzeroual, D | 1 |
| Hattaoui, ME | 1 |
| Rahman, MM | 1 |
| Scalese, MJ | 1 |
| Hansen, RA | 1 |
| Chen, YT | 1 |
| Chen, HT | 1 |
| Hsu, CY | 1 |
| Chao, PW | 1 |
| Kuo, SC | 1 |
| Ou, SM | 1 |
| Shih, CJ | 1 |
| Ooi, SY | 1 |
| Ding, F | 1 |
| Lyu, YL | 1 |
| Xuan, W | 1 |
| Liu, DY | 1 |
| Duan, XQ | 1 |
| Han, X | 1 |
| Freynhofer, MK | 1 |
| Iliev, L | 1 |
| Bruno, V | 1 |
| Hübl, W | 2 |
| Willheim, M | 1 |
| Wojta, J | 1 |
| Wilson, SJ | 1 |
| Newby, DE | 2 |
| Dawson, D | 1 |
| Irving, J | 1 |
| Berry, C | 1 |
| Cabrera-Fuentes, HA | 1 |
| Yoon, SC | 1 |
| Zuliani Mauro, MF | 1 |
| Costa, R | 1 |
| Piva E Mattos, LA | 1 |
| Siqueira, D | 1 |
| Sousa, A | 1 |
| Lim, SW | 1 |
| Kim, BS | 1 |
| Chase, M | 1 |
| Coons, JC | 1 |
| Iasella, CJ | 1 |
| Kane-Gill, SL | 1 |
| Gupta, R | 1 |
| Ozan, MO | 1 |
| Yokoyama, S | 1 |
| Motoyama, Y | 1 |
| Pilgrim, T | 1 |
| Zanchin, T | 1 |
| Steyerberg, EW | 1 |
| Sullivan, J | 1 |
| Amarshi, N | 1 |
| Payne, CD | 1 |
| Li, YG | 1 |
| Brandt, JT | 1 |
| Small, DS | 1 |
| Farid, NA | 1 |
| Salazar, DE | 1 |
| Mertens, L | 1 |
| Eyskens, B | 1 |
| Boshoff, D | 1 |
| Gewillig, M | 1 |
| Eizayaga, F | 1 |
| Pastor, FJ | 1 |
| Marín, F | 4 |
| Cambronero, F | 1 |
| Caro, C | 1 |
| Pascual-Figal, DA | 1 |
| Garrido, IP | 1 |
| Pinar, E | 1 |
| Pride, YB | 1 |
| Col, JJ | 1 |
| Bergovec, M | 1 |
| Zorkun, C | 1 |
| Buros, JL | 1 |
| Kent, DM | 1 |
| Thaler, DE | 1 |
| Ounpuu, S | 1 |
| Lawton, WA | 1 |
| Palesch, Y | 1 |
| Martin, RH | 1 |
| Bath, P | 1 |
| Chan, BP | 1 |
| Chen, ST | 1 |
| Dahlöf, B | 1 |
| De Keyser, J | 1 |
| Estol, C | 1 |
| Gorelick, P | 1 |
| Gu, V | 1 |
| Hermansson, K | 1 |
| Hilbrich, L | 1 |
| Kaste, M | 1 |
| Lu, C | 1 |
| Machnig, T | 2 |
| Roberts, R | 4 |
| Skvortsova, V | 1 |
| Teal, P | 1 |
| Vandermaelen, C | 1 |
| Voigt, T | 1 |
| Weber, M | 1 |
| Wu, TG | 1 |
| Huang, WG | 1 |
| Wei, JR | 1 |
| Huang, LP | 1 |
| Wang, LX | 2 |
| Zancan, A | 1 |
| Locatelli, C | 1 |
| Ramella, F | 1 |
| Tatoni, P | 1 |
| Bacis, G | 1 |
| Vecchio, S | 1 |
| Manzo, L | 1 |
| Jolly, SS | 1 |
| Pogue, J | 9 |
| Haladyn, K | 1 |
| Peters, RJ | 2 |
| Rupprecht, HJ | 4 |
| NEIVERT, H | 1 |
| LIVINGSTON, GS | 1 |
| NEARY, ER | 1 |
| Jackevicius, CA | 1 |
| Tu, JV | 1 |
| Demers, V | 1 |
| Melo, M | 1 |
| Rinfret, S | 3 |
| Kalavrouziotis, D | 1 |
| Johansen, H | 1 |
| Behlouli, H | 1 |
| Newman, A | 1 |
| Pilote, L | 2 |
| Millar, JA | 1 |
| Xiao, L | 1 |
| Alexander, KP | 3 |
| Kosiborod, MN | 1 |
| Rumsfeld, JS | 1 |
| Aronow, HD | 2 |
| Califf, RM | 8 |
| Vallee, M | 2 |
| Graffagnino, C | 2 |
| Fitzgerald, DJ | 4 |
| Ferguson, J | 2 |
| Koudstaal, PJ | 3 |
| Davis, S | 3 |
| Topol, EJ | 17 |
| Giannarini, G | 1 |
| Mogorovich, A | 1 |
| Selli, C | 1 |
| Graw, J | 1 |
| Schwenk, W | 1 |
| Volk, T | 1 |
| Lansky, AJ | 2 |
| Tsuchiya, Y | 1 |
| Brener, M | 1 |
| Cristea, E | 1 |
| Pietras, C | 1 |
| Grines, CL | 2 |
| Tcheng, JE | 5 |
| Turco, M | 2 |
| Carroll, JD | 1 |
| Rutherford, BD | 1 |
| Moses, J | 1 |
| Brambilla, N | 1 |
| Bonizzoni, E | 1 |
| Carlino, M | 1 |
| Bedogni, F | 1 |
| Montorfano, M | 1 |
| John, R | 3 |
| Kamdar, F | 1 |
| Liao, K | 1 |
| Colvin-Adams, M | 1 |
| Miller, L | 1 |
| Joyce, L | 1 |
| Boyle, A | 2 |
| Chrolavicius, S | 6 |
| Jolly, S | 2 |
| Molfese, M | 1 |
| Mihalcsik, L | 1 |
| Mantovani, P | 1 |
| Bass, TA | 1 |
| Della Rovere, F | 1 |
| Heer, T | 2 |
| Juenger, C | 1 |
| Gitt, AK | 1 |
| Bauer, T | 3 |
| Towae, F | 2 |
| Senges, J | 3 |
| Scharf, RE | 1 |
| Shalito, I | 1 |
| Kopyleva, O | 1 |
| Calatzis, A | 1 |
| Hobson, A | 1 |
| Curzen, N | 1 |
| Tay, KH | 2 |
| Schalekamp, T | 1 |
| Souverein, PC | 1 |
| de Boer, A | 1 |
| Sousa, AS | 1 |
| Xavier, SS | 1 |
| Freitas, GR | 1 |
| Hasslocher-Moreno, A | 1 |
| Jolobe, OM | 1 |
| Guasch, E | 1 |
| Sionis, A | 1 |
| Reverter, JC | 1 |
| Andrea, R | 1 |
| Loma-Osorio, P | 1 |
| Freixa, X | 1 |
| Heras, M | 2 |
| Brennan, DM | 5 |
| Berger, PB | 6 |
| Mohler, ER | 1 |
| Mak, KH | 3 |
| Shao, M | 2 |
| Haffner, SM | 2 |
| van den Bergh, PJ | 2 |
| Kievit, PC | 1 |
| Aengevaeren, WR | 2 |
| Veen, G | 3 |
| McCabe, CH | 6 |
| Fung, AY | 1 |
| Densem, C | 2 |
| Jokhi, P | 2 |
| Walsh, SJ | 2 |
| Fox, RS | 1 |
| Humphries, KH | 1 |
| Aymong, E | 1 |
| Ricci, DR | 1 |
| Hamburger, JN | 1 |
| Carere, RG | 1 |
| Buller, CE | 1 |
| Furlan, AJ | 1 |
| Zibaeenezhad, MJ | 1 |
| Mazloum, Y | 1 |
| McMahon, GS | 1 |
| Webster, SE | 1 |
| Hayes, PD | 1 |
| Jones, CI | 1 |
| Goodall, AH | 1 |
| Naylor, AR | 1 |
| Slattery, D | 1 |
| Pollack, CV | 3 |
| Pfeffer, M | 1 |
| Usman, MH | 1 |
| Notaro, LA | 1 |
| Nagarakanti, R | 1 |
| Brahin, E | 1 |
| Dessain, S | 1 |
| Gracely, E | 1 |
| Argüello Viudez, L | 1 |
| Biller, J | 1 |
| Ou, FS | 1 |
| Lordkipanidzé, M | 2 |
| Diodati, JG | 1 |
| Pharand, C | 1 |
| Jähne, J | 2 |
| Schirren, J | 2 |
| Rottbauer, W | 1 |
| Bölükbas, S | 1 |
| Martens, A | 1 |
| Haverich, A | 1 |
| Aleil, B | 1 |
| Jacquemin, L | 1 |
| Zaehringer, M | 1 |
| Cazenave, JP | 1 |
| Dickele, MC | 1 |
| Monassier, JP | 2 |
| Fox, R | 1 |
| Buller, C | 1 |
| Ricci, D | 1 |
| Fung, A | 1 |
| Bali, L | 2 |
| Moro, PJ | 1 |
| Cools, F | 3 |
| Mohan, P | 2 |
| Ruzyllo, W | 3 |
| Verheugt, F | 1 |
| Ageno, W | 2 |
| Cattaneo, R | 1 |
| Manfredi, E | 1 |
| Chelazzi, P | 1 |
| Venco, L | 1 |
| Ghirarduzzi, A | 2 |
| Cimino, L | 1 |
| Filippucci, E | 1 |
| Ricci, AL | 1 |
| Romanelli, D | 1 |
| Incorvaia, C | 1 |
| D'Angelo, S | 1 |
| Campana, F | 1 |
| Molfino, F | 1 |
| Scannapieco, G | 1 |
| Rubbi, F | 1 |
| Blackwell, L | 1 |
| Emberson, J | 1 |
| Godwin, J | 1 |
| Buring, J | 1 |
| Hennekens, C | 1 |
| Kearney, P | 1 |
| Meade, T | 1 |
| Zanchetti, A | 2 |
| Le Tourneau, T | 1 |
| Lim, V | 1 |
| Inamo, J | 1 |
| Miller, FA | 1 |
| Mahoney, DW | 1 |
| Enriquez-Sarano, M | 1 |
| Mega, JL | 1 |
| Mohanavelu, S | 1 |
| Poulter, R | 1 |
| Hricak, V | 1 |
| Barnathan, ES | 1 |
| Bordes, P | 1 |
| Markov, V | 1 |
| Oppenheimer, L | 1 |
| Spinler, SA | 2 |
| Jacobs, LG | 1 |
| Billett, HH | 2 |
| Freeman, K | 1 |
| Dinglas, C | 1 |
| Jumaquio, L | 1 |
| Moussa, ID | 1 |
| Kittisupamongkol, W | 1 |
| Kosar, A | 1 |
| Cipil, HS | 1 |
| Kaya, A | 1 |
| Uz, B | 1 |
| Haznedaroglu, IC | 1 |
| Goker, H | 1 |
| Ozdemir, O | 1 |
| Ercetin, S | 1 |
| Kirazli, S | 1 |
| Firat, HC | 1 |
| Van Werkum, JW | 1 |
| Dill, T | 1 |
| Gosselink, AT | 2 |
| Van Houwelingen, G | 2 |
| Hoorntje, JC | 1 |
| Koopmans, PC | 1 |
| Boyle, AJ | 1 |
| Russell, SD | 2 |
| Teuteberg, JJ | 1 |
| Slaughter, MS | 2 |
| Moazami, N | 1 |
| Pagani, FD | 2 |
| Frazier, OH | 1 |
| Heatley, G | 1 |
| Farrar, DJ | 2 |
| Mathias, JM | 1 |
| Unger, EF | 1 |
| Poyet, R | 1 |
| Gaborit, B | 2 |
| Tamhane, U | 1 |
| Chetcuti, S | 1 |
| Chen, KY | 1 |
| Grossman, MP | 1 |
| Gurm, H | 1 |
| Bagur, R | 2 |
| Bertrand, OF | 2 |
| Larose, E | 2 |
| Nguyen, CM | 2 |
| Noel, B | 1 |
| Larochellière, RD | 1 |
| Poirier, P | 2 |
| Costerousse, O | 2 |
| Roy, L | 2 |
| Aranki, SF | 1 |
| Body, SC | 1 |
| Goldstein, LB | 1 |
| Richard, T | 1 |
| Butaffuoco, F | 1 |
| Vanhaeverbeek, M | 1 |
| Watson, PD | 1 |
| Joy, PS | 1 |
| Nkonde, C | 1 |
| Hessen, SE | 1 |
| Karalis, DG | 1 |
| van Hattum, ES | 1 |
| Lawson, JA | 2 |
| Eikelboom, BC | 2 |
| Proulx, G | 1 |
| Gleeton, O | 1 |
| De Larochellière, R | 1 |
| Badreldin, A | 1 |
| Kroener, A | 1 |
| Kamiya, H | 1 |
| Lichtenberg, A | 1 |
| Hekmat, K | 1 |
| Quinn, J | 1 |
| Von Klemperer, K | 1 |
| Brooks, R | 1 |
| Peebles, D | 1 |
| Walker, F | 1 |
| Cohen, H | 2 |
| Apostolakis, S | 1 |
| Fitchett, D | 2 |
| Fremes, S | 1 |
| Mazer, D | 1 |
| Singh, S | 1 |
| Bittira, B | 1 |
| Brister, S | 1 |
| Graham, J | 1 |
| Gupta, M | 1 |
| Love, M | 1 |
| McArthur, R | 1 |
| Peterson, M | 3 |
| Yau, T | 1 |
| Abildstrom, SZ | 1 |
| Hvelplund, A | 1 |
| Andersson, C | 1 |
| Jørgensen, C | 1 |
| Madsen, JK | 1 |
| Lim, W | 3 |
| Gunay, R | 1 |
| Sensoz, Y | 1 |
| Kayacioglu, I | 1 |
| Demirtas, MM | 1 |
| Lee, BH | 1 |
| Kwak, JJ | 1 |
| Hwang, ES | 1 |
| Kim, SK | 1 |
| Choi, DH | 1 |
| Gitt, A | 2 |
| Jünger, C | 2 |
| Koeth, O | 2 |
| Bestehorn, K | 1 |
| Gerber, RT | 1 |
| Le May, MR | 2 |
| Wells, GA | 2 |
| Glover, CA | 1 |
| So, DY | 1 |
| Froeschl, M | 1 |
| Marquis, JF | 1 |
| O'Brien, ER | 1 |
| Turek, M | 2 |
| Thomas, A | 1 |
| Kass, M | 1 |
| Jadhav, S | 1 |
| Labinaz, M | 1 |
| Naganawa, S | 1 |
| Ishihara, S | 1 |
| Iwano, S | 1 |
| Sone, M | 1 |
| Nakashima, T | 1 |
| Preobrazhenskiĭ, DV | 2 |
| Vural, A | 1 |
| Islek, M | 1 |
| Avsar, O | 1 |
| Moia, M | 2 |
| Mannucci, PM | 3 |
| Wait, SD | 1 |
| Abla, AA | 1 |
| Killory, BD | 1 |
| Starke, RM | 1 |
| Spetzler, RF | 1 |
| Pullicino, P | 3 |
| Tapp, L | 1 |
| Schwalm, JD | 1 |
| Ahmad, M | 1 |
| Salehian, O | 1 |
| Natarajan, MK | 1 |
| Levi, MM | 1 |
| Eerenberg, E | 1 |
| Löwenberg, E | 1 |
| Kamphuisen, PW | 1 |
| Smith, RL | 1 |
| Hesley, GK | 1 |
| Callstrom, MR | 1 |
| Schleck, CD | 1 |
| Harmsen, WS | 1 |
| Charboneau, JW | 1 |
| Welch, TJ | 1 |
| Tsukahara, K | 1 |
| Morita, S | 1 |
| Ebina, T | 1 |
| Kosuge, M | 1 |
| Okuda, J | 1 |
| Iwahashi, N | 1 |
| Maejima, N | 1 |
| Nakachi, T | 1 |
| Ohtsuka, F | 1 |
| Hashiba, K | 1 |
| Tahara, Y | 1 |
| Sugano, T | 1 |
| Umemura, S | 1 |
| Nie, B | 1 |
| Yan, ZX | 1 |
| Jia, de A | 1 |
| Yu, M | 1 |
| Flaker, G | 4 |
| Hart, R | 3 |
| Hohnloser, S | 2 |
| Lawrence, J | 3 |
| Yamada, N | 1 |
| Doraiswamy, VA | 1 |
| Rosove, MH | 1 |
| Harwig, SS | 1 |
| Islam, AM | 1 |
| Patel, PM | 1 |
| Dumont, LA | 1 |
| Rongières, M | 1 |
| Tchénio, P | 1 |
| Gangloff, D | 1 |
| Garrido-Stowhas, I | 1 |
| Mousa, SA | 1 |
| Jeske, WP | 1 |
| Fareed, J | 1 |
| Kennedy, J | 1 |
| Chandratheva, A | 1 |
| Marquardt, L | 1 |
| Buchan, AM | 1 |
| ElBardissi, AW | 1 |
| DiBardino, DJ | 1 |
| Chen, FY | 1 |
| Yamashita, MH | 1 |
| Cohn, LH | 1 |
| Pickett, AM | 1 |
| Taylor, DA | 1 |
| Burrill, PD | 1 |
| Uchida, Y | 1 |
| Stiefelhagen, P | 2 |
| Naka, Y | 1 |
| Conte, JV | 1 |
| Aaronson, KD | 1 |
| Sundareswaran, KS | 1 |
| Scheinowitz, M | 1 |
| Delhaye, C | 2 |
| Syed, AI | 1 |
| Collins, SD | 1 |
| Gonzalez, MA | 1 |
| Gaglia, MA | 1 |
| Kaneshige, K | 1 |
| Suddath, WO | 1 |
| Kent, KM | 1 |
| Sudre, A | 1 |
| Lablanche, JM | 1 |
| Fuster, V | 5 |
| Ambrosio, G | 1 |
| Steinhubl, S | 1 |
| Gresele, P | 3 |
| Tritto, I | 1 |
| Zuchi, C | 1 |
| Bertrand, ME | 2 |
| Lincoff, AM | 5 |
| Moses, JW | 2 |
| Yusuf, SW | 2 |
| Iliescu, C | 1 |
| Bathina, JD | 1 |
| Daher, IN | 1 |
| Durand, JB | 2 |
| Burdess, A | 1 |
| Nimmo, AF | 1 |
| Garden, OJ | 1 |
| Murie, JA | 1 |
| Dawson, AR | 1 |
| Flather, MD | 3 |
| Kondrat'eva, LV | 1 |
| Patrusheva, NL | 1 |
| Patrushev, LI | 1 |
| Aleksandrova, EN | 1 |
| Kovalenko, TF | 1 |
| Ostriakova, EV | 1 |
| Reshetniak, TM | 1 |
| Chen, YY | 1 |
| Yi, CH | 1 |
| Chen, CL | 1 |
| Huang, SC | 1 |
| Schöchl, H | 1 |
| Posch, A | 1 |
| Hanke, A | 1 |
| Voelckel, W | 1 |
| Solomon, C | 1 |
| Kuznetsov, MR | 1 |
| Tepliakov, SA | 1 |
| Sizarev, AV | 1 |
| Tugdumov, BV | 1 |
| Dzhalilova, NS | 1 |
| Pevzner, DV | 1 |
| Staroverov, II | 1 |
| Frolova, NS | 1 |
| Mazurov, AV | 1 |
| Ruda, MY | 1 |
| Hindy-François, C | 1 |
| Le Bonniec, B | 1 |
| Grelac, F | 1 |
| Emmerich, J | 1 |
| Samama, CM | 2 |
| Belch, JJ | 1 |
| Dormandy, J | 1 |
| Biasi, GM | 1 |
| Biasi, BM | 1 |
| Cairols, M | 1 |
| Diehm, C | 1 |
| Eikelboom, B | 1 |
| Golledge, J | 1 |
| Jawien, A | 1 |
| Lepäntalo, M | 1 |
| Becquemin, JP | 1 |
| Bergqvist, D | 2 |
| Clement, D | 1 |
| Stonebridge, P | 1 |
| Vermassen, F | 1 |
| Leizorovicz, A | 1 |
| Merino, A | 1 |
| Roldán, I | 1 |
| Worner, F | 1 |
| Danchin, N | 1 |
| Aïssaoui, N | 1 |
| Nitschmann, S | 2 |
| Buntic, RF | 1 |
| Brooks, D | 1 |
| Joyner, CD | 1 |
| Afzal, R | 2 |
| Jardine, MJ | 1 |
| Ninomiya, T | 1 |
| Perkovic, V | 1 |
| Cass, A | 1 |
| Turnbull, F | 1 |
| Gallagher, MP | 1 |
| Zoungas, S | 1 |
| Lambers Heerspink, HJ | 1 |
| Chalmers, J | 1 |
| Wali, RK | 1 |
| Niiazova-Karben, ZA | 1 |
| Besnili, F | 1 |
| Clausen, MT | 1 |
| Fog-Petersen, ML | 1 |
| Raunsø, J | 2 |
| Gadsbøll, N | 1 |
| Folke, F | 1 |
| Andersen, SS | 1 |
| Schramm, TK | 1 |
| Abildstrøm, SZ | 1 |
| Poulsen, HE | 1 |
| Kim, IS | 1 |
| Yun, SE | 1 |
| Kang, MK | 1 |
| Colli, A | 2 |
| D'Amico, R | 2 |
| Mestres, CA | 1 |
| Pomar, JL | 1 |
| Cámara, ML | 1 |
| Ruyra, X | 1 |
| Mulet, J | 1 |
| Sharifi, M | 1 |
| Mehdipour, M | 1 |
| Bay, C | 1 |
| Emrani, F | 1 |
| Sharifi, J | 1 |
| Gaskell, H | 1 |
| Derry, S | 1 |
| Moore, RA | 1 |
| Wetsch, WA | 1 |
| Spöhr, F | 1 |
| Teschendorf, P | 1 |
| Böttiger, BW | 1 |
| Padosch, SA | 1 |
| Schlitt, A | 2 |
| Mauer, AC | 1 |
| Khazanov, NA | 1 |
| Levenkova, N | 1 |
| Tian, S | 1 |
| Barbour, EM | 1 |
| Khalida, C | 1 |
| Tobin, JN | 1 |
| Coller, BS | 2 |
| Lavitola, Pde L | 1 |
| Oliveira, WA | 1 |
| Bôer, BN | 1 |
| Spina, GS | 1 |
| Grinberg, M | 1 |
| CAHN, L | 1 |
| Ge, FJ | 1 |
| Xu, JM | 1 |
| Shehab, N | 1 |
| Kegler, SR | 1 |
| Budnitz, DS | 1 |
| Galloway, CF | 1 |
| Stevenson, JC | 1 |
| Gendlin, GE | 1 |
| Tronina, OA | 1 |
| Storozhakov, GI | 1 |
| Voisine, P | 1 |
| Tardif, JC | 1 |
| Delarochelliere, R | 1 |
| Naidoo, S | 1 |
| Mesana, TG | 1 |
| Minarelli, M | 1 |
| Rechner, AR | 1 |
| Ivandic, B | 1 |
| Frey, N | 1 |
| Singh, PP | 1 |
| Singh, M | 1 |
| Bedi, U | 1 |
| Molnar, J | 1 |
| Arora, R | 1 |
| Khosla, S | 1 |
| Stavrakis, S | 1 |
| Stoner, JA | 1 |
| Azar, M | 1 |
| Thadani, U | 1 |
| Nagler, M | 1 |
| Haslauer, M | 1 |
| Wuillemin, WA | 1 |
| Huang, ES | 1 |
| Strate, LL | 1 |
| Ho, WW | 1 |
| Lee, SS | 1 |
| Li, XY | 1 |
| Václavík, J | 1 |
| Táborský, M | 1 |
| Cadiou, G | 1 |
| Adam, M | 1 |
| Caussin, M | 1 |
| Landrin, I | 1 |
| Mariette, N | 1 |
| Capet, C | 1 |
| Mouton-Schleifer, D | 1 |
| Remy, E | 1 |
| Kadri, N | 1 |
| Doucet, J | 1 |
| Fouda, UM | 1 |
| Sayed, AM | 1 |
| Abdou, AM | 1 |
| Ramadan, DI | 1 |
| Fouda, IM | 1 |
| Zaki, MM | 1 |
| Htun, P | 1 |
| Fateh-Moghadam, S | 1 |
| Bischofs, C | 1 |
| Banya, W | 1 |
| Müller, K | 1 |
| Bigalke, B | 1 |
| Stellos, K | 2 |
| May, AE | 2 |
| Flather, M | 3 |
| Gawaz, M | 3 |
| Cay, S | 1 |
| Cagirci, G | 1 |
| Aydogdu, S | 1 |
| Balbay, Y | 1 |
| Sen, N | 1 |
| Maden, O | 1 |
| Demir, AD | 1 |
| Erbay, AR | 1 |
| Palumbo, A | 1 |
| Cavo, M | 1 |
| Bringhen, S | 1 |
| Zamagni, E | 1 |
| Romano, A | 1 |
| Patriarca, F | 1 |
| Rossi, D | 1 |
| Gentilini, F | 1 |
| Crippa, C | 1 |
| Nozzoli, C | 1 |
| Ria, R | 1 |
| Marasca, R | 1 |
| Montefusco, V | 1 |
| Baldini, L | 1 |
| Elice, F | 1 |
| Callea, V | 1 |
| Pulini, S | 1 |
| Carella, AM | 1 |
| Zambello, R | 1 |
| Benevolo, G | 1 |
| Magarotto, V | 1 |
| Tacchetti, P | 1 |
| Pescosta, N | 1 |
| Cellini, C | 1 |
| Polloni, C | 1 |
| Evangelista, A | 1 |
| Caravita, T | 1 |
| Morabito, F | 1 |
| Offidani, M | 1 |
| Tosi, P | 1 |
| Boccadoro, M | 1 |
| Vik-Mo, H | 1 |
| Golitsyn, S | 1 |
| Talajic, M | 1 |
| Commerford, P | 1 |
| Tan, RS | 1 |
| Sim, KH | 1 |
| Van Mieghem, W | 2 |
| Lanas-Zanetti, F | 1 |
| Gonzalez-Hermosillo, A | 1 |
| Munawar, M | 1 |
| Lewis, G | 1 |
| Suissa, S | 1 |
| Connor, S' | 1 |
| Payot, L | 2 |
| Bellemain-Appaix, A | 1 |
| Aout, M | 1 |
| Butalia, S | 1 |
| Leung, AA | 1 |
| Ghali, WA | 1 |
| Rabi, DM | 1 |
| Dechartres, A | 1 |
| Mantz, J | 1 |
| Ravaud, P | 1 |
| Lindbäck, J | 1 |
| Hofman-Bang, C | 1 |
| Stenestrand, U | 1 |
| Samnegard, A | 1 |
| Ziegelstein, RC | 1 |
| Green, A | 1 |
| Sauder, M | 1 |
| Guthrie, R | 1 |
| Khder, Y | 1 |
| Roberts, J | 1 |
| Mantovani, F | 1 |
| Demola, MA | 1 |
| Wald, NJ | 1 |
| Morris, JK | 1 |
| Law, MR | 1 |
| Hochholzer, W | 1 |
| Contant, CF | 1 |
| Guo, J | 1 |
| Giugliano, RP | 1 |
| Kang, DW | 1 |
| Yu, K | 1 |
| Kwon, SU | 1 |
| Lee, KB | 1 |
| Rha, JH | 1 |
| Koo, J | 1 |
| Han, MG | 1 |
| Jung, SW | 1 |
| Cohen, MG | 2 |
| Rossi, JS | 1 |
| Garbarino, J | 1 |
| Bowling, R | 1 |
| Motsinger-Reif, AA | 1 |
| Schuler, C | 1 |
| Dupont, AG | 1 |
| Gabriel, D | 1 |
| Smith, JG | 2 |
| Lala, A | 1 |
| Krantz, MJ | 1 |
| Baker, GS | 1 |
| Kilaru, R | 1 |
| Husted, SE | 2 |
| White, H | 1 |
| Geraldes, M | 1 |
| Lindhardsen, J | 2 |
| Ahlehoff, O | 1 |
| Tolstrup, JS | 1 |
| Bakaeen, FG | 1 |
| Chu, D | 1 |
| Dong, MF | 1 |
| Ma, ZS | 1 |
| Ma, SJ | 1 |
| Chai, SD | 1 |
| Tang, PZ | 1 |
| Yao, DK | 1 |
| Di Minno, MN | 1 |
| Guida, A | 1 |
| Camera, M | 1 |
| Colli, S | 1 |
| Di Minno, G | 2 |
| Tremoli, E | 1 |
| Lee, JS | 1 |
| Ahn, SW | 1 |
| Song, JW | 1 |
| Shim, JK | 1 |
| Yoo, KJ | 1 |
| Kwak, YL | 1 |
| Grosdidier, C | 1 |
| Pankert, M | 1 |
| Molines, L | 1 |
| Abu-Yousef, MM | 1 |
| Larson, JH | 1 |
| Kuehn, DM | 1 |
| Wu, AS | 1 |
| Laroia, AT | 1 |
| Awad, HH | 1 |
| Zubaid, M | 1 |
| Alsheikh-Ali, AA | 1 |
| Al Suwaidi, J | 1 |
| Anderson, FA | 1 |
| Gore, JM | 3 |
| Goldberg, RJ | 1 |
| Hollingsworth, B | 1 |
| Kalinczuk, L | 1 |
| Lubiszewska, B | 1 |
| Demkow, M | 1 |
| Morgan, G | 1 |
| Elwood, P | 1 |
| Asinger, RW | 1 |
| Herzog, CA | 1 |
| Duschek, N | 1 |
| Vafaie, M | 1 |
| Skrinjar, E | 1 |
| Hirsch, K | 1 |
| Waldhör, T | 1 |
| Bergmayr, W | 1 |
| Knoebl, P | 1 |
| Assadian, A | 1 |
| Nakamoto, DA | 1 |
| Wilkins, LR | 1 |
| Haaga, JR | 2 |
| Labos, C | 1 |
| Dasgupta, K | 1 |
| Nedjar, H | 1 |
| Turecki, G | 1 |
| Rahme, E | 1 |
| Winkle, RA | 1 |
| Mead, RH | 1 |
| Engel, G | 1 |
| Kong, MH | 1 |
| Patrawala, RA | 1 |
| Dalén, M | 1 |
| van der Linden, J | 1 |
| Lindvall, G | 1 |
| Ivert, T | 1 |
| Fraenkel, L | 1 |
| Street, RL | 1 |
| Fried, TR | 1 |
| Nielsen, VG | 1 |
| Chawla, N | 1 |
| Mangla, D | 1 |
| Gomes, SB | 1 |
| Arkebauer, MR | 1 |
| Wasko, KA | 1 |
| Sadacharam, K | 1 |
| Vosseller, K | 1 |
| Mariscalco, G | 1 |
| Bruno, VD | 1 |
| Cottini, M | 1 |
| Borsani, P | 1 |
| Dominici, C | 1 |
| Beghi, C | 2 |
| Sala, A | 1 |
| Negri, E | 1 |
| Gaeta, M | 1 |
| Pavesi, M | 1 |
| Ng, J | 1 |
| Hirsh, J | 10 |
| French, J | 1 |
| Horrow, J | 2 |
| Lassila, R | 1 |
| Dorresteijn, JA | 1 |
| Visseren, FL | 1 |
| Paynter, NP | 1 |
| Wassink, AM | 1 |
| Cook, NR | 1 |
| Basra, SS | 1 |
| Tsai, P | 1 |
| Lakkis, NM | 1 |
| Rosiello, R | 1 |
| Pant, S | 1 |
| Neupane, P | 1 |
| Ramesh, KC | 1 |
| Barakoti, M | 1 |
| Parvaiz, MA | 1 |
| Korwar, V | 1 |
| McArthur, D | 1 |
| Claxton, A | 1 |
| Dyer, J | 1 |
| Isgar, B | 1 |
| Romero-Ortuno, R | 1 |
| O'Shea, D | 1 |
| Hong, TJ | 1 |
| Chung, WY | 1 |
| Choi, YJ | 1 |
| Kim, BO | 1 |
| Calenda, E | 1 |
| Cardon-Guiton, A | 1 |
| Genevois, O | 1 |
| Gueudry, J | 1 |
| Muraine, M | 1 |
| Eriksson, BI | 1 |
| Rosencher, N | 1 |
| Friedman, RJ | 1 |
| Homering, M | 1 |
| Dahl, OE | 1 |
| Mayor, S | 1 |
| Westheim, BH | 1 |
| Østensen, AB | 1 |
| Aagenæs, I | 1 |
| Sanengen, T | 1 |
| Almaas, R | 1 |
| Warkentin, AE | 1 |
| Spencer, FA | 3 |
| You, JJ | 1 |
| Howard, PA | 1 |
| Eckman, MH | 1 |
| Fang, MC | 1 |
| Schulman, S | 1 |
| Hughes, M | 1 |
| Manning, WJ | 1 |
| Whitlock, RP | 1 |
| Sun, JC | 1 |
| Rubens, FD | 1 |
| Teoh, KH | 2 |
| Veelo, DP | 1 |
| Vlaar, AP | 1 |
| Dongelmans, DA | 1 |
| Binnekade, JM | 1 |
| Paulus, F | 1 |
| Berends, F | 1 |
| Schultz, MJ | 1 |
| Stakos, DA | 1 |
| Tziakas, DN | 1 |
| Zhou, YH | 1 |
| Wei, X | 1 |
| Lu, J | 1 |
| Ye, XF | 1 |
| Wu, MJ | 1 |
| Xu, JF | 1 |
| Qin, YY | 1 |
| He, J | 1 |
| Perera, M | 1 |
| Suarez, A | 1 |
| Luzardo, H | 1 |
| Lopez, J | 1 |
| Molero, T | 1 |
| Ottervanger, JP | 1 |
| Dambrink, JH | 1 |
| Rossi, M | 1 |
| Serraino, GF | 1 |
| Spadafora, A | 1 |
| Renzulli, A | 1 |
| Gerstein, NS | 1 |
| Schulman, PM | 1 |
| Gerstein, WH | 1 |
| Petersen, TR | 1 |
| Tawil, I | 1 |
| Mydin, MI | 1 |
| Dimitrakakis, G | 1 |
| Younis, J | 1 |
| Nowell, J | 1 |
| Athanasiou, T | 1 |
| Kourliouros, A | 1 |
| Wiener-Kronish, JP | 1 |
| Shah, B | 1 |
| Mills, RM | 1 |
| Klaskala, W | 1 |
| Di Pierro, F | 1 |
| Rinaldi, F | 1 |
| Lucarelli, M | 1 |
| Rossoni, G | 1 |
| Casado-Arroyo, R | 1 |
| Gargallo, C | 1 |
| Lanas Arbeloa, A | 1 |
| Ammon, SE | 1 |
| Massie, BM | 1 |
| Sanford, AR | 1 |
| Mejia, V | 1 |
| Gabriel, AP | 1 |
| del Valle, ML | 1 |
| Sheikh-Taha, M | 1 |
| Ghosn, S | 1 |
| Varughese, CJ | 1 |
| Iwabuchi, M | 1 |
| Shizuta, S | 1 |
| Tazaki, J | 1 |
| Ehara, N | 1 |
| Mizoguchi, T | 1 |
| Mitsuoka, H | 1 |
| Araki, M | 1 |
| Kaburagi, S | 1 |
| Eizawa, H | 1 |
| Nakano, A | 1 |
| Takizawa, A | 1 |
| Nohara, R | 1 |
| Fujiwara, H | 1 |
| Mitsudo, K | 1 |
| Nobuyoshi, M | 1 |
| Kita, T | 2 |
| Caudrillier, A | 1 |
| Looney, MR | 1 |
| Schenone, A | 1 |
| Eichinger, S | 1 |
| Bucherini, E | 1 |
| Silingardi, M | 1 |
| Bianchi, M | 1 |
| Vandelli, MR | 1 |
| Grandone, E | 1 |
| Smith, PK | 1 |
| Goodnough, LT | 1 |
| Levy, JH | 1 |
| Poston, RS | 1 |
| Short, MA | 1 |
| Weerakkody, GJ | 1 |
| Lenarz, LA | 1 |
| Harrasser, N | 1 |
| Harnoss, T | 1 |
| Brettner, F | 1 |
| Liska, F | 1 |
| Pauschinger, M | 1 |
| Lawler, E | 2 |
| Young, M | 1 |
| Gaziano, M | 1 |
| Warlé-Van Herwaarden, MF | 1 |
| Roukens, M | 1 |
| Pop, GA | 1 |
| Lamfers, EJ | 1 |
| De Smet, PA | 1 |
| Kramers, C | 1 |
| Ueno, T | 1 |
| Igarashi, K | 1 |
| Kobayashi, M | 1 |
| Ahmad, S | 1 |
| Bessereau, J | 1 |
| Sébastien, A | 1 |
| Anglade, MW | 1 |
| Meng, J | 1 |
| Hagstrom, K | 1 |
| Kluger, J | 1 |
| Foody, JM | 1 |
| Funk, M | 1 |
| Tello-Montoliu, A | 1 |
| Paolasso, E | 1 |
| Schoenefeld, E | 1 |
| Donas, K | 1 |
| Radicke, A | 1 |
| Osada, N | 1 |
| Austermann, M | 1 |
| Torsello, G | 1 |
| Geng, DF | 1 |
| Jin, DM | 1 |
| Wu, W | 1 |
| Wang, JF | 1 |
| Shevelev, VI | 1 |
| Kanorskiĭ, SG | 1 |
| Limper, U | 1 |
| Lynch, J | 1 |
| Sakaeda, T | 1 |
| Kadoyama, K | 1 |
| Okuno, Y | 1 |
| Ruwald, MH | 1 |
| Hansen, CM | 1 |
| Karasoy, D | 1 |
| Kristensen, SL | 1 |
| Raju, NC | 1 |
| Sallum, RH | 1 |
| Katona, B | 1 |
| Maya, J | 1 |
| Ranganathan, G | 1 |
| Mwamburi, M | 1 |
| Yamane, K | 1 |
| Kawato, M | 1 |
| Kondo, H | 1 |
| Shirakawa, R | 1 |
| Higashi, T | 1 |
| Toma, M | 1 |
| Tabuchi, A | 1 |
| Yoshikawa, Y | 1 |
| Horiuchi, H | 1 |
| Vavalle, JP | 1 |
| Gasparovic, H | 1 |
| Petricevic, M | 1 |
| Kopjar, T | 1 |
| Djuric, Z | 1 |
| Svetina, L | 1 |
| Biocina, B | 1 |
| Brennan, JM | 1 |
| Edwards, FH | 1 |
| O'Brien, S | 1 |
| Booth, ME | 1 |
| Dokholyan, RS | 1 |
| Douglas, PS | 1 |
| McClure, LA | 1 |
| Szychowski, JM | 1 |
| El Mallah, W | 1 |
| Chowdhury, R | 1 |
| Abbas, A | 1 |
| Idriz, S | 1 |
| Hoy, A | 1 |
| Rutherford, EE | 1 |
| Smart, JM | 1 |
| Al-Atassi, T | 1 |
| Lam, K | 1 |
| Forgie, M | 1 |
| Boodhwani, M | 1 |
| Rubens, F | 1 |
| Hendry, P | 1 |
| Masters, R | 1 |
| Goldstein, W | 1 |
| Bedard, P | 1 |
| Mesana, T | 1 |
| Michalak, M | 1 |
| Einecke, D | 3 |
| Mascitelli, L | 1 |
| Goldstein, MR | 1 |
| Nemerovski, CW | 1 |
| Salinitri, FD | 1 |
| Morbitzer, KA | 1 |
| Moser, LR | 1 |
| Wieloch, M | 1 |
| Lumsden, J | 1 |
| Rydell, E | 1 |
| Ohman, J | 1 |
| Piotrponikowski, P | 1 |
| Filippatos, G | 1 |
| Rasmussen, LH | 1 |
| Baglikov, AN | 1 |
| Rafal'skiĭ, VV | 1 |
| Batista, RP | 1 |
| Denadai, R | 1 |
| Saad-Hossne, R | 1 |
| Meyer, S | 1 |
| Mann, K | 1 |
| Gallus, A | 1 |
| Ockelford, P | 1 |
| Gibbs, H | 1 |
| Hague, W | 1 |
| Kirby, A | 1 |
| Delluc, A | 1 |
| Mottier, D | 1 |
| Tsukada, YT | 1 |
| Abdel Samie A, A | 1 |
| Sun, R | 1 |
| Vöhringer, U | 1 |
| Theilmann, L | 1 |
| Schlieper, G | 1 |
| Krüger, T | 1 |
| Floege, J | 1 |
| Baumann, M | 1 |
| Seifert, CL | 1 |
| Poppert, H | 1 |
| Sood, MM | 1 |
| Tangri, N | 1 |
| Hanna, EB | 1 |
| Fusari, M | 1 |
| Somes, J | 1 |
| Vernell, M | 1 |
| Stephens Donatelli, N | 1 |
| Weber, R | 1 |
| Connolly, S | 2 |
| van Es, RF | 1 |
| Jonker, JJ | 1 |
| Deckers, JW | 2 |
| Grobbee, DE | 1 |
| Luijten, HE | 1 |
| Hertzberger, DP | 1 |
| van Boven, AJ | 1 |
| Vromans, RP | 1 |
| Uijen, GJ | 1 |
| Frey, MJ | 1 |
| Senatore, F | 1 |
| Lis, J | 1 |
| Mukherjee, R | 1 |
| Bigonzi, F | 2 |
| Turpie, AG | 7 |
| Tognoni, G | 5 |
| Zhao, F | 5 |
| Hunt, D | 1 |
| Franzosi, MG | 1 |
| Hurlen, M | 3 |
| Abdelnoor, M | 1 |
| Smith, P | 3 |
| Erikssen, J | 2 |
| Blann, AD | 1 |
| Herth, FJ | 1 |
| Becker, HD | 2 |
| Ernst, A | 2 |
| Alberts, MJ | 1 |
| van Walraven, C | 1 |
| Laupacis, A | 2 |
| Petersen, P | 4 |
| Hellemons, B | 1 |
| Motomiya, T | 1 |
| Ornato, JP | 1 |
| Lévesque, H | 1 |
| Tan, M | 1 |
| Langer, A | 2 |
| Fine, E | 1 |
| Golmard, JL | 2 |
| Dalby, M | 1 |
| Choussat, R | 2 |
| Ankri, A | 1 |
| Dumaine, R | 1 |
| Lesty, C | 1 |
| Vignolles, N | 2 |
| Thomas, D | 2 |
| Blumenthal, M | 1 |
| Wittlinger, T | 1 |
| Sprague, D | 1 |
| Loewen, P | 1 |
| Eichenberger, A | 1 |
| Pontiggia, L | 1 |
| Beer, JH | 1 |
| Meyer, BJ | 1 |
| Tsakiris, DA | 1 |
| Matías-Guiu, J | 2 |
| Torres, F | 1 |
| Jiménez, MD | 1 |
| Lago, A | 1 |
| Melo, T | 1 |
| Doggrell, SA | 2 |
| Gerschutz, GP | 1 |
| von Bardeleben, RS | 1 |
| Ehrlich, A | 1 |
| Eimermacher, A | 1 |
| Peetz, D | 1 |
| Dahm, M | 1 |
| Ng, HJ | 1 |
| Koh, LP | 1 |
| Lee, LH | 1 |
| Subtil, D | 1 |
| Goeusse, P | 1 |
| Puech, F | 1 |
| Lequien, P | 1 |
| Biausque, S | 1 |
| Breart, G | 1 |
| Uzan, S | 1 |
| Marquis, P | 1 |
| Parmentier, D | 1 |
| Churlet, A | 1 |
| Leung, CS | 1 |
| Tam, KM | 1 |
| Maan, Z | 1 |
| Cutting, CW | 1 |
| Patel, U | 1 |
| Kerry, S | 1 |
| Pietrzak, P | 1 |
| Perry, MJ | 1 |
| Kirby, RS | 1 |
| Bain, BJ | 1 |
| Ginsberg, JS | 2 |
| Edvardsson, N | 2 |
| Juul-Möller, S | 2 |
| Omblus, R | 2 |
| Pehrsson, K | 1 |
| Easton, D | 1 |
| Fitzgerald, D | 1 |
| Granett, J | 1 |
| Sigmon, K | 1 |
| Pieper, K | 1 |
| Willerson, JT | 2 |
| Friess, D | 1 |
| Lämmle, B | 1 |
| Alberio, L | 1 |
| Kopp, CW | 1 |
| Steiner, S | 1 |
| Priglinger, U | 1 |
| Christ, G | 1 |
| Probst, P | 1 |
| Chan, KL | 2 |
| Dumesnil, JG | 2 |
| Cujec, B | 2 |
| Sanfilippo, AJ | 2 |
| Jue, J | 2 |
| Turek, MA | 1 |
| Robinson, TI | 1 |
| Moher, D | 1 |
| PELTOLA, P | 1 |
| WATERSON, AP | 1 |
| FRICK, PG | 1 |
| SOLEM, JH | 1 |
| MELLEMGAARD, L | 1 |
| PYORALA, K | 1 |
| LANGE, HF | 2 |
| HANAUT, A | 1 |
| DARMAILLACQ, R | 1 |
| PELLET, C | 1 |
| LEROY, P | 1 |
| LAMPHIER, TA | 1 |
| YOUNG, WA | 1 |
| LEVRAT, M | 3 |
| LAMBERT, R | 3 |
| SEDAN, J | 1 |
| STUBBE, LT | 2 |
| MUIR, A | 1 |
| COSSAR, IA | 1 |
| Mahé, I | 1 |
| Grenard, AS | 1 |
| Caulin, C | 1 |
| Bergmann, JF | 1 |
| BARREIRO TELLA, P | 1 |
| MARTINEZ FERNANDEZ, A | 1 |
| PIERSON, RN | 2 |
| HOLT, PR | 1 |
| WATSON, RM | 2 |
| KEATING, RP | 1 |
| PLEWINSKI, G | 2 |
| SYMEONIDES, I | 1 |
| BOUGIOUKAS, A | 1 |
| GRAIKOS, D | 1 |
| TAVEAU, P | 1 |
| RICHIER, JL | 1 |
| BOGUAIS, MT | 1 |
| WEISS, A | 1 |
| PITMAN, ER | 1 |
| GRAHAM, EC | 1 |
| BLAMOUTIER, P | 1 |
| CORICCIATI, L | 1 |
| ETIENNE-MARTIN, P | 1 |
| KLEPPING, C | 1 |
| BINET, J | 1 |
| FROLUND, A | 1 |
| BENTLIF, PS | 1 |
| PIETERSEN, JH | 1 |
| LEONARDS, JR | 1 |
| PLEVIN'SKII, G | 1 |
| HONG, IB | 1 |
| ROTH, WL | 1 |
| VALDES-DAPENA, A | 1 |
| PIESES, P | 1 |
| BUCHMAN, E | 1 |
| WOOD, PH | 1 |
| HARVEY-SMITH, EA | 1 |
| DIXON, AS | 1 |
| BRUCKNER, I | 1 |
| STANESCU, M | 1 |
| BRICK, IB | 1 |
| SAPISOCHIN, E | 1 |
| VIGUIE, R | 1 |
| GARDIES, AL | 1 |
| NEUMAN, M | 1 |
| REUTER, SH | 1 |
| MONTGOMERY, WW | 1 |
| GOULSTON, K | 3 |
| ABRAHAMS, C | 1 |
| RUBENSTEIN, AH | 1 |
| LEVIN, NW | 1 |
| WUNDERLICH, U | 1 |
| FISHLER, JJ | 1 |
| LIGNY, G | 1 |
| RESANO, CH | 1 |
| LIZARRAGA, AA | 1 |
| LIBERMTHEN, A | 1 |
| KHOSLA, SN | 1 |
| SKYRING, A | 1 |
| KEDRA, M | 1 |
| FLORKIEWICZ, H | 1 |
| KOLBER-POSTEPSKA, B | 1 |
| LABRAM, C | 1 |
| SCHWIETZER, CH | 1 |
| ROBSON, JM | 1 |
| ANDERSON, KW | 2 |
| JENNINGS, GH | 1 |
| DREYER, MS | 1 |
| MARTI, ML | 1 |
| SEGEL, KH | 1 |
| DAVENPORT, HW | 1 |
| PAUNESCU-PODEANU, A | 1 |
| ILIESCU, A | 1 |
| HARAS, I | 1 |
| Kopecky, SL | 1 |
| Valentin, V | 1 |
| Wodlinger, AM | 1 |
| Pieper, JA | 1 |
| Remes, V | 1 |
| Helenius, I | 1 |
| Otley, CC | 2 |
| Füessl, HS | 1 |
| Kearon, C | 1 |
| Sadeghi, S | 1 |
| Marder, VJ | 1 |
| Stewart, D | 1 |
| Kong, M | 1 |
| Humphries, J | 1 |
| Baumbach, GA | 1 |
| Jesmok, G | 1 |
| Salyers, AK | 1 |
| Szalony, JA | 1 |
| Suleymanov, OD | 1 |
| Parlow, JJ | 1 |
| Wood, RS | 1 |
| South, MS | 1 |
| Nicholson, NS | 1 |
| Exaire, JE | 1 |
| Blankenship, JC | 1 |
| Wolski, K | 1 |
| Raymond, RE | 3 |
| Landolfi, R | 2 |
| Marchioli, R | 2 |
| Kutti, J | 1 |
| Gisslinger, H | 2 |
| Weinrieb, RM | 1 |
| Auriacombe, M | 1 |
| Lynch, KG | 1 |
| Chang, KM | 1 |
| Lewis, JD | 1 |
| SCHAEFFER, JH | 1 |
| BLAISDELL, ER | 1 |
| HERRICK, SE | 1 |
| SMITH, JM | 1 |
| MACKINNON, J | 1 |
| HAWK, BO | 1 |
| KNIGHT, WA | 1 |
| THOMA, GE | 1 |
| Herlitz, J | 1 |
| Holm, J | 1 |
| Karlson, BW | 1 |
| Haglid Evander, M | 1 |
| Erhardt, L | 1 |
| Orford, JL | 1 |
| Fasseas, P | 1 |
| Melby, S | 1 |
| Burger, K | 1 |
| Connolly, DL | 1 |
| Davis, RC | 1 |
| Bhapkar, MV | 1 |
| LaPointe, NM | 1 |
| Kramer, JM | 1 |
| Dutrillaux, F | 1 |
| Maynadié, M | 1 |
| Carli, PM | 1 |
| Arjomand, H | 1 |
| Blich, M | 1 |
| Gross, B | 1 |
| Blazing, MA | 1 |
| DiBattiste, PM | 1 |
| Palmisano, J | 1 |
| Bilheimer, DW | 1 |
| Snapinn, SM | 1 |
| Ramsey, KE | 1 |
| Gardner, LH | 1 |
| Hasselblad, V | 1 |
| Pfeffer, MA | 1 |
| Lewis, EF | 1 |
| Fisher, ES | 1 |
| Robertson, SL | 1 |
| Mayer, JB | 1 |
| Guthmann, R | 1 |
| Gherli, T | 1 |
| Fragnito, C | 1 |
| Nicolini, F | 1 |
| Borrello, B | 1 |
| Saccani, S | 1 |
| Wolski, KE | 1 |
| Peters, R | 1 |
| Lakkis, N | 2 |
| Moore, M | 1 |
| Power, M | 1 |
| Kerr, JL | 1 |
| Oppelt, TF | 1 |
| Rowen, RC | 1 |
| Griffin, JJ | 1 |
| Erdmann, E | 1 |
| Jones, L | 1 |
| Griffin, S | 1 |
| Palmer, S | 1 |
| Main, C | 1 |
| Orton, V | 1 |
| Sculpher, M | 1 |
| Sudlow, C | 1 |
| Henderson, R | 1 |
| Hawkins, N | 1 |
| Riemsma, R | 1 |
| Bogousslavsky, J | 2 |
| Mattle, HP | 1 |
| Blanchet, B | 1 |
| Tanguy, ML | 1 |
| Grüner, S | 1 |
| Prostredna, M | 1 |
| Aktas, B | 1 |
| Moers, A | 1 |
| Schulte, V | 1 |
| Krieg, T | 1 |
| Offermanns, S | 1 |
| Eckes, B | 1 |
| Nieswandt, B | 1 |
| Denardo, SJ | 1 |
| Davis, KE | 1 |
| Elliott, MA | 1 |
| Mackman, N | 1 |
| Wong, HC | 1 |
| Schleinitz, MD | 1 |
| Momi, S | 1 |
| Pitchford, SC | 1 |
| Alberti, PF | 1 |
| Minuz, P | 1 |
| Del Soldato, P | 1 |
| Leopold, JA | 1 |
| Landray, M | 1 |
| Leaper, C | 1 |
| Altmann, P | 1 |
| Baxter, A | 1 |
| Cairns, HS | 1 |
| Foley, RN | 1 |
| Frighi, V | 1 |
| Kourellias, K | 1 |
| Ratcliffe, PJ | 1 |
| Rogerson, M | 1 |
| Scoble, JE | 1 |
| Tomson, CR | 1 |
| Warwick, G | 1 |
| Wheeler, DC | 1 |
| Krane, V | 1 |
| Wanner, C | 1 |
| Hill, KA | 1 |
| Skene, AM | 1 |
| Wahidi, MM | 1 |
| Garland, R | 1 |
| Feller-Kopman, D | 1 |
| Herth, F | 1 |
| Lynn, MJ | 1 |
| Howlett-Smith, H | 1 |
| Stern, BJ | 1 |
| Hertzberg, VS | 1 |
| Frankel, MR | 1 |
| Levine, SR | 1 |
| Chaturvedi, S | 1 |
| Benesch, CG | 1 |
| Sila, CA | 1 |
| Jovin, TG | 1 |
| Romano, JG | 1 |
| Koroshetz, WJ | 1 |
| Huxtable, LM | 1 |
| Tafreshi, MJ | 1 |
| Ondreyco, SM | 1 |
| Buresly, K | 1 |
| Eisenberg, MJ | 1 |
| Scully, MF | 1 |
| Khamashta, MA | 2 |
| Malinin, AI | 1 |
| Baggish, JS | 1 |
| Madi-Jebara, S | 1 |
| Rkeiby-Kassabian, N | 1 |
| Yazigi, A | 1 |
| DiMarco, JP | 1 |
| Waldo, AL | 1 |
| Corley, SD | 1 |
| Greene, HL | 1 |
| Safford, RE | 1 |
| Rosenfeld, LE | 1 |
| Mitrani, G | 1 |
| Nemeth, M | 1 |
| Harrison, CN | 1 |
| Campbell, PJ | 1 |
| Wheatley, K | 1 |
| East, CL | 1 |
| Bareford, D | 1 |
| Wilkins, BS | 1 |
| van der Walt, JD | 1 |
| Reilly, JT | 1 |
| Grigg, AP | 1 |
| Revell, P | 1 |
| Woodcock, BE | 1 |
| Green, AR | 2 |
| Finazzi, G | 4 |
| Weisman, SM | 1 |
| Rothberg, MB | 1 |
| Celestin, C | 1 |
| Fiore, LD | 2 |
| Cook, JR | 1 |
| Costello, R | 1 |
| O'Callaghan, T | 1 |
| Sébahoun, G | 1 |
| Ferguson, JJ | 2 |
| Eikvar, L | 1 |
| Tiaden, JD | 1 |
| Wenzel, E | 1 |
| Berthold, HK | 1 |
| Müller-Oerlinghausen, B | 1 |
| Kannan, S | 1 |
| McQuaid, K | 1 |
| Arab, D | 1 |
| Lewis, B | 1 |
| Cho, L | 1 |
| Steen, L | 1 |
| Joyal, D | 1 |
| Leya, F | 1 |
| Hartung, HP | 1 |
| Siebler, M | 1 |
| White, WB | 1 |
| Parke, AL | 1 |
| Varma, C | 1 |
| Knappertz, V | 1 |
| Gill, SS | 1 |
| Hagiwara, A | 1 |
| Matsuda, T | 1 |
| Shimazaki, S | 1 |
| Saloheimo, P | 1 |
| Ahonen, M | 1 |
| Juvela, S | 1 |
| Pyhtinen, J | 1 |
| Savolainen, ER | 1 |
| Hillbom, M | 1 |
| Tuhrim, S | 1 |
| Bezerra, DC | 1 |
| Cimminiello, C | 1 |
| Avanzini, F | 1 |
| Pangrazzi, I | 1 |
| Brown, DL | 1 |
| Nakamura, T | 1 |
| Yamazaki, M | 1 |
| Kimura, Y | 1 |
| Iwata, M | 1 |
| Sauer, H | 1 |
| Leschke, M | 1 |
| Dalen, JE | 1 |
| Black, HR | 1 |
| Creager, MA | 1 |
| Weber, MA | 1 |
| Fabry-Ribaudo, L | 1 |
| Booth, J | 1 |
| Calvet, D | 1 |
| Touzé, E | 1 |
| Kien-Fong Vu, C | 1 |
| Chang, F | 1 |
| Doig, L | 1 |
| Meenan, J | 1 |
| Khurram, Z | 1 |
| Chou, E | 1 |
| Minutello, R | 1 |
| Bergman, G | 1 |
| Parikh, M | 1 |
| Naidu, S | 1 |
| Wong, SC | 1 |
| McClelland, AJ | 1 |
| Adgey, JA | 1 |
| Porter, A | 1 |
| Konstantino, Y | 1 |
| Iakobishvili, Z | 1 |
| Shachar, L | 1 |
| Battler, A | 1 |
| Hasdai, D | 1 |
| Petrides, PE | 1 |
| Kongsaengdao, S | 1 |
| Arayawichanont, A | 1 |
| Kamalesh, M | 1 |
| Michiels, JJ | 6 |
| Berneman, Z | 1 |
| Schroyens, W | 1 |
| Budde, U | 1 |
| van Vliet, HH | 3 |
| Lee, MS | 1 |
| Smith, SD | 1 |
| Galor, A | 1 |
| Hoffman, GS | 1 |
| Khalifeh, MR | 1 |
| Redett, RJ | 1 |
| Kjaer, J | 1 |
| Larsen, CH | 1 |
| Poulsen, TS | 1 |
| Møller, JE | 1 |
| Mickley, H | 1 |
| Viñuela, F | 1 |
| Nien, YL | 1 |
| Yeh, DT | 1 |
| Vinters, HV | 1 |
| Flaker, GC | 1 |
| Gruber, M | 1 |
| Goldman, S | 2 |
| Chaparro, S | 1 |
| Vahanian, A | 2 |
| Halinen, MO | 1 |
| Di Nisio, M | 1 |
| Di Gennaro, L | 1 |
| Borrelli, G | 1 |
| Leone, G | 1 |
| Marfisi, R | 1 |
| Porreca, E | 1 |
| Ruggeri, M | 2 |
| Rutjes, AW | 1 |
| Soulat, L | 1 |
| Lambert, Y | 1 |
| Lapostolle, F | 1 |
| Adgey, J | 1 |
| Wang, XK | 1 |
| Yang, CM | 1 |
| Liu, GY | 1 |
| Sarkiss, MG | 1 |
| Warneke, CL | 1 |
| Botz, G | 1 |
| Hirch-Ginsburg, C | 1 |
| Champion, JC | 1 |
| Swafford, J | 1 |
| Shaw, AD | 1 |
| Lenihan, DJ | 1 |
| Dizdar, O | 1 |
| Onal, IK | 1 |
| Ozakin, E | 1 |
| Karakiliç, E | 1 |
| Karadag, O | 1 |
| Kalyoncu, U | 1 |
| Coşkun, F | 1 |
| Buyukasik, Y | 1 |
| Sánchez-Torrijos, J | 1 |
| Gudín-Uriel, M | 1 |
| Ridocci-Soriano, F | 1 |
| Dentali, F | 1 |
| Gardner, MJ | 2 |
| Flik, KR | 1 |
| Dreese, JC | 1 |
| Athanasian, EA | 1 |
| Lyden, JP | 1 |
| Gogarten, W | 1 |
| Van Aken, H | 1 |
| Aguilera, C | 1 |
| Agustí, A | 2 |
| Einhäupl, K | 1 |
| Wong, PC | 1 |
| Crain, EJ | 1 |
| Watson, CA | 1 |
| Wexler, RR | 1 |
| Lam, PY | 1 |
| Quan, ML | 1 |
| Knabb, RM | 1 |
| Liao, JK | 1 |
| Ng, PW | 1 |
| Tsoi, TH | 1 |
| Li, HL | 1 |
| Fong, WC | 1 |
| Yeung, J | 1 |
| Wong, CK | 1 |
| Yip, KK | 1 |
| Wong, HB | 1 |
| DeEugenio, D | 1 |
| Kolman, L | 1 |
| DeCaro, M | 2 |
| Andrel, J | 1 |
| Chervoneva, I | 1 |
| Duong, P | 1 |
| Lam, L | 1 |
| McGowan, C | 1 |
| Lee, G | 1 |
| Ruggiero, N | 1 |
| Singhal, S | 1 |
| Greenspon, A | 1 |
| Reeves, RR | 1 |
| Wise, PM | 1 |
| Cox, SK | 1 |
| Hilgevoord, AA | 1 |
| de Vries, JP | 1 |
| van der Mee, M | 1 |
| van de Pavoordt, HD | 1 |
| Ackerstaff, RG | 1 |
| Nguyen, MC | 1 |
| Lim, YL | 1 |
| Walton, A | 1 |
| Allegrone, J | 1 |
| Jackson, AJ | 1 |
| Teenan, RP | 1 |
| Orr, DJ | 1 |
| Falcinelli, E | 1 |
| Giannini, S | 1 |
| Boschetti, E | 1 |
| Brennan, MT | 1 |
| Wynn, RL | 1 |
| Miller, CS | 1 |
| Meinertz, T | 1 |
| Anand, S | 1 |
| Xie, C | 1 |
| Sussex, B | 1 |
| Cina, C | 1 |
| Crowell, R | 1 |
| Gosselin, G | 1 |
| Palareti, G | 1 |
| Cucchini, U | 1 |
| Molinatti, M | 1 |
| Del Bono, R | 1 |
| Baudo, F | 1 |
| Pegoraro, C | 1 |
| Iliceto, S | 1 |
| Chassot, PG | 1 |
| Delabays, A | 1 |
| Spahn, DR | 1 |
| Wang, TH | 1 |
| Scappaticci, FA | 1 |
| Skillings, JR | 1 |
| Holden, SN | 1 |
| Gerber, HP | 1 |
| Miller, K | 1 |
| Kabbinavar, F | 1 |
| Bergsland, E | 1 |
| Ngai, J | 1 |
| Holmgren, E | 1 |
| Hurwitz, H | 1 |
| Helton, TJ | 1 |
| Kumbhani, DJ | 1 |
| Duggal, S | 1 |
| Roukoz, H | 1 |
| Tognolini, M | 1 |
| Ballabeni, V | 1 |
| Bertoni, S | 1 |
| Bruni, R | 1 |
| Impicciatore, M | 1 |
| Barocelli, E | 1 |
| Rivkin, A | 1 |
| Casaní, L | 1 |
| Badimon, L | 1 |
| Brulotte, S | 1 |
| Sénéchal, M | 1 |
| Lemieux, A | 1 |
| Bergeron, S | 1 |
| Glynn, RJ | 1 |
| Scirica, BM | 1 |
| Emanuelsson, H | 1 |
| Riesmeyer, J | 1 |
| Weerakkody, G | 1 |
| Holden, RM | 1 |
| Harman, GJ | 1 |
| Wang, M | 1 |
| Holland, D | 1 |
| Day, AG | 1 |
| Qin, J | 1 |
| Guneri, S | 1 |
| Jacob, AJ | 1 |
| Cacciola, RR | 1 |
| Di Francesco, E | 1 |
| Pezzella, F | 1 |
| Tibullo, D | 1 |
| Giustolisi, R | 1 |
| Cacciola, E | 1 |
| James, AH | 1 |
| Brancazio, LR | 1 |
| Price, T | 1 |
| Simes, RJ | 1 |
| Walker, CW | 1 |
| Dawley, CA | 1 |
| Fletcher, SF | 1 |
| Holzmann, RD | 1 |
| Olbricht, SM | 2 |
| Thomas, VD | 1 |
| Schanbacher, CF | 1 |
| FARFEL, B | 1 |
| Güleç, S | 1 |
| Tam, J | 1 |
| Robinson, T | 1 |
| Williams, K | 1 |
| Yow, E | 1 |
| Berezny, KY | 1 |
| Bokesch, PM | 1 |
| Takahashi, M | 1 |
| Graham, TP | 1 |
| Sanders, SP | 1 |
| Sidi, D | 1 |
| Bonnet, D | 1 |
| Ewert, P | 1 |
| Johnson, SG | 1 |
| Rogers, K | 1 |
| Delate, T | 1 |
| Witt, DM | 1 |
| Mark, B | 1 |
| Gottwik, M | 1 |
| Popławski, C | 1 |
| Jakubczyk, P | 1 |
| Jakubczyk, M | 1 |
| Kwa, AT | 1 |
| Rogers, JH | 1 |
| Reaume, KT | 1 |
| Regal, RE | 1 |
| Dorsch, MP | 1 |
| Drouet, L | 1 |
| Drown, DJ | 1 |
| Marcos Vidal, JM | 1 |
| Baticón Escudero, PM | 1 |
| Higuera Miguelez, E | 1 |
| Fiz Matías, J | 1 |
| Hollander, JE | 1 |
| Schwartz, NE | 1 |
| Madhwal, S | 1 |
| Rolston, DD | 1 |
| Langton, PE | 1 |
| Nishihira, K | 1 |
| Yamashita, A | 1 |
| Imamura, T | 1 |
| Hatakeyama, K | 1 |
| Sato, Y | 1 |
| Nakamura, H | 2 |
| Yodoi, J | 1 |
| Kitamura, K | 1 |
| Asada, Y | 1 |
| Pinkau, T | 1 |
| Mann, JF | 1 |
| Schömig, A | 2 |
| Purushothaman, B | 1 |
| Hermosillo, AJ | 1 |
| Voitk, J | 1 |
| Hasin, Y | 1 |
| Chandna, H | 1 |
| Macias, W | 1 |
| Pareti, FI | 1 |
| Smith, JB | 1 |
| Sautebin, L | 1 |
| Galli, G | 1 |
| Thorngren, M | 1 |
| Shafi, S | 1 |
| Born, GV | 1 |
| Marco, LA | 1 |
| Randels, PM | 1 |
| Kelton, JG | 2 |
| Kakkar, VV | 1 |
| Chapuis, Y | 1 |
| Valone, J | 1 |
| Chesebro, JH | 2 |
| Elveback, LR | 1 |
| McGoon, DC | 1 |
| Pluth, JR | 2 |
| Puga, FJ | 3 |
| Wallace, RB | 1 |
| Danielson, GK | 2 |
| Orszulak, TA | 2 |
| Piehler, JM | 1 |
| Carter, CJ | 1 |
| Skjelbred, P | 2 |
| Schafer, AI | 4 |
| Kennedy, BM | 1 |
| Carrick, DG | 1 |
| Shabalov, NP | 1 |
| Bolotina, ED | 1 |
| Quick, D | 1 |
| Trowbridge, AA | 1 |
| Zoucas, E | 1 |
| Göransson, G | 1 |
| Bengmark, S | 1 |
| Prioleau, WH | 1 |
| Voegele, LD | 1 |
| Hairston, P | 1 |
| Alberhasky, M | 1 |
| Nichols, GR | 1 |
| Montgomery, RR | 1 |
| Hathaway, WE | 1 |
| O'Brien, JR | 1 |
| Müller, P | 1 |
| Kather, H | 1 |
| Dammann, HG | 1 |
| Simon, B | 1 |
| Swanson, E | 1 |
| Dale, J | 1 |
| Myhre, E | 1 |
| Loew, D | 3 |
| Cahuana, A | 1 |
| Trías, E | 1 |
| Oliva, F | 1 |
| Youssef, W | 1 |
| Pou, J | 1 |
| Vilar, P | 1 |
| Varea, V | 1 |
| Covey, TH | 1 |
| Baue, AE | 1 |
| Bachmann, F | 1 |
| Breddin, K | 1 |
| Lechner, K | 1 |
| Uberla, K | 1 |
| Walter, E | 1 |
| Moncada, S | 2 |
| Wessler, S | 1 |
| Romem, M | 1 |
| Singer, L | 1 |
| Friedman, C | 1 |
| Stuart, MJ | 1 |
| Gross, SJ | 1 |
| Elrad, H | 1 |
| Graeber, JE | 1 |
| Paris, GL | 1 |
| Waltuch, GF | 1 |
| Black, RA | 1 |
| Bensinger, RE | 1 |
| Davis, GL | 1 |
| Mutnick, AH | 1 |
| Caen, JP | 2 |
| Michelson, EL | 3 |
| Pavlosky, M | 1 |
| Carreras, LO | 1 |
| Lazzari, MA | 2 |
| Albertal, J | 2 |
| Walker, AM | 1 |
| Jick, H | 1 |
| Isbister, JP | 1 |
| Gage, BF | 1 |
| Cardinalli, AB | 1 |
| Owens, DK | 1 |
| Gurfinkel, EP | 2 |
| Manos, EJ | 1 |
| Mejaíl, RI | 1 |
| Cerdá, MA | 1 |
| Duronto, EA | 1 |
| García, CN | 1 |
| Daroca, AM | 1 |
| Mautner, B | 1 |
| Stormorken, H | 1 |
| Rees, MK | 1 |
| Monreal, M | 1 |
| Lafoz, E | 1 |
| Roca, J | 1 |
| Granero, X | 1 |
| Soler, J | 1 |
| Salazar, X | 1 |
| Olazabal, A | 1 |
| Cohn, SM | 1 |
| Farrell, TJ | 1 |
| Cortelazzo, S | 1 |
| Vestri, O | 1 |
| Rodeghiero, F | 1 |
| Gulløv, AL | 3 |
| Koefoed, BG | 3 |
| Powell, CC | 2 |
| Schultz, SC | 2 |
| Burris, DG | 2 |
| Drucker, WR | 1 |
| Malcolm, DS | 2 |
| Sibai, BM | 1 |
| Caritis, SN | 1 |
| Thom, E | 1 |
| Shaw, K | 1 |
| McNellis, D | 1 |
| Eritsland, J | 1 |
| Kierulf, P | 1 |
| Kooistra, MP | 1 |
| van Es, A | 1 |
| Marx, JJ | 1 |
| Hertsig, ML | 1 |
| Struyvenberg, A | 1 |
| Meade, TW | 3 |
| Miller, GJ | 2 |
| Sámóczi, M | 1 |
| Farkas, A | 1 |
| Sipos, E | 1 |
| Tarján, J | 1 |
| Penny, WJ | 1 |
| Grill, DE | 1 |
| Bailey, KR | 1 |
| Blair, KL | 1 |
| Hatton, AC | 1 |
| White, WD | 1 |
| Smith, LR | 1 |
| Lowe, JE | 1 |
| Wolfe, WG | 1 |
| Young, WG | 1 |
| Oldham, HN | 1 |
| Douglas, JM | 1 |
| Glower, DD | 1 |
| Lawrence, C | 1 |
| Sakuntabhai, A | 1 |
| Tiling-Grosse, S | 1 |
| Howarth, DJ | 1 |
| Brennan, PJ | 2 |
| Fagan, SC | 1 |
| Kertland, HR | 1 |
| Tietjen, GE | 1 |
| Rollag, A | 1 |
| Nguyen, H | 1 |
| Jaffin, J | 1 |
| Sutton, M | 1 |
| Pereyra, D | 1 |
| Segura, EV | 1 |
| Aramburu, DF | 1 |
| Lardani, H | 1 |
| Loeliger, EA | 1 |
| Cannegieter, SC | 1 |
| van der Meer, FJ | 1 |
| Briët, E | 1 |
| Rosendaal, FR | 1 |
| Flordal, PA | 1 |
| Sahlin, S | 1 |
| Gent, M | 3 |
| Latour, Y | 1 |
| Gunstensen, J | 1 |
| Basile, F | 1 |
| Klimek, M | 1 |
| Lekas, MD | 1 |
| Crowley, JP | 1 |
| Simoons, ML | 2 |
| Arnout, J | 1 |
| van den Brand, M | 1 |
| Nÿssen, K | 1 |
| Verstraete, M | 1 |
| Gazelle, GS | 1 |
| Halpern, EF | 1 |
| LeBlanc, JG | 1 |
| Sett, SS | 1 |
| Vince, DJ | 1 |
| Kelsey, M | 1 |
| Fernández-Avilés, F | 1 |
| Alonso, JJ | 1 |
| Durán, JM | 1 |
| Gimeno, F | 1 |
| Muñoz, JC | 1 |
| de la Fuente, L | 1 |
| San Román, JA | 1 |
| Altman, R | 2 |
| Rouvier, J | 2 |
| Gurfinkel, E | 2 |
| Tschugguel, W | 1 |
| Blaicher, A | 1 |
| Kramer, L | 1 |
| Felfernig, M | 1 |
| Jüngling, G | 1 |
| Kurz, M | 1 |
| Gnant, M | 1 |
| Zimpfer, M | 1 |
| Hart, S | 1 |
| Deniz, A | 1 |
| Sommer, B | 1 |
| Kietzmann, M | 1 |
| Nolte, I | 1 |
| Glauber, M | 1 |
| Szefner, J | 1 |
| Gamba, A | 1 |
| Mamprin, F | 1 |
| Fiocchi, R | 1 |
| Somaschini, M | 1 |
| Ferrazzi, P | 1 |
| Codinach Huix, P | 1 |
| Connelly, SJ | 1 |
| Popiel, M | 1 |
| Grajek, S | 1 |
| Cieśliński, A | 1 |
| Salemark, L | 1 |
| Knudsen, F | 1 |
| Dougan, P | 1 |
| Vanderschueren, S | 1 |
| Collen, D | 5 |
| Oler, A | 1 |
| Whooley, MA | 1 |
| Oler, J | 1 |
| Grady, D | 1 |
| Sandler, RS | 1 |
| Casaccia, M | 2 |
| Bertello, F | 1 |
| De Bernardi, A | 1 |
| Sicuro, M | 1 |
| Scacciatella, P | 1 |
| Karrillon, GJ | 1 |
| Benveniste, E | 1 |
| Bunouf, P | 1 |
| Chevalier, B | 1 |
| Commeau, P | 1 |
| Cribier, A | 1 |
| Eiferman, C | 1 |
| Grollier, G | 1 |
| Guerin, Y | 1 |
| Henry, M | 1 |
| Lefevre, T | 1 |
| Livarek, B | 1 |
| Louvard, Y | 1 |
| Marco, J | 1 |
| Makowski, S | 1 |
| Pernes, JM | 1 |
| Rioux, P | 1 |
| Spaulding, C | 1 |
| Zemour, G | 1 |
| Hafner, J | 1 |
| de Moerloose, P | 1 |
| Schulman, SP | 1 |
| Goldschmidt-Clermont, PJ | 1 |
| Navetta, FI | 1 |
| Chandra, NC | 1 |
| Guerci, AD | 1 |
| Yakubov, SJ | 1 |
| Bray, PF | 1 |
| Bahr, RD | 1 |
| Wolfe, CL | 1 |
| Yock, PG | 1 |
| Anderson, HV | 1 |
| Nygaard, TW | 2 |
| Mason, SJ | 1 |
| Fatterpacker, A | 1 |
| Raskin, S | 1 |
| Smith, J | 1 |
| Brashears, L | 1 |
| Gottdiener, P | 1 |
| du Mee, C | 1 |
| Kitt, MM | 1 |
| Gerstenblith, G | 1 |
| Scazziota, A | 1 |
| van Genderen, PJ | 3 |
| Lindemans, J | 1 |
| Griesshammer, M | 4 |
| Heimpel, H | 1 |
| Pearson, TC | 1 |
| Brophy, J | 1 |
| Blankfield, RP | 1 |
| Forbes, C | 1 |
| Sivenius, J | 1 |
| Smets, P | 1 |
| Lowenthal, A | 1 |
| Rollwagen, FM | 1 |
| Pacheco, ND | 1 |
| Pikoulis, E | 1 |
| Leppäniemi, A | 1 |
| Soltero, R | 1 |
| Burris, D | 1 |
| Malcolm, D | 2 |
| Nielsen, TB | 1 |
| Bovill, EG | 2 |
| Tracy, RP | 1 |
| Knatterud, GL | 1 |
| Stone, PH | 1 |
| Nasmith, J | 1 |
| Thompson, BW | 1 |
| Tofler, GH | 1 |
| Kleiman, NS | 4 |
| Cannon, C | 1 |
| Sleight, P | 1 |
| López de Sá, E | 1 |
| Mulder, PG | 1 |
| Waleboer, M | 1 |
| van de Moesdijk, D | 1 |
| Rodríguez Blanco, VM | 1 |
| Barriales Alvarez, V | 1 |
| Morís de la Tassa, C | 1 |
| Bittar, N | 1 |
| Young, L | 1 |
| Hattemer, CR | 1 |
| Gandhi, AJ | 1 |
| Kemp, SM | 1 |
| Hall, EA | 1 |
| Morton, DJ | 1 |
| Yim, J | 1 |
| Vlasses, PH | 1 |
| Simpfendorfer, C | 1 |
| Kottke-Marchant, K | 1 |
| Lowrie, M | 1 |
| Anders, RJ | 1 |
| Burns, DM | 1 |
| Miller, DP | 1 |
| Cove, CS | 1 |
| DeFranco, AC | 1 |
| Sutton, JM | 1 |
| Demers, C | 1 |
| Fromell, GJ | 1 |
| Premmereur, J | 1 |
| Bangerter, M | 2 |
| Leenknegt, H | 1 |
| Wehmeier, A | 1 |
| Südhoff, T | 1 |
| Meierkord, F | 1 |
| Gulati, A | 1 |
| Sen, AP | 1 |
| Sharma, AC | 1 |
| Singh, G | 1 |
| Członkowska, A | 1 |
| Szpak, GM | 1 |
| Werner, W | 2 |
| Wunderlich, H | 1 |
| Leadley, RJ | 1 |
| Kasiewski, CJ | 1 |
| Bostwick, JS | 1 |
| Bentley, R | 1 |
| McVey, MJ | 1 |
| White, FJ | 1 |
| Perrone, MH | 1 |
| Dunwiddie, CT | 1 |
| Iturbe, T | 1 |
| Sánchez, C | 1 |
| Moreno, JA | 1 |
| Olave, T | 1 |
| Azaceta, G | 1 |
| Varo, MJ | 1 |
| Civeira, E | 1 |
| Peleato, J | 1 |
| Cornudella, R | 1 |
| Anzuini, A | 1 |
| Rosanio, S | 1 |
| Tocchi, M | 1 |
| Coppi, R | 1 |
| Bonnier, H | 1 |
| Sheiban, I | 1 |
| Kulbertus, HE | 1 |
| Chierchia, SL | 1 |
| Liem, A | 1 |
| Marsh, RC | 1 |
| Bronzwaer, JG | 1 |
| Rustige, J | 1 |
| Gödicke, J | 1 |
| Marsalek, P | 1 |
| Pedersen, TS | 1 |
| Andersen, ED | 1 |
| Godtfredsen, J | 2 |
| Boysen, G | 3 |
| Dickneite, G | 1 |
| Nicolay, U | 1 |
| Friesen, HJ | 1 |
| Reers, M | 1 |
| Belougne-Malfatti, E | 1 |
| Doutremepuich, F | 1 |
| Lotke, PA | 1 |
| Fleck, E | 1 |
| Bonnier, J | 1 |
| Emmanuelson, H | 1 |
| Missault, L | 1 |
| Chierchia, S | 1 |
| Niccoli, L | 1 |
| Oto, A | 1 |
| White, C | 1 |
| Webb-Peploe, M | 1 |
| Forbes, CD | 2 |
| Ramesh, CV | 1 |
| Malarvannan, P | 1 |
| Jayakumar, R | 1 |
| Jayasundar, S | 1 |
| Puvanakrishnan, R | 1 |
| Baim, DS | 1 |
| Popma, JJ | 1 |
| Gordon, PC | 1 |
| Ho, KK | 1 |
| Giambartolomei, A | 1 |
| Diver, DJ | 1 |
| Lasorda, DM | 1 |
| Williams, DO | 2 |
| Kuntz, RE | 1 |
| Gianetti, J | 1 |
| Gensini, G | 1 |
| Ruf, A | 1 |
| Pogátsa-Murray, G | 1 |
| Dickfeld, T | 1 |
| Zohlnhöfer, D | 1 |
| Evans, MF | 1 |
| Alvarez Sabín, J | 1 |
| Galiano, L | 1 |
| Codina Puiggrós, A | 1 |
| Rodríguez, D | 1 |
| Moussa, I | 1 |
| Oetgen, M | 1 |
| Roubin, G | 1 |
| Iyer, S | 1 |
| Maida, R | 1 |
| Collins, M | 1 |
| Kreps, E | 1 |
| Fischer, SR | 1 |
| Burnet, M | 1 |
| Traber, DL | 2 |
| Prough, DS | 1 |
| Kramer, GC | 2 |
| McCullough, PA | 1 |
| Marks, KR | 1 |
| Moynihan, JL | 1 |
| Al-Mousa, EN | 1 |
| Campsey, M | 1 |
| Gandhi, R | 1 |
| Mattson, S | 1 |
| Ryan, KA | 1 |
| Mesley, R | 1 |
| Swanson, J | 1 |
| Arshad, MN | 1 |
| Marble, SJ | 1 |
| Fuglsang, J | 1 |
| Ravn, HB | 1 |
| Toft, GE | 1 |
| Thorwest, M | 1 |
| Hjortdal, VE | 1 |
| Juran, NB | 1 |
| Benavente, O | 1 |
| McBride, R | 1 |
| Harker, LA | 1 |
| Boissel, JP | 1 |
| Pilgrim, AJ | 1 |
| Quinn, MJ | 1 |
| Vandenbossche, JL | 1 |
| Steiner, M | 1 |
| Dickes, MS | 1 |
| Stammers, AH | 1 |
| Pierce, ML | 1 |
| Alonso, A | 1 |
| Fristoe, L | 1 |
| Taft, KJ | 1 |
| Beck, DJ | 1 |
| Jones, CC | 1 |
| Silverstein, MN | 1 |
| Bergmann, L | 1 |
| Pearson, T | 1 |
| Stulak, JM | 1 |
| Juncos, LA | 1 |
| Haas, JA | 1 |
| Romero, JC | 1 |
| Randi, ML | 2 |
| Rossi, C | 2 |
| Fabris, F | 2 |
| Menapace, L | 1 |
| Girolami, A | 2 |
| MacKinlay, N | 1 |
| Taper, J | 1 |
| Renisson, F | 1 |
| Rickard, K | 1 |
| Frantz, E | 1 |
| Kamishirado, H | 1 |
| Inoue, T | 1 |
| Fujito, T | 1 |
| Akiya, K | 1 |
| Ishiyama, E | 1 |
| Sakuma, M | 1 |
| Takayanagi, K | 1 |
| Hayashi, T | 1 |
| Morooka, S | 1 |
| Chen, ZM | 1 |
| Sandercock, P | 1 |
| Pan, HC | 1 |
| Counsell, C | 1 |
| Liu, LS | 1 |
| Xie, JX | 1 |
| Warlow, C | 1 |
| Hirsch, AT | 1 |
| Ringleb, PA | 1 |
| Lenzi, GL | 1 |
| Lenzi, J | 1 |
| Mostardini, C | 1 |
| Westrich, GH | 1 |
| Haas, SB | 1 |
| Mosca, P | 1 |
| Güthner, C | 1 |
| Beneke, H | 1 |
| Hildebrand, A | 1 |
| Grünewald, M | 1 |
| Akkerhuis, KM | 1 |
| Neuhaus, KL | 1 |
| Wilcox, RG | 1 |
| Boland, JL | 1 |
| Hoffmann, J | 1 |
| Baardman, T | 1 |
| Roth, U | 1 |
| Klootwijk, AP | 1 |
| Taylor, FC | 1 |
| Ebrahim, S | 1 |
| Lowe, GD | 2 |
| Sanmuganathan, PS | 1 |
| Ghahramani, P | 1 |
| Jackson, PR | 1 |
| Wallis, EJ | 1 |
| Ramsay, LE | 1 |
| Skerrett, PJ | 1 |
| Sapp, S | 1 |
| Yip, HK | 1 |
| Chang, HW | 1 |
| Wu, CJ | 1 |
| Chen, MC | 1 |
| Hang, CL | 1 |
| Fang, CY | 1 |
| Hsieh, KY | 1 |
| Hennekes, S | 1 |
| Duly-Bouhanick, B | 1 |
| Menard, S | 1 |
| Hadjadj, S | 1 |
| Soares-Barbosa, S | 1 |
| Plun-Favreau, J | 1 |
| Guilloteau, G | 1 |
| Sonaglia, F | 1 |
| Castellino, G | 1 |
| Cuadrado, MJ | 1 |
| Godfrey, T | 1 |
| Hughes, GR | 1 |
| Hutten, BA | 1 |
| Plokker, HW | 1 |
| Kawano, KI | 1 |
| Hokamura, K | 1 |
| Kondo, K | 1 |
| Suzuki, Y | 1 |
| Umemura, K | 1 |
| Mukherjee, D | 1 |
| Robbins, M | 1 |
| Yadav, JS | 1 |
| Grubitzsch, H | 1 |
| Wollert, HG | 1 |
| Eckel, L | 1 |
| Peterson, P | 1 |
| Cates, C | 1 |
| George, BS | 1 |
| Sane, DC | 1 |
| Cines, DB | 1 |
| Jordan, RE | 1 |
| Mascelli, MA | 1 |
| Langrall, MA | 1 |
| Damaraju, L | 1 |
| Schantz, A | 1 |
| Braden, GA | 1 |
| Fox, KK | 1 |
| Neilipovitz, DT | 1 |
| Bryson, GL | 1 |
| Nichol, G | 1 |
| Jackson, SL | 1 |
| Vial, JH | 1 |
| Daud, R | 1 |
| Ang, SY | 1 |
| Petri, M | 1 |
| McKenna, R | 1 |
| van der Zaag, ES | 1 |
| Legemate, DA | 1 |
| Quilliam, BJ | 1 |
| Lapane, KL | 1 |
| Mor, V | 1 |
| Lechat, P | 1 |
| Lardoux, H | 1 |
| Mallet, A | 1 |
| Sanchez, P | 1 |
| Derumeaux, G | 1 |
| Lecompte, T | 2 |
| Mentre, F | 1 |
| Pousset, F | 1 |
| Lacomblez, L | 1 |
| Pisica, G | 1 |
| Solbes-Latourette, S | 1 |
| Raynaud, P | 1 |
| Chaumet-Riffaud, P | 1 |
| O'Connor, FF | 1 |
| Shields, DC | 1 |
| Fitzgerald, A | 1 |
| Putnam, W | 1 |
| Flowerdew, GJ | 1 |
| Brownell, BF | 1 |
| Nagpal, S | 1 |
| Cox, JL | 1 |
| Chapman, TW | 1 |
| Bowley, DM | 1 |
| Lambert, AW | 1 |
| Walker, AJ | 1 |
| Ashley, SA | 1 |
| Wilkins, DC | 1 |
| Evans, A | 2 |
| Perez, I | 1 |
| Yu, G | 1 |
| Kalra, L | 1 |
| Vane, LA | 1 |
| Funston, JS | 1 |
| Kirschner, R | 1 |
| Harper, D | 1 |
| Deyo, DJ | 1 |
| Traber, LL | 1 |
| Prisco, D | 1 |
| Pauzner, R | 1 |
| Dulitzki, M | 1 |
| Langevitz, P | 1 |
| Livneh, A | 1 |
| Kenett, R | 1 |
| Many, A | 1 |
| Lazar, RM | 1 |
| Kistler, JP | 2 |
| Pettigrew, LC | 1 |
| Adams, HP | 1 |
| Jackson, CM | 1 |
| Haulon, S | 1 |
| Susen, S | 1 |
| Koussa, M | 1 |
| Jude, B | 1 |
| Owen, A | 1 |
| Yende, S | 1 |
| Brophy, MT | 1 |
| Lu, D | 1 |
| Sacco, J | 1 |
| Peduzzi, P | 1 |
| Johnson, WC | 1 |
| Williford, WO | 1 |
| Moraca, RJ | 1 |
| Ragni, MV | 1 |
| Lewis, SC | 1 |
| Sandercock, PA | 1 |
| Sarasin, FP | 1 |
| Jakovljević, D | 1 |
| Tuomilehto, J | 1 |
| Kilpatrick, C | 1 |
| Gerraty, R | 1 |
| Campbell, Do | 1 |
| Greenberg, P | 1 |
| Fisherman, EW | 2 |
| Cohen, GN | 2 |
| O'Grady, J | 1 |
| Rajah, SM | 1 |
| Penny, A | 1 |
| Kester, R | 1 |
| Lessof, MH | 1 |
| Torosian, M | 2 |
| Morganroth, J | 2 |
| MacVaugh, H | 1 |
| Mac Vaugh, H | 1 |
| Rubin, RN | 1 |
| Bowie, EJ | 2 |
| Owen, CA | 2 |
| Album, B | 1 |
| Lokken, P | 1 |
| Whitehouse, MW | 1 |
| Rainsford, KD | 1 |
| Reyers, I | 2 |
| Donati, MB | 3 |
| de Gaetano, G | 3 |
| Janbu, T | 1 |
| Løkken, P | 1 |
| Nesheim, BI | 1 |
| Fields, WS | 1 |
| Lemak, NA | 1 |
| Frankowski, RF | 1 |
| Hardy, RJ | 1 |
| Rose, SD | 1 |
| Ardelt, W | 2 |
| Pasold, K | 1 |
| Hillemanns, HG | 1 |
| Weinger, RS | 1 |
| Cimo, PL | 1 |
| DiSabatino, CA | 1 |
| Clyne, LP | 1 |
| Malawista, SE | 1 |
| Garattini, S | 1 |
| Jobin, F | 1 |
| Yett, HS | 1 |
| Skillman, JJ | 1 |
| Salzman, EW | 3 |
| Thomas, CY | 1 |
| Data, JL | 1 |
| Chang, LC | 1 |
| Nies, AS | 1 |
| Crawford, JS | 2 |
| Davies, DW | 1 |
| Steward, DJ | 1 |
| Schirru, PL | 1 |
| Karchmer, AW | 1 |
| Ellman, L | 1 |
| Lavrinovich, TS | 1 |
| Petukhova, LI | 1 |
| Slutskiĭ, LI | 1 |
| Schuh, W | 1 |
| Liedloff, H | 1 |
| Schramm, G | 1 |
| Schaus, R | 1 |
| Grossman, RC | 1 |
| Lewandowski, RL | 1 |
| Rubenstein, JJ | 1 |
| Locke, GE | 1 |
| Giorgio, AJ | 1 |
| Biggers, SL | 1 |
| Johnson, AP | 1 |
| Salem, F | 1 |
| Paiement, GD | 1 |
| Schutzer, SF | 1 |
| Wessinger, SJ | 1 |
| Harris, WH | 3 |
| Bang, CJ | 1 |
| Riedel, B | 1 |
| Talstad, I | 1 |
| Berstad, A | 1 |
| Jahnmatz, B | 1 |
| Rosén, A | 1 |
| Sørensen, S | 1 |
| Kissinger, D | 1 |
| Garrioch, M | 1 |
| Gratz, I | 1 |
| Koehler, J | 1 |
| Olsen, D | 1 |
| Afshar, M | 1 |
| DeCastro, N | 1 |
| Spagna, PM | 1 |
| Ablaza, SG | 1 |
| Larijani, GE | 1 |
| Nolan, J | 1 |
| Bloomfield, P | 1 |
| Wilkes, HC | 1 |
| Kelleher, CC | 1 |
| Kahn, JK | 1 |
| Andersen, P | 1 |
| Ovrebø, J | 1 |
| Kleiman, N | 2 |
| Aguirre, F | 1 |
| Chaitman, BR | 2 |
| Ross, AM | 2 |
| Lui, SF | 1 |
| Garabedian, HD | 1 |
| Gold, HK | 2 |
| Leinbach, RC | 2 |
| Svizzero, TA | 1 |
| Finkelstein, DM | 1 |
| Guerrero, JL | 1 |
| Shirvani, R | 1 |
| Terrin, ML | 1 |
| Stump, DC | 1 |
| Berke, AD | 1 |
| Frederick, M | 1 |
| Feit, F | 1 |
| Hillis, LD | 1 |
| Lambrew, CT | 1 |
| Kutner, M | 1 |
| Nixon, G | 1 |
| Silverstone, F | 1 |
| Bauman, RA | 1 |
| Przybelski, RJ | 1 |
| Bounds, MJ | 1 |
| Gavaghan, TP | 1 |
| Gebski, V | 1 |
| Baron, DW | 1 |
| Krichbaum, DW | 1 |
| Grabavoy, G | 1 |
| Finley, RC | 1 |
| Hamid, I | 1 |
| Joelson, JM | 1 |
| Hamilton, WP | 1 |
| Chard, RB | 1 |
| Kam, CA | 1 |
| Nunn, GR | 1 |
| Johnson, DC | 1 |
| Meldrum-Hanna, W | 1 |
| Orthner, E | 1 |
| Hertz, H | 1 |
| Kwasny, O | 1 |
| Maier, R | 1 |
| Zekert, F | 1 |
| Schemper, M | 1 |
| Höfer, R | 1 |
| Bergmann, H | 1 |
| Havlick, E | 1 |
| Wohlzogen, FX | 1 |
| Hughes, RA | 1 |
| Gress, DR | 1 |
| Sheehan, MA | 1 |
| Oertel, LB | 1 |
| Maraventano, SW | 1 |
| Blewett, DR | 1 |
| Rosner, B | 1 |
| Johnstone, MT | 1 |
| Andrews, T | 1 |
| Ware, JA | 1 |
| Rudd, MA | 1 |
| George, D | 1 |
| Weinstein, M | 1 |
| Loscalzo, J | 1 |
| Adams, PC | 1 |
| Hawkins, L | 1 |
| Bach, M | 1 |
| Hertz-Picciotto, I | 1 |
| Hopenhayn-Rich, C | 1 |
| Golub, M | 1 |
| Hooper, K | 1 |
| Ruiz, H | 1 |
| Saltzman, B | 1 |
| Shi, Y | 1 |
| Zalewski, A | 1 |
| Walinsky, P | 1 |
| Goldberg, S | 1 |
| Schreiber, TL | 1 |
| Miller, DH | 1 |
| Silvasi, D | 1 |
| McNulty, A | 1 |
| Zola, BE | 1 |
| Watson, CJ | 1 |
| Deane, AM | 1 |
| Doyle, PT | 1 |
| Bullock, KN | 1 |
| Gay, WA | 1 |
| Taggart, DP | 1 |
| Siddiqui, A | 1 |
| Wheatley, DJ | 1 |
| Sethi, GK | 1 |
| Copeland, JG | 1 |
| Moritz, T | 1 |
| Zadina, K | 1 |
| Henderson, WG | 1 |
| Datta, MC | 2 |
| Josephs, J | 1 |
| Tolbert, ME | 1 |
| Anderson, J | 1 |
| Dowla, H | 1 |
| Gavriliuk, AI | 1 |
| Remuzzi, G | 3 |
| Vaughan, DE | 1 |
| Declerck, PJ | 1 |
| De Mol, M | 1 |
| Gimple, LW | 1 |
| Yasuda, T | 1 |
| Johns, JA | 1 |
| Ziskind, AA | 1 |
| Finkelstein, D | 1 |
| Sone, R | 1 |
| Nagayama, T | 1 |
| Shibagaki, Y | 1 |
| Kobayashi, I | 1 |
| Maruyama, S | 1 |
| Kusakabe, K | 1 |
| Moll, AC | 1 |
| van Rij, G | 1 |
| van der Loos, TL | 1 |
| Powers, PJ | 1 |
| Jay, RM | 1 |
| Julian, DH | 1 |
| Levine, M | 1 |
| Tsujinaka, T | 1 |
| Itoh, T | 1 |
| Sakon, M | 1 |
| Kambayashi, J | 1 |
| Mori, T | 1 |
| Livio, M | 1 |
| Benigni, A | 1 |
| Viganò, G | 1 |
| Mecca, G | 1 |
| Crawford, JP | 1 |
| Domschke, W | 1 |
| Hagel, J | 1 |
| Ruppin, H | 1 |
| Kaduk, B | 1 |
| DeCampli, WM | 1 |
| Kosek, JC | 1 |
| Mitchell, RS | 1 |
| Handen, CE | 1 |
| Miller, DC | 1 |
| Ferraris, SP | 1 |
| Lough, FC | 1 |
| Berry, WR | 1 |
| Marcus, M | 1 |
| Biedner, B | 1 |
| Lifshitz, T | 1 |
| Yassur, Y | 1 |
| Danesh, BJ | 1 |
| Saniabadi, AR | 1 |
| Russell, RI | 1 |
| Hays, LJ | 1 |
| Beller, GA | 1 |
| Moore, CA | 1 |
| Burwell, LR | 1 |
| Craddock, GB | 1 |
| Gascho, JA | 1 |
| Smucker, ML | 1 |
| Tedesco, C | 1 |
| Baker, RI | 1 |
| Manoharan, A | 1 |
| Christakis, GT | 1 |
| Weisel, RD | 1 |
| Mee, AV | 1 |
| Ivanov, J | 1 |
| Madonik, MM | 1 |
| Levitt, DS | 1 |
| Rosenfeld, JM | 1 |
| Pinna, AD | 1 |
| Argiolu, F | 1 |
| Marongiu, L | 1 |
| Pinna, DC | 1 |
| Stage, J | 1 |
| Jensen, JH | 1 |
| Bonding, P | 1 |
| Hindman, BJ | 1 |
| Koka, BV | 1 |
| Szelenyi, I | 1 |
| Engler, H | 1 |
| Beck, H | 1 |
| Spears, HJ | 1 |
| Dowla, HA | 1 |
| Rigby, PG | 1 |
| Levine, MN | 1 |
| Hatsuoka, M | 1 |
| Seiki, M | 1 |
| Sasaki, K | 1 |
| Kashii, A | 1 |
| Samama, M | 1 |
| Kitahora, T | 1 |
| Guth, PH | 1 |
| Werblin, TP | 1 |
| Peiffer, RL | 1 |
| Woods, A | 1 |
| Vargas, J | 1 |
| Berri, G | 1 |
| Kreutzer, G | 1 |
| Meschengieser, S | 1 |
| Nuñez, L | 1 |
| Pinto, AG | 1 |
| Larrea, JL | 1 |
| Gil Aguado, M | 1 |
| Connor, FO | 1 |
| Tartaglia, AP | 1 |
| Goldberg, JD | 1 |
| Berk, PD | 1 |
| Wasserman, LR | 1 |
| Chapman, CS | 1 |
| Swart, SS | 1 |
| Wood, JK | 1 |
| Verrier, ED | 1 |
| Tranbaugh, RF | 1 |
| Soifer, SJ | 1 |
| Yee, ES | 1 |
| Turley, K | 1 |
| Ebert, PA | 1 |
| Breyer, RH | 1 |
| Rousou, JA | 1 |
| Engelman, RM | 1 |
| Lemeshow, S | 1 |
| Delahaye, JP | 1 |
| Milon, H | 1 |
| Ffrench, P | 1 |
| Philippe-Bert, J | 1 |
| Malquarti, V | 1 |
| Saradarian, W | 1 |
| Wedgwood, KR | 1 |
| Farmer, RC | 1 |
| Reber, HA | 1 |
| Hadchouel, M | 1 |
| Prieur, AM | 1 |
| Griscelli, C | 1 |
| Stone, LS | 1 |
| Kline, OR | 1 |
| Sklar, C | 1 |
| Barber, A | 1 |
| Green, D | 2 |
| Galluzzo, T | 1 |
| Ts'ao, CH | 1 |
| Plocher, DW | 1 |
| Uppington, J | 1 |
| Bradley, LM | 1 |
| Midgley, FM | 1 |
| Watson, DC | 1 |
| Getson, PR | 1 |
| Scott, LP | 1 |
| O'Reilly, RA | 1 |
| Sahud, MA | 2 |
| Aggeler, PM | 1 |
| Quick, AJ | 6 |
| Perlick, E | 1 |
| Ogston, D | 1 |
| Douglas, AS | 2 |
| Eriksson, M | 2 |
| Dittrich, A | 1 |
| Bolze, H | 1 |
| Athanasoulis, C | 1 |
| Waltman, AC | 1 |
| Baum, S | 1 |
| DeSanctis, RW | 2 |
| Niklasson, PM | 1 |
| Blombäck, M | 1 |
| Lundbergh, P | 1 |
| Strandell, T | 1 |
| Sanfelippo, MJ | 1 |
| Hussey, CV | 1 |
| Rossi, EC | 1 |
| Rabiner, SF | 1 |
| Lyon, LJ | 1 |
| Nevins, MA | 1 |
| McBride, JA | 1 |
| Wallett, LH | 1 |
| Friend, DG | 1 |
| Prentice, CR | 1 |
| Gallus, AS | 1 |
| Naess, K | 1 |
| Palmer, AK | 1 |
| Büttinghaus, K | 1 |
| Tenhaeff, D | 1 |
| Isom, OW | 1 |
| Williams, CD | 1 |
| Falk, EA | 1 |
| Spencer, FC | 1 |
| Glassman, E | 1 |
| Willis, AL | 1 |
| Weiss, HJ | 1 |
| Powell, HR | 1 |
| Ekert, H | 1 |
| Dawson, AA | 1 |
| Walker, W | 1 |
| Wellmer, HK | 1 |
| Baer, U | 1 |
| Merguet, H | 1 |
| Rumpf, P | 1 |
| Petersen, H | 1 |
| Bromig, G | 1 |
| Persch, WF | 1 |
| Marx, FJ | 1 |
| von Bary, SM | 1 |
| Hampton, JW | 1 |
| Done, AK | 1 |
| Temple, AR | 1 |
| Martin, BK | 1 |
| Cronberg, S | 2 |
| Vandam, LD | 1 |
| Zdichynec, B | 1 |
| Mongin, M | 1 |
| de Laforte, C | 1 |
| Papilian, M | 1 |
| Campanacci, D | 1 |
| Byrne, JJ | 1 |
| Migliore, JJ | 1 |
| Beekley, W | 1 |
| Guardione, VA | 1 |
| Williams, LF | 1 |
| Sherry, S | 1 |
| Worsoe-Petersen, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation[NCT01813435] | Phase 3 | 15,991 participants (Actual) | Interventional | 2013-07-01 | Completed | ||
| A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of Age After the Fontan Procedure[NCT02846532] | Phase 3 | 112 participants (Actual) | Interventional | 2016-11-16 | Completed | ||
| A Prospective, Multicenter, Randomized, Open-label Trial to Compare Efficacy and Safety of Clopidogrel vs Ticagrelor in Stabilized Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention; TicAgrelor Versus CLOpidogrel in Stabili[NCT02018055] | Phase 4 | 2,590 participants (Actual) | Interventional | 2014-02-14 | Completed | ||
| COVID-19 Outpatient Thrombosis Prevention Trial A Multi-center Adaptive Randomized Placebo-controlled Platform Trial Evaluating the Efficacy and Safety of Anti-thrombotic Strategies in COVID Adults Not Requiring Hospitalization at Time of Diagnosis[NCT04498273] | Phase 3 | 657 participants (Actual) | Interventional | 2020-09-07 | Terminated (stopped due to an event rate lower than anticipated) | ||
| Analysis of the Platelet Activity State in Patients Implanted With Ventricular Assist Device (VAD)[NCT03255928] | 60 participants (Anticipated) | Observational [Patient Registry] | 2017-06-29 | Recruiting | |||
| XIENCE 28 Global Study[NCT03355742] | 963 participants (Actual) | Interventional | 2018-02-09 | Completed | |||
| A Safety Evaluation of 3-month Dual Antiplatelet Therapy in Subjects at High Risk of Bleeding Undergoing Percutaneous Coronary Intervention With XIENCE.[NCT03218787] | 2,047 participants (Actual) | Interventional | 2017-07-19 | Completed | |||
| XIENCE 28 USA Study[NCT03815175] | 1,605 participants (Actual) | Interventional | 2019-02-25 | Completed | |||
| Mitochondrial Dysfunction in Trauma-related Coagulopathy - Is There Causality? - Study Protocol for a Prospective Observational Study[NCT05004844] | 40 participants (Anticipated) | Observational | 2021-10-31 | Not yet recruiting | |||
| An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Int[NCT02415400] | Phase 4 | 4,614 participants (Actual) | Interventional | 2015-06-04 | Completed | ||
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia[NCT02735707] | Phase 3 | 10,000 participants (Anticipated) | Interventional | 2016-04-11 | Recruiting | ||
| Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE[NCT03871517] | Phase 4 | 5,438 participants (Actual) | Interventional | 2019-06-03 | Completed | ||
| Aspirin to Target Arterial Events in Chronic Kidney Disease[NCT03796156] | Phase 3 | 25,210 participants (Anticipated) | Interventional | 2019-02-25 | Recruiting | ||
| [NCT02513810] | 3,020 participants (Anticipated) | Interventional | 2015-12-02 | Active, not recruiting | |||
| Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen[NCT03023020] | 4,579 participants (Actual) | Interventional | 2017-04-04 | Completed | |||
| An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients With Symptomatic Peripheral Artery Disease Un[NCT02504216] | Phase 3 | 6,564 participants (Actual) | Interventional | 2015-08-18 | Completed | ||
| Study to Evaluate the Safety of Reducing Dual Antiplatelet Therapy (DAPT) Duration to 1 Month for Patients With Acute Coronary Syndrome (ACS) After Implantation of Everolimus-eluting Cobalt-chromium Stent[NCT03462498] | Phase 4 | 3,008 participants (Actual) | Interventional | 2018-04-02 | Active, not recruiting | ||
| ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study[NCT02619760] | Phase 4 | 3,045 participants (Actual) | Interventional | 2015-12-31 | Active, not recruiting | ||
| One Month Dual Antiplatelet Therapy With Ticagrelor in Coronary Artery Bypass Graft Patients[NCT05997693] | Phase 3 | 700 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| Multicenter, Randomized, Placebo Controlled, Double-blind, Parallel Group, Dose-finding Phase 2 Study to Evaluate the Efficacy and Safety of BAY 2433334 in Patients Following an Acute Myocardial Infarction[NCT04304534] | Phase 2 | 1,601 participants (Actual) | Interventional | 2020-06-17 | Completed | ||
| Comparison Between P2Y12 Antagonist MonotHerapy and Dual Antiplatelet Therapy in Patients UndergOing Implantation of Coronary Drug-Eluting Stents[NCT02079194] | 3,000 participants (Actual) | Interventional | 2014-03-18 | Active, not recruiting | |||
| Randomized Control Study of Anticoagulation With Warfarin Por Patients With Aortic Bioprosthesis vs Aspirin Only[NCT03807921] | Phase 4 | 140 participants (Actual) | Interventional | 2019-01-01 | Completed | ||
| Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness[NCT02697916] | 15,076 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| Implementing Screening for Preeclampsia in Norway With Aspirin Discontinuation at 24-28 Weeks - a Randomized Controlled Trial[NCT06108947] | 300 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | |||
| A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ti[NCT01991795] | Phase 3 | 19,271 participants (Actual) | Interventional | 2014-02-10 | Completed | ||
| Pilot, Non-masked, Randomized Clinical Trial for Evaluation of Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).[NCT05868525] | Phase 4 | 98 participants (Anticipated) | Interventional | 2024-04-30 | Recruiting | ||
| Ischemic And Bleeding Risk Assessment After TAVR (FOCUS ONE Registry)[NCT06000943] | 2,500 participants (Anticipated) | Observational [Patient Registry] | 2023-08-01 | Recruiting | |||
| Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography ([NCT02833948] | Phase 3 | 231 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes[NCT02556203] | Phase 3 | 1,653 participants (Actual) | Interventional | 2015-12-16 | Terminated (stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator) | ||
| A Prospective Multi-center Open-label Controlled Trial of Comparison 3 vs 12 Months of Dual Anti-Platelet Therapy After Implantation of Firehawk Sirolimus Target- Eluting Stent in Patients With Stable Coronary Artery Disease[NCT03008083] | Phase 4 | 2,446 participants (Anticipated) | Interventional | 2019-01-10 | Recruiting | ||
| Ticagrelor Versus Clopidogrel in Ischemic Stroke. a Randomized Double-blinded Controlled Trial[NCT05553613] | Phase 3 | 900 participants (Actual) | Interventional | 2022-10-01 | Completed | ||
| Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke, a Randomized Controlled Trial[NCT06120725] | Phase 3 | 580 participants (Actual) | Interventional | 2021-09-01 | Completed | ||
| Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke[NCT00979589] | Phase 3 | 5,100 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| A Phase 1, Open-label, 2-period, Fixed-sequence Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion Coadministered With Clopidogrel in Healthy Subjects[NCT02560688] | Phase 1 | 22 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| A PHASE 1, OPEN LABEL, SINGLE DOSE STUDY, TO ASSESS THE SAFETY AND TOLERABILITY OF A SINGLE IV DOSE OF DS-1040B AFTER 5 DAYS OF ASPIRIN TREATMENT IN HEALTHY SUBJECTS[NCT02071004] | Phase 1 | 18 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| A Prospective Randomised, Open Label, Blinded Endpoint (PROBE) Study to Evaluate DUAL Antithrombotic Therapy With Dabigatran Etexilate (110mg and 150mg b.i.d.) Plus Clopidogrel or Ticagrelor vs. Triple Therapy Strategy With Warfarin (INR 2.0 - 3.0) Plus C[NCT02164864] | Phase 3 | 2,725 participants (Actual) | Interventional | 2014-07-22 | Completed | ||
| VALIDATION OF THE VIBe INTRAOPERATIVE BLEEDING SCALE IN LIVER SURGERY. PROSPECTIVE AND MULTICENTRIC STUDY[NCT05369988] | 259 participants (Anticipated) | Observational [Patient Registry] | 2022-07-01 | Not yet recruiting | |||
| [NCT02494895] | Phase 4 | 3,056 participants (Anticipated) | Interventional | 2015-08-01 | Recruiting | ||
| Safety and Efficacy of Century Clot-Guided Prophylactic Rivaroxaban Therapy for Post ST-Segment Elevation Myocardial Infarction Complicating Left Ventricular Thrombus Compared With Conventional Antiplatelet Therapy[NCT06013020] | Phase 4 | 374 participants (Anticipated) | Interventional | 2023-08-28 | Recruiting | ||
| A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared With ASA in the Prevention of Stroke and Death in Patients With Acute Ischaemic Stroke or Tra[NCT03354429] | Phase 3 | 11,016 participants (Actual) | Interventional | 2018-01-22 | Completed | ||
| Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862] | 350 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | |||
| A REAl-life Study on Short-term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack[NCT05476081] | 1,067 participants (Anticipated) | Observational [Patient Registry] | 2021-02-03 | Recruiting | |||
| Extended Antiplatelet Therapy With Clopidogrel Alone Versus Clopidogrel Plus Aspirin After Completion of 9- to 12-month Dual Antiplatelet Therapy for ACS Patients With Both High Bleeding and Ischemic Risk.[NCT03431142] | Phase 4 | 7,700 participants (Anticipated) | Interventional | 2018-02-12 | Recruiting | ||
| Major Bleeding Risk Associated With Antithrombotics : The SACHA (Surveillance Des Accidents Hémorragiques Graves Sous Antithrombotiques) Study[NCT02886533] | 6,484 participants (Actual) | Observational | 2013-01-01 | Completed | |||
| Pneumatic Compression Versus Anti-thromboembolic Exercises: Effects on Edema of the Lower Limbs and the Outcomes of Patients Undergoing Total Hip Arthroplasty: Randomized Controlled Clinical Trial[NCT05312060] | 48 participants (Anticipated) | Interventional | 2022-04-11 | Enrolling by invitation | |||
| Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation: Multicenter Randomized Clinical Trial[NCT05283356] | Phase 4 | 1,206 participants (Anticipated) | Interventional | 2022-01-21 | Recruiting | ||
| Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation[NCT02247128] | Phase 4 | 1,016 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial) Comparison of the Efficacy and Safety of Biostable Polymer DES ([NCT02193971] | Phase 4 | 3,384 participants (Anticipated) | Interventional | 2014-07-31 | Active, not recruiting | ||
| A Phase 2, Randomized, Open Label, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Rivaroxaban Compared With Vitamin K Antagonism in Patients With Atrial Fibrillation With Bioprosthetic Mitral Valves - RIVER[NCT02303795] | Phase 2 | 1,005 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562] | Phase 3 | 21,379 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embol[NCT02239120] | Phase 3 | 5,390 participants (Actual) | Interventional | 2014-11-27 | Completed | ||
| Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents Guided by Either Intravascular Ultrasound or Angiography in Patients With Acute Coronary Syndrome: The Prospective, Multicenter, Randomized, Placebo-[NCT03971500] | 3,710 participants (Actual) | Interventional | 2019-08-20 | Active, not recruiting | |||
| Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study)[NCT02642419] | Phase 4 | 2,200 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| CRYptogenic STroke And underLying AF Trial[NCT00924638] | Phase 4 | 447 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Smart Angioplasty Research Team: Safety of 6-month Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes (SMART-DATE)[NCT01701453] | 2,712 participants (Actual) | Interventional | 2012-08-31 | Active, not recruiting | |||
| Prospective, Non-interventional Study of Disease Progression and Treatment of Patients With Polycythemia Vera in United States Academic or Community Clinical Practices[NCT02252159] | 2,544 participants (Actual) | Observational | 2014-07-31 | Completed | |||
| Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism[NCT02064439] | Phase 3 | 3,365 participants (Actual) | Interventional | 2014-03-05 | Completed | ||
| A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects With Acute Coronary Syndrom[NCT02293395] | Phase 2 | 3,037 participants (Actual) | Interventional | 2015-04-20 | Completed | ||
| A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872] | Phase 3 | 18,624 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA Trial)[NCT04654052] | Phase 4 | 634 participants (Anticipated) | Interventional | 2021-07-02 | Recruiting | ||
| STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623] | Phase 3 | 1,899 participants (Actual) | Interventional | 2008-03-01 | Completed | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794] | Phase 4 | 222 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298] | Phase 4 | 178 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286] | Phase 4 | 1,700 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Randomized 2x2 Factorial Trial Comparing the Cre8 Amphilimus-sirolimus Eluting Stent vs. the Synergy Everolimus-eluting Stent and a Personalized vs. Standard Duration of Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Int[NCT04135989] | Phase 4 | 2,106 participants (Anticipated) | Interventional | 2020-01-01 | Active, not recruiting | ||
| Nobori Dual Antiplatelet Therapy as Appropriate Duration.[NCT01514227] | Phase 4 | 3,773 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischaemic Stroke or TIA.[NCT01994720] | Phase 3 | 13,307 participants (Actual) | Interventional | 2014-01-07 | Completed | ||
| Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events[NCT05313620] | Phase 4 | 30 participants (Anticipated) | Interventional | 2022-04-01 | Recruiting | ||
| CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2018-05-01 | Recruiting | |||
| Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion[NCT03630055] | Phase 3 | 1,800 participants (Anticipated) | Interventional | 2018-10-03 | Recruiting | ||
| Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Chronic Coronary Syndromes[NCT04347200] | 2,000 participants (Anticipated) | Observational [Patient Registry] | 2015-01-15 | Recruiting | |||
| DUAL Pathway Inhibition (Low-dose Rivaroxaban and Aspirin) as Compared to Aspirin Only to Improve Endothelial Function in Peripheral Artery Disease.[NCT04218656] | Phase 4 | 159 participants (Actual) | Interventional | 2020-06-08 | Completed | ||
| Characterisation of a Novel Regimen of Very Low-dose Aspirin Combined With Rivaroxaban in Patients With Chronic Coronary Syndromes: WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?[NCT04990791] | Phase 4 | 48 participants (Anticipated) | Interventional | 2021-08-26 | Recruiting | ||
| An Exploratory Study of Effectiveness and Safety of Rivaroxaban in Patients With Left Ventricular Thrombus[NCT04970381] | 60 participants (Anticipated) | Interventional | 2021-07-22 | Recruiting | |||
| SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial[NCT02959606] | Phase 4 | 272 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| A Large, International, Placebo-controlled, Factorial Trial to Assess the Impact of Clonidine and Acetyl-salicylic Acid (ASA) in Patients Undergoing Noncardiac Surgery Who Are at Risk of a Perioperative Cardiovascular Event[NCT01082874] | Phase 3 | 10,010 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028] | 100 participants (Anticipated) | Observational | 2021-03-10 | Not yet recruiting | |||
| Effects of Edoxaban on Platelet Aggregation in Patients With Stable Coronary Artery Disease[NCT05122455] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | ||
| Clopidogrel or Ticagrelor in Acute Coronary Syndrome Patients Treated With Newer-Generation Drug-Eluting Stents: CHANGE DAPT[NCT03197298] | 2,062 participants (Actual) | Observational [Patient Registry] | 2012-12-21 | Completed | |||
| Intensified Antiplatelet Therapy in Post-PCI Patients With High On-treatment Platelet Reactivity: the OPTIMA-2 Trial[NCT01955200] | Phase 4 | 1,724 participants (Actual) | Interventional | 2013-10-05 | Completed | ||
| A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation[NCT00412984] | Phase 3 | 20,976 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Clinical Investigation of a Novel Approach for the Prevention of Deep Venous Thrombosis After Total Knee Replacement[NCT04979026] | 90 participants (Actual) | Interventional | 2019-10-17 | Completed | |||
| Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty[NCT01720108] | Phase 3 | 3,426 participants (Actual) | Interventional | 2013-02-24 | Completed | ||
| A Multicenter, Single Arm, Open Label, Phase IV Study to Evaluate Safety and to Describe the Incidence of Major Cardiovascular Events of Ticagrelor in Chinese Patients With Acute Coronary Syndrome(ACS)[NCT01870921] | Phase 4 | 2,004 participants (Actual) | Interventional | 2013-06-26 | Completed | ||
| A Randomized, Open-Label, Parallel-Group, Multi-Center Study Of Adding Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention[NCT01802775] | Phase 2 | 203 participants (Actual) | Interventional | 2013-02-06 | Completed | ||
| Improving Care for Cardiovascular Disease in China: A Collaborative Project of AHA and CSC (CCC Project) - Acute Coronary Syndrome[NCT02306616] | 124,363 participants (Actual) | Observational | 2014-11-30 | Completed | |||
| Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy[NCT04352439] | Phase 4 | 19 participants (Actual) | Interventional | 2020-08-08 | Completed | ||
| Compare the Efficacy of Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery[NCT02201771] | Phase 4 | 500 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| Trial of PCSK9 Inhibition in Patients With Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study With High-resolution MR Vessel Wall Imaging[NCT05001984] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | ||
| Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease[NCT04824911] | Phase 2 | 424 participants (Anticipated) | Interventional | 2021-03-23 | Recruiting | ||
| Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600] | Phase 4 | 400 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| The Origin and Role of Thromboembolism in the Pathogenesis of Ischaemic Stroke[NCT05636748] | 120 participants (Anticipated) | Observational | 2023-02-28 | Recruiting | |||
| Multicenter, Randomized, Double-blind, Double-dummy, Active-comparator, Event-driven, Superiority Phase III Study of Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With a Recent Embolic Stroke of Undetermined Source (ESUS),[NCT02313909] | Phase 3 | 7,213 participants (Actual) | Interventional | 2014-12-23 | Terminated (stopped due to Study halted early due to no efficacy improvement over aspirin at an interim analysis and very little chance of showing overall benefit if study were completed) | ||
| Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events[NCT02616497] | Phase 4 | 1,220 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Effect of Aspirin in Primary Prevention of Cardiovascular Risk in Patients With Chronic Kidney Disease (AASER Study)[NCT01709994] | Phase 3 | 97 participants (Anticipated) | Interventional | 2010-05-31 | Recruiting | ||
| Correlation Between Bleeding Complication and Treatment Failure of DOAC and Its Predictions Based on Cipherome's Pharmacogenomic Technology[NCT04597593] | 200 participants (Actual) | Observational | 2020-10-07 | Completed | |||
| Aspirin Discontinuation After Left Atrial Appendage Occlusion in Atrial Fibrillation[NCT03821883] | 1,120 participants (Anticipated) | Interventional | 2020-06-01 | Recruiting | |||
| Efficacy and Safety of Clopidogrel for Primary Prevention in Patients With Subclinical Coronary Atherosclerosis Identified on Imaging[NCT05845489] | Phase 4 | 9,930 participants (Anticipated) | Interventional | 2023-03-09 | Recruiting | ||
| A Study of Cardiovascular Events iN Diabetes - A Randomized 2x2 Factorial Study of Aspirin Versus Placebo, and of Omega-3 Fatty Acid Supplementation Versus Placebo, for Primary Prevention of Cardiovascular Events in People With Diabetes[NCT00135226] | Phase 4 | 15,480 participants (Actual) | Interventional | 2005-03-31 | Active, not recruiting | ||
| Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II[NCT05702463] | Phase 1 | 30 participants (Anticipated) | Interventional | 2023-06-13 | Recruiting | ||
| Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes: APPEASED Study Phase 1[NCT05105919] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2021-08-26 | Recruiting | ||
| A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum C[NCT02605447] | Phase 4 | 2,009 participants (Actual) | Interventional | 2016-02-16 | Completed | ||
| Aspirin in Reducing Events in the Elderly[NCT01038583] | 19,114 participants (Actual) | Observational | 2010-01-31 | Active, not recruiting | |||
| [NCT02101411] | 334 participants (Actual) | Observational | 2015-01-01 | Completed | |||
| Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study[NCT03387384] | 5,000 participants (Anticipated) | Observational [Patient Registry] | 2018-06-30 | Recruiting | |||
| Japanese Primary Prevention Project With Aspirin in the Elderly With One or More Risk Factors of Vascular Events: JPPP[NCT00225849] | Phase 4 | 10,000 participants | Interventional | 2005-03-31 | Recruiting | ||
| A Clinical Multicenter, Prospective, Observational Cohort Study to Validate a Prediction Mobile APP for Perioperative Hypothermia[NCT05333120] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2021-05-25 | Recruiting | |||
| Influence of Different Inspired Oxygen Fractions on Perioperative Myocardial Biomarkers, Myocardial Strain and Outcome in Patients Undergoing General Anaesthesia for Elective Non-cardiac Surgery: A Prospective Randomized Open-label Single Centre Pilot Stu[NCT04808401] | 110 participants (Anticipated) | Interventional | 2021-05-07 | Recruiting | |||
| Closed Incision Negative Pressure Therapy Compared to Conventional Dressing Following Autologous Abdominal Tissue Breast Reconstruction: A Randomized Control Trial[NCT05907941] | 114 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | |||
| Onyx ONE Study; A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk Patients[NCT03344653] | 2,000 participants (Actual) | Interventional | 2017-11-02 | Completed | |||
| Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects With a Recent Acute Coronary Syndrome[NCT00831441] | Phase 3 | 7,484 participants (Actual) | Interventional | 2009-03-31 | Terminated | ||
| What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing[NCT00769938] | Phase 4 | 573 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Optimal Duration of Dual Antiplatelet Therapy After Drug Eluting Stent (DES) Implantation[NCT00822536] | Phase 4 | 1,798 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Different Approach to Preventing Thrombosis (ADAPT): A Randomized Controlled Trial Comparing Low Molecular Weight Heparin to Acetylsalicylic Acid in Orthopedic Trauma Patients[NCT02774265] | Phase 3 | 329 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| China Registry of Non-disabling Ischemic Cerebrovascular Events: A Prospective Multi-center, National Registry Trail[NCT03079674] | 10,000 participants (Anticipated) | Observational [Patient Registry] | 2017-06-01 | Not yet recruiting | |||
| Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a Parallel Randomized, Open-label, Multicenter, Prospective Study[NCT02869009] | Phase 3 | 3,000 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Efficacy of Drug-Eluting Vertebral Artery Stenting Treatment for Atherosclerotic Vertebral Arteries Stenosis in Real-World Clinical Observations: a Prospective, Multicenter, Open-access, Single-arm Clinical Study[NCT05644314] | 144 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | |||
| Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)[NCT01165710] | 10,179 participants (Actual) | Observational | 2010-06-30 | Completed | |||
| Must Aspirin be Discontinued Prior to TURBT: a Prospective, Randomized, Non-inferiority Trial Comparing Peri-operative Aspirin Continuation Versus Discontinuation.[NCT02350543] | Phase 4 | 50 participants (Actual) | Interventional | 2015-02-28 | Terminated (stopped due to Insufficient recruitment.) | ||
| Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet [NCT01267734] | Phase 4 | 3,750 participants (Anticipated) | Interventional | 2010-06-30 | Recruiting | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atria[NCT00262600] | Phase 3 | 18,113 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Monitor System for the Safety of Dabigatran Anticoagulation Treatment in Nonvalvular Atrial Fibrillation[NCT02414035] | 1,496 participants (Actual) | Observational | 2015-03-22 | Completed | |||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Optimal Duration of Clopidogrel Therapy After Drug-Eluting Stent Implantation to Reduce Late Coronary Arterial Thrombotic Events[NCT01186146] | Phase 4 | 5,000 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients[NCT01623700] | 78,000 participants (Actual) | Observational | 2006-01-31 | Active, not recruiting | |||
| Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor Zotarolimus - Eluting Stent in the Real World Clinical Practice - Optimize Trial[NCT01113372] | Phase 4 | 3,119 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure[NCT03088072] | Phase 4 | 75 participants (Anticipated) | Interventional | 2017-03-23 | Recruiting | ||
| Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation[NCT04357288] | 1,200 participants (Anticipated) | Interventional | 2020-12-16 | Active, not recruiting | |||
| Evaluation of the Occurence of Thrombotic and Bleeding Events After Coronary Angioplasty With Stent According to Aspirin and Clopidogrel Platelet Reactivity Assessed by a Point of Care Assay in the Cathlab (the Verifynow French Registry)[NCT00753753] | 1,001 participants (Actual) | Observational | 2008-02-29 | Completed | |||
| Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835] | 1,492 participants (Anticipated) | Observational [Patient Registry] | 2019-08-01 | Recruiting | |||
| Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and a Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting[NCT00827411] | Phase 4 | 2,500 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Prasugrel in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients[NCT04445623] | Phase 3 | 128 participants (Anticipated) | Interventional | 2020-07-31 | Not yet recruiting | ||
| Multicenter Randomized, Double-blind, Placebo-controlled, Clinical Trial of Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients (Asperum)[NCT04808895] | Phase 3 | 204 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
| Secondary Prevention of Small Subcortical Strokes (SPS3) Trial[NCT00059306] | Phase 3 | 3,020 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| MONET BRIDGE(Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery) - (Mantenimento Della Terapia Antiaggregante Nei Pazienti Portatori di Stent Coronarico Candidati a Chirurgia)[NCT03862651] | Phase 2 | 140 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | ||
| PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy[NCT03392948] | 1,080 participants (Anticipated) | Observational [Patient Registry] | 2018-02-09 | Active, not recruiting | |||
| Ongoing WARfarin and Coronary STENTing. A Multi-center, Prospective Registry on Antithrombotic Treatment.[NCT00722319] | 1,000 participants (Anticipated) | Observational | 2009-03-31 | Active, not recruiting | |||
| A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938] | Phase 4 | 25,682 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Percutaneous Coronary Intervention With the ANgiolite Drug-Eluting Stent: an Optical CoHerence TOmogRaphy Study. The ANCHOR Study[NCT02776267] | 100 participants (Anticipated) | Interventional | 2015-05-31 | Completed | |||
| "Outcome of CHAllenging lesioNs and Patients Treated With Polymer Free Drug-CoatEd Stent (Biofreedom): the CHANCE a Multicenter Study"[NCT03622203] | 1,000 participants (Actual) | Observational [Patient Registry] | 2016-01-01 | Completed | |||
| A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969] | Phase 4 | 2,200 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268] | Phase 4 | 72 participants (Actual) | Interventional | 2019-04-24 | Completed | ||
| Aspirin Withdrawal and Clinical Outcome in Patients With Moderate to High Cardiovascular Risk But Without Cardiovascular Disease[NCT03757156] | 4,118 participants (Anticipated) | Interventional | 2019-03-31 | Not yet recruiting | |||
| Is There A LIfe for DES After Discontinuation of Clopidogrel:The ITALIC PLUS Trial[NCT01476020] | 1,240 participants (Anticipated) | Observational | 2011-11-30 | Not yet recruiting | |||
| Registry of Left Atrial Appendage Occlusion With WATCHMAN® Device in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic Kidney Disease on Hemodialysis[NCT03446794] | 300 participants (Actual) | Observational [Patient Registry] | 2018-03-14 | Completed | |||
| Safety of Ticagrelor Plus Warfarin Versus Clopidogrel+Aspirin+Warfarin in Patients With Persistent or Permanent Atrial Fibrillation and Undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial[NCT02206815] | Phase 4 | 296 participants (Actual) | Interventional | 2014-09-19 | Completed | ||
| THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve[NCT00530894] | 1,057 participants (Actual) | Interventional | 2007-04-30 | Completed | |||
| EDUCATE: a Prospective, Multi-center Study Designed to Collect Real-world Safety and Clinical Outcomes in Subjects Receiving One or More Endeavor Zotarolimus-Eluting Stents and Either Clopidogrel and Aspirin or Prasugrel and Aspirin as Part of a Dual Anti[NCT01069003] | Phase 4 | 2,272 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study[NCT01385319] | Phase 3 | 1,606 participants (Actual) | Interventional | 2011-06-30 | Active, not recruiting | ||
| Personalization of Long-Term Antiplatelet Therapy Using a Novel Combined Demographic/Pharmacogenomic Strategy - The RAPID EXTEND Randomized Study[NCT03729401] | Phase 4 | 390 participants (Anticipated) | Interventional | 2019-08-22 | Suspended (stopped due to Testing supplies unavailable.) | ||
| A Randomized, Single Center Trial to Assess the Endothelial Function With Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of Acute Coronary Syndrome[NCT03881943] | Phase 4 | 200 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg Twice Daily in Elderly Patients With Acute Coronary Syndrome (ACS)[NCT04739384] | Phase 3 | 50 participants (Actual) | Interventional | 2021-04-01 | Completed | ||
| A Multicenter Randomized Trial Evaluating the Efficacy of Sarpogrelate on Ischemic Heart Disease After Drug-eluting Stent Implantation in Patients With Diabetes Mellitus or Renal Impairment[NCT02294643] | Phase 3 | 220 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-segment Elevation Myocardial Infarction[NCT02075125] | Phase 3 | 39 participants (Actual) | Interventional | 2014-01-31 | Terminated (stopped due to Enrolling participants has halted prematurely and will not resume) | ||
| Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention[NCT02334254] | Phase 4 | 420 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double-blind Trial[NCT00496769] | Phase 3 | 6,421 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| GLOBAL LEADERS Adjudication Sub-Study[NCT03231059] | 7,365 participants (Actual) | Observational | 2017-06-01 | Completed | |||
| Zotarolimus Eluting Stent Versus Sirolimus Eluting Stent in High Bleeding Risk Angioplasty[NCT05240781] | 280 participants (Anticipated) | Interventional | 2021-09-29 | Recruiting | |||
| Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794] | 8,575 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery (CABG)[NCT01373411] | Phase 4 | 70 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed[NCT00699998] | Phase 3 | 9,326 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Association of PeriOPerative Aspirin-ResisTance and CardioVascular Outcome[NCT04053894] | 220 participants (Anticipated) | Observational | 2019-08-31 | Not yet recruiting | |||
| Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients: An Observational Single-Arm Study (The PARIS Registry)[NCT00998127] | 5,031 participants (Actual) | Observational | 2009-06-30 | Completed | |||
| Ticagrelol Versus Aspirin in Ischemic Stroke[NCT03884530] | Phase 3 | 169 participants (Actual) | Interventional | 2019-05-01 | Completed | ||
| Impact of IntraVascular UltraSound Guidance on Outcomes of Xience Prime Stents in Long Lesions (IVUS-XPL Study)[NCT01308281] | 1,079 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
| A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705] | 2,927 participants (Actual) | Observational | 2019-09-20 | Completed | |||
| The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-08-01 | Not yet recruiting | ||
| Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491] | Phase 3 | 11,000 participants (Actual) | Interventional | 2018-03-15 | Completed | ||
| Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma. A Double-blind, Placebo-controlled, Multicentre, Randomized Controlled Clinical Trial[NCT03582293] | Phase 3 | 140 participants (Anticipated) | Interventional | 2018-06-19 | Recruiting | ||
| DEPOSITION: Pilot Study Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery[NCT03376061] | Phase 4 | 97 participants (Actual) | Interventional | 2017-12-21 | Completed | ||
| Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery (DEPOSITION) Study[NCT03954314] | Phase 3 | 3,242 participants (Actual) | Interventional | 2019-09-17 | Terminated (stopped due to Upon the Data Safety Monitoring Board review of the interim analysis (75% of participants have finished their follow-up) on November 17, 2023, they made a recommendation to stop recruitment into the trial.) | ||
| Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI)[NCT01777503] | Phase 4 | 2,000 participants (Anticipated) | Interventional | 2012-11-30 | Recruiting | ||
| Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES Trial[NCT03568890] | Phase 4 | 510 participants (Anticipated) | Interventional | 2018-09-01 | Recruiting | ||
| "Prospective Registry of Patients Over 75 Years Old Treated With Xience Sierra Stents. Sierra 75 Study"[NCT03567733] | 1,000 participants (Actual) | Observational [Patient Registry] | 2018-06-18 | Completed | |||
| Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction Treated With Percutaneous Coronary Intervention - The Dan-DAPT Trial[NCT05262803] | Phase 4 | 2,808 participants (Anticipated) | Interventional | 2022-06-17 | Recruiting | ||
| The Predictive Value of PRECISE DAPT Score in Patients With ST Segment Elevation Myocardial Infarction (STEMI) After Primary Percutaneous Coronary Intervention (PPCI)[NCT04549766] | 150 participants (Anticipated) | Observational | 2020-09-30 | Not yet recruiting | |||
| PPD Trial Pilot Study: Plavix, Prasugrel and Drug Eluting Stents[NCT01103843] | 1,000 participants (Anticipated) | Interventional | 2010-04-30 | Recruiting | |||
| PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062] | Phase 4 | 20,332 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy[NCT02049762] | Phase 4 | 29 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.[NCT00335452] | Phase 3 | 25,086 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Clinical and Functional Effects of Cardiac Contractility Modulation in Chagas Heart Disease: a Randomized Study - Contractility - FIX-Chagas[NCT05519046] | 60 participants (Anticipated) | Interventional | 2022-05-06 | Recruiting | |||
| A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low[NCT00050817] | Phase 3 | 15,603 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Bivalirudin Plus Prasugrel vs Abciximab Plus Clopidogrel. Optimizing Ischemic Protection and Bleeding Risk in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention[NCT01158846] | Phase 4 | 800 participants (Anticipated) | Interventional | 2010-08-31 | Not yet recruiting | ||
| A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591] | Phase 3 | 13,619 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial A Drug Reduction Study for Patients With Acute Coronary Syndrome in the Unified Health System[NCT04360720] | Phase 3 | 3,400 participants (Anticipated) | Interventional | 2020-10-15 | Recruiting | ||
| Quantitative Fractional Ratio-guided Non-culprit-vessel Revascularization in STEMI Patients With Multi-vessel Disease: a Prospective Multi-center Randomized Controlled Trial[NCT04259853] | 1,016 participants (Anticipated) | Interventional | 2020-01-30 | Enrolling by invitation | |||
| Cost-effectiveness of CYP2C19 Genotype Guided Treatment With Antiplatelet Drugs in Patients With ST-segment-elevation Myocardial Infarction Undergoing Immediate PCI With Stent Implantation: Optimization of Treatment (POPular Genetics).[NCT01761786] | Phase 4 | 2,700 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention[NCT00111566] | Phase 4 | 624 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention[NCT03114995] | Phase 4 | 140 participants (Actual) | Interventional | 2012-02-01 | Completed | ||
| The Role of Additional Antiplatelet Therapy in the Ischemic Stroke With Atrial Fibrillation and Co-morbiD Atherosclerosis During edOxaban treatmeNt. (ADD-ON) Study, Multicenter Registry-based Analysis[NCT04010955] | 1,200 participants (Anticipated) | Observational [Patient Registry] | 2019-10-01 | Recruiting | |||
| A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00249873] | Phase 3 | 7,554 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| [NCT01032668] | Phase 3 | 192 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| A Phase 2, Placebo-Controlled, Randomized, Double Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients With a Recent Acute Coronary Syndrome.[NCT00313300] | Phase 2 | 1,741 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Parnaparin Versus Aspirin in the Treatment of Retinal Vein Occlusion. A Randomized, Double Blind, Controlled Study[NCT00732927] | Phase 3 | 67 participants (Actual) | Interventional | 2002-07-31 | Terminated (stopped due to slow recruitment rate) | ||
| HOST-EXAM-Ex : Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - EXtended Antiplatelet Monotherapy - EXtended Follow up[NCT05567536] | 5,530 participants (Actual) | Observational | 2014-03-01 | Active, not recruiting | |||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| Improving Equitable Acces and Adherence to Secondary Prevention Therapy With a Fixed-Dose Combination Drug[NCT01321255] | Phase 3 | 2,118 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects at High Estimated Cardiovascular Risk[NCT03206944] | Phase 4 | 82 participants (Actual) | Interventional | 2015-07-01 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coron[NCT00402597] | Phase 2 | 3,490 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Phase IV Study of Aspirin and Clopidogrel Therapy Tailored by Functional Thrombocyte Examination (PFA-100, LTA and VerifyNOW) in Acute Myocardial Infarction[NCT01381185] | Phase 4 | 154 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Sclerotherapy With Polidocanol Foam In The Management Of First, Second And Third-Grade Hemorrhoidal Disease In Patients With Bleeding Disorders: A Prospective Cohort Study[NCT04188171] | Phase 2/Phase 3 | 150 participants (Anticipated) | Interventional | 2018-08-01 | Active, not recruiting | ||
| Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial[NCT04696120] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-03-02 | Not yet recruiting | ||
| Stent-Assisted Coiling Followed by Ticagrelor Monotherapy Instead of Dual Antiplatelet Therapy in Endovascular Treatment of Unruptured Intracranial Aneurysm (SAC-TIDE) ---a Pilot Study[NCT06015477] | 180 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | |||
| Haemocomplettan® P in Patients Experiencing Acute Bleeding While Undergoing Aortic Replacement Surgery[NCT00701142] | Phase 2 | 80 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention[NCT01245725] | Phase 3 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to Study was not initiated, change in clinical development) | |||
| Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913] | Phase 3 | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| A Double-blind, Randomized Study of Clopidogrel 75 mg/d vs Placebo, on a Background of ASA 75-100 mg/d,in Peripheral Arterial Disease (PAD) Patients Receiving a Unilateral Below Knee Bypass Graft.[NCT00174759] | Phase 3 | 1,460 participants (Anticipated) | Interventional | 2004-09-30 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268] | Phase 4 | 107 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events[NCT02762851] | Phase 4 | 5,000 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization[NCT03889574] | 84 participants (Actual) | Observational | 2019-02-26 | Completed | |||
| Impact of Preoperative FFR on Arterial Bypass Graft Functionality: Towards a New CABG Paradigm[NCT02527044] | 120 participants (Anticipated) | Interventional | 2015-11-30 | Active, not recruiting | |||
| Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Low-molecular-weight Heparin Versus Unfractionated Heparin in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome. A Randomized Controlled Trial[NCT01051778] | Phase 2 | 60 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin[NCT05541978] | 140 participants (Actual) | Observational | 2022-09-01 | Completed | |||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| Antithrombotic Therapy After Left Atrial Appendage Occlusion: Double Antiplatelet Therapy vs Apixaban[NCT05632445] | Phase 4 | 160 participants (Actual) | Interventional | 2019-05-01 | Completed | ||
| Interventional Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-risk Patients With Atrial Fibrillation (PRAGUE-17 Study)[NCT02426944] | Phase 4 | 400 participants (Anticipated) | Interventional | 2015-10-13 | Completed | ||
| RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial[NCT02942407] | Phase 4 | 154 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome[NCT02295475] | Phase 4 | 48 participants (Actual) | Interventional | 2014-12-10 | Completed | ||
| The Double-Blind, Randomized, Multi-Center, and Active Controlled Trial for Efficacy and Safety of Cilostazol in Acute Ischemic Stroke[NCT00272454] | Phase 4 | 468 participants (Anticipated) | Interventional | 2006-01-31 | Completed | ||
| Effect of the Omega n3 Fatty on Human Platelet Function[NCT00515541] | Phase 2 | 43 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Antiplatelet Therapy in HIV - Antiplatelet and Immune Modulating Effects of Aspirin or Clopidogrel in Subjects With HIV[NCT02559414] | Phase 2 | 55 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| To Investigate Post-procedure Hemorrhage and Cardiovascular Events in Taiwanese Patients Who Continue or Discontinue Low-Dose Aspirin Before Transrectal Prostate Biopsy: a Prospective Randomized Trial[NCT02744937] | Phase 4 | 150 participants (Anticipated) | Interventional | 2016-04-30 | Not yet recruiting | ||
| Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor[NCT03039205] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-07 | Completed | ||
| Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions[NCT00698607] | Phase 4 | 1,466 participants (Anticipated) | Interventional | 2008-06-30 | Active, not recruiting | ||
| Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265] | 31 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up[NCT02785237] | 70 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| LAte Stent Strut APPosition and COverage After Drug-Eluting Stent ImplantaTIOn by Optical Coherence Tomography in PatieNts With Acute Myocardial Infarction II(APPOSITION-AMI II)[NCT02770651] | 69 participants (Anticipated) | Observational | 2016-05-31 | Enrolling by invitation | |||
| Prospective Study of the Assessment of the Dental Protocol for Tooth Extraction in Patients With Atrial Fibrillation in Continuous Use of New Oral Anticoagulants: A Pilot Study[NCT03181386] | Phase 3 | 60 participants (Actual) | Interventional | 2017-05-03 | Completed | ||
| Childhood Liver Disease Research Network (ChiLDReN): FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE) Study Protocol[NCT02922751] | 552 participants (Actual) | Observational | 2016-11-16 | Active, not recruiting | |||
| Comparison of Accidents and Their Circumstances With Oral Anticoagulants. The CACAO Study[NCT02376777] | 4,162 participants (Actual) | Observational | 2014-04-30 | Completed | |||
| Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928] | Phase 3 | 200 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| Anticoagulant-associated Intracranial Hemorrhage: Patient Characteristics and Outcomes From National Institute of Neurology and Neurosurgery Manuel Velasco: Single-Center Observational Study[NCT06168838] | 1,200 participants (Anticipated) | Observational | 2023-08-09 | Recruiting | |||
| A Prospective, Nonrandomized, Study Comparing the Use of Aspirin and Intraoperative Blood Loss and Postoperative Complications Following Open Inguinal Hernia Repair.[NCT02084615] | 300 participants (Anticipated) | Interventional | 2014-08-31 | Enrolling by invitation | |||
| Association Between Perioperative Bleeding and Aspirin Use in Spine Surgery: A Randomized, Controlled Trial[NCT02807441] | Phase 3 | 0 participants (Actual) | Interventional | 2016-07-31 | Withdrawn | ||
| Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial[NCT00041938] | Phase 3 | 2,305 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Aspirin After Six Months or One Year of Oral Anticoagulants for the Prevention of Recurrent Venous Thromboembolism in Patients With Idiopathic Venous Thromboembolism. The WARFASA Study.[NCT00222677] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2004-05-31 | Active, not recruiting | ||
| Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting[NCT01159639] | Phase 4 | 200 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer[NCT03943966] | 73 participants (Actual) | Interventional | 2019-11-11 | Completed | |||
| Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261] | Phase 4 | 1,001 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular E[NCT02989558] | Phase 3 | 90 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| Postoperative Ibuprofen and the Risk of Bleeding After Tonsillectomy With or Without Adenoidectomy[NCT01605903] | Phase 2 | 741 participants (Actual) | Interventional | 2012-05-03 | Completed | ||
| Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309] | 30 participants (Anticipated) | Interventional | 2006-04-30 | Completed | |||
| Femoral Versus Radial Access for Coronary Intervention in the Acute Phase of ST-Elevation Myocardial Infarction[NCT00356044] | Phase 4 | 439 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| "Transcranial Doppler Assessment of Cerebral Embolization During Early Anti-thrombotic Therapy After Bioprosthetic Aortic Valve Replacement: Comparison of High-dose Aspirin Versus Warfarin Plus Low-dose Aspirin"[NCT00465218] | 56 participants (Actual) | Observational | 2007-03-31 | Completed | |||
| Observatory of Anticoagulation After Bioprosthetic Aortic Valve Replacement[NCT01293188] | 434 participants (Actual) | Observational | 2011-01-31 | Completed | |||
| Multicenter Ambispective Study of Clinical Outcomes of the CoreValve™Evolut R™ 34mm System: All Comers Post-market Registry[NCT03621709] | 100 participants (Anticipated) | Observational | 2017-08-01 | Active, not recruiting | |||
| Maintenance of an Antiaggregation by Acetylsalicylic Acid, Less or Equal to 250mg While a Extracorporeal Lithotripsy (ECL) Session on a Kidney Stone is Perfomed: Comparative Unicentric Prospective Study[NCT03437057] | 300 participants (Anticipated) | Interventional | 2018-01-08 | Recruiting | |||
| Study of Heart and Renal Protection (SHARP): The Effects of Lowering LDL-cholesterol With Simvastatin 20mg Plus Ezetimibe 10mg in Patients With Chronic Kidney Disease: a Randomized Placebo-controlled Trial[NCT00125593] | Phase 4 | 9,438 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Clopidogrel Plus Acetylsalicylic Acid (ASA) Versus ASA Alone in Subjects With Acute ST Elevation Myocardial Infarction (STEMI) Treated With Fibrinolytic Therapy[NCT00714961] | Phase 3 | 3,491 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982] | 1,500 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| The Efficacy and Safety of Proton Pump Inhibitor ( in Patients With Moderate Bleeding Risk and Coronary Artery Disease Undergoing Percutaneous Coronary: A Randomised, Open ,Compared With Control[NCT05820048] | Phase 4 | 300 participants (Anticipated) | Interventional | 2023-05-01 | Not yet recruiting | ||
| Clinical Registration Trial of Intracranial Stenting for Patients With Symptomatic Intracranial Artery Stenosis:A Prospective Multi-center, Registry Trial[NCT01994161] | 840 participants (Anticipated) | Observational [Patient Registry] | 2012-12-31 | Recruiting | |||
| Phase III Study of Pharos Vitesse Neurovascular Stent System Compared to Best Medical Therapy for the Treatment of Ischemic Disease[NCT00816166] | Phase 2/Phase 3 | 125 participants (Actual) | Interventional | 2008-10-31 | Terminated | ||
| Registry of Emergent Large veSsel oCclUsion duE to IntraCranial AtherosclerosiS[NCT05403593] | 600 participants (Anticipated) | Observational [Patient Registry] | 2021-12-15 | Recruiting | |||
| An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis[NCT00929383] | 82 participants (Actual) | Observational | 2009-02-28 | Completed | |||
| A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Efficacy of the Maurora® Sirolimus-Eluting Stent Versus the Apollo Stent in Intracranial Atherosclerotic Stenosis(Maurora ICAS Trial)[NCT05719883] | 156 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | |||
| Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial: a Prospective, Randomized, Open-labelled, Blinded End-point Trial (DREAM-PRIDE)[NCT04948749] | 792 participants (Anticipated) | Interventional | 2021-07-02 | Recruiting | |||
| PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis[NCT03507374] | Early Phase 1 | 20 participants (Actual) | Interventional | 2018-10-30 | Terminated (stopped due to Funding withdrawn) | ||
| Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging[NCT05907629] | 300 participants (Anticipated) | Observational | 2023-12-30 | Not yet recruiting | |||
| China Angioplasty & Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS): a New, Prospective, Multi-center, Randomized Controlled Trial in China[NCT01763320] | Phase 3 | 380 participants (Actual) | Interventional | 2014-03-05 | Completed | ||
| [NCT00000556] | Phase 3 | 0 participants | Interventional | 1995-03-31 | Completed | ||
| The Effect of Inducing the Cytochrome P450 System on the Pharmacodynamic Efficacy of Clopidogrel[NCT01330589] | 0 participants (Actual) | Interventional | 2011-04-30 | Withdrawn (stopped due to Inability to enroll subjects and changes in standard of care for PCI) | |||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| A Multicentre Study of Low Dose Oral Vitamin K for INR Control in Patients Receiving Warfarin[NCT00990158] | Phase 3 | 235 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Phase III Randomized Trial of Warfarin Plus Antiplatelet Therapy Versus Antiplatelet Therapy Alone in Patients With Peripheral Vascular Disease[NCT00125671] | Phase 3 | 2,400 participants | Interventional | 2000-01-31 | Active, not recruiting | ||
| Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb[NCT04229264] | Phase 3 | 200 participants (Anticipated) | Interventional | 2020-01-09 | Recruiting | ||
| A Multicenter, Open-Label, Phase III, Randomized, Active-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of rhuMAb VEGF (Bevacizumab), in Combination With Capecitabine Chemotherapy, in Subjects With Previously Treated Metastatic Bre[NCT00109239] | Phase 3 | 0 participants | Interventional | 2000-11-30 | Completed | ||
| A Phase III, Multicenter, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab) in Combination With Standard Chemotherapy in Subjects With Metastatic Colorectal Cancer[NCT00109070] | Phase 3 | 0 participants | Interventional | 2000-09-30 | Completed | ||
| A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab), a Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, in Combination With 5-[NCT00109226] | Phase 2 | 0 participants | Interventional | 2000-08-31 | Completed | ||
| Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women[NCT00000479] | Phase 3 | 39,876 participants (Actual) | Interventional | 1992-09-30 | Completed | ||
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI With Biologically Active Stents (P2BiTO) Registry[NCT01967615] | 4,500 participants (Actual) | Observational | 2015-01-31 | Completed | |||
| Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention[NCT01456364] | Phase 4 | 70 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| CARDIOBASE Bern PCI Registry[NCT02241291] | 10,000 participants (Anticipated) | Observational | 2009-03-31 | Recruiting | |||
| Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study[NCT00995514] | 4,471 participants (Actual) | Observational | 2009-10-31 | Terminated (stopped due to Administrative reasons) | |||
| Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia: a Multicentric Randomized Non Inferiority Trial.[NCT03289728] | 1,756 participants (Anticipated) | Interventional | 2018-04-04 | Recruiting | |||
| Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435] | 889 participants (Actual) | Interventional | 2013-06-30 | Terminated (stopped due to Ethics Committe decision) | |||
| The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation[NCT01099566] | Phase 4 | 20 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)[NCT02428374] | Phase 4 | 300 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| Correlation Between Bleeding Complication and Treatment Failure on P2Y12 Inhibitors and Its Predictions Based on Cipherome's Pharmacogenomic Technology[NCT04580602] | 200 participants (Actual) | Observational | 2020-10-07 | Completed | |||
| Acute Headache Treatment in Pregnancy: Improvement in Pain Scores With Occipital Nerve Block vs PO Acetaminophen With Caffeine A Randomized Controlled Trial[NCT03951649] | Phase 4 | 62 participants (Actual) | Interventional | 2020-02-10 | Completed | ||
| Dose-Ranging Pharmacodynamic Assessment of Platelet Aggregation Inhibition With Clopidogrel in Children of Blalock-Taussig Shunt Age Categories (Neonates and Infants/Toddlers)[NCT00115375] | Phase 2 | 92 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Dabigatran Versus Warfarin After Mitral and Aortic Bioprosthesis Replacement for the Management of Atrial Fibrillation Postoperatively: Pilot Study[NCT01868243] | Phase 2/Phase 3 | 27 participants (Actual) | Interventional | 2013-08-31 | Terminated (stopped due to because a significant decrease of viable candidates for the study.) | ||
| [NCT00000472] | Phase 3 | 0 participants | Interventional | 1989-04-30 | Completed | ||
| Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients With Embolic Stroke Due to Atrial Fibrillation[NCT02159287] | Phase 2 | 80 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796] | Phase 3 | 1,473 participants (Actual) | Interventional | 2006-12-31 | Active, not recruiting | ||
| A Phase III, Randomized, Double-blind, Multicenter Study to Assess the Efficacy and Safety of OCTAPLEX, a Four-factor Prothrombin Complex Concentrate (4F-PCC), Compared to the 4F-PCC Beriplex® P/N (Kcentra), for the Reversal of Vitamin K Antagonist (VKA) [NCT02740335] | Phase 3 | 208 participants (Actual) | Interventional | 2017-06-08 | Completed | ||
| Early and Long-Term Outcome of Elective Stenting of the Infarct-Related Artery in Patients With Viability in the Infarct-Area Early After Acute Myocardial Infarction. The VIAMI-Trial.[NCT00149591] | 300 participants | Interventional | 2001-04-30 | Active, not recruiting | |||
| A Multicenter, Randomized Trial Evaluating 30-day and 6-month Clinical Outcomes With Three Different Treatment Strategies (Coronary Angioplasty + Abciximab, Intracoronary Stent + Abciximab, and Intracoronary Stent + Placebo) in Patients Undergoing Percuta[NCT00271401] | Phase 3 | 2,399 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| A Post-Market, Prospective, Multi-Center, Study to Evaluate Safety and Efficacy of the StarClose™ Vascular Closure System in Patients Who Are Ambulated Early Post-Diagnostic Catheterization[NCT00736086] | 165 participants (Actual) | Observational | 2006-03-31 | Completed | |||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| The Association Between Plasma or Platelet microRNAs and Clopidogrel Low Response and Its Mechanism[NCT02447809] | Phase 4 | 400 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| A Sequential Phase I - Phase II Pilot Study to Compare Cardiac Imaging Capabilities of ICE With TEE Followed by a Randomized Comparison of ICE Guided Cardioversion With Conventional Cardioversion Strategy in Patients With Atrial Fibrillation[NCT00281073] | Phase 1/Phase 2 | 95 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Echocardiographic Risk Factors of Stroke in Patients With Atrial[NCT03824509] | 140 participants (Actual) | Observational | 2019-01-01 | Completed | |||
| [NCT00000505] | Phase 3 | 0 participants | Interventional | 1983-04-30 | Completed | ||
| Patients Presenting With Acute STEMI Treated With Primary PCI : Comparison of the Impact of the MIMI Approach With a Conventional Strategy of Immediate Stenting[NCT01360242] | Phase 3 | 160 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| [NCT00000517] | Phase 3 | 0 participants | Interventional | 1985-07-31 | Completed | ||
| IV Tranexamic Acid Prior to Hysterectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial[NCT02911831] | Early Phase 1 | 71 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Effect of Low Molecular Weight Heparin vs Unfractionated Heparin on Bleeding After Cardiac Surgery[NCT00420667] | 43 participants (Actual) | Interventional | 2004-11-30 | Completed | |||
| Randomized, Controlled, Prospective Trial to Evaluate the Hemostatic Effect of Lyostypt® Versus Surgicel® in Arterial Bypass Anastomosis[NCT00837954] | Phase 4 | 32 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
"BARC definition. We only considered BARC 3 or 5 for this secondary safety endpoint.~Type 3: Clinical, laboratory, and/or imaging evidence of bleeding with:~Type 3a:~Overt bleeding + Hb drop of 3 to < 5 g/dL (provided Hb drop is related to bleed)~Any transfusion with overt bleeding~Type 3b:~Overt bleeding + Hb drop ≥5 g/dL (provided Hb drop is related to bleed)~Cardiac tamponade~Bleeding requiring surgical intervention (excluding dental/nasal/skin/haemorrhoid)~Bleeding requiring intravenous vasoactive agents~Type 3c:~Intracranial haemorrhage (does not include microbleeds or haemorrhagic transformation, does include intraspinal)~Subcategories confirmed by autopsy or imaging or lumbar puncture~Intraocular bleed compromising vision. Type 5: Fatal bleeding~Type 5a:~• Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious~Type 5b:~Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation" (NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 163 |
| Reference Treatment Strategy | 169 |
Number of Participants with a composite of all-cause mortality or non-fatal new Q-wave MI up to 2 years post randomisation. (NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 304 |
| Reference Treatment Strategy | 349 |
shown are the first event per event type for each patient only. Multiple events of the same type within the same patient are disregarded (NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 362 |
| Reference Treatment Strategy | 416 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 64 |
| Reference Treatment Strategy | 64 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 739 |
| Reference Treatment Strategy | 793 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 80 |
| Reference Treatment Strategy | 82 |
(NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 224 |
| Reference Treatment Strategy | 253 |
(NCT01813435)
Timeframe: 2 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 248 |
| Reference Treatment Strategy | 250 |
(NCT01813435)
Timeframe: 2-year
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Treatment Strategy | 83 |
| Reference Treatment Strategy | 103 |
Absolute prothrombin time was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 15.46 |
| Rivaroxaban (Part B) | 18.02 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 1.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 16.58 |
| Rivaroxaban (Part B) | 18.76 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 17.95 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 1.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 18.73 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 6-8 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 16.13 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: Up to 3 hours predose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 15.21 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 20.13 |
| Rivaroxaban (Part B) | 18.89 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 2.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 19.14 |
| Rivaroxaban (Part B) | 19.69 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: Up to 3 hours predose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 17.59 |
| Rivaroxaban (Part B) | 16.45 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 31.4 |
| Rivaroxaban (Part B) | 30.69 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 0.5-1.5 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 66.93 |
| Rivaroxaban (Part B) | 99.46 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 1.5-4 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 74.06 |
| Rivaroxaban (Part B) | 104.57 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 6-8 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 74.21 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 0.5-1.5 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part B) | 110.90 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 2.5-4 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part B) | 93.48 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: Up to 3 hours predose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 60.51 |
| Rivaroxaban (Part B) | 53.41 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 1.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 32.83 |
| Rivaroxaban (Part B) | 30.25 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 36.17 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average for the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 1.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 37.58 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 6-8 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 32.83 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: Up to 3 hours predose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 33.08 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 0.5-1.5 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 26.60 |
| Rivaroxaban (Part B) | 31.15 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 2.5-4 hours postdose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 26.74 |
| Rivaroxaban (Part B) | 31.67 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: Up to 3 hours predose
| Intervention | seconds (Mean) |
|---|---|
| Rivaroxaban (Part A) | 25.36 |
| Rivaroxaban (Part B) | 28.70 |
TEAEs were defined as those adverse events (AEs) that occurred from the first day of study drug to the last day of study drug + 2 days inclusive. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. (NCT02846532)
Timeframe: Up to 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban (Part A) | 91.7 |
| Rivaroxaban (Part B) | 85.9 |
| Aspirin (Part B) | 85.3 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 0.5-1.5 hours postdose
| Intervention | micrograms per liter (mcg/L) (Mean) |
|---|---|
| Rivaroxaban (Part A) | 46.69 |
| Rivaroxaban (Part B) | 92.86 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 1: 1.5-4 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 86.62 |
| Rivaroxaban (Part B) | 103.61 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 0.5-1.5 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 107.58 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 1.5-4 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 147.18 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: 6-8 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 66.81 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Day 4: Up to 3 hours predose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 36.58 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 0.5-1.5 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 86.25 |
| Rivaroxaban (Part B) | 94.12 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: 2.5-4 hours postdose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 96.67 |
| Rivaroxaban (Part B) | 102.99 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here. (NCT02846532)
Timeframe: Month 3: Up to 3 hours predose
| Intervention | mcg/L (Mean) |
|---|---|
| Rivaroxaban (Part A) | 38.23 |
| Rivaroxaban (Part B) | 29.41 |
Thrombotic event was defined as the appearance of a new thrombotic burden within the cardiovascular system on either routine surveillance or clinically indicated imaging, or the occurrence of a clinical event known to be strongly associated with thrombus (such as cardioembolic stroke, pulmonary embolism). The event included ischemic stroke, pulmonary embolism, venous thrombosis, arterial/intracardiac thrombosis, and other thrombosis. (NCT02846532)
Timeframe: Up to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any thrombotic event | Ischemic stroke | Pulmonary embolism | Venous thrombosis | Arterial/intracardiac thrombosis | Other thrombosis | |
| Aspirin (Part B) | 8.8 | 2.9 | 0 | 5.9 | 0 | 0 |
| Rivaroxaban (Part A) | 8.3 | 0 | 0 | 8.3 | 0 | 0 |
| Rivaroxaban (Part B) | 1.6 | 0 | 1.6 | 0 | 0 | 0 |
Bleeding events were categorized into major, clinically relevant non-major bleeding (CRNM), and trivial bleeding events. Major bleeding: overt bleeding and associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more; or leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults; or occurring in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; or contributing to death. CRNM bleeding: overt bleeding not meeting the criteria for major bleeding but associated with: Medical intervention, or Unscheduled contact with a physician, cessation of study treatment, or Discomfort for the subject such as pain, or Impairment of activities of daily life. Trivial bleeding: any other overt bleeding event that does not meet criteria for CRNM bleeding. (NCT02846532)
Timeframe: Up to 12 months
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Any bleeding event | Major Bleeding | Clinically relevant non-major bleeding | Trivial bleeding | |
| Aspirin (Part B) | 41.2 | 0 | 8.8 | 35.3 |
| Rivaroxaban (Part A) | 33.3 | 0 | 8.3 | 25.0 |
| Rivaroxaban (Part B) | 35.9 | 1.6 | 6.3 | 32.8 |
The primary outcome will be a composite endpoint of need for hospitalization for cardiovascular/pulmonary events, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, ischemic stroke, and all-cause mortality for up to 45 days after initiation of assigned treatment. (NCT04498273)
Timeframe: 45 days
| Intervention | participants (Number) |
|---|---|
| Apixaban 2.5mg | 1 |
| Apixaban 5mg | 1 |
| Asprin | 0 |
| Placebo | 0 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 43 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 13 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 30 |
"Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 27 |
"Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 16 |
"Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 11 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 6 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 3 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 3 |
"TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.~A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);~A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 10 |
"TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.~A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);~A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 7 |
"TLR is defined as any repeat percutaneous intervention of the target lesion (the treated segment from 5 mm proximal to the stent and to 5 mm distal to the stent) or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not CI by the investigator prior to repeat angiography.~A revascularization is considered CI if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if any one below occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g: Doppler flow velocity reserve, fractional flow reserve);~A TLR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 3 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 9 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 5 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 70 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 29 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 41 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 45 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 22 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 23 |
"Net Adverse Clinical Endpoint (NACE):~A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 121 |
"Net Adverse Clinical Endpoint (NACE):~A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 55 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 0 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 42 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 21 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 21 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 44 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 22 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 22 |
"Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:~Type 0~Type 1~Type 2~Type 3~Type 4~Type 5~Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding." (NCT03355742)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| BARC Type 2-5 | BARC Type 3-5 | |
| XIENCE | 61 | 27 |
"Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:~Type 0~Type 1~Type 2~Type 3~Type 4~Type 5~Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding." (NCT03355742)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| BARC Type 2-5 | BARC Type 3-5 | |
| XIENCE | 19 | 7 |
"Bleeding per Bleeding Academic Research Consortium (BARC)definitions are as follows:~Type 0~Type 1~Type 2~Type 3~Type 4~Type 5~Where, Type 0 indicates no bleeding and type 5 indicates fatal bleeding." (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| BARC Type 2-5 | BARC Type 3-5 | |
| XIENCE | 44 | 20 |
"Net Adverse Clinical Endpoint (NACE):~A composite rate of all-cause death, all myocardial infarction (modified Academic Research Consortium [ARC]), stent thrombosis (ARC definite or probable), stroke or major bleeding (Bleeding defined by the Bleeding Academic Research Consortium [BARC] type 2-5)" (NCT03355742)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 2 | 5 | 10 | 15 | 40 |
"All Death:~All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death:~Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death:~Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 54 |
"All Myocardial Infarction (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL~TV-MI: All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be considered related to the target vessel." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 48 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 21 |
"Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography.~Clinically Indicated [CI] Revascularization:~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test~A TLR/TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 16 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 26 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 67 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions are as follows:~Type 3a: Overt bleeding plus Hemoglobin(Hb) drop of 3 to < 5 g/dL; Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage;Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48 h; Reoperation after closure of sternotomy for the purpose of controlling bleeding; Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period; Chest tube output ≥ 2L within a 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding or autopsy or imaging confirmation" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 41 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 66 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 70 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block, development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI: CK-MB > URL or Troponin > URL with baseline value < UR~The propensity score for each individual was calculated using a logistic regression model that included the study group as the outcome & the baseline demographic, clinical and procedural covariates as the predictors" (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 5.4 | 6.7 | 4.0 | 3.6 | 5.8 | 6.9 |
"Type 2: Any overt, actionable sign of hemorrhage~Type 3a: Overt bleeding plus Hb drop of 3 to < 5g/dL;Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL;Cardiac tamponade;Bleeding requiring surgical intervention for control;Bleeding requiring IV vasoactive agents~Type 3c: ICH; Subcategories confirmed by autopsy/imaging/lumbar puncture;Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48h;Reoperation after closure of sternotomy for the purpose of controlling bleeding;Transfusion of ≥ 5 U whole blood or packed RBC within 48h;Chest tube output ≥ 2L within 24h~Type 5: Fatal bleeding~The propensity score for each individual was calculated using a logistic regression model that included the study group as the outcome & the baseline demographic, clinical and procedural covariates as the predictors." (NCT03218787)
Timeframe: From 3 to 12 months
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 5.1 | 3.9 | 2.7 | 5.4 | 6.0 | 7.7 |
"All Death:~All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even inpatients with coexisting potentially fatal non-cardiac disease (e.g. cancer,infection) should be classified as cardiac.~Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death:~Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death:~Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 64 |
"All Death:~All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even inpatients with coexisting potentially fatal non-cardiac disease (e.g. cancer,infection) should be classified as cardiac.~Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death:~Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death:~Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 23 |
"All Death:~All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even inpatients with coexisting potentially fatal non-cardiac disease (e.g. cancer,infection) should be classified as cardiac.~Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death:~Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death:~Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 40 |
"All Myocardial Infarction (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL~TV-MI: All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be considered related to the target vessel." (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 41 |
"All Myocardial Infarction (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL~TV-MI: All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be considered related to the target vessel." (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 18 |
"All Myocardial Infarction (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URL with baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL~TV-MI: All infarcts that cannot be clearly attributed to a vessel other than the target vessel will be considered related to the target vessel." (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 24 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 11 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"An acute symptomatic episode of neurological dysfunction attributed to a vascular cause lasting more than 24 hours or lasting 24 hours or less with a brain imaging study or autopsy showing new infarction.~Ischemic Stroke: An acute symptomatic episode of focal cerebral, spinal, or retinal dysfunction caused by an infarction of central nervous system tissue.~Hemorrhagic Stroke: An acute symptomatic episode of focal or global cerebral or spinal dysfunction caused by a non-traumatic intraparenchymal, intraventricular, or subarachnoid hemorrhage.~Undetermined Stroke: A stroke with insufficient information to allow categorization as ischemic or hemorrhagic.~Pharmacologic, i.e., thrombolytic drug administration, or Non-pharmacologic, i.e., neurointerventional procedure (e.g., intracranial angioplasty)" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 7 |
"Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography.~Clinically Indicated [CI] Revascularization:~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test~A TLR/TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 18 |
"Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography.~Clinically Indicated [CI] Revascularization:~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test~A TLR/TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 8 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g.,Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 29 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g.,Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 15 |
"Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography.~Clinically Indicated [CI] Revascularization:~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test~A TLR/TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 10 |
"TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.~A revascularization is considered clinically indicated if angiography at follow-up shows a percent diameter stenosis ≥ 50% and if one of the following occurs:~A positive history of recurrent angina pectoris, presumably related to the target vessel;~Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel;~Abnormal results of any invasive functional diagnostic test (e.g.,Doppler flow velocity reserve, fractional flow reserve);~A TVR with a diameter stenosis ≥70% in the absence of the above mentioned ischemic signs or symptoms." (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 14 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 103 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 46 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality)~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 57 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URLwith baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 68 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URLwith baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 35 |
"Cardiac death:~Any death due to proximate cardiac cause (e.g. MI, low-output failure,fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~MI (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Periprocedural MI:~Within 48h after PCI: CK-MB >3 x URL or Troponin > 3 x URLwith baseline value < URL~Within 72h after CABG: CK-MB >5 x URL or Troponin > 5 x URL with baseline value < URL~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 33 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions are as follows:~Type 3a: Overt bleeding plus Hemoglobin(Hb) drop of 3 to < 5 g/dL; Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage;Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48 h; Reoperation after closure of sternotomy for the purpose of controlling bleeding; Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period; Chest tube output ≥ 2L within a 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding; no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy or imaging confirmation" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 49 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions are as follows:~Type 3a: Overt bleeding plus Hemoglobin(Hb) drop of 3 to < 5 g/dL; Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage;Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48 h; Reoperation after closure of sternotomy for the purpose of controlling bleeding; Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period; Chest tube output ≥ 2L within a 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding; no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy or imaging confirmation" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 33 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions are as follows:~Type 3a: Overt bleeding plus Hemoglobin(Hb) drop of 3 to < 5 g/dL; Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL; Cardiac tamponade; Bleeding requiring surgical intervention for control; Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage;Subcategories confirmed by autopsy or imaging or lumbar puncture; Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48 h; Reoperation after closure of sternotomy for the purpose of controlling bleeding; Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period; Chest tube output ≥ 2L within a 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding; no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy or imaging confirmation" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 18 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 4 |
"Definite stent thrombosis:~Definite stent thrombosis is considered to have occurred by either angiographic or pathologic confirmation.~Probable stent thrombosis:~Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 0 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 69 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 35 |
TLF is defined as a composite of all cardiac death, myocardial infarction attributed to target vessel or clinically-indicated TLR. (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 34 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 77 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 38 |
TVF is defined as a composite of cardiac death, MI attributed to target vessel, clinically-indicated TLR, or clinically-indicated TVR, non-TLR. (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| XIENCE | 39 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI Definition (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Peripheral MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 3.5 | 4.3 | 4.1 | 2.6 | 2.7 | 3.9 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI Definition (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Peripheral MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 6.7 | 4.3 | 6.7 | 6.0 | 7.9 | 8.4 |
"All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac.~MI Definition (Modified ARC):~Patients present any of the following clinical or imaging evidence of ischemia:~Clinical symptoms of ischemia;~ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch block (LBBB), development of pathological Q waves;~Imaging evidence of a new loss of viable myocardium or a new regional wall motion abnormality~AND confirmed with elevated cardiac biomarkers per ARC criteria:~Peripheral MI~Spontaneous MI (> 48h following PCI, > 72h following CABG): CK-MB > URL or Troponin > URL with baseline value < URL" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 3.2 | 0.0 | 2.7 | 3.4 | 5.5 | 4.4 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions:~Type 2: Any overt, actionable sign of hemorrhage~Type 3a: Overt bleeding plus Hb drop of 3 to < 5g/dL;Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL;Cardiac tamponade;Bleeding requiring surgical intervention for control;Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage; Subcategories confirmed by autopsy/imaging/lumbar puncture;Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48h;Reoperation after closure of sternotomy for the purpose of controlling bleeding;Transfusion of ≥ 5 U whole blood/packed red blood cells within a 48h period;Chest tube output ≥ 2L within 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding;no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy/imaging confirmation" (NCT03815175)
Timeframe: From 1 to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 7.1 | 6.5 | 6.8 | 5.4 | 6.8 | 10.1 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions:~Type 2: Any overt, actionable sign of hemorrhage~Type 3a: Overt bleeding plus Hb drop of 3 to < 5g/dL;Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL;Cardiac tamponade;Bleeding requiring surgical intervention for control;Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage; Subcategories confirmed by autopsy/imaging/lumbar puncture;Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48h;Reoperation after closure of sternotomy for the purpose of controlling bleeding;Transfusion of ≥ 5 U whole blood/packed red blood cells within a 48h period;Chest tube output ≥ 2L within 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding;no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy/imaging confirmation" (NCT03815175)
Timeframe: From 6 to 12 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 2.5 | 2.2 | 1.4 | 3.1 | 2.0 | 3.7 |
"Bleeding per Bleeding Academic Research Consortium (BARC) adjudicated definitions:~Type 2: Any overt, actionable sign of hemorrhage~Type 3a: Overt bleeding plus Hb drop of 3 to < 5g/dL;Any transfusion with overt bleeding~Type 3b: Overt bleeding plus Hb drop ≥ 5 g/dL;Cardiac tamponade;Bleeding requiring surgical intervention for control;Bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage; Subcategories confirmed by autopsy/imaging/lumbar puncture;Intraocular bleed compromising vision~Type 4: CABG-related bleeding: Perioperative intracranial bleeding within 48h;Reoperation after closure of sternotomy for the purpose of controlling bleeding;Transfusion of ≥ 5 U whole blood/packed red blood cells within a 48h period;Chest tube output ≥ 2L within 24-h period~Type 5: Fatal bleeding~Type 5a: Probable fatal bleeding;no autopsy/imaging confirmation but clinically suspicious~Type 5b: Definite fatal bleeding;overt bleeding/autopsy/imaging confirmation" (NCT03815175)
Timeframe: From 1 to 6 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Adjusted Overall Rate | Q1 | Q2 | Q3 | Q4 | Q5 | |
| XIENCE | 4.9 | 4.3 | 5.5 | 2.3 | 5.2 | 7.0 |
"Time to first occurrence during the time the participants were treated with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 24.66 |
| Vitamin K Antagonist | 35.79 |
"Time to first death or ischenic event during the 6-month treatment period with aspirin or placebo.~N is the number of participants treated with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with death or ischemic events in each treatment group during the 6-month treatment period.~Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 15.28 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 17.73 |
"Time to first all-cause death or all-cause hospitalization during the during the 6-month treatment period with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 57.24 |
| Vitamin K Antagonist | 69.19 |
"Time to first all-cause death or all-cause hospitalization during the 6-month period of treatment with aspirin or placebo.~N is the number of participants treated with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 65.72 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 60.56 |
"Time to first ISTH major or CRNM bleeding during the 6-month period of treatment with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with major or CRNM bleeding divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 24.66 |
| Vitamin K Antagonist | 35.79 |
"Time to first ISTH major or CRNM bleeding during the treatment period of 6 months with aspirin or placebo.~N is the number of participants with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 40.51 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 21.03 |
"Time to first occurrence during the 6-month treatment period with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with death or ischemic events in each treatment group during the during the 6-month period of treatment.~Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 15.85 |
| Vitamin K Antagonist | 17.17 |
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 141 |
| Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 135 |
| Aspirin + Ticagrelor | 137 |
(NCT02504216)
Timeframe: For each participant, the first occurrence of the outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1188.48 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 321 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 297 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1062.48 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 584 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 655 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1108.29 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 514 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 588 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1085.13 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 614 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 679 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1108.79 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 433 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 528 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1154.04 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 262 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 356 |
Venous thromboembolic events were reported by investigator only. (NCT02504216)
Timeframe: For each participant, the first occurrence of the outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1187.65 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 25 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 41 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean time in follow-up survival time until ECOD that date was 1109.76 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 508 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 584 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the primary safety outcome after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo).
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 62 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 44 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered (NCT02504216)
Timeframe: For each participant, the first occurrence of the type 3b and above bleeding events according to the BARC classification after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo)
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 93 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 73 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the major bleeding events according to the ISTH classification after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo).
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 140 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 100 |
(NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 10 |
| Asundexian 20 mg | 7 |
| Asundexian 50 mg | 10 |
| Placebo | 7 |
"CV death included death due to stroke, MI, heart failure or cardiogenic shock, sudden death or any other death due to other cardiovascular causes. Death due to non-traumatic hemorrhage was included.~Acute MI was used when there was evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia.~Stroke was defined as an acute episode of focal or global neurological dysfunction caused by an injury of the brain, spinal cord, or retina as a result of hemorrhage or infarction.~ST was defined incorporating diagnostic certainty as well as timing: Definite ST: The highest level of certainty. Either angiographic or pathological confirmation of stent thrombosis. Probable ST: Regardless of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 27 |
| Asundexian 20 mg | 24 |
| Asundexian 50 mg | 22 |
| Placebo | 22 |
CV death included death due to stroke, MI, heart failure or cardiogenic shock, sudden death or any other death due to other cardiovascular causes. Death due to non-traumatic hemorrhage was included. (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 7 |
| Asundexian 20 mg | 4 |
| Asundexian 50 mg | 5 |
| Placebo | 2 |
Acute MI was used when there was evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia. According to MI Universal Definition from 2018 the diagnosis of MI requires combination of: 1. Presence of acute myocardial injury. 2. Evidence of acute myocardial ischemia derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging, or in case of post-mortem pathological findings irrespective of biomarker values. (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 18 |
| Asundexian 20 mg | 20 |
| Asundexian 50 mg | 18 |
| Placebo | 17 |
"ST was defined incorporating diagnostic certainty as well as timing: Definite ST: The highest level of certainty. Either angiographic or pathological confirmation of stent thrombosis. Probable ST: Regardless of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 4 |
| Asundexian 20 mg | 5 |
| Asundexian 50 mg | 4 |
| Placebo | 4 |
Stroke was defined as an acute episode of focal or global neurological dysfunction caused by an injury of the brain, spinal cord, or retina as a result of hemorrhage or infarction. (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 4 |
| Asundexian 20 mg | 3 |
| Asundexian 50 mg | 0 |
| Placebo | 2 |
All bleeding events occurred from first intake of study intervention until 2 days after the last intake of study intervention (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 70 |
| Asundexian 20 mg | 75 |
| Asundexian 50 mg | 82 |
| Placebo | 85 |
Type 1: bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by a healthcare professional; may include episodes leading to self-discontinuation of medical therapy by the patient without consulting a healthcare professional. For BARC bleeding definition 2,3 and 5, please refer to second primary endpoint. (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 70 |
| Asundexian 20 mg | 75 |
| Asundexian 50 mg | 82 |
| Placebo | 85 |
Type 2: any overt, actionable sign of hemorrhage that doesn't fit the criteria for type 3 or 5 but meets at least one of the following criteria: 1) requires nonsurgical, med intervention by a HCP, 2) leads to hospital or rise in level of care, or 3) prompt eval. Type 3a: 1) overt bleed + Hg drop of 3 to <5 g/dl (provided Hg drop is related to bleed); 2 any transfusion with overt bleed. Type 3b: 1) overt bleed + Hg drop ≥5 g/dL (provided Hg drop is related to bleed); 2) cardiac tamponade; 3) bleed requiring surgical intervention for control (exclude dental/nasal /skin/hemorrhoid); 4) bleed requiring IV vasoactive agents. Type 3c: 1) ICH hemorrhage (doesn't include microbleeds or HT, does include intraspinal); subcategories confirmed by autopsy or imaging or LP; 2) intraocular bleed compromising vision. Type 5: fatal bleed. Type 5a: probable fatal bleed; no autopsy or image confirmation but clinical suspicion. Type 5b: definite fatal bleed; overt bleed or autopsy or image confirmation. (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 30 |
| Asundexian 20 mg | 32 |
| Asundexian 50 mg | 42 |
| Placebo | 36 |
| Pooled Asundexian | 104 |
Type 3a: 1) overt bleed + Hg drop of 3 to <5 g/dl (provided Hg drop is related to bleed); 2 any transfusion with overt bleed. Type 3b: 1) overt bleed + Hg drop ≥5 g/dL (provided Hg drop is related to bleed); 2) cardiac tamponade; 3) bleed requiring surgical intervention for control (exclude dental/nasal /skin/hemorrhoid); 4) bleed requiring IV vasoactive agents. Type 3c: 1) ICH hemorrhage (doesn't include microbleeds or HT, does include intraspinal); subcategories confirmed by autopsy or imaging or LP; 2) intraocular bleed compromising vision. Type 5: fatal bleed. Type 5a: probable fatal bleed; no autopsy or image confirmation but clinical suspicion. Type 5b: definite fatal bleed; overt bleed or autopsy or image confirmation. (NCT04304534)
Timeframe: From baseline up to 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Asundexian 10 mg | 5 |
| Asundexian 20 mg | 3 |
| Asundexian 50 mg | 3 |
| Placebo | 5 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 315 |
| ASA 325mg | 357 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 590 |
| ASA 325mg | 569 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 53 |
| ASA 325mg | 44 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 228 |
| ASA 325mg | 213 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 102 |
| ASA 325mg | 92 |
(NCT02697916)
Timeframe: Time of randomization through study completion, approximately 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA 81mg | 471 |
| ASA 325mg | 446 |
Quality of life measures are based on an ordinal scale from 1-5, where 1 corresponds to the best outcome and 5 to the worst. Model-based mean score estimates are obtained from mixed models of each quality of life measure. (NCT02697916)
Timeframe: 2 years
| Intervention | score on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Describe Current Health | Able to Run Errands and Shop | In the past 7 Days, Felt Depressed | In the past 7 Days, Felt Fatigued | In the past 7 Days, Problems with Sleep | Trouble doing Regular Activities | In the past 7 Days, Pain interfered | |
| ASA 325mg | 2.8 | 1.66 | 1.7 | 2.27 | 2.10 | 1.88 | 2.02 |
| ASA 81mg | 2.77 | 1.65 | 1.69 | 2.25 | 2.06 | 1.84 | 2.06 |
Participants with all-cause death. If no event, censoring occurs at the earliest of PACD and last endpoint assessment date. Includes deaths based on publically available vital status data in patients who have withdrawn consent. (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 579 |
| Ticagrelor Placebo | 592 |
Participants with Cardiovascular (CV) death, myocardial infarction (MI) or stroke. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and non-CV death date. (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 736 |
| Ticagrelor Placebo | 818 |
Participants with Cardiovascular (CV) death. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and non-CV death date. (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 364 |
| Ticagrelor Placebo | 357 |
Participants with ischaemic stroke. If no event, censoring occurs at the earliest of PACD, last endpoint assessment date and death date. (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 152 |
| Ticagrelor Placebo | 191 |
Participants with myocardial infarction. If no event, censoring occurs at the earliest of primary analysis censoring date (PACD), last endpoint assessment date and death date (NCT01991795)
Timeframe: From randomisation to primary analysis censoring date (PACD). Median time in study until PACD was 40 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 274 |
| Ticagrelor Placebo | 328 |
Participants with permanent discontinuation of study medication due to any bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and the date of last dose of study medication (NCT01991795)
Timeframe: From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 466 |
| Ticagrelor Placebo | 125 |
Participants with PLATO major bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication (NCT01991795)
Timeframe: From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 310 |
| Ticagrelor Placebo | 145 |
Participants with TIMI major bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication (NCT01991795)
Timeframe: From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 206 |
| Ticagrelor Placebo | 100 |
Participants with TIMI major or minor bleeding event. If no event, censoring occurs at the earliest of last endpoint assessment date, death date and 7 days following the date of last dose of study medication (NCT01991795)
Timeframe: From randomisation to 7 days following the date of last dose of study medication. Maximum duration of exposure was 59 months.
| Intervention | Number of participants with event (Number) |
|---|---|
| Ticagrelor 60 mg | 285 |
| Ticagrelor Placebo | 129 |
"Transprosthetic mean pressure gradiënt as determined by transthoracic echocardiography at three months after randomization.~scale [0-100]" (NCT02833948)
Timeframe: 3 months
| Intervention | mm Hg (Mean) |
|---|---|
| ASA + Clopidogrel | 10 |
| Rivaroxaban + ASA | 10 |
Death, Dichotomization by HALT (NCT02833948)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| HALT (-) | 0 |
| HALT (+) | 0 |
Death, Dichotomization by RLM (NCT02833948)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| RLM>2 (-) | 0 |
| RLM(+) | 0 |
"Effective orifice area (cm2) as determined by transthoracic echocardiography at three months after randomization.~scale [0.1-4.0]" (NCT02833948)
Timeframe: 3 months
| Intervention | cm2 (Mean) |
|---|---|
| ASA + Clopidogrel | 1.8 |
| Rivaroxaban + ASA | 1.8 |
Reduced systolic leaflet excursion is classified as: (I) normal, (II) mildly reduced (<50%), (III) moderate to severely reduced (>50%), and (IV) immobile. Reduced systolic leaflet excursion is considered significant when it is > 50% or immobile. Quantitative assessment of leaflet motion is performed with a blood pool inversion volume rendered cine reconstruction throughout the cardiac cycle evaluating the bioprosthetic leaflets. (NCT02833948)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA + Clopidogrel | 11 |
| Rivaroxaban + ASA | 2 |
The rate of patients with at least one prosthetic leaflet with hypoattenuated leaflet thickening (HALT) as assessed by cardiac 4DCT. (NCT02833948)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| ASA + Clopidogrel | 33 |
| Rivaroxaban + ASA | 12 |
The rate of prosthetic leaflets with RLM> grade 3 as assessed by cardiac 4DCT (NCT02833948)
Timeframe: 3 months
| Intervention | leaflets (Number) |
|---|---|
| ASA + Clopidogrel | 14 |
| Rivaroxaban + ASA | 3 |
The rate of prosthetic leaflet with HALT as assessed by cardiac 4DCT-scan (NCT02833948)
Timeframe: 3 months
| Intervention | Leaflets (Number) |
|---|---|
| ASA + Clopidogrel | 53 |
| Rivaroxaban + ASA | 16 |
Thromboembolic event, Dichotomization by HALT (NCT02833948)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| HALT (-) | 2 |
| HALT (+) | 0 |
Thromboembolic event, Dichotomization by RLM (NCT02833948)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| RLM>2 (-) | 2 |
| RLM(+) | 0 |
Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 83 |
| Antiplatelet | 68 |
Composite of BARC 2,3 or 5 bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 148 |
| Antiplatelet | 85 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 14 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 68 |
| Antiplatelet | 63 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 105 |
| Antiplatelet | 78 |
ISTH major bleeds (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 49 |
| Antiplatelet | 30 |
The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 137 |
| Antiplatelet | 100 |
PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 46 |
| Antiplatelet | 31 |
Composite of TIMI major and minor bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 42 |
| Antiplatelet | 24 |
Time to event analysis of patients with adjudicated all cause death. The number of observed patients with adjudicated all cause death was reported. All cause death is defined as the death from any cause included CV death, non-CV death, and undetermined cause of death. (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 55 |
| Dabigatran Etexilate 150mg | 30 |
| Warfarin | 48 |
| Warfarin (Excluding Elder Patients Outside USA) | 35 |
"Time to event analysis of patients with adjudicated Cardiovascular (CV) death. The number of observed patients with adjudicated Cardiovascular (CV) death was reported.~CV death included death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, death due to CV procedures, death due to CV haemorrhage, and death due to other CV causes." (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 37 |
| Dabigatran Etexilate 150mg | 21 |
| Warfarin | 31 |
| Warfarin (Excluding Elder Patients Outside USA) | 24 |
"Time to event analysis of patients with adjudicated Non-cardiovascular (Non-CV). The number of observed patients with adjudicated Non-CV was reported.~Non-CV death was defined as any death with a specific cause that was not thought to be CV. These were possible examples of non-CV causes of death: Pulmonary, Renal, Gastrointestinal, Hepatobiliary, Pancreatic Infection(included sepsis), Inflammatory (e.g. systemic inflammatory response syndrome) or immune (including autoimmune), Haemorrhage that was neither CV bleeding nor a stroke, Non-CV procedure or surgery, Trauma, Suicide, Non-prescription drug reaction or overdose, Prescription drug reaction or overdose, Neurological (non-CV), Malignancy, Other non-CV" (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 14 |
| Dabigatran Etexilate 150mg | 4 |
| Warfarin | 13 |
| Warfarin (Excluding Elder Patients Outside USA) | 8 |
"Time to event analysis of patients with adjudicated Undetermined cause of death. The number of observed patients with adjudicated Undetermined cause of death was reported.~This is referred to a death not attributable to cardiovascular (CV) death or to a non-cardiovascular (non-CV) cause. Inability to classify the cause of death may have been due to lack of information (e.g. the only available information was patient died) or when there was insufficient supporting information or detail to assign the cause of death." (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 4 |
| Dabigatran Etexilate 150mg | 5 |
| Warfarin | 4 |
| Warfarin (Excluding Elder Patients Outside USA) | 3 |
Time to event analysis of patients with the composite endpoint of death + myocardial infarction (MI) + stroke. The number of observed patients with the composite endpoint of death + myocardial infarction (MI) + stroke was reported. (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 107 |
| Dabigatran Etexilate 150mg | 60 |
| Warfarin | 80 |
| Warfarin (Excluding Elder Patients Outside USA) | 57 |
Time to event analysis of patients with composite endpoint of death or first thrombotic event (all death, myocardial infarction (MI), stroke/systemic embolism (SE)). The number of observed patients with composite endpoint of death or thrombotic event (all death, MI, stroke/SE). (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 108 |
| Dabigatran Etexilate 150mg | 60 |
| Warfarin | 83 |
| Warfarin (Excluding Elder Patients Outside USA | 60 |
| All Dabigatran Etexilate | 168 |
Time to event analysis of patients with death or thrombotic event (all death, myocardial infarction, stroke/systemic embolism) or unplanned revascularisation by Percutaneous Coronary Intervention/Coronary Artery Bypass Graft. The number of observed patients with death or first thrombotic event or unplanned revascularisation by PCI/CABG was reported. (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 149 |
| Dabigatran Etexilate 150mg | 90 |
| Warfarin | 131 |
| Warfarin (Excluding Elder Patients Outside USA) | 98 |
| All Dabigatran Etexilate | 239 |
"Time to event analysis of patients with first adjudicated International Society of Thrombosis and Haemostasis (ISTH) Major Bleeding Event (MBE) or Clinically Relevant Non Major Bleeding Event (CRNMBE). The number of observed patients with adjudicated ISTH MBE or CRNMBE was reported.~Full analysis set (FAS): All consenting patients randomised were analysed in the treatment group to which they were randomised regardless of whether they took trial medication. The start date of the observation period for this analysis set was the date of randomisation. Patients who discontinued trial medication were followed until the end of the trial.~Patients who were lost to follow-up for vital status were censored for the primary endpoint at the time of their last known vital status.~Intention to treat period: The observation period for these analysis was the so called 'intention to treat period'." (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 151 |
| Dabigatran Etexilate 150mg | 154 |
| Warfarin | 264 |
| Warfarin (Excluding Elder Patients Outside USA) | 196 |
Time to event analysis of patients with first adjudicated Myocardial Infarction (MI). The number of observed patients with adjudicated MI was reported (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 44 |
| Dabigatran Etexilate 150mg | 26 |
| Warfarin | 29 |
| Warfarin (Excluding Elder Patients Outside USA) | 22 |
"Time to event analysis of patients with first adjudicated Systemic embolism (SE). The number of observed patients with adjudicated SE was reported.~SE is an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts) and had to be documented by angiography, surgery, scintigraphy, or autopsy." (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 3 |
| Dabigatran Etexilate 150mg | 1 |
| Warfarin | 3 |
| Warfarin (Excluding Elder Patients Outside USA) | 3 |
Time to event analysis of patients with first adjudicated Stent Thrombosis (ST). The number of observed patients with adjudicated ST was reported. (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 15 |
| Dabigatran Etexilate 150mg | 7 |
| Warfarin | 8 |
| Warfarin (Excluding Elder Patients Outside USA) | 7 |
"Time to event analysis of patients with first adjudicated Stroke. The number of observed patients with adjudicated Stroke was reported.~Stroke was defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction" (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 17 |
| Dabigatran Etexilate 150mg | 9 |
| Warfarin | 13 |
| Warfarin (Excluding Elder Patients Outside USA) | 8 |
Time to event analysis of patients with adjudicated unplanned revascularisation by Percutaneous Coronary Intervention (PCI)/Coronary Artery Bypass Graft (CABG). The number of observed patients with adjudicated unplanned revascularisation by PCI/CABG was reported. (NCT02164864)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dabigatran Etexilate 110mg | 76 |
| Dabigatran Etexilate 150mg | 51 |
| Warfarin | 69 |
| Warfarin (Excluding Elder Patients Outside USA) | 52 |
Participants with bleeding event that fulfils serious adverse event criteria and is categorised as GUSTO Moderate/Severe. GUSTO is a bleeding scale (GUSTO = Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries). GUSTO Severe bleeding is defined as any of the following: (1) fatal bleeding, (2) intracranial bleeding, or (3) bleeding that caused haemodynamic compromise requiring intervention. GUSTO Moderate bleeding is a bleeding requiring transfusion of whole blood or packed red blood cells without haemodynamic compromise (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 36 |
| PLACEBO | 11 |
Participants with bleeding event that fulfils serious adverse event criteria and is categorised as GUSTO Severe. GUSTO is a bleeding scale (GUSTO = Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries). GUSTO Severe bleeding is defined as any of the following: (1) fatal bleeding, (2) intracranial bleeding, or (3) bleeding that caused haemodynamic compromise requiring intervention (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 28 |
| PLACEBO | 7 |
Participants with subsequent stroke or death (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 303 |
| PLACEBO | 362 |
Participants with ICH or fatal bleeding event (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 22 |
| PLACEBO | 6 |
Number of participants with ischaemic stroke (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 276 |
| PLACEBO | 345 |
The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death.0 - No symptoms,1 - No significant disability. Able to carry out all usual activities, despite some symptoms. 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3 - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead. (NCT03354429)
Timeframe: Visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 1282 |
| PLACEBO | 1284 |
Participants with premature permanent discontinuation of IP due to bleeding (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 152 |
| PLACEBO | 32 |
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 5.1 |
| Ticagrelor 60 mg | 4.7 |
| Placebo | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.6 |
| Ticagrelor 60 mg | 2.3 |
| Placebo | 1.1 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.9 |
| Ticagrelor 60 mg | 2.9 |
| Placebo | 3.4 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 7.8 |
| Ticagrelor 60 mg | 7.8 |
| Placebo | 9.0 |
Adjudicated composite of non-fatal stroke, non-fatal myocardial infarction (MI), or cardiovascular death is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 4.80 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 5.40 |
Adjudicated fatal bleeding was defined as a bleeding event which the Independent Event Adjudication Committee (IAC) determined as the primary cause of death or contributed directly to death. The annualised event rate represents the average number of events per patient during a 1-year period. Because there were 0 events in one treatment group, the hazard ratio is unable to be calculated. (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.00 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.05 |
"Adjudicated intracranial haemorrhage comprised the subtypes of intracerebral bleeds, intraventricular bleeds, subdural bleeds, epidural bleeds, and subarachnoid bleeds. Microbleeds did not qualify as intracranial haemorrhage, except when they were symptomatic.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.67 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.63 |
Adjudicated ischaemic stroke is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 3.97 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 4.71 |
"Major bleeds were to be classified as life-threatening if they met one or more of the following criteria: fatal bleed, symptomatic intracranial bleed, reduction in haemoglobin of at least 5 grams/ deciliter (g/dL), transfusion of at least 4 units of packed red blood cells (equivalent to 9 units in Japan), associated with hypotension requiring the use of intravenous inotropic agents, or necessitated surgical intervention.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.76 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.91 |
Adjudicated recurrent stroke (ischemic, hemorrhagic, or unspecified) is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, approximately 43 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 4.09 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 4.80 |
All-cause death is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 1.24 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 1.28 |
"This was the sum of all major and minor bleeds (Minor bleeds were clinical bleeds that did not fulfil the criteria for major bleeds), regardless of severity.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 15.21 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 11.64 |
Disabling stroke (modified Rankin Scale greater than or equal to 4, as determined 3 months after recurrent stroke) is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.55 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.93 |
"First major bleed is primary safety endpoint. Major bleeds were defined according to the International Society of Thrombosis and Haemostasis (ISTH) definition as follows:~Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or,~Bleeding (which should be overt) associated with a reduction in haemoglobin of at least 2 grams/ decilitre (g/dL) (1.24 millimoles Per Litre (mmol/L)), or leading to transfusion of ≥2 units of blood or packed cells (equivalent to ≥4.5 units in Japan); the haemoglobin drop should be considered to be due to and temporally related to the bleeding event and/or,~Fatal bleed. The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 1.84 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 1.33 |
Percentage of subjects with AF detected within 12 months of follow-up (NCT00924638)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Continuous Monitoring | 12.4 |
| Control Arm | 2.0 |
Percentage of subjects with AF detected within 6 months of follow-up (NCT00924638)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Continuous Monitoring | 8.9 |
| Control Arm | 1.4 |
Incidence of cardiovascular (CV) or stroke/TIA related hospitalizations within 12 months (NCT00924638)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Continuous Monitoring | 10.5 |
| Control Arm | 7.2 |
EQ-5D VAS (visual analog scale) quality of life score, which is a continuous measure of quality of life ranging from 0 (worst) to 100 (perfect health). (NCT00924638)
Timeframe: 12 months
| Intervention | units on a scale of 0 to 100 (Mean) |
|---|---|
| Continuous Monitoring | 78.9 |
| Control Arm | 76.3 |
Percentage of subjects with recurrent stroke or TIA within 12 months of follow-up (NCT00924638)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Continuous Monitoring | 7.1 |
| Control Arm | 9.1 |
Percentage of subjects who were using antiarrhythmic drugs at the 12 months follow-up visit (NCT00924638)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Continuous Monitoring | 2.0 |
| Control Arm | 1.6 |
Percentage of subjects who were using OAC drugs at the 12 months follow-up visit (NCT00924638)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Continuous Monitoring | 14.7 |
| Control Arm | 6.0 |
AF detection lag (days from AF occurrence to AF diagnosis) characterized by patient assistant (PA) use frequency (NCT00924638)
Timeframe: Follow-up closure
| Intervention | days from AF occurrence to AF diagnosis (Mean) | |||||
|---|---|---|---|---|---|---|
| PA used everyday | PA used most of the time (5-6 days/week) | PA used sometimes (3-4 days/week) | PA used rarely (1-2 days/week) | PA never used | PA use frequency not reported | |
| Continuous Monitoring | 14.0 | 25.0 | 174.8 | 15.3 | 92.0 | 20.0 |
The secondary safety outcome was clinically relevant non-major (CRNM) bleeding, which was adjudicated by the CIAC using the ASA criteria: the bleeding was non-major and the bleeding was associated with a study medication interruption of more than 14 days. (NCT02064439)
Timeframe: Up to 12 months, at least 6 months
| Intervention | participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | 12 |
| Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | 17 |
| Acetylsalicylic (ASA) 100 mg, OD | 12 |
"The principal safety outcome was major bleeding which was defined according to the criteria of the International Society on Thrombosis and Hemostasis (ISTH) as clinically overt bleeding and associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or whole blood, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intra articular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death.~Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant." (NCT02064439)
Timeframe: Up to 12 months, at least 6 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Any major bleeding | Fatal bleeding | Non-fatal critical organ bleed | Non-fatal non-critical organ bleeding | |
| Acetylsalicylic (ASA) 100 mg, OD | 3 | 1 | 1 | 1 |
| Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | 5 | 0 | 2 | 3 |
| Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | 6 | 1 | 4 | 1 |
"The primary efficacy outcomes (i.e., recurrent venous thromboembolism [VTE] defined as composite of fatal or non-fatal symptomatic recurrent VTE, including unexplained death for which pulmonary embolism [PE] could not be ruled out) as confirmed by the central independent adjudication committee (CIAC) were considered up to the end of the individual intended duration of treatment.~Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant." (NCT02064439)
Timeframe: Up to 12 months, at least 6 months
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Composite | Symptomatic recurrent Deep vein thrombosis (DVT) | Symptomatic recurrent PE | Death (PE) | Death (unexplained and PE cannot be ruled out) | |
| Acetylsalicylic (ASA) 100 mg, OD | 50 | 29 | 19 | 1 | 1 |
| Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | 13 | 8 | 5 | 0 | 0 |
| Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | 17 | 9 | 6 | 0 | 2 |
The secondary efficacy outcome is the composite of the primary efficacy outcome, myocardial infarction (MI), ischemic stroke or non-central nervous system (CNS) systemic embolism. Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant. (NCT02064439)
Timeframe: Up to 12 months, at least 6 months
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Composite | Ischemic stroke | Non-CNS systemic embolism | Myocardial infarction | Symptomatic recurrent DVT | Symptomatic recurrent PE | Death (PE) | Death (unexplained and PE cannot be ruled out) | Death (cardiovascular: myocardial infarction) | Death (cardiovascular: ischemic stroke) | |
| Acetylsalicylic (ASA) 100 mg, OD | 56 | 2 | 1 | 4 | 29 | 18 | 1 | 1 | 0 | 0 |
| Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | 18 | 4 | 1 | 0 | 8 | 5 | 0 | 0 | 0 | 0 |
| Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | 19 | 2 | 0 | 1 | 9 | 6 | 0 | 1 | 0 | 0 |
Non CABG-related TIMI clinically significant bleeding events are sum of non CABG-related TIMI major bleeding events, TIMI minor bleeding events and TIMI bleeding events requiring medical attention. Major: any symptomatic intracranial bleeding: clinically overt signs of hemorrhage with hemoglobin (Hb) drop of greater than or equal to (>=)5 gram per deciliter (g/dl) (or absolute drop in hematocrit of >=15%) and fatal bleeding (results in death within 7 days); Minor: clinically overt sign of hemorrhage with Hb drop of 3 - <5 g/dl (or drop in hematocrit of 9 - <15%); requiring medical attention: bleeding event that required medical, surgical treatment/laboratory evaluation and did not meet criteria for major/minor bleeding event. (NCT02293395)
Timeframe: From start of study treatment until follow-up (up to 390 days)
| Intervention | participants (Number) |
|---|---|
| Rivaroxaban 2.5 mg Twice Daily (BID) | 80 |
| Acetylsalicylic Acid 100 mg Once Daily (OD) | 74 |
Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 901 |
| CLOPIDOGREL | 1065 |
Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1290 |
| CLOPIDOGREL | 1456 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 569 |
| CLOPIDOGREL | 668 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 864 |
| CLOPIDOGREL | 1014 |
Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 961 |
| CLOPIDOGREL | 929 |
Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 619 |
| CLOPIDOGREL | 654 |
Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 329 |
| CLOPIDOGREL | 341 |
Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 399 |
| CLOPIDOGREL | 506 |
Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 353 |
| CLOPIDOGREL | 442 |
Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1339 |
| CLOPIDOGREL | 1215 |
Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 504 |
| CLOPIDOGREL | 593 |
Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 362 |
| CLOPIDOGREL | 306 |
Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 235 |
| CLOPIDOGREL | 180 |
Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 125 |
| CLOPIDOGREL | 106 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 21 |
| CLOPIDOGREL | 16 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 84 |
| CLOPIDOGREL | 51 |
This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 50 |
| Primary PCI (Group B) | 43 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 59 |
| Primary PCI (Group B) | 73 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 100 |
| Primary PCI (Group B) | 123 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 117 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 77 |
| Primary PCI (Group B) | 85 |
This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 43 |
| Primary PCI (Group B) | 42 |
The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 116 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 31 |
| Primary PCI (Group B) | 32 |
This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 41 |
| Primary PCI (Group B) | 56 |
This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 57 |
| Primary PCI (Group B) | 72 |
This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 9 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 6 |
| Primary PCI (Group B) | 3 |
This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 61 |
| Primary PCI (Group B) | 45 |
This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 206 |
| Primary PCI (Group B) | 191 |
This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 23 |
| Primary PCI (Group B) | 21 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 45 |
| Primary PCI (Group B) | 41 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 19 |
| Primary PCI (Group B) | 11 |
This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 1 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 32 |
| Primary PCI (Group B) | 38 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 10 |
| Primary PCI (Group B) | 29 |
This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 2 |
| Primary PCI (Group B) | 0 |
This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 7 |
| Primary PCI (Group B) | 4 |
This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 8 |
| Primary PCI (Group B) | 1 |
This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 267 |
| Primary PCI (Group B) | 236 |
This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 15 |
| Primary PCI (Group B) | 5 |
"EQ-5D index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: End of treatment visit (Day 90+-7d)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.85 |
| ASA 100 mg | 0.84 |
"EQ-5D index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Premature treatment discontinuation visit(<15 days after last dose)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.72 |
| ASA 100 mg | 0.68 |
"EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Visit 1 (Enrolment)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.70 |
| ASA 100 mg | 0.70 |
"EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Visit 2 (Day 7+-2d)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.80 |
| ASA 100 mg | 0.79 |
Participants with stroke, MI, death or life-threatening bleeding. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 457 |
| ASA 100 mg | 508 |
"Analysis of severity of stroke and overall disability of patients, using the modified Rankin Score, mRS.~Modified Rankin Score:~0 - No symptoms.~- No significant disability. Able to carry out all usual activities, despite some symptoms.~- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.~- Moderate disability. Requires some help, but able to walk unassisted.~- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.~- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.~- Dead.~Disability defined as mRS > 1.~Odds ratio and p-value are calculated for ticagrelor versus ASA from a logistic regression model with treatment group, history of stroke and NIHSS (National Institutes of Health Stroke Scale) at baseline as explanatory variables." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 1107 |
| ASA 100 mg | 1194 |
Participants with all-cause death. If no event, censoring at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 68 |
| ASA 100 mg | 58 |
Participants with ischaemic stroke, MI or CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 423 |
| ASA 100 mg | 475 |
Participants with stroke, MI or death. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 442 |
| ASA 100 mg | 497 |
Participants with CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 41 |
| ASA 100 mg | 35 |
Participants with disabling stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 277 |
| ASA 100 mg | 307 |
Participants with fatal stroke. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 18 |
| ASA 100 mg | 17 |
Participants with ischaemic stroke. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 385 |
| ASA 100 mg | 441 |
Participants with MI. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97) (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 25 |
| ASA 100 mg | 21 |
"Participants with PLATO Major bleeding. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).~PLATO Major bleeding is defined as a bleed that is any one of:~Fatal~Intracranial (excluding asymptomatic haemorrhagic transformations of ischemic brain infarctions and excluding micro-hemorrhages <10 mm evident only on gradient-echo MRI)~Intrapericardial bleed with cardiac tamponade~Hypovolaemic shock or severe hypotension due to bleeding and requiring pressors or surgery~Significantly disabling (eg. intraocular with permanent vision loss)~Clinically overt or apparent bleeding associated with a decrease in Hb of more than 30 g/L (1.9 mmol/L; 0.465 mmol/L)~Transfusion of 2 or more units (whole blood or packed red blood cells [PRBCs]) for bleeding." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 31 |
| ASA 100 mg | 38 |
Participants discontinuation of study drug due to any bleeding adverse event. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: Time from first dose and up to and including 7 days following the date of last dose of the study
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 82 |
| ASA 100 mg | 37 |
Participants with stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97) (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 390 |
| ASA 100 mg | 450 |
"Change from baseline to end of treatment visit in NIHSS (National Institutes of Health Stroke Scale):~0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=-5 | -4 | -3 | -2 | -1 | 0 | 1 | 2 | 3 | 4 | 5 | >5 | Missing | |
| ASA 100 mg | 127 | 438 | 810 | 1073 | 1131 | 683 | 79 | 31 | 16 | 11 | 6 | 14 | 450 |
| Ticagrelor 90 mg | 132 | 403 | 779 | 1088 | 1099 | 681 | 67 | 28 | 18 | 13 | 6 | 10 | 474 |
(NCT01082874)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Active Clonidine and Active ASA | 173 |
| Active Clonidine and Placebo ASA | 194 |
| Placebo Clonidine and Active ASA | 178 |
| Placebo Clonidine and Placebo ASA | 161 |
All bleeding events include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding. Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 2356 |
| Warfarin | 3060 |
ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more, and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 327 |
| Warfarin | 462 |
Death was defined as all-cause mortality. All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, myocardial infarction (MI), sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death). (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 603 |
| Warfarin | 669 |
Major bleeding=bleeding that is clinically overt and that either resulted in a decrease in hemoglobin of 2 g/dL or more over a 24-hour period, led to a transfusion of 2 or more units of packed red blood cells, occurred in a critical site, or led to death. CRNM bleeding=bleeding that is clinically overt, that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event, that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 613 |
| Warfarin | 877 |
Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 459 |
| Warfarin | 608 |
For descriptions of Stroke and SE, see Outcome Measure 1. For description of Major bleeding, see Outcome Measure 3. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | participants (Number) |
|---|---|
| Apixaban | 229 |
| Warfarin | 285 |
All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, MI, sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death). (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 3.52 |
| Warfarin | 3.94 |
Rate=number of adjudicated major (ISTH) bleed events per 100 patient years. ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 2.13 |
| Warfarin | 3.09 |
Rate=Number of adjudicated stroke or SE events per 100 patient years. Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 1.27 |
| Warfarin | 1.60 |
"Rate=number of all bleeding events per 100 patient years. All bleeding events include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding. Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death." (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 18.08 |
| Warfarin | 25.82 |
(NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 3.21 |
| Warfarin | 4.06 |
Rate=number of major or CRNM bleed events per 100 patient years. Major=clinically overt and either 1) resulted in a decrease in hemoglobin of 2 g/dL or more, or 2) led to a transfusion of 2 or more units of packed red blood cells, or 3) occurred in a critical site, or 4) led to death. CRNM bleeding=clinically overt, but satisfied no additional criteria required to be adjudicated as a major bleeding event, and led to either 1) hospital admission for bleeding or 2) physician guided medical or surgical treatment for bleeding or 3) a change in antithrombotic therapy. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | number of events / 100 patient years (Number) |
|---|---|
| Apixaban | 4.07 |
| Warfarin | 6.01 |
Rate=number of events of net-clinical benefit per 100 patient years. Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | Number of events per 100 patient years (Number) |
|---|---|
| Apixaban | 3.01 |
| Warfarin | 4.09 |
AE: all SAEs or AEs with onset from first dose through 2 days (AEs) or 30 days (SAEs) after the last dose of blinded study drug (BSD). SAE: all SAEs with onset from first dose through 30 days after the last dose of BSD. Bleeding AE: all serious or non-serious bleeding-related AEs with onset from first dose through 2 days after the last dose of BSD. Discontinuations due to AE: all SAEs or AEs with onset from first dose of BSD and with action taken=drug discontinued. Deaths: all deaths occurring from first dose through 30 days after the last dose of BSD. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| AE | SAE | Bleeding AE | Discontinuations due to AE | Deaths | |
| Apixaban | 7406 | 3182 | 2288 | 688 | 429 |
| Warfarin | 7521 | 3302 | 2961 | 758 | 468 |
All suspected efficacy events were adjudicated by the Central Events Committee (CEC). Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing. (NCT00412984)
Timeframe: "Time to first event in Intended Treatment Period: started on day of randomization, ended at efficacy cut-off date (date target number of primary efficacy events [448] was expected to have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | participants (Number) | ||
|---|---|---|---|
| Ischemic or Unspecified Stroke | Hemorrhagic Stroke | Systemic Embolism | |
| Apixaban | 159 | 38 | 15 |
| Warfarin | 173 | 76 | 16 |
Rate=number of adjudicated GUSTO bleeding events per 100 patient years. GUSTO Bleeding Criteria: GUSTO severe (or life-threatening) bleeding: either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention. GUSTO moderate bleeding: bleeding that requires blood transfusion but does not result in hemodynamic compromise. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | Number of events per 100 patient years (Number) | |
|---|---|---|
| Severe (n=80, 172)) | Severe or Moderate (n=199, 328) | |
| Apixaban | 0.52 | 1.29 |
| Warfarin | 1.13 | 2.18 |
Rate=number of adjudicated TIMI bleeding events per 100 patient years. TIMI Bleeding Criteria: Major bleeding=Intracranial bleeding and/or clinically overt bleeding associated with ≥5 gm/dL fall in Hgb or 15% fall in hematocrit (Hct) from baseline, accounting for transfusions. Minor bleeding=Clinically overt bleeding associated with ≥3 gm/dL fall in Hgb or a ≥10% fall in Hct from baseline, accounting for transfusions. (NCT00412984)
Timeframe: "Treatment Period started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group."
| Intervention | Number of events per 100 patient years (Number) | |
|---|---|---|
| Major (n=148, 256) | Major or Minor (n=239, 370) | |
| Apixaban | 0.96 | 1.55 |
| Warfarin | 1.69 | 2.46 |
Diagnosis for an acute or evolving MI=elevation of creatine kinase-MB isoenzyme (CK-MB) or Troponin T or I ≥ 2 × the upper limit of normal (ULN), or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads. For descriptions of Stroke and SE, see Outcome Measure 1. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) | |||
|---|---|---|---|---|
| Ischemic or Unspecified Stroke (n=162, 175) | Hemorrhagic Stroke (n=40, 78) | Systemic Embolism (n=15, 17) | Myocardial Infarction (n=90, 102) | |
| Apixaban | 0.97 | 0.24 | 0.09 | 0.53 |
| Warfarin | 1.05 | 0.47 | 0.10 | 0.61 |
Diagnosis for an acute or evolving MI=elevation of CK-MB or Troponin T or I ≥ 2 × the ULN, or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads. For descriptions of Stroke and SE, see Outcome Measure 1. For description of ACD, see Outcome Measure 5. (NCT00412984)
Timeframe: "Intended Treatment Period started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding)."
| Intervention | Number of events per 100 patient years (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Stroke / SE / Major Bleeding (n=521, 666) | Stroke / SE / All-Cause Death (ACD) (n=752, 837) | Stroke / SE / Major Bleeding / ACD (n=1009, 1168) | Stroke / SE / MI / ACD (n=810, 906) | Ischemic or Unspecified Stroke / ACD (n=725, 796) | Hemorrhagic Stroke / ACD (n=622, 703) | SE / ACD (n=613, 679) | MI / ACD (n=663, 740) | |
| Apixaban | 3.17 | 4.49 | 6.13 | 4.85 | 4.32 | 3.68 | 3.63 | 3.93 |
| Warfarin | 4.11 | 5.04 | 7.20 | 5.49 | 4.78 | 4.20 | 4.05 | 4.43 |
Combination of CV death, MI, and stroke (NCT01870921)
Timeframe: 12 months
| Intervention | Participants (Number) |
|---|---|
| Ticargrelor | 85 |
SAEs except the blending events which have aleady been reported as SAEs. (NCT01870921)
Timeframe: 12 months
| Intervention | Participants (Number) |
|---|---|
| Ticargrelor | 116 |
PLATO-defined fatal/life threatening, major, major+minor,major+minor+minimal (NCT01870921)
Timeframe: 12 months
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Fatal/life threatening | Major | Major + minor | Major + minor + minimal | |
| Ticargrelor | 17 | 27 | 93 | 426 |
Number of Adjudicated Major Adverse Cardiovascular Events (MACE) which is a composite of non-fatal myocardial infarction (MI), non-fatal stroke and cardiovascular death (NCT01802775)
Timeframe: within 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 1 |
| Edoxaban | 3 |
Number of participants with amputations within 6 months (NCT01802775)
Timeframe: within 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 3 |
| Edoxaban | 1 |
Percentage of participants with re-stenosis/re-occlusion during treatment within 6 months - only the first occurrence of re-stenosis / re-occlusion was counted for each participant (NCT01802775)
Timeframe: within 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Clopidogrel | 34.7 |
| Edoxaban | 30.9 |
"Number of participants with serious adverse events (SAEs) within 6 months~Note: Based on changes to the database structure, clinically significant changes in physical or laboratory parameters are recorded as adverse events (AEs). Details of non-serious adverse events are reported at the 5% reporting threshold in the AE module, as is all-cause mortality." (NCT01802775)
Timeframe: within 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 30 |
| Edoxaban | 31 |
Percentage of participants with clinically relevant bleeding, defined as major bleeding or clinical relevant non-major bleeding, in the on-treatment period based on International Society of Thrombosis and Haemostasis (ISTH) (NCT01802775)
Timeframe: at 3 months
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Including Access Site Bleeding (IASB) | Excluding Access Site Bleed (EASB) | |
| Clopidogrel | 8 | 6 |
| Edoxaban | 11 | 6 |
The percentage of participants with major, clinically relevant non-major, and minor bleeding occurring during treatment, within 3 months (NCT01802775)
Timeframe: within 3 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| IASB : Major Bleeding | IASB: CRNM Bleeding | IASB: Minor Bleeding | EASB : Major Bleeding | EASB : CRNM Bleeding | EASB : Minor Bleeding | |
| Clopidogrel | 5 | 4 | 20.8 | 4 | 3 | 17.8 |
| Edoxaban | 1 | 10 | 20 | 1 | 5 | 19 |
(NCT04352439)
Timeframe: Up to six months
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 4 |
Adverse events will only include those that are determined to be related to the study drug. (NCT04352439)
Timeframe: Up to six months
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 0 |
"According to modified TIMI criteria, the Major Bleeding Events is defined as the combination of CABG-related bleeding and non-CABG-related major bleeding(Intracranial bleeding, Clinically overt signs of hemorrhage with hemoglobin drop ≥5 g/dL and Fatal bleeding)." (NCT02201771)
Timeframe: up to 12 months
| Intervention | events (Number) |
|---|---|
| Aspirin | 0 |
| Ticagrelor Plus Aspirin | 3 |
| Ticagrelor | 2 |
MACE, composite of CV death, myocardial infarction or stroke (ischaemic or unknown etiology) (NCT02201771)
Timeframe: up to 12 months
| Intervention | events (Number) |
|---|---|
| Aspirin | 9 |
| Ticagrelor Plus Aspirin | 4 |
| Ticagrelor | 3 |
"assessed by MSCTA or CAG. FitzGibbon grade A (stenosis <50%) is defined as patency." (NCT02201771)
Timeframe: up to 7 days
| Intervention | percentage of patent SV grafts (Number) |
|---|---|
| Aspirin | 91.1 |
| Ticagrelor Plus Aspirin | 94.9 |
| Ticagrelor | 94.3 |
"assessed by multislice computed tomography angiography (MSCTA) or coronary angiography(CAG). FitzGibbon grade A (stenosis <50%) is defined as patency." (NCT02201771)
Timeframe: up to 12 months
| Intervention | percentage of patent SV grafts (Number) |
|---|---|
| Aspirin | 76.5 |
| Ticagrelor Plus Aspirin | 88.7 |
| Ticagrelor | 82.8 |
Number of Participants Free of Angina per CCS Classification (NCT02201771)
Timeframe: up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 154 |
| Ticagrelor Plus Aspirin | 158 |
| Ticagrelor | 155 |
Number of Participants with Post-operative Atrial Fibrillation after CABG (NCT02201771)
Timeframe: up to 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 23 |
| Ticagrelor Plus Aspirin | 20 |
| Ticagrelor | 13 |
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
Major bleeding event (as per ISTH), defined as bleeding event that met at least one of following: fatal bleeding; symptomatic bleeding in a critical area or organ (intraarticular, intramuscular with compartment syndrome, intraocular, intraspinal, pericardial, or retroperitoneal); symptomatic intracranial haemorrhage; clinically overt bleeding associated with a recent decrease in the hemoglobin level of greater than or equal to (>=) 2 grams per decilitre (g/dL) (20 grams per liter [g/L]; 1.24 millimoles per liter [mmol/L]) compared to the most recent hemoglobin value available before the event; clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. The results were based on classification of events that have been positively adjudicated as major bleeding events. Incidence rate estimated as number of subjects with incident events divided by cumulative at-risk time, where subject is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.82 |
| Acetylsalicylic Acid 100 mg OD | 0.67 |
All-cause mortality includes all deaths of participants due to any cause. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.88 |
| Acetylsalicylic Acid 100 mg OD | 1.50 |
Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. Cardiovascular death includes death due to hemorrhage and death with undetermined/unknown cause. Systemic embolism is defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms. The diagnosis of myocardial infarction requires the combination of: 1)evidence of myocardial necrosis (either changes in cardiac biomarkers or post-mortem pathological findings); and 2)supporting information derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 6.20 |
| Acetylsalicylic Acid 100 mg OD | 5.85 |
Non-major clinically relevant bleeding was defined as non-major overt bleeding but required medical attention (example: hospitalization, medical treatment for bleeding), and/or was associated with the study drug interruption of more than 14 days. The results were based on the outcome events at or after randomization until the efficacy cut-off date. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 3.52 |
| Acetylsalicylic Acid 100 mg OD | 2.32 |
Intracranial hemorrhage included all bleeding events that occurred in intracerebral, sub arachnoidal as well as subdural or epidural sites. The below table displays results for all randomized participants and the outcomes at or after randomization until the efficacy cut-off date. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 0.70 |
| Acetylsalicylic Acid 100 mg OD | 0.35 |
Life-threatening bleeding was defined as a subset of major bleeding that met at least one of the following criteria: 1) fatal bleeding; 2) symptomatic intracranial haemorrhage; 3) reduction in hemoglobin of at least 5 g/dl (50 g/l; 3.10 mmol/L); 4) transfusion of at least 4 units of packed red cells or whole blood; 5) associated with hypotension requiring the use of intravenous inotropic agents; 6) necessitated surgical intervention. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.02 |
| Acetylsalicylic Acid 100 mg OD | 0.43 |
Components of composite efficacy outcome (adjudicated) includes stroke (ischemic, hemorrhagic, and undefined stroke, TIA with positive neuroimaging) and systemic embolism. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 5.14 |
| Acetylsalicylic Acid 100 mg OD | 4.78 |
"Disabling stroke is defined as stroke with modified Rankin score (mRS) greater than or equal to (>=) 4 as assessed by investigator. mRS spans 0-6, running from perfect health to death. A score of 0-3 indicates functional status ranging from no symptoms to moderate disability (defined in the mRS as requiring some help, but able to walk without assistance); mRS 4-6 indicates functional status ranging from moderately severe disability (unable to walk or to attend to own bodily needs without assistance)through to death. CV death includes death due to hemorrhage and death with undetermined/unknown cause. Diagnosis of myocardial infarction requires combination of: 1) evidence of myocardial necrosis either changes in cardiac biomarkers or post-mortem pathological findings); 2) supporting information derived from clinical presentation, electrocardiographic changes, or results of myocardial or coronary artery imaging." (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) | ||||
|---|---|---|---|---|---|
| Stroke | Ischemic stroke | Disabling stroke | CV death(includes death due to hemorrhage) | Myocardial infarction | |
| Acetylsalicylic Acid 100 mg OD | 4.71 | 4.56 | 0.84 | 0.66 | 0.67 |
| Rivaroxaban 15 mg OD | 5.11 | 4.71 | 1.20 | 0.99 | 0.49 |
"Secondary efficacy assessments of aspirin involve intention-to-treat comparisons during the scheduled treatment period among all randomized participants on the first occurrence of:~Any incident gastrointestinal (GI) tract cancer (i.e. any GI cancer excluding pancreas and hepatobiliary), overall and after exclusion of the first three years of follow-up." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 157 |
| Placebo Aspirin | 158 |
"Secondary efficacy assessments involve intention-to-treat comparisons among all randomized participants of allocation to aspirin versus placebo and, separately, of omega-3 versus placebo on the first occurrence of the expanded vascular endpoint of SVE or revascularization (including coronary and non-coronary revascularizations)." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 833 |
| Placebo Aspirin | 936 |
| Omega-3 | 882 |
| Placebo Omega-3 | 887 |
"Incidence of fatal or non-fatal cancers. Any cancer excludes non-fatal non-melanoma skin cancer and non-fatal recurrence of a cancer that had occurred before randomization.~A single participant may have had multiple cancers." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 897 |
| Placebo Aspirin | 887 |
| Omega-3 | 894 |
| Placebo Omega-3 | 890 |
Includes fatal and non-fatal events. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Omega-3 | 166 |
| Placebo Omega-3 | 135 |
Includes fatal and non-fatal cancers. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 97 |
| Placebo Aspirin | 96 |
| Omega-3 | 103 |
| Placebo Omega-3 | 90 |
Includes fatal and non-fatal renal, bladder, prostate, gynaecological and other GU cancers (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 332 |
| Placebo Aspirin | 294 |
| Omega-3 | 323 |
| Placebo Omega-3 | 303 |
Includes fatal and non-fatal cancers. Includes leukaemia and lymphoma. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 88 |
| Placebo Aspirin | 86 |
| Omega-3 | 94 |
| Placebo Omega-3 | 80 |
Includes fatal and non-fatal melanomas. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 50 |
| Placebo Aspirin | 59 |
| Omega-3 | 55 |
| Placebo Omega-3 | 54 |
Includes fatal and non-fatal events, excludes atrial fibrillation. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Omega-3 | 83 |
| Placebo Omega-3 | 99 |
Includes fatal and non-fatal cancers not included elsewhere (where the type of cancer is known). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 25 |
| Placebo Aspirin | 30 |
| Omega-3 | 23 |
| Placebo Omega-3 | 32 |
Includes fatal and non-fatal cancers. Excludes cancers reported in the gastrointestinal tract category (see secondary outcome measure #4), and includes hepatobiliary and pancreatic cancers. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 87 |
| Placebo Aspirin | 82 |
Includes fatal and non-fatal cancers. Includes lung and larynx cancer. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 101 |
| Placebo Aspirin | 103 |
| Omega-3 | 104 |
| Placebo Omega-3 | 100 |
Includes fatal and non-fatal cancers of unknown type. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 26 |
| Placebo Aspirin | 31 |
| Omega-3 | 25 |
| Placebo Omega-3 | 32 |
Fatal 'All stroke' events include deaths from: Haemorrhagic stroke (Intracerebral haemorrhage; Subarachnoid haemorrhage); Non-haemorrhagic stroke (Cerebral infarction; Stroke not specified as haemorrhage or infarction). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 38 |
| Placebo Aspirin | 34 |
| Omega-3 | 35 |
| Placebo Omega-3 | 37 |
'All-cause mortality' includes all recorded deaths. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 748 |
| Placebo Aspirin | 792 |
| Omega-3 | 752 |
| Placebo Omega-3 | 788 |
Fatal 'Cancer' events include any death attributed to cancer. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 309 |
| Placebo Aspirin | 315 |
| Omega-3 | 305 |
| Placebo Omega-3 | 319 |
Fatal 'Coronary' events include deaths from: Acute MI and other CHD (unspecified Acute ischaemic heart disease; Atherosclerotic heart disease; Ischaemic cardiomyopathy; unspecified Chronic ischaemic heart disease). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 105 |
| Placebo Aspirin | 122 |
| Omega-3 | 100 |
| Placebo Omega-3 | 127 |
Fatal 'External cause' events include deaths from: Injury; Fracture; Self harm; and Medical and surgical complications (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 18 |
| Placebo Aspirin | 21 |
| Omega-3 | 17 |
| Placebo Omega-3 | 22 |
Fatal 'Other medical' events include deaths from: Non-vascular medical causes (excluding cancer and respiratory, including Fatal GI bleed or perforation); and deaths from Renal disease and Diabetes. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 126 |
| Placebo Aspirin | 157 |
| Omega-3 | 158 |
| Placebo Omega-3 | 125 |
Fatal 'Other vascular' events include deaths from: Heart failure (excluding ischaemic cardiomyopathy); Other vascular death (excluding stroke; and Cardiac death (excluding CHD). (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 67 |
| Placebo Aspirin | 70 |
| Omega-3 | 61 |
| Placebo Omega-3 | 76 |
Fatal 'Respiratory' events include any death attributed to respiratory causes. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 82 |
| Placebo Aspirin | 69 |
| Omega-3 | 73 |
| Placebo Omega-3 | 78 |
Any death for which the cause is not known. (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 3 |
| Placebo Aspirin | 4 |
| Omega-3 | 3 |
| Placebo Omega-3 | 4 |
"The primary safety assessments involve intention-to-treat comparisons among all randomized patients of allocation to aspirin versus placebo on the first occurrence of any major bleed, defined as:~any confirmed intracranial hemorrhage (including intracerebral, subarachnoid, subdural or any other intracranial hemorrhage); or~sight-threatening eye bleeding; or~any other serious bleeding episode." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 314 |
| Placebo Aspirin | 245 |
"The primary efficacy assessments involve intention-to-treat comparisons among all randomized participants of allocation to aspirin versus placebo and, separately, of omega-3 fatty acids versus placebo on the first occurrence of any Serious Vascular Event (SVE), defined as:~non-fatal myocardial infarction; or~non-fatal stroke (excluding confirmed intracranial hemorrhage) or TIA; or~vascular death excluding confirmed intracranial hemorrhage (defined as International Classification of Diseases 10th revision [ICD-10] I00-52 or I63-99, i.e. excluding subarachnoid hemorrhage [I60], intracerebral hemorrhage [I61], and other non-traumatic intracranial hemorrhage [I62])." (NCT00135226)
Timeframe: Randomized treatment phase during a mean of 7.4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin | 658 |
| Placebo Aspirin | 743 |
| Omega-3 | 689 |
| Placebo Omega-3 | 712 |
Rate of death or myocardial infarction (NCT02605447)
Timeframe: 3 to 15 months
| Intervention | Participants (Count of Participants) |
|---|---|
| SYNERGY Stent + 3 Month DAPT | 84 |
"Rate of Bleeding, per Bleeding Academic Consortium definition (BARC2, 3a, 3b, 3c, 4, 5a and 5b)~Type 0: No Bleeding~Type 1: Bleeding that is not actionable and does not cause the patient to seek treatment~Type 2: Any clinically overt sign of hemorrhage that is actionable and requires diagnostic studies, hospitalization, or treatment by a health care professional~Type 3a: Overt bleeding plus hemoglobin drop of 3 to < 5 g/dL (provided hemoglobin drop is related to bleed); transfusion with overt bleeding~Type 3b: Overt bleeding plus hemoglobin drop ≥5 g/dL (provided hemoglobin drop is related to bleed); cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents~Type 3c: Intracranial hemorrhage confirmed by autopsy, imaging, or lumbar puncture; intraocular bleed compromising vision~Type 4: CABG-related bleeding within 48 hours~Type 5a: Probable fatal bleeding~Type 5b: Definite fatal bleeding" (NCT02605447)
Timeframe: 3 to 15 months
| Intervention | Participants (Count of Participants) |
|---|---|
| SYNERGY Stent + 3 Month DAPT | 103 |
"Rate of stent thrombosis: definite + probable, using the Academic Research Consortium (ARC) definition Confirmed/Definite (is considered either angiographic confirmed or pathologic confirmed) Probable~Clinical definition of probable stent thrombosis is considered to have occurred in the following cases:~Any unexplained death within the first 30 days~Irrespective of the time after the index procedure and MI in the absence of any obvious cause which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis Possible Clinical definition of possible stent thrombosis is considered to have occurred with any unexplained death beyond 30 days." (NCT02605447)
Timeframe: 3 to 15 months
| Intervention | Participants (Count of Participants) |
|---|---|
| SYNERGY Stent + 3 Month DAPT | 3 |
MACE(major adverse cardiac event) include: death, myocardial infarction, revascularization. (NCT02101411)
Timeframe: 24 months
| Intervention | numbers of participants with MACE (Number) |
|---|---|
| Aspirin+Clopidogrel | 1 |
| Aspirin+Ticagrelor | 1 |
| Aspirin+Clopidogrel+Cilostazol | 2 |
Bleeding events were adjudicated by the Adjudication Committee and classified according to Thrombolysis in Myocardial Infarction (TIMI) major, minor, minimal, and International Society on Thrombosis and Hemostasis (ISTH) major and clinically relevant non-major bleeding (CRNM) criteria. The adjudicated results based on TIMI and ISTH classifications, and programmatically identified events (not adjudicated) according to Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) classification were used in the analyses of bleeding endpoints. GUSTO Bleed Criteria included Severe or life-threatening: Intracranial hemorrhage, or bleeding that causes hemodynamic compromise requiring intervention; Moderate: Bleeding that requires a blood transfusion, but does not result in hemodynamic compromise; Mild: Bleeding that does not meet criteria for either severe or moderate bleeding. Treatment Period=events with onset from first dose to last dose plus 2 days. (NCT00831441)
Timeframe: From first dose to first occurrence of event (Bleeding) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 16.33 |
| Apixaban 5 mg BID | 39.98 |
Event rate was percent of participants with an event of cardiovascular (CV) death, myocardial infarction (MI), or ischemic stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Study was terminated early and last patient, last visit was in Year 2. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes (eg, cardiogenic shock, heart failure, arrhythmia/sudden death, cardiac rupture, ischemic stroke, pulmonary embolism, venous/arterial thrombotic events) and other sudden deaths for which an alternative cause was not identified. Intended Treatment Period: the period that started on the day of randomization and ended at the efficacy cut-off date (cut-off date: the date all sites were informed that study drug should be discontinued for all participants, 18 November 2010). (NCT00831441)
Timeframe: Randomization (Day 1) to first event (CV death, MI, ischemic stroke), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 13.96 |
| Apixaban 5 mg BID | 13.20 |
"Cause of death was determined by the principal condition that caused the death, not the immediate mode of death.~CV death: included deaths due to CV causes. Non-CV death: included non-CV deaths caused primarily by a malignancy, infection, bleeding, trauma, non-CV system organ failure, or non-CV surgery. Unknown: included deaths that were not attributable to one of the above categories of CV death or to a non-CV cause. MI accounted whether the participant had a recent PCI or CABG surgery. Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause. Only events confirmed by the adjudication committee were included in analyses. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination)." (NCT00831441)
Timeframe: Randomization (Day 1) to first event (All Cause Death, MI, or Stroke), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 15.65 |
| Apixaban 5 mg BID | 15.48 |
Event rate was percent of participants with an event of CV death, fatal bleed, MI, or stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. CV death included deaths due to CV causes; Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause; Fatal bleeding defined as bleeding that Adjudication Committee determined was the primary cause of death or contributed directly to death; MI took into account whether the participant had a recent PCI or CABG surgery. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination). (NCT00831441)
Timeframe: Randomization (Day 1) to first event (CV death, Fatal Bleed, MI, or stroke), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 14.27 |
| Apixaban 5 mg BID | 13.97 |
Event rate was percent of participants with an event of CV death, MI, unstable angina (UA), or ischemic stroke (number of participants with event/number randomized) per 100-pt years. Only events confirmed by the adjudication committee were included in the analyses. Each type of event was counted once per participant, but participants could have been counted in multiple categories. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off date (notification of study termination). (NCT00831441)
Timeframe: Randomization (Day 1) to first event (CV death, MI, UA, Ischemic Stroke, up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 17.95 |
| Apixaban 5 mg BID | 16.92 |
ISTH Major bleed: acute clinically overt bleeding accompanied by one or more of the following: A decrease in Hgb of 2 g/dL or more over 24 hours; A transfusion of 2 or more units of packed RBCs; Bleeding that occurs in at least one of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; Bleeding that was fatal. CRNM: acute clinically overt bleeding that did not satisfy additional criteria required for the bleeding event to be defined as a major bleeding event and meets at least one of the following: Hospital admission for bleeding; Physician guided medical or surgical treatment for bleeding; Change in anti-thrombotic treatment (anticoagulant or antiplatelet) therapy. Bleeding events were adjudicated by the Adjudication Committee. Treatment Period=events with onset from first dose to last dose plus 2 days. (NCT00831441)
Timeframe: From first dose to first occurrence of event (ISTH major or CRNM bleed) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 2.29 |
| Apixaban 5 mg BID | 6.15 |
ISTH Criteria: Acute clinically overt bleeding defined as new onset, visible bleeding or signs or symptoms suggestive of bleeding confirmed by imaging techniques, which can detect the presence of blood (eg, ultrasound, CT, MRI). Major bleeding: acute clinically overt bleeding accompanied by one or more of the following: A decrease in Hgb of 2 g/dL or more over 24 hours; A transfusion of 2 or more units of packed red blood cells (RBCs); Bleeding that occurs in at least one of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; Bleeding that was fatal. Bleeding events were adjudicated by the Adjudication Committee. Event rate was percent of participants with an event (number with event/number randomized) per 100-pt years. Treatment Period=events with onset from first dose to last dose plus 2 days. (NCT00831441)
Timeframe: From first dose to first occurrence of event (ISTH major bleed) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 2.04 |
| Apixaban 5 mg BID | 5.13 |
TIMI Major Bleed Criteria: Fatal bleeding, intracranial hemorrhage, and clinically overt bleeding with a hemoglobin (Hgb) drop of ≥ 5 grams per deciliter (g/dL), or ≥15% absolute decrease in hematocrit. To account for transfusions, Hgb measurements were adjusted for transfusions. A transfusion of 1 unit of blood was assumed to result in an increase by 1 g/dL in Hgb or 3% in hematocrit. Event rate was percent of participants with an event of Major Bleed as per TIMI (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Treatment Period=events with onset from first dose to last dose plus 2 days. (NCT00831441)
Timeframe: From first dose to first occurrence of event (TIMI major bleeding) during Treatment Period (first dose to last dose + 2 days), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 0.91 |
| Apixaban 5 mg BID | 2.40 |
MI took into account whether the participant had a recent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery. Selected key criteria: Elevation of cardiac biomarkers (eg, Creatine Kinase MB fraction (CKMB), Troponin T, Troponin I) above the upper reference limit (URL) plus ischemic symptoms, ECG changes, or imaging evidence of new loss of viable myocardium or new regional wall motion abnormality; Death of CV etiology with new ST-segment elevation or left bundle branch block (LBBB) or fresh intracoronary thrombus by angiography or at autopsy occurring before biomarkers could be obtained or before their appearance in the blood; Following a PCI, elevation of cardiac biomarkers more than 3*URL; Following CABG surgery, elevation of cardiac biomarkers more than 5*URL; New, significant (≥0.04 s) Q waves in ≥2 contiguous leads; Pathologic findings of acute MI. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off notice. (NCT00831441)
Timeframe: Randomization (Day 1) to first event (MI), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 9.20 |
| Apixaban 5 mg BID | 8.59 |
Stent thrombosis: Definite stent thrombosis considered to have occurred by either angiographic or pathological confirmation; Probable stent thrombosis considered to have occurred in the following cases: any unexplained death within the first 30 days after stent implantation; irrespective of the time after the procedure, any MI that was related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause; Possible stent thrombosis considered to have occurred with any unexplained death from 30 days after intracoronary stenting until end of study (in Year 2). Event rate was percent of participants with an event of stent thrombosis (number with event/number randomized) per 100-pt years. Only events confirmed by the adjudication committee were included in the analyses. Intended Treatment Period: Day of randomization (Day 1) to efficacy cut-off notice of study termination. (NCT00831441)
Timeframe: Randomization (Day 1) to first event (stent thrombosis), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 2.21 |
| Apixaban 5 mg BID | 1.61 |
Event rate was percent of participants with an event of stroke (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Diagnosis of stroke required a new, non-traumatic, focal neurological deficit of sudden onset, lasting at least 24 hours that was not due to a readily identifiable non-vascular cause (ie, brain tumor). All strokes were classified as hemorrhagic (documentation on imaging (eg computed tomography scan or magnetic resonance imaging) of hemorrhage in the cerebral parenchyma, or a subdural or subarachnoid hemorrhage), non-hemorrhagic/ischemic stroke, ischemic stroke with hemorrhagic conversion, or type unknown. Intended Treatment Period: the period that started on the day of randomization (Day 1) and ended at the efficacy cut-off date (notification of study termination). (NCT00831441)
Timeframe: Randomization (Day 1) to first event (stroke), up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 1.85 |
| Apixaban 5 mg BID | 1.65 |
Unstable Angina (UA) defined as worsening or recurrent severe or repetitive angina symptoms at rest lasting at least 10 minutes with at least 2 of the following: New and dynamic electrocardiogram (ECG) changes; angina symptoms leading to inpatient hospitalization; angina symptoms leading to an unplanned or urgent cardiac catheterization, with or without revascularization, that showed evidence of hemodynamically and clinically significant stenosis. Event rate was percent of participants with an event of unstable angina (number of participants with event/number randomized) per 100 patient (100-pt) years. Only events confirmed by the adjudication committee were included in the analyses. Intended Treatment Period: the period that started on the day of randomization and ended at the efficacy cut-off date (cut-off date: the date all sites were informed that study drug should be discontinued for all participants, 18 November 2010). (NCT00831441)
Timeframe: Randomization (Day 1) to first event of UA, up to March 2011, approximately 2 years
| Intervention | percentage of participants/100-pt years (Number) |
|---|---|
| Placebo | 4.21 |
| Apixaban 5 mg BID | 3.95 |
DVT and how the diagnosis was made will be recorded. The number of events in participants in each arm will be compared to evaluate efficacy. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 5 |
| VTE Prophylaxis With Aspirin 81mg BID | 9 |
Bases on imaging obtained for symptoms. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 6 |
| VTE Prophylaxis With Aspirin 81mg BID | 2 |
Includes a greater than 2g/dL drop in hemoglobin, blood transfusion, hematoma evacuation, re-operation for a deep surgical site infection or minor procedure for bleeding and GI bleed (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 52 |
| VTE Prophylaxis With Aspirin 81mg BID | 53 |
Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST>3xULN and total bilirubin > 2 x ULN (NCT00262600)
Timeframe: 36 months
| Intervention | participants (Number) |
|---|---|
| Dabigatran 110 mg | 11 |
| Dabigatran 150 mg | 14 |
| Warfarin | 21 |
Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 1.54 |
| Dabigatran 150 mg | 1.11 |
| Warfarin | 1.71 |
Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 4.85 |
| Dabigatran 150 mg | 4.32 |
| Warfarin | 5.20 |
Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) |
|---|---|
| Dabigatran 110 mg | 4.26 |
| Dabigatran 150 mg | 3.68 |
| Warfarin | 4.35 |
"Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25~Major bleeds are adjudicated, whereas minor bleeds are investigator reported." (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage) (Number) | |
|---|---|---|
| Major bleeds | Minor bleeds | |
| Dabigatran 110 mg | 2.99 | 13.16 |
| Dabigatran 150 mg | 3.55 | 14.85 |
| Warfarin | 3.81 | 16.37 |
Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH) (NCT00262600)
Timeframe: 36 months
| Intervention | yearly event rate (percentage)] (Number) | |
|---|---|---|
| intracerebral hemorrhage | intracranial hemorrhage (ICH) | |
| Dabigatran 110 mg | 0.12 | 0.23 |
| Dabigatran 150 mg | 0.10 | 0.32 |
| Warfarin | 0.38 | 0.76 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 1.70 |
| Propensity-matched BMS | 2.61 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.69 |
| DES 12-month DAPT | 1.45 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.40 |
| DES 12-month DAPT | 1.35 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.03 |
| BMS 12-month DAPT | 0.90 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.09 |
| BMS 12-month DAPT | 1.05 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.74 |
| DES 12-month DAPT | 1.88 |
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.53 |
| DES 12-month DAPT | 1.57 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 11.37 |
| Propensity-matched BMS | 13.24 |
(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.04 |
| BMS 12-month DAPT | 4.69 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.68 |
| BMS 12-month DAPT | 5.48 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 5.62 |
| DES 12-month DAPT | 6.49 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 4.34 |
| DES 12-month DAPT | 5.92 |
Death from any cause or repeat hospitalization after intervention. (NCT00530894)
Timeframe: duration of study
| Intervention | participants (Number) |
|---|---|
| Inoperable: TAVR | 76 |
| Inoperable: Medical Therapy | 126 |
Death from any cause. (NCT00530894)
Timeframe: 1 Year
| Intervention | participants (Number) |
|---|---|
| High Risk: TAVR | 84 |
| High Risk: SAVR | 89 |
| Inoperable: TAVR | 55 |
| Inoperable: Medical Therapy | 89 |
NYHA classification change from baseline to 1 year visit. NYHA provides a way of classifying the extent of heart failure. New York Heart Association (NYHA) is a functional classification of heart failure based on how much a patient is limited during physical activity. The rating ranges from I - IV, with the lowest (I) as no limitations and the highest (IV) unable to carry on any physical activity without discomfort. (NCT00530894)
Timeframe: Baseline to 1 year
| Intervention | Units on scale (Least Squares Mean) |
|---|---|
| High Risk: TAVR | 2.50 |
| High Risk: SAVR | 2.60 |
| Inoperable: TAVR | 2.88 |
| Inoperable: Medical Therapy | 3.92 |
Number of participants with MACCE definition includes death, myocardial infarction (MI), stroke and renal failure (NCT00530894)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| High Risk: TAVR | 93 |
| High Risk: SAVR | 97 |
| Inoperable: TAVR | 61 |
| Inoperable: Medical Therapy | 93 |
Total hospital days from the index procedure or randomization into control arm to one year post procedure or randomization. (NCT00530894)
Timeframe: 1 year
| Intervention | Days (Mean) |
|---|---|
| High Risk: TAVR | 17.42 |
| High Risk: SAVR | 20.14 |
| Inoperable: TAVR | 25.24 |
| Inoperable: Medical Therapy | 17.04 |
"The QOL questionnaire consisted of: Kansas City Cardiomyopathy (KCCQ), The Medical Outcomes Study Short-Form 12 (SF-12) - physical and metal states.~KCCQ scores are on a range of 0-100, in which 100 reflects the best health status and 0 reflects the worst health status.~SF-12 questionnaire was used in which 100 reflects the best health status and 0 reflects the worst health status." (NCT00530894)
Timeframe: Baseline and 1 Year
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| KCCQ Overall | SF-12 Physical | SF-12 Mental | |
| High Risk: SAVR | 71.1 | 36.9 | 52.9 |
| High Risk: TAVR | 70.0 | 36.3 | 52.0 |
| Inoperable: Medical Therapy | 46.98 | 29.68 | 46.59 |
| Inoperable: TAVR | 69.41 | 34.85 | 53.31 |
(NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo Arm | 1.8 |
| Thienopyridine Therapy | 2.0 |
| Surveillance Arm | 4.8 |
"All definite and probable Stent Thrombosis (ST) are adjudicated by an independent committee according to the definition based on Academic Research Consortium (ARC)~Definite is defined as angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region and at least 1 of the following: Acute ischemic symptoms, Ischemic ECG changes, Elevated cardiac biomarkers~Probable defined as any unexplained death within the first 30 days of procedure and any myocardial infarction, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo Arm | 1.0 |
| Thienopyridine Therapy | 0.5 |
| Surveillance Arm | 2.4 |
(NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo Arm | 4.3 |
| Thienopyridine Therapy | 4.8 |
| Surveillance Arm | 16.9 |
Any adverse reaction related to study drug until 30 days after percutaneous coronary intervention. (NCT02075125)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Prasugrel | 0 |
| Ticagrelor | 0 |
Any event related to bleeding including access site bleeding and peri-procedural bleeding based on Bleeding Academic Research Consortium (BARC) criteria. (NCT02075125)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Prasugrel | 0 |
| Ticagrelor | 0 |
Any major adverse cardiac and cerebrovascular event including (death, myocardial infarction, or revascularization and stroke) until day 30. (NCT02075125)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Prasugrel | 0 |
| Ticagrelor | 0 |
Platelet reactivity was measured using VerifyNow (volumetrics accuretic, San Diego, California, USA). Platelet reactivity values were presented as P2Y12 reaction units (PRU). (NCT02075125)
Timeframe: Baseline
| Intervention | PRU units (Median) |
|---|---|
| Prasugrel | 259 |
| Ticagrelor | 261 |
Platelet reactivity was measured using vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay. Platelet reactivity values were presented as platelet reactivity index (PRI). (NCT02075125)
Timeframe: Baseline
| Intervention | percentage (Median) |
|---|---|
| Prasugrel | 51.2 |
| Ticagrelor | 47.5 |
Platelet reactivity were measured by VerifyNow (volumetrics accuretic，San Diego, California, USA), and vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay (BioCytex, Marseille, France) with FACSCalibur flow cytometer (BD Biosciences, San Jose, California, USA) using. Measurement time gap +/- 12 hours were allowed. High platelet reactivity (HPR) is defined as the result of P2Y12 reaction units (PRU) >235 and platelet reactivity index (PRI) >50%. (NCT02075125)
Timeframe: 48 hours after loading dose of study drug
| Intervention | participants (Number) | |
|---|---|---|
| PRU>235 | VASP-PRI>50% | |
| Prasugrel | 0 | 0 |
| Ticagrelor | 0 | 0 |
Platelet reactivity were measured using VerifyNow (volumetrics accuretic, San Diego, California, USA), and vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay (BioCytex, Marseille, France) with FACSCalibur flow cytometer (BD Biosciences, San Jose, California, USA) using. Measurement time gap +/- 12 hours were allowed. Low platelet reactivity (LPR) is defined as the result of P2Y12 reaction units (PRU) <85 and platelet reactivity index (PRI)<16%. The PRU value for LPR, 18 patients were in prasugrel groups and 19 patients in ticagrelor groups, regarding the PRI value for LPR, 16 patients were in each groups. (NCT02075125)
Timeframe: 48 hours after loading dose of study drug
| Intervention | participants (Number) | |
|---|---|---|
| PRU<85 | VASP-PRI<16% | |
| Prasugrel | 18 | 16 |
| Ticagrelor | 19 | 16 |
Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)
| Intervention | Percentage of events per year (Number) |
|---|---|
| Apixaban, 2.5 or 5 mg Twice Daily | 4.21 |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 6.35 |
Event rate=percent of participants with an event divided by the total participants in the arm. Intended-treatment period=date of randomization to the efficacy cutoff date, which was to be the date on which at least 226 unrefuted original primary efficacy events occurred (date revised to May 28, 2010 following cessation of study for superior efficacy.) (NCT00496769)
Timeframe: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)
| Intervention | Percentage of events (Number) |
|---|---|
| Apixaban, 2.5 or 5 mg Twice Daily | 1.62 |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 3.63 |
Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: Day 1 to first bleeding event up to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)
| Intervention | Percentage of events per year (Number) |
|---|---|
| Apixaban, 2.5 or 5 mg Twice Daily | 10.85 |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 8.32 |
Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)
| Intervention | Percentage of events per year (Number) | ||
|---|---|---|---|
| All-cause death (n=111, 140) | Net clinical benefit (n=163, 220) | Vascular death (n=84, 96) | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 4.42 | 7.13 | 3.03 |
| Apixaban, 2.5 or 5 mg Twice Daily | 3.51 | 5.23 | 2.65 |
Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: First dose of study drug (Day 1) to the earlier of a patient's discontinuation of double-blind study drug or the attainment of at least 226 primary efficacy events up to May 28, 2010
| Intervention | Percentage of events per year (Number) | ||
|---|---|---|---|
| Major bleeding | Major or CRNM bleeding | All bleeding | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 0.92 | 3.24 | 8.32 |
| Apixaban, 2.5 or 5 mg Twice Daily | 1.41 | 4.46 | 10.85 |
BL=baseline, LLN=lower limit of normal, ULN=upper limit of normal. Hemoglobin (g/dL), low: BL>2 or value ≤8; hematocrit(%), low: <0.75*BL; erythrocytes (*10^6 cells/μL), low: <0.75*BL; platelet count (*10^9 cells/L),low: <100*10^9 cells/L; leukocytes (*10^3 cells/μL), low if <0.8*BL and BL
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin, low (n=1956, 1893) | Hemoglobin, high (n=1956, 1893) | Hematocrit, low (n=1728, 1687) | Hematocrit, high (n=1728, 1687) | Erythrocytes, low (n=1728, 1687) | Erythrocytes, high (n=1728, 1687) | Platelet count, low (n=2148, 2098) | Platelet count, high (n=2148, 2098) | Leukocytes, low (n=1738, 1698) | Leukocytes, high (n=1738, 1698) | Neutrophils (absolute), low (n=2170, 2138) | Neutrophils (absolute), high (n=2170, 2138) | Eosinophils (absolute), low (n=2170, 2138) | Eosinophils (absolute), high (n=2170, 2138) | Basophils (absolute), low (n=2170, 2138) | Basophils (absolute), high (n=2170, 2138) | Monocytes (absolute), low (n=2170, 2138) | Monocytes (absolute), high (n=2170, 2138) | Lymphocytes (absolute), low (n=2170, 2138) | Lymphocytes (absolute), high (n=2170, 2138) | Alkaline phosphatase (ALP), low (n=2781, 2758) | ALP, high (n=2781, 2758) | Aspartate phosphatase (AST), low (n=2779, 2753) | AST, high (n=2779, 2753) | Alanine aminotransferase (ALT), low (n=2779, 2753) | ALT, high (n=2779, 2753) | Bilirubin (total), low (n=2781, 2758) | Bilirubin (total), high (n=2781, 2758) | Bilirubin (direct), low (n=2773, 2750) | Bilirubin (direct), high (n=2773, 2750) | Blood urea nitrogen (BUN), low (n=2201, 2172) | BUN, high (n=2201, 2172) | Creatinine, low (n=2209, 2178) | Creatinine, high (n=2209, 2178) | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 120 | 0 | 9 | 0 | 12 | 0 | 10 | 0 | 14 | 18 | 1 | 0 | 0 | 68 | 0 | 0 | 0 | 2 | 62 | 5 | 0 | 27 | 0 | 33 | 0 | 31 | 0 | 43 | 0 | 248 | 0 | 50 | 0 | 71 |
| Apixaban, 2.5 or 5 mg Twice Daily | 131 | 0 | 13 | 0 | 12 | 0 | 7 | 0 | 12 | 14 | 2 | 0 | 0 | 48 | 0 | 0 | 0 | 0 | 52 | 4 | 0 | 34 | 0 | 28 | 0 | 23 | 0 | 30 | 0 | 241 | 0 | 42 | 0 | 67 |
LLN=lower limit of normal; ULN=upper limit of normal; BL=baseline. Sodium, serum (mEq/L):low if <0.95*BL and BL
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug
| Intervention | Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sodium (serum), low (n=1768, 1740) | Sodium (serum), high (n=1768, 1740) | Potassium (serum), low (n=1763, 1737) | Potassium (serum), high (n=1763, 1737) | Chloride (serum), low (n=1768, 1740) | Chloride (serum), high (n=1768, 1740) | Calcium (total), low (n=106, 109) | Calcium (total), high (n=106, 109) | Bicarbonate, low (n=1664, 1619) | Bicarbonate, high (n=1664, 1619) | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 6 | 2 | 8 | 28 | 3 | 1 | 0 | 0 | 0 | 0 |
| Apixaban, 2.5 or 5 mg Twice Daily | 2 | 1 | 6 | 20 | 0 | 0 | 0 | 0 | 0 | 0 |
ULN=upper limit of normal; LLN=lower limit of normal; BL=baseline. Creatine kinase (U/L), high:>5*ULN; protein, total(g/L):low if <0.90*BL when BL
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug
| Intervention | Participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Creatine kinase, low (n=2780, 2758) | Creatine kinase, high (n=2780, 2758) | Protein (total), low (n=103, 109) | Protein (total), high (n=103, 109) | Uric acid, low (n=386, 390) | Uric acid, high (n=386, 390) | Glucose (urine), low (n=2, 3) | Glucose (urine), high (n=2, 3) | Protein (urine), low (n=3, 5) | Protein (urine), high (n=3, 5) | Blood (urine), low (n=3, 5) | Blood (urine), high (n=3, 5) | Leukocyte esterase (urine), low (n=3,5) | Leukocyte esterase (urine), high (n=3,5) | Red blood cells (RBC) (urine), low (n=2,2) | RBC (urine), high (n=2,2) | White blood cells (urine), low (n=2,2) | WBC (urine), high (n=2,2) | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 0 | 25 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Apixaban, 2.5 or 5 mg Twice Daily | 0 | 13 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. (NCT00496769)
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| AEs | SAEs | Bleeding AEs | Discontinuations due to AE | Deaths | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 1925 | 804 | 259 | 362 | 115 |
| Apixaban, 2.5 or 5 mg Twice Daily | 1833 | 657 | 281 | 266 | 91 |
The percentage of participants is the total number of participants experiencing an all-cause death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.61 |
| Prasugrel: 75 Years of Age or Older | 27.04 |
| Clopidogrel: <75 Years of Age | 11.12 |
| Clopidogrel: 75 Years of Age or Older | 26.83 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.06 |
| Prasugrel: 75 Years of Age or Older | 24.64 |
| Clopidogrel: <75 Years of Age | 10.96 |
| Clopidogrel: 75 Years of Age or Older | 24.13 |
The percentage of participants is the total number of participants experiencing a CV death or nonfatal MI divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 9.61 |
| Prasugrel: 75 Years of Age or Older | 22.53 |
| Clopidogrel: <75 Years of Age | 10.21 |
| Clopidogrel: 75 Years of Age or Older | 22.69 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, nonfatal stroke or re-hospitalization for a recurrent UA divided by number of participants in the treatment arm. Endpoints events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 12.13 |
| Prasugrel: 75 Years of Age or Older | 26.27 |
| Clopidogrel: <75 Years of Age | 12.83 |
| Clopidogrel: 75 Years of Age or Older | 25.67 |
Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to hemodynamic stress and is a biomarker associated with increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 6 Months
| Intervention | picograms per milliliter (pg/mL) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=725, 125, 701, 174) | |
| Clopidogrel: <75 Years of Age | 319.345 | 250.982 |
| Clopidogrel: 75 Years of Age or Older | 951.359 | 722.750 |
| Prasugrel: <75 Years of Age | 313.494 | 253.434 |
| Prasugrel: 75 Years of Age or Older | 1082.396 | 770.132 |
C-Reactive Protein (CRP) is a biomarker associated with inflammation and increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and Month 6
| Intervention | milligrams per liter (mg/L) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=755, 143, 745, 178) | |
| Clopidogrel: <75 Years of Age | 2.287 | 2.149 |
| Clopidogrel: 75 Years of Age or Older | 2.226 | 1.543 |
| Prasugrel: <75 Years of Age | 2.330 | 2.272 |
| Prasugrel: 75 Years of Age or Older | 2.441 | 1.593 |
Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire containing 11 questions (Q) yielding 5 summary scales related to angina: physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception. In this study only angina frequency and the physical limitations scales were assessed. Anginal Frequency was assessed using Q3 and Q4 which consists of a Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how often a patient is having symptoms now. Physical limitations was assessed using Q1 which contains 9 items each assessed via Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how much a participant's condition is hampering their ability to do what they want to do. Scale scores are transformed to a 0-100 by subtracting the lowest possible score, dividing by the range of the scale, and multiplying by 100. Higher values equal better quality of life. (NCT00699998)
Timeframe: Baseline and follow-up (24 months)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline, physical limitations | Baseline, angina frequency | 24 Months, physical limitations (n=420, 412) | 24 Months, angina frequency (n=420, 412) | |
| Clopidogrel | 67.0 | 73.1 | 74.5 | 89.5 |
| Prasugrel | 67.8 | 73.6 | 75.1 | 89.7 |
Variation in the genes encoding the cytochrome P450 (CYP) enzymes (CYP2C19) can reduce the ability to metabolize clopidogrel and a reduced platelet response and have been associated with increased rates of CV events including CV death. Participants were classified as extensive metabolizers (EM); reduced metabolizers (RM); or unknown (UNK) metabolizers based on their CYP2C19 genotype. Possible extensive metabolizer (EM) phenotypes include EM=extensive metabolizer, UM=ultra-rapid metabolizer, and EM (non-UM) that are not UM. Possible reduced metabolizer (RM) phenotypes include IM=intermediate metabolizer and PM=poor metabolizer. Genotypes associated with each predicted phenotype are presented; predicted phenotype is presented first followed by the genotype. Percentage=(number of participants with the predicted phenotype and genotype divided by the total number of participants per arm) multiplied by 100. (NCT00699998)
Timeframe: Baseline
| Intervention | percentage participants with geneotype (Number) | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UM, *1/*17 | UM, *17/*17 | EM (non-UM), *1/*1 | IM, *1/*2 | IM, *1/*3 | IM, *1/*4 | IM, *1/*6 | IM, *1/*8 | PM, *2/*2 | PM, *2/*3 | PM, *2/*4 | PM, *2/*6 | PM, *2/*8 | PM, *3/*3 | UNK, *1/*10 | UNK, *1/*13 | UNK, *1/*9 | UNK, *1/*9, *9/*17 | UNK, *13/*17 | UNK, *2/*13 | UNK, *2/*17 | UNK, *2/*9 | UNK, *3/*17 | UNK, *4/*17 | UNK, *4/*9 | UNK, *6/*17 | UNK, *8/*17 | UNK, *9/*17 | UNK, Undefined genotype | |
| Clopidogrel: <75 Years of Age | 25.1 | 5.4 | 35.7 | 19.8 | 0.5 | 0.1 | 0.0 | 0.4 | 4.3 | 0.3 | 0.2 | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.8 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.5 |
| Clopidogrel: 75 Years of Age or Older | 21.8 | 4.3 | 41.2 | 19.7 | 0.6 | 0.3 | 0.2 | 0.3 | 3.8 | 0.3 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.2 | 0.0 | 0.3 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.6 |
| Prasugrel: <75 Years of Age | 24.0 | 5.1 | 38.8 | 18.6 | 0.8 | 0.4 | 0.0 | 0.1 | 3.9 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 6.3 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.7 |
| Prasugrel: 75 Years of Age or Older | 25.0 | 3.6 | 42.1 | 18.3 | 0.6 | 0.0 | 0.2 | 0.5 | 2.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 6.1 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 |
Platelet aggregation was measured by as measured by Accumetrics Verify Now™ P2Y12. Results were reported in P2Y12 Reaction Units (PRU). PRU represents the rate and extent of adenosine (ADP)-stimulated platelet aggregation. Lower values indicate greater P2Y12 platelet inhibition and lower platelet activity and aggregation. ANCOVA Model was used and values were corrected for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 12 Months
| Intervention | P2Y12 Reaction Units (PRU) (Least Squares Mean) | |
|---|---|---|
| Day 30 | Month 12 (n=386, 76, 400, 103) | |
| Clopidogrel: <75 Years of Age | 193.489 | 199.003 |
| Clopidogrel: 75 Years of Age or Older | 200.285 | 181.360 |
| Prasugrel: <75 Years of Age | 93.280 | 94.529 |
| Prasugrel: 75 Years of Age or Older | 151.872 | 135.096 |
All deaths, regardless of possible relatedness, with the exception of 1 event, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table. The 1 event which was not adjudicated was a result of the revocation of consent by the participant prior to their death. Deaths possibly related to study drug in the opinion of the investigator are also contained in the Serious Adverse Event (SAE) module. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | participants (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Congestive Heart Failure | Cardiogenic Shock | Cardiac Rupture | Myocardial Infarction | Dysrhythmia | Stent Thrombosis | Directly Related to Revascularization-CABG or PCI | Intracranial Hemorrhage | Non-Hemorrhagic Stroke | Sudden death due to cardiovascular event | Pulmonary Embolism | Stroke, unknown type | Other Cardiovascular Event | Cardiovascular event, unknown type | Accidental | Trauma | Hemorrhage, not intracranial | Infection | Malignancy | Suicide | Other Non-Cardiovascular event | Cause unknown (nonadjudicated event) | |
| Clopidogrel: <75 Years of Age | 13 | 10 | 0 | 24 | 6 | 0 | 1 | 4 | 4 | 70 | 2 | 0 | 0 | 45 | 1 | 0 | 0 | 16 | 14 | 0 | 8 | 0 |
| Clopidogrel: 75 Years of Age or Older | 23 | 9 | 0 | 21 | 3 | 0 | 1 | 1 | 3 | 43 | 1 | 0 | 1 | 45 | 1 | 1 | 4 | 17 | 11 | 0 | 6 | 0 |
| Prasugrel: <75 Years of Age | 10 | 8 | 0 | 16 | 5 | 0 | 1 | 2 | 4 | 75 | 0 | 0 | 6 | 40 | 1 | 2 | 1 | 14 | 14 | 1 | 8 | 0 |
| Prasugrel: 75 Years of Age or Older | 21 | 4 | 1 | 24 | 2 | 0 | 1 | 1 | 4 | 39 | 1 | 1 | 1 | 41 | 0 | 3 | 1 | 21 | 7 | 0 | 4 | 1 |
[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum
| Intervention | grams per deciliter (Mean) |
|---|---|
| Tranexamic Acid | -1.8 |
| Placebo | -1.9 |
Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days
| Intervention | days (Median) |
|---|---|
| Tranexamic Acid | 3 |
| Placebo | 3 |
(NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 35 |
| Placebo | 32 |
This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 108 |
| Placebo | 109 |
This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 233 |
| Placebo | 231 |
[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 892 |
| Placebo | 986 |
Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 20 |
| Placebo | 19 |
This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 29 |
| Placebo | 31 |
This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 649 |
| Placebo | 732 |
[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 12 |
| Placebo | 13 |
[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 339 |
| Placebo | 368 |
Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 201 |
| Placebo | 233 |
[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 162 |
| Placebo | 125 |
This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 2 |
| Placebo | 0 |
Plasma TxA concentrations measured from blood samples taken upon arrival in the ICU (NCT03376061)
Timeframe: on arrival in ICU within 3 hours
| Intervention | microgram per milliliter per kilogram (Mean) |
|---|---|
| Topical TxA (Intervention) | 0.58 |
| Intravenous TxA (Control) | 1.10 |
Number of hours participants spent in the intensive care unit (ICU) (NCT03376061)
Timeframe: Number of hours spent in ICU from arrival to exit (collected at the Post-Operative Visit).
| Intervention | hours (Median) |
|---|---|
| Topical TxA (Intervention) | 23 |
| Intravenous TxA (Control) | 26 |
Cumulative volume (mL) of fluid collected from mediastinal drainage tubes 24 hours after the surgical procedure (NCT03376061)
Timeframe: Fluid collected in the first 24 hours after the surgical procedure
| Intervention | mL (Median) |
|---|---|
| Topical TxA (Intervention) | 500 |
| Intravenous TxA (Control) | 540 |
The occurrence of death due to any cause (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 1 |
| Intravenous TxA (Control) | 1 |
Patients requiring a red blood cell transfusion (NCT03376061)
Timeframe: Intra-operative and post-operative RBC transfusions
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 19 |
| Intravenous TxA (Control) | 23 |
Occurrence of re-operation for the purpose of bleeding or cardiac tamponade (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 0 |
| Intravenous TxA (Control) | 1 |
Patients experiencing a post-operative seizure (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 0 |
| Intravenous TxA (Control) | 1 |
Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 1333 |
| Clopidogrel | 1333 |
Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 1367 |
| Placebo | 1463 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 916 |
| Clopidogrel | 898 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 880 |
| Placebo | 934 |
(NCT00153062)
Timeframe: Randomization to final patient contact
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 125 |
| Placebo | 151 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Clopidogrel 300/75/75 mg + ASA Low Dose | 267 |
| Clopidogrel 300/75/75 mg + ASA High Dose | 290 |
| Clopidogrel 600/150/75 mg + ASA Low Dose | 282 |
| Clopidogrel 600/150/75 mg + ASA High Dose | 240 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel + ASA High Dose | 527 | 211 | 251 | 65 |
| Clopidogrel + ASA Low Dose | 546 | 231 | 260 | 55 |
"The primary endpoint is the first occurrence of any of the following events:~Cardiovascular death (any death with a clear cardiovascular or unknown cause),~Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)~Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)~reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC)." (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 557 | 222 | 274 | 61 |
| Clopidogrel 600/150/75 mg + ASA | 522 | 226 | 237 | 59 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 392 | 132 | 225 | 35 |
| Clopidogrel 600/150/75 mg + ASA | 330 | 130 | 172 | 28 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel + ASA High Dose | 282 | 216 | 73 |
| Clopidogrel + ASA Low Dose | 285 | 215 | 74 |
Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel 300/75/75 mg + ASA | 255 | 195 | 65 |
| Clopidogrel 600/150/75 mg + ASA | 313 | 236 | 83 |
This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Stent trombosis | - Definite | - Probable | |
| Clopidogrel 300/75/75 mg + ASA | 200 | 111 | 89 |
| Clopidogrel 600/150/75 mg + ASA | 135 | 58 | 77 |
The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 692 |
| Clopidogrel | 822 |
The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 797 |
| Clopidogrel | 938 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 502 | 573 |
| Prasugrel | 389 | 462 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) | ||
|---|---|---|---|
| UA/NSTEMI (n=5044, n=5030) | STEMI (n=1769, n=1765) | All ACS (n=6813, n=6795) | |
| Clopidogrel | 565 | 216 | 781 |
| Prasugrel | 469 | 174 | 643 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 504 | 588 |
| Prasugrel | 399 | 472 |
TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| TIMI Major or Minor Bleeding | TIMI Major Bleeding | TIMI Major Bleeding - Life-threatening (LT) | LT - Fatal | LT - Symptomatic intracranial hemorrage (ICH) | LT - Requiring inotropes | LT - Requiring surgical intervention | LT - Requiring transfusion (>=4 units) | TIMI Minor Bleeding | |
| Clopidogrel | 231 | 111 | 56 | 5 | 17 | 8 | 19 | 30 | 125 |
| Prasugrel | 303 | 146 | 85 | 21 | 19 | 21 | 19 | 45 | 164 |
An area under the curve of serial levels of Troponin I and creatine kinase-MB isoenzyme during 36 hours (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Hours*ng/ml (Median) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 38.0 | 92.7 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 121.4 | 185.6 |
| Group A (High Platelet Reactivity - Tirofiban) | 197.2 | 252.5 |
"Percentage of participants with periprocedural myonecrosis under the criteria described below.~When the cardiac biomarkers before the procedure were within the 99th percentile upper reference limit (URL), more than a 5-fold elevation in the URL within 12 hours after percutaneous coronary intervention (PCI) was defined as periprocedural myonecrosis. If the cardiac biomarker level was already above the 99th percentile URL before the procedure and the trend was stationary or decreasing, a ≥20% increase compared to the previous level was considered periprocedural myonecrosis. If the trend was still increasing, the levels at the post-6 hour and 12-hour were compared to determine periprocedural myonecrosis." (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 15 | 10 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 26 | 25 |
| Group A (High Platelet Reactivity - Tirofiban) | 16 | 11 |
The number of participants with at least one major bleeding, validated by the Event Adjudication Committee are counted over the duration of the follow-up (including after permanent discontinuation of the study drug). (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 251 |
| Placebo + ASA | 162 |
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 825 |
| Placebo + ASA | 841 |
The event is the occurence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) after validation of the Event Adjudication Committee . The analysis is performed on the time from randomization to the occurrence of this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 296 |
| Placebo + ASA | 408 |
"The primary event is the first occurence of any adjudicated component of the following cluster over the duration of follow-up :~stroke (nonfatal or fatal)~myocardial infarction (nonfatal or fatal)~non-CNS systemic embolism~vascular death~The primary efficacy analysis is performed on the time from randomization to this primary event. Numbers of patients with the composite event over the duration of the follow-up are presented by arm group." (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| All components | - Myocardial Infarction (fatal or not) | - Stroke (fatal or not) | - Non-CNS systemic embolism | - Vascular death | |
| Clopidogrel + ASA | 832 | 84 | 285 | 50 | 413 |
| Placebo + ASA | 924 | 105 | 391 | 48 | 380 |
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events included major bleeding, clinically relevant non-major bleeding and minor bleeding. Phase B Adjusted Treatment Period=safety events occurring in the period from first dose through 2 days (or through 30 days for SAE tabulations) after the earliest of last dose date or 1-Oct-2007 (termination date for the 10 mg BID group). (NCT00313300)
Timeframe: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 6.1 |
| Apixaban 2.5mg BID | 15.1 |
| Apixaban 10mg QD | 17.6 |
| Apixaban 10mg BID | 24.2 |
| Apixaban 20 mg QD | 23.9 |
Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events includes major bleeding, clinically relevant non-major bleeding and minor bleeding. Treatment Period refers to the period from first dose through 2 days, or through 30 days for Serious Adverse Event (SAE) tabulations, after discontinuation of study drug. Data in this outcome are combined across Phase A and Phase B. (NCT00313300)
Timeframe: first dose (Day 1) to last dose plus 2 days (or for SAEs, plus 30 days), up to Year 2 of the Study
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 10.5 |
| Apixaban 2.5mg BID | 20.6 |
| Apixaban 10mg QD | 22.5 |
Bleeding was assessed using ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The analyses of Phase B data across all doses of apixaban are secondary because of the premature termination of the apixaban high-dose groups and the lower duration of exposure. Phase B Adjusted Treatment Period=safety events occurring in the period from first dose through 2 days (or through 30 days for SAE tabulations) after the earliest of last dose date or 1-Oct-2007 (termination date for the 10 mg BID group). (NCT00313300)
Timeframe: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.8 |
| Apixaban 2.5mg BID | 5.0 |
| Apixaban 10mg QD | 5.6 |
| Apixaban 10mg BID | 7.8 |
| Apixaban 20 mg QD | 7.3 |
Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The primary outcome is based on data for the placebo and 2 apixaban low-dose groups (2.5 mg BID and 10 mg QD) combined across Phase A and Phase B. The analyses of Phase B data across all doses of apixaban are secondary because of the premature termination of the apixaban high-dose groups (10mg BID, 20mg QD) and the resulting lower duration of exposure for these groups. (NCT00313300)
Timeframe: From first dose of study drug (Day 1) to last dose plus 2 days, up to Year 2 of the Study
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 3.0 |
| Apixaban 2.5mg BID | 5.7 |
| Apixaban 10mg QD | 7.9 |
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated (%). (NCT00313300)
Timeframe: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.0 |
| Apixaban 2.5mg BID | 0.8 |
| Apixaban 10mg QD | 0.0 |
| Apixaban 10mg BID | 2.9 |
| Apixaban 20 mg QD | 4.1 |
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the Clinical Events Committee. Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). (NCT00313300)
Timeframe: from first dose (Day 1) to last dose plus 2 days, up to Year 2 of the Study
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.8 |
| Apixaban 2.5mg BID | 1.6 |
| Apixaban 10mg QD | 1.9 |
Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). Intended Treatment Period refers to the period starting on the day of randomization and ending 182 days after the day of randomization (for a total period duration of 183 days). Data in this outcome are combined across Phase A and Phase B (NCT00313300)
Timeframe: Day of randomization to 182 days after day of randomization (183 days)
| Intervention | participants (Number) |
|---|---|
| Placebo | 54 |
| Apixaban 2.5mg BID | 24 |
| Apixaban 10mg QD | 20 |
Events were adjudicated by the Clinical Events Committee (CEC). Intended Treatment Period refers to the period starting on the day of randomization and ending 182 days after the day of randomization (for a total period duration of 183 days). Data in this outcome are combined across Phase A and Phase B. (NCT00313300)
Timeframe: Randomization to 182 days after randomization (183 days)
| Intervention | participants (Number) |
|---|---|
| Placebo | 53 |
| Apixaban 2.5mg BID | 24 |
| Apixaban 10mg QD | 19 |
Phase B Adjusted Intended Treatment Period=day of randomization and ends on termination date of high dose apixaban, 1-Oct-2007. The analyses of Phase B data across all doses of apixaban are secondary due to the premature termination of the apixaban high dose groups and the lower duration of exposure. (NCT00313300)
Timeframe: Day of randomization and ends on high dose termination date, 1-Oct-2007
| Intervention | participants (Number) |
|---|---|
| Placebo | 16 |
| Apixaban 2.5mg BID | 6 |
| Apixaban 10mg QD | 4 |
| Apixaban 10mg BID | 8 |
| Apixaban 20 mg QD | 7 |
Phase B Adjusted Intended Treatment Period=day of randomization and ends on 1-Oct-2007. The analyses of Phase B data across all doses of apixaban are secondary due to the premature termination of the apixaban high dose groups and the lower duration of exposure. (NCT00313300)
Timeframe: Day of randomization up to high dose termination, 1-Oct-2007
| Intervention | participants (Number) |
|---|---|
| Placebo | 16 |
| Apixaban 2.5mg BID | 6 |
| Apixaban 10mg QD | 4 |
| Apixaban 10mg BID | 8 |
| Apixaban 20 mg QD | 7 |
The number of patients who died due to any cause or had a first occurrence of MI (including repeat MI) or stroke (ischemic, hemorrhagic or unknown) or severe recurrent ischemia requiring revascularization from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 83 |
| Riva 5 mg Total Daily Dose (TDD) | 23 |
| Riva 10 mg TDD | 55 |
| Riva 15 mg TDD | 27 |
| Riva 20 mg TDD | 36 |
The number of patients with the composite endpoint of cardiovascular death or MI or stroke that occurred from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 63 |
| Riva 5 mg Total Daily Dose (TDD) | 18 |
| Riva 10 mg TDD | 40 |
| Riva 15 mg TDD | 21 |
| Riva 20 mg TDD | 21 |
The number of patients who died due to any cause or had a first occurrence of MI (or repeat MI), or stroke, or severe recurrent ischemia requiring revascularization, or TIMI (major or minor bleeding) from the time of randomization to the last date of patient contact to assess the net clinical benefit of rivaroxaban. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 88 |
| Riva 5 mg Total Daily Dose (TDD) | 24 |
| Riva 10 mg TDD | 71 |
| Riva 15 mg TDD | 35 |
| Riva 20 mg TDD | 48 |
The number of patients who died due to any cause or had a first occurrence of MI (or repeat MI) or stroke from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 66 |
| Riva 5 mg Total Daily Dose (TDD) | 18 |
| Riva 10 mg TDD | 40 |
| Riva 15 mg TDD | 21 |
| Riva 20 mg TDD | 22 |
The number of patients who died due to any cause from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 18 |
| Riva 5 mg Total Daily Dose (TDD) | 11 |
| Riva 10 mg TDD | 9 |
| Riva 15 mg TDD | 4 |
| Riva 20 mg TDD | 9 |
The number of patients with a first occurrence of a TIMI clinically significant bleeding event that occurred from the time of randomization to the time of the last patient contact. TIMI clinically significant bleeding events included TIMI minor bleeding events, TIMI major bleeding events, or any bleeding that required medical attention. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 36 |
| Riva 5 mg Total Daily Dose (TDD) | 17 |
| Riva 10 mg TDD | 109 |
| Riva 15 mg TDD | 43 |
| Riva 20 mg TDD | 89 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 4 |
| Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 1 |
| Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
| Intervention | percentage (Number) |
|---|---|
| 75mg Clopidogrel | 94.3 |
| Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
| Intervention | mm (Mean) |
|---|---|
| 75mg Clopidogrel | 4.1 |
| Placebo | 4.5 |
Live birth occurs when a fetus (> 24 weeks ) , exits the maternal body and subsequently shows signs of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord. (NCT01051778)
Timeframe: pregnancy > 24weeks gestation
| Intervention | Percentage of pregnancies (Number) |
|---|---|
| Enoxaparin 40 mg /Day Plus Low Dose Aspirin | 24 |
| Heparin Calcium 5,000 U Twice Daily Plus Low Dose Aspirin | 20 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Apixaban 2.5 mg | 59.7 |
| Apixaban 5 mg | 97.9 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0-12 hours after the dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Apixaban 2.5 mg | 28.2 |
| Apixaban 5mg | 49.7 |
Evaluate the pharmacokinetics of apixaban in ESRD NVAF patients on hemodialysis. The measurement was done from 0 to 12 hours after dose was given on Day 1. (NCT02942407)
Timeframe: 0-12 hours post-dose
| Intervention | ng*h/mL (Geometric Mean) |
|---|---|
| Apixaban 2.5 mg | 507 |
| Apixaban 5mg | 868 |
"Assess the safety of apixaban versus warfarin regarding ISTH major bleeding or clinically relevant non-major bleeding events in patients with NVAF (nonvalvular atrial fibrillation) and ESRD (end-stage renal disease) on hemodialysis.~Major bleeding event is defined as:Acute clinically overt bleeding (including access site related bleeding) accompanied by 1 or more of the following: Decrease in Hgb of 2g/dL or more with overt bleeding; Transfusion of 2 or more units of packed RBCs in the setting of an overt bleeding event; Bleeding within a critical site. Hemorrhagic stroke (primary or infarction with hemorrhagic conversion) were classified as major bleeds.~Non-major bleeding event is defined as: Acute or sub-acute clinically overt bleeding (including access site related bleeding) that does not meet criteria for major bleeding & results in Hospital admission for bleeding, physician guided medical or surgical treatment for bleeding, or change in antithrombotic therapy" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 21 |
| Warfarin | 16 |
Evaluate mortality rates for those participants randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 21 |
| Warfarin | 13 |
"Adjudcated stroke defined as a new, non-traumatic episode of focal or global neurological dysfunction of sudden onset caused by central nervous system (CNS) vascular injury as a result of hemorrhage or infarction and not due to a readily identifiable non-vascular cause (i.e. brain tumor). CNS includes brain, spinal cord and retina. The required duration of the deficit is ≥ 24 hours.~Events with neurologic deficit lasting for < 24 hours and an imaging modality showing evidence of an acute stroke will be counted as stroke as well.~A retinal ischemic event (embolism, infarction) will be considered a stroke" (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 2 |
| Warfarin | 2 |
Number of participants experiencing adjudicated stroke or systemic embolism. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 2 |
| Warfarin | 2 |
"Evaluate those experiencing stroke, systemic embolism, ISTH major bleeding, or all-cause mortality for those randomized to warfarin and apixaban in patients with NVAF and ESRD on hemodialysis~Definitions of stroke and systemic embolism are provided under the measurement description of the secondary outcomes for each individual event. Definition of major bleed is provided in outcome measurement description of the primary outcome measure." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 27 |
| Warfarin | 29 |
"Adjudicated diagnosis of systemic arterial embolism (Non-pulmonary, non-cranial events) will require a positive clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), which is supported by evidence of embolism/thrombosis from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.~Clinical presentation would include:~Abrupt development of pain, absent pulses, pallor, and/or paresis in an extremity (at least an entire digit) without previous severe claudication or findings of severe peripheral vascular disease.~Renal embolism will be diagnosed when sudden flank pain or a change in renal laboratory findings occurred.~Abdominal vascular/visceral embolism was considered definite if acute abdominal symptoms or referred symptoms developed along with a change in abdominal examination or appropriate laboratory values." (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Apixaban | 0 |
| Warfarin | 0 |
Evaluate days between time from initiation to discontinuation of randomized therapy. (NCT02942407)
Timeframe: Randomization up to Month 15/Final Visit
| Intervention | Days (Mean) |
|---|---|
| Apixaban | 304.4 |
| Warfarin | 279.6 |
was there any bleeding occurance during the accessed interval (NCT00515541)
Timeframe: up to and including closeout at 24 weeks
| Intervention | Number of occurance (Number) |
|---|---|
| Group A: Subject on Lovaza Only | 0 |
| Group B: Subject on Lovaza + Aspirin | 1 |
| Group C: Subject on Lovaza + Clopidogrel + Aspirin | 0 |
| Group D: Subject on Lovaza + Warfarin + Aspirin | 0 |
Bleeding time is a measure of how well platelets interact with blood vessel walls to form a clot. A manual blood pressure cuff is placed 2 inches above the antecubital fossa and inflated to 40mmHg. Using a standard Surgicutt device, a small incision is made and a stopwatch is started. The incision edge is blotted at 30 second intervals with standard filter paper until the bleeding has stopped. The time to hemostasis is noted. (NCT00515541)
Timeframe: up to and including closeout at 24 weeks
| Intervention | seconds (Median) | ||||
|---|---|---|---|---|---|
| Baseline (Week 0) | 1 gram Lovaza Daily (Week 6) | 2 grams Lovaza Daily (Week 12) | 4 grams Lovaza Daily (Week 18) | 8 grams Lovaza Daily (Week 24) | |
| Group A: Subject on Lovaza Only | 150 | 240 | 240 | 255 | 255 |
| Group B: Subject on Lovaza + Aspirin | 240 | 345 | 390 | 330 | 360 |
| Group C: Subject on Lovaza + Clopidogrel + Aspirin | 570 | 720 | 690 | 600 | 600 |
| Group D: Subject on Lovaza + Warfarin + Aspirin | 240 | 285 | 285 | 240 | 270 |
Measurements were made using a modified device (EQELS) to specifications of constant current, high electric field and a scattering angle of 30 degrees. EQELS provides a sensitive assessment of subtle changes in the cell surface that occurs with activation, ligand binding or apoptosis. These changes are the result of different distributions of charged groups that define a surface charge finger print for the current state of activation of the cell. Resting state platelets have a negative surface charge, whereas fully activated platelets have a positive surface charge. (NCT00515541)
Timeframe: up to and including closeout at 24 weeks
| Intervention | mobility units (Median) | ||||
|---|---|---|---|---|---|
| Baseline (Week 0) | 1 gram Lovaza Daily (Week 6) | 2 grams Lovaza Daily (Week 12) | 4 grams Lovaza Daily (Week 18) | 8 grams Lovaza Daily (Week 24) | |
| Group A: Subject on Lovaza Only | 0.28 | -0.45 | -0.95 | -1.08 | -0.88 |
| Group B: Subject on Lovaza + Aspirin | -0.04 | -0.72 | -1.30 | -0.94 | -0.97 |
| Group C: Subject on Lovaza + Clopidogrel + Aspirin | -1.04 | -0.73 | -1.29 | -1.14 | -0.89 |
| Group D: Subject on Lovaza + Warfarin + Aspirin | -1.10 | -0.50 | -0.58 | -0.44 | -0.19 |
The PAP-8E measures platelet aggregation in platelet rich plasma (PRP). Platelet responses to a series of common agonists cause changes in optical density that are measured. The instrument is blanked (100% baseline (optimal transmission)) by inserting a platelet poor plasma (PPP) specimen into the appropriate channel. The PRP is then inserted into the same well. The difference in optical density between the PPP and the PRP 0% baseline (optical transmission) is recorded for several minutes when the agonist reagent is added to the PRP. (NCT00515541)
Timeframe: up to and including closeout at 24 weeks
| Intervention | percent (Median) | ||||
|---|---|---|---|---|---|
| Baseline (Week 0) | 1 gram Lovaza Daily (Week 6) | 2 grams Lovaza Daily (Week 12) | 4 grams Lovaza Daily (Week 18) | 8 grams Lovaza Daily (Week 24) | |
| Group A: Subject on Lovaza Only | 79.5 | 79.5 | 87.5 | 82 | 83 |
| Group B: Subject on Lovaza + Aspirin | 0 | 3 | 2.5 | 0 | 3 |
| Group C: Subject on Lovaza + Clopidogrel + Aspirin | 5.5 | 6.5 | 6 | 4 | 5 |
| Group D: Subject on Lovaza + Warfarin + Aspirin | 8 | 9 | 12 | 10 | 22 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to endothelial function. (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 14.06 |
| Placebo Follow up | 13.84 |
| Aspirin Baseline | 11.18 |
| Aspirin Randomization | 12.11 |
| Clopidogrel Baseline | 13.06 |
| Clopidogrel Randomization | 12.29 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to immune activity (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 15.53 |
| Placebo Follow up | 15.43 |
| Aspirin Baseline | 13.15 |
| Aspirin Follow up | 14.96 |
| Clopidogrel Baseline | 16.03 |
| Clopidogrel Follow up | 14.85 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to inflammation (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
(NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
The primary objective of these analyses will be to compare the effects of aspirin versus control and clopidogrel versus control for the outcome of platelet activity. Aspirin is expected to decrease arachidonic acid-induced platelet aggregation by 50% versus control. Clopidogrel is expected to decrease ADP-induced platelet aggregation by 50% versus control. (NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 72.35 |
| Placebo Follow up | 79.11 |
| Aspirin Baseline | 72.79 |
| Aspirin Randomization | 26.77 |
| Clopidogrel Baseline | 71.07 |
| Clopidogrel Randomization | 65.00 |
The time, in years, from randomization to the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years. Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until the date of the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to 6 years
| Intervention | events per 100 patient-years (Number) |
|---|---|
| Aspirin | 7.93 |
| Warfarin | 7.47 |
Time, in years, from randomization to death component of secondary composite outcome. This measure counts only deaths that were not preceded by heart failure hospitalization, myocardial infarction, ischemic stroke, or intracerebral hemorrhage. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of death component of secondary composite outcome, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 4.41 |
| Warfarin | 4.43 |
Time, in years, from date of randomization to date of heart failure hospitalization, up to 6 years. Includes hospitalizations for heart failure during follow-up that were not preceded by myocardial infarction. Event rate per 100 patient years = 100*(number of subjects with heart failure hospitalization)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of heart failure hospitalization component of secondary composite outcome, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 5.67 |
| Warfarin | 6.79 |
Time, in years, from date of randomization to date of intracerebral hemorrhage component of secondary composite outcome. Includes only intracerebral hemorrhages not preceded by myocardial infarction or heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of intracerebral hemorrhage component of secondary composite outcome, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 0.06 |
| Warfarin | 0.11 |
Ischemic stroke component of secondary composite endpoint. Includes only ischemic strokes that were not preceded by a myocardial infarction or heart failure hospitalization. The number of ischemic strokes that are components of the secondary outcome does not therefore match the number of ischemic strokes that are components of the primary outcome. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of ischemic stroke component of secondary composite outcome, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 1.14 |
| Warfarin | 0.57 |
Time, in years, from date of randomization to date of myocardial infarction, up to 6 years. Includes only myocardial infarctions that occurred during follow-up, before any heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with myocardial infarction)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of myocardial infarction component of secondary composite outcome, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 0.87 |
| Warfarin | 0.80 |
"The time, in years, from date of randomization to the date of the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to 6 years.~Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25." (NCT00041938)
Timeframe: From randomization to the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years.
| Intervention | events per 100 patient-years (Number) |
|---|---|
| Aspirin | 12.15 |
| Warfarin | 12.70 |
Time, in years, from date of randomization to date of death component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of death component of primary composite outcome, up to 6 years
| Intervention | events per 100 patient-years (Number) |
|---|---|
| Aspirin | 6.52 |
| Warfarin | 6.63 |
Time, in years, from date of randomization to date of intracerebral hemorrhage component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of intracerebral hemorrhage component of primary composite outcome, up to 6 years
| Intervention | rate per 100 patient years (Number) |
|---|---|
| Aspirin | 0.05 |
| Warfarin | 0.12 |
Time, in years, from date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years
| Intervention | rate per 100 patient years (Number) |
|---|---|
| Aspirin | 1.36 |
| Warfarin | 0.72 |
Rate/100 patient-years of major hemorrhage. Includes all major hemorrhages in any patient. Major hemorrhage was defined as intracerebral, epidural, subdural, subarachnoid, spinal intramedullary, or retinal hemorrhage; any other bleeding causing a decline in the hemoglobin level of more than 2 g per deciliter in 48 hours; or bleeding requiring transfusion of 2 or more units of whole blood, hospitalization, or surgical intervention. Event rate per 100 patient years = 100*(number of major hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until end of scheduled follow-up, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 0.87 |
| Warfarin | 1.78 |
Rate per 100 patient years of minor hemorrhage. Includes all minor hemorrhages. Minor hemorrhage was defined as any non-major hemorrhage. Event rate per 100 patient years = 100*(number of minor hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until the end of scheduled follow-up, up to 6 years
| Intervention | events per 100 patient-years (Number) |
|---|---|
| Aspirin | 7.34 |
| Warfarin | 11.6 |
Postoperative hemorrhage is defined as any history of bleeding occurring within the 14 day postoperative period. Hemorrhage will be stratified into 3 levels of severity. Level 1: includes children with a history of postoperative bleeding evaluated and/or treated by a physician in the emergency room, inpatient unit or operating room; Level 2: children requiring inpatient admission for postoperative bleeding regardless of the need for operative intervention; Level 3: children requiring inpatient admission and return to the operating room for control of post-tonsillectomy hemorrhage. (NCT01605903)
Timeframe: Data about post-tonsillectomy bleeding will be obtained after the end of a 14-day postoperative period.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment With Ibuprofen | 10 |
| Treatment With Acetaminophen | 4 |
Revascularization included any arterial revascularization procedure, whether surgical or percutaneous, but excluded revascularization performed for hemodialysis vascular access (e.g. fistuloplasty) or to the donor kidney transplant artery. Revascularization included amputations for vascular disease (rather than for trauma or infection). All potential revascularization events (including angiography) were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 284 |
| Placebo | 352 |
End-stage renal disease was defined as initiation of maintenance dialysis or renal transplantation. Temporary dialysis was excluded. All potential dialysis and transplant events were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 1057 |
| Placebo | 1084 |
Major atherosclerotic events defined as non-fatal myocardial infarction or coronary death, non-hemorrhagic stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 526 |
| Placebo | 619 |
Major coronary events defined as coronary death or non-fatal myocardial infarction. Myocardial infarction adjudicated based on the presence of serial changes in cardiac biomarkers (e.g. troponin, creatine kinase), typical ECG changes and typical cardiac symptoms. If myocardial infarction was fatal and post-mortem examination findings were available, this information was also assessed. All potential coronary events were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 213 |
| Placebo | 230 |
Major vascular events defined as non-fatal myocardial infarction or cardiac death, any stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 701 |
| Placebo | 814 |
Major vascular events defined as non-fatal myocardial infarction or cardiac death, any stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 639 |
| Placebo | 749 |
Stroke was defined as rapid onset of focal or global neurological deficit, with duration greater than 24 hours. Clinical notes and brain imaging were sought to determine the stroke etiology, and if the stroke was fatal and post-mortem examination findings were available, this information was also assessed. All potential stroke events (including transient ischemic attack and intracerebral hemorrhage) were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 131 |
| Placebo | 174 |
"The primary effectiveness endpoint was a composite of the two following outcomes:~Stroke in the same territory (distal to the target lesion) as the presenting event within 12 months of randomization~Hard Transient Ischemic Attack (TIA) in the same territory (distal to the target lesion) as the presenting event from day 2 through month 12 post-randomization~A subject was deemed to be a primary endpoint success if neither of these outcomes occurred.~The Kaplan-Meier success rate at 12-months post-operatively was calculated with Kaplan-Meier time-to-event methodology, where the time variable for patients who were successful (no stroke within 12 months or hard TIA between 2 days and 12 months) was censored at the time of last follow-up, and the time variable for patients who were not successful (had a stroke within 12 months or hard TIA between 2 days and 12 months) was censored at the time of the first event (stroke with 12 months or hard TIA between 2 days and 12 months)." (NCT00816166)
Timeframe: One Year
| Intervention | percent probability (Number) |
|---|---|
| Stent Group | 62.24 |
| Medical Therapy Group | 83.68 |
"Any stroke or neurological death at NCT00929383)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 12 |
The cumulative stroke rate at 12 months (any stroke or neurological death /= 31 days is 15.9% or 13 events per 82 patients (NCT00929383)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 13 |
The rate of recurrent ischemic stroke from 31 days to 12 months post procedure was 1.3% or 1 event per 77 patients analyzed. (NCT00929383)
Timeframe: 12 Months
| Intervention | participants (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 1 |
"The rate of restenosis at 12 months was defined as the degree of residual stenosis greater than 50% as determined by the study sites using the WASID method. There was a 10.4% rate of restenosis >50% or 8 patients out of 77 analyzed. The differences in this analysis population N=77 vs. ITT N= 82 populations results from exclusion of N=4 patients with no stent implanted and N=1 patient who died prior to any follow up measures of restenosis.~The WASID method is a standardized protocol for measuring intracranial arterial stenosis.~[1-(Dstenosis/Dnormal)] x100=% stenosis (where D=vessel diameter)" (NCT00929383)
Timeframe: 12 Months
| Intervention | participants (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 8 |
The number of Wingspan Stents successfully deployed across the target lesion. (NCT00929383)
Timeframe: Peri-procedural
| Intervention | patients w stent implanted (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 78 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | participants (Number) | |
|---|---|---|
| Total invasive cancer | Cancer death | |
| Aspirin + Vitamin E | 716 | 152 |
| Aspirin Only | 722 | 132 |
| Both Placebos | 706 | 143 |
| Vitamin E Only | 721 | 156 |
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Major cardiovascular event | Stroke | Myocardial infarction | Cardiovascular death | |
| Aspirin + Vitamin E | 232 | 108 | 102 | 54 |
| Aspirin Only | 245 | 113 | 96 | 66 |
| Both Placebos | 272 | 133 | 99 | 74 |
| Vitamin E Only | 250 | 133 | 94 | 52 |
(NCT03951649)
Timeframe: 7 days
| Intervention | days (Median) |
|---|---|
| Occipital Nerve Block | 6 |
| Oral Acetaminophen/Caffeine Group | 1 |
(NCT03951649)
Timeframe: 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 9 |
| Oral Acetaminophen/Caffeine Group | 4 |
(NCT03951649)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 7 |
| Oral Acetaminophen/Caffeine Group | 2 |
Other: Pain at injection site (NCT03951649)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 0 |
| Oral Acetaminophen/Caffeine Group | 2 |
(NCT03951649)
Timeframe: 7 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 0 |
| Oral Acetaminophen/Caffeine Group | 0 |
(NCT03951649)
Timeframe: 4 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 9 |
| Oral Acetaminophen/Caffeine Group | 14 |
(NCT03951649)
Timeframe: 5 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 4 |
| Oral Acetaminophen/Caffeine Group | 2 |
Emergency department for treatment of headache since treatment asked at 28 day follow up (NCT03951649)
Timeframe: 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 5 |
| Oral Acetaminophen/Caffeine Group | 1 |
(NCT03951649)
Timeframe: 120 min
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 5 |
| Oral Acetaminophen/Caffeine Group | 5 |
Based on guidelines from the International Headache Society the primary outcome is the portion of women who experience resolution of headache or improvement of headache to mild range (VRS ≤ 3) at 2 hours following treatment with Occipital nerve block as compared to acetaminophen/caffeine cocktail. (NCT03951649)
Timeframe: 60-300 min
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 20 |
| Oral Acetaminophen/Caffeine Group | 16 |
"Visual/verbal Rating Score (VRS). VRS is used to assess pain in patients. With 0 representing no pain at all and 10 representing worst possible pain.~Total Minimum score=0 Total Maximum score=10~Higher values represent worse pain. If VRS=0, then the headache pain is considered resolved." (NCT03951649)
Timeframe: 60 min
| Intervention | score on a scale (Median) |
|---|---|
| Occipital Nerve Block | 6 |
| Oral Acetaminophen/Caffeine Group | 3 |
"Visual/verbal Rating Score (VRS). VRS is used to assess pain in patients. With 0 representing no pain at all and 10 representing worst possible pain.~Total Minimum score=0 Total Maximum score=10~Higher values represent worse pain. If VRS=0, then the headache pain is considered resolved." (NCT03951649)
Timeframe: 180min
| Intervention | score on a scale (Median) |
|---|---|
| Occipital Nerve Block | 6 |
| Oral Acetaminophen/Caffeine Group | 4 |
"Visual/verbal Rating Score (VRS). VRS is used to assess pain in patients. With 0 representing no pain at all and 10 representing worst possible pain.~Total Minimum score=0 Total Maximum score=10~Higher values represent worse pain. If VRS=0, then the headache pain is considered resolved." (NCT03951649)
Timeframe: 2 hrs
| Intervention | score on a scale (Median) |
|---|---|
| Occipital Nerve Block | 6.0 |
| Oral Acetaminophen/Caffeine Group | 6.5 |
The primary endpoint was the detection of intracardiac thrombus in TEE at the end of follow-up (90 days). (NCT01868243)
Timeframe: 90 days
| Intervention | participants (Number) |
|---|---|
| Dabigatran | 0 |
| Warfarin | 1 |
Spontaneous Echo Contrast showed in Transesophageal echocardiography (NCT01868243)
Timeframe: 90 days
| Intervention | participants (Number) |
|---|---|
| Dabigatran | 2 |
| Warfarin | 1 |
"Change in coagulation factor levels from baseline to after the end of infusion using the Hodges-Lehmann Estimator for median differences: o Factor II~The Hodges-Lehmann Estimator is a method of robust estimation. This estimator is used to give an estimate of the difference between the values in two sets of data. If the two sets of data contain m and n data points respectively, m × n pairs of points (one from each set) can be formed and each pair gives a difference of values. The Hodges-Lehmann estimator for the difference is defined as the median of the m × n differences." (NCT02740335)
Timeframe: 30 minutes after the end of infusion
| Intervention | mg/dL (Mean) |
|---|---|
| Octaplex | 49.5 |
| Beriplex P/N (Kcentra) | 51.0 |
"Change in coagulation factor levels from baseline to after the end of infusion using the Hodges-Lehmann Estimator for median differences: o Factor II Factor IX~The Hodges-Lehmann Estimator is a method of robust estimation. This estimator is used to give an estimate of the difference between the values in two sets of data. If the two sets of data contain m and n data points respectively, m × n pairs of points (one from each set) can be formed and each pair gives a difference of values. The Hodges-Lehmann estimator for the difference is defined as the median of the m × n differences." (NCT02740335)
Timeframe: 30 minutes after the end of infusion
| Intervention | m/dL (Mean) |
|---|---|
| Octaplex | 33.0 |
| Beriplex P/N (Kcentra) | 31.5 |
"Change in coagulation factor levels from baseline to after the end of infusion using the Hodges-Lehmann Estimator for median differences: o Factor VII~The Hodges-Lehmann Estimator is a method of robust estimation. This estimator is used to give an estimate of the difference between the values in two sets of data. If the two sets of data contain m and n data points respectively, m × n pairs of points (one from each set) can be formed and each pair gives a difference of values. The Hodges-Lehmann estimator for the difference is defined as the median of the m × n differences." (NCT02740335)
Timeframe: 30 minutes after the end of infusion
| Intervention | mg/dL (Mean) |
|---|---|
| Octaplex | 35.0 |
| Beriplex P/N (Kcentra) | 23.0 |
"Change in coagulation factor levels from baseline to after the end of infusion using the Hodges-Lehmann Estimator for median differences: o Factor X~The Hodges-Lehmann Estimator is a method of robust estimation. This estimator is used to give an estimate of the difference between the values in two sets of data. If the two sets of data contain m and n data points respectively, m × n pairs of points (one from each set) can be formed and each pair gives a difference of values. The Hodges-Lehmann estimator for the difference is defined as the median of the m × n differences." (NCT02740335)
Timeframe: 30 minutes after the end of infusion
| Intervention | mg/dL (Mean) |
|---|---|
| Octaplex | 50.0 |
| Beriplex P/N (Kcentra) | 63.0 |
To demostrate clinical non-inferiority of treatment with Octaplex to treatment with Beriplex P/N (Kcentra) with respect to hemostatic success. Effective hemostatis includes Excellent and Good ratings, while Ineffective hemostasis includes Moderate, None and missing ratings from Global hemostatic efficacy observed by IEAB (NCT02740335)
Timeframe: At the end of surgery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Effective | Ineffective | |
| Beriplex P/N (Kcentra) | 97 | 6 |
| Octaplex | 99 | 6 |
Hemostatic Efficacy rated by the Independent Endpoint Adjudication Committee based on a 1 to 4 point hemostatic efficacy scale, taking into account blood loss and transfusion requirements in the context of the surgery. Hemostatic efficacy was assessed based on objective criteria in the categories 'excellent', 'good', 'moderate', or 'none'. Ratings of 'excellent' and 'good' were considered as 'effective' hemostasis, while ratings of 'moderate' and 'none' were considered as 'ineffective' hemostasis. (NCT02740335)
Timeframe: At the end of the surgery
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Excellent - 4 | Good - 3 | Moderate - 2 | None - 1 | Effective | Ineffective | |
| Beriplex P/N (Kcentra) | 50 | 47 | 6 | 0 | 97 | 6 |
| Octaplex | 41 | 58 | 6 | 0 | 99 | 6 |
Number of patients with an international normalized ratio (INR) value of less or equal to 1.5 at 30 min (± 15 min) after the end of infusion. (NCT02740335)
Timeframe: 30 minutes after the end of infusion
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| <=1.5 | > 1.5 | Missing | |
| Beriplex P/N (Kcentra) | 74 | 29 | 0 |
| Octaplex | 82 | 23 | 0 |
548 reviews available for aspirin and Bleeding
| Article | Year |
|---|---|
Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Diabetic Cardiomyop | 2021 |
Efficacy and Safety of Aspirin for Primary Cardiovascular Risk Prevention in Younger and Older Age: An Updated Systematic Review and Meta-analysis of 173,810 Subjects from 21 Randomized Studies.
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Heart Disease Risk Factors; Hemorrhage; Humans; Morta | 2022 |
Comparison between use of direct oral anticoagulants and aspirin for risk of thromboembolism complications in patients undergoing total knee and hip arthroplasty: a systematic review and meta-analysis.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Factor Xa Inhibitors | 2021 |
Antiplatelet Monotherapy Is Associated with an Increased Risk of Bleeding After Endoscopic Sphincterotomy.
Topics: Adult; Aspirin; Cholangiopancreatography, Endoscopic Retrograde; Hemorrhage; Humans; Platelet Aggreg | 2022 |
Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attack: An overview of systematic reviews and meta-analysis.
Topics: Aspirin; Brain Ischemia; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu | 2021 |
Antiplatelet therapy in cardiovascular disease: Current status and future directions.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet | 2022 |
Risk of colonoscopic post-polypectomy bleeding in patients on single antiplatelet therapy: systematic review with meta-analysis.
Topics: Aspirin; Colonic Polyps; Colonoscopy; Hemorrhage; Humans; Intestinal Polyps; Platelet Aggregation In | 2022 |
A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Drug Therapy, Combination; Europe; Female; Hemorrhage; Hum | 2022 |
Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making.
Topics: Aspirin; Canada; Clinical Decision-Making; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhag | 2022 |
What is the optimal management of thromboprophylaxis after liver transplantation regarding prevention of bleeding, hepatic artery, or portal vein thrombosis? A systematic review of the literature and expert panel recommendations.
Topics: Anticoagulants; Aspirin; Hemorrhage; Hepatic Artery; Humans; Liver Diseases; Liver Transplantation; | 2022 |
Editor's Choice - Peri-Operative Outcomes of Carotid Endarterectomy are Not Improved on Dual Antiplatelet Therapy vs. Aspirin Monotherapy: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Carotid Stenosis; Endarterectomy, Carotid; Hematoma; Hemorrhage; Hemorrhagi | 2022 |
Low-Molecular-Weight Heparin Versus Aspirin in Early Management of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Aspirin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Ischemic Stroke | 2022 |
Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention.
Topics: Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percutaneous Coronary Interven | 2022 |
Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and network meta-analysis.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Hemorrhage; Humans; Network Meta-Analysis; Percutaneo | 2022 |
Duration and kind of dual antiplatelet therapy for acute coronary syndrome patients: a network meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Middle Aged; Myocardial Infarctio | 2023 |
Clopidogrel Vs Aspirin Monotherapy Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.
Topics: Aspirin; Clopidogrel; Death; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; P | 2023 |
High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Dyspnea; Hemorrhage; Humans | 2022 |
Ticagrelor for patients undergoing coronary artery bypass grafting: A meta-analysis of randomized controlled trials.
Topics: Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Hemorrhage; Humans; Platelet Aggregation | 2023 |
Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement.
Topics: Adult; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Computer Simulation; Hemorrhage; Huma | 2022 |
Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Hemorrhage; Humans; Primary Prevention; Rand | 2022 |
Clopidogrel Monotherapy versus Aspirin Monotherapy in Patients with Established Cardiovascular Disease: Systematic Review and Meta-Analysis.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platel | 2022 |
Comparison of Aspirin and P2Y
Topics: Aspirin; Brain Ischemia; Hemorrhage; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Secon | 2023 |
Does aspirin have an effect on risk of death in patients with COVID-19? A meta-analysis.
Topics: Aspirin; COVID-19 Drug Treatment; Critical Illness; Hemorrhage; Humans; Pandemics | 2022 |
P2Y12 Inhibitors versus Aspirin Monotherapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Disease Events: A Systematic Review and Meta-analysis.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Infarction; Percut | 2022 |
Antiplatelet agents and anticoagulants for hypertension.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; M | 2022 |
Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure After Coronary Artery Bypass Graft Surgery: A Systematic Review and Meta-analysis.
Topics: Aged; Aspirin; Coronary Artery Bypass; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; | 2022 |
Apixaban for Anticoagulation After Robotic Mitral Valve Repair.
Topics: Aftercare; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Hemorrhage; Humans; Male; Middle Ag | 2023 |
Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials.
Topics: Aspirin; Cilostazol; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic S | 2022 |
Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
Topics: Adult; Anticoagulants; Arthroscopy; Aspirin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Huma | 2022 |
Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis.
Topics: Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Network Meta-Analysis; Peripheral Art | 2022 |
Antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack.
Topics: Anticoagulants; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Factor XI; Fibrinolyt | 2022 |
[Aspirin in primary cardiovascular prevention - a 2022 update].
Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Primary | 2022 |
Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Stroke; Platelet Aggre | 2022 |
Risks and benefits of continuation and discontinuation of aspirin in elective craniotomies: a systematic review and pooled-analysis.
Topics: Aspirin; Craniotomy; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prospective Studies; Risk | 2023 |
Anticoagulation alone as an effective and safe antithrombotic therapy in LVAD: When less is more.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Warfarin | 2023 |
Anticoagulation alone as an effective and safe antithrombotic therapy in LVAD: When less is more.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Warfarin | 2023 |
Anticoagulation alone as an effective and safe antithrombotic therapy in LVAD: When less is more.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Warfarin | 2023 |
Anticoagulation alone as an effective and safe antithrombotic therapy in LVAD: When less is more.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Warfarin | 2023 |
Anticoagulation alone as an effective and safe antithrombotic therapy in LVAD: When less is more.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Warfarin | 2023 |
Anticoagulation alone as an effective and safe antithrombotic therapy in LVAD: When less is more.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Warfarin | 2023 |
Anticoagulation alone as an effective and safe antithrombotic therapy in LVAD: When less is more.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Warfarin | 2023 |
Anticoagulation alone as an effective and safe antithrombotic therapy in LVAD: When less is more.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Warfarin | 2023 |
Anticoagulation alone as an effective and safe antithrombotic therapy in LVAD: When less is more.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Warfarin | 2023 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
P2Y
Topics: Aspirin; Bayes Theorem; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneo | 2022 |
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregatio | 2023 |
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregatio | 2023 |
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregatio | 2023 |
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregatio | 2023 |
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregatio | 2023 |
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregatio | 2023 |
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregatio | 2023 |
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregatio | 2023 |
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregatio | 2023 |
Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications.
Topics: Aspirin; Atherosclerosis; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibi | 2023 |
Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications.
Topics: Aspirin; Atherosclerosis; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibi | 2023 |
Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications.
Topics: Aspirin; Atherosclerosis; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibi | 2023 |
Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications.
Topics: Aspirin; Atherosclerosis; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibi | 2023 |
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis.
Topics: Aspirin; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Agg | 2023 |
Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?
Topics: Aspirin; Blood Platelets; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prostaglandin-Endoper | 2023 |
Thromboprophylaxis in Patients With Fontan Circulation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Fontan Procedure; Hemorrhage; Hu | 2023 |
Acetylsalicylic Acid (Aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Hemorrhage; Humans; Myocardial Infarction; Prim | 2023 |
Dual Antiplatelet Therapy Does Not Increase Bleeding Risk in Percutaneous Gastrostomy Tube Placement: Network Meta-Analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Gastrostomy; Hemorrhage; Humans; Network Meta-Analy | 2023 |
P2Y
Topics: Aspirin; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percutaneous Cor | 2023 |
Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis.
Topics: Aspirin; Atherosclerosis; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combina | 2023 |
Effects of Aspirin on Kidney Biopsy Bleeding Complications: A Systematic Review and Meta-Analysis (PROSPERO 2021 CRD42021261005).
Topics: Aspirin; Biopsy; Hemorrhage; Humans; Kidney | 2023 |
Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines.
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack | 2023 |
Efficacy and Safety of Ticagrelor versus Aspirin and Clopidogrel for Stroke Prevention in Patients with Vascular Disease: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhages; Ische | 2023 |
Comparison of De-escalation of DAPT Intensity or Duration in East Asian and Western Patients with ACS Undergoing PCI: A Systematic Review and Meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemia; Percutan | 2023 |
Antiplatelet therapy for coronary artery disease in 2023: current status and future prospects.
Topics: Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Per | 2023 |
Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; East Asian People; Hemorrhage; Humans; Myocardial Inf | 2023 |
Fixed dose combination therapies in primary cardiovascular disease prevention in different groups: an individual participant meta-analysis.
Topics: Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Hemorrhage; Huma | 2023 |
Personalized Dual Antiplatelet Therapy in Acute Coronary Syndromes: Striking a Balance Between Bleeding and Thrombosis.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Corona | 2023 |
Personalised antiplatelet therapies for coronary artery disease: what the future holds.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Hemorrhage; Humans; Myocardial Infarction | 2023 |
P2Y
Topics: Aspirin; Coronary Artery Disease; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary I | 2023 |
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Thrombosis; Hemorrhage; Humans; Percutaneous Coronary Int | 2023 |
Antithrombotic treatment following percutaneous coronary intervention in patients with high bleeding risk.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Huma | 2023 |
Pharmacological interventions for asymptomatic carotid stenosis.
Topics: Aspirin; Atherosclerosis; Atorvastatin; Carotid Stenosis; Chlorthalidone; Fluvastatin; Hemorrhage; H | 2023 |
Ticagrelor plus aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Isc | 2023 |
Dual antiplatelet management in the perioperative period: updated and expanded systematic review.
Topics: Adult; Aspirin; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibit | 2023 |
The efficacy and safety of aspirin in preventing venous thrombosis in major orthopedic surgery: An updated meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Aspirin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Orthopedic Procedures; P | 2023 |
Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Bayes Theorem; Clopidogrel; Fibrinolytic Agents; H | 2023 |
Tailoring antiplatelet therapy in older patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Dual Ant | 2023 |
Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip Replacement: A Systematic Review and Network Meta-Analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Bayes Theorem; Cost-Benefit Analysis; Elect | 2019 |
Aspirin and Primary Prevention in Patients with Diabetes-A Critical Evaluation of Available Randomized Trials and Meta-Analyses.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Diabetes Complications; D | 2019 |
Aspirin in primary prevention of cardiovascular disease in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascul | 2020 |
The role of aspirin as antiaggregant therapy in primary prevention. An update.
Topics: Aspirin; Cardiovascular Diseases; Clinical Decision-Making; Hemorrhage; Humans; Platelet Aggregation | 2019 |
Aspirin for prevention of venous thromboembolism in recipients of major lower-limb orthopedic surgery: a systematic review of Level I evidence.
Topics: Anticoagulants; Aspirin; Evidence-Based Medicine; Hemorrhage; Humans; Lower Extremity; Orthopedic Pr | 2019 |
Aspirin Use for Primary Prevention of Cardiovascular Disease in Older Patients: A Review of Clinical Guidelines and Updated Evidence.
Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention; Risk Factors | 2019 |
A Meta-Analysis Comparing Aspirin Alone Versus Dual Antiplatelet Therapy for the Prevention of Venous Graft Failure Following Coronary Artery Bypass Surgery.
Topics: Aged; Aspirin; Bayes Theorem; Coronary Artery Bypass; Coronary Artery Disease; Dual Anti-Platelet Th | 2020 |
Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Aspirin; Enoxaparin; Female; Hemorrhage; Humans; Pregnancy; Pregnancy Complications; | 2020 |
Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint.
Topics: Aspirin; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention | 2020 |
Omitting aspirin in PCI patients: Myth or reality?
Topics: Aspirin; Clinical Decision-Making; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; H | 2019 |
Is there a cardiovascular protective effect of aspirin in chronic kidney disease patients? A systematic review and meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Renal Insuffi | 2020 |
Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug | 2020 |
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc | 2019 |
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc | 2019 |
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc | 2019 |
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc | 2019 |
Aspirin Therapy for Primary Prevention: The Case for Continuing Prescribing to Patients at High Cardiovascular Risk-A Review.
Topics: Aged; Aspirin; Cardiology; Cardiovascular Diseases; Cardiovascular System; Diabetes Complications; H | 2020 |
Direct Oral Anticoagulants and Coronary Artery Disease: The Debacle of the Aspirin Era?
Topics: Administration, Oral; Animals; Aspirin; Blood Coagulation; Coronary Artery Disease; Coronary Thrombo | 2020 |
Aspirin for primary cardiovascular prevention: why the wonder drug should not be precipitously dismissed.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Meta-Analysis as To | 2020 |
[Aspirin for primary cardiovascular prevention : the end of an era ?]
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention; Risk Assessment | 2020 |
[Short dual antiplatelet therapy: how, when and why].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Dual Anti-Platelet Therapy; H | 2020 |
Double or Triple Antithrombotic Treatment in Atrial Fibrillation Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Percut | 2021 |
Meta-Analysis Comparing P2Y
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Graft Occlusion, Vascular; Hemorrhage | 2020 |
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Age | 2020 |
[Current antiplatelet agents, new inhibitors and therapeutic targets].
Topics: Aspirin; Blood Coagulation; Blood Platelets; Cardiovascular Diseases; Hemorrhage; Humans; Molecular | 2020 |
Perioperative management of antiplatelet therapy in noncardiac surgery.
Topics: Aspirin; Elective Surgical Procedures; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation | 2020 |
Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
Topics: Adult; Anticoagulants; Arthroscopy; Aspirin; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecula | 2020 |
Monotherapy with a P2Y
Topics: Aged; Aspirin; Atherosclerosis; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Female; He | 2020 |
Complexity of Antiplatelet Therapy in Coronary Artery Disease Patients.
Topics: Aspirin; Coronary Artery Disease; Hemorrhage; Humans; Multiple Chronic Conditions; Platelet Aggregat | 2021 |
The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Cost | 2020 |
Role of Aspirin for Primary Prevention in Persons with Diabetes Mellitus and in the Elderly.
Topics: Aged; Aspirin; Cardiovascular Diseases; Case-Control Studies; Diabetes Complications; Diabetes Melli | 2020 |
Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses.
Topics: Abruptio Placentae; Aspirin; Female; Fetal Growth Retardation; Hemorrhage; Humans; Hypertension, Pre | 2020 |
Very short dual antiplatelet therapy after PCI and new DES: a meta-analysis of 5 randomized trials.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Percutaneo | 2021 |
Dual versus mono antiplatelet therapy for acute non- cardio embolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis - updated meta-analysis.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; | 2020 |
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percu | 2020 |
Is There Still a Role for Aspirin in Primary Prevention in Women in 2020?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; | 2020 |
Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atherosclerosis; Dose-Response Relationship, Drug; | 2020 |
An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Disease; Diabetes Complications; Drug Therapy, Co | 2020 |
Aspirin: Bitter pill or miracle drug?
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Female; Hemorrhage; Humans; Male; Platel | 2020 |
Aspirin and low-dose rivaroxaban - the dual pathway concept in patients with stable atherosclerotic disease: a comprehensive review.
Topics: Aspirin; Atherosclerosis; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Humans; Perip | 2020 |
Toward Brief Dual Antiplatelet Therapy and P2Y12 Inhibitors for Monotherapy After PCI.
Topics: Aspirin; Drug Administration Schedule; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percutaneous | 2021 |
Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials.
Topics: Acute Coronary Syndrome; Aspirin; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percutaneous Coron | 2021 |
An Update on Venous Thromboembolism Rates and Prophylaxis in Hip and Knee Arthroplasty in 2020.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fibrinolytic Agents; Hemor | 2020 |
Aspirin after Acute Ischemic Stroke.
Topics: Aspirin; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Stroke; Mortality; Odds Ratio; Plate | 2020 |
Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans | 2020 |
The Role of Aspirin After High-Risk Percutaneous Coronary Intervention: The Ticagrelor with Aspirin or Alone in High-Risk Patients After Coronary Intervention Clinical Trial Experience.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; H | 2020 |
Aspirin in primary prevention. Meta-analysis stratified by baseline cardiovascular risk.
Topics: Aspirin; Cardiovascular Diseases; Heart Disease Risk Factors; Hemorrhage; Humans; Ischemic Stroke; M | 2020 |
Optimizing Monotherapy Selection, Aspirin Versus P2Y12 Inhibitors, Following Percutaneous Coronary Intervention.
Topics: Algorithms; Aspirin; Dual Anti-Platelet Therapy; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneo | 2020 |
Antiplatelet Therapy for Transient Ischemic Attack and Minor Stroke.
Topics: Aspirin; Clopidogrel; Drug Resistance; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemic Atta | 2020 |
2020 International Consensus on First Aid Science With Treatment Recommendations.
Topics: Aspirin; Bandages; Emergency Medical Services; First Aid; Glucose; Heat Stroke; Hemorrhage; Humans; | 2020 |
Current Studies of Aspirin as an Anticancer Agent and Strategies to Strengthen its Therapeutic Application in Cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Hemorrhage; Humans; Neoplas | 2021 |
The 2020 breakthroughs in early secondary prevention: dual antiplatelet therapy versus single antiplatelet therapy.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Early Medical Intervention; Hemorrh | 2021 |
Risk Factors for Bleeding and Clinical Ineffectiveness Associated With Clopidogrel Therapy: A Comprehensive Meta-Analysis.
Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Dual Anti-Platelet Therapy; Hemorrhage; Huma | 2021 |
Aspirin in Primary Prevention: What Changed? A Critical Appraisal of Current Evidence.
Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Evidence-Based Medicine; Heart Disease Ri | 2021 |
Does aspirin prevent venous thromboembolism?
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Hemorrhage; Humans; Male; Venous Thromboembolis | 2020 |
Aspirin Therapy in Cardiovascular Disease with Glucose-6-Phosphate Dehydrogenase Deficiency, Safe or Not?
Topics: Aspirin; Cardiovascular Diseases; Glucosephosphate Dehydrogenase Deficiency; Hemoglobins; Hemolysis; | 2021 |
Low molecular weight heparin and aspirin for prevention of deep vein thrombosisafter orthopaedic surgery: a systematic review and meta-analysis.
Topics: Anticoagulants; Aspirin; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Orthopedic Proc | 2021 |
Antithrombotic therapy after transcatheter aortic valve replacement: current perspective.
Topics: Aortic Valve; Aortic Valve Stenosis; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggr | 2021 |
Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Coronary Restenosis; Dual Anti-Platelet Therapy; Duration of Therapy; Hemorrhage; Humans; P | 2021 |
Pharmacological Interventions for the Prevention of Fetal Growth Restriction: A Systematic Review and Network Meta-Analysis.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Fetal Growth Retardation; Hemorrhage; He | 2021 |
Meta-Analysis Comparing the Safety and Efficacy of Single vs Dual Antiplatelet Therapy in Post Transcatheter Aortic Valve Implantation Patients.
Topics: Aortic Valve Stenosis; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemi | 2021 |
Aspirin in people with dementia, long-term benefits, and harms: a systematic review.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardio | 2021 |
Aspirin Alone Versus Dual Antiplatelet Therapy after Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis.
Topics: Aortic Valve; Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Huma | 2022 |
Aspirin Versus Dual Antiplatelet Therapy in Patients Undergoing Trans-Catheter Aortic Valve Implantation, Updated Meta-Analysis.
Topics: Aortic Valve; Aspirin; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Platelet Aggregation Inhibito | 2022 |
Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies.
Topics: Adolescent; Adult; Aspirin; Calreticulin; Disease-Free Survival; Erythrocyte Transfusion; Female; Fo | 2021 |
Aspirin to prevent pre-eclampsia.
Topics: Aspirin; Drug Administration Schedule; Female; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2021 |
The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Aspirin; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemia; Lower Extremity; Periph | 2021 |
Interventions for preventing thrombosis in solid organ transplant recipients.
Topics: Anticoagulants; Aspirin; Bias; Dipyridamole; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hum | 2021 |
Usefulness of Antiplatelet Therapy After Transcatheter Aortic Valve Implantation.
Topics: Aortic Valve Stenosis; Aspirin; Cause of Death; Clopidogrel; Dual Anti-Platelet Therapy; Endothelium | 2021 |
Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: A meta-analysis.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage | 2021 |
Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack: Meta-Analysis of Randomized Controlled Trials.
Topics: Aspirin; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggreg | 2021 |
Ticagrelor vs Clopidogrel in addition to Aspirin in minor ischemic stroke/ transient ischemic attack-Protocol for a systematic review and network meta-analysis.
Topics: Aspirin; Bayes Theorem; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Dual Anti-Platelet T | 2021 |
Anticoagulation versus placebo for heart failure in sinus rhythm.
Topics: Administration, Oral; Anticoagulants; Aspirin; Cardiomyopathy, Dilated; Chronic Disease; Heart Failu | 2021 |
No Significant Difference in Post-ERCP Bleeding Rates Between Dual Antiplatelet Agents and Aspirin Alone: A Systematic Review and Meta-analysis.
Topics: Aspirin; Cholangiopancreatography, Endoscopic Retrograde; Drug Therapy, Combination; Hemorrhage; Hum | 2022 |
P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack.
Topics: Aspirin; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemic Attack, Transient; Purinergic P2Y | 2021 |
Meta-Analysis of Duration of Dual Antiplatelet Therapy in Acute Coronary Syndrome Treated With Coronary Stenting.
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Drug-Eluting Stents; Dual Anti-Platelet Therapy; D | 2021 |
Thrombotic Events and Anticoagulants in Beta-thalassemia Patients with Focus on Anticoagulants for Atrial Fibrillation: A Brief Review.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; beta-Thalassemia; Hemorrhage; Hu | 2022 |
Meta-Analysis of Usefulness of Antiplatelet Therapy in Ischemic Stroke or Transient Ischemic Attack.
Topics: Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Early Medical Intervention; Hemorrhage; Humans; Is | 2021 |
Meta-Analysis of Short vs. Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation and Role of Continuation with either Aspirin or a P2Y
Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarction; | 2022 |
P2Y12 receptor inhibitor plus aspirin versus aspirin treated within 24 hours of acute noncardioembolic ischemic stroke or TIA: Meta-analysis.
Topics: Aspirin; Cerebral Infarction; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhage | 2022 |
Aspirin for the primary prevention of cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.
Topics: Adult; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention; Renal Insufficiency | 2022 |
Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease.
Topics: Aged; Aspirin; Clopidogrel; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; L | 2021 |
Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2017 |
Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials.
Topics: Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Intracranial Hemorrhages; Myocardial Infarction; P | 2017 |
Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2017 |
Dual Antiplatelet Therapy Continuation Beyond 1 Year After Drug-Eluting Stents: A Meta-Analysis of Randomized Trials.
Topics: Aged; Aspirin; Bayes Theorem; Chi-Square Distribution; Coronary Disease; Coronary Thrombosis; Drug A | 2017 |
Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty.
Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Aspirin; Dabigatran; Hemorrhage; Hepa | 2017 |
[Management of the bleeding risk associated with antiplatelet agents].
Topics: Adenosine; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans | 2017 |
Antiplatelet Therapy, Platelet Function Testing, and Bleeding Complications in Cardiac Surgery Patients.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Hemorrhage; Humans; Platelet Aggregation Inhi | 2017 |
Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk.
Topics: Aspirin; Cardiology; Cardiovascular Agents; Cardiovascular Diseases; Hemorrhage; Humans; Patient Sel | 2017 |
Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Drug Therapy, Combination; H | 2017 |
Updates in venous thromboembolism management: evidence published in 2016.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Factor Xa | 2017 |
The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis.
Topics: Anticoagulants; Aspirin; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Dabigatran; Dipyridamo | 2017 |
Dual Antiplatelet Therapy Beyond One Year in Patients After Stent Placement: A Review.
Topics: Aspirin; Clinical Trials as Topic; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Factors | 2018 |
Perioperative Venous Thromboembolism: A Review.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductas | 2017 |
Triple Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: a Fading Role.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Meta-Analysis | 2017 |
[Antiplatelet agents and transfusion].
Topics: Adenosine; Antidotes; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Pla | 2017 |
[Impact of different antithrombotic therapy strategy on prognosis in coronary heart disease patients combining with atrial fibrillation: a meta analysis].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Fibrinolytic Agents; He | 2017 |
Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis.
Topics: Anticoagulants; Aspirin; Databases, Factual; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Join | 2017 |
Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: A comparison between the DAPT study and 9 other trials evaluating DAPT duration.
Topics: Aspirin; Cardiovascular Diseases; Databases, Factual; Drug-Eluting Stents; Hemorrhage; Humans; Myoca | 2017 |
Thirty days only double antiplatelet therapy after drug-eluting stenting: could a 'short-term' treatment be advantageous?
Topics: Aspirin; Clinical Decision-Making; Coronary Artery Disease; Coronary Thrombosis; Drug Administration | 2018 |
The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Disease; Fibrinolytic Agents; Hemorrhage; Humans; | 2018 |
Prolonged Dual Antiplatelet Therapy After MI Reduces Major Adverse Cardiac Events.
Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Hemorrhage; Humans; Mortality; Myocardi | 2017 |
The Benefits and Risks of Oral Antiplatelet Therapy in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Cardiology; Evidence-Based M | 2017 |
Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Drug Interact | 2018 |
The role of prasugrel in the management of acute coronary syndromes: a systematic review.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2017 |
Dual antiplatelet therapy after percutaneous coronary intervention for stable CAD or ACS : Redefining the optimal duration of treatment.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; D | 2018 |
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platel | 2017 |
Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Aspirin; Hemorrhage; Humans; Myocardial Infarction; Randomized | 2017 |
Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage.
Topics: Abruptio Placentae; Aspirin; Female; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Pre-Eclamp | 2018 |
Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis.
Topics: Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy, Combination; Female; He | 2018 |
Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach.
Topics: Aspirin; Atrial Fibrillation; Hemorrhage; Humans; Myocardial Ischemia; Platelet Aggregation Inhibito | 2018 |
A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Embolism; Glomerular | 2019 |
Venous Thromboembolism Prophylaxis after Total Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Chemoprevention; Early Ambulation; Hemorrh | 2018 |
Comparison of single versus dual antiplatelet therapy after TAVR: A systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2018 |
Perioperative aspirin therapy in non-cardiac surgery: A systematic review and meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Mortality; Perioperative Care; Platelet Aggreg | 2018 |
Rivaroxaban plus aspirin, compared with aspirin alone, reduced cardiovascular events in patients with stable peripheral or carotid artery disease, but increased the risk of major bleeding.
Topics: Aspirin; Carotid Artery Diseases; Double-Blind Method; Hemorrhage; Humans; Rivaroxaban | 2018 |
Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders.
Topics: Aspirin; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; P-Selectin; Platelet Aggreg | 2018 |
Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; DNA; Drug Therapy, Combination; Facto | 2018 |
Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Intracranial Hemorrhages; | 2018 |
Efficacy and safety of triple therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing coronary stenting: A meta-analysis.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Combinations; Drug-Related Side Effects and Adverse | 2018 |
Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non-cardiac surgery.
Topics: Adult; Aspirin; Cause of Death; Clopidogrel; Elective Surgical Procedures; Hemorrhage; Humans; Ische | 2018 |
Meta-analysis of efficacy and safety of dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass grafting.
Topics: Aged; Aspirin; Coronary Artery Bypass; Coronary Thrombosis; Dual Anti-Platelet Therapy; Female; Graf | 2019 |
Dual versus single antiplatelet therapy after coronary artery bypass graft surgery: An updated meta-analysis.
Topics: Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Hum | 2018 |
Antithrombotic strategies after interventional left atrial appendage closure: an update.
Topics: Anticoagulants; Antifibrinolytic Agents; Aspirin; Atrial Appendage; Atrial Fibrillation; Embolism; H | 2018 |
Dual versus triple therapy in patients on oral anticoagulants and undergoing coronary stent implantation: A systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; D | 2018 |
Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation: The Triple Trouble.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Thrombosis; Drug Therapy, Combination; Drug-E | 2018 |
Antithrombotic therapy management of adult and pediatric cardiac surgery patients.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Blood Coagulation; Cardiac Surgical Procedures; Cardiolo | 2018 |
Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: a jump with a weak parachute?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Decision-Making; Clopidogrel; Evidence-Based | 2019 |
Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Combined Modality Therapy; Coron | 2019 |
Triple therapy: worth the risk?
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Factor Xa Inhibitor | 2018 |
Update on extended treatment for venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Hemorrhage; Humans; | 2018 |
Harms and Benefits of Using Aspirin for Primary Prevention of Cardiovascular Disease: A Narrative Overview.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Neoplasms; Platelet Aggregation Inhibitors; Pr | 2019 |
Single versus Dual Antiplatelet Therapy after Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis.
Topics: Aortic Valve; Aspirin; Cerebrovascular Disorders; Clopidogrel; Drug Therapy, Combination; Heart Valv | 2018 |
[Bleeding risk in patients with acute coronary syndromes treated with antiplatelet agents: incidence, prognosis and clinical evaluation. From research to clinical practice].
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Incidence; Platelet | 2018 |
Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemor | 2019 |
Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack | 2018 |
Novel Oral Anticoagulants in Peripheral Artery Disease: Current Evidence.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Hemorrhage; Humans; | 2018 |
Short-term versus long-term triple antithrombotic therapy for patients with coronary stents and requiring oral anticoagulation: a meta-analysis of randomized clinical trials.
Topics: Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; He | 2019 |
Omission of aspirin in patients taking oral anticoagulation after percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Age Factors; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Coronary Artery Disease; Dru | 2019 |
Antithrombotic Therapy After Transcatheter Aortic Valve Replacement.
Topics: Anticoagulants; Aortic Valve Stenosis; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Ther | 2019 |
Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Female; Hemorrhage; Hum | 2019 |
Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseases; Drug Therapy, Combination; Factor | 2019 |
Antithrombotic Agents.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clinical Trials a | 2019 |
Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy.
Topics: Aged; Anticoagulants; Aspirin; Atherosclerosis; Cardiology; Cardiovascular Diseases; Carotid Arterie | 2019 |
Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials.
Topics: Anticoagulants; Aspirin; Canada; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Rea | 2019 |
Role of Platelet Transfusion in the Reversal of Anti-Platelet Therapy.
Topics: Aspirin; Blood Loss, Surgical; Blood Platelets; Cyclooxygenase Inhibitors; Hemorrhage; Hemostasis; H | 2019 |
Impact of acetylsalicylic acid on primary prevention of cardiovascular diseases: A meta-analysis of randomized trials.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention; Pro | 2019 |
Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Coagulation; Female; Hemorrhage; Heparin, Low-M | 2019 |
Development of New Antithrombotic Regimens for Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrino | 2019 |
Effects of Ultra-Low-Dose Aspirin in Thrombosis and Haemorrhage.
Topics: Animals; Aspirin; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Hemorrhage; Homeopathy; Human | 2019 |
Early Secondary Prevention in Transient Ischemic Attack (TIA) and Minor Stroke.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Pla | 2019 |
Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.
Topics: Anticoagulants; Aspirin; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Ne | 2019 |
Clinical Outcomes of Antithrombotic Strategies for Patients with Atrial Fibrillation After Percutaneous Coronary Intervention.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Observational St | 2019 |
A Meta-Analysis of Aspirin for the Primary Prevention of Cardiovascular Diseases in the Context of Contemporary Preventive Strategies.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Intracranial Hemorrhages; Platelet Aggregation | 2019 |
Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; | 2019 |
Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; | 2019 |
Aspirin for Primary Prevention of Cardiovascular Disease.
Topics: Aspirin; Atherosclerosis; Cardiovascular Agents; Cause of Death; Evidence-Based Medicine; Hemorrhage | 2019 |
Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Dabigatran; Glycosaminoglycans; Hemorrhage; Hum | 2020 |
Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Cerebral Revascularization; Clopidogrel; Cytochro | 2019 |
Aspirin for primary prevention of cardiovascular disease: is it time to move on?
Topics: Adult; Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Hemorrhage; Humans; Middle Aged; Pla | 2019 |
Role of rivaroxaban in the prevention of atherosclerotic events.
Topics: Animals; Aspirin; Atherosclerosis; Cardiovascular Diseases; Drug Therapy, Combination; Factor Xa Inh | 2019 |
Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Decision-Making; Hemorrhage; Human | 2019 |
An aspirin a day? Clinical utility of aspirin therapy for the primary prevention of cardiovascular disease.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Hemorrhage; Humans; Practice Guide | 2019 |
Total Thrombus-Formation Analysis System (T-TAS): Clinical Application of Quantitative Analysis of Thrombus Formation in Cardiovascular Disease.
Topics: Anticoagulants; Area Under Curve; Aspirin; Blood Platelets; Cardiovascular Diseases; Catheter Ablati | 2019 |
Rivaroxaban versus Aspirin in Prevention of Venous Thromboembolism: A Meta-Analysis of 9 Randomized Controlled Trials comprising 7,656 Patients.
Topics: Administration, Oral; Anticoagulants; Aspirin; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage | 2019 |
Aspirin for the primary prevention of cardiovascular disease: latest evidence.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Decision Making; Hemorrhage; Humans; Hydroxymethy | 2019 |
Aspirin and recurrent venous thromboembolism.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Patient Selection; Risk Assessment | 2013 |
[Treatment of essential thrombocythemia].
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progress | 2013 |
Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?
Topics: Aspirin; Cardiology; Cardiovascular Agents; Cardiovascular Diseases; Diabetes Mellitus; Evidence-Bas | 2014 |
Antiplatelet therapy for preventing stroke in patients with chronic kidney disease.
Topics: Aspirin; Cerebrovascular Circulation; Cohort Studies; Endothelium, Vascular; Female; Hemorrhage; Hum | 2013 |
Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?
Topics: Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase 2; Epide | 2013 |
Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
Topics: Anticoagulants; Aspirin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Platelet Aggregation Inh | 2013 |
Medical management after coronary stent implantation: a review.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet | 2013 |
Antiplatelet and anticoagulation for patients with prosthetic heart valves.
Topics: Administration, Oral; Anticoagulants; Aspirin; Dipyridamole; Drug Therapy, Combination; Heart Valve | 2013 |
The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review.
Topics: Aspirin; Bleeding Time; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggreg | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpr | 2013 |
Complications of prostate biopsy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bacterial Infections; Biopsy; Ciprofloxacin; Drug | 2013 |
Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Hemorrhage; Humans; Ischemi | 2013 |
Perioperative management of antiplatelet therapy in patients with a coronary stent who need noncardiac surgery: a systematic review of clinical practice guidelines.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Elective Surgical Procedures; Hemorrhage; Humans; Met | 2013 |
[The most important aspects of risk assessment].
Topics: Algorithms; Aspirin; Cardiovascular Diseases; Clopidogrel; Digestive System Surgical Procedures; Dru | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; | 2013 |
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; | 2013 |
The ankle-brachial index for peripheral artery disease screening and cardiovascular disease prediction among asymptomatic adults: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Adult; Ankle Brachial Index; Aspirin; Asymptomatic Diseases; Cardiovascular Diseases; Fibrinolytic A | 2013 |
Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Hemorrhage; Humans | 2014 |
[Thrombocyte aggregation inhibitors: what are the risks?].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Interactions | 2013 |
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Fibrinolytic Agent | 2013 |
Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Hemorrhage; Humans; Mal | 2013 |
Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Hemorrhage; Humans; Lupus Erythema | 2014 |
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Hemorrhage; H | 2013 |
Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Drug Interactions; Drug Therapy, Combination; Hem | 2014 |
[Differentiated antiplatelet therapy for acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrh | 2014 |
[Upstream administration of oral antiplatelet agents in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention].
Topics: Administration, Oral; Aspirin; Coronary Angiography; Hemorrhage; Humans; Myocardial Infarction; Perc | 2014 |
Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials.
Topics: Aspirin; Cerebrovascular Disorders; Chi-Square Distribution; Coronary Thrombosis; Drug Administratio | 2015 |
Optimal aspirin dose in acute coronary syndromes: an emerging consensus.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Hemorrhage; Humans; M | 2014 |
Antiplatelet and anticoagulative medication during shockwave lithotripsy.
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Contraindications; Disease Susceptibility; Hemorrh | 2014 |
Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: a systematic review and meta-analysis.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fema | 2014 |
Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Risk; Safety; Strok | 2014 |
Decade in review--acute coronary syndromes: Successes and future objectives in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Hemorrhage; Humans; My | 2014 |
Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2014 |
Dual versus single antiplatelet therapy in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Myocardial Infarc | 2015 |
Resistance to antiplatelet drugs: what progress has been made?
Topics: Aspirin; Clopidogrel; Graft Occlusion, Vascular; Hemorrhage; Humans; Percutaneous Coronary Intervent | 2014 |
[Added value of clopidogrel in cardiology and neurology].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2014 |
Antiplatelet therapy after drug-eluting stent implantation.
Topics: Aspirin; Drug Administration Schedule; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Ischemia; | 2015 |
Use of antiplatelet drugs after cardiac operations.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Administration Schedule; Drug Therapy, Combinatio | 2014 |
Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Pla | 2015 |
[Managing antithrombotic therapy in vitreoretinal surgery].
Topics: Anesthesia, Local; Anticoagulants; Aspirin; Blood Coagulation; Eye Diseases; Fibrinolytic Agents; He | 2015 |
Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Hemorr | 2015 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine | 2014 |
Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Female; Hemorrhage; Humans; Male; Mi | 2015 |
Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention.
Topics: Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; H | 2015 |
Antithrombotic therapy in a patient with mild haemophilia A and atrial fibrillation: case report and brief review of the literature.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Aspirin; Atrial Fibrillation; Disease Management; Dronedar | 2015 |
P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggre | 2015 |
Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials.
Topics: Aspirin; Combined Modality Therapy; Coronary Artery Disease; Drug Administration Schedule; Drug Ther | 2015 |
Does aspirin reduce recurrence after completing anticoagulant treatment for an idiopathic thromboembolic event?
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled | 2015 |
Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Pressur | 2015 |
Antiplatelet therapy following transcatheter aortic valve implantation.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Cardiac Catheteriz | 2015 |
Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents: Meta-Analysis of Randomized Trials.
Topics: Aspirin; Confidence Intervals; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting | 2015 |
Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation.
Topics: Age Factors; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Como | 2015 |
PPI versus Histamine H2 Receptor Antagonists for Prevention of Upper Gastrointestinal Injury Associated with Low-Dose Aspirin: Systematic Review and Meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Gastrointestinal Diseases; Hemo | 2015 |
Role of aspirin for prevention and treatment of perioperative cardiovascular events.
Topics: Animals; Aspirin; Cardiovascular Agents; Drug Administration Schedule; Hemorrhage; Humans; Myocardia | 2015 |
Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
Topics: Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation; Pl | 2015 |
Clopidogrel and Aspirin versus Aspirin Alone for Stroke Prevention: A Meta-Analysis.
Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Stroke; Ticlopidine | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials.
Topics: Aspirin; Clinical Trials as Topic; Databases, Factual; Drug-Eluting Stents; Hemorrhage; Humans; Myoc | 2015 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary | 2015 |
Bleeding versus thrombosis: role of short DAPT in complex lesions.
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans | 2015 |
Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Half-Life; Hemorrhage; Humans; L | 2015 |
Retroperitoneal haematoma associated with enoxaparin use in an elderly woman with chronic kidney disease.
Topics: Aged, 80 and over; Anticoagulants; Aspirin; Enoxaparin; Erythrocyte Transfusion; Female; Hematoma; H | 2015 |
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Diabetes Mellitu | 2015 |
Part 9: First Aid: 2015 International Consensus on First Aid Science With Treatment Recommendations.
Topics: Airway Management; Aspirin; Asthma; Cardiopulmonary Resuscitation; Chest Pain; Emergencies; Emergenc | 2015 |
Part 15: First Aid: 2015 American Heart Association and American Red Cross Guidelines Update for First Aid.
Topics: Anaphylaxis; Aspirin; Burns; Chest Pain; Dehydration; Emergency Medical Services; Epinephrine; First | 2015 |
Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study.
Topics: Algorithms; Anticoagulants; Aspirin; Brain Ischemia; Calibration; Cerebral Hemorrhage; Dipyridamole; | 2016 |
Emergency Reversal Strategies for Anticoagulation and Platelet Disorders.
Topics: Animals; Anticoagulants; Aspirin; Blood Platelets; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; | 2015 |
Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Aspirin; Data Collection; Drug Administration Schedule; Female; Hemorrhage; Humans; | 2015 |
[Acetylsalicylic acid for the prevention of primary myocardial infarction and ischemic stroke].
Topics: Aspirin; Chemoprevention; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 2015 |
Evolving strategies to prevent stroke and thromboembolism in nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Dabigatran; Equipment and Supplies; | 2015 |
Risk of major bleeding in patients receiving vitamin K antagonists or low doses of aspirin. A systematic review and meta-analysis.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Intracranial Hemorrhages; Odds Rat | 2016 |
[Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack].
Topics: Aspirin; Clopidogrel; Databases, Factual; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic At | 2015 |
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage | 2016 |
Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Topics: Aspirin; Cilostazol; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2016 |
Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Assoc
Topics: Advisory Committees; American Heart Association; Aspirin; Cardiology; Coronary Artery Disease; Drug | 2016 |
Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Percu | 2016 |
Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force.
Topics: Adult; Aspirin; Cardiovascular Diseases; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Hemorrhag | 2016 |
Stroke Prevention in Atrial Fibrillation in Patients With Chronic Kidney Disease.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Creatinine; Diabetes C | 2016 |
What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation?
Topics: Aspirin; Clopidogrel; Drug Administration Schedule; Drug-Eluting Stents; Hemorrhage; Humans; Percuta | 2016 |
Safety and Use of Anticoagulation After Aortic Valve Replacement With Bioprostheses: A Meta-Analysis.
Topics: Anticoagulants; Aortic Valve; Aspirin; Bioprosthesis; Drug Administration Schedule; Heart Valve Dise | 2016 |
Aspirin as Thromboprophylaxis in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fibrinolytic Agents; Hemor | 2016 |
Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Female; Hem | 2016 |
Dual antiplatelet therapy after coronary stenting.
Topics: Aspirin; Drug-Eluting Stents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggre | 2016 |
Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis.
Topics: Adult; Aspirin; Blood Pressure; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as T | 2016 |
Aspirin use for primary prevention in elderly patients.
Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregat | 2016 |
Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of randomized controlled trials.
Topics: Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; H | 2016 |
[Dual antiplatelet therapy for treatment and secondary prevention of coronary artery disease: indications, modalities and duration].
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregatio | 2016 |
[Bleeding in patients receiving dual antiplatelet therapy after acute coronary syndrome - significance, prevention and interdisciplinary management].
Topics: Acute Coronary Syndrome; Aspirin; Evidence-Based Medicine; Hemorrhage; Humans; Patient Care Team; Pl | 2016 |
Short- versus standard-term dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: A meta-analysis.
Topics: Aged; Aspirin; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarc | 2017 |
Clinical outcomes associated with per-operative discontinuation of aspirin in patients with coronary artery disease: A systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiac Surgical Procedures; Chi-Square Distribution; Coronary Art | 2017 |
Prasugrel hydrochloride for the treatment of acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Hu | 2016 |
Management of idiopathic venous thromboembolism.
Topics: Anticoagulants; Aspirin; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Hemorrhage; Hu | 2016 |
Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy; Fibrinolytic Agents; He | 2016 |
Efficacy and safety of aspirin combined with warfarin after acute coronary syndrome : A meta-analysis.
Topics: Acute Coronary Syndrome; Adult; Aged; Anticoagulants; Aspirin; Causality; Comorbidity; Dose-Response | 2017 |
A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease.
Topics: Adenosine; Antithrombins; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; | 2016 |
Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly.
Topics: Adenine; Aged; Aspirin; Diarrhea; Hemorrhage; Humans; Lymphoma, Mantle-Cell; Male; Neoplasm Staging; | 2016 |
Anticoagulation for stroke prevention in elderly patients with non-valvular atrial fibrillation: what are the obstacles?
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Hemorrhage; Humans; Risk Assessment | 2016 |
Meta-analysis of major bleeding events on aspirin versus vitamin K antagonists in randomized trials.
Topics: Aspirin; Global Health; Hemorrhage; Humans; Incidence; Platelet Aggregation Inhibitors; Randomized C | 2017 |
The aspirin story - from willow to wonder drug.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antipyretics; Aspirin; Cardiovascular Diseases; Drug Discov | 2017 |
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopid | 2017 |
Duration of dual antiplatelet therapy in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Coronary Thrombosis; Drug Administration Schedule | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; H | 2017 |
Dual antiplatelet therapy with clopidogrel and aspirin.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Contraindications; Coronary Artery Bypass; Hemorrhage | 2008 |
Rational thromboprophylaxis in medical inpatients: not quite there yet.
Topics: Anticoagulants; Aspirin; Australia; Clinical Trials as Topic; Cost-Benefit Analysis; Evidence-Based | 2008 |
[Acquired platelet function disorders: pathogenesis, classification, frequency, diagnosis, clinical management].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelet Disorders; Blood Platelets; Coronar | 2008 |
Prasugrel development - claims and achievements.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascu | 2009 |
Monitoring platelet function to reduce the risk of ischemic and bleeding complications.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Hemo | 2009 |
Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Evidence-Based Me | 2009 |
Does timing matter? Upstream or downstream administration of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Algorithms; Aspirin; Clopidogrel; Coronary Angiography; Drug Administration | 2009 |
Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?
Topics: Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dipyridamole; Drug Com | 2009 |
Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clinical Trials as Topic; | 2009 |
Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Platel | 2009 |
[Drug-eluting stents: implications for modern coronary revascularization].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Bias; Clopidogrel; Comorbidity; Coronary Artery Bypass; Cor | 2009 |
Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Drug | 2008 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Humans; M | 2009 |
Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Hemorrhage; H | 2009 |
Antiplatelet therapy discontinuation following drug-eluting stent placement: dangers, reasons, and management recommendations.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Co | 2009 |
Platelet function testing and implications for clinical practice.
Topics: Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Hemorrhage; Hemostasis; Humans; Ischemia; Pl | 2009 |
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Restenosis | 2009 |
[Long-term use of oral antiplatelet therapy: from studies to practice].
Topics: Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Combinations; Fibrinolytic | 2010 |
Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Chronic Disease; Hemorrhage; Humans; Platele | 2009 |
Antiphospholipid antibody syndrome.
Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Blood Transfus | 2009 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. III. therapeutic application of clopidogrel as monotherapy (without acetylsalicylic acid)].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platel | 2009 |
Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management.
Topics: Anticoagulants; Antithrombins; Aspirin; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Heparin; Hepa | 2010 |
Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Hem | 2010 |
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase III as Topi | 2010 |
Prolonged infusion of eptifibatide as bridge therapy between bare-metal stent insertion and cardiovascular surgery: case report and review of the literature.
Topics: Angioplasty; Anticoagulants; Aspirin; Cardiovascular Surgical Procedures; Clopidogrel; Coronary Arte | 2010 |
Dosing strategies for antiplatelet therapy in percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedu | 2010 |
Safety evaluation of tirofiban.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 2010 |
[Reduction of haemorrhagic risk in acute coronary syndromes].
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Huma | 2011 |
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopido | 2010 |
[Acetylsalicylic acid in the primary and secondary prevention of vascular disease].
Topics: Aspirin; Cerebral Hemorrhage; Germany; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregati | 2010 |
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Hemorrhage; H | 2010 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular D | 2010 |
Is there an association between low dose aspirin and anemia (without overt bleeding)? Narrative review.
Topics: Age Factors; Anemia; Animals; Aspirin; Erythrocyte Indices; Hemorrhage; Humans; Narration; Randomize | 2010 |
[Thrombolysis during cardio-pulmonary resuscitation].
Topics: Aspirin; Cardiopulmonary Resuscitation; Contraindications; Death, Sudden, Cardiac; Fibrinolytic Agen | 2010 |
[New aspects on "triple therapy" after coronary stent implantation].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; | 2010 |
[Generation mechanisms and management strategies of adverse reactions to Bevacizumab during cancer treatment].
Topics: Angiogenesis Inhibitors; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Monoclonal; Antibodie | 2010 |
[Antithrombotic therapy in patients with prosthetic heart valves].
Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Drug Monitoring; Heart Valve Diseases | 2010 |
Platelet function testing in clinical diagnostics.
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Hemorrhage; Humans; Intracranial Embolism; Intracranial T | 2011 |
[New approaches and indications for the analysis of platelet function in cardiology].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombos | 2011 |
Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fib | 2011 |
Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Dose-Response Relationship, Drug; Hemorrha | 2011 |
Antiplatelet therapy in the perioperative period.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; H | 2011 |
Antiplatelet agents in cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2011 |
Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Diabetes Complications; Evidence-Based Medi | 2011 |
Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Headache; Hemorrhage; Humans; Ischemi | 2011 |
Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials.
Topics: Aspirin; Cardiovascular Diseases; Global Health; Hemorrhage; Humans; Morbidity; Platelet Aggregation | 2011 |
Transrectal ultrasound-guided prostate biopsies in patients taking aspirin for cardiovascular disease: A meta-analysis.
Topics: Aspirin; Biopsy; Cardiovascular Diseases; Hematuria; Hemorrhage; Hemospermia; Humans; Male; Platelet | 2011 |
Antiplatelet options for secondary prevention in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hum | 2011 |
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; | 2011 |
Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Coagulation; Confidence Intervals; Evidence- | 2012 |
Mechanisms of platelet activation in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Animals; Aspirin; Blood Platelets; Drug Design; Drug Therapy, Combination; | 2012 |
Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar | 2012 |
What do you do with the antiplatelet agents in patients with drug eluting stents who then receive a mechanical valve?
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Benchmarking | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome.
Topics: Aspirin; Blood Platelets; Cardiac Surgical Procedures; Cardiovascular Diseases; Hemorrhage; Humans; | 2012 |
Optimal thromboprophylaxis following bioprosthetic aortic valve replacement: still a matter of debate?
Topics: Anticoagulants; Aortic Valve; Aspirin; Bioprosthesis; Evidence-Based Medicine; Fibrinolytic Agents; | 2012 |
Balancing the risk and benefits of low-dose aspirin in clinical practice.
Topics: Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Gastrointestinal Hemorrhage; Hemorrhage; Hum | 2012 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogr | 2012 |
Platelet-neutrophil interactions as a target for prevention and treatment of transfusion-related acute lung injury.
Topics: Acute Lung Injury; Animals; Aspirin; Blood Platelets; Blood Transfusion; Drug Delivery Systems; Hemo | 2012 |
[Antiplatelet therapy after coronary stenting and its importance in total joint arthroplasty].
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2012 |
Clinical use of aspirin in ischemic heart disease: past, present and future.
Topics: Animals; Aspirin; Blood Platelets; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Hemorrhage; History, | 2012 |
Development and clinical use of prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Hem | 2012 |
Pharmacogenetics of the antiplatelet effect of aspirin.
Topics: Animals; Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Drug Resistance; Genotype; Hemorrhage; | 2012 |
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug | 2012 |
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazole | 2012 |
Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary A | 2012 |
Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials.
Topics: Adult; Aged; Aspirin; Cause of Death; Cerebral Hemorrhage; Clopidogrel; Data Interpretation, Statist | 2012 |
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil | 2012 |
Advances in monitoring of aspirin therapy.
Topics: Aspirin; Blood Platelets; Dose-Response Relationship, Drug; Drug Administration Schedule; Hemorrhage | 2012 |
The aspirin controversy in primary prevention.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Meta-Analysis as Topic; Myocardial Infarction; | 2012 |
Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Coronary Art | 2012 |
Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Hemorr | 2012 |
Aspirin for primary prevention of cardiovascular disease events.
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Evidence-Based Medicine; Female; Hemorr | 2012 |
[Aspirin for secondary prevention of venous thromboembolism. WARFASA: far from being conclusive].
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Pulmonary Embolism; Randomized Controlled Trials as Top | 2013 |
Clopidogrel, aspirin and proton pump inhibition after percutaneous valve implants: an update.
Topics: Aspirin; Clopidogrel; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; Platelet Aggregation | 2013 |
Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biomarkers; Echocardiography; Female; Fibrinolyt | 2013 |
State of the art--a journey through the world of antithrombotic therapy.
Topics: Ambulatory Care; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Coronary Disease; Fibrinolytic A | 2002 |
Bleeding risks of antithrombotic therapy.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; R | 2002 |
Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Hemor | 2002 |
[Coronary thrombolysis with urokinase and t-PA--comparison of intracoronary thrombolysis and intravenous coronary thrombolysis].
Topics: Anticoagulants; Aspirin; Coronary Vessels; Drug Therapy, Combination; Hemorrhage; Heparin; Humans; I | 1994 |
[Aspirin for primary prevention of asymptomatic atherosclerosis].
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Mid | 2002 |
[Antiaggregation: aspirin].
Topics: Administration, Oral; Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Di | 2003 |
Oral anticoagulants in patients with coronary artery disease.
Topics: Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Int | 2003 |
Low-dose aspirin in the primary prevention of cardiovascular disease: how to balance the benefits and the risks.
Topics: Angina, Unstable; Aspirin; Coronary Disease; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Ri | 2003 |
Prevention of vascular events in patients with atrial fibrillation: evidence, guidelines, and practice.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Contraindications; Controlled Cl | 2003 |
[Which antithrombotic treatment should be used in the treatment of an elderly patient with chronic atrial fibrillation?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibril | 2003 |
The role of clopidogrel in the management of acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; C | 2003 |
Continuation of medically necessary aspirin and warfarin during cutaneous surgery.
Topics: Anticoagulants; Aspirin; Dermatologic Surgical Procedures; Hemorrhage; Humans; Intraoperative Compli | 2003 |
Duration of venous thromboembolism prophylaxis after surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Drug Admin | 2003 |
A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients.
Topics: Analgesics; Antidepressive Agents; Antiviral Agents; Aspirin; Depressive Disorder; Drug Interactions | 2003 |
Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemor | 2004 |
Should aspirin be continued in patients started on warfarin?
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Randomi | 2004 |
Clinical inquiries. Does combining aspirin and warfarin decrease the risk of stroke for patients with nonvalvular atrial fibrillation?
Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Drug Therapy, C | 2004 |
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Bl | 2004 |
Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Hemorrhage; Humans; | 2004 |
Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Delayed-Action Preparations; Diarrhea; Dipyridamole; Dr | 2004 |
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.
Topics: Aged; Aspirin; Hemorrhage; Humans; Hydroxyurea; Middle Aged; Polycythemia Vera; Risk Factors; Thromb | 2005 |
Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials.
Topics: Aspirin; Drug Administration Schedule; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomiz | 2005 |
Risk of hemorrhagic stroke with aspirin use: an update.
Topics: Adult; Aged; Aged, 80 and over; Angiography; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain | 2005 |
Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit.
Topics: Acute Disease; Anticoagulants; Aspirin; Coronary Disease; Female; Fibrinolytic Agents; Hemorrhage; H | 2005 |
[Treatment of essential thrombocythemia].
Topics: Aspirin; Enzyme Inhibitors; Hemorrhage; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; | 2005 |
Antiplatelet therapy in anticoagulated patients requiring coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hem | 2005 |
New anticoagulants in ischemic heart disease.
Topics: Anticoagulants; Aspirin; Azetidines; Benzylamines; Cerebral Hemorrhage; Coronary Thrombosis; Drug Th | 2005 |
Anticoagulation plus aspirin following acute myocardial infarction: yes or no ... and if the latter, why not?
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Risk Factor | 2006 |
Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Platelet | 2006 |
Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?
Topics: Aspirin; Clopidogrel; Depressive Disorder; Drug Interactions; Hemorrhage; Humans; Platelet Aggregati | 2006 |
[Patient with antithrombotic medication. Which do bleedings or preoperative?].
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atherosc | 2006 |
Aspirin to prevent heart attack and stroke: what's the right dose?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Female; H | 2006 |
[Adding aspirin to clopidogrel in secondary prevention of ischemic stroke: no significant benefits. Results of the Match study].
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; | 2006 |
Clopidogrel in the treatment of ischaemic heart disease.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Hemorrhage; H | 2006 |
MATCH results: implications for the internist.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Controlled Clinical Trials as Topic; Double-Blind Method; Dru | 2006 |
Anagrelide: what was new in 2004 and 2005?
Topics: Antineoplastic Agents; Aspirin; Blood Platelets; Clinical Trials, Phase III as Topic; Drug Therapy, | 2006 |
Update on diagnosis and management of essential thrombocythemia.
Topics: Age Factors; Antineoplastic Agents; Aspirin; Drug Antagonism; Female; Fibrinolytic Agents; Hemorrhag | 2006 |
The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Topics: Aspirin; Bleeding Time; Blood Platelets; Deamino Arginine Vasopressin; Hemorrhage; Humans; Microcirc | 2006 |
The management of patients on anticoagulants prior to cutaneous surgery: case report of a thromboembolic complication, review of the literature, and evidence-based recommendations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Damage, | 2006 |
Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials.
Topics: Administration, Oral; Anticoagulants; Aspirin; Drug Therapy, Combination; Heart Valve Prosthesis; He | 2007 |
[The use of antithrombotic drugs during various surgical procedures].
Topics: Analgesia, Patient-Controlled; Anesthesia, Epidural; Anesthesia, Spinal; Aspirin; Female; Fibrinolyt | 2007 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
Topics: Adenosine Diphosphate; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Biomarkers | 2007 |
SSRIs & the risk of abnormal bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cohort Studies; Databases, F | 2007 |
Aspirin and bleeding in dentistry: an update and recommendations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cardiovascular Diseases; Dental C | 2007 |
Perioperative use of anti-platelet drugs.
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Elective Surgical Procedures; Hemorrhage; Humans; Periope | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2007 |
PRO: Should aspirin be used in all women older than 65 years to prevent stroke?
Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Cost of Illness; Evidence-Based Practice; Femal | 2007 |
Clopidogrel: who, when, and how?
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug A | 2007 |
Aspirin and reproductive outcomes.
Topics: Abnormalities, Drug-Induced; Antibodies, Antiphospholipid; Aspirin; Cyclooxygenase Inhibitors; Dose- | 2008 |
Aspirin combined with clopidogrel (Plavix) decreases cardiovascular events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Evidence-B | 2007 |
[Aspirin in patients undergoing percutaneous coronary intervention].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Drug Administration Schedule; Hemorrhage; | 2007 |
Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; A | 2008 |
Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Clopidogrel; Coron | 2008 |
Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding.
Topics: Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; | 2008 |
Antiplatelet therapy in acute coronary syndromes: the emergency physician's perspective.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypas | 2008 |
Use of antiplatelet agents to prevent stroke: what is the role for combinations of medications?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy, Combi | 2008 |
Should patients on long-term warfarin take aspirin for heart disease?
Topics: Anticoagulants; Aspirin; Drug Synergism; Heart Diseases; Hemorrhage; Humans; Platelet Aggregation In | 2008 |
Will prasugrel supersede clopidogrel for acute coronary syndromes?
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Art | 2008 |
Antiplatelet agents and arterial thrombosis.
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggreg | 2008 |
Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Interactions; Drug Therapy, Com | 2008 |
Bleeding associated with antithrombotic therapy.
Topics: 4-Hydroxycoumarins; Aspirin; Dextrans; Dipyridamole; Dose-Response Relationship, Drug; Fibrinolytic | 1980 |
Prevention of venous thromboembolism.
Topics: Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Dextrans; Dihydroergotamine; Dipyridamo | 1981 |
Proliferative diabetic retinopathy and patient age: presentation, prognosis, and management.
Topics: Adolescent; Adult; Age Factors; Anticoagulants; Aspirin; Diabetes Mellitus, Type 1; Diabetic Retinop | 1984 |
Bleeding and thrombosis in the myeloproliferative disorders.
Topics: Alkylating Agents; Arachidonic Acids; Aspirin; Blood Viscosity; Epinephrine; Hematocrit; Hemorrhage; | 1984 |
Aspirin and surgery--a review.
Topics: Adult; Aspirin; Bleeding Time; Dose-Response Relationship, Drug; Epoprostenol; Ethanol; Female; Hemo | 1984 |
Hypothesis: polypharmacy. The treatment of thrombotic risk.
Topics: Aspirin; Blood Coagulation Tests; Clofibrate; Hemorrhage; Heparin; Humans; Thrombosis; Warfarin | 1980 |
Low-dose heparin: an aid to therapy.
Topics: Aspirin; Clinical Trials as Topic; Dihydroergotamine; Double-Blind Method; Electric Stimulation; Hem | 1980 |
Diagnostic approach to mild bleeding disorders.
Topics: Aspirin; Bleeding Time; Blood Platelet Disorders; Blood Platelets; Contusions; Genetic Variation; He | 1980 |
The role of prostacyclin and thromboxane A2 in the regulation of platelet behaviour.
Topics: Aspirin; Dipyridamole; Epoprostenol; Hemorrhage; Humans; Platelet Aggregation; Prostaglandins; Throm | 1980 |
Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bleeding Time; Blood Platelets; Cyclooxygenase Inh | 1995 |
[Bleeding complications in oral anticoagulant treatment].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Heart Valve Prosthesis; Hemorrhage; Humans; Myocardial | 1995 |
Oral anticoagulant treatment with and without aspirin.
Topics: Administration, Oral; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Dipyridam | 1995 |
Advances in antithrombotic therapy: novel agents.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Antithrombins; Aspirin; Clinical Trials as Topic; | 1995 |
[Atrial fibrillation due to non-valvular causes: indications for antithrombotic therapy].
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as To | 1996 |
[Antithrombotic treatment of atrial fibrillation].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Clinical Trials as Topic; Fibrinolyti | 1996 |
[Contemporary opinions on the use of aspirin, heparin and thrombolytic therapy in unstable angina pectoris--pathogenetic findings versus results of many clinical tests].
Topics: Angina, Unstable; Angiography; Aspirin; Hemorrhage; Heparin; Humans; Thrombolytic Therapy; Thrombosi | 1996 |
Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Drug Therapy, Combination; Hemorrhage; He | 1996 |
Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer.
Topics: Adenocarcinoma; Adenoma; Adenomatous Polyposis Coli; Adult; Animals; Anti-Inflammatory Agents, Non-S | 1996 |
Oral anticoagulation alone or in combination with aspirin: risks and benefits.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Coagulation Tests; Cardiovascular Diseases; Dru | 1996 |
Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia.
Topics: Adult; Aged; Aspirin; Busulfan; Double-Blind Method; Erythromelalgia; Female; Gangrene; Hemorrhage; | 1996 |
Essential thrombocythemia and pregnancy.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Aspirin; Busulfan; Combined Modality Therapy; Di | 1996 |
Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction.
Topics: Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Hepa | 1997 |
[Pulmonary hemorrhage after thrombolysis in acute myocardial infarct].
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Lung Diseases; Male; Mi | 1997 |
Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents.
Topics: Aspirin; Dipyridamole; Hemorrhage; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Pla | 1997 |
Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
Topics: Anti-Inflammatory Agents; Arachidonic Acid; Arteriosclerosis; Aspirin; Blood Platelets; Cyclooxygena | 1997 |
Aspirin in essential thrombocythemia: status quo and quo vadis.
Topics: Abortion, Habitual; Aspirin; Cerebrovascular Disorders; Cohort Studies; Contraindications; Erythrome | 1997 |
Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
Topics: Alkylating Agents; Arachidonic Acid; Aspirin; Bleeding Time; Blood Platelets; Bone Marrow; Hematopoi | 1997 |
Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; As | 1998 |
[The risk of hemorrhage in long-term use of aspirin and triflusal].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebral Infarction; Female; Follow-Up Stud | 1998 |
Dosing and administration of ReoPro (c7E3 Fab).
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Coronary | 1994 |
Aspirin and ticlopidine after routine coronary stenting: the gold standard as of 1999.
Topics: Anemia, Aplastic; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Co | 1999 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anti | 1999 |
Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy?
Topics: Abciximab; Administration, Oral; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Be | 1999 |
Effects of nonsteroidal anti-inflammatory therapy on platelets.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cyclooxygenase 1; Cyclooxygenase | 1999 |
Aspirin in the prevention of strokes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topi | 1999 |
Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors | 1999 |
Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors.
Topics: Anticoagulants; Aspirin; Drug Combinations; Fibrinolytic Agents; Hemorrhage; Hemostasis; Heparin; Hu | 1999 |
Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Catheterization, Peripheral; Coronary Di | 1999 |
Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Hemorrhage; Humans; Placebo | 1999 |
Ticlopidine and clopidogrel.
Topics: Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Angina, Unstable; Aspirin; Bo | 1999 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In | 1998 |
Fertility, pregnancy and the management of myeloproliferative disorders.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Alkylating Agents; Animals; Aspirin; Bone Marrow | 1998 |
Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups.
Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrha | 2000 |
The pathogenesis and management of essential thrombocythaemia.
Topics: Acute Disease; Alkylating Agents; Aspirin; Cardiovascular Diseases; Clone Cells; Gene Expression; He | 1999 |
Meta-analysis of thromboembolic prophylaxis after total knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Bandages; Combined Modality Therapy; Hemor | 2000 |
[Acetylsalicylic acid versus coumarin derivatives in atrial fibrillation].
Topics: Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Coumarins; Dose-Respo | 2000 |
Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Hemorrhage; Humans; Isoindoles; Phenylbutyrates; Plate | 2001 |
Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Coronary Disease; Female; Hemorrhage; Humans; Male; Mortality; Myo | 2001 |
Aspirin in the treatment and prevention of cardiovascular disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Studie | 2000 |
Stroke prevention: antiplatelet and antithrombolytic therapy.
Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Carotid Stenosis; Clinical Trials as Topic; Clopidog | 2000 |
Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
Topics: Administration, Oral; Alanine; Aspirin; Benzamidines; Clinical Trials, Phase III as Topic; Coronary | 2001 |
[Prevention of cardiovascular diseases in type 2 diabetes with aspirin].
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Prescriptions; Evidence-Based Medi | 2001 |
Low-molecular-weight heparins in the management of unstable angina.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Combined Modality Therapy; Double-Blind Method; Drug Admi | 2000 |
The effect of perioperative aspirin therapy in peripheral vascular surgery: a decision analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Decision Support Techniques; Hemorrhage; Humans; I | 2001 |
Management of thrombosis in antiphospholipid antibody syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Hemorrhage; Heparin; Humans; Lupus Erythematosus | 2001 |
Abnormal coagulation in the postoperative period contributing to excessive bleeding.
Topics: Adult; Anticoagulants; Aspirin; Blood Coagulation; Blood Coagulation Disorders; Blood Transfusion; D | 2001 |
[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Colo | 2001 |
[Thromboembolism in non-rheumatic atrial fibrillation].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical | 2001 |
[Peripheral arterial revascularization: which antithrombotic agents?].
Topics: 4-Hydroxycoumarins; Anticoagulants; Arteries; Aspirin; Drug Therapy, Combination; Fibrinolytic Agent | 2001 |
Acquired anti-FVIII inhibitors in children.
Topics: Adolescent; Aspirin; Autoantibodies; Autoimmune Diseases; Child; Child, Preschool; Compartment Syndr | 2002 |
Hemostatic failure in clinical medicine.
Topics: Acute Disease; Amyloidosis; Anticoagulants; Aspirin; Blood Platelet Disorders; Blood Vessels; Chroni | 1977 |
Side-effects of anti-inflammatory drugs: are they essential or can they be circumvented?
Topics: Abnormalities, Drug-Induced; Animals; Anti-Inflammatory Agents; Aspirin; Drug Evaluation, Preclinica | 1977 |
Orthodontics and dentistry for the hemophilic patient.
Topics: Anesthesia, Dental; Aspirin; Blood Platelets; Buttocks; Factor VIII; Gingival Hemorrhage; Hemophilia | 1975 |
Use of antithrombotic agents during pregnancy.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Fetal Diseases; Hemorrhage; Humans; Oste | 1992 |
Non-rheumatic atrial fibrillation: warfarin or aspirin for all?
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Hemorrhage; Humans; Randomized Controlled T | 1992 |
Anticoagulant therapy for atrial fibrillation. Recommendations from major studies.
Topics: Acute Disease; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Chronic Disease; Electric Co | 1992 |
Use of desmopressin in the management of aspirin-related and intractable haemorrhage after cardiopulmonary bypass.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Blood Coagulation Tests; Cardiopulmonary Bypass; Deamino Arg | 1990 |
The risks and benefits of taking aspirin during pregnancy.
Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Female; Fetus; Hemorrhage; Humans; Infant, Newborn; P | 1990 |
Bleeding disorders in uremia: pathophysiology and treatment.
Topics: Aspirin; Blood Platelet Disorders; Deamino Arginine Vasopressin; Estrogens; Hemorrhage; Humans; Urem | 1989 |
Bleeding in renal failure.
Topics: Anemia; Aspirin; Bleeding Time; Blood Platelets; Blood Transfusion; Cryoprotective Agents; Deamino A | 1988 |
Effectiveness of anticoagulants.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Angina, Unstable; Anticoagulants; Aspirin; Blood | 1986 |
[Long-term antithrombotic treatment in patients with valve prostheses. Practical management and complications].
Topics: Anticoagulants; Aspirin; Bioprosthesis; Dipyridamole; Heart Valve Prosthesis; Hemorrhage; Humans; Th | 1985 |
Hemostasis in surgical procedures.
Topics: Acetylcholine; Antimetabolites; Aspirin; Autonomic Nervous System; Blood Circulation; Blood Coagulat | 1969 |
Management of thrombotic diseases.
Topics: Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Cerebrovascular Disorders; Coronary Dis | 1971 |
Disorders of platelet function.
Topics: Adenosine Diphosphate; Adolescent; Aspirin; Blood Coagulation Disorders; Blood Coagulation Factors; | 1972 |
Bleeding in uremia.
Topics: Adenine Nucleotides; Aspirin; Blood Coagulation Disorders; Blood Platelet Disorders; Capillary Fragi | 1972 |
Prevention of thromboembolism after hip fracture.
Topics: Aged; Anticoagulants; Aspirin; Bandages; Coumarins; Dextrans; Exercise Therapy; Femoral Neck Fractur | 1973 |
The clinical relevance of platelet function tests.
Topics: Adenosine Diphosphate; Aspirin; Blood Cell Count; Blood Coagulation Factors; Blood Coagulation Tests | 1972 |
Aspirin: the unique drug.
Topics: Aspirin; Blood Platelets; Drug Interactions; Drug Synergism; Gastrointestinal Hemorrhage; Hemorrhage | 1974 |
Anticoagulants.
Topics: Anticoagulants; Aspirin; Blood Platelet Disorders; Dipyridamole; Enzyme Therapy; Factor IX; Factor V | 1974 |
The diagnosis and prevention of post operative venous thrombosis.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Depression, Chemical; Dextrans; Fibr | 1973 |
Treatment of salicylate poisoning.
Topics: Acetaminophen; Acid-Base Equilibrium; Acidosis; Acute Kidney Injury; Alkalosis, Respiratory; Aspirin | 1971 |
The formulation of aspirin.
Topics: Administration, Oral; Aspirin; Biopharmaceutics; Dosage Forms; Drug Compounding; Evaluation Studies | 1971 |
505 trials available for aspirin and Bleeding
| Article | Year |
|---|---|
Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Dual An | 2021 |
Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study.
Topics: Anticoagulants; Aspirin; Child; Factor Xa Inhibitors; Hemorrhage; Humans; Rivaroxaban; Stroke; Throm | 2021 |
Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial.
Topics: Aged; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Age | 2021 |
Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial.
Topics: Adult; Aspirin; COVID-19; COVID-19 Drug Treatment; Dose-Response Relationship, Drug; Double-Blind Me | 2021 |
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.
Topics: Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Drug-Eluting Stents; Dual Anti-Plate | 2021 |
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.
Topics: Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Drug-Eluting Stents; Dual Anti-Plate | 2021 |
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.
Topics: Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Drug-Eluting Stents; Dual Anti-Plate | 2021 |
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.
Topics: Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Drug-Eluting Stents; Dual Anti-Plate | 2021 |
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.
Topics: Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Drug-Eluting Stents; Dual Anti-Plate | 2021 |
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.
Topics: Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Drug-Eluting Stents; Dual Anti-Plate | 2021 |
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.
Topics: Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Drug-Eluting Stents; Dual Anti-Plate | 2021 |
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.
Topics: Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Drug-Eluting Stents; Dual Anti-Plate | 2021 |
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.
Topics: Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Drug-Eluting Stents; Dual Anti-Plate | 2021 |
The PAR4 Platelet Thrombin Receptor Variant rs773902 does not Impact the Incidence of Thrombotic or Bleeding Events in a Healthy Older Population.
Topics: Aged; Aspirin; Blood Platelets; Hemorrhage; Humans; Incidence; Platelet Aggregation; Platelet Aggreg | 2022 |
Age-Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events: A Post Hoc Analysis of the TICO Randomized Trial.
Topics: Acute Coronary Syndrome; Age Distribution; Aged; Aspirin; Cardiovascular Diseases; Drug Therapy, Com | 2021 |
Validation of Cardiovascular End Points Ascertainment Leveraging Multisource Electronic Health Records Harmonized Into a Common Data Model in the ADAPTABLE Randomized Clinical Trial.
Topics: Aspirin; Electronic Health Records; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation | 2021 |
Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Ge | 2022 |
Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Factor Xa Inhibitors; Female; Hemorrhage; Hum | 2022 |
Pre-admission antiplatelet therapy and treatment effect of ticagrelor vs. prasugrel in patients with acute coronary syndromes-a subgroup analysis of the ISAR-REACT 5 trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2022 |
Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary | 2022 |
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Topics: Adult; Anticoagulants; Aspirin; Bayes Theorem; COVID-19; COVID-19 Drug Treatment; Critical Illness; | 2022 |
Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet | 2022 |
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD.
Topics: Aspirin; Diabetes Mellitus; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Pe | 2022 |
Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial.
Topics: Aspirin; Brain Ischemia; Hemorrhage; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Strok | 2022 |
Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiov
Topics: Adolescent; Adult; Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Multicenter S | 2022 |
Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; D | 2022 |
Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarcti | 2022 |
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry.
Topics: Aged; Aspirin; Coronary Artery Disease; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Peri | 2022 |
Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrha | 2022 |
Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD.
Topics: Arteries; Aspirin; Endovascular Procedures; Female; Hemorrhage; Humans; Lower Extremity; Male; Perip | 2022 |
Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial.
Topics: Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; He | 2022 |
Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial.
Topics: Asian People; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Perip | 2022 |
Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial.
Topics: Aspirin; Cerebral Infarction; Cilostazol; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combi | 2023 |
Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'targe
Topics: Acute Coronary Syndrome; Adolescent; Aspirin; Clopidogrel; Cohort Studies; Dinucleoside Phosphates; | 2022 |
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study.
Topics: Aspirin; Coronary Artery Bypass; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarctio | 2022 |
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Double-Blind Method; Factor XIa; Female; Hem | 2022 |
Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Factor XIa; Fibrinolytic Agent | 2022 |
Body Mass Index and Major Adverse Events During Chronic Antiplatelet Monotherapy After Percutaneous Coronary Intervention With Drug-Eluting Stents - Results From the HOST-EXAM Trial.
Topics: Aspirin; Body Mass Index; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Obesit | 2023 |
Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarc | 2022 |
Early anticoagulation after aortic valve replacement with porcine bioprosthesis randomized control trial (ANTIPRO).
Topics: Animals; Anticoagulants; Aortic Valve; Aspirin; Bioprosthesis; Heart Valve Prosthesis; Heart Valve P | 2022 |
Sex differences among patients receiving ticagrelor monotherapy or aspirin after coronary bypass surgery: A prespecified subgroup analysis of the TiCAB trial.
Topics: Aspirin; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Interven | 2023 |
Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Ischemic S | 2023 |
Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar | 2023 |
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial D | 2023 |
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial D | 2023 |
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial D | 2023 |
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial D | 2023 |
Rivaroxaban plus aspirin versus acenocoumarol to manage recurrent venous thromboembolic events despite systemic anticoagulation with rivaroxaban.
Topics: Acenocoumarol; Anticoagulants; Aspirin; Hemorrhage; Humans; Ischemic Stroke; Pilot Projects; Pulmona | 2023 |
Genotype-Guided Dual Antiplatelet Use for Transient Ischemic Attack and Minor Stroke by Imaging Status: Subgroup Analysis of the CHANCE-2 Trial.
Topics: Aspirin; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Genotype; Hemorrhage; Humans; | 2023 |
Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial.
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Human | 2023 |
Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial.
Topics: Anemia; Aspirin; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggr | 2023 |
Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture.
Topics: Adult; Anticoagulants; Aspirin; Chemoprevention; Extremities; Fractures, Bone; Hemorrhage; Heparin, | 2023 |
The standard versus prolonged dual antiplatelet therapy after the XINSORB bioresorbable scaffold implantation (SPARTA) trial: study protocol for a randomized controlled trial.
Topics: Absorbable Implants; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; My | 2023 |
Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclero
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Atorvastatin; Brain Ischemia; Clopidogrel; | 2023 |
Dual Antiplatelet Therapy With Cilostazol for Secondary Prevention in Lacunar Stroke: Subanalysis of the CSPS.com Trial.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; | 2023 |
Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Enoxaparin; Female; Hemorrhage; Humans; Male; Platelet Aggre | 2023 |
Stroke Recurrence and Antiplatelets in Posterior Versus Anterior Circulation Minor Stroke or Transient Ischemic Attack.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Infarction; Ischemic Attack, Tr | 2023 |
Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial.
Topics: Adult; Aspirin; Biomarkers; Female; Hemorrhage; Humans; Infant, Newborn; Peripartum Period; Placenta | 2023 |
Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority ra
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Gastrointestinal Diseases; | 2023 |
Dual antiplatelet Use for extended period taRgeted to AcuTe ischemic stroke with presumed atherosclerotic OrigiN (DURATION) trial: Rationale and design.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Strok | 2023 |
Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Neoplasm Recu | 2023 |
Sex Differences in Outcomes of Ticagrelor Therapy With or Without Aspirin After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Secondary Analysis of the TICO Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aspirin; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Percutaneou | 2023 |
Aspirin vs Clopidogrel for Long-term Maintenance After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the HOST-EXAM Trial.
Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male | 2023 |
Sex Differences in Outcomes After Transcatheter Aortic Valve Replacement: A POPular TAVI Subanalysis.
Topics: Anticoagulants; Aortic Valve; Aortic Valve Stenosis; Aspirin; Female; Hemorrhage; Humans; Male; Myoc | 2023 |
Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new-generation drug-eluting stent: OPtimal management of anTIthroMbotic Agents (OPTIMA)-4 trial.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combin | 2023 |
A randomized controlled trial to investigate the use of acute coronary syndrome therapy in patients hospitalized with COVID-19: the COVID-19 Acute Coronary Syndrome trial.
Topics: Acute Coronary Syndrome; Aspirin; Bayes Theorem; COVID-19; Hemorrhage; Humans; SARS-CoV-2; Treatment | 2023 |
Design and Rationale of the BIOFLOW-DAPT Trial: a Prospective, Randomized, Multicenter Study to Assess the Safety of the Orsiro Mission Stent Compared to the Resolute Onyx Stent in Subjects at High Risk for Bleeding in Combination with 1-Month Dual Antipl
Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Percutaneous Coronary I | 2023 |
Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; East Asian People; Female; Hemorrhage; Humans; | 2023 |
Rationale and design of a randomized study comparing the Watchman FLX device to DOACs in patients with atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Embolism; Female; Follow-Up Studies; | 2023 |
P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans | 2023 |
Effect of Low-Dose Aspirin Versus Placebo on Incidence of Anemia in the Elderly : A Secondary Analysis of the Aspirin in Reducing Events in the Elderly Trial.
Topics: Aged; Aged, 80 and over; Anemia; Aspirin; Australia; Double-Blind Method; Ferritins; Hemoglobins; He | 2023 |
Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack.
Topics: Aspirin; Body Mass Index; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attac | 2023 |
Association Between Claims-Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study.
Topics: Aged; Aspirin; Child, Preschool; Drug Therapy, Combination; Frailty; Hemorrhage; Humans; Medicare; P | 2023 |
Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia.
Topics: Acute Disease; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female | 2023 |
Less bleeding by omitting aspirin in non-ST-segment elevation acute coronary syndrome patients: Rationale and design of the LEGACY study.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Corona | 2023 |
Compliance-Adjusted Estimates of Aspirin Effects Among Older Persons in the ASPREE Randomized Trial.
Topics: Aged; Aged, 80 and over; Aspirin; Australia; Double-Blind Method; Hemorrhage; Humans; United States | 2023 |
Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions.
Topics: Aspirin; Heart; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibit | 2023 |
Comparison of Antiplatelet Monotherapies After Percutaneous Coronary Intervention According to Clinical, Ischemic, and Bleeding Risks.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Pe | 2023 |
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Hemorrhage; | 2023 |
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention.
Topics: Aspirin; Drug Therapy, Combination; Dyspnea; Hemorrhage; Humans; Percutaneous Coronary Intervention; | 2023 |
Progression of Gastrointestinal Injury During Antiplatelet Therapy After Percutaneous Coronary Intervention: A Secondary Analysis of the OPT-PEACE Randomized Clinical Trial.
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneo | 2023 |
Sex-Based Outcomes of P2Y12 Inhibitor Monotherapy After Three Months of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention.
Topics: Aspirin; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percuta | 2023 |
Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Case-Control Studies; Cause of Death; Drug Therapy, Combinat | 2019 |
Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
Topics: Aged; Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy | 2019 |
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Hemo | 2019 |
Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin.
Topics: Aged; Aspirin; Coronary Artery Disease; Drug Combinations; Factor Xa Inhibitors; Female; Hemorrhage; | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; | 2019 |
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Agents; | 2019 |
Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Continuity of Patient Care; Dose-Response Relation | 2019 |
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI.
Topics: Aged; Aspirin; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Reva | 2019 |
Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial.
Topics: Aged; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hem | 2020 |
Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clopid | 2020 |
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clopidogrel; Drug Th | 2020 |
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2019 |
Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2019 |
Prospective multicentre open-label randomised controlled trial of 3-month versus 12-month dual antiplatelet therapy after implantation of the new generation biodegradable polymer sirolimus TARGET-eluting coronary stent: protocol of the TARGET DAPT trial.
Topics: Absorbable Implants; Aspirin; China; Clinical Trials, Phase IV as Topic; Coronary Angiography; Coron | 2019 |
Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial.
Topics: Aged; Aspirin; Biomarkers; China; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Femal | 2020 |
Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; China; Clopidogrel; Drug Substi | 2020 |
Rivaroxaban in Peripheral Artery Disease after Revascularization.
Topics: Aged; Aspirin; Cardiovascular Diseases; Combined Modality Therapy; Double-Blind Method; Drug Therapy | 2020 |
Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.
Topics: Aspirin; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Hemorrhage; Humans; Perc | 2020 |
Ticagrelor With or Without Aspirin After Complex PCI.
Topics: Aged; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage | 2020 |
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; C | 2020 |
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
Topics: Aged; Aged, 80 and over; Aspirin; Comorbidity; Coronary Artery Disease; Double-Blind Method; Drug Ad | 2021 |
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Drug-Eluting S | 2020 |
Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population.
Topics: Age Factors; Aged; Aspirin; Australia; Blood Platelets; Cardiovascular Diseases; Double-Blind Method | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aged; Aged, 80 and over; Aspirin; Disability Evaluation; Double-Blind Method; Drug Therapy, Combinat | 2020 |
Optimal duration of dual antiplatelet therapy following PTA of the superficial femoral artery: the DAPT-SFA protocol.
Topics: Angioplasty; Aspirin; Clopidogrel; Drug Administration Schedule; Femoral Artery; Hemorrhage; Humans; | 2020 |
Incidence of Cardiovascular Events and Safety Profile of Prasugrel in Korean Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting | 2020 |
Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the O
Topics: Acute Coronary Syndrome; Adult; Aspirin; Clopidogrel; Double-Blind Method; Drug-Eluting Stents; Dual | 2020 |
Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial.
Topics: Adult; Aged; Anticoagulants; Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Fractures, Bone; Hemo | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug T | 2020 |
Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Budgets; Cardiovascular Diseases; Ci | 2021 |
Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Dose-Response Relationship, Drug; Dual Anti-Platelet Therapy | 2020 |
Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Hemorrhage; Humans; Renal Insu | 2021 |
Dual Antiplatelet Therapy Beyond 90 days in Symptomatic Intracranial Stenosis in the SAMMPRIS Trial.
Topics: Aged; Angioplasty; Aspirin; Clopidogrel; Drug Administration Schedule; Dual Anti-Platelet Therapy; F | 2020 |
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Double | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Cause of Death; Drug Administration Schedule; Drug-Eluting | 2021 |
A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial.
Topics: Administration, Oral; Aspirin; Atrial Fibrillation; Atrial Flutter; Bioprosthesis; Brazil; Cause of | 2021 |
Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS).
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Stenosis; Drug-Eluting Stents; Dual Anti-Platelet T | 2021 |
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Europe; Female; Follow-U | 2021 |
Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis.
Topics: Asia, Eastern; Asian People; Aspirin; Cohort Studies; Dabigatran; Double-Blind Method; Embolic Strok | 2021 |
Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multice
Topics: Acute Coronary Syndrome; Adult; Aspirin; Coronary Angiography; Drug-Eluting Stents; Dual Anti-Platel | 2021 |
Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Factor Xa Inhibitors; Fema | 2021 |
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Female; Hemorrhage; Hospitalization; Humans | 2021 |
P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Dual Anti-Platelet Therapy | 2021 |
P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Dual Anti-Platelet Therapy | 2021 |
P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Dual Anti-Platelet Therapy | 2021 |
P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Dual Anti-Platelet Therapy | 2021 |
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Multimorbidity; Rivaroxaban | 2022 |
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
Topics: Adult; Aged; Aspirin; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Femal | 2017 |
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Double-Blind M | 2017 |
Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Dru | 2017 |
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug | 2017 |
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Combina | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomi
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Balloon Valvuloplasty; Canada; Clopidogrel; Drug The | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2017 |
Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, | 2017 |
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; D | 2017 |
6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedu | 2017 |
Effects of preoperative aspirin on perioperative platelet activation and dysfunction in patients undergoing off-pump coronary artery bypass graft surgery: A prospective randomized study.
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Bypass, Off-Pump; Female; Hemorrhage; Humans; Male; | 2017 |
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
Topics: Aged; Aspirin; Clinical Decision-Making; Clopidogrel; Coronary Disease; Coronary Thrombosis; Decisio | 2017 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy | 2017 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy | 2017 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy | 2017 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combinat | 2017 |
SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial.
Topics: Amputation, Surgical; Aspirin; Clinical Protocols; Clopidogrel; Computed Tomography Angiography; Con | 2017 |
Dual antiplatelet therapy may increase the risk of non-intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial.
Topics: Aged; Aspirin; China; Clopidogrel; Double-Blind Method; Dual Anti-Platelet Therapy; Hemorrhage; Huma | 2016 |
Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial.
Topics: Adenosine; Aspirin; Clinical Protocols; Coronary Artery Disease; Drug Therapy, Combination; England; | 2017 |
Aspirin in Patients With Previous Percutaneous Coronary Intervention Undergoing Noncardiac Surgery.
Topics: Aged; Antihypertensive Agents; Aspirin; Biomarkers; Clonidine; Drug Administration Schedule; Drug Th | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Dose-Response Relationship, Drug; D | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response | 2018 |
Impact of quality of anticoagulation control on outcomes in patients with atrial fibrillation taking aspirin: An analysis from the SPORTIF trials.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation; Female; Follow-Up Studies; He | 2018 |
Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopid | 2017 |
Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopid | 2017 |
Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopid | 2017 |
Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopid | 2017 |
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb | 2018 |
Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Clopidogrel; Drug Therapy, Combination; Female; | 2018 |
Guanxinning tablet for patients who switch from dual antiplatelet therapy to aspirin alone after percutaneous coronary intervention: study protocol for a cluster randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; China; Coronary Artery Di | 2018 |
Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Drug Monitoring; Female | 2018 |
Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.
Topics: Adult; Aspirin; Coronary Restenosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrh | 2018 |
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Double-Blind Method; | 2018 |
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Double-Blind Method; | 2018 |
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Double-Blind Method; | 2018 |
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Double-Blind Method; | 2018 |
Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; China; Drug Therapy, Combination; | 2018 |
Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Endovascular Procedures; Europe; Factor Xa In | 2018 |
Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial.
Topics: Adenosine; Adult; Aged; Aspirin; Coronary Artery Bypass; Coronary Restenosis; Drug Therapy, Combinat | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Topics: Aged; Aspirin; Brain Ischemia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Emboli | 2018 |
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Topics: Aged; Aspirin; Brain Ischemia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Emboli | 2018 |
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Topics: Aged; Aspirin; Brain Ischemia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Emboli | 2018 |
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Topics: Aged; Aspirin; Brain Ischemia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Emboli | 2018 |
Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial.
Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Cyclooxygenase Inhibitors; Female; Greece; H | 2019 |
An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rat
Topics: Acute Coronary Syndrome; Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Hemorrha | 2018 |
Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study).
Topics: Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Disease Progression; Female; Glomerul | 2018 |
Clinical pharmacodynamics and long-term efficacy of Talcom vs. Plavix in patients undergoing coronary stent implantation: a randomized study with 5-year follow-up.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up St | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus | 2018 |
Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention.
Topics: Aged; Aspirin; Brazil; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug | 2018 |
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Double-B | 2018 |
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Double-B | 2018 |
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Double-B | 2018 |
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Double-B | 2018 |
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Double-B | 2018 |
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Double-B | 2018 |
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Double-B | 2018 |
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Double-B | 2018 |
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Cardiovascular Diseases; Double-B | 2018 |
Effect of Aspirin on All-Cause Mortality in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Cause of Death; Female; Follow-Up | 2018 |
Effect of Aspirin on Disability-free Survival in the Healthy Elderly.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Australia; Dementia; Disabled Persons; Disea | 2018 |
Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial.
Topics: Aged; Antifibrinolytic Agents; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Coronary Th | 2019 |
Tranexamic acid in coronary artery surgery: One-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial.
Topics: Activities of Daily Living; Aged; Antifibrinolytic Agents; Aspirin; Coronary Artery Bypass; Coronary | 2019 |
DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan.
Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Diamines; Female; Hemorrhage; Humans; Male; | 2019 |
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).
Topics: Aged; Asian People; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus; Dyslipidem | 2019 |
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Chronic Disease; Corona | 2019 |
Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial.
Topics: Aged; Aged, 80 and over; Aspirin; Endpoint Determination; Female; Hemorrhage; Humans; Ischemic Attac | 2019 |
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fib | 2019 |
Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection: The Cervical Artery Dissection in Stroke Study (CADISS) Randomized Clinical Trial Final Results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Carotid Artery, Internal, Disse | 2019 |
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Doub | 2019 |
Safety and Efficacy of Low-Dose Prasugrel as Part of Triple Therapy With Aspirin and Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention - From the TWMU-AF PCI Registry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; | 2019 |
Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2019 |
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial.
Topics: Aged; Aspirin; Coronary Artery Disease; Correlation of Data; Double-Blind Method; Drug Therapy, Comb | 2019 |
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
Topics: Aged; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Incidence | 2019 |
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
Topics: Aged; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Incidence | 2019 |
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
Topics: Aged; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Incidence | 2019 |
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
Topics: Aged; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Incidence | 2019 |
Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial.
Topics: Aspirin; Hemorrhage; Humans; Ischemic Attack, Transient; Mortality; Myocardial Infarction; Observer | 2019 |
Personalised antiplatelet therapy based on pharmacogenomics in acute ischaemic minor stroke and transient ischaemic attack: study protocol for a randomised controlled trial.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2019 |
Improving Adherence to Ticagrelor in Patients After Acute Coronary Syndrome: Results from the PROGRESS Trial.
Topics: Acute Coronary Syndrome; Aged; Appointments and Schedules; Aspirin; Drug Administration Schedule; Du | 2020 |
P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Administration Schedul | 2019 |
Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent.
Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans | 2019 |
Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT) in the UK: study protocol for three population-based cohort studies emulating 'target trials' (the ADAPTT Stu
Topics: Acute Coronary Syndrome; Adult; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug T | 2019 |
Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy.
Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Immunosuppressive Agent | 2019 |
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2019 |
Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2019 |
Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke.
Topics: Acute Disease; Aspirin; Clinical Protocols; Clopidogrel; Drug Therapy, Combination; Drug-Related Sid | 2019 |
Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial.
Topics: Aged; Aspirin; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Factor Xa Inhibito | 2019 |
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; | 2013 |
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; | 2013 |
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; | 2013 |
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; | 2013 |
Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial.
Topics: Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; D | 2013 |
Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Dalteparin; Drug Administration Sche | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; F | 2013 |
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Disease Managem | 2013 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpr | 2013 |
Risks and complications of transurethral resection of bladder tumor among patients taking antiplatelet agents for cardiovascular disease.
Topics: Aged; Aspirin; Blood Transfusion; Cardiovascular Diseases; Female; Follow-Up Studies; Hemorrhage; Hu | 2014 |
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, | 2013 |
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Topics: Age Factors; Aged; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Diabetes | 2014 |
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Topics: Age Factors; Aged; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Diabetes | 2014 |
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Topics: Age Factors; Aged; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Diabetes | 2014 |
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
Topics: Age Factors; Aged; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Diabetes | 2014 |
Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Arte | 2014 |
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Double-Blind Method; Drug | 2014 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up.
Topics: Aged; Aspirin; Brain Ischemia; Dyspepsia; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; | 2014 |
Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial.
Topics: Aged; Aspirin; Atrial Fibrillation; Double-Blind Method; Drug Administration Schedule; Factor Xa Inh | 2014 |
Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Epidemiologic Methods; Female; Hemorrhage; Humans; | 2014 |
Warfarin compared with aspirin for older Chinese patients with stable coronary heart diseases and atrial fibrillation complications.
Topics: Age Factors; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation; Chi | 2014 |
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Drug Th | 2014 |
Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
Topics: Aged; Angina, Stable; Aspirin; Belgium; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coron | 2014 |
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Ad | 2014 |
Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial.
Topics: Adolescent; Adult; Aged; Aspirin; Coronary Artery Disease; Drug Administration Schedule; Drug Therap | 2014 |
Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; H | 2014 |
Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; H | 2014 |
Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; H | 2014 |
Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; H | 2014 |
Predictors of mortality in patients with lacunar stroke in the secondary prevention of small subcortical strokes trial.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged | 2014 |
Perioperative aspirin and clonidine and risk of acute kidney injury: a randomized clinical trial.
Topics: Acute Kidney Injury; Administration, Cutaneous; Administration, Oral; Adrenergic alpha-2 Receptor Ag | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; D | 2014 |
Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations.
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-El | 2014 |
6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Drug-Elu | 2015 |
Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS.
Topics: Adenosine; Adolescent; Adult; Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combina | 2015 |
Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement.
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Clopidogrel; Echocardiography; Female; Foll | 2014 |
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinat | 2015 |
Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
Topics: Aged; Aged, 80 and over; Aspirin; Biocompatible Materials; Clopidogrel; Coronary Angiography; Corona | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule | 2015 |
Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Restenosis; Double-Blind Method; Drug Therapy, Comb | 2015 |
A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
Topics: Aged; Angioplasty; Aspirin; Clopidogrel; Drug Therapy, Combination; Europe; Factor Xa Inhibitors; Fe | 2015 |
Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus; Drug Therapy, Co | 2015 |
Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction.
Topics: Adenosine; Adult; Aged; Asian People; Aspirin; Cardiac Catheterization; Double-Blind Method; Female; | 2015 |
Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study.
Topics: Aspirin; Clinical Protocols; Double-Blind Method; Drug Administration Schedule; Fibrinolytic Agents; | 2015 |
Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention.
Topics: Adenosine; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug | 2015 |
Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes.
Topics: Adult; Aspirin; Cardiovascular Diseases; Cross-Over Studies; Cyclooxygenase Inhibitors; Diabetes Mel | 2016 |
Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man.
Topics: Adenosine; Adult; Animals; Aspirin; Blood Platelets; Cross-Over Studies; Cyclooxygenase 1; Cyclooxyg | 2015 |
Thromboembolism Prophylaxis in Hip Arthroplasty: Routine and High Risk Patients.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Female; Hemorrhage; Humans; In | 2015 |
Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin.
Topics: Aged; Anticoagulants; Aspirin; Female; Heart Failure; Hemorrhage; Humans; Male; Middle Aged; Platele | 2015 |
Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients.
Topics: Aged; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Factor Xa Inhibitors; Female; Hemorrhage; | 2015 |
Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Female; Fusion Proteins, bcr-abl; | 2015 |
Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
Topics: Acute Coronary Syndrome; Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind | 2016 |
Causes of late mortality with dual antiplatelet therapy after coronary stents.
Topics: Aspirin; Cause of Death; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; | 2016 |
Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Factor Xa Inhibi | 2016 |
Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Drug Combin | 2016 |
Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2015 |
Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2015 |
Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2015 |
Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2015 |
Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Co | 2015 |
Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.
Topics: Aged; Aspirin; Cardiovascular Agents; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Met | 2016 |
Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Blood Platelets; Blood Pressure; Creatine Kinase; Female; Heart Rate; Hemorrhage; Hum | 2016 |
Ticagrelor and aspirin for the prevention of cardiovascular events after coronary artery bypass graft surgery.
Topics: Adenosine; Aged; Aspirin; British Columbia; Chi-Square Distribution; Computed Tomography Angiography | 2016 |
Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Aspirin; Chi-Square Distribution; China; Clopidogrel; Disease Progression; Double-Blind Method | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Administration Schedu | 2016 |
DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction.
Topics: Aspirin; Decision Support Techniques; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; M | 2016 |
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.
Topics: Adenosine; Aged; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemor | 2016 |
Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA?
Topics: Acute Coronary Syndrome; Adenosine; Asian People; Aspirin; Black People; Clopidogrel; Hemorrhage; Hu | 2016 |
Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study.
Topics: Aged; Anemia; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinat | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Adenosine; Aged; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Ischemic Attack, Transien | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Adenosine; Aged; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Ischemic Attack, Transien | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Adenosine; Aged; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Ischemic Attack, Transien | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Adenosine; Aged; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Ischemic Attack, Transien | 2016 |
6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
Topics: Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular | 2016 |
Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Drug-Eluting | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Alleles; Asian People; Aspirin; China; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Co | 2016 |
Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Topics: Aspirin; Atrial Fibrillation; Blood Transfusion; Clopidogrel; Drug Therapy, Combination; Drug-Elutin | 2017 |
Aspirin use and bleeding volume in skin cancer patients undergoing surgery: a randomized controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Intraoperative Compl | 2016 |
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; D | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; D | 2016 |
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; C | 2016 |
Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Artery Disease; Double-Blin | 2016 |
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm
Topics: Adenosine; Aged; Aspirin; Coronary Artery Disease; Female; Hemorrhage; Humans; Intracranial Hemorrha | 2016 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy | 2016 |
Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes).
Topics: Adenosine; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asian People; Aspirin; Cohort Studies; Dou | 2017 |
Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy
Topics: Acute Coronary Syndrome; Adult; Aspirin; Clopidogrel; Drug Monitoring; Drug-Eluting Stents; Everolim | 2016 |
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Coronary Restenosis; Double-Blind Method; Drug Th | 2016 |
Antithrombotic therapy after bioprosthetic aortic valve implantation: Warfarin versus aspirin, a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aortic Valve; Aspirin; Bioprosthesis; Heart Valve Prosthesi | 2017 |
Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Aspirin; Clopidogrel; Drug Therapy, Combination; Female | 2017 |
The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients: A randomized and controlled trail.
Topics: Arterial Occlusive Diseases; Aspirin; China; Clopidogrel; Dose-Response Relationship, Drug; Drug The | 2017 |
Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and 300 mg p. o. in ACS (ACUTE).
Topics: Acute Coronary Syndrome; Administration, Intravenous; Administration, Oral; Adult; Aged; Aspirin; Bi | 2017 |
[Bleeding control of periodontal mechanical therapy for patients taking aspirin].
Topics: Aspirin; Chronic Periodontitis; Contraindications; Coronary Disease; Dental Scaling; Hemorrhage; Hem | 2017 |
Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
Topics: Aspirin; Cilostazol; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Corona | 2017 |
Efficacy of cilostazol-based dual antiplatelet treatment in patients undergoing carotid artery stenting.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Cilostazol; Clopidogrel; Drug Therapy, Combinati | 2017 |
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
Topics: Adenosine Diphosphate; Adult; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Corona | 2008 |
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Death, Sudden, Cardiac; Double-Blind Method; F | 2009 |
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopi | 2008 |
Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, C | 2009 |
The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease.
Topics: Aged; Aspirin; Body Mass Index; Clopidogrel; Coronary Disease; Female; Fibrinolytic Agents; Hemorrha | 2009 |
Prolonged anticoagulation therapy adjunctive to aspirin after successful fibrinolysis: from early reduction in reocclusion to improved long-term clinical outcome.
Topics: Aged; Anticoagulants; Aspirin; Coronary Occlusion; Coumarins; Hemorrhage; Humans; International Norm | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Met | 2009 |
Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Disease; Double-B | 2009 |
Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Disease; Double-B | 2009 |
Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Disease; Double-B | 2009 |
Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Disease; Double-B | 2009 |
Heparin infusion after successful percutaneous coronary intervention: a prospective, randomized trial.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Female; | 2009 |
Low molecular weight heparin significantly reduces embolisation after carotid endarterectomy--a randomised controlled trial.
Topics: Adenosine Diphosphate; Aged; Anticoagulants; Arachidonic Acid; Aspirin; Carotid Artery Diseases; Dal | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emb | 2009 |
Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel | 2008 |
The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease | 2008 |
Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Blood Platelets; C | 2008 |
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Dose-Resp | 2009 |
Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study.
Topics: Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female | 2010 |
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Chest Pain; Dose-Response Relationship, Drug | 2009 |
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Dis | 2009 |
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Restenosis | 2009 |
Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coron | 2009 |
Bleeding increases the risk of ischemic events in patients with peripheral arterial disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cerebral Hemorrhage; Confide | 2009 |
Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoag | 2009 |
Use of high intensity adjusted dose low molecular weight heparin in women with mechanical heart valves during pregnancy: a single-center experience.
Topics: Anticoagulants; Aspirin; Factor Xa Inhibitors; Female; Heart Valve Prosthesis; Hemorrhage; Heparin, | 2009 |
Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiograp | 2009 |
Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Embolism; Feasibility Studies | 2010 |
Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Drug Administration Sche | 2010 |
Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events.
Topics: Aged; Aged, 80 and over; Asian People; Aspirin; Cohort Studies; Diabetes Mellitus; Dose-Response Rel | 2010 |
Confirmation that ethanol potentiates aspirin-induced prolongation of the bleeding time.
Topics: Alcoholic Beverages; Aspirin; Bleeding Time; Drug Interactions; Ethanol; Hemorrhage; Humans; Platele | 1983 |
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR
Topics: Aged; Aspirin; Clopidogrel; Disease Management; Double-Blind Method; Drug Therapy, Combination; Fema | 2010 |
Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Drug A | 2011 |
Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia.
Topics: Aged; Amputation, Surgical; Aspirin; Clopidogrel; Double-Blind Method; Female; Flow Cytometry; Hemor | 2010 |
[Recurrent thromboses and hemorrhagic complications in patients with antiphospholipid syndrome during therapy with warfarin plus aspirin].
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Coag | 2010 |
[Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clop | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W.
Topics: Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, Combination; Fibrinolyt | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Chronic Disease; Creatinine; Female; Glom | 2010 |
Enhanced platelet inhibition by adjunctive cilostazol to dual antiplatelet therapy after drug-eluting stent implantation for complex lesions.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; F | 2010 |
Warfarin or aspirin in embolism prevention in patients with mitral valvulopathy and atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Bioprosthesis; Heart Valve Prosthesis; Hemorrhag | 2010 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Dr | 2010 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Dr | 2010 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Dr | 2010 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Dr | 2010 |
Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Corona | 2011 |
Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome.
Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; | 2011 |
Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study.
Topics: Acute Coronary Syndrome; Administration, Cutaneous; Age Factors; Aged; Angioplasty, Balloon, Coronar | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhi | 2011 |
Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; As | 2011 |
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose- | 2011 |
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab wi
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombi | 2011 |
Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged | 2011 |
Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial.
Topics: Aged; Aspirin; Cilostazol; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage | 2011 |
Insights into the inhibition of platelet activation by omega-3 polyunsaturated fatty acids: beyond aspirin and clopidogrel.
Topics: Adult; Aspirin; Bleeding Time; Blood Platelets; Chi-Square Distribution; Clopidogrel; Dose-Response | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Apixaban with antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combina | 2011 |
Anticoagulation therapy with combined low dose aspirin and warfarin following mechanical heart valve replacement.
Topics: Adult; Anticoagulants; Aspirin; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Rea | 2011 |
Effect of hydroxyethyl starch 130/0.4 on blood loss and coagulation in patients with recent exposure to dual antiplatelet therapy undergoing off-pump coronary artery bypass graft surgery.
Topics: Aged; Aspirin; Blood Coagulation; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass, Off-Pum | 2011 |
Warfarin in atrial fibrillation patients with moderate chronic kidney disease.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation; Canada; Chi-Square Distributi | 2011 |
Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial.
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Drug Therapy, Combination; Endothelium, Vascular; Enoxap | 2011 |
Optimal timing of discontinuation of clopidogrel and risk of blood transfusion after coronary surgery. Propensity score analysis.
Topics: Aged; Aspirin; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; Clopidogrel; Fe | 2011 |
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial | 2011 |
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind | 2011 |
Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects.
Topics: Aged; Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Female; Hemorrhage; Humans; Mi | 2011 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement, Knee; Aspi | 2012 |
Correction of subclinical coagulation disorders before percutaneous dilatational tracheotomy.
Topics: Aged; Aspirin; Blood Coagulation Disorders; Blood Platelets; Female; Hemorrhage; Humans; Male; Middl | 2012 |
Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypas | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Cause | 2012 |
Clopidogrel trial in patients with elective percutaneous coronary intervention for stable angina and old myocardial infarction (CLEAN).
Topics: Adult; Aged; Angina, Stable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality | 2012 |
Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Biomarkers; Chi-Square Distribution; Creatinine; Double-Blind Me | 2012 |
Dual antiplatelet therapy in patients with aspirin resistance following coronary artery bypass grafting: study protocol for a randomized controlled trial [NCT01159639].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Bypass; Croatia; Drug Resistance; Dru | 2012 |
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hem | 2012 |
Cerebral microembolization after bioprosthetic aortic valve replacement: comparison of warfarin plus aspirin versus aspirin only.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aortic Valve Stenosis; Aspirin; Bioprosthesis; Collagen; Co | 2012 |
Increased risk of minor bleeding and antiplatelet therapy cessation in patients with acute coronary syndromes and low on-aspirin platelet reactivity. A prospective cohort study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle | 2013 |
Low-dose aspirin for preventing recurrent venous thromboembolism.
Topics: Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle | 2012 |
Clopidogrel added to aspirin adds no benefit but bleeding risk in patients with recent lacunar stroke.
Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combinati | 2013 |
Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
Topics: Aged; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Fibrinolytic Agents; Health Status Indic | 2013 |
Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Netherlands; | 2002 |
Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial.
Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Coumarins; Disease-Free Survival; D | 2002 |
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combin | 2002 |
Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups.
Topics: Acute Disease; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Drug Therapy, Comb | 2002 |
Warfarin, aspirin, or both after myocardial infarction.
Topics: Aged; Anticoagulants; Aspirin; Disease-Free Survival; Drug Therapy, Combination; Female; Hemorrhage; | 2002 |
Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide.
Topics: Acute Disease; Aged; Aspirin; Coronary Disease; Electrocardiography; Enoxaparin; Eptifibatide; Femal | 2003 |
Early and late effects of clopidogrel in patients with acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combinatio | 2003 |
Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial.
Topics: Aspirin; Cardiovascular Diseases; Cerebral Infarction; Double-Blind Method; Female; Hemorrhage; Huma | 2003 |
Warfarin and aspirin give more benefit than aspirin alone but also more bleeding after myocardial infarction.
Topics: Aged; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; International Normalized Ratio; Myocar | 2003 |
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Heart Failure | 2003 |
Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA).
Topics: Administration, Oral; Adult; Aged; Aortic Valve; Aspirin; Clopidogrel; Drug Therapy, Combination; Fe | 2003 |
Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (Part 1).
Topics: Adult; Aspirin; Blood Transfusion; Double-Blind Method; Female; Hemorrhage; Humans; Parity; Platelet | 2003 |
Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Double-Blind Method; Female; | 2003 |
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Benzodiazepines; Cerebrovascular Diso | 2003 |
Parameters of the tissue factor pathway with coumadin/dipyridamole versus ticlopidine as adjunct antithrombotic-drug regimen in coronary artery stenting.
Topics: Adult; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; C | 2003 |
A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis.
Topics: Aged; Anti-Bacterial Agents; Aspirin; Double-Blind Method; Drug Therapy, Combination; Echocardiograp | 2003 |
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blin | 2003 |
Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination | 2004 |
Efficacy and safety of low-dose aspirin in polycythemia vera.
Topics: Aspirin; Cardiovascular Diseases; Disease-Free Survival; Double-Blind Method; Female; Hemorrhage; Hu | 2004 |
A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients.
Topics: Analgesics; Antidepressive Agents; Antiviral Agents; Aspirin; Depressive Disorder; Drug Interactions | 2003 |
Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study.
Topics: Aged; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; | 2004 |
Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation.
Topics: Acute Disease; Aged; Aspirin; Coronary Disease; Female; Hemorrhage; Humans; Kidney Function Tests; M | 2003 |
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Topics: Aged; Angina Pectoris; Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans | 2004 |
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V | 2004 |
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V | 2004 |
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V | 2004 |
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V | 2004 |
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V | 2004 |
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V | 2004 |
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V | 2004 |
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V | 2004 |
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V | 2004 |
Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
Topics: Acute Disease; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2004 |
Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Topics: Abciximab; Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Angioplasty, Ba | 2004 |
Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Aspirin; Blood Coagulation; Cohort Studies; Coronary Artery Dis | 2005 |
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
Topics: Adult; Aged; Alanine Transaminase; Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Chronic Disea | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Ar | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Female; Fibrinol | 2005 |
Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Combined Mod | 2005 |
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; F | 2005 |
Occult bleeding in three different antithrombotic regimes after myocardial infarction. A WARIS-II subgroup analysis.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Fibrinolytic Agents; Follow-Up Studies; | 2006 |
Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Thera | 2005 |
Antiplatelets in stroke prevention: the MATCH trial. Some answers, many questions and countless perspectives.
Topics: Age Factors; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Drug Therapy, Combination; Femal | 2005 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Data Interpretation, | 2006 |
Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial.
Topics: Aged; Ambulances; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Emergency Me | 2007 |
Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction.
Topics: Aged; Aspirin; Blood Coagulation; Drug Administration Schedule; Drug Therapy, Combination; Electroca | 2006 |
ESPRIT study design and outcomes--a critical appraisal.
Topics: Aspirin; Biomarkers; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; H | 2007 |
Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arterial Occlusive Diseases; A | 2007 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LI
Topics: Aged; Anticoagulants; Aortic Valve; Aspirin; Female; Heart Valve Prosthesis Implantation; Hemorrhage | 2007 |
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Disease-Free Survival; Drug Th | 2007 |
Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial.
Topics: Aspirin; Double-Blind Method; Drug Administration Schedule; Female; Fibrinolytic Agents; Follow-Up S | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRAC
Topics: Aged; Aspirin; Diabetes Complications; Drug Therapy, Combination; Electrocardiography; Enoxaparin; F | 2007 |
Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
Topics: Adult; Aged; Antithrombin III; Aspirin; Drug Therapy, Combination; Female; Fibrin Fibrinogen Degrada | 2007 |
Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; Myoc | 2008 |
Effect of long-term aspirin use on embolic events in infective endocarditis.
Topics: Aged; Aspirin; Embolism; Endocarditis, Bacterial; Female; Hemorrhage; Humans; Male; Middle Aged; Pro | 2008 |
Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial.
Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Hemorrhage; Humans; Infant; Infant, Newborn; | 2008 |
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Com | 2008 |
Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Heart Valve Prosthesis; | 1983 |
The effects of acetylsalicylic acid on swelling, pain and other events after surgery.
Topics: Adolescent; Adult; Aspirin; Body Temperature; Clinical Trials as Topic; Double-Blind Method; Edema; | 1984 |
Low-dose heparin: an aid to therapy.
Topics: Aspirin; Clinical Trials as Topic; Dihydroergotamine; Double-Blind Method; Electric Stimulation; Hem | 1980 |
Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon.
Topics: 4-Hydroxycoumarins; Aged; Aspirin; Clinical Trials as Topic; Female; Hemorrhage; Humans; Male; Middl | 1980 |
Drug prophylaxis for arterial thromboembolism--1981.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coumarins; Decision M | 1981 |
Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Chi-Square Distribution; Drug Therapy, Combination; Female; | 1995 |
Platelet count, antiplatelet therapy and pulmonary embolism--a prospective study in patients with hip surgery.
Topics: Aged; Aged, 80 and over; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage | 1995 |
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Female; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; | 1995 |
[Bleeding complications in oral anticoagulant treatment].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Heart Valve Prosthesis; Hemorrhage; Humans; Myocardial | 1995 |
Low-dose aspirin in nulliparous women: safety of continuous epidural block and correlation between bleeding time and maternal-neonatal bleeding complications. National Institute of Child Health and Human Developmental Maternal-Fetal Medicine Network.
Topics: Analysis of Variance; Anesthesia, Epidural; Anesthesia, Obstetrical; Aspirin; Bleeding Time; Blood C | 1995 |
Long-term effects of n-3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary artery disease.
Topics: Aged; Antithrombin III; Arteriosclerosis; Aspirin; Bleeding Time; Coronary Artery Bypass; Coronary D | 1995 |
Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin.
Topics: Adult; Anemia; Aspirin; Cross-Over Studies; Double-Blind Method; Erythropoietin; Female; Hematocrit; | 1994 |
Combined use of aspirin and warfarin in primary prevention of ischemic heart disease in men at high risk.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemorrhage; Humans; Inci | 1995 |
[Adverse effects of combined use of acenocoumarol and acetylsalicylic acid after myocardial infarct and unstable angina].
Topics: Acenocoumarol; Angina, Unstable; Aspirin; Drug Synergism; Drug Therapy, Combination; Female; Hemorrh | 1995 |
Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Hemorrhage; Heparin; Hirudin Therapy; Hirudins; Humans; | 1994 |
Comparison of anticoagulation regimens after Carpentier-Edwards aortic or mitral valve replacement.
Topics: Aortic Valve; Aspirin; Atrial Fibrillation; Bioprosthesis; Female; Follow-Up Studies; Heart Valve Pr | 1994 |
Effects of low intensity antithrombotic regimes on the haemoglobin level.
Topics: Aged; Aspirin; Drug Synergism; Drug Therapy, Combination; Fibrinolytic Agents; Hemoglobins; Hemorrha | 1994 |
Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. EMERAS (Estudio Multicéntrico Estreptoquinasa Repúblicas de América del Sur) Collaborative Group.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Confidence Intervals; Drug Hypersensiti | 1993 |
Use of desmopressin to prevent bleeding complications in patients treated with aspirin.
Topics: Adult; Aged; Aspirin; Bleeding Time; Cholecystectomy; Deamino Arginine Vasopressin; Female; Hemorrha | 1993 |
A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Confidence Intervals; Double-Blind Method; Drug Therapy, Co | 1993 |
Subacute occlusion, bleeding complications, hospital stay and restenosis after Palmaz-Schatz coronary stenting under a new antithrombotic regimen.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Aspirin; Coronary Angiography; | 1996 |
Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. CLASP collaborative group.
Topics: Aspirin; Body Height; Body Weight; Canada; Cohort Studies; Developmental Disabilities; Double-Blind | 1995 |
Platelet disorders in uraemia before and after haemodialysis under the influence of low dose aspirin.
Topics: Adult; Aged; Aspirin; Bleeding Time; Blood Platelets; Female; Hematocrit; Hemorrhage; Humans; Male; | 1995 |
Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular | 1996 |
Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry.
Topics: Aged; Anticoagulants; Aspirin; Coronary Vessels; Female; France; Hemorrhage; Heparin, Low-Molecular- | 1996 |
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Bleeding Time; Dose-Respo | 1996 |
Comparison of high-dose with low-dose aspirin in patients with mechanical heart valve replacement treated with oral anticoagulant.
Topics: Administration, Oral; Adult; Aged; Aspirin; Dose-Response Relationship, Drug; Female; Heart Valve Pr | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.
Topics: Adult; Aged; Aspirin; Cerebrovascular Disorders; Demography; Dipyridamole; Double-Blind Method; Fema | 1996 |
Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial).
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Hemorrhage; Heparin; Humans; Plasminogen Activators | 1997 |
First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions.
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Benzamidines; Coronary Arter | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Female; Hemorrhage; Humans; Male; Middle Aged; Platel | 1997 |
Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Double-Blind Method; | 1998 |
Wiktor stent for treatment of chronic total coronary artery occlusions: short- and long-term clinical and angiographic results from a large multicenter experience.
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Catheterization, Peri | 1998 |
[Clinical safety using the thrombocyte aggregation inhibitor c7E3 in interventional cardiology in 520 patients].
Topics: Abciximab; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Angina, Unstable | 1997 |
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolyti | 1998 |
International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Gl
Topics: Acetates; Aged; Angina, Unstable; Anticoagulants; Aspirin; Female; Hemorrhage; Heparin; Humans; Male | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disord | 1998 |
Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results.
Topics: Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombin | 1998 |
Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study.
Topics: Administration, Oral; Aged; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Coronary Disease; | 1998 |
Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Delayed-Action Preparations; Dipyridamole; Disease-Free Su | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
Do intensive blood pressure lowering and low-dose ASA help our hypertensive patients?
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1998 |
Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Thrombosis; Diarrhea; D | 1999 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anti | 1999 |
Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disord | 1999 |
Intravenous acetylsalicylic acid, magnesium and their combination in experimental arterial thrombosis in rats.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Pressure; Double-Blind Method; Hemorrhage; Magnesium; Male | 1999 |
Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Gastrointest | 1999 |
Vitamin E, a modifier of platelet function: rationale and use in cardiovascular and cerebrovascular disease.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Double-Blind Method; H | 1999 |
Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Busulfan; Coronary Disease; Dise | 1999 |
Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Busulfan; Disease-Free Survival; Female; Hemorr | 1999 |
Cardiac surgery and catheterization in patients with haemophilia.
Topics: Adolescent; Adult; Aged; Aortic Valve; Aspirin; Cardiac Catheterization; Coronary Angiography; Coron | 2000 |
Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups.
Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrha | 2000 |
Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators.
Topics: Aspirin; Brain Ischemia; Cause of Death; Clopidogrel; Confidence Intervals; Double-Blind Method; Fem | 2000 |
Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
Topics: Aged; Angina, Unstable; Anticoagulants; Aspirin; Biphenyl Compounds; Double-Blind Method; Female; He | 2000 |
A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction.
Topics: Aged; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; Coronary Vessel | 2000 |
Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group.
Topics: Acenocoumarol; Adult; Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis Implantation; Female | 2001 |
Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes.
Topics: Aged; Aspirin; Cause of Death; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Com | 2001 |
Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications.
Topics: Administration, Oral; Aneurysm, False; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cere | 2001 |
Abciximab readministration: results of the ReoPro Readministration Registry.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies; Antibodies, Monoclonal; Aspirin; Coronary Dis | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
The effect of perioperative aspirin therapy in peripheral vascular surgery: a decision analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Decision Support Techniques; Hemorrhage; Humans; I | 2001 |
Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS).
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dose-Response Relationship | 2001 |
Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes.
Topics: Aged; Alanine; Angina, Unstable; Antigens, Human Platelet; Aspirin; Double-Blind Method; Female; Gen | 2001 |
Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation?
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fi | 2001 |
Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Autoimmune D | 2001 |
A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind Method; Female | 2001 |
Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; | 2002 |
Clopidogrel: a CURE in acute coronary syndromes?
Topics: Acute Disease; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Hemorrhage | 2002 |
Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Blood Vessel Prosthesis; Boston; Combined Modal | 2002 |
Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Topics: Ambulatory Care; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Cost-Benefit Analysis; Dal | 2002 |
Aspirin: A paradoxical effect on bleeding-time.
Topics: Adult; Anticoagulants; Aspirin; Clot Retraction; Dose-Response Relationship, Drug; Female; Hemorrhag | 1978 |
Acetylsalicylic acid vs paracetamol: effects on post-operative course.
Topics: Acetaminophen; Adolescent; Adult; Aspirin; Clinical Trials as Topic; Female; Hemorrhage; Humans; Mal | 1977 |
Effect of pretreatment with acetylsalicylate on surgical bleeding and peroperative mortality in rats undergoing kidney transplantation.
Topics: Animals; Aspirin; Clinical Trials as Topic; Hemorrhage; Kidney Transplantation; Lysine; Male; Preope | 1978 |
Effect of acetylsalicylic acid, paracetamol, and placebo on pain and blood loss in dysmenorrhoeic women.
Topics: Acetaminophen; Adult; Aspirin; Clinical Trials as Topic; Double-Blind Method; Dysmenorrhea; Female; | 1978 |
Prostaglandin E2 prevents aspirin-induced blood loss.
Topics: Adult; Aspirin; Clinical Trials as Topic; Erythrocyte Membrane; Erythrocytes; Feces; Hemorrhage; Hum | 1979 |
Controlled trial of aspirin in cerebral ischemia (AITIA study).
Topics: Actuarial Analysis; Aspirin; Clinical Trials as Topic; Double-Blind Method; Follow-Up Studies; Hemor | 1979 |
Prophylaxis of thromboembolic disease.
Topics: Abdomen; Aspirin; Clinical Trials as Topic; Dextrans; Double-Blind Method; Early Ambulation; Hemorrh | 1979 |
The hazards of aspirin plus heparin.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Heparin; Hip Fractures; Humans; Thrombophlebitis; Wa | 1978 |
Influence of prophylaxis on proximal venous thrombus formation after total hip arthroplasty.
Topics: Adult; Aspirin; Combined Modality Therapy; Dextrans; Female; Gravity Suits; Hemorrhage; Hip Prosthes | 1992 |
Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group.
Topics: Aged; Angina Pectoris; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Male; Myocardial In | 1992 |
The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations.
Topics: Aged; Aspirin; Blood Coagulation Factors; Cardiopulmonary Bypass; Coronary Artery Bypass; Deamino Ar | 1992 |
Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation.
Topics: Administration, Oral; Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combinatio | 1992 |
Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators.
Topics: Aspirin; Coronary Angiography; Coronary Vessels; Hemorrhage; Heparin; Humans; Myocardial Infarction; | 1992 |
An evaluation of clinical aspects of post-operative autotransfusion, either alone or in conjunction with pre-operative aspirin, in cardiac surgery.
Topics: Aspirin; Blood Transfusion, Autologous; Coronary Artery Bypass; Hemorrhage; Hemostasis, Surgical; Hu | 1991 |
Stroke Prevention in Atrial Fibrillation Study. Final results.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Embolism; Female; Follow-Up Studies; | 1991 |
Stroke Prevention in Atrial Fibrillation Study. Final results.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Embolism; Female; Follow-Up Studies; | 1991 |
Stroke Prevention in Atrial Fibrillation Study. Final results.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Embolism; Female; Follow-Up Studies; | 1991 |
Stroke Prevention in Atrial Fibrillation Study. Final results.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Embolism; Female; Follow-Up Studies; | 1991 |
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
Topics: Aspirin; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 1991 |
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
Topics: Aspirin; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 1991 |
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
Topics: Aspirin; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 1991 |
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
Topics: Aspirin; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 1991 |
Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study.
Topics: Angiography; Aspirin; Blood Transfusion; Coronary Artery Bypass; Graft Occlusion, Vascular; Hemorrha | 1991 |
Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo-controlled, randomized trial.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angiography; Aspirin; Cardiac Catheterization; Coronary Ang | 1990 |
A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.
Topics: Administration, Oral; Aspirin; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Humans; Infus | 1990 |
[Prevention of thromboembolism in para-articular femoral fractures of the hip--results of a prospective randomized study of heparin-DHE and ASS-DHE].
Topics: Aged; Aged, 80 and over; Aspirin; Bone Screws; Cause of Death; Dihydroergotamine; Drug Combinations; | 1990 |
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Hemorrhage | 1990 |
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Hemorrhage | 1990 |
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Hemorrhage | 1990 |
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Hemorrhage | 1990 |
Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group).
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Artery | 1990 |
Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy.
Topics: Aspirin; Blood Transfusion; Coronary Artery Bypass; Dipyridamole; Double-Blind Method; Graft Occlusi | 1990 |
A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Female; Follow-Up Studies; Hemorr | 1989 |
Antithrombotic therapy in the primary prevention of acute myocardial infarction.
Topics: Aged; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Male; Mi | 1989 |
Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting.
Topics: Aged; Aspirin; Blood Transfusion; Coronary Artery Bypass; Female; Hemorrhage; Humans; Male; Middle A | 1988 |
Aspirin and secondary bleeding after traumatic hyphema.
Topics: Adult; Aspirin; Clinical Trials as Topic; Eye Injuries; Hemorrhage; Humans; Hyphema; Recurrence; Wou | 1988 |
Therapeutic potential of choline magnesium trisalicylate as an alternative to aspirin for patients with bleeding tendencies.
Topics: Adolescent; Adult; Aspirin; Choline; Clinical Trials as Topic; Hemorrhage; Humans; In Vitro Techniqu | 1987 |
Dipyridamole preserved platelets and reduced blood loss after cardiopulmonary bypass.
Topics: Administration, Oral; Aspirin; Blood Platelets; Blood Transfusion; Cardiopulmonary Bypass; Dipyridam | 1988 |
Post-tonsillectomy haemorrhage and analgesics. A comparative study of acetylsalicylic acid and paracetamol.
Topics: Acetaminophen; Adolescent; Adult; Aspirin; Child; Child, Preschool; Female; Hemorrhage; Hemostasis, | 1988 |
Effectiveness of anticoagulants.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Angina, Unstable; Anticoagulants; Aspirin; Blood | 1986 |
Hemorrhagic complications of anticoagulant therapy.
Topics: Administration, Oral; Animals; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorde | 1986 |
A critical appraisal of the clinical efficiency of anti-platelet drugs.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1986 |
[Clinical aspects of postoperative embolism prevention using acetylsalicylic acid].
Topics: Adult; Aspirin; Embolism; Female; Hemorrhage; Humans; Middle Aged; Postoperative Complications | 1973 |
[Prevention of postoperative thrombo-embolism with acetylsalicyclic acid (author's transl)].
Topics: Age Factors; Angina Pectoris; Aspirin; Body Weight; Diabetes Complications; Female; Follow-Up Studie | 1974 |
Reduction in venous thromboembolism by agents affecting platelet function.
Topics: Adult; Aged; Arthroplasty; Aspirin; Blood Platelets; Chromium Alloys; Dextrans; Dipyridamole; Female | 1971 |
1075 other studies available for aspirin and Bleeding
| Article | Year |
|---|---|
Synthesis and evaluation of dual antiplatelet activity of bispidine derivatives of N-substituted pyroglutamic acids.
Topics: Animals; Blood Coagulation; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Hemorrhage; Hu | 2016 |
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Hemor | 2022 |
In-hospital Bleeding Outcomes of Oral Anticoagulant and Dual Antiplatelet Therapy During Percutaneous Coronary Intervention: An Analysis From the Japanese Nationwide Registry.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Dual Anti-Platelet Therapy | 2021 |
Eastern Association for the Surgery of Trauma Multicenter Trial: Comparison of pre-injury antithrombotic use and reversal strategies among severe traumatic brain injury patients.
Topics: Aged; Anticoagulant Reversal Agents; Aspirin; Brain Injuries, Traumatic; Cardiovascular Diseases; Co | 2022 |
In ASCVD, 81 mg and 325 mg of aspirin did not differ for CV or bleeding events.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans | 2021 |
Utility of a pharmacogenetic-driven algorithm in guiding dual antiplatelet therapy for patients undergoing coronary drug-eluting stent implantation in China.
Topics: Aged; Algorithms; Asian People; Aspirin; Cardiovascular Diseases; China; Clopidogrel; Comorbidity; C | 2022 |
Aspirin Thromboprophylaxis Is Associated With Less Major Bleeding Events Following Total Joint Arthroplasty.
Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Hip; Aspirin; Hemorrhage; Humans; Retrospec | 2022 |
Left atrial appendage closure: a new strategy for cardioembolic events despite oral anticoagulation.
Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Hemorrhage; Humans; Retrospective St | 2023 |
Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Fibrinolytic Agents; He | 2022 |
Thromboelastography with platelet mapping: Limited predictive ability in detecting preinjury antiplatelet agent use.
Topics: Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Blood Platelets; Domperidone; Female; Hemorrhage | 2021 |
Bleeding in patients with continuous-flow left ventricular assist devices: acquired von Willebrand disease or antithrombotics?
Topics: Aspirin; Fibrinolytic Agents; Heart-Assist Devices; Hemorrhage; Humans; von Willebrand Diseases; von | 2022 |
Dual pathway inhibition in atherothrombosis prevention: yes, now we can!
Topics: Aspirin; Cardiovascular Diseases; Drug-Eluting Stents; Hemorrhage; Humans; Platelet Aggregation Inhi | 2023 |
Dual Antiplatelet Therapy Is Superior to Aspirin in Preventing Short-Term Recurrent Stroke at the Cost of More Major Bleeding.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggrega | 2021 |
Platelet function assessed by ROTEM
Topics: Aspirin; Clopidogrel; Deamino Arginine Vasopressin; Hemorrhage; Humans; Platelet Aggregation Inhibit | 2022 |
Appraising the contemporary role of aspirin for primary and secondary prevention of atherosclerotic cardiovascular events.
Topics: Aspirin; Atherosclerosis; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Primary Prevention; S | 2021 |
Mitochondrial Dysfunction in Trauma-Related Coagulopathy: Is There Causality? Study Protocol for a Prospective Observational Study.
Topics: Aspirin; Blood Coagulation Disorders; Hemorrhage; Hemostasis; Humans; Observational Studies as Topic | 2023 |
Increased relative risk of delayed hemorrhage in patients taking anticoagulant/antiplatelet medications with concurrent aspirin therapy: implications for clinical practice based on 3-year retrospective analysis in a large health system.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Retrospective Studies; Risk | 2022 |
Aspirin Administered for Venous Thromboembolism Prophylaxis May Protect Against Stiffness Following Total Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Hemorrhage | 2022 |
Impact of Drug Interactions on Major Bleed Rates in Patients Taking Direct Oral Anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Drug Interactions; H | 2023 |
When and How to Combine Antiplatelet and Anticoagulant Drugs?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Hemorrhage; Humans; Platele | 2022 |
Anticoagulation Therapy After the Fontan Procedure.
Topics: Anticoagulants; Aspirin; Child; Fontan Procedure; Hemorrhage; Humans; Retrospective Studies; Thrombo | 2022 |
Conservative versus aggressive antiplatelet strategy for emergent carotid stenting during stroke thrombectomy.
Topics: Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Retrospective Studies; Stents; Stroke; | 2023 |
Association Between Platelet Reactivity and Long-Term Bleeding Complications After Percutaneous Coronary Intervention According to Diabetes Status.
Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Hemorrhage; Humans; Percutaneous Coronary Intervention; Pla | 2022 |
Dual versus mono antiplatelet therapy in mild-to-moderate stroke during hospitalization.
Topics: Aspirin; Clopidogrel; Cohort Studies; Hemorrhage; Hospitalization; Humans; Hydroxymethylglutaryl-CoA | 2022 |
Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa.
Topics: Animals; Anticoagulants; Aspirin; Factor XIa; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggr | 2022 |
Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Drug Therapy, Combination; Fibrinolyti | 2022 |
Risk of post-polypectomy bleeding after endoscopic mucosal resection in patients receiving antiplatelet medication: comparison between the continue and hold groups.
Topics: Aspirin; Clopidogrel; Colonic Polyps; Colonoscopy; Endoscopic Mucosal Resection; Hemorrhage; Humans; | 2022 |
Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack.
Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemia; Ischemic Attack, Tra | 2022 |
Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study.
Topics: Adult; Aspirin; COVID-19; Critical Illness; Hemorrhage; Humans; Intensive Care Units; Propensity Sco | 2022 |
Hemorrhages in Polycythemia Vera and Essential Thrombocythemia: Epidemiology, Description, and Risk Factors-Learnings from a Large Cohort.
Topics: Aspirin; Hemorrhage; Humans; Hydroxyurea; Male; Polycythemia Vera; Risk Factors; Thrombocythemia, Es | 2022 |
An antiplatelet response gene expression signature is associated with bleeding.
Topics: Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Transcriptome; Treatment O | 2023 |
Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
Topics: Acute Coronary Syndrome; Aspirin; Australia; Clopidogrel; Hemorrhage; Hospital Mortality; Humans; Pe | 2022 |
Fixed-dose aspirin monotherapy compared with thromboelastography directed antiplatelet therapy in long-term management of left ventricular assist devices.
Topics: Aspirin; Heart Failure; Heart-Assist Devices; Hemorrhage; Humans; Platelet Aggregation Inhibitors; R | 2022 |
Association between ticagrelor plasma concentration and bleeding events in Chinese patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; China; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhib | 2022 |
Elective percutaneous liver biopsy and use of aspirin.
Topics: Aspirin; Biopsy; Hemorrhage; Humans; Liver; Platelet Aggregation Inhibitors | 2022 |
Safety and efficacy comparison between OACs plus single antiplatelet and dual antiplatelet therapy in patients with cerebral venous sinus stenosis poststenting.
Topics: Adult; Anticoagulants; Aspirin; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combination; Fe | 2022 |
Low platelet reactivity in patients with myocardial infarction treated with aspirin plus ticagrelor.
Topics: Adenosine Diphosphate; Aspirin; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhi | 2022 |
Exploratory Use of Glycoprotein IIb/IIIa Inhibition in Prevention of Blalock-Taussig Shunt Thrombosis.
Topics: Anticoagulants; Aspirin; Blalock-Taussig Procedure; Cohort Studies; Fibrinolytic Agents; Hemorrhage; | 2022 |
[Recent developments in secondary cardiovascular prevention: the pros and cons of dual pathway inhibition].
Topics: Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Hemorrhage; Human | 2022 |
Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients.
Topics: Aspirin; Body Weight; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, T | 2022 |
Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase.
Topics: Aspirin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemia; Male; Myocardial Infarction; Pl | 2022 |
The effect of low-dose and high-dose low-molecular-weight-heparin and aspirin thromboprophylaxis on clinical outcome and mortality in critical ill patients with COVID-19: A retrospective cohort study.
Topics: Anticoagulants; Aspirin; COVID-19; Critical Illness; Hemorrhage; Heparin, Low-Molecular-Weight; Huma | 2022 |
P2Y12 reaction units and ischemic and bleeding events after neuro-endovascular treatment.
Topics: Aspirin; Clopidogrel; Endovascular Procedures; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2022 |
Association between body mass index and bleeding events associated with the use of aspirin in ischemic stroke or transient ischemic attack patients.
Topics: Aspirin; Body Mass Index; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; | 2022 |
Some Points for the KDIGO 2021 Guideline for Prophylactic Anticoagulation in Membranous Nephropathy: Is It Clear Enough for Us to Follow?
Topics: Anticoagulants; Aspirin; Glomerulonephritis, Membranous; Hemorrhage; Heparin, Low-Molecular-Weight; | 2023 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Myocard | 2022 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Myocard | 2022 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Myocard | 2022 |
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Myocard | 2022 |
Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation I | 2022 |
Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Cholesterol; Clopidogrel; Cohort Studies; Coronary Ar | 2022 |
Effect of Chronic Antiplatelet and Anticoagulant Medication in Neck Hematoma and Perioperative Outcomes after Carotid Endarterectomy.
Topics: Anticoagulants; Aspirin; Endarterectomy, Carotid; Hematoma; Hemorrhage; Humans; Retrospective Studie | 2023 |
Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation.
Topics: Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Hemorrhage; Humans; Male; Middle Aged; Venous T | 2022 |
Risk of bleeding after percutaneous native kidney biopsy in patients receiving low-dose aspirin: a single-center retrospective study.
Topics: Aspirin; Biopsy; Hemorrhage; Humans; Kidney; Nephrectomy; Platelet Aggregation Inhibitors; Retrospec | 2023 |
Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial.
Topics: Aspirin; Drug-Eluting Stents; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Perc | 2022 |
Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemic Str | 2023 |
Oral anticoagulant management of patients with mechanical heart valves at the Salam Centre of Khartoum: Observations on quality of anticoagulation and thrombotic risk.
Topics: Adult; Anticoagulants; Aspirin; Blood Coagulation; Female; Heart Valves; Hemorrhage; Humans; Male; T | 2022 |
Effect of aspirin on primary prevention of cardiovascular disease and mortality among patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Middle Aged; Platelet | 2022 |
Eptifibatide-induced acute profound thrombocytopenia: A case report.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Eptifibatide; Glycoproteins; Hemorrhage; Humans; Male | 2022 |
Concordance Between Patient-Reported Health Data and Electronic Health Data in the ADAPTABLE Trial.
Topics: Aged; Aspirin; Electronic Health Records; Female; Hemorrhage; Humans; Male; Myocardial Infarction; P | 2022 |
Comparison of Cilostazol versus Clopidogrel in Addition to Aspirin in Patients with Ischemic Stroke who Underwent Intracranial or Extracranial Artery Stent Implantation.
Topics: Arteries; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Platele | 2023 |
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Platele | 2023 |
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Platele | 2023 |
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Platele | 2023 |
Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study.
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Human | 2022 |
Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study.
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Human | 2022 |
Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study.
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Human | 2022 |
Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study.
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Human | 2022 |
Efficacy and safety of single versus dual antiplatelet therapy in carotid artery stenting.
Topics: Aspirin; Carotid Arteries; Carotid Stenosis; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Re | 2023 |
Tailoring oral antiplatelet therapy in acute coronary syndromes: from guidelines to clinical practice.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Hemorrhage; | 2023 |
Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation.
Topics: Aspirin; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percutaneous Cor | 2023 |
No Antithrombotic Therapy After Transcatheter Aortic Valve Replacement: Insight From the OCEAN-TAVI Registry.
Topics: Aortic Valve; Aortic Valve Stenosis; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Platele | 2023 |
Ticagrelor versus clopidogrel dual antiplatelet therapy for unruptured intracranial aneurysms treated with flowdiverter.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Re | 2023 |
Monitoring antiplatelet therapy: where are we now?
Topics: Anticoagulants; Aspirin; Atherosclerosis; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneou | 2023 |
De-escalation in intensity or duration of dual antiplatelet therapy in patients with coronary artery disease: More than alternative treatment options.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Hu | 2023 |
Safety and Efficacy of Rivaroxaban in Primary Total Hip and Knee Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2023 |
Time Course of Death After Acute Coronary Syndrome Treated With Dual Antiplatelet Therapy for 1 Year.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Percut | 2023 |
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneou
Topics: Aspirin; Cardiology; Clopidogrel; Coronary Artery Disease; Fibrinolytic Agents; Hemorrhage; Humans; | 2023 |
Prasugrel Monotherapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Platinum-Chromium Everolimus Eluting Stent for Japanese Patients With Chronic Coronary Syndrome (ASET-JAPAN).
Topics: Aspirin; Drug-Eluting Stents; East Asian People; Everolimus; Hemorrhage; Humans; Japan; Percutaneous | 2023 |
Exposure to maternal acetylsalicylic acid and the risk of bleeding events in extreme premature neonates.
Topics: Aspirin; Hemorrhage; Humans; Infant, Newborn | 2023 |
Sex-Related Bleeding Risk in Acute Coronary Syndrome Patients Receiving Dual Antiplatelet Therapy with Aspirin and a P2Y12 Inhibitor.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous | 2023 |
Acute coronary syndrome in very elderly patients-a real-world experience.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; | 2023 |
Association of Clinical Outcomes With Sex in Patients Receiving Chronic Maintenance Antiplatelet Monotherapy After Percutaneous Coronary Intervention: A Post Hoc Gender Analysis of the HOST-EXAM Study.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Femal | 2023 |
Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, C | 2023 |
Dual Antiplatelet Therapy Duration After Multivessel Optimal Intravascular Ultrasound-Guided Percutaneous Coronary Intervention.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet | 2023 |
Risk of secondary stroke subsequent to restarting aspirin in chronic stroke patients suffering from traumatic brain injury in Taiwan.
Topics: Adult; Aspirin; Brain Damage, Chronic; Brain Injuries, Traumatic; Drug Therapy, Combination; Female; | 2023 |
Comparison of clinical outcomes with cangrelor plus aspirin versus oral dual antiplatelet therapy in patients supported with venoarterial extracorporeal membrane oxygenation.
Topics: Aspirin; Drug Therapy, Combination; Extracorporeal Membrane Oxygenation; Hemorrhage; Humans; Percuta | 2023 |
Heterogeneity after harmonisation: A retrospective cohort study of bleeding and stroke risk after the introduction of direct oral anticoagulants in four Western European countries.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Hemorrhage; Humans; Retrospectiv | 2023 |
Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE.
Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Infarction; Renal Insufficien | 2023 |
The Plasma Concentration of Ticagrelor and Aspirin as a Predictor of Bleeding Complications in Chinese Acute Coronary Syndrome Patients With Dual Antiplatelet Therapy: A Prospective Observational Study.
Topics: Acute Coronary Syndrome; Aspirin; East Asian People; Hemorrhage; Humans; Percutaneous Coronary Inter | 2023 |
A novel de-escalation antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
[Comparison of Various Regimens of Antithrombotic Therapy in Patients With Valvular Heart Disease and Coronary Artery Disease After Surgical and Interventional Interventions].
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Female; Fibrinolytic Agents; Heart Va | 2023 |
Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attac | 2023 |
De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneo | 2023 |
Perioperative continuation or ultra-early resumption of antithrombotics in elective neurosurgical cranial procedures.
Topics: Aspirin; Elective Surgical Procedures; Fibrinolytic Agents; Hemorrhage; Humans; Neurosurgical Proced | 2023 |
DAPT and GPVI: an antiplatelet triple threat.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet | 2023 |
In CAD, P2Y12 inhibitor vs. aspirin monotherapy reduces a composite CV outcome without increasing major bleeding.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet | 2023 |
DAPT Is Comparable to OAC Following LAAC With WATCHMAN FLX: A National Registry Analysis.
Topics: Aged; Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Female; Hemorrhage; Humans; Ma | 2023 |
De-escalation from potent P2Y12 inhibitors to clopidogrel: an alternative to short DAPT duration in HBR patients?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Interventio | 2023 |
Re: Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation I | 2019 |
Evaluation of commonly used tests to measure the effect of single-dose aspirin on mouse hemostasis.
Topics: Animals; Aspirin; Disease Models, Animal; Drug Evaluation, Preclinical; Hemorrhage; Hemostasis; Male | 2019 |
Major cardiovascular and bleeding events with long-term use of aspirin in patients with prior cardiovascular diseases: 1-year follow-up results from the Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study.
Topics: Aged; Aspirin; Cardiovascular Diseases; Drug Administration Schedule; Female; Fibrinolytic Agents; H | 2020 |
Effect of concomitant antiplatelet therapy in patients with nonvalvular atrial fibrillation initiating non-vitamin K antagonists.
Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Comb | 2019 |
Aspirin, cancer, and bleeding: an equation to solve.
Topics: Aspirin; Feasibility Studies; Hemorrhage; Humans; Neoplasms | 2019 |
Management of Extracranial Blunt Cerebrovascular Injuries: Experience with an Aspirin-Based Approach.
Topics: Adolescent; Adult; Aged; Anticoagulants; Aortic Dissection; Aspirin; Carotid Artery Injuries; Caroti | 2020 |
Individualize Treatment With Aspirin for Primary Prevention.
Topics: Aspirin; Hemorrhage; Humans; Primary Prevention | 2019 |
Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention: A Benefit-Harm Analysis.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Middle Aged; Platel | 2019 |
Is Bleeding Always Bad?: Bad Boy Bleeding.
Topics: Aspirin; Factor Xa Inhibitors; Hemorrhage; Humans; Male; Peripheral Arterial Disease; Rivaroxaban | 2019 |
Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Agents; | 2019 |
Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With High Bleeding Risk: Insight From the STOPDAPT-2 Trial.
Topics: Aged; Aspirin; Chromium Alloys; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Drug | 2019 |
[Dual Pathway Inhibition in Atherosclerosis - Which Patients Benefit?]
Topics: Aspirin; Atherosclerosis; Factor Xa Inhibitors; Heart Diseases; Hemorrhage; Humans; Peripheral Arter | 2019 |
Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75-100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study.
Topics: Aspirin; Coronary Artery Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregatio | 2020 |
Estimating short- and long-term reference change values and index of individuality for tests of platelet function.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Biological Variation, Population; Female; Follow-U | 2019 |
The evidence strength of a meta-analysis of aspirin for primary prevention of cancer.
Topics: Aspirin; Hemorrhage; Humans; Incidence; Neoplasms; Primary Prevention | 2020 |
Preoperative Light Transmission Aggregometry Values Predict for Thromboembolic Complications After Stent-Assisted Coil Embolization.
Topics: Aspirin; Clopidogrel; Embolization, Therapeutic; Endovascular Procedures; Female; Hematoma; Hemorrha | 2020 |
Review: In newer CVD primary prevention trials, aspirin vs no aspirin does not reduce MI and increases major bleeding.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention | 2019 |
Prasugrel for Japanese Patients With Ischemic Heart Disease in Long-Term Clinical Practice (PRASFIT-Practice II) - 1-Year Follow-up Results of a Postmarketing Observational Study.
Topics: Aged; Aged, 80 and over; Anemia; Aspirin; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; | 2019 |
Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2 | 2020 |
Management of blunt hepatic and splenic injuries (grade ≤ III) in patients receiving antithrombotic therapy.
Topics: Acenocoumarol; Adult; Aged; Aged, 80 and over; Aspirin; Blood Coagulation Factors; Blood Transfusion | 2019 |
Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percut
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cor | 2020 |
Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study).
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopi | 2020 |
In stable CAD with type 2 diabetes, adding ticagrelor to aspirin reduced CV events but increased major bleeding.
Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Hemorrhage; Humans; Ticagrelor | 2020 |
After PCI and 3 mo of DAPT, ticagrelor for 12 mo reduced bleeding vs continued DAPT and did not increase ischemic events.
Topics: Aspirin; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ti | 2020 |
Impact of Anemia on the Risk of Bleeding Following Percutaneous Coronary Interventions in Patients ≥75 Years of Age.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Angina, Unstable; Anticoagulants; Antithro | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P | 2020 |
Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Topics: Administration, Oral; Adult; Area Under Curve; Aspirin; Clinical Trials as Topic; Clinical Trials, P | 2020 |
[Management of antithrombotic therapy in patients with bleeding after percutaneous coronary intervention].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percut | 2020 |
Aspirin in Primary and Secondary Prevention of Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Primary Preve | 2020 |
Haemorrhagic transformation following ischaemic stroke: A retrospective study.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Hemorrhage; Humans; Intr | 2020 |
Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Thrombosis; Fa | 2020 |
Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis).
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Decision-Making; Computed Tomography Angiography; Coronar | 2020 |
Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Clo | 2020 |
Primary prophylaxis of venous thromboembolism in extragonadal germ-cell tumour.
Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Cisplatin; Enoxaparin; Hemorrhage; Humans; Male; Med | 2020 |
Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Topics: Aged; Asian People; Aspirin; Cilostazol; Clopidogrel; Databases, Factual; Dual Anti-Platelet Therapy | 2020 |
Ischemic Versus Bleeding Outcomes After Percutaneous Coronary Interventions in Patients With High Bleeding Risk.
Topics: Aged; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Artery Disease; Dual Anti-Platelet | 2020 |
PURL: Aspirin, Yes, for at-risk elderly-but what about the healthy elderly?
Topics: Aged; Aspirin; Cardiovascular Diseases; Health Status; Hemorrhage; Humans; Primary Prevention | 2020 |
Risk Factors for Postoperative Events in Patients on Antiplatelet Therapy Undergoing Off-Pump Coronary Artery Bypass Grafting Surgery.
Topics: Aged; Aged, 80 and over; Aspirin; Beijing; Clopidogrel; Coronary Artery Bypass, Off-Pump; Drug Admin | 2020 |
Concomitant Aspirin and Anticoagulation Is Associated With Increased Risk for Major Bleeding in Surgical Patients Requiring Postoperative Intensive Care.
Topics: Anticoagulants; Aspirin; Critical Care; Female; Hemorrhage; Humans; Male; Middle Aged; Postoperative | 2020 |
Risk of major bleeding associated with aspirin use in non-surgical critically ill patients receiving therapeutic anticoagulation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Critical Illness; Drug Therapy, Co | 2020 |
Aspirin for primary prevention of cardiovascular disease in women.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Female; Hemorrh | 2020 |
Cilostazol for Chinese Patients with Aspirin Intolerance after Coronary Drug-Eluting Stent Implantation.
Topics: Aspirin; China; Cilostazol; Coronary Artery Disease; Drug-Eluting Stents; Dual Anti-Platelet Therapy | 2020 |
Cranberry supplementation as a cause of major intraoperative bleeding during vascular surgery due to aspirin-like platelet inhibition.
Topics: Aged; Aortic Aneurysm, Thoracic; Aspirin; Blood Loss, Surgical; Dietary Supplements; Female; Hemorrh | 2020 |
Aspirin Is Associated With Reduced Rates of Venous Thromboembolism in Older Patients With Cancer.
Topics: Aged; Aged, 80 and over; Aspirin; Databases, Factual; Female; Fibrinolytic Agents; Hemorrhage; Hospi | 2020 |
Add-On Therapies in Cardiovascular Disease: Reviewing ICER's Report and the Potential Effect on Payers.
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Dr | 2020 |
Concomitant use of direct oral anticoagulants and aspirin versus direct oral anticoagulants alone in atrial fibrillation and flutter: a retrospective cohort.
Topics: Acute Coronary Syndrome; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; | 2020 |
Should aspirin be used for prophylaxis of COVID-19-induced coagulopathy?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Autopsy; Blood Coagulation Disorde | 2020 |
Lower Platelet Aggregation Is a Risk Factor for Dual Antiplatelet Therapy-Associated Bleeding: A Preliminary Retrospective Study with Genotype Analysis.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Case-Control Studie | 2020 |
Post-extraction bleeding complications in patients on uninterrupted dual antiplatelet therapy-a prospective study.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors | 2021 |
Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Coronary Artery Disease; Dual An | 2020 |
Nonusefulness of Antithrombotic Therapy After Surgical Bioprosthetic Aortic Valve Replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aortic Valve; Aortic Valve Insufficiency; Aortic Val | 2020 |
[Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
Topics: Acute Coronary Syndrome; Acute Disease; Aspirin; Atrial Fibrillation; Clopidogrel; Combined Modality | 2020 |
Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events.
Topics: Aspirin; Data Interpretation, Statistical; Dual Anti-Platelet Therapy; Endpoint Determination; Equiv | 2020 |
Major bleeding risk and mortality associated with antiplatelet drugs in real-world clinical practice. A prospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Databases, Factual | 2020 |
Is aspirin safer than a direct oral anticoagulant for patients with atrial fibrillation at high risk of bleeding?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Hemorrhage; Humans | 2020 |
Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.
Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug | 2020 |
Successful management of COVID-19 and associated coagulopathy in a patient with durable left ventricular assist device.
Topics: Adult; Anticoagulants; Aspirin; Biomarkers; Blood Transfusion; COVID-19; Cytokine Release Syndrome; | 2020 |
Safety and Efficacy of Single Versus Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiovascular Diseases; Cl | 2020 |
In established atherosclerosis, P2Y12 inhibitor vs. aspirin monotherapy reduces MI but not stroke or mortality.
Topics: Aspirin; Atherosclerosis; Hemorrhage; Humans; Patients; Percutaneous Coronary Intervention; Platelet | 2020 |
Comparison of Antithrombotic Strategies in Chinese Patients in Sinus Rhythm after Bioprosthetic Mitral Valve Replacement: Early Outcomes from a Multicenter Registry in China.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Bioprosthesis; China; Comorbidity; Drug Therapy, Combina | 2021 |
Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action.
Topics: Adult; Aged; Anticoagulants; Aspirin; COVID-19; Critical Illness; Female; Hemorrhage; Heparin, Low-M | 2020 |
Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Algorithms; Aspirin; Case-Control Studies; | 2020 |
Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease.
Topics: Adult; Aspirin; Atherosclerosis; Cohort Studies; Coronary Artery Disease; Coronary Disease; Eye Hemo | 2021 |
Complex intracranial vascular complications caused by essential thrombocythemia: a critical case report.
Topics: Adult; Aspirin; Blood Platelets; Female; Hemorrhage; Humans; Magnetic Resonance Imaging; Mutation; M | 2020 |
Outstanding research paper awards of the Journal of the Chinese Medical Association in 2019.
Topics: Arthroplasty, Replacement, Knee; Aspirin; Awards and Prizes; Biomedical Research; Hemorrhage; Humans | 2020 |
Perioperative Coagulation Profile with Thromboelastography in Aspirin-Treated Patients Undergoing Posterior Lumbar Fusion.
Topics: Adult; Aged; Aspirin; Blood Coagulation; Blood Coagulation Tests; China; Female; Hemorrhage; Humans; | 2020 |
1-Year Safety of 3-Month Dual Antiplatelet Therapy Followed by Aspirin or P2Y
Topics: Absorbable Implants; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; My | 2020 |
Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Dual | 2021 |
Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty: A protocol for meta-analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Blood Transfusion; Hemorrhage; Humans; Met | 2020 |
Targeting Thymidine Phosphorylase With Tipiracil Hydrochloride Attenuates Thrombosis Without Increasing Risk of Bleeding in Mice.
Topics: Animals; Aspirin; Blood Platelets; Carotid Artery Thrombosis; Chlorocebus aethiops; COS Cells; Disea | 2021 |
Stopping aspirin 1 to 3 mo after PCI reduces bleeding without increasing MACE vs. continued DAPT.
Topics: Aspirin; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2020 |
Comparison of Warfarin to Dual Antiplatelet Therapy Following Transcatheter Aortic Valve Replacement.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2021 |
Continuation of aspirin perioperatively for lung resection: a propensity matched analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Child; Female; Hemorrhage; Humans; Lung; Male; | 2021 |
A trial of antithrombotic therapy in patients with refractory migraine and antiphospholipid antibodies: A retrospective study of 75 patients.
Topics: Adolescent; Adult; Aged; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Child; Cl | 2021 |
"To take or not to take an aspirin?" The age-old question of cardiovascular disease primary prevention for people with chronic kidney disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention; Renal Insufficiency, | 2021 |
Long-term outcomes of warfarin versus aspirin after Fontan surgery.
Topics: Anticoagulants; Aspirin; Australia; Bone Density; Chemoprevention; Child; Cohort Studies; Female; Fo | 2021 |
Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Case-Control Studies; Clopidogrel; Diabete | 2021 |
Risk definition and outcomes with the application of the PEGASUS-TIMI 54 trial inclusion criteria to a "real world" STEMI population: results from the Italian "CARDIO-STEMI SANREMO" registry.
Topics: Aged; Aspirin; Clinical Decision-Making; Clinical Trials as Topic; Drug Administration Schedule; Dua | 2021 |
Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Clinical Trials as Topic; Cost-Benefit Analysis; Dabi | 2021 |
Real-World Experience With Antiplatelet Agents After Percutaneous Coronary Intervention in Patients With an Indication for an Oral Anticoagulant.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Dual An | 2021 |
Bleeding associated with co-administration of clopidogrel and ACEi in patients undergoing PCI and DAPT.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clopidogrel; Cohort Studies; Drug Therapy, | 2021 |
Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Female; Hemorrh | 2021 |
Assessing the Efficacy and Safety of Tirofiban in Combination With Dual-antiplatelet Therapy in Progressive Ischemic Stroke Patients.
Topics: Aged; Aspirin; Clopidogrel; Disability Evaluation; Dual Anti-Platelet Therapy; Female; Functional St | 2021 |
The impact of antiplatelet and antithrombotic regimen after TAVI: Data from the VIenna CardioThOracic Aortic Valve RegistrY (VICTORY).
Topics: Aged; Aged, 80 and over; Anticoagulants; Aortic Valve Stenosis; Aspirin; Austria; Clopidogrel; Dual | 2021 |
Pregnancy in patients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Diabetes, Gestational; Female; Fetal Death; Hemo | 2021 |
Bleeding Risk and Mortality Associated With Uninterrupted Antithrombotic Therapy During Percutaneous Endoscopic Gastrostomy Tube Placement.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Fibrinolytic Agents; Gastrostomy; Hemorrhage; | 2021 |
Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Polycythemia Vera; Pro | 2022 |
Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998-2018.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Denmark; Female; Hemorrhage; | 2021 |
Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Acute Coronary Syndrome Patients With a High Risk of Ischemic Events.
Topics: Acute Coronary Syndrome; Aspirin; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet A | 2021 |
Aspirin I.V. Loading during Elective Percutaneous Coronary Intervention.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Dose-Respons | 2021 |
Aspirin dosing for atherosclerotic cardiovascular disease: should we be more ADAPTABLE?
Topics: Aspirin; Atherosclerosis; Blood Platelets; Disease Progression; Dose-Response Relationship, Drug; Dr | 2021 |
Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Body Mass Index; Case-Control Studies; China; Clopido | 2021 |
Hemostatic effects of the ticagrelor antidote MEDI2452 in pigs treated with ticagrelor on a background of aspirin.
Topics: Adenosine; Adenosine Diphosphate; Animals; Antibodies, Neutralizing; Antidotes; Aspirin; Biotinylati | 2017 |
Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry.
Topics: Aged; Aspirin; Coronary Artery Disease; Coronary Thrombosis; Diabetes Mellitus; Drug Administration | 2017 |
Cessation of oral anticoagulants in antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Aged, 80 and over; Antibodies, Antiphospholipid; Anticoagulants; Antiph | 2017 |
Early Antithrombotic Therapy after Bioprosthetic Aortic Valve Replacement in Elderly Patients: A Single-Center Experience.
Topics: Aged; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Stenosis; Aspirin; Bioprosthesis; Chi-S | 2017 |
Buying Over-the-Counter Antacid Products Containing Aspirin? FDA Drug Safety Communication for Serious Bleeding Risk.
Topics: Antacids; Aspirin; Drug Combinations; Drug Interactions; Hemorrhage; Humans; Nonprescription Drugs; | 2017 |
Acute coronary syndromes: Similar bleeding risks with low-dose rivaroxaban versus aspirin.
Topics: Acute Coronary Syndrome; Aspirin; Double-Blind Method; Hemorrhage; Humans; Platelet Aggregation Inhi | 2017 |
Previous hypertensive hemorrhage increases the risk for bleeding and ischemia for PCI patients on dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Clopidogrel; Drug Therapy, Combinatio | 2017 |
Total Thrombus-formation Analysis System Predicts Periprocedural Bleeding Events in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Artery Disease; Fem | 2017 |
Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; | 2017 |
Antiplatelet therapy: New score for predicting bleeding risk after DAPT.
Topics: Aspirin; Clinical Trials as Topic; Coronary Restenosis; Hemorrhage; Humans; Long Term Adverse Effect | 2017 |
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM)
Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; F | 2016 |
Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Coronary A | 2017 |
Risk of Hemorrhage Attributed to Underlying Chronic Diseases and Uninterrupted Aspirin Therapy of Patients Undergoing Minor Oral Surgical Procedures: A Retrospective Cohort Study.
Topics: Adult; Aged; Anticoagulants; Aspirin; Chronic Disease; Female; Hemorrhage; Humans; Male; Middle Aged | 2017 |
Quantification of bleeding during dental extraction in patients on dual antiplatelet therapy.
Topics: Aspirin; Blood Loss, Surgical; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Dental Ca | 2017 |
Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study.
Topics: Age Distribution; Age Factors; Aged; Aged, 80 and over; Aspirin; Cohort Studies; England; Female; Ga | 2017 |
In VTE, extending anticoagulation with rivaroxaban vs aspirin reduced recurrence without increasing bleeding.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Recurrence; Rivaroxaban; Venous Thromboembolism | 2017 |
Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Female; Hemorrhage; Hospita | 2017 |
Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; Enoxaparin; Factor X | 2017 |
Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcome
Topics: Adenosine; Aged; Aspirin; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Purinergic P | 2017 |
Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Computer Simulation; Coronary Thrombosis; Cost-Benefi | 2017 |
Efficacy and Safety of Triple Therapy and Dual Therapy With Direct Oral Anticoagulants Compared to Warfarin.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Coronary Artery Disease; Dose-Response Relation | 2017 |
[Evaluation of the antithrombotic strategy in low thrombotic risk patients who underwent aortic valve replacement with a bioprosthesis].
Topics: Adult; Aged; Anticoagulants; Aortic Valve; Aspirin; Bioprosthesis; Drug Therapy, Combination; Female | 2018 |
I Do Not Have Heart Disease-Should I Be Taking Aspirin?
Topics: Aspirin; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidel | 2017 |
Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Drug Resi | 2017 |
Antiplatelet therapy: Aspirin in the elderly - tailored approaches ahead?
Topics: Age Factors; Aged; Aspirin; Hemorrhage; Humans; Medication Therapy Management; Platelet Aggregation | 2017 |
[Continued anticoagulation for unprovoked venous thromboembolism: guidance through the maze of recent studies].
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Rivaroxaban; Venous Thromboembolism | 2017 |
Proton Pump Inhibitors may Reduce Bleeding Risk in Older Patients on Antiplatelet Therapy.
Topics: Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Risk; Risk Fac | 2017 |
Tailoring naringenin conjugates with amplified and triple antiplatelet activity profile: Rational design, synthesis, human plasma stability and in vitro evaluation.
Topics: Aspirin; Cardiovascular Diseases; Computer Simulation; Cyclooxygenase 1; Docosahexaenoic Acids; Flav | 2017 |
Safety of Antiplatelet Agents: Analysis of 'Real-World' Data from the Italian National Pharmacovigilance Network.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Aspirin; Female; Hemorrhage; Humans; Italy; Male; Middle | 2017 |
Which is the best antiaggregant or anticoagulant therapy after TAVI? A propensity-matched analysis from the ITER registry. The management of DAPT after TAVI.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Female; Hemorrhage; Humans; Male; Pla | 2017 |
Letter: bleeding in cirrhotics receiving coronary stenting and antiplatelet therapy.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Liver Cirrhosis; Platelet Aggregation Inhibi | 2017 |
Letter: bleeding in cirrhotics receiving coronary stenting and antiplatelet therapy - author's reply.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Liver Cirrhosis; Platelet Aggregation Inhibi | 2017 |
Dual Antiplatelet Therapy Is Associated With Coagulopathy Detectable by Thrombelastography in Acute Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Coagulation; Clopidogrel; Dual Anti-Platelet Therapy; Female | 2020 |
Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Female; Hemorrhage; Human | 2017 |
Pretreatment with dual antiplatelet therapy in patients with ST-elevation myocardial infarction.
Topics: Aged; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Humans; | 2018 |
Discontinuation of Oral Antiplatelet Agents before Dental Extraction - Necessity or Myth?
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Bulgaria; Clopidogrel; Cohort Studies | 2017 |
Outcome of Transurethral Resection of Bladder Tumor: Does Antiplatelet Therapy Really Matter? Analysis of a Retrospective Series.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Carcinoma, Transitional Cell; Clopidogrel; C | 2017 |
Assessing Bleeding Risk in Patients Taking Anticoagulants.
Topics: Age Factors; Alcohol Drinking; Anemia; Anticoagulants; Aspirin; Atrial Fibrillation; Decision Suppor | 2017 |
Routine haemostasis testing before transplanted kidney biopsy: a cohort study.
Topics: Aged; Aspirin; Biopsy; Cohort Studies; Female; Hemorrhage; Humans; Kidney; Kidney Transplantation; M | 2018 |
European guidelines on perioperative venous thromboembolism prophylaxis: Chronic treatments with antiplatelet agents.
Topics: Anesthesiology; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; European Union; Hemorrhage; | 2018 |
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery D | 2017 |
In stable CVD, rivaroxaban plus aspirin reduced CV events and increased bleeding compared with aspirin alone.
Topics: Aspirin; Factor Xa Inhibitors; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Rivaroxaban | 2017 |
The use of preoperative aspirin in cardiac surgery: The ruling on the field stands.
Topics: Acute Kidney Injury; Aspirin; Coronary Artery Bypass; Erythrocyte Transfusion; Hemorrhage; Humans; M | 2017 |
Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context.
Topics: Aspirin; Atherosclerosis; Biomedical Research; Blood Platelets; Cardiology; Drug Therapy, Combinatio | 2017 |
Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS : The end of triple therapy?
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2018 |
Perioperative Management of Dual Antiplatelet Therapy.
Topics: Aspirin; Elective Surgical Procedures; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation | 2018 |
Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atr | 2018 |
Rivaroxaban with or without aspirin for prevention of cardiovascular disease.
Topics: Aspirin; Blood Coagulation; Cardiovascular Diseases; Clinical Decision-Making; Evidence-Based Medici | 2018 |
Dual antiplatelet therapy is safe and efficient after left atrial appendage closure.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Clopidogrel; Drug Therapy, | 2018 |
Short-term dual antiplatelet therapy after interventional left atrial appendage closure with different devices.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Cathet | 2018 |
Comparison of the 9-month intra-stent conditions and 2-year clinical outcomes after Resolute zotarolimus-eluting stent implantation between 3-month and standard dual antiplatelet therapy.
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Vessels; Drug Administratio | 2018 |
Charting the Course: Risk Scores for Major Bleeding in Transient Ischemic Attack and Ischemic Stroke.
Topics: Aspirin; Brain Ischemia; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibi | 2018 |
A clinical risk score to identify patients at high risk of very late stent thrombosis.
Topics: Aspirin; Case-Control Studies; Female; Hemorrhage; Humans; Long Term Adverse Effects; Male; Middle A | 2018 |
Antithrombotic Therapy Underutilization in Patients With Atrial Flutter.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial | 2018 |
Platelet function testing: dead or alive.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Cardiovascular Diseases; Cell Adhesio | 2018 |
Dual antithrombotic plus adjunctive antiinflammatory therapy to improve cardiovascular outcome in atrial fibrillation patients with concurrent acute coronary syndrome: A triple-pathway strategy.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents; Anticoagulants; Arrhythmias, Cardiac; Aspirin; At | 2018 |
In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Corona
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aspirin; China; Clopidogrel; Database | 2018 |
Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Electronic Health Records; Female; H | 2018 |
Drug plasma level measurement in management of severe bleeding during direct oral anticoagulant treatment: case report and perspective.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Drug Monitoring; Female; Hemorrhage; Humans; Ri | 2018 |
Impact of Aspirin on Warfarin Control as Measured by Time in Therapeutic Range.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Inte | 2018 |
[ANMCO/ANCE/ARCA/GICR-IACPR intersociety consensus document: long-term antiplatelet therapy in patients with coronary artery disease].
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Ho | 2018 |
Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Female; H | 2019 |
Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alleles; Aspirin; ATP Binding Cassette Transporter | 2018 |
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?
Topics: Aspirin; Atherosclerosis; Chronic Disease; Clinical Trials as Topic; Death; Drug Therapy, Combinatio | 2019 |
Annual Risk of Major Bleeding Among Persons Without Cardiovascular Disease Not Receiving Antiplatelet Therapy.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hosp | 2018 |
Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction.
Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Germany; Hemorrhage; Humans; Male; Middle Aged; Pe | 2018 |
Evaluation of Potential Drug-Drug Interactions With Direct Oral Anticoagulants in a Large Urban Hospital.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Dabigatran; Drug Comb | 2020 |
Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Conf | 2018 |
Real clinical experiences of dual versus triple antithrombotic therapy after percutaneous coronary intervention.
Topics: Absorbable Implants; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Coronar | 2018 |
Bleeding after stenting: statistics in daily practice.
Topics: Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Percutaneous Coronary I | 2018 |
Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocar | 2018 |
Adverse Effect of Antithrombotic Medications on Bleeding Events and Comparison of Antithrombotic Agents in Hemodialysis Patients.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Diabetic Nephropathies; Drug Monitoring; Female; Fibrinolyti | 2019 |
The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhag | 2019 |
Antithrombotic therapy after mitral valve repair: VKA or aspirin?
Topics: Aged; Aspirin; Cardiac Surgical Procedures; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; M | 2018 |
A Case Report of Cangrelor Bridge Therapy for a Diagnostic Bronchoscopy With Biopsy.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Aspirin; Biopsy; Bronchoscopy; Clopidogrel; | 2020 |
External Validation of the DAPT Score in a Nationwide Population.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Decision Support Techniques; Drug Therapy, Combinat | 2018 |
Clinical Characteristics, Procedural Factors, and Outcomes of Percutaneous Coronary Intervention in Patients With Mechanical and Bioprosthetic Heart Valves.
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Clopidogrel; Drug Therapy, Combination; Female; Heart | 2018 |
Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population.
Topics: Anticoagulants; Aspirin; Cost Savings; Dose-Response Relationship, Drug; Drug Monitoring; Female; He | 2018 |
Patients with Peripheral Artery Disease in the COMPASS Trial.
Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Hemorrhage; Humans; Peripheral Arterial | 2018 |
In embolic stroke of undetermined source, rivaroxaban vs aspirin did not reduce recurrence and increased bleeding.
Topics: Aspirin; Hemorrhage; Humans; Rivaroxaban; Stroke | 2018 |
Impact of oral anticoagulants on 30-day readmission: a study from a single academic centre.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Comorbidity; Confounding Factors, Epidemiologic | 2019 |
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans; | 2019 |
Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease.
Topics: Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Coronar | 2018 |
Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease?
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Human | 2018 |
Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Decision Support Technique | 2018 |
Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease?
Topics: Adult; Aged; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; | 2018 |
A delicate balance: Bleeding versus thrombosis?
Topics: Aspirin; Coronary Artery Bypass; Hemorrhage; Humans; Thrombosis; Tranexamic Acid | 2019 |
Preoperative continuation of aspirin administration in patients undergoing major abdominal malignancy surgery.
Topics: Abdominal Neoplasms; Aged; Aged, 80 and over; Aspirin; Blood Transfusion; Cohort Studies; Female; He | 2019 |
Design and rationale for the ASSOS study: Appropriateness of aspirin use in medical outpatients a multicenter and observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cohort Studies; Colorectal Neo | 2018 |
Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective.
Topics: Aged; Aspirin; Australia; Carotid Artery Diseases; Cost-Benefit Analysis; Decision Support Technique | 2019 |
Performance of PRECISE-DAPT Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, Combination; Female; Hemorrha | 2018 |
In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years.
Topics: Aspirin; Diabetes Mellitus; Hemorrhage; Humans; Primary Prevention | 2018 |
Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Aspirin; Cardiac Surgical Procedures; Cl | 2019 |
Oral anticoagulation and left atrial appendage closure: a new strategy for recurrent cardioembolic stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Cardiac Surgical Procedures; Ech | 2019 |
Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry.
Topics: Aged; Aspirin; Drug Administration Schedule; Female; Hemorrhage; Humans; Incidence; Male; Medication | 2019 |
No Difference Between Low- and Regular-dose Aspirin for Venous Thromboembolism Prophylaxis After THA.
Topics: Aged; Arthroplasty, Replacement, Hip; Aspirin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Inci | 2019 |
In healthy older adults, aspirin did not affect disability-free survival or CVD but increased death and bleeding.
Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention | 2019 |
Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents | 2019 |
Rivaroxaban (Xarelto) plus aspirin for secondary prevention of cardiovascular events.
Topics: Aspirin; Blood Coagulation; Cardiovascular Diseases; Drug Interactions; Drug Therapy, Combination; F | 2018 |
Aspirin for Primary Prevention: Clinical Considerations in 2019.
Topics: Aspirin; Hemorrhage; Humans; Primary Prevention | 2019 |
What have we learned about using aspirin for primary prevention from the ASCEND and ARRIVE trials?
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Decision-Making; Diabetes Mellitus | 2019 |
Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Data | 2019 |
Stroke prevention in atrial fibrillation: Closing the gap.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Health Services Misu | 2019 |
Comparing Australian orthopaedic surgeons' reported use of thromboprophylaxis following arthroplasty in 2012 and 2017.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Australia; | 2019 |
Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention.
Topics: Aged; Aged, 80 and over; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Co | 2019 |
Assessment of Late Thromboembolic Complications Post-Fontan Procedure in Relation to Different Antithrombotic Regimens: 30-Years' Follow-up Experience.
Topics: Aspirin; Child, Preschool; Female; Fibrinolytic Agents; Follow-Up Studies; Fontan Procedure; Hemorrh | 2019 |
Are We There Yet? Another Milepost in the Journey to Identify Appropriate Candidates for Aspirin Primary Prevention.
Topics: Aspirin; Cardiovascular Diseases; Cohort Studies; Hemorrhage; Humans; Primary Prevention | 2019 |
Predicting Bleeding Risk to Guide Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Cohort Study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Female; Hemo | 2019 |
Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Therapy, | 2019 |
Plant latex thrombin-like cysteine proteases alleviates bleeding by bypassing factor VIII in murine model.
Topics: Animals; Asclepias; Aspirin; Calotropis; Carica; Cysteine Endopeptidases; Disease Models, Animal; Fa | 2019 |
Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Administration Schedule; Dual Anti-Platelet Therapy; Eu | 2020 |
Contractile forces in platelet aggregates under microfluidic shear gradients reflect platelet inhibition and bleeding risk.
Topics: Adult; Aspirin; Blood Coagulation; Blood Platelets; Computer Simulation; Cross-Sectional Studies; Dr | 2019 |
Aspirin for the Primary Prevention of Cardiovascular Disease: Weighing Up the Evidence.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Hemorr | 2019 |
Clinical Effectiveness of Aspirin as Multimodal Thromboprophylaxis in Primary Total Hip and Knee Arthroplasty: A Review of 6078 Cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthropl | 2019 |
Direct oral anticoagulants versus aspirin for venous thromboembolism prophylaxis after orthopedic surgery.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Blood Transfusion; Female; Hemorrhage; Humans; | 2019 |
Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocar | 2019 |
Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Pressure; Diabetes Mellitus; Dyslipidemias; Female; Hemorrha | 2019 |
Aspirin for Primary Prevention Reduces Cardiovascular Events, Increases Bleeding Risk.
Topics: Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Platelet Aggregat | 2019 |
Administrative claims data to support pragmatic clinical trial outcome ascertainment on cardiovascular health.
Topics: Administrative Claims, Healthcare; Aged; Aspirin; Cardiovascular Diseases; Electronic Health Records | 2019 |
Thrombus targeting aspirin particles for near infrared imaging and on-demand therapy of thrombotic vascular diseases.
Topics: Animals; Aspirin; Cytokines; Disease Models, Animal; Fibrinolytic Agents; Hemorrhage; Hydrogen Perox | 2019 |
A prospective interventional registry of short-term dual-antiplatelet treatment after implantation of drug-eluting stents in patients with atrial fibrillation requiring oral anticoagulation therapy.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug-Eluting Stents; Dual Anti-Plat | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Review: In adults without CVD, aspirin reduces CV events and increases major bleeding compared with no aspirin.
Topics: Adult; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention | 2019 |
The impact of
Topics: Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P450 Family 4; Female; Genotype; Hemorrhage; Humans; | 2019 |
Should aspirin be used for primary prevention in the healthy elderly?
Topics: Aged; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention | 2019 |
Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention | 2019 |
Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention | 2019 |
Meta-analysis of Aspirin for Primary Prevention of Cardiovascular Events-Reply.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Primary Prevention | 2019 |
Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54.
Topics: Aged; Aspirin; Drug Approval; Drug Labeling; Drug Therapy, Combination; Europe; Female; Hemorrhage; | 2019 |
Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients.
Topics: Aged; Aspirin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ischemia; Male | 2019 |
Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients.
Topics: Aged; Aspirin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ischemia; Male | 2019 |
Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients.
Topics: Aged; Aspirin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ischemia; Male | 2019 |
Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients.
Topics: Aged; Aspirin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ischemia; Male | 2019 |
Critical appraisal of the AUGUSTUS trial.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Fact | 2019 |
Trajectories of Adherence to Low-Dose Aspirin Treatment Among the French Population.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Comorbidity; Datab | 2020 |
Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Drug-Eluting Stents; Europe; Female | 2019 |
Characterisation of non-warfarin-associated bleeding events reported to the Norwegian spontaneous reporting system.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Aging; Anti-Inflammatory Ag | 2013 |
A Boolean view separates platelet activatory and inhibitory signalling as verified by phosphorylation monitoring including threshold behaviour and integrin modulation.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Iloprost; Integr | 2013 |
Aspirin for long term maintenance therapy of venous thromboembolism.
Topics: Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Factors; Sec | 2013 |
[Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administ | 2013 |
Bleeding complications during percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidog | 2004 |
The use, misuse and abuse of dabigatran.
Topics: Advertising; Anticoagulants; Antithrombins; Aspirin; Australia; Benzimidazoles; beta-Alanine; Cardio | 2013 |
Low molecular weight heparin in patients undergoing free tissue transfer following head and neck ablative surgery: review of efficacy and associated complications.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Dalteparin; Dose-Response Relationship, Dru | 2013 |
Is platelet transfusion efficient to restore platelet reactivity in patients who are responders to aspirin and/or clopidogrel before emergency surgery?
Topics: Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregatio | 2013 |
Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Hemorrhage; Humans; Incidence; Mal | 2014 |
Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Electrocardiography; F | 2013 |
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; | 2013 |
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabet | 2013 |
Hidden implications: potential antiplatelet effects of adjuvant anaesthetic agents.
Topics: Adenosine Diphosphate; Adjuvants, Anesthesia; Aged; Aspirin; Cholecystectomy, Laparoscopic; Clopidog | 2013 |
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; | 2013 |
Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Administration S | 2013 |
Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Blood Coagulation; Clopidogrel; Co | 2014 |
Balancing thromboembolic risk against vitamin K antagonist-related bleeding and accelerated calcification: is fondaparinux the Holy Grail for end-stage renal disease patients with atrial fibrillation?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Contraindications; Factor Xa Inhibitors; Fondaparinux; | 2013 |
Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index in adults: U.S. Preventive Services Task Force recommendation statement.
Topics: Adult; Ankle Brachial Index; Aspirin; Asymptomatic Diseases; Cardiovascular Diseases; Cost of Illnes | 2013 |
[Triple therapy for patients with stent and atrial fibrillation? Yes!].
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combinat | 2013 |
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Substitution; | 2014 |
Novel uses for platelet function testing in the clinical laboratory: where are we now?
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Drug Monitoring; Hemorrhage; Humans; Platelet Aggrega | 2014 |
Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aspirin; Child; Child, Preschool; | 2014 |
Bleeding-related symptoms in colorectal cancer: a 4-year nationwide population-based study.
Topics: Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Anticoagulants; Aspirin; Colorectal Neoplasms; Fem | 2014 |
Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; | 2014 |
An aspirin a day? Aspirin use across a spectrum of risk: cardiovascular disease, cancers and bleeds.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Neoplasms; Platelet Aggregation Inhibitors; Pr | 2014 |
Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.
Topics: Aged; Angioplasty; Aspirin; Brain Ischemia; Carotid Stenosis; Cilostazol; Clopidogrel; Diffusion Mag | 2014 |
[Can local administration of tranexamic acid reduce aspirin-induced bleeding in off-pump coronary artery bypass grafting( CABG) ?].
Topics: Antifibrinolytic Agents; Aspirin; Coronary Artery Bypass, Off-Pump; Female; Hemorrhage; Humans; Male | 2013 |
Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Biomarkers; Female; Fibrinolytic Agents; Gl | 2014 |
Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Thera | 2014 |
Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Dipyridamole | 2014 |
Perioperative outcomes of cardiac surgery patients with ongoing ticagrelor therapy: boon and bane of a new drug.
Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Blood Transfusion; Coronary Artery Bypass; Female; Hemo | 2014 |
Acute dysphagia after myocardial infarction: an unusual complication of anticoagulation therapy.
Topics: Anticoagulants; Aspirin; Cysts; Deglutition Disorders; Electrocardiography; Fibrinolytic Agents; Hem | 2014 |
Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Cohort Studies; | 2014 |
Warfarin: Impact on hemostasis after radial catheterization.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cardiac Catheterization; Catheterization, Peripher | 2015 |
Dual antiplatelet therapy (clopidogrel and aspirin) is associated with increased all-cause mortality after carotid revascularization for asymptomatic carotid disease.
Topics: Aged; Alabama; Angioplasty; Aspirin; Asymptomatic Diseases; Carotid Stenosis; Clopidogrel; Drug Ther | 2014 |
Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cost-Benefit Analysis; Drug Costs; Factor Xa Inh | 2014 |
Dual antiplatelet therapy over 6 months increases the risk of bleeding after biodegradable polymer-coated sirolimus eluting stents implantation: insights from the CREATE study.
Topics: Aspirin; Biodegradable Plastics; Clopidogrel; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; | 2014 |
[Bullous hemorrhagic dermatosis induced by heparin: description of 2 new cases].
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Drug Eruptions; Enoxaparin; Hemo | 2014 |
Impact of acellular hemoglobin-based oxygen carriers on brain apoptosis in rats.
Topics: Animals; Apoptosis; Aspirin; Blood Substitutes; Brain; Cell Hypoxia; Drug Evaluation, Preclinical; E | 2014 |
Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Corona | 2014 |
Aspirin's role in preventing recurring deep vein blood clots.
Topics: Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Risk Assessment; Secondary Prevention; Venous Thro | 2013 |
Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Therapy, Combina | 2014 |
Aspirin continues to attract research and debate, 115 years after its synthesis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Plate | 2013 |
Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; France; Hemorrha | 2014 |
Cardiovascular and bleeding risk of non-cardiac surgery in patients on antiplatelet therapy.
Topics: Aged; Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Heparin; Humans; Male; Membrane Proteins | 2014 |
Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Calcium; Coronary Disease; Coronary Vessels; Ethn | 2014 |
Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives.
Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Attitude of Health Personnel; Female; Fib | 2015 |
Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectives.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Attitude of Health Personnel; Card | 2014 |
Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies.
Topics: Anesthesiology; Aspirin; Cardiac Surgical Procedures; Cardiology; Clopidogrel; Eptifibatide; Hemorrh | 2014 |
Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey.
Topics: Age Distribution; Aged; Alcohol Drinking; Anticoagulants; Aspirin; Atrial Fibrillation; Diabetes Com | 2014 |
Antiplatelet therapy during perioperative period: double-edged sword.
Topics: Aspirin; Coronary Artery Disease; Hemorrhage; Humans; Percutaneous Coronary Intervention; Perioperat | 2014 |
A short-term effect of low-dose aspirin on major hemorrhagic risks in primary prevention: a case-crossover design.
Topics: Adult; Aspirin; Cross-Over Studies; Hemorrhage; Humans; Male; Middle Aged; Primary Prevention; Risk; | 2014 |
Comparative effects of the anti-platelet drugs, clopidogrel, ticlopidine, and cilostazol on aspirin-induced gastric bleeding and damage in rats.
Topics: Animals; Aspirin; Cilostazol; Clopidogrel; Hemoglobins; Hemorrhage; Male; Peroxidase; Platelet Aggre | 2014 |
Safety and efficacy of switching anticoagulation to aspirin three months after successful radiofrequency catheter ablation of atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Female; Hemorrhage; Humans; K | 2014 |
Low-dose aspirin for prevention of cardiovascular disease in patients with chronic kidney disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabete | 2014 |
Extract of Antrodia camphorata exerts neuroprotection against embolic stroke in rats without causing the risk of hemorrhagic incidence.
Topics: Animals; Antrodia; Aspirin; Brain; Drug Therapy, Combination; Hemoglobins; Hemorrhage; Male; Neuropr | 2014 |
Perioperative aspirin: to give or not to give?
Topics: Aspirin; Blood Transfusion; Coronary Artery Bypass; Coronary Disease; Female; Fibrinolytic Agents; H | 2014 |
Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium.
Topics: Aged; Aspirin; Atrial Fibrillation; Belgium; Cost-Benefit Analysis; Factor Xa Inhibitors; Female; He | 2014 |
Diffuse alveolar hemorrhage secondary to apixaban administration.
Topics: Aged; Aspirin; Atrial Fibrillation; Continuous Positive Airway Pressure; Female; Fibrinolytic Agents | 2014 |
Anticoagulants as a risk factor in patients operated on for abdominal hernia.
Topics: Adult; Aged; Anticoagulants; Aspirin; Blood Coagulation Disorders; Drainage; Female; Hemorrhage; Hep | 2014 |
Assessment of platelet function with light transmission aggregometry in 24 patients supported with a continuous-flow left ventricular assist device: a single-center experience.
Topics: Aged; Arachidonic Acid; Aspirin; Drug Administration Schedule; Drug Monitoring; Female; France; Hear | 2014 |
Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Female; Hemor | 2014 |
[Aspirin or non-steroidal analgesics increase risk of bleeding in anticoagulated patients].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Female; Hemorrhage; Humans; Male; | 2014 |
Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Substitution; Female; H | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten | 2015 |
Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Databases, Bibliographic | 2014 |
Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Databases, Bibliographic | 2014 |
Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Databases, Bibliographic | 2014 |
Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Databases, Bibliographic | 2014 |
Rebleeding after initial endoscopic hemostasis in peptic ulcer disease.
Topics: Antithrombins; Aspirin; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hemostasis, Endoscopic; Hum | 2014 |
Reviewing a clinical decision aid for the selection of anticoagulation treatment in patients with nonvalvular atrial fibrillation: applications in a US managed care health plan database.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Databases, Factual; Decision Support | 2014 |
Aspirin for primary prevention: what's a clinician to do?
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Physician's Role; Primary Prevention | 2015 |
Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogr | 2015 |
Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
Topics: Administration, Oral; Anticoagulants; Aspirin; Female; Hemorrhage; Humans; Male; Middle Aged; Mortal | 2015 |
Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Denmark; Female; Follow-Up Studi | 2014 |
Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; China; Cohort St | 2015 |
Patterns of Antiplatelet Therapy in Patients Who Have Experienced an Acute Coronary Event: A Descriptive Study in UK Primary Care.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Female; Foll | 2015 |
[Perioperative complications of transurethral resection of bladder tumor in patients receiving antithrombotic therapy].
Topics: Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Cystectomy; Female; Fibrinolytic Agents; Hemorrha | 2014 |
Is aspirin a dangerous drug?
Topics: Aspirin; Hemorrhage; History, 20th Century; Humans; Platelet Aggregation Inhibitors | 2014 |
From innovation to implementation: optimizing long-term outcomes after TAVR.
Topics: Aortic Valve Stenosis; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Ticlopidine; Transcat | 2014 |
A short-term risk-benefit analysis of occasional and regular use of low-dose aspirin in primary prevention of vascular diseases: a nationwide population-based study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Databases, | 2015 |
Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Decision Support Techniques; Drug-Eluting Stents; Fem | 2015 |
Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.
Topics: Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; D | 2015 |
Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected].
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Hem | 2015 |
Heart failure in sinus rhythm: no routine antithrombotic therapy.
Topics: Aspirin; Fibrinolytic Agents; Heart Failure; Hemorrhage; Humans; Patient Safety; Randomized Controll | 2015 |
[Triple anticoagulant therapy - now what can I give for pain?].
Topics: Aged; Analgesics; Anticoagulants; Aspirin; Back Pain; Benzimidazoles; beta-Alanine; Clopidogrel; Con | 2015 |
Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Chi-Square Distributi | 2015 |
Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Case-Control Studies; Clopido | 2015 |
Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist.
Topics: Animals; Aspirin; Bleeding Time; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Lactone | 2015 |
Primary prevention of coronary artery disease by aspirin.
Topics: Aspirin; Coronary Artery Disease; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Primary Preve | 2015 |
Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; | 2015 |
Glanzmann's thrombasthenia: meeting the anticoagulation challenge.
Topics: Aminocaproic Acid; Aspirin; Clopidogrel; Factor VIIa; Hemorrhage; Humans; Isoantibodies; Male; Middl | 2015 |
Should all stent patients have prolonged dual antiplatelet therapy?
Topics: Aspirin; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, C | 2015 |
Management and outcome of major bleeding in patients on triple therapy after coronary stenting. Clues from the WARfarin and coronary STENTing (WAR-STENT) registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; He | 2015 |
Pre-procedural dual antiplatelet therapy and bleeding events following transcatheter aortic valve implantation (TAVI).
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregatio | 2015 |
Pre-treatment with dual antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Australia; Clopidogrel; Female; Hemorrhage; Humans; Logistic | 2015 |
Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Comorbidity; Coronary Disease; Coronary Restenosis; Drug Sub | 2015 |
INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Fe | 2015 |
Redesigning TRACER trial after TRITON.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Evaluation; Drug Thera | 2015 |
Perioperative Management of Antiplatelets and Anticoagulants Among Patients Undergoing Elective Transurethral Resection of the Prostate--A Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogre | 2015 |
Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Blood Coagulation; California; Comorbidity; D | 2015 |
Antithrombotic Therapy Practices in Older Adults Residing in the Long-Term Care Setting.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Body Mass Index; Drug Therapy | 2015 |
Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Decision Support Techni | 2015 |
Assessing the optimal strategy for dual antiplatelet therapy.
Topics: Aspirin; Coronary Artery Disease; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Pyridines; Ri | 2015 |
The Effect of Aspirin on Bleeding and Transfusion in Contemporary Cardiac Surgery.
Topics: Aged; Aspirin; Blood Transfusion; Coronary Artery Bypass; Female; Hemorrhage; Humans; Male; Middle A | 2015 |
Antithrombotic strategy after bioprosthetic aortic valve replacement in patients in sinus rhythm: evaluation of guideline implementation.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Aortic Valve; Aspirin; Bioprosthesis; Electrocardiography; F | 2016 |
Platelet reactivity in MitraClip patients.
Topics: Aspirin; Clopidogrel; Cohort Studies; Heart Valve Prosthesis Implantation; Hemorrhage; Ischemia; Mit | 2016 |
Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Drug Therapy, Combination; Fe | 2015 |
Utility of VerifyNow for Point-of-Care Identification of an Aspirin Effect Prior to Emergency Cardiac Surgery.
Topics: Aspirin; Cardiovascular Diseases; Emergencies; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male | 2015 |
Platelet reactivity and hemorrhage risk in neurointerventional procedures under dual antiplatelet therapy.
Topics: Aged; Aspirin; Carotid Stenosis; Clopidogrel; Drug Therapy, Combination; Embolization, Therapeutic; | 2016 |
Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Mor | 2015 |
Platelet function recovery following exposure to triple anti-platelet inhibitors using an in vitro transfusion model.
Topics: Apoptosis Regulatory Proteins; Arachidonic Acid; Aspirin; Blood Platelets; Blood Transfusion; Clopid | 2015 |
Primary Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction and Concurrent Active Gastrointestinal Bleeding.
Topics: Aged; Aspirin; Blood Vessel Prosthesis Implantation; Cardiopulmonary Resuscitation; Dopamine; Drug-E | 2015 |
Risk factors for adverse in-hospital outcomes in acute colonic diverticular hemorrhage.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Transfusion; Colonoscopy; Diverticulum | 2015 |
[INTERNATIONAL NORMALIZED RATIO VALUES AND HEMORRHAGE IN HOSPITALIZED PATIENTS STARTING WARFARIN THERPY: AN OBSERVATIONAL STUDY].
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Drug Therapy, Com | 2015 |
Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbi | 2016 |
Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study).
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2016 |
Endobronchial Ultrasound-guided Transbronchial Needle Aspiration while Receiving Aspirin and Clopidogrel: Is It Always Safe?
Topics: Aspirin; Clopidogrel; Contraindications; Echocardiography, Doppler, Color; Endoscopic Ultrasound-Gui | 2015 |
Antiplatelet effects of clopidogrel and aspirin after interventional patent foramen ovale/ atrium septum defect closure.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cardiac Surgical Procedures; Clopidogrel; Comorbidity; Female | 2016 |
A long-term risk-benefit analysis of low-dose aspirin in primary prevention.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Databases, Factual; Female; Gastro | 2016 |
[Long term aspirin in stable coronary disease with an indication for anticoagulation: is it reasonable?].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Disease; Drug Therapy, Combination; Hemorrhag | 2015 |
Cochlear Implantation in the Setting of Perioperative Anticoagulation and Antiplatelet Therapy.
Topics: Aged; Anticoagulants; Aspirin; Blood Loss, Surgical; Clopidogrel; Cochlear Implantation; Female; Hem | 2016 |
[Impact of preoperative dual antiplatelet therapy on perioperative bleeding in patients undergoing off-pump coronary artery bypass grafting].
Topics: Aspirin; Blood Transfusion; Clopidogrel; Coronary Artery Bypass, Off-Pump; Hemorrhage; Humans; Plate | 2015 |
Do Not Use Novel Antiplatelet Agents in Patients on Oral Anticoagulants After Stenting.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Drug Therapy, Combination; H | 2015 |
Antiplatelet Therapy and Adverse Hematologic Events During Heart Mate II Support.
Topics: Adult; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Dipyridamole; Disease-Free Survival; | 2016 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr | 2015 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr | 2015 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr | 2015 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr | 2015 |
The Effectiveness of a Risk Stratification Protocol for Thromboembolism Prophylaxis After Hip and Knee Arthroplasty.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspiri | 2016 |
Diffuse alveolar hemorrhage associated with low molecular weight heparin and dual anti-platelet therapy after percutaneous coronary intervention.
Topics: Adenosine; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Therapy, Combination; Fatal Outcom | 2017 |
Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. Results of the ACCEL-BLEED study.
Topics: Aged; Asia, Eastern; Asian People; Aspirin; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 C | 2016 |
Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study).
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Endovascular Procedures; F | 2016 |
Hemorrhagic esophageal mucosal injuries caused by transesophageal echocardiogram.
Topics: Aged; Aspirin; Echocardiography, Transesophageal; Esophageal Mucosa; Heart Failure; Hemorrhage; Huma | 2016 |
Stroke prevention in atrial fibrillation and 'real world' adherence to guidelines in the Balkan Region: The BALKAN-AF Survey.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Balkan Peni | 2016 |
Ticagrelor in the Real World: The Midland Regional Cardiac Network Experience.
Topics: Adenosine; Aged; Aspirin; Cohort Studies; Dyspnea; Female; Hemorrhage; Humans; Male; Medication Adhe | 2015 |
Comparison of Three Tests to Distinguish Platelet Reactivity in Patients with Renal Impairment during Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Hemorrhage; | 2016 |
Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Human | 2016 |
Dual antiplatelet therapy reduces stroke but increases bleeding at the time of carotid endarterectomy.
Topics: Aged; Aspirin; Asymptomatic Diseases; Carotid Artery Diseases; Chi-Square Distribution; Clopidogrel; | 2016 |
Hsp70 protects from stroke in atrial fibrillation patients by preventing thrombosis without increased bleeding risk.
Topics: Animals; Aspirin; Atrial Fibrillation; Bleeding Time; Carotid Artery Diseases; Case-Control Studies; | 2016 |
Clinical Features and Outcomes of Diffuse Alveolar Hemorrhage During Antithrombotic Therapy: A Retrospective Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Connective Tissue Diseases; Female | 2016 |
Prevalence and Prognosis of High-risk Myocardial Infarction Patient Candidates to Extended Antiplatelet Therapy.
Topics: Adenosine; Age Factors; Aged; Aged, 80 and over; Aspirin; Diabetes Mellitus; Drug Therapy, Combinati | 2016 |
Platelets are dispensable for antibody-mediated transfusion-related acute lung injury in the mouse.
Topics: Animals; Antibodies, Monoclonal; Aspirin; Blood Platelets; Blood Transfusion; Clopidogrel; Diphtheri | 2016 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.
Topics: Adult; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Fibrinolytic | 2016 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.
Topics: Adult; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Fibrinolytic | 2016 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.
Topics: Adult; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Fibrinolytic | 2016 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.
Topics: Adult; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; Fibrinolytic | 2016 |
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Anemia; Aspirin; Body Mass Index; Clopidogrel; Cohort St | 2016 |
Dual anti-platelet therapy after coronary drug-eluting stent implantation and surgery-associated major adverse events.
Topics: Aged; Aspirin; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Drug-Eluting Stents; F | 2016 |
Moving From Clinical Trials to Precision Medicine: The Role for Predictive Modeling.
Topics: Aspirin; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention | 2016 |
Aspirin Can Be Used as Prophylaxis for Prevention of Venous Thromboembolism After Revision Hip and Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fema | 2016 |
Aspirin use and the risk of bleeding complications after therapeutic bronchoscopy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Bronchoscopy; Female; Hemorrhage; Humans; Male | 2016 |
[Safety of implantation permanent pacemaker at different times in patients with dual antiplatelet therapy].
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hematoma; Hemo | 2016 |
Utility of the HAS-BLED Score in Risk Stratifying Patients on Dual Antiplatelet Therapy Post 12 Months After Drug-Eluting Stent Placement.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug Administration Schedu | 2017 |
Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clopido | 2017 |
No difference between aspirin and warfarin after extracardiac Fontan in a propensity score analysis of 475 patients.
Topics: Anticoagulants; Aspirin; Australia; Female; Fontan Procedure; Heart Defects, Congenital; Hemorrhage; | 2016 |
A State Transition Model for Health Outcomes Associated with Vorapaxar Treatment as an Add-on to Standard Care Antiplatelet Therapy in the Prevention of Thrombotic Events for Patients with a Recent Myocardial Infarction.
Topics: Aspirin; Cardiovascular System; Clopidogrel; Hemorrhage; Humans; Lactones; Myocardial Infarction; Pl | 2016 |
Bleeding Complications in Patients Undergoing Percutaneous Spinal Cord Stimulator Trials and Implantations.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Electrodes, Implanted | 2016 |
[Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy].
Topics: Aspirin; Beijing; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; | 2016 |
Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease: Shared Decision Making in Clinical Practice.
Topics: Age Factors; Aged; Algorithms; Aspirin; Cardiovascular Diseases; Cause of Death; Colorectal Neoplasm | 2016 |
Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations.
Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cause of Death; Clinical Trial | 2016 |
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Comorbidity; Creatinine; Dabig | 2016 |
Early Clinical Experience with a Polymer-Free Biolimus A9 Drug-Coated Stent in DES-Type Patients Who Are Poor Candidates for Prolonged Dual Anti-Platelet Therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting S | 2016 |
The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2016 |
To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cardiovascular Agents; Disability Evaluation; Dise | 2016 |
Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Hemorrhage; Humans; I | 2016 |
The Effect of Antiplatelet Agents on Bleeding-Related Complications After Ureteroscopy.
Topics: Adenosine; Adult; Aged; Anticoagulants; Aspirin; Blood Platelets; Clopidogrel; Female; Hemorrhage; H | 2016 |
Stroke: So much to do, still so poorly resourced!
Topics: Aspirin; Clinical Trials as Topic; Developing Countries; Hemorrhage; Humans; Stroke | 2016 |
Aspirin for Primary and Secondary Prevention of Cardiovascular Disease.
Topics: Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Mid | 2016 |
New antiplatelet drugs and new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aspirin; Drug Monitoring; Hemorrhage; Humans; Perioperative Ca | 2016 |
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Drug Therapy, Combination; Embolism | 2016 |
Effect of Drugs Associated With Bleeding Tendency on the Complications and Outcomes of Transforaminal Epidural Steroid Injection.
Topics: Aged; alpha-Cyclodextrins; Alprostadil; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Contr | 2017 |
Optimal duration of dual anti-platelet therapy after percutaneous coronary intervention: 2016 consensus position of the Italian Society of Cardiology.
Topics: Adenosine; Aspirin; Cardiology; Drug Administration Schedule; Drug-Eluting Stents; Hemorrhage; Human | 2017 |
Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug Antagonism; Drug | 2017 |
Aspirin reduces cardiovascular events in primary prevention of cardiovascular disease but at a near equivalent risk of increased bleeding.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Primary Preve | 2016 |
Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy | 2016 |
Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Databases, Factual; Drug Administration Schedul | 2017 |
Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Creatinine; Drug Therapy, Co | 2017 |
OTC Antacids Containing Aspirin Carry Risk of Bleeding.
Topics: Antacids; Aspirin; Hemorrhage; Humans; Nonprescription Drugs; United States; United States Food and | 2016 |
Different impact of aspirin on renal progression in patients with predialysis advanced chronic kidney disease with or without previous stroke.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cause of Death; Comorbidity; Female; Hematinics; Hemorrhage; | 2017 |
Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy.
Topics: Aged; Aspirin; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; D | 2016 |
Anticoagulation After Biological Aortic Valve Replacement: Is There An Optimal Regimen?
Topics: Aged; Anticoagulants; Aortic Valve; Aspirin; Bioprosthesis; Blood Coagulation; Brain Ischemia; Femal | 2016 |
Effects of Aspirin Therapy on Ultrasound-Guided Renal Allograft Biopsy Bleeding Complications.
Topics: Adult; Age Factors; Aged; Allografts; Aspirin; Blood Coagulation; Chi-Square Distribution; Drug Admi | 2017 |
Platelet aggregation and the risk of stent thrombosis or bleeding in elective percutaneous coronary intervention patients.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Elective Surgical Procedures; Fema | 2017 |
New evidence on old drugs; warfarin versus aspirin after bioprosthetic aortic valve placement.
Topics: Anticoagulants; Aortic Valve; Aspirin; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; | 2017 |
Platelet Inhibition in Shunted Infants on Aspirin at Short and Midterm Follow-Up.
Topics: Aspirin; Cardiac Surgical Procedures; Female; Follow-Up Studies; Heart Defects, Congenital; Hemorrha | 2017 |
Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Female; Foll | 2017 |
Percutaneous left atrial appendage closure followed by single antiplatelet therapy: Short- and mid-term outcomes.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Cl | 2017 |
Pulmonary alveolar hemorrhage mimicking a pneumopathy: a rare complication of dual antiplatelet therapy for ST elevation myocardial infarction.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Lung Diseases; Middle A | 2016 |
Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse Events.
Topics: Adverse Drug Reaction Reporting Systems; Aspirin; Clopidogrel; Dipeptidyl-Peptidase IV Inhibitors; H | 2017 |
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.
Topics: Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Ther | 2017 |
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2017 |
Platelet turnover predicts outcome after coronary intervention.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Chi-Square D | 2017 |
Mortality and cancer after 12 versus 30 months dual antiplatelet therapy. The Korean Outcomes Registry Evaluating Antithrombotics (KOREA).
Topics: Aged; Aspirin; Cause of Death; Chi-Square Distribution; Clopidogrel; Disease-Free Survival; Drug Adm | 2017 |
A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery s
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Coronary Stenosis; Drug Therapy, Comb | 2017 |
State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Lactones; Male; Middle Aged; Myocardial Infarction | 2017 |
Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention: An Evaluation of Prasugrel or Ticagrelor Versus Clopidogrel.
Topics: Adenosine; Aged; Aspirin; Cohort Studies; Drug Therapy, Combination; Female; Hemorrhage; Humans; Mal | 2017 |
Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2017 |
Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.
Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combinati | 2017 |
Safety and efficacy of clopidogrel in children with heart disease.
Topics: Adolescent; Aspirin; Child; Child, Preschool; Clopidogrel; Female; Heart Diseases; Hemorrhage; Human | 2008 |
Prothrombotic and hemorrhagic effects of aspirin.
Topics: Animals; Aspirin; Disease Models, Animal; Dose-Response Relationship, Drug; Hemorrhage; Rats; Substa | 2009 |
Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; As | 2008 |
Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Combined Modality Therapy; C | 2009 |
Stroke prevention--insights from incoherence.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Clopidogrel; Dipyridam | 2008 |
A new model of pharmacovigilance? A pilot study.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N | 2009 |
Acetylsalicylic acid and bleeding from the tonsillar wound.
Topics: Aspirin; Hemorrhage; Humans; Lymphatic Diseases; Palatine Tonsil; Pharynx | 1948 |
The question of prothrombinopenic hemorrhage from post-tonsillectomy use of chewing gum containing acetylsalicylic acid.
Topics: Aspirin; Blood; Chewing Gum; Hemorrhage; Hemostatics; Humans; Prothrombin; Salicylates; Tonsillectom | 1948 |
Cardiovascular outcomes after a change in prescription policy for clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Co | 2008 |
Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding.
Topics: Acute Disease; Adult; Aged; Aspirin; Female; Follow-Up Studies; Hematocrit; Hemorrhage; Hospitals; H | 2008 |
Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug | 2008 |
Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug | 2008 |
Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial).
Topics: Aged; Aspirin; Cause of Death; Coronary Disease; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ma | 2008 |
Re: transrectal ultrasound-guided biopsy of the prostate: aspirin increases the incidence of minor bleeding complications.
Topics: Antifibrinolytic Agents; Aspirin; Biopsy; Hemorrhage; Humans; Male; Postoperative Hemorrhage; Prosta | 2008 |
[Perioperative discontinuation of antiplatelet therapy of patients with coronary stents. Reevaluating the risks].
Topics: Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Decision Tree | 2009 |
Clopidogrel under scrutiny.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap | 2008 |
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coron | 2008 |
Incidence of bleeding and compliance on prolonged dual antiplatelet therapy (aspirin + thienopyridine) following drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Confidence Intervals; Drug Therapy, Combination; Drug | 2008 |
Low thromboembolic risk for patients with the Heartmate II left ventricular assist device.
Topics: Adult; Aged; Anticoagulants; Aspirin; Female; Heart-Assist Devices; Hemorrhage; Humans; Male; Middle | 2008 |
Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease-Free Survival; D | 2008 |
Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Evaluation; Drug Therapy, Combination; Dru | 2009 |
Another view on prasugrel.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascu | 2009 |
Improving outcomes with antiplatelet therapies in percutaneous coronary intervention and stenting.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug-Eluting Stents; | 2009 |
Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: is clopidogrel any safer than aspirin when combined with warfarin?
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Coagulation; Clopidogrel; Coumarins; Dipyridamo | 2008 |
Effect of oral antiplatelet agents on major bleeding in users of coumarins.
Topics: Acenocoumarol; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Coagula | 2008 |
Prevention strategies of cardioembolic ischemic stroke in Chagas' disease.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Chagas Cardiomyopathy; Epidemiologic Methods; Female; Hemor | 2008 |
The choice of aspirin dose for primary prevention of embolic complications of nonvalvular atrial fibrillation in elderly people.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Dose-Response Relationship, Drug; Embolism; H | 2009 |
Safety issues of adjunctive clopidogrel in patients discharged after percutaneous coronary intervention with stent placement and requiring oral anticoagulation.
Topics: Administration, Oral; Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidog | 2011 |
Summaries for patients. What aspirin dose is safest and most effective for preventing heart disease?
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2009 |
Summaries for patients. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans | 2009 |
Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Femal | 2009 |
Does the combination of warfarin and aspirin have a place in secondary stroke prevention? No.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibit | 2009 |
Does the combination of warfarin and aspirin have a place in secondary stroke prevention? Yes.
Topics: Anticoagulants; Aspirin; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combi | 2009 |
[Do antiplatelet agents (aspirin and other antiplatelets such as clopidogrel) increase the risk of hemorrhagic complications after endoscopic polypectomy or endoscopic sphincterotomy and should these drugs therefore be withdrawn 7-10 days before these pro
Topics: Aspirin; Clopidogrel; Colonic Polyps; Colonoscopy; Hemorrhage; Humans; Platelet Aggregation Inhibito | 2009 |
Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Clopido | 2009 |
[Introduction to the topic: drug eluting stents. An underestimated problem in surgery].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Hemo | 2009 |
[Patients with coronary artery stents: when and how should operations be carried out?].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cooperative Behavior; Coronary Restenosis; Dru | 2009 |
[Drug-eluting stents: implications for surgery patients].
Topics: Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cooperative Behavior; Coronary Res | 2009 |
Achieved anticoagulation vs prosthesis selection for mitral mechanical valve replacement: a population-based outcome study.
Topics: Adult; Aged; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Female; Follow-Up Studies; H | 2009 |
Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
Topics: Accidental Falls; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Dementia; F | 2009 |
Clopidogrel in ESRD patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Kidney Failure, Chronic; Platelet | 2009 |
The efficacy of Ankaferd Blood Stopper in antithrombotic drug-induced primary and secondary hemostatic abnormalities of a rat-bleeding model.
Topics: Analysis of Variance; Animals; Anticoagulants; Aspirin; Disease Models, Animal; Enoxaparin; Female; | 2009 |
Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti | 2009 |
SCIP: VTE prevention controversy.
Topics: Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Postoperative Complications; Quality A | 2009 |
Weighing benefits and risks--the FDA's review of prasugrel.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Causality; Clini | 2009 |
Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Biomarkers; Cell Ad | 2009 |
Antiplatelet agents used for early intervention in acute coronary syndrome: myocardial salvage versus bleeding complications.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Platelet | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu | 2009 |
Clopidogrel plus aspirin in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu | 2009 |
Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel--versus--aspirin + clopidogrel in patients with cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combi | 2009 |
[Prasugrel or clopidogrel in patients with coronary intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Double-Blind Method; Endpoint | 2009 |
Effect of clopidogrel on perioperative blood loss and transfusion in coronary artery bypass graft surgery.
Topics: Aged; Aspirin; Blood Transfusion; Cardiopulmonary Bypass; Clopidogrel; Coronary Artery Bypass; Drug | 2010 |
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
P2Y12 inhibitors: thienopyridines and direct oral inhibitors.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Corona | 2009 |
Pro: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation".
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; | 2009 |
Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation".
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Clinica | 2009 |
There is no place like home after successful percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Ar | 2009 |
Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combina | 2009 |
Balancing thromboembolism and bleeding risks: insights from anticoagulation for prosthetic heart valves.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dose-Response Relationship, Drug; Heart Valve Prosthes | 2009 |
The right oral antithrombotics in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
eComment: Controversies on the antiplatelet therapy before coronary artery bypass grafting surgery.
Topics: Aspirin; Blood Transfusion; Cardiopulmonary Bypass; Clopidogrel; Coronary Artery Bypass; Drug Therap | 2010 |
The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Fibrinolytic Agents; Fol | 2010 |
Impact of chronic antithrombotic therapy on hospital course of patients with acute myocardial infarction.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Bundle-Branch Block; Coumarins; Diabetes Mellitus; Femal | 2009 |
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; | 2008 |
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should not be continued for more than 1 year and preferably indefinitely.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Restenosis; Cor | 2008 |
Detection of presumed hemorrhage in the ampullar endolymph of the semicircular canal: a case report.
Topics: Aspirin; Chronic Disease; Contrast Media; Endolymph; Female; Functional Laterality; Gadolinium DTPA; | 2009 |
Dabigatran versus warfarin in patients with atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Therapy, Combination; | 2009 |
Safety of carotid endarterectomy while on clopidogrel (Plavix). Clinical article.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Clopidogrel; Cohort Studies; Edema; E | 2010 |
Stroke in heart failure: atrial fibrillation revisited?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Heart Failure; Hemorrhage; Humans; Patient Selection; | 2010 |
Aspirin--a drug whose time has gone?
Topics: Aspirin; Evidence-Based Medicine; Hemorrhage; Humans; Meta-Analysis as Topic; Platelet Aggregation I | 2010 |
Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin.
Topics: Aspirin; Biopsy; Female; Hemorrhage; Humans; Incidence; Logistic Models; Male; Radiography, Interven | 2010 |
Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Laser-Assisted; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Ther | 2010 |
Aspirin as preventive therapy in patients with asymptomatic vascular disease.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Hemorrhage; Humans; Platelet Aggregation Inhibito | 2010 |
Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Dis | 2010 |
Letter by Doraiswamy regarding article, "Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring
Topics: Anticoagulants; Aspirin; Clopidogrel; Confounding Factors, Epidemiologic; Double-Blind Method; Drug | 2010 |
[Multicentric study of thrombosis prevention in upper-extremity microsurgery. Survey at the Fesum centers].
Topics: Aspirin; Clopidogrel; Drug Monitoring; Evidence-Based Practice; Fibrinolytic Agents; France; Hemorrh | 2010 |
Preliminary evidence of a high risk of bleeding on aspirin plus clopidogrel in aspirin-naïve patients in the acute phase after TIA or minor ischaemic stroke.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fol | 2010 |
Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm?
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Bioprosthesis; Chi-Square Distribution; Drug Adminis | 2010 |
Aspirin in primary prevention. Evidence is lacking.
Topics: Aged; Aspirin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarc | 2010 |
Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Coronary Dis | 2010 |
[Balancing act in antithrombotic therapy. Between hemorrhage and embolism].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Coronar | 2010 |
Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy.
Topics: Anticoagulants; Aspirin; Drug Administration Schedule; Female; Heart Failure; Heart Transplantation; | 2010 |
Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Di | 2010 |
Aspirin as antiplatelet agent in diabetes: Cons.
Topics: Aspirin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Hemorrhage; Humans; Platelet Aggregation | 2010 |
AAA- a further step towards a moratorium for aspirin in the primary prevention.
Topics: Aged; Ankle Brachial Index; Aspirin; Atherosclerosis; Cardiovascular Agents; Cardiovascular Diseases | 2010 |
Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogr | 2010 |
Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective.
Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Tri | 2010 |
Hemorrhagic cholecystitis after anticoagulation therapy.
Topics: Adenocarcinoma; Aged; Angina, Unstable; Anticoagulants; Aspirin; Cholecystitis; Female; Gallbladder | 2010 |
High-dose fibrinogen concentrate for haemostatic therapy of a major trauma patient with recent clopidogrel and aspirin intake.
Topics: Aspirin; Clopidogrel; Drug Interactions; Fibrinogen; Glasgow Coma Scale; Hemorrhage; Hemostatics; Hu | 2010 |
[Antiplatelet therapy in patients with chronic obliterating diseases of lower-limb arteries].
Topics: Arteriosclerosis Obliterans; Aspirin; Chronic Disease; Fibrinolytic Agents; Hemorrhage; Humans; Leg; | 2010 |
Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel.
Topics: Animals; Aspirin; Carotid Arteries; Clopidogrel; Disease Models, Animal; Drug Therapy, Combination; | 2010 |
Standardized protocol for artery-only fingertip replantation.
Topics: Adolescent; Adult; Amputation, Traumatic; Arteries; Aspirin; Child; Child, Preschool; Cohort Studies | 2010 |
Fine-tuning therapy for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Angiography; Hemorr | 2010 |
Aspirin and the prevention of cardiovascular disease in chronic kidney disease: time to move forward?
Topics: Aspirin; Cardiovascular Diseases; Chronic Disease; Creatinine; Glomerular Filtration Rate; Hemorrhag | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Is early antithrombotic therapy necessary after tissue mitral valve replacement?
Topics: Aged; Aged, 80 and over; Animals; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Cattle; Ch | 2010 |
Effect of anticoagulation on endothermal ablation of the great saphenous vein.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Drug Thera | 2011 |
Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Contusions; Epistaxis; Ethnicity; Female; Hemo | 2011 |
Acetylsalicylic acid (aspirin) as a cause of bleeding.
Topics: Aspirin; Hemorrhage; Humans; Salicylates | 1945 |
Emerging oral antiplatelet therapies for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Cardiology; Clopidogrel; Drug The | 2010 |
National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin.
Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; | 2010 |
National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin.
Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; | 2010 |
National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin.
Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; | 2010 |
National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin.
Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; | 2010 |
Aspirin in the primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Female; Hemorrhage; Humans; Male; Platelet | 2011 |
Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Fibrinolytic Age | 2010 |
Do you need aspirin therapy? Your risks of heart attack and stroke based upon your current and past medical history must be weighed against the chances of internal bleeding.
Topics: Aspirin; Coronary Artery Disease; Health Knowledge, Attitudes, Practice; Hemorrhage; Humans; Platele | 2009 |
Long-term anticoagulation with fondaparinux in a patient with a mechanical heart valve.
Topics: Anticoagulants; Aortic Valve Stenosis; Aspirin; Drug Therapy, Combination; Fondaparinux; Heart Valve | 2011 |
A prospective study of aspirin use and the risk of gastrointestinal bleeding in men.
Topics: Aged; Aspirin; Blood Transfusion; Cohort Studies; Gastrointestinal Hemorrhage; Hemorrhage; Humans; M | 2010 |
[Bleeding risk related to combined aspirin and other antithrombotic drug use in patients with acute coronary syndrome: prevention and therapy strategies].
Topics: Acute Coronary Syndrome; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans | 2010 |
Antiplatelet drugs in the elderly: prescriptions often inappropriate and reduced tolerance by associated diseases and drugs.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; | 2012 |
Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chronic Disease; Clopidogrel; Cohort Studies; Coronar | 2011 |
[Warfarin combined with blood platelet inhibition].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Hemorrhage; Humans | 2011 |
Immortal person-time bias in observational studies in cardiac surgery.
Topics: Aspirin; Bias; Clopidogrel; Coronary Artery Bypass; Data Interpretation, Statistical; Drug Therapy, | 2011 |
Delphi-consensus weights for ischemic and bleeding events to be included in a composite outcome for RCTs in thrombosis prevention.
Topics: Aspirin; Hemorrhage; Humans; Ischemia; Randomized Controlled Trials as Topic; Stroke; Thrombosis; Tr | 2011 |
Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; | 2011 |
Dual antiplatelet therapy and the risk of bleeding.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhag | 2011 |
[The CURRENT-OASIS 7 study].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2011 |
Aspirin in the prevention of cancer.
Topics: Age Distribution; Age Factors; Aged; Aged, 80 and over; Anticarcinogenic Agents; Antihypertensive Ag | 2011 |
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Graft Occlusion, Vascular; Hemor | 2011 |
Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cohort Studies; Denmark; Drug Evaluation; Fem | 2011 |
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting.
Topics: Aspirin; Cerebrovascular Circulation; Clopidogrel; Coronary Artery Bypass; Coronary Vessels; Drug Th | 2011 |
Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.
Topics: Aspirin; Atherosclerosis; Drug Delivery Systems; Drug Design; Hemorrhage; Humans; Myocardial Infarct | 2011 |
Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Angioplasty, B | 2011 |
Safety of ultrasound-guided fine needle aspiration biopsy of neck lesions in patients taking antithrombotic/anticoagulant medications.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Biopsy, Fine-Needle; Chi-Square | 2011 |
Comparison of characteristics, management practices, and outcomes of patients between the global registry and the gulf registry of acute coronary events.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Aspiri | 2011 |
Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Aspirin; Australia; Cardiovascular Diseases; Computer Simu | 2013 |
Normal chest radiograph and ground glass opacities on a thoracic computed tomographic scan in a patient with diffuse alveolar haemorrhage due to dual antiplatelet therapy prescribed after patent foramen ovale percutaneous device closure.
Topics: Adult; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Foramen Ovale, Patent; Hemoptysis; H | 2011 |
Aspirin bleeding in perspective.
Topics: Anti-Inflammatory Agents; Anticoagulants; Aspirin; Cardiovascular Diseases; Colorectal Neoplasms; He | 2011 |
Hemostasis effects of direct intraparenchymal injection of platelets and fresh frozen plasma before cutting needle biopsy in an animal model.
Topics: Animals; Anticoagulants; Aspirin; Biopsy, Needle; Blood Platelets; Hemorrhage; Hemostasis; Hemostati | 2011 |
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Ag | 2011 |
The use of dabigatran immediately after atrial fibrillation ablation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; | 2012 |
Correlation between point-of-care platelet function testing and bleeding after coronary artery surgery.
Topics: Aged; Aspirin; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Coronary Vessels; Female; Hem | 2012 |
Development of a tool to improve the quality of decision making in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Decision Support Techniques; Hemorrhage; Humans; Patie | 2011 |
Update on aspirin. People with heart disease should take aspirin; the decision is trickier for those without it.
Topics: Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; | 2011 |
Carbon monoxide-releasing molecule-2 enhances coagulation in rabbit plasma and decreases bleeding time in clopidogrel/aspirin-treated rabbits.
Topics: Administration, Oral; Animals; Aspirin; Bleeding Time; Blood Coagulation; Carbon Monoxide; Clopidogr | 2011 |
Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D | 2012 |
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistan | 2011 |
Large retroperitoneal haematoma: an unexpected complication of ilioinguinal nerve block for inguinal hernia repair.
Topics: Aged; Anesthesia, General; Aspirin; Blood Transfusion; Digestive System Surgical Procedures; Hemorrh | 2012 |
Aspirin versus warfarin in atrial fibrillation: decision analysis may help patients' choice.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Decision Support Techniques; Decision Trees; Hemorrhag | 2012 |
[Essential acetylsalicylic acid: over 100 years old and still good for surprises (interview by Dr. med. Jochen Aumiller)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Dose-Response Relationship, | 2011 |
Peribulbar block in 500 patients scheduled for eye procedures and treated with acetyl salicylic acid.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Hemorrhage | 2011 |
Risks of aspirin outweigh benefits in people without cardiovascular disease, shows analysis.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Meta-Analysis as Topic; Risk Factors | 2012 |
Evaluation of risk factors for bleeding after liver biopsy in children.
Topics: Adolescent; Aspirin; Biopsy; Blood Coagulation Disorders; Child; Child, Preschool; Confidence Interv | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; | 2012 |
Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Aspirin; Catheterization; Combined Modality Therapy; Ductus Arteriosus, Patent; Evidence-Based Medic | 2012 |
Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia.
Topics: Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Aspirin; Clopidogrel; Drug Resistance; Hemor | 2012 |
Continuing aspirin in the perioperative patient.
Topics: Aspirin; Hemorrhage; Humans; Perioperative Care; Platelet Aggregation Inhibitors | 2012 |
What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation?
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemor | 2012 |
Triple antithrombotic therapy after coronary stenting in the elderly with atrial fibrillation: necessary or too hazardous?
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platelet A | 2012 |
Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Dose-Response Relat | 2012 |
Interaction between ticlopidine or warfarin or cardioaspirin with a highly standardized deterpened Ginkgo biloba extract (VR456) in rat and human.
Topics: Animals; Aspirin; Blood Pressure; Drug Interactions; Ginkgo biloba; Ginkgolides; Heart Rate; Hemorrh | 2010 |
Aspirin provides minimal cardiac protection to healthy adults. Risk of serious internal bleeding far outweighs any benefit.
Topics: Adult; Age Factors; Aged; Aspirin; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Middle | 2012 |
Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study.
Topics: Aged; Alabama; Antithrombins; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Elective Surgi | 2012 |
Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: landmark analyses from the CREDO-Kyoto PCI/CABG Registry Cohort-2.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Cohort Studies; | 2012 |
Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Thera | 2012 |
Adherence to guidelines for the prescribing of double and triple combinations of antithrombotic agents.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Attitude of Health Personnel; Clopidogrel; Community Pharma | 2014 |
Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Contraindications; Cost-Benefit Analysis; Drug C | 2012 |
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inh | 2012 |
Perioperative use of aspirin for patients undergoing carotid endarterectomy.
Topics: Administration, Oral; Aged; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Drug Administration | 2012 |
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazo | 2012 |
Diabetes: Does aspirin increase the risk of major bleeds?
Topics: Aspirin; Diabetes Mellitus; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Assessment | 2012 |
[Removal of epidural catheter under dual antiplatelet therapy following acute coronary syndrome : scenario without special consideration to the current guidelines on epidural regional anesthesia].
Topics: Acute Coronary Syndrome; Analgesia, Epidural; Aspirin; Catheterization; Clopidogrel; Digestive Syste | 2012 |
Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS.
Topics: Adverse Drug Reaction Reporting Systems; Aspirin; Clopidogrel; Data Mining; Hemorrhage; Humans; Plat | 2012 |
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fi | 2012 |
Impact of platelet reactivity on long-term clinical outcomes and bleeding events in Japanese patients receiving antiplatelet therapy with aspirin.
Topics: Aged; Aspirin; Blood Platelets; Body Mass Index; Cardiovascular Diseases; Female; Follow-Up Studies; | 2012 |
Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Decision Making; Female; Fibrinolytic Agents; He | 2012 |
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure, | 2012 |
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure, | 2012 |
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure, | 2012 |
Stroke and bleeding in atrial fibrillation with chronic kidney disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Kidney Failure, | 2012 |
Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aortic Valve; Aspirin; Bioprosthesis; Cohort Studies; Drug | 2012 |
Early and late outcome associated with bleeding events in the setting of dual antiplatelet therapy following stent placement.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Hem | 2012 |
Should warfarin or aspirin be stopped prior to prostate biopsy? An analysis of bleeding complications related to increasing sample number regimes.
Topics: Aged; Anticoagulants; Aspirin; Biopsy; Hemorrhage; Humans; Male; Prospective Studies; Prostatic Neop | 2012 |
[General antithrombotic therapy practice facing fundamental change].
Topics: Aspirin; Cause of Death; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Fibrinolytic A | 2012 |
Could progressive iron loss from mucosal microbleeding represent a mechanism of cancer prevention from prolonged aspirin use?
Topics: Aspirin; Hemorrhage; Humans; Iron; Mucous Membrane; Neoplasms | 2013 |
Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Comorb | 2012 |
Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.
Topics: Anticoagulants; Aspirin; Case-Control Studies; Coronary Thrombosis; Europe; Fibrinolytic Agents; Hea | 2012 |
[The value of compliance during chronic administration of acetylsalicylic acid in patients with acute coronary syndrome: results of the study FORPOST].
Topics: Abdominal Pain; Acute Coronary Syndrome; Aged; Aspirin; Drug-Related Side Effects and Adverse Reacti | 2012 |
Effects of aspirin on mesenteric lymph nodes of rabbits as basis for its use on lymph nodes metastases.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aspirin; Drug Screening Assays, Antitumor; Germinal Cente | 2012 |
[Platelet inhibition in clinical practice].
Topics: Aged; Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Cerebral Infarction; Clo | 2012 |
[Adverse effects of cardiovascular agents in Japan--update 2012].
Topics: Anticoagulants; Antidiuretic Hormone Receptor Antagonists; Aspirin; Benzazepines; Cardiovascular Age | 2012 |
Safety of endoscopic sphincterotomy in patients under dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cholangiopancreatography, Endoscopic Retrograde; Clopidogre | 2013 |
Atrial fibrillation and chronic kidney disease.
Topics: Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Male; Renal Insufficie | 2012 |
Atrial fibrillation and chronic kidney disease.
Topics: Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Male; Renal Insufficie | 2012 |
Atrial fibrillation and chronic kidney disease.
Topics: Aspirin; Atrial Fibrillation; Female; Hematologic Agents; Hemorrhage; Humans; Male; Renal Insufficie | 2012 |
Dual antiplatelet therapy in peripheral arterial disease and after peripheral percutaneous revascularization.
Topics: Aspirin; Clopidogrel; Endovascular Procedures; Hemorrhage; Humans; Peripheral Arterial Disease; Plat | 2012 |
[First WARFASA, now ASPIRE. The new career of ASS in long-term thromboembolism prevention].
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; | 2012 |
Excessive bleeding: not really due to "blood thinners".
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthritis; Aspirin; Bloo | 2013 |
Antithrombotic therapy after myocardial infarction.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Plate | 2002 |
Aspirin does not increase bleeding complications after transbronchial biopsy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy, Needle; Br | 2002 |
Clopidogrel plus aspirin for stroke prevention.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Follow- | 2002 |
Aspirin or warfarin: what's best after a heart attack? Risk of bleeding counters warfarin's edge in efficacy.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; | 2002 |
Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Creatinine; Drug Monitoring; Eno | 2003 |
Bedside calculation of stroke risk in patients with atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Computers, Handheld; Hemorrh | 2003 |
[Anticoagulation and antiaggregation in cardiac patients].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Clo | 2003 |
[New antiaggregants and their importance for the practitioner].
Topics: Abciximab; Administration, Oral; Adult; Anesthesia, Spinal; Antibodies, Monoclonal; Aspirin; Cardiov | 2003 |
Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin.
Topics: Adult; Anticoagulants; Arteriovenous Shunt, Surgical; Aspirin; Factor VIIa; Female; Hemorrhage; Hepa | 2003 |
Antithrombotic treatment of atrial fibrillation in a regional hospital in Hong Kong.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Chronic Disease; Contraindications; Fe | 2003 |
Morbidity of transrectal ultrasonography-guided prostate biopsies in patients after the continued use of low-dose aspirin.
Topics: Aspirin; Biopsy, Needle; Blood; Cohort Studies; Gastrointestinal Hemorrhage; Hematuria; Hemorrhage; | 2003 |
Bone marrow biopsy morbidity and mortality.
Topics: Anticoagulants; Aspirin; Biopsy, Needle; Bone Marrow Examination; Hemorrhage; Humans; Myeloprolifera | 2003 |
Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
Topics: Acute Disease; Anticoagulants; Aspirin; Coronary Disease; Female; Hemorrhage; Heparin; Humans; Male; | 2003 |
Qualitative platelet defect and thrombohaemorrhagic complications in a patient with polycythaemia vera. Case 10.
Topics: Aged; Aspirin; Blood Platelet Disorders; Clopidogrel; Hemorrhage; Humans; Male; Platelet Aggregation | 2003 |
Hemorrhage due to acetylsalicylic acid; report of a case.
Topics: Aspirin; Hemorrhage; Humans; Liver; Salicylates | 1953 |
Aspirin and gastric haemorrhage.
Topics: Aspirin; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Stomach; Stomach Diseases | 1955 |
Hemorrhagic diathesis with increased capillary fragility caused by salicylate therapy.
Topics: Aspirin; Capillaries; Capillary Fragility; Hemorrhage; Hemorrhagic Disorders; Humans; Salicylates; V | 1956 |
[Causes of bleeding in acetylsalicylic acid poisoning].
Topics: Aspirin; Hemorrhage; Humans; Salicylates | 1956 |
[Gastric hemorrhage following acetylsalicylic acid ingestion].
Topics: Aspirin; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Stomach; Stomach Diseases | 1957 |
[Gastric hemorrhage caused by acetylsalicylic acid].
Topics: Aspirin; Hemorrhage; Humans; Stomach | 1957 |
Salicylates and gastric hemorrhage. I. Occult bleeding.
Topics: Aspirin; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Salicylates; Stomach; Stomach Diseases | 1957 |
Salicylates and gastric hemorrhage. II. Manifest bleeding.
Topics: Aspirin; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Salicylates; Stomach; Stomach Diseases | 1957 |
[Unforeseen complication of salicylotherapy].
Topics: Aspirin; Hemorrhage; Humans; Joint Diseases; Rectum | 1957 |
[Severe ulcerous hemorrhage after aspirin injection in a pregnant woman].
Topics: Aspirin; Female; Hemorrhage; Humans; Injections; Peptic Ulcer; Peptic Ulcer Hemorrhage; Pregnancy; P | 1957 |
Bleeding from the upper part of the gastrointestinal tract secondary to ingestion of acetylsalicylic acid (aspirin).
Topics: Aspirin; Gastrointestinal Hemorrhage; Gastrointestinal Tract; Hemorrhage; Humans | 1958 |
[Gastroduodenal ulcers and digestive hemorrhages induced by aspirin].
Topics: Aspirin; Gastrointestinal Hemorrhage; Gastrointestinal Tract; Hemorrhage; Humans; Peptic Ulcer | 1958 |
[Acute hemorrhagic papillitis during subacute aspirin poisoning].
Topics: Aspirin; Eye Diseases; Hemorrhage; Humans; Papilledema; Salicylates | 1958 |
Occult blood in faeces after administration of aspirin.
Topics: Arthritis; Arthritis, Rheumatoid; Aspirin; Feces; Gastrointestinal Hemorrhage; Hemorrhage; Humans; O | 1958 |
[Digestive hemorrhages & gastroduodenal ulcers caused by aspirin; concerning 52 cases].
Topics: Aspirin; Gastrointestinal Hemorrhage; Gastrointestinal Tract; Hemorrhage; Humans; Peptic Ulcer; Pept | 1958 |
Aspirin and gastric haemorrhage.
Topics: Aspirin; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Stomach; Stomach Diseases | 1959 |
[Digestive hemorrhages induced by the ingestion of acetylsalicylate].
Topics: Aspirin; Digestion; Eating; Gastrointestinal Hemorrhage; Hemorrhage; Humans | 1960 |
Aspirin and gastrointestinal bleeding. Chromate blood loss studies.
Topics: Aspirin; Chromates; Gastrointestinal Hemorrhage; Hemorrhage; Humans | 1961 |
[Gastric hemorrhage after aspirin].
Topics: Aspirin; Gastrointestinal Hemorrhage; Hemorrhage; Stomach Diseases | 1961 |
[Hemorrhage of the digestive system caused by the ingestion of acetylsalicylic acid (aspirin)].
Topics: Aspirin; Digestive System; Eating; Gastrointestinal Hemorrhage; Hemorrhage | 1960 |
[Severe digestive hemorrhage following the prolonged absorption of aspirin].
Topics: Aspirin; Digestion; Gastrointestinal Hemorrhage; Hemorrhage | 1961 |
Effect of anticoagulant therapy upon aspirin-induced gastrointestinal bleeding.
Topics: Anticoagulants; Aspirin; Gastrointestinal Hemorrhage; Hemorrhage; Humans | 1961 |
Aspirin and gastric bleeding. Gastroscopic observations, with review of literature.
Topics: Aspirin; Gastrointestinal Hemorrhage; Hemorrhage | 1961 |
[Allergy to aspirin. Gastric nemorrnages preceding the appearance of asthma, urticaria or Quincke's edema].
Topics: Angioedema; Aspirin; Asthma; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Hypersensitivity; Urti | 1960 |
[Hemorrhagic cystitis and allergy to drugs].
Topics: Aspirin; Cystitis; Hemorrhage; Humans; Hypersensitivity; Immune System Diseases; Medical Records | 1960 |
[Digestive hemorrhages triggered by aspirin in the course of ulcerous or undetermined syndromes. (Apropos of 10 cases)].
Topics: Aspirin; Digestion; Hemorrhage; Humans; Peptic Ulcer Hemorrhage; Precipitating Factors; Syndrome | 1960 |
[The ability of acetylsalicylic acid to cause gastrointestinal hemorrhages as determined by benzidine reactions in the feces].
Topics: Aspirin; Benzidines; Feces; Gastrointestinal Hemorrhage; Hemorrhage; Humans | 1960 |
Aspirin, gastrointestinal bleeding, and peptic ulcer.
Topics: Aspirin; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Peptic Ulcer; Peptic Ulcer Hemorrhage | 1960 |
Drug-induced gastrointestinal bleeding.
Topics: Aspirin; Gastrointestinal Hemorrhage; Hemorrhage | 1962 |
Aspirin preperations and their noxious effect on the gastro-intestinal tract.
Topics: Aspirin; Gastrointestinal Hemorrhage; Hemorrhage; Humans | 1962 |
Aspirin and gastrointestinal blood loss.
Topics: Aspirin; Gastrointestinal Hemorrhage; Hemorrhage; Humans | 1963 |
[Hemorrhage from the digestive tract caused by the ingestion of aspirin].
Topics: Aspirin; Eating; Gastrointestinal Hemorrhage; Hemorrhage; Humans | 1963 |
[Aspirin used chronic rheumatoid arthritis patients and chronic gastrointestinal bleeding].
Topics: Arthritis, Rheumatoid; Aspirin; Gastrointestinal Hemorrhage; Hemorrhage; Humans | 1963 |
Topical action of salicylates in gastrointestinal erosion and hemorrhage.
Topics: Aspirin; Gastrointestinal Tract; Hemorrhage; Humans; Mouth; Mucous Membrane; Phenacetin; Salicylates | 1963 |
Salicylates and gastrointestinal bleeding. Acetylsalicylic acid and aspirin derivatives.
Topics: Aspirin; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Salicylates | 1962 |
[DIGESTIVE HEMORRHAGE PRODUCED BY SALICYLATES].
Topics: Aspirin; Digestion; Gastrointestinal Hemorrhage; Hemorrhage; Salicylates; Toxicology | 1963 |
[EFFECT ON ASPIRIN OF BLEEDING FROM THE DIGESTIVE SYSTEM].
Topics: Aspirin; Digestive System; Gastrointestinal Hemorrhage; Hemorrhage; Toxicology | 1963 |
THE MANAGEMENT OF GASTROINTESTINAL HEMORRHAGE.
Topics: Aspirin; Diagnosis; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Peptic Ulcer Hemorrhage; Steroi | 1963 |
[ACUTE DIGESTIVE HEMORRHAGES].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticoagulants; Aspirin; Gastrointestinal Hemo | 1963 |
[IS ASPIRIN A DANGEROUS DRUG?].
Topics: Anemia; Anemia, Hypochromic; Angioedema; Anticoagulants; Aspirin; Asthma; Blood Coagulation Disorder | 1963 |
[RECENT ANALGESICS, ANTIRHEUMATIC AGENTS AND URICOSURIC AGENTS].
Topics: Aminopyrine; Analgesics; Analgesics, Non-Narcotic; Antipyretics; Antirheumatic Agents; Aspirin; Colc | 1963 |
ASPIRIN VS ACETAMINOPHEN AFTER TONSILLECTOMY. A COMPARATIVE DOUBLE-BLIND CLINICAL STUDY.
Topics: Acetaminophen; Adenoidectomy; Adolescent; Analgesics; Analgesics, Non-Narcotic; Antipyretics; Aspiri | 1964 |
GASTRO-INTESTINAL BLEEDING.
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Antipyretics; Aspirin; Chromium Isotopes; Gastr | 1964 |
EXPERIMENTALLY INDUCED ANALGESIC NEPHRITIS IN RATS.
Topics: Analgesics; Aspirin; Caffeine; Hemorrhage; Kidney Papillary Necrosis; Leukocytes; Lymphocytes; Nephr | 1964 |
EFFECTS OF ASPIRIN, ACETAMINOPHEN, AND SALICYLAMIDE ON GASTRIC MUCOSA OF DOGS.
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Antipyretics; Aspirin; Dogs; Gastric Mucosa; Ga | 1964 |
[DIGESTIVE COMPLICATIONS INITIATED BY ASPIRIN ADMINISTERED BY THE ORAL ROUTE].
Topics: Aspirin; Gastrointestinal Hemorrhage; Hemorrhage; Occult Blood; Peptic Ulcer; Toxicology | 1964 |
[MEGAESOPHAGUS AND DRUG-INDUCED HEMORRHAGE].
Topics: Aspirin; Cortisone; Esophageal Achalasia; Esophagus; Geriatrics; Hemorrhage; Toxicology | 1964 |
A CASE OF THE BEMUSED MEDIC.
Topics: Aspirin; Colon; Depression; Diagnosis, Differential; Diverticulitis; Diverticulitis, Colonic; Gastro | 1964 |
ASPIRIN-INDUCED HAEMATEMESIS.
Topics: Aspirin; Gastrointestinal Hemorrhage; Hematemesis; Hemorrhage; Humans; Melena; Toxicology | 1964 |
EFFECT OF PARACETAMOL (N-ACETYL-P-AMINOPHENOL) ON GASTROINTESTINAL BLEEDING.
Topics: Acetaminophen; Aspirin; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Occult Blood; Pharmacology; | 1964 |
[PATHOGENESIS OF GASTROINTESTINAL HEMORRHAGE FOLLOWING ASPIRIN THERAPY].
Topics: 17-Hydroxycorticosteroids; Aspirin; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Peptic Ulcer; T | 1964 |
[THERAPEUTIC COMPLICATIONS OF ANALGESIC MEDICATIONS].
Topics: Agranulocytosis; Aminopyrine; Analgesics; Anemia; Anemia, Hemolytic; Aspirin; Drug Hypersensitivity; | 1964 |
[THE SALTS OF ACETYLSALICYLIC ACID ARE ALSO DANGEROUS].
Topics: Anemia; Anemia, Hypochromic; Aspirin; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Melena; Salts | 1964 |
TOXIC EFFECTS OF ASPIRIN AND PHENACETIN.
Topics: Aspirin; Gastrointestinal Hemorrhage; Hematologic Diseases; Hemorrhage; Phenacetin; Toxicology | 1965 |
A STUDY OF THE GASTRIC LESIONS INDUCED BY ASPIRIN IN LABORATORY ANIMALS.
Topics: Animals; Animals, Laboratory; Aspirin; Gastric Mucosa; Gastrointestinal Hemorrhage; Guinea Pigs; Hem | 1964 |
A STUDY OF THE GASTRIC LESIONS INDUCED IN LABORATORY ANIMALS BY SOLUBLE AND BUFFERED ASPIRIN.
Topics: Animals; Animals, Laboratory; Antacids; Aspirin; Buffers; Fasting; Gastric Mucosa; Gastrointestinal | 1964 |
PARACETAMOL OR ASPIRIN?
Topics: Acetaminophen; Aspirin; Gastrointestinal Hemorrhage; Hemorrhage; Toxicology | 1965 |
[IATROGENIC DISEASE CAUSED BY ASPIRIN].
Topics: Aspirin; Gastrointestinal Hemorrhage; Geriatrics; Hemorrhage; Iatrogenic Disease; Toxicology | 1965 |
[ONCE MORE ON THE HAZARDS OF ACETYLSALICYLIC ACID, ITS SALTS AND COMBINATIONS].
Topics: Antacids; Aspirin; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Hemorrhage; Salts; Toxicology | 1964 |
DAMAGE TO THE GASTRIC MUCOSA: EFFECTS OF SALICYLATES AND STIMULATION.
Topics: Absorption; Animals; Aspirin; Bethanechol Compounds; Denervation; Dogs; Gastric Mucosa; Gastrins; Ga | 1965 |
ASPIRIN AND GASTROINTESTINAL BLEEDING.
Topics: Aspirin; Drug Therapy; Gastrointestinal Hemorrhage; Hemorrhage; Toxicology | 1965 |
[Digestive hemorrhages after administration of acetylsalicylic acid. Contributions to their pathogenesis, prophylaxis and treatment].
Topics: Aspirin; Digestion; Gastrointestinal Hemorrhage; Hemorrhage; Humans | 1960 |
Drug-induced gastrointestinal bleeding.
Topics: Aspirin; Gastrointestinal Hemorrhage; Hemorrhage | 1961 |
[Sudden edema and pain in the knee].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactio | 2003 |
[Before polyp removal. To stop or not to stop ASA?].
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Polyps; Endoscopy; Ga | 2003 |
Safety of plasmin in the setting of concomitant aspirin and heparin administration in an animal model of bleeding.
Topics: Animals; Aspirin; Bleeding Time; Drug Interactions; Drug Therapy, Combination; Fibrinolysin; Fibrino | 2003 |
Assessment of bleeding propensity in non-human primates by combination of selective tissue factor/VIIa inhibition and aspirin compared to warfarin and aspirin treatment.
Topics: Aminobenzoates; Animals; Anticoagulants; Aspirin; Bleeding Time; Dose-Response Relationship, Drug; D | 2004 |
Hemorrhagic tendency of aspirin therapy: a case report.
Topics: Aspirin; Hemorrhage; Humans | 1951 |
Aetiology of aspirin bleeding.
Topics: Aspirin; Hemorrhage; Humans; Tooth Extraction | 1951 |
Gastrointestinal hemorrhage from a large dose of acetylsalicylic acid.
Topics: Aspirin; Gastrointestinal Hemorrhage; Gastrointestinal Tract; Hemorrhage; Humans; Vitamin K | 1951 |
When guidelines collide...
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy | 2004 |
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2004 |
A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis.
Topics: Aspirin; Endocarditis, Bacterial; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Thrombo | 2004 |
Low-dose aspirin in polycythemia vera.
Topics: Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Polycythemia Vera; Thrombocythemia, Es | 2004 |
Thromboembolic prophylaxis in nonrheumatic atrial fibrillation: utilization patterns, efficacy, and complications in a long-term follow-up of community patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Femal | 2004 |
Perioperative hemorrhage and combined clopidogrel and aspirin therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Combinations; Endarterectomy, Carotid; Female; G | 2004 |
[Secondary prevention of TIA and stroke. How much must thrombocytes not be inhibited?].
Topics: Aspirin; Cerebral Infarction; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Hemo | 2004 |
[Peridural injections during acetylsalicylic acid and clopidogrel therapy?].
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Injections, Epidural; I | 2004 |
[Clopidogrel protection is not increased further by ASS!].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2004 |
[Clopidogrel as basic therapy in high-risk stroke patients].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Hemo | 2004 |
Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes.
Topics: Acute Disease; Administration, Oral; Aged; Aspirin; Cardiovascular Agents; Cohort Studies; Drug Ther | 2004 |
Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antibodies, Monoclonal; | 2004 |
Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combinat | 2005 |
Summaries for patients. Is it cost-effective to treat high-risk cardiac patients with clopidogrel plus aspirin as opposed to aspirin alone?
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice.
Topics: Animals; Aspirin; Blood Coagulation Tests; Clopidogrel; Disease Models, Animal; Drug Therapy, Combin | 2005 |
Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug A | 2005 |
Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us?
Topics: Aspirin; Cardiovascular Diseases; Cholesterol; Chronic Disease; Disease Progression; Hemorrhage; Hum | 2005 |
Effect of clopidogrel with and without aspirin on bleeding following transbronchial lung biopsy.
Topics: Animals; Aspirin; Biopsy, Needle; Bronchoscopy; Clopidogrel; Hemorrhage; Lung; Platelet Aggregation | 2005 |
Warfarin, aspirin, and intracranial vascular disease.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Fibrinolytic Agents; Hemorrhage; Humans; | 2005 |
A protocol for the use of enoxaparin during pregnancy: results from 85 pregnancies including 13 multiple gestation pregnancies.
Topics: Adult; Aspirin; Clinical Protocols; Dose-Response Relationship, Drug; Drug Monitoring; Enoxaparin; F | 2005 |
Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Case-Control Studies; Clopidogrel; Cohort Studies; Drug | 2005 |
Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? Yes.
Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Clinical Trials as Topic; | 2005 |
Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No.
Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Clinical Trials as Topic; | 2005 |
[Antiplatelet agents and regional anaesthesia: experience in 130 patients].
Topics: Aged; Aspirin; Autonomic Nerve Block; Blood Loss, Surgical; Blood Vessel Prosthesis Implantation; Cl | 2005 |
Aspirin and women--age matters. Aspirin can help healthy women over age 56 prevent both strokes and heart attacks. For younger women, the hazards of aspirin outweigh the benefits.
Topics: Age Factors; Aspirin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Middle Aged; Myocardial Infar | 2005 |
When and how to treat essential thrombocythemia.
Topics: Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxyurea; Leukemia | 2005 |
Summaries for patients. Benefits and harms of warfarin plus aspirin after acute coronary events.
Topics: Acute Disease; Anticoagulants; Aspirin; Coronary Disease; Female; Fibrinolytic Agents; Hemorrhage; H | 2005 |
Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
Topics: Aged; Anticoagulants; Aspirin; Cardiac Catheterization; Enoxaparin; Female; Hemorrhage; Heparin; Hum | 2005 |
Adverse reactions to anticoagulants and to antiplatelet drugs recorded by the German spontaneous reporting system.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Anticoagulants; Aspirin; Association; | 2005 |
Molecular mechanism of Clopidogrel and Aspirin therapy-induced bleeding episodes.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Eicosanoids; Hemorrhage; Humans; Ticlopidine | 2006 |
Bleeding complications related to aspirin dose.
Topics: Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors | 2005 |
[Cerebral secondary prevention--clopidogrel alone or in combination with ASS].
Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Huma | 2005 |
Acute pain in the tip of the index finger.
Topics: Acute Disease; Amlodipine; Arterial Occlusive Diseases; Aspirin; Cyanosis; Diagnostic Errors; Female | 2005 |
Comments in response to "Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials".
Topics: Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; | 2005 |
Bleeding complications in elderly patients following acute myocardial infarction.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardia | 2005 |
Platelet aggregation in portal hypertension and its modification by ultra-low doses of aspirin.
Topics: Adenosine Diphosphate; Animals; Aspirin; Fibrinogen; Hemorrhage; Humans; Hypertension, Portal; Injec | 2005 |
Life-threatening subcutaneous hemorrhage following minor blunt trauma in an elderly patient taking ticlopidine and aspirin: a case report.
Topics: Abdominal Injuries; Accidental Falls; Aged, 80 and over; Aspirin; Embolization, Therapeutic; Female; | 2005 |
Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cerebral Hemorrhage; Cohort | 2006 |
Aspirin-use before ICH: a potentially treatable iatrogenic coagulopathy?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebral Hemorrhage; Clinical Trials as Topic; Hem | 2006 |
Is aspirin effective in diabetic patients? No.
Topics: Aspirin; Diabetes Complications; Diabetes Mellitus; Hemorrhage; Humans; Risk Assessment; Treatment F | 2005 |
New modalities and aspects of antiplatelet therapy for stroke prevention.
Topics: Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Design; Drug Resistance; Drug Therapy, Combi | 2006 |
[Recommendations for peri-procedural thrombocyte aggregation inhibition].
Topics: Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; He | 2006 |
A prospective control study of the safety and cellular yield of EUS-guided FNA or Trucut biopsy in patients taking aspirin, nonsteroidal anti-inflammatory drugs, or prophylactic low molecular weight heparin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Biopsy, Fine-Needle; Biopsy, Needl | 2006 |
Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; He | 2006 |
Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Coagulation Tests; Coronary Ang | 2006 |
Clopidogrel for the prevention of atherothrombotic events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Incide | 2006 |
Clopidogrel for the prevention of atherothrombotic events.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Platel | 2006 |
Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Dose- | 2006 |
[Bleeding complications after treatment with antithrombotic agents after acute coronary syndrome].
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Fibrinolytic Agent | 2006 |
[Bleeding complications after treatment with clopidogrel and acetylsalicylic acid after acute coronary syndrome].
Topics: Age Factors; Aged; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Com | 2006 |
Swine model of carotid artery atherosclerosis: experimental induction by surgical partial ligation and dietary hypercholesterolemia.
Topics: Angiography; Angioplasty, Balloon; Animals; Aspirin; Calcinosis; Carotid Arteries; Carotid Artery In | 2006 |
[Old patient with atrial fibrillation: do you too hesitate to use anticoagulants?].
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrilla | 2006 |
Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Drug Therapy, Combinat | 2006 |
The haematocrit and platelet target in polycythemia vera.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Disease Progression; Female; Follow-Up Studi | 2007 |
Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Female; Hem | 2007 |
Research for bleeding tendency in patients presenting with significant epistaxis.
Topics: Aspirin; Biomarkers; Blood Coagulation Disorders, Inherited; Epistaxis; Family Health; Female; Hemor | 2007 |
[Safety of aspirin, clopidogrel, and acenocumarol combination in patients requiring anticoagulation].
Topics: Acenocoumarol; Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorr | 2006 |
Atraumatic compartment syndrome of the dorsal compartment of the upper arm.
Topics: Acute Disease; Aged; Arm; Aspirin; Compartment Syndromes; Diagnosis, Differential; Enoxaparin; Femal | 2006 |
[Low dose of aspirin during pregnancy].
Topics: Abnormalities, Drug-Induced; Abortion, Habitual; Abortion, Spontaneous; Adult; Animals; Anti-Inflamm | 2007 |
Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.
Topics: Animals; Aspirin; Blood Coagulation; Clopidogrel; Disease Models, Animal; Drug Therapy, Combination; | 2007 |
Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio | 2007 |
Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Hemorrhag | 2007 |
The use of clopidogrel in carotid endarterectomy: an audit of current practice.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Endarterectomy, Carotid; Hemorrhage; Humans; Medica | 2007 |
Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring.
Topics: Aged; Anticoagulants; Aspirin; Aspirin, Dipyridamole Drug Combination; Clopidogrel; Dextrans; Dipyri | 2007 |
Platelets release active matrix metalloproteinase-2 in vivo in humans at a site of vascular injury: lack of inhibition by aspirin.
Topics: Administration, Oral; Adult; Aspirin; Bleeding Time; Blood Platelets; Female; Fibrinolytic Agents; F | 2007 |
[Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atrial Fibrillation; Bipheny | 2007 |
I recently had cardiac symptoms and high troponin levels in my blood. Prior to a coronary angiogram, I was given an intravenous dose of heparin and now take 12.5 milligrams of metoprolol, a beta-blocker, twice a day. I bleed a lot and bruise when I have a
Topics: Adrenergic beta-Antagonists; Aspirin; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Myocardial I | 2007 |
Stroke prevention in elderly patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fi | 2007 |
Protective effect of Foeniculum vulgare essential oil and anethole in an experimental model of thrombosis.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Aorta; Aspirin; Blood Coagulation; Collagen; Disease Mo | 2007 |
Admissions to a medical intensive care unit related to adverse drug reactions.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse | 2007 |
A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
Topics: Administration, Oral; Animals; Aorta; Aspirin; Bleeding Time; Blood Coagulation; Clopidogrel; Diseas | 2007 |
Safety of the cardiac triple therapy: the experience of the Quebec Heart Institute.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fema | 2007 |
Summaries for patients. Occurrence of venous thromboembolism in women taking low-dose aspirin.
Topics: Aspirin; Double-Blind Method; Drug Administration Schedule; Female; Fibrinolytic Agents; Follow-Up S | 2007 |
Intensifying platelet inhibition--navigating between Scylla and Charybdis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischem | 2007 |
Major bleeding in hemodialysis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Drug Therapy, Combination; Fema | 2008 |
Hemorrhagic foreign body granuloma after cutaneous surgery occurring in the setting of aspirin therapy or thrombocytopenia: a presentation of six cases.
Topics: Aged; Aged, 80 and over; Aspirin; Biopsy; Diagnosis, Differential; Female; Fibrinolytic Agents; Gran | 2008 |
Marked hypoprothrombinemia with hemorrhagic manifestations due to acetylsalicylic acid; report of a case.
Topics: Aspirin; Blood Coagulation; Hemorrhage; Hypoprothrombinemias; Salicylates | 1948 |
Outcomes associated with combined antiplatelet and anticoagulant therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disea | 2008 |
Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cerebrovascular Disorders; Clopido | 2008 |
Analysis of the upper gastrointestinal tract bleeding prevalence in patients treated due ischaemic heart disease.
Topics: Acenocoumarol; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Body Mass Index; Clopidogrel; Fe | 2007 |
Aspirin dose do's and don'ts.
Topics: Aspirin; Cyclooxygenase Inhibitors; Hemorrhage; Humans; Middle Aged; Neoplasms; Platelet Aggregation | 2007 |
[Prescription, monitoring of antithrombotic treatment: 1--antiplatelet agents].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Contraindica | 2007 |
Aspirin revisited: helpful or harmful? What is the correct dose for a certain population?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors | 2008 |
[Severe bleeding from the radial artery after puncture for blood gas analysis in a patient with kidney failure receiving antiplatelet therapy].
Topics: Aged, 80 and over; Aspirin; Blood Gas Analysis; Combined Modality Therapy; Deamino Arginine Vasopres | 2008 |
What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Clopidogrel; Fibri | 2008 |
Thioredoxin in coronary culprit lesions: possible relationship to oxidative stress and intraplaque hemorrhage.
Topics: Aged; Angina Pectoris; Aspirin; Female; Gene Expression Regulation; Glycophorins; Hemorrhage; Humans | 2008 |
Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 2008 |
Anti-platelet agents and surgical delay in elderly patients with hip fractures.
Topics: Aged; Aspirin; Bleeding Time; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hip Fractures; Hum | 2008 |
Congenital deficiency of thromboxane and prostacyclin.
Topics: Adenosine Diphosphate; Adult; Arachidonic Acids; Aspirin; Blood Coagulation Tests; Blood Platelet Di | 1980 |
Thromboxane A2 in skin-bleeding-time blood and in clotted venous blood before and after administration of acetylsalicylic acid.
Topics: Adenosine Diphosphate; Adult; Aspirin; Bleeding Time; England; Hemorrhage; Hemostasis; Humans; Male; | 1983 |
Drug interactions in alcoholic patients.
Topics: Alcoholism; Anesthetics; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Antihypertensi | 1981 |
[Hemorrhagic complications of preventive anticoagulant therapy in surgery].
Topics: Anticoagulants; Aspirin; Dextrans; Dose-Response Relationship, Drug; Drug Interactions; Hemorrhage; | 1983 |
The effect of aspirin on the size of the hemostatic plug.
Topics: Animals; Aspirin; Blood Platelets; Epoprostenol; Hemorrhage; Hemostasis; Rabbits; Sodium Salicylate | 1983 |
Salicylates and post-tonsillectomy haemorrhage.
Topics: Acetaminophen; Aspirin; Hemorrhage; Humans; Pain, Postoperative; Postoperative Complications; Prospe | 1984 |
[Acetylsalicylic acid and thrombocyte function].
Topics: Adolescent; Aspirin; Blood Platelet Disorders; Child; Child, Preschool; Female; Hemorrhage; Humans; | 1984 |
Use of anticoagulants. Therapy and prophylaxis for thromboembolic phenomena.
Topics: Anticoagulants; Aspirin; Blood Platelets; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Thromboe | 1984 |
Comparative evaluation of local hemostatic agents in experimental liver trauma: a study in the rat.
Topics: Animals; Aspirin; Cellulose, Oxidized; Collagen; Ethanol; Gelatin Sponge, Absorbable; Hemorrhage; He | 1984 |
Aspirin and postoperative hemorrhage.
Topics: Aspirin; Hemorrhage; Humans; Male; Middle Aged; Postoperative Complications | 1984 |
Aspirin and maternal or neonatal hemostasis.
Topics: Aspirin; Female; Hemorrhage; Hemostasis; Humans; Infant, Newborn; Infant, Newborn, Diseases; Materna | 1983 |
Fatal hemorrhage from minor trauma following massive salicylate ingestion.
Topics: Alcoholism; Aspirin; Death, Sudden; Hemorrhage; Humans; Lung Diseases; Male; Mediastinal Diseases; M | 1984 |
Acute bleeding emergencies.
Topics: Acute Disease; Aspirin; Blood Coagulation Disorders; Blood Platelet Disorders; Blood Vessels; Child; | 1980 |
[Can prostaglandins in low cytoprotective doses heal peptic ulcers?].
Topics: Aspirin; Hemorrhage; Humans; Peptic Ulcer; Prostaglandins | 1982 |
Aspirin usage and perioperative blood loss in patients undergoing unexpected operations.
Topics: Arachidonic Acids; Aspirin; Bleeding Time; Blood Coagulation; Blood Platelets; Hemorrhage; Humans; I | 1983 |
Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement.
Topics: Anticoagulants; Aortic Valve; Aspirin; Bleeding Time; Blood Platelets; Cerebral Hemorrhage; Double-B | 1980 |
[Hematemesis in childhood. Use of the fiberscope in diagnosis].
Topics: Adolescent; Aspirin; Child; Child, Preschool; Duodenitis; Endoscopy; Esophagitis; Female; Fiber Opti | 1982 |
[Intraocular hemorrhage due to systemic drugs].
Topics: Adult; Aged; Aspirin; Dipyridamole; Eye Diseases; Female; Hemorrhage; Humans; Male; Middle Aged; Qui | 1982 |
Effects of acetylsalicylic-acid ingestion on maternal and neonatal hemostasis.
Topics: Adult; Aspirin; Blood Coagulation Tests; Female; Fetus; Gestational Age; Hemoglobinometry; Hemorrhag | 1982 |
Salicylate-induced bleeding problem in ophthalmic plastic surgery.
Topics: Aspirin; Bleeding Time; Blood Platelets; Eyelid Diseases; Eyelids; Female; Hemorrhage; Humans; Middl | 1982 |
Bilateral subconjunctival hemorrhage after acetylsalicylic acid overdose.
Topics: Adult; Aspirin; Conjunctival Diseases; Hemorrhage; Humans; Male; Suicide, Attempted | 1982 |
Case study: complications associated with anticoagulant therapy.
Topics: Adult; Anticoagulants; Aspirin; Drug Interactions; Hemorrhage; Heparin; Humans; Male; Thrombophlebit | 1981 |
[From logical discovery to therapy (author's transl)].
Topics: Animals; Arachidonic Acids; Aspirin; Blood Platelets; Dogs; Fibrinolytic Agents; Glycoproteins; Hemo | 1981 |
Aspirin and perioperative blood loss.
Topics: Aspirin; Hemorrhage; Humans; Surgical Procedures, Operative | 1981 |
[Hemorrhagic complications in anticoagulant therapy].
Topics: Acenocoumarol; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation; Prothro | 1981 |
Predictors of bleeding during heparin therapy.
Topics: Adult; Aged; Alcohol Drinking; Aspirin; Dose-Response Relationship, Drug; Epistaxis; Female; Hematom | 1980 |
Aspirin and postoperative bleeding.
Topics: Aspirin; Hemorrhage; Humans; Postoperative Complications | 1980 |
Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; California; Cerebrovascular Disorders; Cost-Bene | 1995 |
[Do we honour those who deserve to be honoured?].
Topics: Anticoagulants; Aspirin; Europe; Gastrointestinal Hemorrhage; Hemorrhage; History, 20th Century; Hum | 1995 |
Use of low-dose aspirin as a preventive measure.
Topics: American Cancer Society; American Heart Association; Aspirin; Cerebral Hemorrhage; Coronary Disease; | 1995 |
Effect of aspirin and nonsteroidal antiinflammatory drug therapy on bleeding complications in dermatologic surgical patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Coagulation; Blood Coagulation Tests; Dermat | 1995 |
Diaspirin cross-linked hemoglobin resuscitation of hemorrhage: comparison of a blood substitute with hypertonic saline and isotonic saline.
Topics: Animals; Aspirin; Hemodynamics; Hemoglobins; Hemorrhage; Isotonic Solutions; Male; Oxygen Consumptio | 1995 |
Subcutaneous oxygen tension: a useful adjunct in assessment of perfusion status.
Topics: Analysis of Variance; Animals; Aspirin; Blood Gas Monitoring, Transcutaneous; Evaluation Studies as | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
High risk of thromboemboli early after bioprosthetic cardiac valve replacement.
Topics: Adult; Age Factors; Aged; Aortic Valve; Aspirin; Bioprosthesis; Dipyridamole; Female; Follow-Up Stud | 1995 |
Effect of aspirin and nonsteroidal antiinflammatory drug therapy on bleeding complications in dermatologic surgical patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bandages; Blood Co | 1994 |
Safety of combination aspirin and anticoagulation in acute ischemic stroke.
Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Cohort Stud | 1994 |
Comparison of bleeding complications of warfarin and warfarin plus acetylsalicylic acid: a study in 3166 outpatients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Aspirin; Chi-Square Distribution; Drug | 1994 |
The efficacy of diaspirin crosslinked hemoglobin solution resuscitation in a model of uncontrolled hemorrhage.
Topics: Animals; Aspirin; Blood Pressure; Disease Models, Animal; Hemodynamics; Hemoglobins; Hemorrhage; Iso | 1994 |
Experience with moderate intensity anticoagulation and aspirin after mechanical valve replacement. A retrospective, non-randomized study.
Topics: Acenocoumarol; Adult; Aged; Aspirin; Blood Coagulation Tests; Dose-Response Relationship, Drug; Drug | 1993 |
Oral anticoagulant therapy recommendations.
Topics: Administration, Oral; Aspirin; Clinical Protocols; Hemorrhage; Humans; Thromboembolism; Thrombophleb | 1994 |
Warfarin and aspirin after heart-valve replacement.
Topics: Aspirin; Drug Therapy, Combination; Embolism; Heart Valve Prosthesis; Hemorrhage; Humans; Warfarin | 1994 |
Easy bruisability, aspirin intolerance, and response to DDAVP.
Topics: Adult; Aspirin; Bleeding Time; Deamino Arginine Vasopressin; Female; Hemorrhage; Humans; Middle Aged | 1993 |
Retreatment with alteplase for early signs of reocclusion after thrombolysis. The European Cooperative Study Group.
Topics: Adult; Aged; Aspirin; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Female; | 1993 |
Hemostatic protein polymer sheath: improvement in hemostasis at percutaneous biopsy in the setting of platelet dysfunction.
Topics: Animals; Aspirin; Biopsy, Needle; Blood Platelets; Hemorrhage; Hemostasis; Liver; Lysine; Platelet A | 1993 |
Antiplatelet therapy in children with left-sided mechanical prostheses.
Topics: Adolescent; Aortic Valve; Aspirin; Child; Child, Preschool; Dipyridamole; Female; Follow-Up Studies; | 1993 |
The antiplatelet effects of aspirin and related component drugs on the surgical patient.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Hemorrhage; Humans; Male; Nur | 1993 |
[Effect of acetylsalicylic acid on platelet aggregation and capillary bleeding in healthy cats].
Topics: Adenosine Diphosphate; Animals; Aspirin; Capillaries; Cats; Collagen; Dose-Response Relationship, Dr | 1995 |
Reduction of haemorrhagic complications during mechanically assisted circulation with the use of a multi-system anticoagulation protocol.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Antithrombin III; Aprotinin; Aspirin; Assisted Circulati | 1995 |
The effect of combined treatment with dextran 40 and acetylsalicylic acid on patency in severely traumatized small veins and arteries: an experimental study in the rabbit.
Topics: Animals; Arteries; Aspirin; Dextrans; Hemorrhage; Rabbits; Vascular Patency; Veins | 1996 |
Comparative effects of staphylokinase and alteplase in rabbit bleeding time models.
Topics: Animals; Aspirin; Bleeding Time; Drug Interactions; Female; Fibrinolytic Agents; Hemorrhage; Heparin | 1996 |
[Prehospital management of acute myocardial infarct in an experimental metropolitan system of medical emergencies].
Topics: Adult; Age Distribution; Aged; Aspirin; Chest Pain; Electrocardiography; Emergency Medical Services; | 1996 |
Benefit of heparin plus aspirin vs aspirin alone in unstable angina.
Topics: Angina, Unstable; Aspirin; Hemorrhage; Heparin; Humans; Myocardial Infarction | 1996 |
Benefit of heparin plus aspirin vs aspirin alone in unstable angina.
Topics: Angina, Unstable; Aspirin; Hemorrhage; Heparin; Humans; Myocardial Infarction | 1996 |
Cellular responses to surgical trauma, hemorrhage, and resuscitation with diaspirin cross-linked hemoglobin in rats.
Topics: Animals; Aspirin; Bacterial Translocation; Blood Pressure; Cell Division; Hemoglobins; Hemorrhage; I | 1997 |
[Should individuals without evidence of coronary disease and with risk factors receive continuous treatment with aspirin? Arguments against].
Topics: Aspirin; Hemorrhage; Humans; Myocardial Ischemia; Risk Factors | 1996 |
Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Female; Follow-Up Studies; Hemorrhage; Huma | 1997 |
Clinical characteristics and management of acute stroke in patients with atrial fibrillation admitted to US university hospitals.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia | 1997 |
The paradox of bleeding and thrombosis in thrombocythemia: is von Willebrand factor the link?
Topics: Aged; Alkylating Agents; Aspirin; Erythromelalgia; Female; Fibrinolytic Agents; Hemorrhage; Hemorrha | 1997 |
Role of ET and NO in resuscitative effect of diaspirin cross-linked hemoglobin after hemorrhage in rat.
Topics: Animals; Aspirin; Blood Substitutes; Cyclic GMP; Endothelin-1; Endothelins; Enzyme Inhibitors; Gases | 1997 |
Interpretation of IST and CAST stroke trials. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Hemorrhage; Heparin; Humans; Platelet Aggregation Inhibitor | 1997 |
Acetylsalicylic acid-induced bleeding disorder.
Topics: Aspirin; Hemorrhage; Humans; Incidence; Organ Transplantation; Platelet Aggregation Inhibitors; Risk | 1997 |
Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Topics: Adenosine Diphosphate; Animals; Aspirin; Bleeding Time; Collagen; Coronary Thrombosis; Dogs; Drug Ev | 1997 |
[Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses].
Topics: Acenocoumarol; Adult; Aged; Anticoagulants; Aspirin; Coronary Disease; Dipyridamole; Drug Evaluation | 1997 |
High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study.
Topics: Administration, Oral; Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Case-Con | 1998 |
Anticoagulation to prevent stroke in atrial fibrillation and its implications for managed care.
Topics: Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Cost-Benefit Analysi | 1998 |
Development of an anti-bleeding agent for recombinant hirudin induced skin bleeding in the pig.
Topics: Animals; Aspirin; Bleeding Time; Factor VIII; Hemorrhage; Hirudins; Infusions, Intravenous; Male; Pl | 1998 |
Combination of two doses of acetyl salicylic acid: experimental study of arterial thrombosis.
Topics: Administration, Cutaneous; Animals; Aspirin; Hemorrhage; Lasers; Male; Mesenteric Arteries; Platelet | 1998 |
DVT prophylaxis options: facts & fictions.
Topics: Arthroplasty, Replacement, Knee; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Postoperative Com | 1998 |
Effect of a novel tetrapeptide derivative in a model of isoproterenol induced myocardial necrosis.
Topics: Adrenergic beta-Agonists; Animals; Aspirin; Body Weight; Creatine Kinase; Disease Models, Animal; Fe | 1998 |
A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy -- equivalence of costs as a possible case for oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Coagulation Tests; Coronary Disease; Cost-Benef | 1998 |
Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 1998 |
[Anticoagulation in aged patients with chronic non-rheumatic atrial fibrillation].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascul | 1999 |
Plasma volume expansion with solutions of hemoglobin, albumin, and Ringer lactate in sheep.
Topics: Animals; Aspirin; Female; Hemoglobins; Hemorrhage; Isotonic Solutions; Plasma Substitutes; Plasma Vo | 1999 |
[The thromboembolic risk of atrial fibrillation].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coumarins; Echocardiography; Electric Countershock; He | 1999 |
Outcome analysis of coronary artery bypass grafting: minimally invasive versus standard techniques.
Topics: Aged; Aged, 80 and over; Arrhythmias, Cardiac; Aspirin; Coronary Artery Bypass; Female; Heart Failur | 1999 |
Systemic hemodynamics and renal function in hemorrhaged dogs resuscitated with cross-linked hemoglobin.
Topics: Animals; Aspirin; Cardiovascular System; Dextrans; Diuresis; Dogs; Hemodynamics; Hemoglobins; Hemorr | 2000 |
Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Topics: Acute Disease; Adult; Age Factors; Arteriosclerosis; Aspirin; Busulfan; Cohort Studies; Disease-Free | 2000 |
[What anticoagulant therapy should be used for what form of atrial fibrillation?].
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Controlled Clinical Trials as Topic | 2000 |
Idiopathic adrenal hemorrhage.
Topics: Adrenal Gland Diseases; Aged; Aspirin; Female; Hematoma; Hemorrhage; Humans | 2000 |
Thromboembolic neurologic events in patients with antiphospholipid-antibody syndrome.
Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Autoimmune Diseases; Hemor | 1999 |
Pregnancy in essential thrombocythaemia: treatment and outcome of 17 pregnancies.
Topics: Abortion, Spontaneous; Adult; Aspirin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Pl | 2000 |
Who should take aspirin for primary prophylaxis of coronary heart disease?
Topics: Aspirin; Cardiovascular Diseases; Coronary Disease; Hemorrhage; Humans; Platelet Aggregation Inhibit | 2001 |
Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antiphospholipid Syndrome; Asp | 2001 |
Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding.
Topics: Amides; Animals; Anticoagulants; Aspirin; Biphenyl Compounds; Bleeding Time; Blood Platelets; Drug S | 2001 |
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibod | 2001 |
Emergency coronary artery bypass grafting: does excessive preoperative anticoagulation increase bleeding complications and transfusion requirements?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Transfusion, Autologous; Cardiopulmon | 2001 |
Long term anticoagulation or antiplatelet treatment. Giving warfarin always depends on balancing risks.
Topics: Anticoagulants; Aspirin; Drug Administration Schedule; Hemorrhage; Humans; Platelet Aggregation Inhi | 2001 |
Long term anticoagulation or antiplatelet treatment. How do we decide between warfarin and aspirin?
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Assessment; Strok | 2001 |
Outcomes in the management of atrial fibrillation: clinical trial results can apply in practice.
Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Databases, Factual; Fema | 2001 |
[Prevention of occlusions after infra-inguinal bypass surgery with oral anticoagulants or acetylsalicylic acid; a randomized comparison].
Topics: Administration, Oral; Anticoagulants; Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; He | 2001 |
Effect of antiplatelet and anticoagulant agents on risk of hospitalization for bleeding among a population of elderly nursing home stroke survivors.
Topics: Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Black People; Case-Control Studi | 2001 |
Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Attitude of Health Personn | 2001 |
Haemorrhage associated with combined clopidogrel and aspirin therapy.
Topics: Aged; Aged, 80 and over; Aortic Aneurysm, Abdominal; Aspirin; Clopidogrel; Drug Therapy, Combination | 2001 |
Comparison of transfusion with DCLHb or pRBCs for treatment of intraoperative anemia in sheep.
Topics: Anemia; Anesthesia; Animals; Aspirin; Blood Gas Analysis; Blood Pressure; Blood Substitutes; Blood V | 2002 |
[Guidelines for antithrombotic therapy in atrial fibrillation: what the Italian Hemostasis and Thrombosis Society thinks].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Diabetes | 2001 |
Treatment of acute coronary syndromes.
Topics: Acute Disease; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; | 2002 |
Treatment of acute coronary syndromes.
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Hemorrhage; | 2002 |
Warfarin or aspirin for recurrent ischemic stroke.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Data Interpretation, Statistical; Hemorrhage; Humans; Plate | 2002 |
Warfarin or aspirin for recurrent ischemic stroke.
Topics: Administration, Oral; Anticoagulants; Aspirin; Brain Ischemia; Hemorrhage; Humans; International Nor | 2002 |
Use of selective serotonin reuptake inhibitors and the risk of stroke: is there reason for concern?
Topics: Aged; Aspirin; Case-Control Studies; Depression; Drug Interactions; Female; Hemorrhage; Humans; Male | 2002 |
The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Australia; Embolism; Hemorrha | 2002 |
A serum factor in aspirin intolerance disease.
Topics: Aspirin; Blood Coagulation; Blood Coagulation Tests; Drug Hypersensitivity; Drug Tolerance; gamma-Gl | 1976 |
Aspirin and bleeding-time.
Topics: Aspirin; Dose-Response Relationship, Drug; Epoprostenol; Hemorrhage; Humans; Platelet Aggregation; T | 1978 |
Psotcardiotomy syndrome: pathogenesis and management.
Topics: Adrenal Cortex Hormones; Antibodies; Antigen-Antibody Complex; Aspirin; Heart Diseases; Hemorrhage; | 1976 |
Aspirin- and coumadin-related bleeding after coronary- artery bypass graft surgery.
Topics: Aged; Aspirin; Coronary Artery Bypass; Female; Hemorrhage; Humans; Male; Middle Aged; Postoperative | 1978 |
Relation of preoperative use of aspirin to increased mediastinal blood loss after coronary artery bypass graft surgery.
Topics: Adult; Aged; Aspirin; Coronary Artery Bypass; Drainage; Hemorrhage; Humans; Male; Mediastinal Diseas | 1978 |
Aspirin and postsurgery bleeding.
Topics: Aspirin; Coronary Artery Bypass; Hemorrhage; Humans; Postoperative Complications | 1978 |
Aspirin and postoperative bleeding.
Topics: Aspirin; Blood Coagulation Tests; Coronary Artery Bypass; Hemorrhage; Humans; Postoperative Complica | 1979 |
Effect of acetylsalicylate on surgical bleeding, postoperative mortality and allograft survival in rats undergoing heart transplantation.
Topics: Animals; Aspirin; Blood Coagulation; Female; Graft Rejection; Heart Transplantation; Hemorrhage; Myo | 1979 |
[Side effects of drug for thromboembolism prophylaxis. Results from the University Women's Clinic Freiburg/Br].
Topics: Adult; Anaphylaxis; Anticoagulants; Aspirin; Dextrans; Female; Hemorrhage; Heparin; Humans; Necrosis | 1979 |
Platelet function abnormalities.
Topics: Aspirin; Blood Platelets; Hemorrhage; Humans; Wounds and Injuries | 1979 |
A circulating anticoagulant directed against factor XIa in systemic lupus erythematosus.
Topics: Adult; Aspirin; Blood Coagulation Disorders; Blood Coagulation Tests; Factor XI; Female; Hemorrhage; | 1979 |
Clinical importance of side-effects of drugs inhibiting platelet function.
Topics: Aspirin; Carbenicillin; Female; Hemorrhage; Humans; Nitrofurantoin; Penicillin G; Platelet Aggregati | 1977 |
[Platelet-inhibiting drugs].
Topics: Anti-Bacterial Agents; Aspirin; Dextrans; Dipyridamole; Hemorrhage; Humans; Indomethacin; Platelet A | 1978 |
Platelets in thrombocythemia.
Topics: Aspirin; Female; Hemorrhage; Humans; Platelet Aggregation; Thrombocytosis; Thrombosis | 1978 |
Alteration of canine renal vascular response to hemorrhage by inhibitors of prostaglandin synthesis.
Topics: Animals; Aspirin; Blood Pressure; Cardiac Output; Cyclooxygenase Inhibitors; Depression, Chemical; D | 1976 |
The effect of aspirin on rebleeding in traumatic hyphema.
Topics: Aspirin; Child; Hemorrhage; Humans; Hyphema; Recurrence | 1976 |
Unexpected excessive bleeding during operation: role of acetyl salycilic acid.
Topics: Adolescent; Aspirin; Blood Platelets; Fibrinolysis; Hemorrhage; Hemostasis; Humans; Infant; Platelet | 1977 |
[Behaviour of "haemorrhage times" in hypocolinesterasic subjects after administration of acetil-salicylic acid (author's transl)].
Topics: Aspirin; Blood Coagulation; Cholinesterases; Hemorrhage; Hepatitis; Humans; Liver Cirrhosis; Preoper | 1977 |
Letter: Petechiae due to drug-induced platelet dysfunction.
Topics: Aspirin; Blood Platelet Disorders; Capillaries; Carbenicillin; Drug Synergism; Hemorrhage; Humans; M | 1976 |
[Comparative evaluation of aspirin and indirect-action anticoagulants in the prevention of venous thromboses in traumatology and orthopedic practice].
Topics: Adult; Anticoagulants; Aspirin; Drug Evaluation; Female; Fractures, Bone; Hemorrhage; Humans; Male; | 1976 |
[Intraoperative tendency to bleeding under micristine therapy in major surgery of the hip joint].
Topics: Adult; Aged; Aspirin; Female; Hemorrhage; Hip Joint; Humans; Joint Prosthesis; Male; Middle Aged; Po | 1976 |
[Adverse effects of acetylsalicylic acid].
Topics: Aspirin; Hemorrhage; Humans | 1976 |
Induced bleeding changes with aspirin in various tolerant and intolerant patient groups.
Topics: Aspirin; Blood Coagulation Tests; Butylated Hydroxyanisole; Butylated Hydroxytoluene; Diabetes Melli | 1975 |
The effect of aspirin on rebleeding in traumatic hyphema.
Topics: Aspirin; Eye Injuries; Hemorrhage; Humans; Hyphema; Platelet Adhesiveness; Recurrence | 1975 |
Letter: Aspirin, heparin and hemorrhage.
Topics: Aspirin; Blood Platelets; Drug Interactions; Hemorrhage; Heparin; Humans | 1976 |
Acute spinal epidural hematoma secondary to aspirin-induced prolonged bleeding.
Topics: Acute Disease; Adult; Aspirin; Hematoma, Epidural, Cranial; Hemorrhage; Humans; Male; Radiography; S | 1976 |
Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans.
Topics: Adult; Aspirin; Bleeding Time; Drug Interactions; Female; Gastric Mucosa; Gastrointestinal Hemorrhag | 1992 |
Diaspirin cross-linked hemoglobin solution as a resuscitative fluid following severe hemorrhage in the rat.
Topics: Animals; Aspirin; Blood Pressure; Blood Substitutes; Blood Transfusion; Cross-Linking Reagents; Eval | 1992 |
[Prevention of thrombosis with warfarin or acetylsalicylic acid related to the risk of hemorrhage].
Topics: Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Risk Factors; Warfarin | 1992 |
Multiple complications of the antiphospholipid syndrome with apparent response to aspirin therapy.
Topics: Adult; Anemia, Hemolytic; Antiphospholipid Syndrome; Aspirin; Cyclophosphamide; Dose-Response Relati | 1992 |
Bleeding time prolongation and bleeding during infusion of recombinant tissue-type plasminogen activator in dogs: potentiation by aspirin and reversal with aprotinin.
Topics: Animals; Aprotinin; Aspirin; Bleeding Time; Dogs; Drug Synergism; Fibrinolysis; Hemorrhage; Hemostas | 1991 |
Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Aspirin; Atrial Fibrillation; Attitude of Health Personnel; Cerebrovascu | 1991 |
The effects of alpha-alpha cross-linked hemoglobin on the feeding and locomotor activity of rats.
Topics: Animals; Appetitive Behavior; Aspirin; Blood Substitutes; Body Weight; Circadian Rhythm; Cross-Linki | 1991 |
Use of alteplase for myocardial infarction in two community hospitals.
Topics: Adult; Aged; Aspirin; Drug Therapy, Combination; Drug Utilization; Female; Hemorrhage; Heparin; Hosp | 1990 |
Bleeding time prolongation with streptokinase and its reduction with 1-desamino-8-D-arginine vasopressin.
Topics: Animals; Antigens; Aspirin; Bleeding Time; Deamino Arginine Vasopressin; Female; Hemorrhage; Platele | 1990 |
Risk of preoperative aspirin in patients undergoing coronary artery bypass surgery.
Topics: Aspirin; Coronary Artery Bypass; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Premedication | 1990 |
Aspirin-induced bilateral renal hemorrhage after extracorporeal shock wave lithotripsy therapy: implications and conclusions.
Topics: Aged; Aspirin; Hemorrhage; Humans; Kidney Calculi; Kidney Diseases; Lithotripsy; Male; Tomography, X | 1990 |
Does antiplatelet therapy enhance myocardial salvage after coronary reperfusion?
Topics: Animals; Aspirin; Dogs; Fibrinolytic Agents; Heart Diseases; Hemodynamics; Hemorrhage; Myocardial In | 1990 |
Superiority of warfarin over aspirin long term after thrombolytic therapy for acute myocardial infarction.
Topics: Aspirin; Drug Evaluation; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Humans; Myocardial Inf | 1990 |
Identifiable factors in post-prostatectomy haemorrhage: the role of aspirin.
Topics: Aged; Aspirin; Blood Transfusion; Female; Hemorrhage; Humans; Male; Platelet Aggregation; Postoperat | 1990 |
Aspirin, blood loss, and transfusion.
Topics: Aspirin; Blood Transfusion; Cardiac Surgical Procedures; Hemorrhage; Humans; Length of Stay | 1990 |
Low-dose preoperative aspirin therapy, postoperative blood loss, and transfusion requirements.
Topics: Aspirin; Blood Transfusion; Coronary Artery Bypass; Coronary Disease; Erythrocyte Transfusion; Femal | 1990 |
Acetylsalicylic acid antagonizes the bleeding-induced changes in hemoglobin proportions in normal adult rats.
Topics: Animals; Aspirin; Dose-Response Relationship, Drug; Erythropoiesis; Fetal Hemoglobin; Hemoglobin A; | 1986 |
[Fibrinolytic hemorrhages in patients with prostatic adenoma treated with acetylsalicylic acid in the preoperative period].
Topics: Aged; Aspirin; Hemorrhage; Humans; Male; Middle Aged; Postoperative Complications; Premedication; Pr | 1987 |
Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits.
Topics: Animals; Aspirin; Drug Combinations; Glycoproteins; Hemorrhage; Hemostasis; Plasminogen Inactivators | 1989 |
Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator.
Topics: Adenosine Diphosphate; Aspirin; Bleeding Time; Emergencies; Fibrin Fibrinogen Degradation Products; | 1989 |
Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Aged, 80 and over; Aspirin; beta-Thromboglobulin; Blood P | 1989 |
Anticoagulant therapy and cataract surgery.
Topics: Anticoagulants; Aspirin; Cataract Extraction; Hemorrhage; Humans; Postoperative Care; Preoperative C | 1989 |
Clinical application of a new in vitro bleeding time device on surgical patients.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aspirin; Bleeding Time; Epoprostenol; Hemorrhage; Hemostasis; H | 1988 |
Moderate doses of aspirin and risk of bleeding in renal failure.
Topics: Adolescent; Adult; Aged; Aspirin; Bleeding Time; Female; Hemorrhage; Hemostasis; Humans; Infusions, | 1986 |
Pharmacological modulation of localized inflammatory reactions: the nonsteroidal anti-inflammatory drug as an adjunct to therapy.
Topics: Animals; Arthus Reaction; Aspirin; Capillary Permeability; Female; Hemorrhage; Indomethacin; Inflamm | 1988 |
Antacid protection of gastric mucosa.
Topics: Aluminum Hydroxide; Animals; Antacids; Aspirin; Electrophysiology; Gastric Mucosa; Hemorrhage; Human | 1986 |
Effects of aspirin, dipyridamole, and cod liver oil on accelerated myointimal proliferation in canine veno-arterial allografts.
Topics: Animals; Aspirin; Cholesterol, Dietary; Cod Liver Oil; Dipyridamole; Dogs; Elastic Tissue; Endotheli | 1988 |
Short-term infarct vessel patency with aspirin and dipyridamole started 24 to 36 hours after intravenous streptokinase.
Topics: Angiography; Aspirin; Dipyridamole; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardi | 1988 |
Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with time.
Topics: Aged; Aspirin; Blood Platelet Disorders; Blood Platelets; Female; Follow-Up Studies; Hemorrhage; Hum | 1988 |
Indications and results for splenectomy for beta thalassemia in two hundred and twenty-one pediatric patients.
Topics: Aspirin; Blood Transfusion; Cerebrovascular Disorders; Child; Dipyridamole; Female; Follow-Up Studie | 1988 |
Usefulness of the post-aspirin bleeding time.
Topics: Adolescent; Aspirin; Bleeding Time; Blood Platelets; Hemorrhage; Hemostasis; Humans; Intraoperative | 1986 |
Aluminium hydroxide inhibits acetylsalicylic acid-induced gastric erosions in cats with Heidenhain-pouch.
Topics: Aluminum Hydroxide; Animals; Aspirin; Cats; Dinoprostone; Gastric Mucosa; Hemorrhage; Kinetics; Pros | 1986 |
Relationship between plasma PGE2 level and changes in hemoglobin proportions during bleeding-induced anemia in adult rats.
Topics: Anemia; Animals; Aspirin; Dinoprostone; Erythropoiesis; Gene Expression Regulation; Hemoglobins; Hem | 1987 |
Bleeding.
Topics: Aspirin; Blood Coagulation Disorders; Blood Platelet Disorders; Female; Hemorrhage; Hemostasis; Huma | 1987 |
Hemostatic effects of microfibrillar collagen hemostat (MCH) in experimental coagulopathy model and its mechanism of hemostasis.
Topics: Animals; Aspirin; Blood Coagulation Disorders; Cattle; Collagen; Dogs; Hemorrhage; Hemostatic Techni | 1986 |
Effect of aspirin plus hydrochloric acid on the gastric mucosal microcirculation.
Topics: Animals; Aspirin; Capillaries; Constriction, Pathologic; Drug Interactions; Gastric Mucosa; Hemorrha | 1987 |
Persistent hemorrhage after extracapsular surgery associated with excessive aspirin ingestion.
Topics: Aged; Aspirin; Cataract Extraction; Eye Diseases; Hemorrhage; Humans; Male; Postoperative Complicati | 1987 |
Antithrombotic therapy in children and adolescents.
Topics: Acenocoumarol; Adolescent; Age Factors; Aspirin; Child; Child, Preschool; Drug Therapy, Combination; | 1986 |
Oral anticoagulation is not necessary for patients with bioprosthetic mitral valve replacement in atrial fibrillation.
Topics: Anticoagulants; Aortic Valve; Aspirin; Atrial Fibrillation; Bioprosthesis; Dipyridamole; Drug Therap | 1986 |
Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera.
Topics: Aspirin; Dipyridamole; Female; Hemorrhage; Humans; Male; Phosphorus Radioisotopes; Platelet Aggregat | 1986 |
Oesophageal apoplexy associated with aspirin ingestion in polycythaemia rubra vera.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Esophagus; Female; Hemorrhage; Humans; Polycythemia Vera | 1986 |
Aspirin anticoagulation in children with mechanical aortic valves.
Topics: Adolescent; Adult; Anticoagulants; Aortic Valve; Aspirin; Child; Child, Preschool; Dipyridamole; Fem | 1986 |
Late postoperative tamponade following coronary artery bypass grafting in patients on antiplatelet therapy.
Topics: Adult; Aspirin; Cardiac Tamponade; Coronary Artery Bypass; Dipyridamole; Female; Hemorrhage; Humans; | 1985 |
A model of hemorrhagic pancreatitis in cats--role of 16,16-dimethyl prostaglandin E2.
Topics: 16,16-Dimethylprostaglandin E2; Animals; Aspirin; Capillary Permeability; Cats; Ethanol; Glycodeoxyc | 1986 |
Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection.
Topics: Acute Disease; Arthritis, Juvenile; Aspirin; Bacterial Infections; Child; Child, Preschool; Coma; Di | 1985 |
Intraocular lenses and anticoagulation and antiplatelet therapy.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Lenses, Intraocular; Surveys and Questionnaires; Warfar | 1985 |
The bleeding time as a preoperative screening test.
Topics: Aspirin; Bleeding Time; Blood Coagulation Disorders; Hemorrhage; Humans; Intraoperative Complication | 1985 |
Ophthalmic response to inverted posture.
Topics: Adult; Aspirin; Conjunctival Diseases; Esotropia; Eye; Eye Diseases; Hemorrhage; Humans; Intraocular | 1985 |
Anesthetic management of patients with coagulation disorders.
Topics: Anesthetics; Anticoagulants; Aspirin; Blood Coagulation; Blood Coagulation Disorders; Cardiopulmonar | 1985 |
Anticoagulation therapy in children with mechanical prosthetic cardiac valves.
Topics: Aspirin; Child; Child, Preschool; Dipyridamole; Heart Valve Prosthesis; Hemorrhage; Humans; Thromboe | 1985 |
Impact of aspirin and chlorthalidone on the pharmacodynamics of oral anticoagulant drugs in man.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Adult; Anticoagulants; Aspirin; Blood Coagulation Tes | 1971 |
Bleeding time after aspirin ingestion.
Topics: Aspirin; Hemorrhage; Humans; von Willebrand Diseases | 1968 |
[Collagen and thrombocytes].
Topics: Aorta; Arteriosclerosis; Aspirin; Blood Platelets; Collagen; Hemorrhage; Humans; Phenylbutazone; Pla | 1969 |
Blood and neoplastic diseases. Haemostasis, haemorrhage, and thrombosis.
Topics: Adenosine Diphosphate; Animals; Aspirin; Blood Coagulation; Blood Coagulation Factors; Blood Platele | 1974 |
Salicylate-induced foetal damage late in pregnancy. An experimental study in mice.
Topics: Abnormalities, Drug-Induced; Animals; Animals, Newborn; Aspirin; Carbon Isotopes; Coumarins; Female; | 1971 |
[Comparison of the prevention of thrombo-embolism by heparin and sintrom and by Macrodex and Colfarit in gynecologic surgery of the elderly (author's transl)].
Topics: Acenocoumarol; Aged; Anticoagulants; Aspirin; Blood Coagulation Disorders; Dextrans; Drug Therapy, C | 1974 |
Comparison of warfarin, low-molecular-weight dextran, aspirin, and subcutaneous heparin in prevention of venous thromboembolism following total hip replacement.
Topics: Aspirin; Dextrans; Female; Hemorrhage; Heparin; Hip Joint; Humans; Injections, Subcutaneous; Joint P | 1974 |
Thrombocytopenia and bleeding complications in severe cases of meningococcal infection treated with heparin, dextran 70 and chlorpromazine.
Topics: Adolescent; Adult; Aspirin; Blood Platelet Disorders; Cephalothin; Chlorpromazine; Dexamethasone; De | 1972 |
Thrombopathy. Identification and distribution.
Topics: Adenosine Diphosphate; Aspirin; Blood Coagulation Factors; Blood Coagulation Tests; Blood Platelet D | 1974 |
[Analgesics and bleeding tendency].
Topics: Adult; Aspirin; Blood Coagulation; Female; Hemorrhage; Humans; Thrombosis | 1972 |
Clinical and biochemical characteristics of a primary platelet disorder.
Topics: Adenine Nucleotides; Adenosine Diphosphate; Ascorbic Acid; Aspirin; Blood Coagulation Factors; Blood | 1972 |
Sporadic malformations in laboratory animals and their influence on drug testing.
Topics: Abnormalities, Drug-Induced; Animals; Animals, Laboratory; Aspirin; Bone and Bones; Congenital Abnor | 1972 |
Evaluation of anticoagulant therapy in cloth-covered prosthetic valves.
Topics: Anticoagulants; Aortic Valve; Aspirin; Cerebral Hemorrhage; Heart Valve Diseases; Heart Valve Prosth | 1973 |
A congenital defect in platelet prostaglandin production associated with impaired hemostasis in storage pool disease.
Topics: Aspirin; Blood Cell Count; Blood Platelet Disorders; Blood Platelets; Chromatography, Thin Layer; Co | 1973 |
Streptokinase and anti-thrombotic therapy in the hemolytic-uremic syndrome.
Topics: Aspirin; Biopsy; Child; Child, Preschool; Dipyridamole; Hemolytic-Uremic Syndrome; Hemorrhage; Hepar | 1974 |
Blood and neoplastic diseases. Blood formation and the pathogenesis of anaemia.
Topics: Adolescent; Adult; Aged; Anemia; Anemia, Hypochromic; Anemia, Macrocytic; Aspirin; Bilirubin; Bone M | 1974 |
Bleeding disorders during surgery.
Topics: Adrenal Cortex Hormones; Aspirin; Blood Coagulation Disorders; Blood Coagulation Factors; Blood Coag | 1974 |
Release reaction in washed platelet suspensions induced by kaolin and other particles.
Topics: Adenine Nucleotides; Adenosine Diphosphate; Aspirin; Blood Platelet Disorders; Blood Platelets; Calc | 1971 |
Analgetic drugs--the mild analgetics.
Topics: Acetaminophen; Acetanilides; Administration, Oral; Analgesics; Aspirin; Codeine; Dextropropoxyphene; | 1972 |
Aspirin and bleeding.
Topics: Aspirin; Drug Tolerance; Hemorrhage; Humans | 1971 |
Salicylate-induced foetal damage during late pregnancy in mice: a comparison between sodium salicylate, acetylsalicylic acid and salicylsalicylic acid.
Topics: Animals; Aspirin; Female; Fetal Death; Gestational Age; Hemorrhage; Liver Glycogen; Mice; Pregnancy; | 1971 |
Aspirin and bleeding.
Topics: Advertising; Aspirin; Female; Hemorrhage; Humans; Infant, Newborn; Pregnancy; Television | 1971 |
[Side effects of Acylpyrin: suitability of the use of Superpyrin Spofa. (Discussion on Acylpyrin, Cs Pediat. 26,1971,3:143-6)].
Topics: Aluminum Hydroxide; Antacids; Aspirin; Cell Membrane Permeability; Child; Hemorrhage; Humans | 1971 |
[Value of the in-vivo aspirin test in the study of a new vascular wall drug].
Topics: Aspirin; Blood Coagulation; Blood Coagulation Tests; Blood Vessels; Female; Flavonoids; Hemorrhage; | 1971 |
Aspirin, platelets, and bleeding.
Topics: Adenine Nucleotides; Animals; Aspirin; Blood Coagulation; Blood Platelets; Gastrointestinal Hemorrha | 1969 |
[Changes in coagulation and hemostasis induced with common drugs].
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Aspirin; Autonomic Agents; Blood Coagulation; Blo | 1970 |
Salicylates and bleeding.
Topics: Aspirin; Hemorrhage; Humans; Telangiectasis | 1970 |
[Current aspects of aspirin therapy].
Topics: Aspirin; Blood Coagulation; Embolism; Hemorrhage; Humans; Joint Diseases; Myocardial Infarction; Thr | 1970 |
Aspirin and bleeding time.
Topics: Aspirin; Blood Coagulation Tests; Hemorrhage; Hemostasis; Humans | 1970 |
Platelet response to induction of hemorrhagic pancreatitis.
Topics: Animals; Anti-Bacterial Agents; Aspirin; Blood Cell Count; Dipyridamole; Disease Models, Animal; Dog | 1971 |
[Acetylsalycylic acid and hemostasis].
Topics: Aspirin; Blood Platelets; Hemophilia A; Hemorrhage; Humans | 1971 |
Thrombosis prevention.
Topics: Animals; Arteries; Arthroplasty; Aspirin; Blood Platelets; Dextrans; Dipyridamole; Hemorrhage; Hip; | 1971 |
Platelets and aspirin.
Topics: Aspirin; Blood Platelet Disorders; Female; Hemorrhage; Humans; Middle Aged | 1969 |
Aspirin and salicylic acid, et al.
Topics: Aspirin; Drug Tolerance; Hemorrhage; Humans; Salicylates | 1969 |
Secondary post-tonsillectomy haemorrhage.
Topics: Aspirin; Child; Child, Preschool; Hemorrhage; Humans; Neomycin; Postoperative Care; Postoperative Co | 1966 |